

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN (print): 0250-7005; ISSN (online): 1791-7530

VOLUME 40

2020

This volume is dedicated to the memory of  
M.M. BURGER  
I.J. FIDLER

## Editorial Board

<b>P. A. Abrahamsson</b>	Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden
<b>B. B. Aggarwal</b>	Director, Inflammation Research Center, San Diego, CA, USA
<b>T. Akimoto</b>	Division of Particle Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan
<b>P. Z. Anastasiadis</b>	Department of Cancer Biology, Mayo Cancer Center, Jacksonville, FL, USA
<b>A. Argiris</b>	Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA
<b>J. P. Armand</b>	Institut Claudius Regaud, Toulouse, France
<b>V. I. Avramis</b>	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
<b>D.-T. Bau</b>	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
<b>G. Bauer</b>	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
<b>E. E. Baulieu</b>	INSERM U488 and College de France, Le Kremlin-Bicetre, France
<b>E. J. Benz, Jr.</b>	Dana-Farber Cancer Institute, Boston, MA, USA
<b>J. Bergh</b>	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
<b>F. T. Bosman</b>	Institute of Pathology, University of Lausanne, Switzerland
<b>M. Bouvet</b>	Department of Surgery, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
<b>J. Boyd</b>	Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
<b>G. Broich</b>	Gruppo Policlinico di Monza, Monza, Italy
<b>Ø. S. Bruland</b>	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
<b>J. M. Buatti</b>	Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA
<b>M. M. Burger</b>	Novartis, Basel, Switzerland
<b>M. Carbone</b>	Cancer Research Center of Hawaii, Honolulu, HI, USA
<b>C. Carlberg</b>	Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
<b>J. Carlsson</b>	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
<b>A. F. Chambers</b>	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
<b>P. Chandra</b>	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
<b>L. Cheng</b>	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
<b>J.-G. Chung</b>	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
<b>R. Clarke</b>	Georgetown University Medical Center, Washington, DC, USA
<b>E. De Clercq</b>	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
<b>W. Den Otter</b>	VUMC, Department of Urology, Amsterdam, The Netherlands
<b>E. P. Diamandis</b>	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
<b>G. Th. Diamandopoulos</b>	Department of Pathology, Harvard Medical School, Boston, MA, USA
<b>L. Egevad</b>	Department of Pathology, Karolinska University Hospital, Stockholm, Sweden
<b>D. W. Felsher</b>	Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
<b>J. A. Fernandez-Pol</b>	Metalloproteomics, LLC, Chesterfield, MO, USA
<b>I. J. Fidler</b>	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
<b>A. P. Fields</b>	Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA
<b>H. Fu</b>	Discovery and Developmental Therapeutics Program of Winship Cancer Institute, Emory University, Atlanta, GA, USA
<b>B. Fuchs</b>	Balgrist University Hospital, Zurich, Switzerland
<b>D. Fuchs</b>	Center for Chemistry and Biomedicine, Innsbruck Medical University, Innsbruck, Austria
<b>D. Fukumura</b>	Edwin L. Steele Laboratories, Department of Radiation Oncology, Harvard Medical School, Boston, MA, USA

- G. Gabbiani** Department of Pathology, University of Geneva, Switzerland
- R. Ganapathi** Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
- A. F. Gazdar** Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
- A. Giordano** Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
- G. Gitsch** Department of Gynecology and Obstetrics, University of Freiburg, Germany
- M. Gnant** Department of Surgery, Medical University of Vienna, Austria
- R. H. Goldfarb** R. H. Goldfarb Sopherion Therapeutics, LLC and Translational Oncology and ImmunoEngineering Consulting, Guilford, CT, USA
- A. Helland** Oslo University Hospital-Radium Hospital, Oslo, Norway
- L. Helson** Sign Path Pharma, Inc., Quakertown, PA, USA
- R. Henriksson** Department of Experimental Oncology, Umeå University, Umeå, Sweden
- R. M. Hoffman** Department of Surgery, University of California, San Diego, CA, USA
- S. C. Jhanwar** Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
- J. V. Johannessen** Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
- R. Jones** Sarcoma Unit, Royal Marsden Hospital, London, UK
- B. Kaina** Institute of Toxicology, University of Mainz, Germany
- P. -L. Kellokumpu-Lehtinen** Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland
- D. G. Kieback** Helios Medical Center Schleswig, Schleswig, Germany
- R. Klapdor** Medical Clinic, University of Hamburg, Germany
- H. Kobayashi** Laboratory of Molecular Theranostics, NCI/NIH, Bethesda, MD, USA
- S. D. Kottaridis** Department of Virology, Hellenic Anticancer Institute, Athens, Greece
- G. R. F. Krueger** Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
- Pat M. Kumar** Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
- Shant Kumar** Department Pathology, University of Manchester Medical School, Manchester, UK
- O. D. Laerum** Department of Pathology, The Gade Institute, University of Bergen, Norway
- F. J. Lejeune** Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
- S. Linder** Department of Medicine and Health, Linköping University, Linköping, Sweden
- L. F. Liu** Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
- D. M. Lopez** Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
- E. Lundgren** Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
- Y. Maehara** Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
- J. Maher** Department of Research Oncology, Division of Cancer Studies, King's College London School of Medicine, Guy's Hospital Campus, London, UK
- J. Marescaux** IRCAD, University of Strasbourg, France
- J. Mark** Department of Pathology, Kärnshuset, Skövde, Sweden
- S. S. Martin** Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA
- S. Mitra** The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA
- S. Miyamoto** Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
- S. Moncada** Manchester Cancer Research Centre, University of Manchester, Manchester, UK
- M. Mueller** Hochschule Furtwangen University, Villingen-Schwenningen, Germany
- F. M. Muggia** New York University Cancer Institute, School of Medicine, NY, USA

<b>M. Namiki</b>	Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan
<b>R. Narayanan</b>	Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
<b>K. Nilsson</b>	Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
<b>S. Pathak</b>	Department of Cell Biology, University of Texas, Houston, TX, USA
<b>J. L. Persson</b>	Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden
<b>G. J. Pilkington</b>	Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK
<b>C. D. Platsoucas</b>	College of Sciences, Old Dominion University, Norfolk, VA, USA
<b>A. Polliack</b>	Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
<b>D. Rades</b>	Department of Radiation Oncology, University of Lübeck, Lübeck, Germany
<b>M. Rigaud</b>	Laboratory Biochimie et Génétique Molécules, Faculté de Médecine de Limoges, France
<b>U. Ringborg</b>	Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
<b>M. Roselli</b>	Department of Medical Oncology, University of Rome "Tor Vergata", Italy
<b>S.T. Rosen</b>	Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
<b>A. Schauer</b>	Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
<b>M. Schneider</b>	Department of Organic Chemistry, Bergische University, Wuppertal, Germany
<b>J. Sehouli</b>	Department of Gynecology, Center for Oncological Surgery, Charité Comprehensive Cancer Center, Berlin, Germany
<b>A. Seth</b>	Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
<b>G. V. Sherbet</b>	Cancer Research Unit, University of Newcastle-upon-Tyne, UK
<b>A. Slominski</b>	Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA
<b>G.-I. Soma</b>	Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan
<b>G. S. Stein</b>	Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
<b>T. Stigbrand</b>	Department of Immunology, Umeå University, Umeå, Sweden
<b>T. M. Theophanides</b>	Department of Chemistry, Technical University of Athens, Greece
<b>P. M. Ueland</b>	Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
<b>H. Van Vlierberghe</b>	Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
<b>R.G. Vile</b>	Department of Immunology, Mayo Clinic, Rochester, MN, USA
<b>M. Weller</b>	Department of Neurology, University Hospital Zurich, Zurich, Switzerland
<b>J. Westermarck</b>	Centre for Biotechnology, University of Turku, Turku, Finland
<b>B. Westermarck</b>	Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
<b>Y. Yen</b>	Taipei Medical University, Taipei, Taiwan, ROC
<b>M. R. I. Young</b>	Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA
<b>B. Zumoff</b>	Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

## Acknowledgements

The IJAR appreciates the support of the following Foundations, Institutions, Organizations and Universities for the works published in Anticancer Research, Volume 40, 2020.

- AbbVie Pharmaceuticals, Lake Bluff, IL, U.S.A.  
 Academy of Finland, Helsinki, Finland  
 AceStatistics Support Co, Ltd., Essex, U.K.  
 Advanced Intelligence Project (AIP) - Public/Private R&D Investment Strategic Expansion Program (PRISM), Japan  
 Science and Technology Agency (JST), Kawaguchi, Japan  
 Advanced Light Microscopy Facility, University of Patras, Patras, Greece  
 Advanced Research Foundation, U.S.A.  
 Agency for Medical Research, Ministry of Health of the Czech Republic, Czech Republic  
 Agioi Anargyroi General Hospital, Athens, Greece  
 Ajmera Family Chair in Urologic Oncology, Sunnybrook Hospital, Toronto, ON, Canada  
 All Children's Hospital Foundation, St Petersburg, FL, U.S.A.  
 American Cancer Society, Atlanta, GA, U.S.A.  
 American College of Surgeons, Committee on Cancer (CoC), Chicago, IL, U.S.A.  
 American Medical Association, Chicago, IL, U.S.A.  
 Amgen, Thousand Oaks, CA, U.S.A.  
 An Nan Hospital, China Medical University, Tainan, Taiwan, R.O.C.  
 Analytic Healthcare Quality User Information Program of the National Research, Development and Innovation Fund, Hungarian Government, Hungary  
 Animal Biotechnology Center, Feature Areas Research Center Program, Higher Education Sprout Project, Ministry of Education in Taiwan, Taiwan, R.O.C.  
 Applied Medical Research Laboratory, Japan  
 ARC Foundation, Vancouver, BC, Canada  
 Archie and Betty McCallum, U.S.A.  
 Armauer Hansen Research Institute, Addis Ababa, Ethiopia  
 Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea  
 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, U.S.A.  
 Asia University, Taichung, Taiwan, R.O.C.  
 Asociación Costarricense de Oncología Médicos (ACOMED), San José, Costa Rica  
 Association of Healthcare Corporation, Japan  
 Associazione Italiana per la Ricerca sul Cancro (AIRC), Milan, Italy  
 Ateneo Sapienza University, Rome, Italy  
 Augusta University Georgia Cancer Center, Augusta, GA, U.S.A.  
 Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea  
 BBMRI-CZ, Bank of Clinical Specimens Focused on Cancer, Brno, Czech Republic  
 Berlin Air Quality Network, Berlin, Germany  
 Berlin Institute of Health, Berlin, Germany  
 Bethel University, Saint Paul, MN, U.S.A.  
 Biobank of Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan, R.O.C.  
 Biobank of the Center for Integrated Oncology Cologne Bonn, University Hospital Bonn, Bonn, Germany  
 Biohit Oyj, Helsinki, Finland  
 Biomedical Research Institute Grant, Kyungpook National University Hospital, Daegu, Republic of Korea  
 Biomedical Research Institute, Gyeongsang National University Hospital, Jinju, Republic of Korea  
 Bio-oriented Technology Research Advancement Institution (BRAIN), National Agriculture and Food Research Organization (NARO), Japan  
 Biophotonics Laboratory, Centro de Biotecnologia (CBiotec), Universidade Federal da Paraíba (UFPB), Brazil  
 Biosignal Research Center, Kobe University, Kobe, Japan  
 Bonati Research Stipend, U.S.A.  
 Boston Medical Center Plastic Surgery Department, Boston, MA, U.S.A.  
 Breast Cancer Hope Foundation, London, U.K.  
 Canadian Breast Cancer Foundation Endowed Chair in Breast Cancer Research, Canada  
 Canadian Cancer Society, Toronto, ON, Canada  
 Canadian Institutes of Health Research, Ottawa, ON, Canada  
 Canadian Tumour Repository Network (CTRNet), Canada  
 Cancer Association of South Africa (CANSA), South Africa  
 Cancer Center Amsterdam, Amsterdam, the Netherlands  
 Cancer Center, Buddhist Tzu Chi General Hospital, Hualien City, Taiwan, R.O.C.

- Cancer Society of Finland, Helsinki, Finland  
 Carnegie Large Research Grant, Carnegie Corporation  
 Transformation Programme, University of the  
 Witwatersrand, Johannesburg, South Africa  
 Center for Animal Experiments, Central Research  
 Facilities, Kindai University Faculty of Medicine, Osaka,  
 Japan  
 Center for Morphological Analyses, Kindai University  
 Faculty of Medicine, Osaka, Japan  
 Center for NMR Research Facilities, Penn State College of  
 Medicine, Hershey, PA, U.S.A.  
 Center for Research Advancement and Collaboration, Japan  
 Center for Strategic Research Project, University of the  
 Ryukyus, Nishihara, Japan  
 Center for the Integrative and Evolutionary Galliformes  
 Genomics (iEGG), Taiwan, R.O.C.  
 Center of Biotechnology (CBIOT), Universidade Federal  
 do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil  
 Center of Reconstruction Neuroscience –NEURORECON,  
 Czech Republic  
 Central Health Council, Ministry of Health of Greece,  
 Athens, Greece  
 Central Norway Regional Health Authority, Norway  
 Centre de Radiothérapie et d'Oncologie de Moyenne  
 Garonne, Agen, France  
 Centre Hospitalier de l'Agglomération Montargoise,  
 Amilly, France  
 Centre Hospitalier de Cholet, Cholet, France  
 Centre Oscar Lambret, Lille, France  
 Centro de Microscopia e Microanálise (CMM),  
 Universidade Federal do Rio Grande do Sul (UFRGS),  
 Porto Alegre, Brazil  
 Chang Bing Show Chwan Memorial Hospital, Changhua,  
 Taiwan, R.O.C.  
 Changhua Christian Hospital, Changhua, Taiwan, R.O.C.  
 Charité - Universitätsmedizin Berlin, Berlin, Germany  
 Charles and Mary Latham Foundation Fund, Washington,  
 DC, U.S.A.  
 Charles University in Prague, Prague, Czech Republic  
 Charles University Research Fund (PROGRES), Charles  
 University in Prague, Prague, Czech Republic  
 Chia-Yi Christian Hospital, Chia-Yi, Taiwan, R.O.C.  
 Children's Oncology Group, Seattle, WA, U.S.A.  
 Chi-Mei Medical Center, Tainan, Taiwan, R.O.C.  
 China Medical University Hospital, Taichung, Taiwan,  
 R.O.C.  
 China Medical University, Taichung, Taiwan, R.O.C.  
 China Scholarship Council (CSC), P.R. China  
 Cholangiocarcinoma Research Institute (CARI), Thailand  
 Chosun University, Gwangju, Republic of Korea  
 CHU de Poitiers - Hôpital de la Milétrie, Poitiers, France  
 CHU Limoges – Dupuytren, Limoges, France  
 Chuden Hospital, Hiroshima, Japan  
 Chulalongkorn University, Bangkok, Thailand  
 CIF Grant, Faculty of Science, Mahidol University, Salaya,  
 Thailand  
 City of Hope, National Medical Center, Duarte, CA,  
 U.S.A.  
 Cleveland Clinic - Global Cardiovascular Innovations  
 Center, Cleveland, OH, U.S.A.  
 Clinical Medicine Research Institute, Chosun University  
 Hospital, Gwangju, Republic of Korea  
 Clinical Medicine Research Laboratory, National Yang-  
 Ming University Hospital, Yilan, Taiwan, R.O.C.  
 Clinical Research Center, Dokkyo Medical University  
 School of Medicine, Mibu, Japan  
 Clinical Study Support Center, Wakayama Medical  
 University Hospital, Wakayama, Japan  
 Clinique de l'Union, Saint-Jean, France  
 Cohera Medical Inc., Pittsburgh, PA, U.S.A.  
 Comisión de Operación y Fomentode Actividades  
 Académicas (COFAA), Instituto Politécnico Nacional  
 (IPN), Mexico City, Mexico  
 Consejo Nacional De Ciencia y Tecnología (CONACyT),  
 Mexico City, Mexico  
 Conselho Nacional de Desenvolvimento Científico e  
 Tecnológico (CNPq), Brasília, Brazil  
 Control of Innate Immunity Technology Research  
 Association, Takamatsu, Japan  
 Coordenação de Aperfeiçoamento de Pessoal de Nível  
 Superior (CAPES), Brasília, Brazil  
 Core Laboratory, Department of Research, Taipei Tzu Chi  
 Hospital, Buddhist Tzu Chi Medical Foundation, Hualien  
 City, Taiwan, R.O.C.  
 Council for Science, Technology and Innovation (CSTI),  
 Cabinet Office, Japan  
 Cross-ministerial Strategic Innovation Promotion Program  
 (SIP), Japan  
 CytoGen Inc., Seoul, Republic of Korea  
 Czech Science Foundation, Czech Republic  
  
 Daisan Hospital, Jikei University, Tokyo, Japan  
 Daiwa Securities Health Foundation, Tokyo, Japan  
 Danish Cancer Association, Copenhagen, Denmark  
 Danish Gynaecological Cancer Database, Copenhagen,  
 Denmark  
 Dean of Research and Graduate Studies, Federal University  
 of Pará, Belem, Brazil

- Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Saudi Arabia
- DEKART Proteomics Laboratory, Kocaeli University Medical School, Kocaeli, Turkey
- Department of Biostatistics, Catholic Research Coordinating Center, The Catholic University of Korea, Daejeon, Republic of Korea
- Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan
- Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
- Department of Chemistry, Howard University, Washington, DC, U.S.A.
- Department of Clinical and Translational Physiology, Kyoto Pharmaceutical University, Kyoto, Japan
- Department of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto, Japan
- Department of Clinical Statistics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
- Department of Education Title III Program, Clark Atlanta University, Atlanta, GA, U.S.A.
- Department of Environmental Medicine, Kurume University School of Medicine, Kurume, Japan
- Department of Experimental, Diagnostic and Specialty Medicine (DIMES), S. Orsola-Malpighi University Hospital, Bologna, Italy
- Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Osaka, Japan
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Okayama, Japan
- Department of Histology and Embryology, Lithuanian University of Health Sciences, Kaunas, Lithuania
- Department of Integrated Diagnostic Pathology, Nippon Medical School, Tokyo, Japan
- Department of Internal Medicine – Oncology, General Hospital of Thessaloniki Papageorgiou, Thessaloniki, Greece
- Department of International Medical Communications, Tokyo Medical University, Tokyo, Japan
- Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
- Department of Medicine Clinic III, Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany
- Department of Neuroscience, Imaging and Clinical Sciences, “G. D’Annunzio” University of Chieti, Chieti, Italy
- Department of Next Generation Cell and Immune Therapy, Juntendo University School of Medicine, Tokyo, Japan
- Department of Oncology, University Hospital of Lausanne-CHUV, Lausanne, Switzerland
- Department of Otorhinolaryngology Head and Neck Surgery, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
- Department of Pathology and Laboratory Medicine, Nagoya University of Hospital, Nagoya, Japan
- Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan
- Department of Pathology, Kangbuk Samsung Hospital, Seoul, Republic of Korea
- Department of Pathology, Medical School, University of Athens, Athens, Greece
- Department of Pathology, Nagasaki University Hospital, Nagasaki, Japan
- Department of Pathology, Osaka University Hospital, Osaka, Japan
- Department of Pathology, Saitama Medical University International Medical Center, Saitama, Japan
- Department of Pathology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
- Department of Pediatrics, University of California San Diego School of Medicine, San Diego, CA, U.S.A.
- Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Kuwait University, Kuwait City, Kuwait
- Department of Physiology, School of Medicine, Autonomous National University of Mexico (UNAM), Mexico City, Mexico
- Department of Preventive Medicine, Tokai University School of Medicine, Hiratsuka, Japan
- Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Japan
- Department of Radiation Oncology, Osaka International Cancer Institute, Osaka, Japan
- Department of Radiation Oncology, Stanford University School of Medicine, California, CA, U.S.A.
- Department of Radiotherapy, Yamaguchi University Graduate School of Medicine, Ube, Japan
- Department of Surgery, International University of Health and Welfare Hospital, Ōtawara, Japan
- Department of Surgery, University of Pécs Medical School, Pécs, Hungary
- Department of Urology, Arad Hospital, Tehran, Iran
- Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan
- Departments of Medicine and Radiation Oncology, Rutgers New Jersey Medical School, Newark, NJ, U.S.A.



- Departments of Pathology and Thoracic Surgery, Kanazawa Medical University, Uchinada, Japan
- Departments of Surgery and Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA, U.S.A.
- Development of Characteristic Education Grant, Japan Private School Promotion Foundation, Japan
- Ditmanson Medical Foundation, Chiayi Christian Hospital, Chiayi, Taiwan, R.O.C.
- Division of Oncology, Department of Medicine, University General Hospital, Patras, Greece
- Dutch Cancer Society, Amsterdam, the Netherlands
- E-Da Cancer Hospital, Kaohsiung, Taiwan, R.O.C.
- EDGC, Inc., Incheon, Republic of Korea
- Edmond Odette Foundation, Toronto, ON, Canada
- Engdahl Family Foundation, Anoka, MN, U.S.A.
- Engineering Division, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil
- Epidemiological Strategy and Medical Economics (ESME) Scientific Committee,
- Erasmus University Rotterdam, Rotterdam, the Netherlands
- Estímulo alDesempeño de los Investigadores (EDI) of IPN, Paris, France
- Ethicon Endosurgery, Cincinnati, OH, U.S.A.
- Ethiopian Airlines Health Office, Addis Ababa, Ethiopia
- European MRI and Rectal Cancer Surgery (EuMaRCS) Study Group
- European Regional Development Fund (ERDF), Brussels, Belgium
- European Research Council
- European Social Fund, Brussels, Belgium
- European Union's Seventh Framework Program
- EVO-funding, Kuopio University Hospital, Kuopio, Finland
- Excellence Program, State of Mecklenburg-Vorpommern, Germany
- Experimental, Educational and Research Center ELPEN, Greece
- Faculty of Dentistry, Thammasat University, Bangkok, Thailand
- Faculty of Medicine, University of Porto, Porto, Portugal
- Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
- Far Eastern Memorial Hospital, New Taipei, Taiwan, R.O.C.
- Federal Ministry of Science, Research and Economy (BMWFV), Vienna, Austria
- Federal Ministry of Transport, Innovation and Technology (BMVIT), Vienna, Austria
- Federal University of Rio Grande do Sul, Porto Alegre, Brazil
- Financiadora de Estudos e Projetos (FINEP), Brazil
- First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
- Fondation du Cancer du Sein du Québec, Montreal, Canada
- Fondazione Cassa di Risparmio di Perugia, Perugia, Italy
- Fondazione Roma, Rome, Italy
- Fonds de Recherche du Québec - Santé (FRQS), Montreal, Canada
- Foundation for the Promotion of Cancer Research, Japan
- Foundation of Osaka Cancer Research, Osaka, Japan
- Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany
- Fukuoka Foundation for Sound Health Cancer Research Fund, Japan
- Fukuoka Wajiro Hospital, Fukuoka, Japan
- Fulbright Program, U.S.A.
- Fundação de Amparo à Pesquisa do Estado do Piauí (FAPEPI), Brazil
- Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Brazil
- Fundação de Amparo à Pesquisa do Estadodo Rio Grande do Sul (FAPERGS), Brazil
- Fundação de Apoio à Pesquisa do Estado da Paraíba (FAPESQ-PB),Brazil
- Fundação para a Ciência e a Tecnologia (FCT), Ministério da Ciência e Ensino Superior, Portugal
- Fundo Europeu de Desenvolvimento Regional (FEDER), Lisbon, Portugal
- Gachon University, Incheon, Republic of Korea
- General Hospital of Heraklion Pananio-Venizelio, Heraklion, Greece
- General University Hospital in Prague, Prague, Czech Republic
- Georgia Research Alliance (GRA) Venture Lab Grant, U.S.A.
- German Cancer Research Center (DKFZ), Heidelberg, Germany
- German Federal Ministry of Education and Research (BMBF), Germany
- Gil Medical Center, Gachon University, Incheon, Republic of Korea
- GINECO Study Office
- GlaxoSmithKline plc, London, U.K.

- Global Robotics Institute, Florida Hospital, Orlando, FL, U.S.A.
- Graduate Research Group of the Hospital de Clínicas de Porto Alegre (GPPG), Porto Alegre, Brazil
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan
- Graduate School, Chulalongkorn University, Bangkok, Thailand
- Graduate School, Khon Kaen University, Khon Kaen, Thailand
- Grand Forks Human Nutrition Research Center, Washington, DC, U.S.A.
- Grant-in-Aid for Scientific Research, Ministry of Health, Labor and Welfare, Tokyo, Japan
- Grants-in-Aid for Scientific Research (KAKENHI), Japan Society for the Promotion of Science, Tokyo, Japan
- Greek National Funds, Athens, Greece
- Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania
- Grünenthal Foundation, Portugal
- GSTU Foundation, Palermo, Italy
- Gunma University Heavy-Ion Medical Center, Gunma, Japan
- Gunma University Hospital, Gunma, Japan
- Gyeongsang National University Hospital Biomedical Research Institute, Jinju, Republic of Korea
- Hadassah Braun School of Public Health, Hebrew University, Jerusalem, Israel
- Hallym University Research Fund, Chuncheon, Republic of Korea
- Harasanshin Hospital, Fukuoka, Japan
- Heikki, Aino and Aarne Korhonen Foundation, Finland
- Hellenic Society of Medical Oncology (HeSMO), Athens, Greece
- Helsinki University Central Hospital Research Foundation, Helsinki, Finland
- Heuermann HF Technik, Aachen, Germany
- Higashiosaka City Medical Center, Osaka, Japan
- High Throughput Biomedicine Unit (HTB), Institute for Molecular Medicine Finland (FIMM), Finland
- Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan
- Hôpital Privé DrômeArdèche - Clinique Pasteur, Guilhaud-Granges, France
- Hôpital Privé Sainte-Marie, Chalon-sur-Saône, France
- Hospital Bichat, Paris, France
- Howard University, Washington, D.C., U.S.A.
- Human Genome Center, Japan
- Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan
- Icahn School of Medicine at Mount Sinai, New York, NY, U.S.A.
- Ichiro Kanehara Foundation, Promotion of Medical Science and Medical Care, Japan
- IC-MedTech Co., San Diego, CA, U.S.A.
- Iizuka Hospital, Fukuoka, Japan
- Inje University Busan Paik Hospital, Busan, Republic of Korea
- Innovative Medicines Initiative, Brussels, Belgium
- Institut Jean Godinot, Reims, France
- Institute for Experimental Surgery, University of Rostock, Rostock, Germany
- Institute of Biomathematics, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
- Institute of Cytology and Genetics, Novosibirsk, Russia
- Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University, Prague, Czech Republic
- Institute of Medical Biometry and Statistics, University of Freiburg, Freiburg im Breisgau, Germany
- Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Institute of Molecular and Cellular Biology, Novosibirsk, Russia
- Instituto de Pesquisa em Fármacos e Medicamentos (IPeFarM), Universidade Federal da Paraíba (UFPB), Brazil
- Intégrale Co., Ltd., Tokushima, Japan
- International Research Network, Thailand Research Fund (TRF), Thailand
- Interreg Deutschland-Danmark, Kiel, Germany
- Intramural Funding of the School of Medicine and Health Sciences, University of Oldenburg, Oldenburg, Germany
- Intramural Research Program, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A.
- Inui Immunotherapy Clinic, Osaka, Japan
- Iran National Scientific Foundation (INSF), Iran
- I-Shou University, Kaohsiung, Taiwan, R.O.C.
- Italian Association of Radiation Oncology (AIRO) Group for Gastrointestinal Cancer, Italy
- Italian Ministry of Health, Italy
- Jane and Aatos Erkkö Foundation, Finland
- Japan Agency for Medical Research and Development (AMED), Tokyo, Japan

- Japan Science and Technology Agency (JST), Kawaguchi, Japan
- Japanese Respiratory Foundation, Tokyo, Japan
- Japanese Society for Radiation Oncology, Japan
- JCHO Kyushu Hospital, Kitakyushu, Japan
- Jikei University School of Medicine, Tokyo, Japan
- K2M Group, Leesburg, VA, U.S.A.
- Kanagawa Cancer Center Hospital-Research Institute, Kanagawa, Japan
- Kanzawa Medical Research Foundation, Yoshino, Japan
- Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, R.O.C.
- Karolinska Institute, Stockholm, Sweden
- Kawaguchi Municipal Medical Center, Kawaguchi, Japan
- Kawasaki Medical School General Medical Center, Okayama, Japan
- Kawasaki Medical School, Kurashiki, Japan
- K-computer, RIKEN Advanced Institute for Computational Science, HPCI System Research Project, Japan
- Khon Kaen University Research Fund, Khon Kaen, Thailand
- Khon Kaen University, Khon Kaen, Thailand
- KI.EI.OTO.YO Support Foundation, MSD Life Science Foundation, Astellas Research Support, Astellas Pharma Inc., Tokyo, Japan
- Kissei Pharmaceutical Co. Ltd., Matsumoto, Japan
- Kitakyushu Municipal Medical Center, Kitakyushu, Japan
- KKU Publication Clinic, Thailand
- Knut & Alice Wallenberg Foundation, Uppsala, Sweden
- Kobe University, Kobe, Japan
- Kocaeli University, Izmit, Turkey
- Korea Chemical Ban, Korea Research Institute of Chemical Technology, Republic of Korea
- Korea Health Technology R&D Project, Korea Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Seoul, Republic of Korea
- Korea Institute of Oriental Medicine (KIOM), Republic of Korea
- Korea Institute of Radiological and Medical Sciences (KIRAMS), Ministry of Science, ICT and Future Planning (MSIP), Gwacheon, Republic of Korea
- Korea National University of Transportation, Chungju, Republic of Korea
- Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea
- Korea University Grant, Seoul, Republic of Korea
- Korean Research Institute of Bioscience and Biotechnology Research Initiative Program (KRIBB), Republic of Korea
- Kuopio University Hospital Research Foundation, Kuopio, Finland
- Kuwait University, Seoul, Republic of Korea
- Kyoto Pharmaceutical University, Kyoto, Japan
- Kyung Hee University, Seoul, Republic of Korea
- Kyungpook National University Hospital, Daegu, Republic of Korea
- Kyushu Breast Cancer Study Group, Fukuoka, Japan
- Kyushu Central Hospital, Fukuoka, Japan
- Laboratório Central de Microscopia Eletrônica (LCME), Universidade Federal de Santa Catarina (UFSC), Florianópolis, SC, Brazil
- Laboratório de Tecnologia Mineral e Ambiental (LTM), Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
- Laboratório Multiusuários de Estudos em Biologia (LAMEB), Centro de Ciências Biológicas (CCB), Universidade Federal de Santa Catarina (UFSC), Florianópolis, SC, Brazil
- Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Hellenic Cooperative Oncology Group, Aristotle University of Thessaloniki, Greece
- Laboratory of Natural Products (LPN), Universidade Federal do Piauí (UFPI), Teresina, Brazil
- Leading Graduate Schools, Cultivating Global Leaders in Heavy-Ion Therapeutics and Engineering, Japan
- LEO Foundation, Copenhagen, Denmark
- Lindhés Advokatbyrå AB, Stockholm, Sweden
- Lion's 5M Hearing Center Grant, Minneapolis, MN, U.S.A.
- Lithuanian Research Council, Lithuania
- Macrophi Inc., Kagawa, Japan
- Mahidol University, Salaya, Thailand
- Marmara University Scientific Research Projects, Istanbul, Turkey
- Mayo Clinic Center for Individualized Medicine, Rochester, MN, U.S.A.
- Medical Centre Rotterdam, Rotterdam, the Netherlands
- Medical Faculty, University of Pecs, Pecs, Hungary
- Medical Research Center (MRC) Program, National Research Foundation of Korea (NRF), Republic of Korea
- Medical Research Core Facilities Center, Office of Research & Development, China Medical University, Taichung, Taiwan, R.O.C.
- Medical Research Council (MRC), London, U.K.
- Medical Science Research Institute Grant, Kyunghee University Hospital, Gangdong, Republic of Korea

- Medical University of Bialystok, Bialystok, Poland  
 Medical University of Gdansk, Gdansk, Poland  
 Medical University of Lublin, Lublin, Poland  
 Medical University Science Park in Košice, Slovakia  
 Medicinal Plants Research Center (NPPM), Federal  
 University of Piauí, Teresina, Brazil  
 Medtronic plc, Fridley, MN, U.S.A.  
 Merck Serono S.A., Darmstadt, Germany  
 Mesothelioma Applied Research Foundation, Washington,  
 D.C., U.S.A.  
 Middle Tennessee State University, Murfreesboro, TN,  
 U.S.A.  
 Minerva Foundation, Finland  
 Ministério da Ciência e Tecnologia (MCT), Brazil  
 Ministry of Education and Science of the Russian  
 Federation  
 Ministry of Education, Culture, Sports, Science and  
 Technology (MEXT), Tokyo, Japan  
 Ministry of Education, Youth and Sports of the Czech  
 Republic  
 Ministry of Health and Welfare, Taiwan, R.O.C.  
 Ministry of Health of the Czech Republic  
 Ministry of Innovation and Technology, Hungary  
 Ministry of Science and Technology, Taiwan, R.O.C.  
 Ministry of Science, ICT & Future Planning (MSIP),  
 Republic of Korea  
 Minor Equipment Grant WHC Dividend, Faculty of Health  
 Sciences, University of the Witwatersrand, Johannesburg,  
 South Africa  
 Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan
- Nagasaki University Hospital, Nagasaki, Japan  
 Nanjing Medical Science and Technology Development  
 Foundation, P.R. China  
 National Cancer Institute (NCI), National Institutes of  
 Health, Department of Health and Human Services,  
 Bethesda, MD, U.S.A.  
 National Cancer Research Institute, Tokyo, Japan  
 National Center for Advancing Translational Sciences  
 (NCATS), National Institutes of Health, Department of  
 Health and Human Services, Bethesda, MD, U.S.A.  
 National Center for Research and Development, Warsaw,  
 Poland  
 National Centre for Research and Development  
 Strategmed, Poland  
 National Clinician Scholars Program, Duke University,  
 Durham, NC, U.S.A.  
 National Health and Medical Research Council of Australia  
 National Health Research Institute, Taiwan, R.O.C.
- National Hospital Organization Osaka National Hospital,  
 Osaka, Japan  
 National Institute for General Medical Science (NIGMS),  
 National Institutes of Health (NIH), Department of  
 Health and Human Services, Bethesda, MD, U.S.A.  
 National Institute of Minority Health and Health  
 Disparities (NIMHD), NIH, Bethesda, MD, U.S.A.  
 National Institute of Nursing Research, National Institutes  
 of Health (NIH), Bethesda, MD, U.S.A.  
 National Institutes of Health (NIH), Department of Health  
 and Human Services, Bethesda, MD, U.S.A.  
 National Natural Science Foundation of China  
 National Research Foundation (NRF)-Thuthuka Grant,  
 Pretoria, South Africa  
 National Science Centre Grant Opus, Poland  
 Natural Science Foundation of Guangxi, P.R. China  
 Nelson Mandela University, Port Elizabeth, South Africa.  
 Newton Advanced Fellowship, Thailand Research Fund,  
 Thailand  
 Nihon University, Chiyoda, Japan  
 Nikkyoko Research Award, Japan  
 Norwegian University of Science and Technology (NTNU),  
 Trondheim, Norway  
 Novartis International AG, Basel, Switzerland  
 Novartis Oncology (Hellas), Athens, Greece  
 Novartis Pharma GmbH, Nuremberg, Germany
- Ogata Foundation, Japan  
 Ohio State University College of Pharmacy, Columbus,  
 OH, U.S.A.  
 OHSU Knight BioLibrary, Portland, OR, U.S.A.  
 OHSU Knight Diagnostic Laboratories, Portland, OR,  
 U.S.A.  
 Oita Cancer Research Foundation, Oita, Japan  
 Oita Red Cross Hospital, Oita, Japan  
 Okayama University Graduate School of Medicine,  
 Dentistry and Pharmaceutical Sciences, Okayama, Japan  
 Onassis Foundation, Athens, Greece  
 Oncodesign, France  
 Oncology Department, University of Oxford, Oxford, U.K.  
 Oncolyze Inc., New York, NY, U.S.A.  
 Ono pharmaceutical Co., Ltd, Osaka, Japan  
 Opal Oncology Ltd., Cambridge, U.K.  
 Operational Programme “Innovative Economy”, European  
 Regional Development Fund (ERDF), European Union  
 Operational Programme Competitiveness, Entrepreneurship  
 and Innovation (EPAnEK), European Union  
 Operational Programme Research, Development and  
 Education (OP RDE), European Union

- Organic Synthesis Shared Resource, Penn State Cancer Institute, Hershey, PA, U.S.A.
- Osaka City University Graduate School of Medicine, Osaka, Japan
- Osaka City University Hospital, Osaka, Japan
- Osaka General Medical Center, Osaka, Japan
- Oulu University Hospital MRC Grant, Oulu, Finland
- Päivikki ja Sakari Sohlberg Foundation, Helsinki, Finland
- Palacky University Olomouc, Olomouc, Czech Republic
- Penn State Hershey Milton S. Hershey Medical Center, Hershey, PA, U.S.A.
- Pharma Crea Kobe Co.Ltd., Kobe, Japan
- PharmaMar, Colmenar Viejo, Spain
- Picower Institute, Massachusetts Institute of Technology, Cambridge, MA, U.S.A.
- Plastic Surgery Foundation, Arlington Heights, IL, U.S.A.
- Polish Adult Leukemia Group (PALG), Poland
- Polish Ministry of Science and Higher Education
- Polish National Science Center
- Polka Dot Mama Melanoma Foundation, Cary, NC, U.S.A.
- Priority Issue on Post-K Computer, Tokyo, Japan
- Programa de Apoio a Núcleos Emergentes (PRONEM), Brazil
- Programa Institucional de Formação de Investigadores del IPN (PIFI), Mexico
- Programa Operacional Capital Humano (POCH), Portugal
- Project for Cancer Research and Therapeutic Evolution (P-CREATE), Japan Agency for Medical Research and Development (AMED), Tokyo, Japan
- Pró-Saúde Associação Beneficente de Assistência Social e Hospitalar, Brazil
- Public Trust Surgery Research Fund, Japan
- QST Hospital, Chiba, Japan
- Quantum and Radiological Science and Technology (QST), National Institute of Radiological Sciences (NIRS), Chiba, Japan
- Radiumhospitalets Legater, Oslo, Norway
- Ratchadaphiseksomphot Fund, Chulalongkorn University, Bangkok, Thailand
- RayVio Corp., Hayward, CA, U.S.A.
- Research Administration, Kuwait University Research Grant, Kuwait City, Kuwait
- Research Center for Molecular Medicine, Analysis Center of Life Science, Faculty of Medicine, Hiroshima University, Hiroshima, Japan
- Research Fund of Istanbul University, Istanbul, Turkey
- Research Fund of the Department of Medical Research, China Medical University Hospital, Taichung, Taiwan, R.O.C.
- Research Fund of Tung's Taichung Metro Harbor Hospital, Taichung, Taiwan, R.O.C.
- Research in Design for Discovery Within Learning Environments (RIDDLE Lab), New York, NY, U.S.A.
- Research Incentive Fund, Fundo de Incentivo à Pesquisa e Eventos (FIPE), Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil
- Research Institute for Convergence of Biomedical Science and Technology Grant, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea
- Research Instrument Center, Khon Kaen University, Khon Kaen, Thailand
- Research Project with Heavy Ions, National Institute of Radiological Sciences, Technology of Japan, Chiba, Japan
- Research Resettlement Fund, Seoul National University, Seoul, Republic of Korea
- Research Support Center, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
- Réseau de recherche sur le cancer, Canada
- Roche S.A.S., Paris, France
- Roswell Country Club Prostate Cancer Research Award, Winship Cancer Institute, Emory University, Atlanta, GA, U.S.A.
- Roswell Park Cancer Institute, Buffalo, NY, U.S.A.
- Royal College of Surgeons of England, London, U.K.
- Royal Society, Bangkok, Thailand
- Russian Ministry of Science and High Education
- Ryukyu Society for the Promotion of Oto-Rhino-Laryngology, Japan
- S&P GmbH, Augsburg, Germany
- Sagara Hospital, Alappuzha, India
- Saudi Arabian Ministry of Education
- Science Achievement Scholarship, Thailand
- Science of Health Care Delivery, Robert D. and Patricia E. Kern Center, Rochester, MN, U.S.A.
- Scientific Cancer Cell Biology Group, Wroclaw Medical University, Wroclaw, Poland
- Screening Laboratory of Biological Activity Test and Collection of Biological Material, Faculty of Pharmacy, Division of Laboratory Diagnostics, Wroclaw Medical University, Wroclaw, Poland
- Senior Research Scholar Grant, Thailand Research Fund, Bangkok, Thailand
- Seoul National University Hospital (SNUH) Research Fund, Seoul, Republic of Korea

- SGH Foundation, Japan  
 Shinshu Medical Foundation, Matsumoto, Japan  
 Shizuoka Cancer Center Hospital, Shizuoka, Japan  
 Shizuoka Prefectural Government, Japan  
 Showa University, Shinagawa, Japan  
 Sigma Zeta National Science & Mathematics Honor Society Student Research Award, Lebanon, IL, U.S.A.  
 Sigrid Jusélius Foundation, Finland  
 Sistema Nacional de Investigadores (SNI), Mexico City, Mexico  
 Slovak Grant Agency, Bratislava, Slovakia  
 Slovak Research and Development Agency, Bratislava, Slovakia  
 Smoking Research Foundation, Japan  
 Social Hearth Corporation Foundation Pond Friends Association, Fukuoka Wajiro Hospital, Fukuoka, Japan  
 Soonchunhyang University Research Fund, Asan, Republic of Korea  
 St. Luke's International University, Tokyo, Japan  
 Statutory Funds, Department of Molecular and Cellular Biology, National Science Centre, Warsaw, Poland  
 Stellenbosch University, Stellenbosch, South Africa  
 Stockholm Cancer Society, Stockholm, Sweden  
 Stockholm City Council, Stockholm, Sweden  
 Strategic Promotion for Practical Application of Innovative Medical Technology (TR-SPRINT), Japan  
 Strategic Research Council of Denmark, Denmark  
 Stroke Grant  
 Styrian Business Promotion Agency (SFG), Graz, Austria  
 Sunplanet Co., Ltd., Tokyo, Japan  
 Supercomputer System, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan  
 Support Centre for Medical Research and Education, Tokai University, Tokyo, Japan  
 Swedish Cancer and Allergy Foundation, Sweden  
 Swedish Cancer Foundation, Sweden  
 Swedish Cancer Society, Sweden  
 Swedish Childhood Cancer Fund, Sweden  
 Swedish Heart and Lung Foundation, Sweden  
 Swedish Research Council, Sweden  
 Szegeed Foundation for Cancer Research, Szegeed, Hungary
- Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.  
 Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.  
 Taiho Pharmaceutical Co., Ltd., Tokyo, Japan  
 Taipei Municipal Wanfang Hospital, Taipei, Taiwan, R.O.C.  
 Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei, Taiwan, R.O.C.
- Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.  
 Taiwan Ministry of Science and Technology  
 Takeda Foundation for Medical Science, Japan  
 Takeda Science Foundation, Japan  
 Taoyuan General Hospital, Ministry of Health and Welfare, Taipei, Taiwan, R.O.C.  
 Taussig Cancer Center Bridge Grant Program, Cleveland, OH, U.S.A.  
 Tella Inc., Tokyo, Japan  
 Thailand Research Fund, Bangkok, Thailand  
 Thailand Science Research and Innovation, Thailand  
 Research Fund, Bangkok, Thailand  
 Thammasat University, Bangkok, Thailand  
 The Cancer Foundation of Northern Savo, Finland  
 The City University of New York, New York, NY, U.S.A.  
 The Elsa U. Pardee Foundation, Midland, MI, U.S.A.  
 The Finnish Cultural Foundation, Finland  
 The Second Century Fund (C2F), Thailand  
 Thomas Jefferson University, Philadelphia, PA, U.S.A.  
 Tissue Bank, China Medical University, Taichung, Taiwan, R.O.C.  
 Tokai University School of Medicine Research Aid, Tokyo, Japan  
 Tokushima University Graduate School, Tokushima, Japan  
 Tokyo Association for Clinical Surgery, Tokyo, Japan  
 Tokyo Medical University, Tokyo, Japan  
 Tokyo Shinagawa Hospital, Tokyo, Japan  
 Tokyo University of Science, Tokyo, Japan  
 TPP Global Development, Edinburgh, U.K.  
 Translational Research Laboratory, Taiho Pharmaceutical Co., Ltd., Tokyo, Japan  
 Translational Research Program, Japan  
 Tsukuba Research Laboratories, Eisai Co., Ltd., Ibaraki, Japan
- UC Davis Paul Calabresi Career Development Award for Clinical Oncology, National Cancer Institute/National Institutes of Health, Bethesda, MD, U.S.A.  
 Unidad de Investigación Médica en Enfermedades Oncológicas (UIMEO), Mexico City, Mexico  
 Unidad de Servicio de Apoyo a la Investigación y a la Industria (USAI), Faculty of Chemistry, National Autonomous University of Mexico (UNAM), Mexico City, Mexico  
 Unidade de Investigação em Epidemiologia (EPIUnit), Instituto de Saúde Pública da Universidade do Porto (ISPUP), Porto, Portugal  
 United States Patent and Trademark Office (USPTO), Alexandria, VA, U.S.A.

University Hospital Pilsen, Pilsen, Czech Republic  
University Hospital Sharjah, Sharjah, United Arab Emirates  
University of Adelaide, Adelaide, Australia  
University of Alabama at Birmingham (UAB) Flow  
Cytometry Core, Birmingham, AL, U.S.A.  
University of Pecs, Pecs, Hungary  
University of South Florida (USF) Research Computing,  
Tampa, FL, U.S.A.  
University of the Witwatersrand, Johannesburg, South  
Africa  
University of Tokushima Graduate School, Tokushima, Japan  
University of Tokyo, Tokyo, Japan  
University of Tsukuba, Tsukuba, Japan  
UNT Health Science Center (UNTHSC), Fort Worth, TX,  
U.S.A.  
URC Grant, University Research Committee, University of  
the Witwatersrand, Johannesburg, South Africa  
Veterans Administration Merit Awards, Washington, DC,  
U.S.A.

Vienna Business Agency, Vienna, Austria  
Wake Forest University, Winston-Salem, NC, U.S.A.  
Walailak University, Nakhon Si Thammarat, Thailand  
Western University of Health Sciences, Pomona, CA,  
U.S.A.  
Wilhelm-Sander Foundation, Munich, Germany  
Wroclaw Centre of Biotechnology, Wroclaw, Poland  
Wroclaw Medical University, Wroclaw, Poland  
Yamaga City Medical Center, Yamaga, Japan  
Yamaguchi Rosai Hospital, Sanyo-Onoda, Japan  
Yao Municipal Hospital, Osaka, Japan  
Yen Tjing Ling Medical Foundation, Taipei, Taiwan,  
R.O.C.  
Yokohama Surgical Research Group, Yokohama,  
Japan  
Yoshiki Dermatology Clinic Ginza, Tokyo, Japan  
Zeincro Hellas, Athens, Greece

## Contents, Volume 40, 2020

### Number 1, January

#### Review

- Current Treatment of Colorectal Liver Metastasis as a Chronic Disease. N.M. DÖRR, M. BARTELS, M.H. MORGUL (*Leipzig; Münster, Germany*)..... 1

#### Experimental Studies

- SAHA and EGCG Promote Apoptosis in Triple-negative Breast Cancer Cells, Possibly Through the Modulation of cIAP2. K.L. STEED, H.R. JORDAN, T.O. TOLLEFSBOL (*Birmingham, AL, USA*) ..... 9

- Genetic Polymorphisms in IL-10 Promoter Are Associated With Smoking and Prostate Cancer Risk in African Americans. M. ABBAS, T. MASON, A. IBAD, M. KHRAIWESH, V. APPREY, Y. KANAAN, B. WILSON, G. DUNSTON, L. RICKS-SANTI, H. BRIM (*Washington, DC; Silver Spring, MD; Hampton, VA, USA*)..... 27

- High Expression of *c-Met*, *PKCλ* and *ALDH1A3* Predicts a Poor Prognosis in Late-stage Breast Cancer. H. MOTOMURA, Y. NOZAKI, C. ONAGA, A. OZAKI, S. TAMORI, T.-A. SHIINA, S. KANAI, C. OHIRA, Y. HARA, Y. HARADA, R. TAKASAWA, T. HANAWA, S.-I. TANUMA, Y. MANO, T. SATO, K. SATO, K. AKIMOTO (*Chiba, Japan*)..... 35

- Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines. S. HOLZHAUSER, M. LUKOSEVICIUTE, T. ANDONOVA, R.G. URSU, T. DALIANIS, M. WICKSTRÖM, O.N. KOSTOPOULOU (*Stockholm, Sweden; Iasi, Romania*) ..... 53

- Cisplatin Induced the Expression of *SEI1 (TRIP-Br1)* Oncogene in Human Oral Squamous Cancer Cell Lines. J. LI, Z. VANGUNDY, M. POI (*Columbus, OH, USA*)..... 67

- Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer. T. KIJIMA, T. ARIGAMI, Y. UENOSONO, T. HIRAKI, S. YANAGITA, D. MATSUSHITA, K. OKUBO, M. SHIMONOSONO, S. ISHIGAMI, K. MAEMURA, A. TANIMOTO, S. NATSUGOE (*Kagoshima, Japan*)..... 75

- Prognostic Significance of ZKSCAN3 (ZNF306) Expression in Gastric Carcinoma. Y. TAKANO, A. SHIDA, M. FUJISAKI, N. MITSUMORI, K. YANAGA (*Tokyo, Japan*)..... 81

- Further Quantitative Structure–Cytotoxicity Relationship Analysis of 3-Styrylchromones. K. TAKAO, K. HOSHI, H. SAKAGAMI, H. SHI, K. BANDOW, J. NAGAI, Y. UESAWA, A. TOMOMURA, M. TOMOMURA, Y. SUGITA (*Saitama; Tokyo; Chiba, Japan; Shanghai, PR China*)..... 87

- Chronic Expanding Hematoma with a t(11;19)(q13;q13) Chromosomal Translocation. I. PANAGOPOULOS, L. GORUNOVA, I. KOSTOLOMOV, I. LOBMAIER, B. BJERKEHAGEN, S. HEIM (*Oslo, Norway*)..... 97

- Assessment of the Changes in Mitochondrial Gene Polymorphism in Ulcerative Colitis and the Etiology of Ulcerative Colitis-associated Colorectal Cancer. T. TANAKA, T. KOBUNAI, Y. YAMAMOTO, K. MURONO, S. EMOTO, M. HIYOSHI, M. KANEKO, K. SASAKI, Y. SHUNO, T. NISHIKAWA, K. HATA, K. KAWAI, H. NOZAWA, S. ISHIHARA (*Tokyo, Japan*)..... 101

- Taxotere Induces Dephosphorylation of MET in Patient-derived Tumor Models. H. MUN, S.-H. LEE, C.-H. LEE, S.-Y. JO, J.-H. OH, A. LEE, B. LEE, S.J. JANG, Y.-A. SUH (*Seoul; Daegu, Republic of Korea*)..... 109

- Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis. H. YAMANA, K. KATO, H. KOBARA, S. FUJIHARA, K. FUJITA, D. NAMIMA, N. FUJITA, K. KOBAYASHI, H. KAMADA, A. MORISHITA, K. TSUTSUI, H. IWAMA, T. MASAKI (*Kagawa, Japan*) ..... 121



PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines. J. LI, Z. VANGUNDY, M. POI ( <i>Columbus, OH, USA</i> ).....	133
Serum Adiponectin Levels Do Not Distinguish Primary from Metastatic Liver Tumors. S. FEDER, A. KANDULSKI, D. SCHACHERER, T.S. WEISS, C. BUECHLER ( <i>Regensburg, Germany</i> ).....	143
Galloflavin Plus Metformin Treatment Impairs Pancreatic Cancer Cells. E.H.U. WENDT, M. SCHOENROGGE, B. VOLLMAR, D. ZECHNER ( <i>Rostock, Germany</i> ).....	153
Development of a Novel Oncolytic Adenovirus Expressing a Short-hairpin RNA Against Cullin 4A. K. WAKABAYASHI, F. SAKURAI, R. ONO, T. FUJIWARA, H. MIZUGUCHI ( <i>Osaka; Okayama, Japan</i> ).....	161
Characterization of CD44-positive Cancer Stem-like Cells in COLO 201 Cells. H. OKUYAMA, W. NOGAMI, Y. SATO, H. YOSHIDA, Y. TONA, Y. TANAKA ( <i>Fukuoka; Osaka, Japan</i> ).....	169
COUP-TFII Knock-down Promotes Proliferation and Invasion in Colorectal Cancer Cells via Activation of Akt Pathway and Up-regulation of FOXC1. S.-H. YUN, S.-H. HAN, J.-I. PARK ( <i>Busan, Republic of Korea</i> ).....	177
Circulating Tumor DNA in Saliva in an Orthotopic Head and Neck Cancer Mouse Model. Y.-G. EUN, Y.J. YOON, K.Y. WON, Y.C. LEE ( <i>Seoul, Republic of Korea</i> ).....	191
The Significance of Molecular Biomarkers on Clinical Survival Outcome Differs Depending on Colon Cancer Sidedness. S. HIRABAYASHI, M. HAYASHI, G. NAKAYAMA, S. MII, N. HATTORI, H. TANABE, M. KANDA, C. TANAKA, D. KOBAYASHI, S. YAMADA, M. KOIKE, M. FUJIWARA, M. TAKAHASHI, Y. KODERA ( <i>Nagoya, Japan</i> ).....	201
Kisspeptin Promotes Glioblastoma Cell Invasiveness Via the Gq-PLC-PKC Pathway. T.-H. KIM, J.H. YOON, S.-G. CHO ( <i>Chungbuk, Republic of Korea</i> ).....	213
Chronic Stimulation of the Autophagy-inducing Ingredient of Areca Nut Promotes Tumor Growth <i>In Vivo</i> Through Up-regulation of Tumoral Autophagy. C.-T. CHIU, S.-Y. LIU, C.-Y. YEN, B.-Y. LIU, Z.-Y. SUN, C.-Y. WU, J.-L. DENG, Y.-C. LIU, M.-H. LIN ( <i>Tainan; Taipei; Kaohsiung, Taiwan, ROC</i> ).....	221
<i>In Vitro</i> Analysis of the Combinatory Effects of Novel Aminonaphthoquinone Derivatives and Curcumin on Breast Cancer Progression. M.C. PEREIRA, R. MOHAMMED, W.A.L. VAN OTTERLO, C.B. DE KONING, H. DAVIDS ( <i>Port Elizabeth; Johannesburg; Western Cape, South Africa</i> ).....	229
Expression Level of MicroRNA-449a Predicts the Prognosis of Patients With Gastric Cancer. D. ISHIKAWA, K. YOSHIKAWA, C. TAKASU, H. KASHIHARA, M. NISHI, T. TOKUNAGA, J. HIGASHIJIMA, M. SHIMADA ( <i>Tokushima, Japan</i> ).....	239
<i>Clinical Studies</i>	
High Rate of Detection of Human ESPL1-HBV S Fusion Gene in Patients With HBV-related Liver Cancer: A Chinese Case-Control Study. B. HU, W. HUANG, R. WANG, W. ZANG, M. SU, H. LI, H. WANG, B. CAO, D. DENG, Q.Q. LI, J. JIANG ( <i>Nanning; Hefei, PR China; Bethesda, MD, USA</i> ).....	245
The Rectus Sheath Block (RSB) Analgesia Following Laparotomy Could Affect Malondialdehyde (MDA) Concentrations in Benign Disease and Cancer. M. RUOTTINEN, V. KUOSMANEN, I. SAIMANEN, V. KAARONEN, D. RAHKOLA, A. HOLOPAINEN, T. SELANDER, H. KOKKI, M. KOKKI, M. ESKELINEN ( <i>Kuopio, Finland</i> ).....	253
Prognostic Significance of Tumor Immunity in Surgically Resected Pulmonary Pleomorphic Carcinoma. K. KAIRA, K. SHIMIZU, H. ENDOH, K. IMAIZUMI, M. KAMIYOSHIHARA, M. SUGANO, O. KAWASHIMA, S. TANAKA, A. FUJITA, H. IMAI, Y. KOGURE, T. OYAMA, T. ASAO, K. SHIRABE ( <i>Maebashi; Saitama; Saku; Toyoake; Maebashi; Takasaki; Shibukawa; Isesaki; Ota; Nagoya, Japan</i> ).....	261

Prediction of Tumor Grade and Nodal Status in Oropharyngeal and Oral Cavity Squamous-cell Carcinoma Using a Radiomic Approach. V. ROMEO, R. CUOCOLO, C. RICCIARDI, L. UGGA, S. COCOZZA, F. VERDE, A. STANZIONE, V. NAPOLITANO, D. RUSSO, G. IMPROTA, A. ELEFANTE, S. STAIBANO, A. BRUNETTI (Naples, Italy).....	271
Evaluation of Concordance Between Histopathological, Radiological and Biomolecular Variables in Breast Cancer Neoadjuvant Treatment. O.C. BUONOMO, A. GRASSO, C.A. PISTOLESE, L. ANEMONA, I. PORTARENA, R. MEUCCI, L. MORANDO, C. DEIANA, M. MATERAZZO, G. VANNI (Rome, Italy) .....	281
A Disease-specific Score for Estimating Survival After Irradiation of Bone Metastases from Colorectal Cancer. R. HAUS, S. JANSSEN, S.E. SCHILD, D. RADES (Lübeck; Hannover, Germany; Scottsdale, AZ, USA).....	287
Prognostic Factors in Patients With Recurrent Pancreatic Cancer: A Multicenter Database Analysis. K. FURUKAWA, H. SHIBA, R. HAMURA, K. HARUKI, Y. FUJIWARA, T. USUBA, Y. NAKABAYASHI, T. MISAWA, T. OKAMOTO, K. YANAGA (Tokyo; Saitama; Chiba, Japan) .....	293
Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin. D. WATANABE, H. FUJII, Y. YAMADA, H. IIHARA, T. ISHIHARA, N. MATSUHASHI, T. TAKAHASHI, K. YOSHIDA, A. SUZUKI (Gifu, Japan).....	299
Management of Cancer-associated Thrombosis (CAT): Symptomatic or Incidental. P. PPAKOTOUULAS, N. TSOUKALAS, A. CHRISTOPOULOU, A. ARDAVANIS, G. KOUMAKIS, C. PAPANDREOU, G. PAPATSIMPAS, P. PPAKOSTAS, G. SAMELIS, C. ANDREADIS, G. ARAVANTINOS, N. ZIRAS, C. KALOFONOS, E. SAMANTAS, M. SOUGGLERI, P. MAKRANTONAKIS, G. PENTHEROUDAKIS, A. ATHANASIADIS, H. STERGIU, S. TRIPODAKI, A. BOKAS, A. GRIVAS, E. TIMOTHEADOU, E. BOURNAKIS, I. VARTHALITIS, I. BOUKOVINAS (Thessaloniki; Athens; Patras; Larissa; Kifissia; Piraeus; Ioannina, Greece) .....	305
The Use of Magnetic Seeds and Radiofrequency Identifier Tags in Breast Surgery for Non-palpable Lesions. S. TAYEH, R. GERA, N. PERRY, M. MICHELL, A. MALHOTRA, K. MOKBEL (London, UK).....	315
Papuanine Inhibits Viability of Non-small Cell Lung Cancer Cells by Inducing Mitochondrial Dysfunction. H.-Y. MIN, Y. JUNG, K.H. PARK, H.-Y. LEE (Seoul, Republic of Korea) .....	323
Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel. M. SHIOTA, M. NAKAMURA, A. YOKOMIZO, T. TOMODA, N. SAKAMOTO, N. SEKI, S. HASEGAWA, T. YUNOKI, M. HARANO, K. KUROIWA, M. ETO (Fukuoka; Oita; Kitakyushu; Miyazaki, Japan).....	335
Role of COX2 as a Biomarker for Estimating Survival of Patients With Clinical Stage I Gastric Cancer. H.J. YOO, T.J. KIM, D.J. KIM, W. KIM (Seoul, Republic of Korea) .....	341
The FSHR Expression in Head and Neck Squamous Cell Cancer. A Pilot Immunohistochemical Study. T. OLEJAR, D. VETVICKA, J. BOUCEK, M. ZABRODSKY, J. BENES, M. KABESOVA, P. POUCKOVA (Prague, Czech Republic) .....	349
The Role of Anthracyclines in Acute Myeloid Leukemia Consolidation. J.M. BYUN, J.-O. LEE, K.J. SUH, J. LEE, D.-Y. SHIN, Y. KOH, J. HONG, S.-M. BANG, I. KIM, S.-S. YOON (Seoul; Seongnam, Republic of Korea).....	357
A Simple Clinical Instrument to Predict the Survival Probability of Breast Cancer Patients Receiving Radiotherapy for Bone Metastases. S. JANSSEN, R. HAUS, S.E. SCHILD, D. RADES (Lübeck; Hannover, Germany; Scottsdale, AZ, USA) .....	367
Evaluation of Anastomosis With ICG Fluorescence Method Using VISERA ELITE2 During Laparoscopic Colorectal Cancer Surgery. S. RYU, K. SUWA, T. KITAGAWA, M. AIZAWA, T. USHIGOME, T. OKAMOTO, K. ETO, K. YANAGA (Tokyo, Japan) .....	373

Safety and Efficacy of Carbon-ion Radiotherapy Alone for Stage III Non-small Cell Lung Cancer. M. ANZAI, N. YAMAMOTO, K. HAYASHI, M. NAKAJIMA, A. NOMOTO, K. OGAWA, H. TSUJI ( <i>Osaka; Chiba, Japan</i> ).....	379
Is there a Role for the Appleby Procedure in 2020? Results from a Matched-Pair-Analysis. T. MALINKA, L. TIMMERMANN, F. KLEIN, D. GEISEL, J. PRATSCHKE, M. BAHRA ( <i>Berlin, Germany</i> ).....	387
Pulmonary Oligometastases Treated by Stereotactic Body Radiation Therapy: A Nationwide Survey of 1,378 Patients. Y. NIIBE, T. YAMAMOTO, H. ONISHI, H. YAMASHITA, K. KATSUI, Y. MATSUMOTO, R.-J. OH, M. AOKI, T. SHINTANI, K. YAMADA, M. KOBAYASHI, M. OZAKI, Y. MANABE, K. YAHARA, A. NISHIKAWA, H. KAKUHARA, K. YAMAMOTO, T. INOUE, Y. TAKADA, K. NAGATA, O. SUZUKI, A. TERAHARA, K. JINGU ( <i>Tokyo; Okayama; Sendai; Yamanashi; Niigata; Osaka; Hirosaki; Kyoto; Sapporo; Shizuoka; Hiroshima; Nagoya; Fukuoka; Ehime; Iwate; Nagasaki, Japan</i> ).....	393
Clip on Staple Method to Prevent Bile Leakage in Anatomical Liver Resection Using Stapling Devices. M. NINOMIYA, T. TOMINO, R. MATONO, T. NISHIZAKI ( <i>Ehime, Japan</i> ).....	401
The Impact of Intraoperative Blood Loss on the Long-term Prognosis after Curative Resection for Borrmann Type IV Gastric Cancer: A Retrospective Multicenter Study. H. TAMAGAWA, T. AOYAMA, K. KANO, M. NUMATA, Y. ATSUMI, K. HARA, K. KAZAMA, K. KOUMORI, M. MURAKAWA, I. HASHIMOTO, Y. MAEZAWA, T. YAMADA, N. YUKAWA, T. YOSHIKAWA, M. MASUDA, T. OSHIMA, Y. RINO ( <i>Yokohama; Tokyo, Japan</i> ) .....	405
Application of Cluster Analysis to Distant Metastases from Lung Cancer. H. WATANABE, S. OKAUCHI, H. YAMADA, S. SATO, K. MIYAZAKI, T. KODAMA, H. SATOH, N. HIZAWA ( <i>Tsukuba; Mito; Hitachinaka; Ryugasaki, Japan</i> ).....	413
The Prognosis of Lung Cancer With Different Metastatic Patterns. S. OKAUCHI, H. WATANABE, H. YAMADA, S. SATO, K. MIYAZAKI, T. KODAMA, H. SATOH, N. HIZAWA ( <i>Mito; Tsukuba; Hitachinaka; Ryugasaki, Japan</i> ).....	421
Efficacy of Anti-PD1/PD-L1 Therapy (IO) in KRAS Mutant Non-small Cell Lung Cancer Patients: A Retrospective Analysis. L. GIANONCELLI, G. SPITALERI, A. PASSARO, D. RADICE, C. FUMAGALLI, E. DEL SIGNORE, V. STATI, C.M. CATANIA, E. GUERINI-ROCCO, M. BARBERIS, F. DE MARINIS ( <i>Milan, Italy</i> ) .....	427
Recurrence-free Survival and Safety of Imatinib in Patients With Gastrointestinal Stromal Tumour (GIST) in Greece. I. BOUKOVINAS, A. KOTSAKIS, N. ANDROULAKIS, G. ARAVANTINOS, V. MICHALAKI, C. CHRISTODOULOU, A. AVGERINOS, C. PAPANDREOU, V. SIDIROPOULOU, O. KOUSIDOU, P. KOSMIDIS ( <i>Thessaloniki; Heraklion; Athens; Piraeus; Larissa, Greece</i> ).....	435
Clinical Influence of Anastomotic Leakage on Esophageal Cancer Survival and Recurrence. T. AOYAMA, K. KAZAMA, Y. ATSUMI, H. TAMAGAWA, A. TAMAGAWA, K. KOMORI, D. MACHIDA, Y. MAEZAWA, K. KANO, K. HARA, M. MURAKAWA, M. NUMATA, T. OSHIMA, N. YUKAWA, M. MASUDA, Y. RINO ( <i>Yokohama, Japan</i> ) .....	443
Prognostic Value of Hematological Parameters in Locally Advanced Cervical Cancer Patients Treated With Concurrent Chemoradiotherapy. H.J. LEE, J.M. KIM, Y.J. CHIN, G.O. CHONG, S.-H. PARK, Y.H. LEE, D.G. HONG, Y.S. LEE ( <i>Daegu, Republic of Korea</i> ).....	451
Comparison of Dose Distributions When Using Carbon Ion Radiotherapy Versus Intensity-modulated Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Retrospective Analysis. S. SHIBA, K. SHIBUYA, M. KAWASHIMA, N. OKANO, T. KAMINUMA, M. OKAMOTO, Y. KUBOTA, T. NAKANO, T. OHNO ( <i>Maebashi, Japan</i> ).....	459

Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1). A. ARCELLI, A. GUIDO, M. BUWENGE, N. SIMONI, R. MAZZAROTTO, G. MACCHIA, F. DEODATO, S. CILLA, P. BONOMO, V. SCOTTI, L. BELGIOIA, G. TOLENTO, F. CELLINI, E. GRASSI, M. DI MARCO, R. CASADEI, A.G. MORGANTI, S. CAMMELLI ( <i>Bologna; Verona; Campobasso; Florence; Pisa; Genoa; Rome, Italy</i> ) .....	465
<b>Proceedings of the Joint International Symposium “Vitamin D in Prevention and Therapy” and “Biologic Effects of Light”, 5-7 June, 2019 (Homburg/Saar, Germany)</b>	
Relevance of Vitamin D in Melanoma Development, Progression and Therapy. A.A. BROŻYNA, R.M. HOFFMAN, A.T. SLOMINSKI ( <i>Toruń, Poland; San Diego, CA; Birmingham, AL, USA</i> ).....	473
Review of Recent Advances in Understanding the Role of Vitamin D in Reducing Cancer Risk: Breast, Colorectal, Prostate, and Overall Cancer. W.B. GRANT ( <i>San Francisco, CA, USA</i> ) .....	491
Sunbeds and Melanoma Risk: Many Open Questions, Not Yet Time to Close the Debate. J. REICHRATH, P.G. LINDQVIST, S. PILZ, W. MÄRZ, W.B. GRANT, M.F. HOLICK, F.R. DE GRUIJL ( <i>Homburg; Heidelberg; Mannheim, Germany; Stockholm, Sweden; Graz, Austria; San Francisco, CA; Boston, MA, USA; Leiden, the Netherlands</i> ) .....	501
Improving Photoprotection and Implications for 25(OH)D Formation. H.C. WULF, P.A. PHILIPSEN ( <i>Copenhagen, Denmark</i> ) .....	511
Recent Developments Towards the Synthesis of Vitamin D Metabolites. L. KATTNER ( <i>Saarbrücken, Germany</i> ) .....	519
Vitamin D in Preclinical Models of Fatty Liver Disease. E. KARATAYLI, C.S. STOKES, F. LAMMERT ( <i>Homburg, Germany</i> ) .....	527
Variable Genomic and Metabolomic Responses to Varying Doses of Vitamin D Supplementation. A. SHIRVANI, T.A. KALAJIAN, A. SONG, R. ALLEN, N. CHAROENNGAM, R. LEWANCZUK, M.F. HOLICK ( <i>Boston, MA, USA; Edmonton, AB, Canada</i> ).....	535
Comparison of Serum 25-Hydroxyvitamin D Levels in Patients With Malignant and Benign Gynaecological Disease. L. KOLNSBERG, M. RIFFELMANN, M. FRIEDRICH ( <i>Krefeld, Germany</i> ).....	545
The Effect of Various Doses of Oral Vitamin D3 Supplementation on Gut Microbiota in Healthy Adults: A Randomized, Double-blinded, Dose-response Study. N. CHAROENNGAM, A. SHIRVANI, T.A. KALAJIAN, A. SONG, M.F. HOLICK ( <i>Boston, MA, USA</i> ) .....	551
Lifetime UVR Dose and Skin Cancer Risk, Determined by Their Common Relation to Solar Lentigines. A.-S.S. HOLM-SCHOU, P.A. PHILIPSEN, L.W. IDORN, E. THIEDEN, H.C. WULF ( <i>Copenhagen, Denmark</i> ).....	557
Evaluation of Effectiveness of Ultraviolet Emitting Lamps on the Cutaneous Production of Vitamin D3: Relationship of the Lamps Vitamin D3 Producing Potential to the Production of 8-Hydroxy-2'-Deoxyguanosine and Nitric Oxide. A. SHIRVANI, K.S. PERSONS, M.F. HOLICK ( <i>Boston, MA, USA</i> ) .....	565
Errata .....	573

**Number 2, February**

*Reviews*

Colorectal Cancer Screening With Traditional and New-generation Fecal Immunochemical Tests: A Critical Review of Fecal Occult Blood Tests. J. MEKLIN, K. SYRJÄNEN, M. ESKELINEN (*Kuopio; Kaarina, Finland; Barretos, Brazil*)..... 575

Association of Vitamin D Receptor Gene Polymorphisms With Melanoma Risk: A Meta-analysis and Systematic Review. M. BIRKE, J. SCHÖPE, S. WAGENPFEIL, T. VOGT, J. REICHRATH (*Homburg, Germany*) ..... 583

Specific Toxicity of Maintenance Olaparib *Versus* Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis. A.D. RICCI, A. RIZZO, M. NOVELLI, S. TAVOLARI, A. PALLONI, N. TOBER, F. ABBATI, V. MOLLICA, S. DE LORENZO, D. TURCHETTI, M. DI MARCO, G. BRANDI (*Bologna, Italy*) ..... 597

C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug Target. P. CHANVORACHOTE, N. SRIRATANASAK, N. NONPANYA (*Bangkok, Thailand*)..... 609

Impact of Anastomotic Leakage on Overall and Disease-free Survival After Surgery for Gastric Carcinoma: A Systematic Review. P. AURELLO, M. CINQUEPALMI, N. PETRUCCIANI, G. MOSCHETTA, L. ANTOLINO, F. FELLI, D. GIULITTI, G. NIGRI, F. D'ANGELO, S. VALABREGA, G. RAMACCIATO (*Rome, Italy*) ..... 619

Primary Angiosarcoma of the Kidney: Literature Review of a Rare Nosologic Entity. A. MASTORAKI, D. SCHIZAS, T. GIANNAKAS, P.P. PAPADOPOULOS, L. NAAR, C. VERGADIS, I. ANASTASIOU, P. VASSILIU, E. PIKOULIS, T. LIAKAKOS (*Athens, Greece*) ..... 625

*Experimental Studies*

APELA/ELA32 Reduces Iodixanol-induced Apoptosis, Inflammatory Response and Mitochondrial and DNA Damage in Renal Tubular Epithelial Cells. Y. LI, J. HUANG, S. HE, Z. LU, J. ZHANG, X. LI, Z. YANG, R.M. HOFFMAN, Q. WU (*Nanchang; Nanjing; Yangzhou, PR China; San Diego, CA, USA*)..... 635

HER2 Gene Amplification in ER-positive HER2 Immunohistochemistry 0 or 1+ Breast Cancer With Early Recurrence. H. YAMASHITA, N. ISHIDA, Y. HATANAKA, K. HAGIO, T. OSHINO, T. TAKESHITA, H. KANNO-OKADA, A. SHIMIZU, K.C. HATANAKA, Y. MATSUNO (*Sapporo, Japan*) ..... 645

PGC-1 $\alpha$  Regulates Cell Proliferation and Invasion via AKT/GSK-3 $\beta$ / $\beta$ -catenin Pathway in Human Colorectal Cancer SW620 and SW480 Cells. S.-H. YUN, J.-I. PARK (*Busan, Republic of Korea*) ..... 653

Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib. K. YAMAMOTO, T. KUZUYA, T. HONDA, T. ITO, Y. ISHIZU, M. NAKAMURA, R. MIYAHARA, H. KAWASHIMA, M. ISHIGAMI, M. FUJISHIRO (*Nagoya, Japan*) ..... 665

Genetic Variations of VEGFA Gene Are Associated With Infiltration of Adjacent Tissues and the Clinical Outcome of Patients With Nasopharyngeal Carcinoma. E. PSOMA, G.-A. KOLIOU, F.-I. DIMITRAKOPOULOS, K. PAPADOPOULOU, D. RONTOGIANNI, M. BOBOS, A. VISVIKIS, P.A. KOSMIDIS, G. FOUNTZILAS, J. CONSTANTINIDIS, A. KALOGERA-FOUNTZILA (*Thessaloniki; Athens; Patras, Greece; Limassol, Cyprus*)..... 677

Delivery of Apoptosis-inducing Piperine to Triple-negative Breast Cancer Cells via Co-polymeric Nanoparticles. J.G. RAD, D.W. HOSKIN (*Halifax, NS, Canada*) ..... 689

The Association of <i>MMP7</i> Promoter Polymorphisms With Gastric Cancer. C.-K. FU, Y.-C. CHIEN, H.-Y. CHUANG, Y.-C. WANG, J.-J. HWANG, M.-D. YANG, C.-C. YU, J.-C. CHEN, W.-S. CHANG, D.-T. BAU, C.-W. TSAI ( <i>Taichung; Kaohsiung; Taipei; Changhua, Taiwan, ROC</i> ) .....	695
The Significant Association of <i>MMP-1</i> Genotypes With Taiwan Pterygium. C.-B. TSAI, N.-Y. HSIA, Y.-C. WANG, Z.-H. WANG, Y.-T. CHIN, T.-L. HUANG, C. YU, W.-S. CHANG, C.-W. TSAI, M.-C. YIN, D.-T. BAU ( <i>Chia-Yi; Taichung, Taiwan, ROC</i> ) .....	703
Expression of Kisspeptin (KISS1) and its Receptor GPR54 (KISS1R) in Prostate Cancer. I. XOYAKOS, C. PETRAKI, P. MSAUEL, A. ARMAKOLAS, A. GRIGORAKIS, S. STEFANAKIS, M. KOUTSILIERIS ( <i>Athens; Piraeus, Greece</i> ) .....	709
Evaluation of an Ultraviolet B Light Emitting Diode (LED) for Producing Vitamin D3 in Human Skin. A.J. VERONIKIS, M.B. CEVIK, R.H. ALLEN, A. SHIRVANI, A. SUN, K.S. PERSONS, M.F. HOLICK ( <i>Boston, MA, USA</i> ).....	719
Luteolin-regulated MicroRNA-301-3p Targets Caspase-8 and Modulates TRAIL Sensitivity in PANC-1 Cells. S. MOENG, S.W. SON, H.A. SEO, J.S. LEE, C.K. KIM, H.J. KUH, J.K. PARK ( <i>Chuncheon; Suwon; Seoul, Republic of Korea</i> ).....	723
Inhibition of Cell-surface Molecular GPR87 With GPR87-suppressing Adenoviral Vector Disturb Tumor Proliferation in Lung Cancer Cells. Y. KITA, T. GO, N. NAKASHIMA, D. LIU, Y. TOKUNAGA, X. ZHANG, T. NAKANO, K. NII, S.S. CHANG, H. YOKOMISE ( <i>Kagawa, Japan</i> ) .....	733
Hepatic Stellate Cells Contribute to the Tumor Malignancy of Hepatocellular Carcinoma Through the IL-6 Pathway. S. IWAHASI, F. RUI, Y. MORINE, S. YAMADA, Y. SAITO, T. IKEMOTO, S. IMURA, M. SHIMADA ( <i>Tokushima, Japan</i> ) .....	743
Rosmarinic Acid/Blue Light Combination Treatment Inhibits Head and Neck Squamous Cell Carcinoma <i>In Vitro</i> . C.N. WAER, P. KAUR, Z. TUMUR, D.D. HUI, B. LE, C. GUERRA, B. HENSON, D. SELEEM, J. LEWIS ( <i>Pomona, CA, USA</i> ).....	751
Establishment and Characterization of a Novel Primitive Yolk Sac Tumour Cell Line, TC587. T. IWASAKI, K. KOHASHI, M. OHNO, T. TAGUCHI, Y. ODA ( <i>Fukuoka; Nagoya, Japan</i> ).....	759
COUP-TFII Overexpression Inhibits Cell Proliferation and Invasion <i>via</i> Increased Expression of p53 and PTEN and Decreased Akt Phosphorylation in Human Colorectal Cancer SNU-C4 Cells. S.-H. YUN, J.-I. PARK ( <i>Busan, Republic of Korea</i> ).....	767
25-Hydroxycholesterol Induces Death Receptor-mediated Extrinsic and Mitochondria-dependent Intrinsic Apoptosis in Head and Neck Squamous Cell Carcinoma Cells. J.-S. YOU, H. LIM, T.-H. KIM, J.-S. OH, G.-J. LEE, Y.-S. SEO, D.K. KIM, S.-K. YU, H.-J. KIM, C.S. KIM, J.-S. KIM ( <i>Gwang-Ju, Republic of Korea</i> ) .....	779
Tumor Suppression in Asymptomatic Postmenopausal Endometrial Polyps. L. ADOMAITIENE, R. NADISAUSKIENE, M. NICKKHO-AMIRY, A. CIZAUSKAS, J. PALUBINSKIENE, C. HOLLAND, M.W. SEIF ( <i>Kaunas, Lithuania; Manchester, UK</i> ) .....	789
Approbation of the Cancer Treatment Approach Based on the Eradication of TAMRA+ Cancer Stem Cells in a Model of Murine Cyclophosphamide Resistant Lymphosarcoma. P.E. KISARETOVA, S.S. KIRIKOVICH, G.S. RITTER, Y.R. EFREMOV, O.S. TARANOV, T.D. DUBATOLOVA, A.S. PROSKURINA, E.A. POTTER, E.V. DOLGOVA, S.V. SIDOROV, A.A. OSTANIN, E.R. CHERNYCH, S.S. BOGACHEV ( <i>Novosibirsk, Russia</i> ) .....	795
Topoisomerase IIa Protein Expression Patterns in Laryngeal Squamous Cell Carcinoma. V. PAPANIKOLAOU, A. CHRYSOVERGIS, N. MASTRONIKOLIS, E. TSIAMBAS, V. RAGOS, D. PESCHOS, C. STAVRAKA, D. ROUKAS, E. KYRODIMOS ( <i>Athens; Patras; Ioannina, Greece; London, UK</i> ) .....	807

Olaparib Potentiates Anticancer Drug Cytotoxicity <i>via</i> 53BP1 in Oesophageal Squamous Cell Carcinoma Cells. K. MIYAMOTO, T. MINEGAKI, S. HIRANO, I. HAYASHI, M. TSUJIMOTO, K. NISHIGUCHI ( <i>Kyoto, Japan</i> ) ....	813
Effect of Small-molecule Tyrosine Kinase Inhibitors on PDGF-AA/BB and PDGFR $\alpha/\beta$ Expression in SCC According to HPV16 Status. L. HUBER, R. BIRK, N. ROTTER, C. ADERHOLD, A. LAMMERT, F. JUNGBAUER, B. KRAMER ( <i>Mannheim; Marburg, Germany</i> ) .....	825
VDR Agonists Increase Sensitivity of MCF-7 and BT-474 Breast Cancer Cells to 5 FU. D. KLOPOTOWSKA, J. MATUSZYK ( <i>Wroclaw, Poland</i> ) .....	837
The Effect of Cold Atmospheric Plasma on the Membrane Permeability of Human Osteosarcoma Cells. L. HARALAMBIEV, A. NITSCH, R. EINENKEL, D.O. MUZZIO, N. GELBRICH, M. BURCHARDT, M. ZYGMUNT, A. EKKERNKAMP, M.B. STOPE, D. GÜMBEL ( <i>Greifswald; Berlin, Germany</i> ) .....	841
<i>Clinical Studies</i>	
Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database. H.A. ASSI, S. MUKHERJEE, M. MACHIORLATTI, S. VESELY, V. PAREEK, H. HATOUM ( <i>Oklahoma City, OK; Buffalo, NY, USA</i> ) .....	847
Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer. A. PHILIPOVSKIY, A. CAMPBELL, R. HEYDARIAN, B. CASTILLO, A.K. DWIVEDI, R. MCCALLUM, R. AGUILERA, S. GAUR, N. ZEINA ( <i>El Paso, TX; Weston, FL, USA</i> ) .....	857
Postoperative Exacerbation of Oxaliplatin-induced Neurotoxicity in Gastrointestinal Cancers: A Case Series. A. GONZALEZ, E.J. WALKER, K. VAN LOON, P. CINAR, C.E. ATREYA ( <i>San Francisco, CA, USA</i> ) .....	865
Effects of Alkalinization Therapy on Chemotherapy Outcomes in Metastatic or Recurrent Pancreatic Cancer. R. HAMAGUCHI, R. NARUI, H. WADA ( <i>Kyoto, Japan</i> ) .....	873
Racial Disparities in Outcomes Among Asians With Gastric Cancer in the USA. R. LEMINI, M.S. JORGENSEN, K. ATTWOOD, T. ALMEREY, E.F. ELLI, D.T. COLIBASEANU, S.P. BAGARIA, E. GABRIEL ( <i>Jacksonville, FL; Buffalo, NY, USA</i> ) .....	881
Progressive Disease in Sentinel-negative Melanoma Patients: Biological Differences and Importance of Sentinel Lymph Node Biopsy. A. CONRAD, M. REINEHR, D. HOLZMANN, J. MANGANA, M. WANNER, M. HUELLNER, R.L. BARNHILL, C. LUGASSY, N. LINDENBLATT, D. MIHIC-PROBST ( <i>Zurich, Switzerland; Paris, France</i> ) .....	891
Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer. G. IOANNIDIS, C. PAPADAKI, E. LAGOUDAKI, M. TZARDI, M. TRYPAKI, E. STATHOPOULOS, D. MAVROUDIS, V. GEORGOULIAS, J. SOUGLAKOS ( <i>Heraklion, Greece; Nicosia, Cyprus</i> ) .....	901
Impact of Primary Pegfilgrastim Prophylaxis on Relative Dose Intensity in Neoadjuvant/Adjuvant FEC-100 Chemotherapy. T. YOKOKAWA, K. SUZUKI, T. SUGISAKI, K. KOBAYASHI, D. SHOUJI, H. WATANABE, K. KAWAKAMI, T. TAKIGUCHI, T. AOYAMA, K. KOBAYASHI, S. TAKAHASHI, Y. ITO, S. OHNO, T. HAMA ( <i>Tokyo, Japan</i> ) .....	915
Efficacy of PD-1 Inhibitors in Older Non-small Cell Lung Cancer Patients. Y. NAKAMURA, K. MIYAZAKI, N. AIKO, Y. MISUMI, Y. AGEMI, Y. TANIGUCHI, M. ISHI, T. SHIMOKAWA, H. OKAMOTO, T. YAMANAKA ( <i>Yokohama, Japan</i> ) .....	923
First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study. J. SGOUROS, G. ARAVANTINOS, G.-A. KOLIOU, G. PENTHEROUDAKIS, F. ZAGOURI, A. PSYRRI, D.I. LAMPROPOULOU, S. DEMIRI, D. PECTASIDES, E. RAZIS, G. FOUNTZILAS, E. SAMANTAS ( <i>Athens; Ioannina; Thessaloniki, Greece; Limassol, Cyprus</i> ) .....	929

Reducing the Number of Unnecessary Percutaneous Biopsies: The Role of Second Opinion by Expert Breast Center Radiologists. C.A. PISTOLESE, F. LAMACCHIA, D. TOSTI, L. ANEMONA, F. RICCI, M. CENSI, M. MATERAZZO, G. VANNI, A. COLLURA, F. DI GIULIANO, T. PERRETTA, O.C. BUONOMO ( <i>Rome, Italy</i> ) .....	939
Aggressive Local Control With Multisite Stereotactic Body Radiation in Metastatic Ewing Sarcoma: A Literature Review and Case Report. A.M. KARIMI, S.R. CAMPBELL, S. PARSANI, L. ANGELOV, J. SCOTT, P. QI, P. ANDERSON, S.T. CHAO, E.S. MURPHY ( <i>Cleveland, OH, USA</i> ) .....	951
Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study. S. OKAUCHI, T. NUMATA, T. NAWA, H. ICHIMURA, T. SAITO, K. HAYASHIHARA, H. YAMADA, H. SATOH, T. ENDO, Y. INAGE, T. KABURAGI, M. KIYOSHIMA, Y. YAMADA, T. TAMURA, K. SAITO, M. INAGAKI, N. HIZAWA, Y. SATO, T. SHIOZAWA, I. SEKINE, H. ISHIKAWA, K. KURIHIMA, M. SAKAI, K. KAMIYAMA, M. KIMURA, N. KIKUCHI, H. NAKAMURA, K. FURUKAWA, T. KODAMA, K. MIYAZAKI, T. YAMASHITA, S. HAYASHI, Y. FUNAYAMA, A. NOMURA ( <i>Mito; Hitachi; Tokai; Kasama; Tsuchiura; Tsukuba; Ami-machi; Ryugasaki; Toride; Sakai-machi, Japan</i> ) .....	957
Utilization and Efficacy of Palliative Chemotherapy for Locally Advanced or Metastatic Gastroesophageal Carcinoma. R. BAUMGARTNER, H. TAGHIZADEH, G. JOMRICH, S.F. SCHOPPMANN, M. PREUSSER, A. ILHAN-MUTLU ( <i>Vienna, Austria</i> ) .....	965
Confirmatory Analysis of QUARTZ Study Results: Survival Prolongation After Whole-brain Radiotherapy. C. NIEDER, A. DALHAUG, A. PAWINSKI ( <i>Bodø; Tromsø, Norway</i> ) .....	977
Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. A. PEZZUTO, F. CAPPUZZO, M. D'ARCANGELO, M. CICCOCCHI, L. NAVARINI, S. GUERRINI, A. RICCI, M. D'ASCANIO, E. CARICO ( <i>Rome; Ravenna, Italy</i> ) .....	983
S-1, Oxaliplatin, Nab-paclitaxel and Itraconazole for Conversion Surgery for Advanced or Recurrent Gastric Cancer. M. SAWASAKI, H. TSUBAMOTO, Y. NAKAMOTO, A. KAKUNO, T. SONODA ( <i>Nishinomiya, Japan</i> ) .....	991
Selection Criteria and Clinical Outcomes of Patients With Asymmetrical Cervical Cancer Treated With Various High-dose-rate Brachytherapy Techniques. K.N. MUROFUSHI, Y. YOSHIOKA, H. ISHIKAWA, M. SUMI, T. OKUMURA, M. OGUCHI, H. SAKURAI ( <i>Tokyo; Ibaraki, Japan</i> ) .....	999
Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer. T. NAKANO, T. GO, N. NAKASHIMA, D. LIU, H. YOKOMISE ( <i>Kagawa, Japan</i> ) .....	1007
Can Diagnostic Low-dose Whole-body CT Reflect Bone Marrow Findings in Systemic Mastocytosis? H.-J. MEYER, W. PÖNISCH, A. MONECKE, P. GUNDERMANN, A. SUROV ( <i>Leipzig, Germany</i> ) .....	1015
Efficacy of Staging Laparoscopy for Pancreatic Cancer. K. YAMAMURA, Y.-I. YAMASHITA, T. YAMAO, D. KURODA, T. ETO, Y. KITANO, K. ARIMA, T. MIYATA, H. OKABE, H. NITTA, D. HASHIMOTO, H. BABA ( <i>Kumamoto, Japan</i> ) .....	1023
The Role of Neoadjuvant Chemotherapy in Resectable Primary Synovial Sarcoma. Y. MINAMI, S. MATSUMOTO, K. AE, T. TANIZAWA, K. HAYAKAWA, Y. FUNAUCHI, M. SAITO, Y. TSUDA ( <i>Tokyo, Japan</i> ) .....	1029
The Extracompartmental Tumoral Invasion of Extraskelatal Myxoid Chondrosarcoma Induces Distant Metastasis. Y. MINAMI, S. MATSUMOTO, K. AE, T. TANIZAWA, K. HAYAKAWA, Y. FUNAUCHI, M. SAITO ( <i>Tokyo, Japan</i> ) .....	1035
Treatment and Other Healthcare Use of Breast Cancer Patients With a Previous Cancer Diagnosis. S. MORAIS, A.R. COSTA, L. LOPES-CONCEICAO, M. BRANDAO, M. BORGES, N. ARAUJO, T. DIAS, F. FONTES, S. PEREIRA, N. LUNET ( <i>Porto; Lisbon, Portugal; Brussels, Belgium</i> ) .....	1041



Aortic Reconstruction by Cadaveric Graft After Radical Resection of Recurrent Retroperitoneal Leiomyosarcoma – A Case Report and Literature Review. I. BREZAN, S. PETREA, V. BRASOVEANU, E. CATRINA, S. ALDOESCU, M. VILCU, I. BALESCU, N. BACALBASA ( <i>Bucharest, Romania</i> ) .....	1049
National Analysis of Patients With Ulcerated Melanoma in the United States. D. BOCZAR, A. SISTI, D.J. RESTREPO, M.T. HUAYLLANI, O.J. MANRIQUE, X. LU, A.C. SPAULDING, S.P. BAGARIA, A.S. PARKER, A.J. FORTE ( <i>Jacksonville, FL; Rochester, CA; New Haven, NY, USA</i> ) .....	1055
Residual Tumor on Wide Excisional Margins After Treatment of Invasive Melanoma. M.T. HUAYLLANI, S.P. BAGARIA, D.J. RESTREPO, D. BOCZAR, A. SISTI, J.J. COCHUYT, A.C. SPAULDING, E.M. GABRIEL, B.D. RINKER, A.J. FORTE ( <i>Jacksonville, FL, USA</i> ) .....	1059
Wide Excisional Surgery in Invasive Melanoma Treatment: Factors Driving Non-compliance With National Guidelines. M.T. HUAYLLANI, S.P. BAGARIA, D.J. RESTREPO, D. BOCZAR, A. SISTI, J.J. COCHUYT, A.C. SPAULDING, H. RUIZ-GARCIA, B.D. RINKER, A.J. FORTE ( <i>Jacksonville, FL, USA</i> ) .....	1065
Risk Factors of Severe Benign Cicatricial Stricture After Definitive Chemoradiation for Localized T3 Esophageal Carcinoma. N. SATOMI-TSUSHITA, Y. HONMA, K. NAGASHIMA, Y. ITO, H. HIRANO, H. SHOJI, A. TAKASHIMA, S. IWASA, K. KATO, T. HAMAGUCHI, J. ITAMI, N. BOKU ( <i>Tokyo, Japan</i> ) .....	1071
Long-term Results After Neoadjuvant Chemotherapy for Breast Cancer: A Single-center Experience. M. GIANI, I. RENDA, A. VALLARIO, K. TAVELLA, A. VILLANUCCI, J. NORI, E. VANZI, S. BIANCHI, T. SUSINI ( <i>Florence, Italy</i> ) .....	1079
The Short- and Long-term Outcomes of Esophagectomy for Esophageal Cancer in Patients Older than 75 Years. T. AOYAMA, K. HARA, K. KAZAMA, Y. ATSUMI, H. TAMAGAWA, A. TAMAGAWA, D. MACHIDA, K. KOMORI, Y. MAEZAWA, K. KANO, I. HASHIMOTO, T. OSHIMA, M. MURAKAWA, M. NUMATA, N. YUKAWA, M. MASUDA, Y. RINO ( <i>Yokohama, Japan</i> ) .....	1087
A Pre-operative Score to Discriminate Fibroepithelial Lesions of the Breast: Phyllode Tumor or Fibroadenoma? C. MIMOUN, A. ZELLER, J. SEROR, L. MAJOULET, E. MARCHAND, M. MEZZADRI, P. CHEREL, V. PLACE, F. CORNELIS, J.-L. BENIFLA, R. ROUZIER ( <i>Saint-Cloud; Paris; Versailles, France</i> ).....	1095
Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-metastatic Castration-resistant Prostate Cancer. H. MIYAKE, K. WATANABE, Y. MATSUSHITA, H. WATANABE, K. TAMURA, D. MOTOYAMA, T. ITO, T. SUGIYAMA, A. OTSUKA ( <i>Hamamatsu, Japan</i> ).....	1101
Characteristics of Five-year Survivors After Liver Resection for Colorectal Liver Metastases in Modern Chemotherapy. T. NAKAMOTO, D. HOKUTO, T. NOMI, T. YOSHIKAWA, N. KAMITANI, Y. MATSUO, S. OBARA, H. KUGE, F. KOYAMA, M. SHO ( <i>Nara, Japan</i> ) .....	1107
Prognosis of <i>EGFR</i> -mutant Lung Adenocarcinoma Patients With Malignant Pleural Effusion Receiving First-line <i>EGFR</i> -TKI Therapy Without Pleurodesis: A Single-institute Retrospective Study. K. KASHIWABARA, S. FUJI, S. TSUMURA, K. SAKAMOTO ( <i>Kumamoto, Japan</i> ).....	1117
Merkel Cell Carcinoma Clinically Mimicking a Traumatic Suture Scar in the Nasal Vestibule: Earlier Diagnosis for Better Prognosis. P. JIANG, J. LAI ( <i>Gainesville, FL; Sacramento, CA, USA</i> ).....	1123
Prognostic Value of Age and Distant Metastasis in Differentiated Thyroid Carcinoma Undergoing Salvage Surgery. H. SUZUKI, D. NISHIKAWA, S. BEPPU, H. TERADA, M. SAWABE, N. HANAI ( <i>Nagoya, Japan</i> ).....	1127
Diagnosis of Malignant Pleural Effusion Using CT Scan and Pleural-fluid Cytology Together. A Preliminary Case-Control Study. S.M.M. BASSO, F. LUMACHI, A. DEL CONTE, S. SULFARO, F. MAFFEIS, P. UBIALI ( <i>Pordenone; Padua, Italy</i> ) .....	1135

The Efficacy of Second-line Chemotherapy for Advanced or Metastatic Urothelial Cancer. R. NAITO, K. IZUMI, S. KADOMOTO, T. MAKINO, H. IWAMOTO, H. YAEGASHI, K. SHIGEHARA, Y. KADONO, A. MIZOKAMI ( <i>Kanazawa, Japan</i> ).....	1141
A Giant Gastric Gastrointestinal Stromal Tumor Successfully Resected Following Neoadjuvant Treatment With Imatinib Mesylate. R. TAKAHASHI, T. TOYOKAWA, M. YOSHII, T. TAMURA, H. TANAKA, S. LEE, K. MUGURUMA, M. YASHIRO, M. OHIRA ( <i>Osaka, Japan</i> ) .....	1147
Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery. M. OHSAWA, Y. HAMAI, M. EMI, F. TAKAOKI, Y. IBUKI, K. TOMOAKI, T. YOSHIKAWA, M. OKADA ( <i>Hiroshima, Japan</i> ).....	1153
Preoperative Survival Prediction in Patients With Glioblastoma by Routine Inflammatory Laboratory Parameters. D. PIERSCIANEK, Y. AHMADIPOUR, A. MICHEL, M. CHIHI, M.D. OPPONG, S. KEBIR, M. GLAS, M. STUSCHKE, U. SURE, R. JABBARLI ( <i>Essen, Germany</i> ).....	1161
Safety of Prophylactic Gastrostomy Tube Placement and Gastrostomy Tube Usage in Patients Treated by Radio(chemo)therapy for Head and Neck Cancer. H.L. SIERON, F. EBERLE, T.M. GRESS, A.H. MAHNKEN, S. WIEGAND ( <i>Marburg; Ulm; Leipzig, Germany</i> ).....	1167
Association Between Sarcopenia and Clinical Outcomes in Patients With Esophageal Cancer Under Neoadjuvant Therapy. C.-H. HUANG, K.-H. LUE, T.-C. HSIEH, S.-H. LIU, T.-F. WANG, T.-C. PENG ( <i>Hualien, Taiwan, ROC</i> ) .....	1175
Errata.....	1183
Book Reviews .....	1185
Announcements.....	1187

### Number 3, March

#### Reviews

The Mystery of Chemotherapy Brain: Kynurenines, Tubulin and Biophoton Release. P.P. SORDILLO, L.A. SORDILLO ( <i>New York, NY, USA</i> ) .....	1189
Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment. M.D. ROMBOUITS, E.L. SWART, A.J.M. VAN DEN EERTWEGH, M. CRUL ( <i>Amsterdam, the Netherlands</i> ) .....	1201
Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors. O. FIALA, O. SOREJS, J. SUSTR, R. KUCERA, O. TOPOLCAN, J. FINEK ( <i>Pilsen, Czech Republic</i> ) .....	1219
Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art. A. RIZZO, A.D. RICCI, M. SAPONARA, A. DE LEO, A.M. PERRONE, P. DE IACO, M.A. PANTALEO, M. NANNINI ( <i>Bologna, Italy</i> ).....	1229

#### Experimental Studies

An Unbalanced Chromosome Translocation Between 7p22 and 12q13 Leads to <i>ACTB-GLI1</i> Fusion in Pericytoma. I. PANAGOPOULOS, L. GORUNOVA, T.V. RISE, K. ANDERSEN, F. MICCI, S. HEIM ( <i>Oslo; Trondheim, Norway</i> ).....	1239
---	------

Troglitazone, a Selective Ligand for PPAR $\gamma$ , Induces Cell-cycle Arrest in Human Oral SCC Cells. M. SAITO, Y. FUJITA, N. KURIBAYASHI, D. UCHIDA, Y. KOMIYAMA, C. FUKUMOTO, T. HASEGAWA, H. KAWAMATA ( <i>Tochigi, Japan</i> ) .....	1247
Characteristics of Leiomyosarcoma: Induction of Hematogenous Metastasis by Isolated Uterine Mesenchymal Tumor Stem-like Cells. T. HAYASHI, K. SANO, T. ICHIMURA, Y. KANAI, D. ZHARHARY, H. ABURATANI, N. YAEGASHI, I. KONISHI ( <i>Nagano; Osaka; Tokyo; Miyagi; Kyoto, Japan; Rehovot, Israel</i> ) .....	1255
Characterization of Pancreatic and Biliary Cancer Stem Cells in Patient-derived Tissue. J. GOGOLOK, E. SEIDEL, A. STRÖNISCH, A. REUTZEL-SELKE, I.M. SAUER, J. PRATSCHKE, M. BAHRA, R.B. SCHMUCK ( <i>Berlin, Germany</i> ) .....	1267
Cigarette Smoke Reduces the Efficacy of Cisplatin in Head and Neck Cancer Cells – Role of ABCG2. F. SIMON, S. SCHWENK-ZIEGER, S. BECKER, K. UNGER, O. GIRES, P. BAUMEISTER ( <i>Munich; Tübingen, Germany</i> ) .....	1277
Androgen Receptor Enhances the Efficacy of Sorafenib Against Hepatocellular Carcinoma Through Enriched EpCAM Stemness. H.-C. LAI, W.-M. CHUNG, C.-M. CHANG, P.-Y. LIAO, Y.-T. SU, C.-C. YEH, L.-B. JENG, W.-L. MA, W.-C. CHANG ( <i>Taichung, Taiwan, ROC; Dallas, TX, USA</i> ) .....	1285
Association of <i>Adiponectin</i> Genotypes With Colorectal Cancer Susceptibility in Taiwan. Y.-C. HUNG, W.-S. CHANG, A.-K. CHOU, J.-S. PEI, M.-D. YANG, H.-R. YANG, T.-M. YANG, Y.-C. WANG, Y.-C. HSIAU, C.-P. CHEN, C.-C. CHEN, C.-C. YU, C.-W. TSAI, D.-T. BAU ( <i>Taichung; Taoyuan; Tainan, Taiwan, ROC</i> ) .....	1297
ADAR2 Regulates Malignant Behaviour of Mesothelioma Cells Independent of RNA-editing Activity. K.-I. SAKATA, K. MAEDA, N. SAKURAI, S. LIANG, S. NAKAZAWA, K. YANAGIHARA, T. KUBO, H. YOSHIYAMA, Y. KITAGAWA, J.-I. HAMADA, H. IIZASA ( <i>Sapporo; Izumo; Tokyo; Hiroshima; Hokkaido, Japan; Dalian, PR China</i> ) .....	1307
Human Glioma Cells Acquire Temozolomide Resistance After Repeated Drug Exposure <i>Via</i> DNA Mismatch Repair Dysfunction. K. YAMASHIRO, K. NAKAO, S. OHBA, Y. HIROSE ( <i>Toyoake, Japan</i> ) .....	1315
Gut Microbiota and Host Gene Mutations in Colorectal Cancer Patients and Controls of Iranian and Finnish Origin. V. SARHADI, L. LAHTI, F. SABERI, O. YOUSSEF, A. KOKKOLA, T. KARLA, M. TIKKANEN, H. RAUTELIN, P. PUOLAKKAINEN, R. SALEHI, S. KNUUTILA ( <i>Helsinki; Turku; Vantaa, Finland; Isfahan, Iran; Uppsala, Sweden</i> ) .....	1325
Silencing Delta-like 1 Expression Induces Migratory Features in Pancreatic Cancer Cells Through Stimulation of Src and p38 Signalling Pathway. J. LEE, J. LEE, D.H. KIM, J.H. KIM ( <i>Jeju-do, Republic of Korea</i> ) .....	1335
The Dual Function of Aryl Hydrocarbon Receptor in Bladder Carcinogenesis. J. YU, Y. LU, S. MUTO, H. IDE, S. HORIE ( <i>Heilongjiang, PR China; Tokyo, Saitama, Japan</i> ) .....	1345
Short- and Long-term Histological Changes in Liver Parenchyma After Different Resection Methods and Their Potential Role in Treatment of Colorectal Liver Metastasis. A. PALKOVICS, A. VERECZKEI, A. FINCSUR, I. KISS, B. NÉMETH, I. TAKÁCS, A. PAPP ( <i>Pécs, Hungary</i> ) .....	1359
RNF126 as a Marker of Prognosis and Proliferation of Gastric Cancer. K. MIGITA, S. MATSUMOTO, K. WAKATSUKI, T. KUNISHIGE, H. NAKADE, S. MIYAO, M. SHO ( <i>Nara, Japan</i> ) .....	1367
Silencing of Growth Differentiation Factor-15 Promotes Breast Cancer Cell Invasion by Down-regulating Focal Adhesion Genes. V. GKRETSI, A. STYLIANOU, M. KALLI, M. LOUCA, C. VOUTOURI, A. ZARAVINOS, T. STYLIANOPOULOS ( <i>Nicosia, Cyprus; Doha, Qatar</i> ) .....	1375
Hypoxia Suppresses Cysteine Deprivation-induced Cell Death <i>Via</i> ATF4 Regulation in MDA-MB-231 Breast Cancer Cells. S.-E. HONG, M.-R. KIM, S.-K. JANG, M.-K. SEONG, H.-A. KIM, W.C. NOH, H.-O. JIN, I.-C. PARK ( <i>Seoul, Republic of Korea</i> ) .....	1387

Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition. D. KIM, Y. KOH, S.-S. YOON ( <i>Seoul, Republic of Korea</i> ) .....	1395
Antihelminthic Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells <i>In Vitro</i> and <i>In Vivo</i> . W.-H. CHAI, Y.-R. LI, S.-H. LIN, Y.-H. CHAO, C.-H. CHEN, P.-C. CHAN, C.-H. LIN ( <i>Changhua; Taichung, Taiwan, ROC</i> ) .....	1405
Casein Kinase 2 $\alpha$ Enhances 5-Fluorouracil Resistance in Colorectal Cancer Cells by Inhibiting Endoplasmic Reticulum Stress. H.J. KIM, Y.-S. HAN, J.H. LEE, S.H. LEE ( <i>Seoul; Cheonan, Republic of Korea</i> ) .....	1419
<i>miR-187*</i> Enhances SiHa Cervical Cancer Cell Oncogenicity <i>Via</i> Suppression of WWOX. P.-S. HUNG, F.-J. CHUANG, C.-Y. CHEN, C.-H. CHOU, H.-F. TU, S.-S. LO ( <i>Yilan, Taipei, Taiwan, ROC</i> ).....	1427
Polyamine Analogues of Propanediamine Series Inhibit Prostate Tumor Cell Growth and Activate the Polyamine Catabolic Pathway. M.V. PLOSKONOS, S.P. SYATKIN, E.V. NEBORAK, A. HILAL, K.Y. SUNGRAPOVA, R.I. SOKUYEV, M.L. BLAGONRAVOV, A.Y. KORSHUNOVA, A.A. TEREITYEV ( <i>Astrakhan; Moscow, Russian Federation; Daraa, Syria</i> ) .....	1437
Changes in Serum Interleukin-8 and sRAGE Levels in Multiple Myeloma Patients. A. ALLEGRA, E. PACE, G. TARTARISCO, V. INNAO, E. DI SALVO, A.G. ALLEGRA, M. FERRARO, C. MUSOLINO, S. GANGEMI ( <i>Messina; Palermo, Italy</i> ) .....	1443
Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells. Y. LIU, R.M. HUBER, R. KIEFL, A. TUFMAN, D. KAUFFMANN-GUERRERO ( <i>Munich, Germany</i> ) .....	1451
<i>Clinical Studies</i>	
Soluble Endoglin (sCD105) as a Novel Biomarker for Detecting Aggressive Prostate Cancer. A.C. VIDAL, F. DUONG, L.E. HOWARD, E. WIGGINS, S.J. FREEDLAND, N.A. BHOWMICK, J. GONG ( <i>Los Angeles, CA; Durham, NC, USA</i> ) .....	1459
Radiotherapy Does Not Impact Long-term Function Following Resection of Soft-tissue Sarcomas of the Hand. N.F. MUNARETTO, A.L. LOGLI, P.S. ROSE, I.A. PETERSEN, S.K. AHMED, K. BAKRI, S.L. MORAN, M.T. HOUDEK ( <i>Rochester, MN, USA</i> ) .....	1463
Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan. P.J. HURLEY, N. BOSE, G. JHA, M. GARGANO, N. OTTOSON, K. GORDEN, B. RATHMANN, B. HARRISON, X. QIU, A.Z. DUDEK ( <i>St. Paul; Eagan; Minneapolis, MN, USA</i> ) .....	1467
Long-term Survival After Surgical Treatment of Spinal Metastasis – The Predictive Role of Sex. D. KARIMI, S.S. MORGEN, S. FRUERGAARD, M. GEHRCHEN, B. DAHL ( <i>Copenhagen, Denmark; Houston, TX, USA</i> ) .....	1475
Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer: Evaluation of Side Effects in a Single Institution Cohort. M. FRIEDRICH, W. ZINN, L. KOLNSBERG, C. KRAFT, W. KUHN ( <i>Krefeld; Deggendorf, Germany</i> ).....	1481
Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma. H.-S. KIM, S.-I. DO, D.-H. KIM, S. APPLE ( <i>Seoul, Republic of Korea; Duarte, CA, USA</i> ) .....	1487
Association Between the Functional <i>miR-146a</i> SNP <i>rs2910164</i> and Risk of Digestive System Cancer: Updated Meta-analysis. R. PARK, L. LOPES, A. SAEED ( <i>Framingham, MA; Kansas City, KS, USA</i> ) .....	1495
The Prognostic Value of the Perioperative Systemic Inflammation Score for Patients With Advanced Gastric Cancer. K. HARA, T. AOYAMA, T. YAMADA, M. NAKAZONO, S. NAGASAWA, Y. SHIMODA, Y. KUMAZU, M. NUMATA, T. HAYASHI, H. TAMAGAWA, M. SHIOZAWA, S. MORINAGA, N. YUKAWA, Y. RINO, M. MASUDA, T. OGATA, T. OSHIMA ( <i>Yokohama, Japan</i> ) .....	1503

Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women. S. MEKURIA, M. JERKEMAN, O. FORSLUND, S. FIKRU, C. BORGFELDT ( <i>Lund, Sweden; Addis Abeba, Ethiopia</i> ).....	1513
Chondrosarcoma of the Chest Wall: A Review of 53 Cases from Two Institutions. U. LENZE, A. ANGELINI, F. POHLIG, C. KNEBEL, G. TROVARELLI, A. BERIZZI, A.F. MAVROGENIS, J. THEISEN, R. VON EISENHART-ROTHER, P. RUGGIERI ( <i>Munich, Germany; Padua, Italy</i> ) .....	1519
Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report. L. ZARLING, H. EMAMEKHOO, G. BHUTANI, T. ZIEMLEWICZ, K.A. MATKOWSKYJ, C.E. KYRIAKOPOULOS ( <i>Madison, WI, USA</i> ) .....	1527
Sessile Serrated Polyps Without Dysplasia Thrives With Asymmetric Relocation of Cell Proliferation-domains. C.A. RUBIO, P.T. SCHMIDT ( <i>Stockholm, Sweden</i> ) .....	1535
Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study. A. GADDUCCI, S. COSIO, A.A. LISSONI, V. ZIZIOLI, M. ADORNI, A.M. FERRERO, F. LANDONI, E. SARTORI ( <i>Pisa; Milan; Brescia; Turin, Italy</i> ).....	1543
Symptom Burden in Patients With Oligometastases at the Start of Palliative Radiotherapy. C. NIEDER, T.A. KÄMPE ( <i>Bodø; Tromsø, Norway</i> ) .....	1551
Correlation of Insulin-like Growth Factor 1 Receptor Expression With Different Molecular Subtypes of Breast Cancer in the UAE. N. ALKHAYYAL, I. TALAAT, A. VINODNADAT, A. MAGHAZACHI, S. ABUSNANA, K. SYRJÄNEN, R. BENDARDAF ( <i>Sharjah, United Arab Emirates; Helsinki, Finland</i> ) .....	1555
Impact of Extent of Lymphadenectomy on Survival in Patients With Endometrial Cancer: A Matched Cohort Study. L. PAULY, L. BENOIT, M. KOSKAS ( <i>Paris; Montigny Le Bretonneux, France</i> ) .....	1563
Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC. H. IMAI, K. KAIRA, I. NARUSE, N. KASAHARA, Y. KAMIDE, A. ONO, T. MASUDA, N. SUNAGA, K. MINATO, T. HISADA ( <i>Ota; Maebashi; Hidaka; Takasaki, Japan</i> ) .....	1571
Nab-paclitaxel Monotherapy for Relapsed Small Cell Lung Cancer: Retrospective Analysis and Review. M. NAKAO, K. FUJITA, Y. SUZUKI, S. ARAKAWA, Y. SAKAI, H. SATO, H. MURAMATSU ( <i>Yatomi, Japan</i> ) .....	1579
Efficacy of Video-assisted Thoracoscopic Esophagectomy for Stage II/III Esophageal Cancer: Analysis Using the Propensity Scoring System. K. IGUCHI, C. KUNISAKI, S. SATO, Y. TANAKA, H. MIYAMOTO, T. KOSAKA, K. SATO, H. AKIYAMA, I. ENDO, N. YUKAWA, Y. RINO, M. MASUDA, T. YAMANAKA ( <i>Yokohama, Japan</i> ) .....	1587
Prevalence and Risk Factors for Oral HPV in Healthy Population, in Central Europe. S. MALEROVA, A. HEJTMANKOVA, E. HAMSIKOVA, M. SALAKOVA, J. SMAHELOVA, J. KLOZAR, R. TACHEZY ( <i>Prague; Vestec, Czech Republic</i> ) .....	1597
Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer. M. KIMURA, E. USAMI, H. TERAMACHI, T. YOSHIMURA ( <i>Gifu, Japan</i> ) .....	1605
Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma. M. OGAWA, S. YAMAMOTO, T. INOUE, N. NUMAO, T. YUASA, H. MASUDA, I. FUKUI, J. YONESE ( <i>Tokyo; Oita; Chiba, Japan</i> ).....	1613
Metastatic Malignant Peripheral Nerve Sheath Tumor With NF1 Successfully Treated With ‘Gradual Subtraction’ ICE Chemotherapy. Y. WANG, H. KATAGIRI, H. MURATA, J. WASA, M. MIYAGI, Y. KAKUDA, M. TAKAHASHI ( <i>Shizuoka, Japan; Hangzhou, PR China</i> ) .....	1619
Rapid Sarcomatoid Transformation of Lung Squamous Cell Carcinoma After Neoadjuvant Therapy: A Case Report. J. ARSHI, M. SAUER, F. YIN ( <i>Columbia, MO, USA</i> ) .....	1625

Adult Lymphangioma of the Oropharynx: A Case Report. H.-K. CHEN, H.-H. HSIEH, C.-H. HUA, C.-J. TAI, D.-T. BAU, M.-H. TSAI, L.-C. SHIH ( <i>Taichung, Taiwan, ROC</i> ) .....	1631
Combination of Extracorporeally-irradiated Autograft and Vascularized Bone Graft for Reconstruction of Malignant Musculoskeletal Tumor. A. MIHARA, K. MURAMATSU, T. HASHIMOTO, R. IWANAGA, K. IHARA, T. SAKAI ( <i>Yamaguchi, Japan</i> ).....	1637
Is Proton Beam Radiotherapy Worthwhile in the Management of Angiosarcoma of the Scalp? V. VITOLO, A. BARCELLINI, A. MIRANDOLA, A. FACOETTI, A. IANNALFI, B. VISCHIONI, M.R. FIORE, S. BRUGNATELLI, S. SECONDINO, S. RONCHI, M. BONORA, L. PREDA, F. VALVO ( <i>Pavia, Italy</i> ) .....	1645
Mucinous Adenocarcinoma as a High-risk Factor in Stage II Colorectal Cancer: A Propensity Score-matched Study from Japan. L. WANG, Y. HIRANO, G. HENG, T. ISHII, H. KONDO, K. HARA, N. OBARA, M. ASARI, T. KATO, S. YAMAGUCHI ( <i>Hidaka, Japan</i> ).....	1651
A Scoring Tool to Estimate the Survival of Elderly Patients With Brain Metastases from Esophageal Cancer Receiving Whole-brain Irradiation. T. NGUYEN, T. BARTSCHT, S.E. SCHILD, D. RADES ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ) .....	1661
Performance Status Is Associated With Survival in Elderly Patients Irradiated for Cerebral Metastases from Prostate Cancer. T. NGUYEN, T. BARTSCHT, S.E. SCHILD, D. RADES ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ) .....	1665
Could Mismatch Repair Status Serve as a Biomarker for Immunotherapy in Endometrial Carcinoma? S. VAGIOS, T. DOULGERAKI, E. GIANNIKAKI, E. KAVOURA, C. PAPADIMITRIOU, H. GAKIOPOULOU, K. PAVLAKIS ( <i>Athens; Heraklion, Greece</i> ).....	1669
Assessment of Daily Replanning and Geometrical Variation of High-dose-rate Brachytherapy for the Prostate. H. UCHIDA, T. HIRATA, K. OTANI, O. SUZUKI, M. ODA, Y. AKINO, I. SUMIDA, K. HATANO, K. FUJITA, M. UEMURA, R. IMAMURA, D. EINO, Y. YOSHIOKA, N. NONOMURA, K. OGAWA ( <i>Osaka; Tokyo, Japan</i> ).....	1677
Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1. H. WATANABE, T. HAYASHI, K. KOMORI, K. HARA, Y. MAEZAWA, K. KANO, Y. SHIMODA, H. FUJIKAWA, T. AOYAMA, T. YAMADA, N. YAMAMOTO, H. CHO, H. ITO, M. SHIOZAWA, N. YUKAWA, S. MORINAGA, T. YOSHIKAWA, Y. RINO, M. MASUDA, T. OGATA, T. OSHIMA ( <i>Yokohama; Tokyo, Japan</i> ) .....	1683
Elevated Gastric Juice Carbohydrate Antigen 72.4 (Ca 72.4) Is an Independent Prognostic Factor of Poor Survival for Gastric Cancer Patients. E. VIRGILIO, A. PROIETTI, R. D'URSO, P. CARDELLI, E. GIARNIERI, M.R. GIOVAGNOLI, M. MONTAGNINI, S. VILLANI, G. BALDUCCI, M. CAVALLINI ( <i>Rome, Italy</i> ) .....	1691
Primary Sarcoma of the Lung – Prognostic Value of Clinicopathological Characteristics of 26 Cases. J. DURAN-MORENO, S. KOKKALI, V. RAMFIDIS, M. SALOMIDOU, A. DIGKLIA, A. KOUMARIANOU, P. TOMOS, N. KOUFOPOULOS, I. VAMVAKARIS, E. PSYCHOGIOU, K. SYRIGOS ( <i>Athens, Greece; Lausanne, Switzerland</i> ) .....	1697
Factors Affecting Colorectal Polyp and Cancer Detection Rates in Patients Referred Urgently for Suspected Bowel Cancer. D.N. NAUMANN, Q. AIN, C.F.M. EVANS, A. BAJWA ( <i>Birmingham; Coventry, UK</i> ).....	1705
Current Role of Intraoperative Frozen Section Examination of Sentinel Lymph Node in Early Breast Cancer. C. CIPOLLA, G. GRACEFFA, D. CABIBI, G. GANGI, M. LATTERI, M.R. VALERIO, S. VIENI ( <i>Palermo, Italy</i> ) .....	1711

Evaluation of Ultrasound-guided 8-Gauge Vacuum-assisted Excision System for the Removal of US-detectable Breast Lesions. T. PERRETTA, F. LAMACCHIA, D. FERRARI, E. BENINATI, F. DI TOSTO, V. DE STASIO, R. MEUCCI, C. DI STEFANO, O.C. BUONOMO, G. VANNI, C.A. PISTOLESE ( <i>Rome, Italy</i> ).....	1719
Surgical Outcomes of Laparoscopic and Open D3 Dissection for Clinical Stage II/III Descending Colon Cancer. T. KOJIMA, H. HINO, A. SHIOMI, H. KAGAWA, Y. YAMAOKA, S. MANABE, M. HANAOKA, S. KATO ( <i>Shizuoka, Japan</i> ).....	1731
The Prognostic Value of Systemic Inflammatory Markers in Advanced Renal Cell Carcinoma Patients Treated With Molecular Targeted Therapies. K. UEDA, N. OGASAWARA, S. YONEKURA, Y. MATSUNAGA, R. HOSHINO, H. KUROSE, K. CHIKUI, K. UEMURA, M. NAKIRI, K. NISHIHARA, M. MATSUO, S. SUEKANE, T. IGAWA ( <i>Kurume, Japan; Villejuif, France</i> ) .....	1739
Non-steroidal Anti-inflammatory Drugs Are a Risk Factor for Cisplatin-induced Nephrotoxicity: A Meta-analysis of Retrospective Studies. K. OKAMOTO, Y. SAITO, K. NARUMI, A. FURUGEN, K. ISEKI, M. KOBAYASHI ( <i>Sapporo, Japan</i> ).....	1747
Hybrid Minimally-invasive Esophagectomy for Esophageal Cancer: Clinical and Oncological Outcomes. S. DAVAKIS, A. SYLLAIOS, E. SDRALIS, B. LORENZI, A. CHARALABOPOULOS ( <i>Chelmsford, Essex, UK; Athens, Greece</i> ) .....	1753
Prognosis and Treatment Outcomes of Patients Undergoing Resection of Brain Metastases from Breast Cancer. P. ÁRKOSY, J. TÓTH, E. BÉRES, D. TÓTH, L. SZIVOS, J. NAGY, A. KLEKNER, J. VIRGA ( <i>Debrecen, Hungary</i> ).....	1759
Adjuvant Chemotherapy and Dose Escalation in Definitive Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. H.K. KOH, Y. PARK, T. KOO, H.J. PARK, M.Y. LEE, A.R. CHANG, S. HONG, H. BAE ( <i>Seoul; Gyeonggi-do, Republic of Korea</i> ) .....	1771
Ultrasound Assessment of Synchronous Thyroid Nodules in Patients With Papillary Thyroid Cancer: A Nodule-by-nodule Analysis Between Ultrasound and Pathology. H.J. KIM, H.J. LEE, J.H. JUNG, W.W. KIM, J.Y. PARK, K.M. SHIN, W.H. KIM, S.H. CHO ( <i>Daegu, Republic of Korea</i> ) .....	1779
Erratum .....	1787

## Number 4, April

### Reviews

Pathogenesis and Treatment of Pancreatic Cancer Related Pain. I. LOHSE, S.P. BROTHERS ( <i>Miami, FL, USA</i> ).....	1789
Association Between BMI and DNA Methylation in Blood or Normal Adult Breast Tissue: A Systematic Review. D. DRAGIC, K. ENNOUR-IDRISSI, A. MICHAUD, S.-L. CHANG, F. DUROCHER, C. DIORIO ( <i>Quebec City, QC, Canada</i> ).....	1797
Evolving Role of Magseed in Wireless Localization of Breast Lesions: Systematic Review and Pooled Analysis of 1,559 Procedures. R. GERA, S. TAYEH, S. AL-REEFY, K. MOKBEL ( <i>London, UK; Manama, Bahrain</i> ).....	1809
New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications. A. MARJANSKA, P. GALAZKA, M. WYSOCKI, J. STYCZYNSKI ( <i>Bydgoszcz, Poland</i> ).....	1817

*Experimental Studies*

Plasma Metabolomic Changes in Mice With Time-restricted Feeding-attenuated Spontaneous Metastasis of Lewis Lung Carcinoma. L. YAN, B.M. RUST, M.J. PICKLO (*Grand Forks, ND, USA*)..... 1833

Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. F. SONOHARA, S. YAMADA, S. TAKEDA, M. HAYASHI, M. SUENAGA, Y. SUNAGAWA, M. TASHIRO, H. TAKAMI, M. KANDA, C. TANAKA, D. KOBAYASHI, G. NAKAYAMA, M. KOIKE, M. FUJIWARA, Y. KODERA (*Nagoya, Japan*) ..... 1843

Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers. T.-T. LUU, D.-H. BACH, D. KIM, R. HU, H.J. PARK, S.K. LEE (*Seoul, Republic of Korea*) ..... 1855

Hypoxia Inducible Factor-1 $\alpha$  Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells. T. SHUKUYA, J. OYANAGI, M. SERIZAWA, M. WATANABE, N. YAMAMOTO, Y. KOH (*Shizuoka; Tokyo; Wakayama, Japan*) ..... 1867

Detection of Mediastinal Lymph Node Metastases Using Indocyanine Green (ICG) Fluorescence Imaging in an Orthotopic Implantation Model. S. ZHAO, X. GUO, M. TANIGUCHI, K. KONDO, S. YAMADA, C. GU, H. URAMOTO (*Liaoning, PR China; Ishikawa; Tokushima, Japan*) ..... 1875

Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer. H. LEE, M. LEE, J.-H. SEO, G. GONG, H.J. LEE (*Seoul, Republic of Korea*) ..... 1883

Comparison of Strength of Anastomosis Between Four Different Techniques for Colorectal Surgery. K. TOMORI, K. ETO, K. HARUKI, H. SUGANO, Y. IMAIZUMI, T. KUMAMOTO, N. TAKADA, Y. SHIMOYAMA, K. YANAGA (*Tokyo, Japan*) ..... 1891

Clinical Significance of Jagged-1 Activated by APEX1 as a Chemoresistance Factor in Advanced Gastric Cancer. H.-B. KIM, H.-J. LEE, G.-B. KIM, H.-J. LIM, J.H. PARK, S.-G. PARK (*Gwangju, Republic of Korea*)..... 1897

Effect of Methylsulfonylmethane on Proliferation and Apoptosis of A549 Lung Cancer Cells Through G<sub>2</sub>/M Cell-cycle Arrest and Intrinsic Cell Death Pathway. D.H. KIM, N. SP, D.Y. KANG, E.S. JO, A. RUGAMBA, K.-J. JANG, Y.M. YANG (*Seoul, Republic of Korea*) ..... 1905

A New Model Applied for Evaluating a Rhenium-diselenium Drug: Breast Cancer Cells Stimulated by Cytokines Induced from Polynuclear Cells by LPS. V. VEENA, A. HARIKRISHNAN, B. LAKSHMI, S. KHANNA, D. DESMAELE, P. COLLERY (*Bangalore; Chennai; Mumbai, India; Châtenay-Malabry; Algajola, France*) ..... 1915

Role of FOXO3A in Trastuzumab Combination Chemotherapy in Esophageal Squamous Cell Carcinoma. M. TAKAHASHI, K. FUKUDA, Y. SAIKAWA, R. NAKAMURA, N. WADA, H. KAWAKUBO, H. TAKEUCHI, Y. KITAGAWA (*Tokyo; Hamamatsu, Japan*)..... 1921

ROCK1 and ROCK2 Are Down-regulated in Aggressive and Advanced Skin Melanomas – A Clinicopathological Perspective. M. KACZOROWSKI, P. BIECEK, P. DONIZY, M. PIENIĄŻEK, R. MATKOWSKI, A. HAŁOŃ (*Wroclaw; Warsaw; Opole, Poland*) ..... 1931

PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma. Y. SEKINO, T. HAGURA, X. HAN, T. BABASAKI, K. GOTO, S. INOUE, T. HAYASHI, J. TEISHIMA, M. SHIGETA, D. TANIYAMA, K. KURAOKA, K. SENTANI, W. YASUI, A. MATSUBARA (*Hiroshima; Kure, Japan*)..... 1943

Knockdown of CARD14 Inhibits Cell Proliferation and Migration in Breast Cancer Cells. J.-Y. LIM, S.W. KIM, B. KIM, S.-J. PARK (*Gwangju, Republic of Korea*) ..... 1953



Menadione/Ascorbate Induces Overproduction of Mitochondrial Superoxide and Impairs Mitochondrial Function in Cancer: Comparative Study on Cancer and Normal Cells of the Same Origin. S. SEMKOVA, Z. ZHELEV, T. MILLER, K. SUGAYA, I. AOKI, T. HIGASHI, R. BAKALOVA ( <i>Chiba, Japan; Sofia; Stara Zagora, Bulgaria; San Diego, CA, USA</i> ).....	1963
Nucleolin and Nucleophosmin Expression in Gleason 3 and Gleason 4 Prostate Cancer With Seminal Vesicles Invasion (pT3b). M. MASIUK, M. LEWANDOWSKA, E. DOBAK, E. URASINSKA ( <i>Szczecin, Poland</i> )....	1973
Experimental Animal Model of Re-irradiation to Evaluate Radiation-induced Damage in the Normal Intestine. H. DOI, M. TAMURA, K. NAKAMATSU, H. MONZEN, Y. NISHIMURA ( <i>Osaka, Japan</i> ) .....	1981
Potential Anticancer Effect of Calcium-mediated Src Degradation on Hormone-dependent Breast Cancer. S.Y. PARK, J.K. LEE, M.H. PARK, K.-Y. JEONG, H.M. KIM ( <i>Incheon, Republic of Korea</i> ).....	1989
The Alterations in Alcohol Dehydrogenase Activity in the Sera of Women With Intrahepatic Cholestasis of Pregnancy. W. JELSKI, J. PIECHOTA, K. ORYWAL, B. MROCZKO ( <i>Bialystok; Warsaw, Poland</i> ).....	1997
Association Between <i>MMP8</i> Gene Polymorphisms and Laryngeal Squamous Cell Carcinoma. R. INSODAITE, V. LIUTKEVICIUS, V. ULOZA, R. SOLOVEJUTE, A. SMALINSKIENE ( <i>Kaunas, Lithuania</i> ).....	2003
Association of Nijmegen Breakage Syndrome 1 Genotypes With Bladder Cancer Risk. M. CHEN, W.-S. CHANG, T.-C. SHEN, C.-L. GONG, M.-L. LIN, Z.-H. WANG, Y.-C. WANG, C.-H. CHEN, H.-C. WU, D.-T. BAU, C.-W. TSAI ( <i>Beijing, PR China; Taichung, Taiwan, ROC</i> ).....	2011
Alteration of Cell Surface Markers CD38 and CD138 in Lymphoproliferative Disorders in the Ocular Adnexa. Y. SUIMON, S. KASE, I. MIURA, K. ISHIJIMA, S. ISHIDA ( <i>Sapporo; Obihiro, Japan</i> ) .....	2019
Grape Stem Extracts From Three Native Greek Vine Varieties Exhibit Strong Antioxidant and Antimutagenic Properties. A.S. VESKOUKIS, E. VASSI, K. POULAS, M. KOKKINAKIS, E. ASPRODINI, S. HAROUTOUNIAN, D. KOURETAS ( <i>Larissa; Patras; Heraklion; Athens, Greece</i> ).....	2025
SRSF3 Depletion Leads to an Increase in SF3B4 Expression in SNU-368 HCC Cells. J. LEE, G. SEO, W. HUR, S.K. YOON, S.W. NAM, J.-H. LEE ( <i>Seoul, Republic of Korea</i> ) .....	2033
<i>Clinical Studies</i>	
B-cell Receptor Recombinations in Lung Adenocarcinoma Exome Files Correlate With a Higher Overall Survival Rate. Y.N. TU, W.L. TONG, B.M. CALLAHAN, B.I. CHOBRUTSKIY, G. BLANCK ( <i>Tampa, FL, USA</i> ).....	2043
Stereotactic Body Radiotherapy Using CyberKnife® for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial. R. NAKAMURA, T. HIRATA, O. SUZUKI, K. OTANI, N. KAI, K. HATANO, K. FUJITA, M. UEMURA, R. IMAMURA, K. TANAKA, Y. YOSHIOKA, N. NONOMURA, K. OGAWA ( <i>Osaka; Tokyo, Japan</i> ) .....	2053
Prolonged Steroid Dependence in Adult Patients With Glioma. E.C. MANTILLA Jr., J. ABRAMOWITZ, T. DAN, E. PAN ( <i>Fort Worth; Dallas, TX, USA</i> ).....	2059
Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors. T. YAMAMOTO, Y. NIIBE, Y. MATSUMOTO, Y. DEKURA, R.-J. OH, H. YAMASHITA, H. KAKUHARA, M. AOKI, K. JINGU ( <i>Sendai; Tokyo; Okayama; Niigata; Sapporo; Osaka; Morioka; Hirosaki, Japan</i> ) .....	2065
Diagnostic Value of FDG-PET/CT for the Identification of Extranodal Extension in Patients With Head and Neck Squamous Cell Carcinoma. R. TOYA, T. SAITO, T. MATSUYAMA, Y. KAI, S. SHIRAIISHI, D. MURAKAMI, R. YOSHIDA, T. WATAKABE, F. SAKAMOTO, N. TSUDA, H. ARIMURA, Y. ORITA, H. NAKAYAMA, N. OYA ( <i>Kumamoto; Fukuoka, Japan</i> ) .....	2073

Predicting Difficult Laparoscopic Total Mesorectal Excision for Locally-advanced Mid-low Rectal Cancer: The <i>EuMaRCS</i> Score Validation. N. de'ANGELIS, A. MARTÍNEZ-PÉREZ, G.C. VITALI, F. PIGNEUR, A. LUCIANI, F. BRUNETTI, M. KRAFT, E. MARTÍ-MARTÍNEZ, P. MORONI, E. ESPIN, F. RIS, S. PUCCIARELLI ( <i>Créteil, France; Valencia; Barcelona, Spain; Geneva, Switzerland; Padua, Italy</i> ).....	2079
Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma. T. KUZUYA, M. ISHIGAMI, T. ITO, Y. ISHIZU, T. HONDA, T. ISHIKAWA, M. FUJISHIRO ( <i>Nagoya, Japan</i> ).....	2089
Impact of Bevacizumab <i>Versus</i> Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group. G. MOUNTZIOS, X. MAVROPOULOU, G.-A. KOLIOU, H. LINARDOU, E. SAMANTAS, P. KOSMIDIS, G. FOUNTZILAS, A. CHARITANDI, A. KALOGERA-FOUNTZILA ( <i>Athens; Thessaloniki, Greece; Limassol, Cyprus</i> ).....	2095
Textbook Outcomes Among Patients Undergoing Retroperitoneal Sarcoma Resection. D. MORIS, M. CERULLO, D.P. NUSSBAUM, D.G. BLAZER 3rd ( <i>Durham, NC, USA</i> ).....	2107
Oropharyngeal HPV Detection Techniques in HPV-associated Head and Neck Cancer Patients. T.K. EGGERSMANN, P. BAUMEISTER, J. KUMBRINK, D. MAYR, E. SCHMOECKEL, C.J. THALER, C. DANNECKER, U. JESCHKE, T. NAGLER, S. MAHNER, K. SHARAF, J.K.S. GALLWAS ( <i>Munich; Augsburg; Goettingen, Germany; Leiden, the Netherlands</i> ) .....	2117
Clinical Imaging of the Heterogeneous Group of Triple-negative Breast Cancer. M. MÜLLER, U. GÜTH, Z. VARGA, K. REEVE, V. BJELIC-RADISIC, M. FLEISCH, C.J. TAUSCH, C. ELFGEN ( <i>Zurich, Switzerland; Wuppertal; Witten-Herdecke, Germany</i> ) .....	2125
EZH2 and MMSET Were Identified as Potentially Useful Therapeutic Targets in Metaplastic Breast Carcinoma. H. NAKAYAMA, K. KAWACHI, N. SUGANUMA, T. YOSHIDA, T. YAMASHITA, T. YAMANAKA, Y. MATSUBARA, K. KOHAGURA, S. TODA, Y. NAKAMURA, Y. MIYAGI, Y. RINO, M. MASUDA ( <i>Yokohama, Japan</i> ) .....	2133
Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes. R. FUKUI, Y. FUJIMOTO, T. WATANABE, N. INOUE, A. BUN, T. HIGUCHI, M. IMAMURA, K. MORIMOTO, S. HIROTA, Y. MIYOSHI ( <i>Nishinomiya; Hyogo; Osaka; Saitama, Japan</i> ).....	2141
Outcome in Patients Treated With Cytoreductive Surgery and HIPEC for Gastric Cancer With Peritoneal Carcinomatosis. F. BRAEUER, I. FISCHER, L. BRAMMEN, G. PRESSL, R. FUEGGER, K. ROHREGGER, H. WUNDSAM ( <i>Linz; Vienna, Austria</i> ) .....	2151
Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab. L. SIMETIĆ, K. BLAŽIČEVIĆ, K. MEĐUGORAC, M. GOLČIĆ, D. HERCEG ( <i>Zagreb; Rijeka, Croatia</i> ) .....	2157
Outcomes of Laparoscopic Surgery in Colorectal Cancer Patients With Dialysis. N. HIGASHINO, T. MATSUDA, H. HASEGAWA, K. YAMASHITA, H. SAKAMOTO, M. FUJIKAWA, M. YAMAMOTO, S. KANAJI, T. OSHIKIRI, T. NAKAMURA, S. SUZUKI, Y. KAKEJI ( <i>Kobe, Japan</i> ) .....	2165
Nomogram for Predicting the Pathological Tumor Response from Pre-treatment Clinical Characteristics in Rectal Cancer. B.-H. KANG, C. SONG, S.-B. KANG, K.-W. LEE, H.S. LEE, J.-S. KIM ( <i>Seoul; Seongnam, Republic of Korea</i> ) .....	2171
Comparison of Patient Satisfaction on a Day-case Mastectomy Pathway for Breast Cancer <i>Versus</i> a Traditional Inpatient Delivery Model, Using a Validated Questionnaire. S. DAVEY, A. ROCHE, I. PEGBA-OTEMOLU, A. IBRAHIM, R. AINSWORTH ( <i>Bristol; Livingston; Oxford, East Grinstead, UK</i> ) .....	2179

Correlation of Ductoscopic and Histopathological Findings and Their Relevance as Predictors for Malignancy: A German Multicenter Study. R. OHLINGER, C. FLIEGER, W. HAHNDORF, S. PAEPKE, J.-U. BLOHMER, S. GRUNWALD, Z. ALWAFAI, R. FLIEGER, O. CAMARA, U. DEICHERT, U. PEISKER, T. KOHLMANN, I. BUCHHOLZ, K. HEGENSCHIED, K. UTPATEL, A. STOMPS, U. RECHENBERG, M. ZYGMUNT, M. HAHN ( <i>Greifswald; Munich; Berlin; Jena; Cuxhaven; Erkelenz; Tuebingen, Germany</i> ) .....	2185
Positron Emission Tomography/Computed Tomography in Platinum-sensitive Recurrent Ovarian Cancer: A Single-center Italian Study. A. GADDUCCI, E. SIMONETTI, G. MANCA, F. GUIDOCCIO, A. FANUCCHI, S. COSIO, D. VOLTERRANI ( <i>Pisa, Italy</i> ) .....	2191
The Influence of Neoadjuvant Chemoradiation for Middle and Lower Rectal Cancer on Anorectal Function. Y. HIRATA, H. NOZAWA, K. KAWAI, K. HATA, T. TANAKA, T. NISHIKAWA, K. SASAKI, M. KANEKO, S. EMOTO, K. MURONO, H. SONODA, S. ISHIHARA ( <i>Tokyo, Japan</i> ) .....	2199
Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer. M. SVATON, M. ZEMANOVA, P. ZEMANOVA, J. KULTAN, O. FISCHER, J. SKRICKOVA, L. JAKUBIKOVA, M. CERNOVSKA, M. HRNCIARIK, M. JIROUSEK, J. KREJCI, D. KREJCI, O. BILEK, J. BLAZEK, K. HURDALKOVA, M. BARINOVA, B. MELICHAR ( <i>Pilsen; Prague; Olomouc; Brno; Hradec Kralove, Czech Republic</i> ).....	2209
Prevalence of Cervico-vaginal High-risk HPV Types and Other Sexually Transmitted Pathogens in Anogenital Warts Patients. D. MORTAKI, E. TSITSOPOULOS, E. LOUIZOU, E. TSIAMBAS, D. PESCHOS, V. SIOULAS, A. GALANOS, A. TAGKA, S. GREGORIOU, A. STRATIGOS, D. RIGOPOULOS, E. NICOLAIDOU ( <i>Athens; Ioannina, Greece</i> ) .....	2219
Primary Hepatic Carcinosarcoma Composed of Hepatocellular Carcinoma, Cholangiocarcinoma, Osteosarcoma and Rhabdomyosarcoma With Poor Prognosis. L. LIU, E. AHN, K. STUDEMAN, K. CAMPBELL, J. LAI ( <i>Baltimore; College Park, MD; Sacramento, CA, USA</i> ) .....	2225
Ultrasound-guided Interfascial Plane Blocks for Non-anesthesiologists in Breast Cancer Surgery: Functional Outcomes and Benefits. A. GRASSO, P. ORSARIA, F. COSTA, V. D'AVINO, E. CAREDDA, A. HAZBOUN, R. CARINO, G. PASCARELLA, M. ALTOMARE, O.C. BUONOMO, F.E. AGRÒ, V. ALTOMARE ( <i>Rome; Milan, Italy</i> ) .....	2231
Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation. M. TONE, M. INOMATA, N. AWANO, N. KUSE, T. JO, H. YOSHIMURA, J. MINAMI, K. TAKADA, S. MIYAMOTO, T. IZUMO ( <i>Tokyo, Japan</i> ) .....	2239
Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer. K. KATO, Y. NARITA, S. MITANI, K. HONDA, T. MASUISHI, H. TANIGUCHI, S. KADOWAKI, T. URA, M. ANDO, M. TAJIKA, K. MURO ( <i>Aichi; Osaka; Chiba; Kyoto, Japan</i> ) .....	2247
An Instrument to Guide Physicians when Estimating the Survival of Elderly Patients With Brain Metastasis from Gynecological Cancer. D. RADES, T. NGUYEN, S. JANSSEN, S.E. SCHILD ( <i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i> ) .....	2257
Remaining Lifespan of Patients Aged $\geq 65$ Years Receiving Whole-brain Irradiation for Metastases from Cancer of Unknown Primary. D. RADES, T. NGUYEN, M.T. KHOA, S. JANSSEN, S.E. SCHILD ( <i>Lübeck; Hannover, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA</i> ) .....	2261
Antitumor Activity of Cabozantinib in Metastatic Adult Ewing Sarcoma: A Case Report. D. SCHALLIER, P. LESFEVRE, H. EVERAERT ( <i>Brussels, Belgium</i> ).....	2265
Individualisation of Radiation Therapy for Older Persons With Secondary Brain Lesions from Carcinoma of the Breast. D. RADES, T. NGUYEN, S. JANSSEN, M.T. KHOA, S.E. SCHILD ( <i>Lübeck; Hannover, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA</i> ) .....	2271

Effect of Muscle Mass Loss After Esophagectomy on Prognosis of Oesophageal Cancer. Y. SHIMODA, T. YAMADA, K. KOMORI, H. WATANABE, H. OSAKABE, K. KANO, H. FUJIKAWA, T. HAYASHI, H. CHO, M. SHIOZAWA, T. YOSHIKAWA, S. MORINAGA, Y. OTA, K. KATSUMATA, A. TSUCHIDA, T. OGATA, T. OSHIMA ( <i>Yokohama; Tokyo, Japan</i> ).....	2275
Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. T. KUZUYA, M. ISHIGAMI, T. ITO, Y. ISHIZU, T. HONDA, T. ISHIKAWA, M. FUJISHIRO ( <i>Nagoya, Japan</i> ).....	2283
Therapeutic Effect of Ethinylestradiol in Castration-resistant Prostate Cancer. T. NAKANO, Y. KADONO, H. IWAMOTO, H. YAEGASHI, M. IJIMA, S. KAWAGUCHI, T. NOHARA, K. SHIGEHARA, K. IZUMI, A. MIZOKAMI ( <i>Kanazawa, Japan</i> ).....	2291
The Preoperative Prognostic Nutritional Index Predicts the Development of Deep Venous Thrombosis After Pancreatic Surgery. T. IGUCHI, K. SUGIMACHI, Y. MANO, M. KONO, M. KAGAWA, T. NAKANOKO, H. UEHARA, M. SUGIYAMA, M. OTA, M. IKEBE, M. MORITA, Y. TOH ( <i>Fukuoka, Japan</i> ).....	2297
Optimal Tumor Reduction Rate and Modalities for Predicting pCR in Women With Breast Cancer. S. KUBA, S. MAEDA, M. MATSUMOTO, K. YAMANOUCHI, T. IWATA, M. MORITA, C. SAKIMURA, R. OTSUBO, H. YANO, S. SATO, K. KANETAKA, T. NAGAYASU, S. EGUCHI ( <i>Nagasaki, Japan</i> ).....	2303
Clinical Significance of Dynamic Neutrophil-lymphocyte Ratio Changes in Patients With Colorectal Cancer. N. ASHIZAWA, S. FURUYA, S. KATSUTOSHI, M. SUDO, H. AKAIKE, N. HOSOMURA, Y. KAWAGUCHI, H. AMEMIYA, H. KAWAIDA, S. INOUE, H. KONO, D. ICHIKAWA ( <i>Yamanashi, Japan</i> ).....	2311
Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy. M. HOFFMANN, D. REITZ, J. TAUGNER, O. ROENGVORAPHOJ, L. KÄSMANN, C. EZE, M. KARIN, C. BELKA, F. MANAPOV ( <i>Munich, Germany</i> ).....	2319
Association of Triiodothyronine Levels With Prostate Cancer Histopathological Differentiation and Tumor Stage. P. PETRANOVIĆ OVČARIČEK, A. FRÖBE, F.A. VERBURG, J. MURGIĆ, M. BOSAK BUTKOVIĆ, S. OVČARIČEK, B. MAŽURAN, B. KRUŠLIN, D. JAKOVČEVIĆ, Š. ŠOIPI, B. RUŽIĆ, M. MILOŠEVIĆ, D. KRILIĆ, M. FRANCESCHI, T. JUKIĆ ( <i>Zagreb; Osijek, Croatia; Marburg, Germany</i> )....	2323
Cholecystectomy as Part of Cytoreductive Surgery for Advanced Ovarian Cancer: Perioperative Outcomes. C.G. LIAKOU, N. AKRIVOS, B. KUMAR, T.J. DUNCAN, H.L. TURNBULL, J.J. NIETO, N. BURBOS ( <i>Norwich, UK</i> ).....	2331
Short-term Outcomes Following Robotic-assisted Laparoscopic Surgery for Technically Demanding Rectal Cancer. M. NUMATA, K. KAZAMA, A. ONODERA, K. HARA, Y. ATSUMI, H. OKAMOTO, T. AOYAMA, H. TAMAGAWA, T. GODAI, H. SAEKI, N. YUKAWA, M. SHIOZAWA, Y. RINO, M. MASUDA ( <i>Yokohama; Fujisawa, Japan</i> ).....	2337
Prediction of Sentinel Lymph Node Metastasis Using the Platelet-to-lymphocyte Ratio in T1 Breast Cancer. K. TAKADA, S. KASHIWAGI, Y. ASANO, W. GOTO, R. KOUHASHI, A. YABUMOTO, T. MORISAKI, M. SHIBUTANI, T. TAKASHIMA, H. FUJITA, K. HIRAKAWA, M. OHIRA ( <i>Osaka, Japan</i> ).....	2343
Prognostic Factors for Para-aortic Lymph Node Dissection After Neoadjuvant Chemotherapy for Gastric Cancer. S. ENDO, M. IKENAGA, T. YAMADA, S. TAMURA, Y. SASAKI ( <i>Osaka, Japan</i> ).....	2351
Postoperative Bleeding After Esophagectomy for Esophageal Cancer in Patients Receiving Antiplatelet and Anticoagulation Treatment. T. AOYAMA, Y. ATSUMI, K. HARA, K. KAZAMA, H. TAMAGAWA, A. TAMAGAWA, K. KOMORI, Y. MAEZAWA, K. KANO, I. HASHIMOTO, T. OSHIMA, M. MURAKAWA, M. NUMATA, N. YUKAWA, M. MASUDA, Y. RINO ( <i>Yokohama, Japan</i> ).....	2359

Influence of the Preoperative C-Reactive Protein-to-Albumin Ratio on Survival and Recurrence in Patients With Esophageal Cancer. H. TAMAGAWA, T. AOYAMA, A. TAMAGAWA, K. KOMORI, Y. MAEZAWA, K. KANO, M. MURAKAWA, Y. ATSUMI, K. HARA, K. KAZAMA, M. NUMATA, T. OSHIMA, N. YUKAWA, M. MASUDA, Y. RINO ( <i>Yokohama, Japan</i> ) .....	2365
Upfront Surgery for Small Intestinal Non-Hodgkin's Lymphoma. T. IIDA, H. NOZAWA, H. SONODA, K. TOYAMA, K. KAWAI, K. HATA, T. TANAKA, T. NISHIKAWA, K. SASAKI, Y. SHUNO, M. KANEKO, K. MURONO, S. EMOTO, H. ISHII, M. KUROKAWA, S. ISHIHARA ( <i>Tokyo, Japan</i> ) .....	2373
Dose Adjustment of Oxaliplatin Based on Renal Function in Patients With Metastatic Colorectal Cancer. D. WATANABE, H. FUJII, N. MATSUHASHI, H. IIHARA, Y. YAMADA, T. ISHIHARA, T. TAKAHASHI, K. YOSHIDA, A. SUZUKI ( <i>Gifu, Japan</i> ) .....	2379
Clinical Outcomes and Prognostic Factors of Patients With Esophageal Squamous Cell Carcinoma With Oligo-recurrence Treated With Radical Re-irradiation. C.-Y. LIN, H.-Y. FANG, M.-Y. LEIN, C.-C. LIN, L.-Y. BAI, M.-H. TSAI, C.-C. CHEN, T.-C. HSIEH, Y.-C. WANG, J.-A. LIANG, C.-C. LI, C.-R. CHIEN ( <i>Taichung; Hsinchu, Taiwan, ROC</i> ) .....	2387
Epidemiological Correlations Between Head and Neck Cancer and Hepatitis B Core Antibody Positivity. M. FUKUSHIMA KOMORI, T. KIMURA, S. KARIYA, T. ONODA, S. TAKEDA, N. MIZUKAWA, S. IIDA, Y. KIMATA, K. NISHIZAKI ( <i>Okayama; Tamano, Japan</i> ) .....	2393
Book Reviews .....	2405

## Number 5, May

### Reviews

Skeletal Muscle Mass Change During Chemotherapy: A Systematic Review and Meta-analysis. M.K. JANG, C. PARK, S. HONG, H. LI, E. RHEE, A.Z. DOORENBOS ( <i>Chicago, IL, USA</i> ) .....	2409
A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer. B. ZHANG, M. LEECH ( <i>Dublin, Ireland; Singapore, Singapore</i> ) .....	2419
Endometriosis-associated Extraovarian Malignancies: A Challenging Question for the Clinician and the Pathologist. A. GADDUCCI, G.F. ZANNONI ( <i>Pisa; Rome, Italy</i> ) .....	2429
Urinary Tract Large Cell Neuroendocrine Carcinoma: Diagnostic, Prognostic and Therapeutic Issues. F. SANGUEDOLCE, B. CALÒ, M. CHIRICO, S. TORTORELLA, G. CARRIERI, L. CORMIO ( <i>Foggia, Italy</i> ) ....	2439
The Licensing Factor Cdt1 Links Cell Cycle Progression to the DNA Damage Response. A. KANELLOU, N.N. GIAKOUMAKIS, A. PANAGOPOULOS, S.C. TSANIRAS, Z. LYGEROU ( <i>Patras, Greece</i> ) .....	2449
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives. M. MASSIMINO, S. STELLA, E. TIRRO', M.S. PENNISI, S.R. VITALE, A. PUMA, C. ROMANO, S. DI GREGORIO, C. TOMARCHIO, F. DI RAIMONDO, L. MANZELLA ( <i>Catania, Italy</i> ) .....	2457

### Experimental Studies

Noncalcemic Vitamin D Hydroxyderivatives Inhibit Human Oral Squamous Cell Carcinoma and Down-regulate Hedgehog and WNT/ $\beta$ -Catenin Pathways. A.S.W. OAK, G. BOCHEVA, T.-K. KIM, A.A. BROŻYNA, Z. JANJETOVIC, M. ATHAR, R.C. TUCKEY, A.T. SLOMINSKI ( <i>Birmingham, AL, USA; Sofia, Bulgaria; Toruń, Poland; Perth, WA, Australia</i> ) .....	2467
---	------

Eribulin Regresses a Cisplatin-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model. J. YAMAMOTO, T. MURATA, N. SUGISAWA, T. HIGUCHI, Y. TASHIRO, H. NISHINO, S. INUBUSHI, Y. SUN, H. LIM, K. MIYAKE, K. SHIMOYA, T. NOMURA, J. KUREBAYASHI, H. TANINO, C. HOZUMI, M. BOUVET, S.R. SINGH, I. ENDO, R.M. HOFFMAN ( <i>San Diego, CA; Frederick, MD, USA; Yokohama; Okayama; Kurashiki; Kobe; Narita, Japan</i> ) .....	2475
A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model. H.I. LIM, J. YAMAMOTO, S. INUBUSHI, H. NISHINO, Y. TASHIRO, N. SUGISAWA, Q. HAN, Y. SUN, H.J. CHOI, S.J. NAM, M.B. KIM, J.S. LEE, C. HOZUMI, M. BOUVET, S.R. SINGH, R.M. HOFFMAN ( <i>San Diego, CA; Frederick, MD, USA; Changwon; Seoul, Republic of Korea; Narita, Japan</i> ) .....	2481
Gene Expression of Kallikreins in Breast Cancer Cell Lines. R. WATROWSKI, D.C. CASTILLO-TONG, E. OBERMAYR, R. ZEILLINGER ( <i>Freiburg, Germany; Vienna, Austria</i> ) .....	2487
Pegylated Liposomal Doxorubicin/Oxaliplatin Chemotherapy Can Overcome Cisplatin Resistance in Spectrin $\alpha$ II-Overexpressing Ovarian Carcinoma. O. MAEDA, H. KAJIYAMA, K. SHIBATA, S. NAKAMURA, F. KIKKAWA ( <i>Nagoya, Japan</i> ) .....	2497
A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib. J. YAMAMOTO, T. MURATA, Y. TASHIRO, T. HIGUCHI, N. SUGISAWA, H. NISHINO, S. INUBUSHI, Y. SUN, H. LIM, K. MIYAKE, A. HONGO, T. NOMURA, W. SAITOH, T. MORIYA, H. TANINO, C. HOZUMI, M. BOUVET, S.R. SINGH, I. ENDO, R.M. HOFFMAN ( <i>San Diego, CA; Frederick, MD, USA; Yokohama; Okayama; Kurashiki; Kobe; Narita, Japan</i> ) .....	2509
Recombinant Methioninase Combined With Tumor-targeting <i>Salmonella typhimurium</i> A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma. K. IGARASHI, K. KAWAGUCHI, M. ZHAO, Q. HAN, Y. TAN, T. KIYUNA, K. MIYAKE, T. HIGUCHI, S.D. NELSON, S.M. DRY, Y. LI, N. YAMAMOTO, K. HAYASHI, H. KIMURA, S. MIWA, S.R. SINGH, H. TSUCHIYA, R.M. HOFFMAN ( <i>San Diego; Los Angeles, CA; Frederick, MD, USA; Kanazawa, Japan</i> ) .....	2515
Histone Methyltransferase Inhibition Has a Cytotoxic Impact on Transformed Mast Cells: Implications for Mastocytosis. S. ALANAZI, F.R. MELO, G. PEJLER ( <i>Uppsala, Sweden</i> ) .....	2525
Radiation Induces Autophagy <i>via</i> Histone H4 Lysine 20 Trimethylation in Non-small Cell Lung Cancer Cells. T.-G. LEE, S.-Y. KIM, H.-R. KIM, H. KIM, C.H. KIM ( <i>Seoul, Republic of Korea</i> ) .....	2537
Sonodynamically-induced Anticancer Effects of Polyethylene Glycol-Modified Carbon Nano Tubes. N. YUMITA, Y. IWASE, S.-I. UMEMURA, F.-S. CHEN, Y. MOMOSE ( <i>Yokohama; Sendai; Funabashi, Japan; Hualien, Taiwan, ROC</i> ) .....	2549
Androgen-induced Epigenetic Profiles of Polycomb and Trithorax Genes in Prostate Cancer Cells. S. WANG, K. TAILOR, B. KWABI-ADDO ( <i>Washington, DC, USA</i> ) .....	2559
High Spatial Resolution Digital Positron Emission Tomography Images With Dedicated Source-to-background Algorithm for Radiotherapy Planning. T. WATAKABE, R. TOYA, T. SAITO, T. MATSUYAMA, S. SHIRAISHI, Y. KAI, Y. SHIMOHIGASHI, N. OYA ( <i>Kumamoto; Fukuoka, Japan</i> ) .....	2567
Role of Death Receptors-associated Lipid Rafts in Oxaliplatin-induced Death Mode Regulation of HepG2 Cells. S.-C. LIM, K.R. PARAJULI, S.I. HAN ( <i>Gwangju, Republic of Korea</i> ) .....	2573
Benzoxazine Dimer Analogue Targets Integrin $\beta$ 3 in Lung Cancer Cells and Suppresses Anoikis Resistance and Migration. N. SRIRATANASAK, N. NONPANYA, W. WATTANATHANA, P. CHANVORACHOTE ( <i>Bangkok, Thailand</i> ) .....	2583

The Application of a Low-temperature Physical Plasma Device Operating Under Atmospheric Pressure Leads to the Production of Toxic NO <sub>2</sub> . K. KLETTSCHKUS, L. HARALAMBIEV, A. NITSCH, F. PFISTER, G. KLINKMANN, A. KRAMER, S. BEKESCHUS, A. MUSTEA, M.B. STOPE ( <i>Greifswald; Berlin; Bonn; Rostock; Greifswald, Germany</i> ).....	2591
ABHD12 Knockdown Suppresses Breast Cancer Cell Proliferation, Migration and Invasion. S. JUN, S.W. KIM, J.-Y. LIM, S.-J. PARK ( <i>Gwangju, Republic of Korea</i> ) .....	2601
3PO as a Selective Inhibitor of 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3 in A375 Human Melanoma Cells. K. KOTOWSKI, S. SUPPLITT, D. WICZEW, D. PRZYSTUPSKI, W. BARTOSIK, J. SACZKO, J. ROSSOWSKA, M. DRĄG-ZALESIŃSKA, O. MICHEL, J. KULBACKA ( <i>Wroclaw, Poland</i> ) .....	2613
Periostin Plays a Key Role in Radioresistance of Head and Neck Cancer Cells <i>Via</i> Epithelial-to-Mesenchymal Transition. J.J. PARK, Y.-S. HAH, S. RYU, S.Y. CHEON, H.Y. CHO, J.P. KIM, S.J. WON, J.S. LEE, J.S. HWA, J.H. SEO, H.W. CHANG, S.Y. KIM ( <i>Jinju; Seoul, Republic of Korea</i> ) .....	2627
Establishment of a Liver Transplant Patient-derived Tumor Xenograft (PDX) Model Using Cryopreserved Pancreatic Ductal Adenocarcinoma. R. TANAKA, K. KAGEYAMA, K. KIMURA, S. EGUCHI, J. TAUCHI, H. SHINKAWA, G. OHIRA, S. YAMAZOE, A. YAMAMOTO, S. TANAKA, R. AMANO, H. TANAKA, M. YASHIRO, S. KUBO, M. OHIRA ( <i>Osaka, Japan</i> ) .....	2637
<i>MALAT1</i> Decreases the Sensitivity of Head and Neck Squamous Cell Carcinoma Cells to Radiation and Cisplatin. K. KANGBOONRUANG, P. WONGTRAKOONGATE, K. LERTSUWAN, S. KHACHONKHAM, P. CHANGKAEW, P. TANGBOONDUNANGJIT, T. SIRIPOON, N. NGAMPHAIBOON, A. CHAIROUNGDUAN ( <i>Bangkok, Thailand</i> ).....	2645
High Nitric Oxide Adaptation in Isogenic Primary and Metastatic Head and Neck Cancer Cells. K. UTISPAN, S. KOONTONGKAEW ( <i>Pathum Thani; Bangkok, Thailand</i> ) .....	2657
Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic <i>BRAF</i> Mutation. S. MIYAUCHI, K. SHIEN, T. TAKEDA, K. ARAKI, K. NAKATA, A. MIURA, Y. TAKAHASHI, E. KURIHARA, Y. OGOSHI, K. NAMBA, K. SUZAWA, H. YAMAMOTO, M. OKAZAKI, J. SOH, S. TOMIDA, M. YAMANE, M. SAKAGUCHI, S. TOYOOKA ( <i>Okayama, Japan</i> ) .....	2667
Inhibition of Jurkat T Cell Growth by <i>N</i> -farnesyl-norcantharimide Through Up-regulation of Tumor Suppressor Genes and Down-regulation of Genes for Steroid Biosynthesis, Metabolic Pathways and Fatty Acid Metabolism. J.-Y. WU, E.-T. TSAI, F.-Y. YANG, J.-F. LIN, H.-F. LIAO, Y.-J. CHEN, C.-D. KUO ( <i>Chiayi; Taipei; Changhua, Taiwan, ROC</i> ) .....	2675
Urethane-induced Mammary Carcinogenesis Susceptibility in Transgenic Mice Expressing a Dominant-negative TGF- $\beta$ Type II Receptor. M.-A. SHIBATA, E. SHIBATA, J. MORIMOTO, Y. KONDO ( <i>Takatsuki; Suita, Japan</i> ) .....	2687
Tumour Budding Is an Independent Predictive Factor of Cutaneous Squamous-cell Carcinoma Aggressiveness. G. KARAYANNOPOULOU, E. PANTERIS, J. KANITAKIS ( <i>Thessaloniki, Greece; Lyon; Pierre Bénite, France</i> ) .....	2695
A Rat Model of Oral Mucositis Induced by Cancer Chemotherapy for Quantitative Experiments. I. TAKEUCHI, R. KAWAMATA, K. MAKINO ( <i>Chiba, Japan</i> ) .....	2701
Adjuvant Postoperative CD40 Agonist and PD-1 Antagonist Combination Therapy in Syngeneic Tongue Cancer Mouse Model. S.-H. AHN, S. SONG, S. KIM ( <i>Seoul, Republic of Korea</i> ).....	2707
Tumor-associated Macrophages Facilitate Bladder Cancer Progression by Increasing Cell Growth, Migration, Invasion and Cytokine Expression. C.-P. HUANG, L.-X. LIU, C.-R. SHYR ( <i>Taichung, Taiwan, ROC</i> ) .....	2715

Glioblastoma Factors Increase the Migration of Human Brain Endothelial Cells <i>In Vitro</i> by Increasing MMP-9/CXCR4 Levels. L.V. DE OLIVEIRA ROSARIO, B.G. DA ROSA, T. LOPES GONCALVES, D.I. LOURENCO MATIAS, C. FREITAS, V. PEREIRA FERRER ( <i>Rio de Janeiro; Niteroi, Brazil; London, UK</i> ) .....	2725
Cell Cycle Arrest and Apoptotic Effect of 7-(4-(N-substituted carbamoylmethyl) piperazin-1-yl) Ciprofloxacin-derivative on HCT 116 and A549 Cancer Cells. R. ALAAELDIN, M.H. NAZMY, M. ABDEL-AZIZ, G.E.-D.A. ABUO-RAHMA, M. FATHY ( <i>Minia, Egypt; Toyama, Japan</i> ) .....	2739
<i>Clinical Studies</i>	
Utility of the Free Vascularized Fibula Flap to Reconstruct Oncologic Defects in the Upper Extremity. M.R. CLAXTON, M.B. SHIRLEY, K. BAKRI, P.S. ROSE, S.L. MORAN, M.T. HOUDEK ( <i>Rochester, MN, USA</i> ) .....	2751
MRI Lymph Node Evaluation for Prediction of Metastases in Rectal Cancer. K. ALMLÖV, M. WOISETSCHLÄGER, P. LOFTÅS, O. HALLBÖÖK, N.O. ELANDER, P. SANDSTRÖM ( <i>Norrköping; Linköping, Sweden</i> ) .....	2757
Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer. A.W. EKMANN-GADE, C.K. HOGDALL, S.A. ENGELHOLM, C.L. FAGO-OLSEN ( <i>Copenhagen, Denmark</i> ) .....	2765
Ultrasound-guided Percutaneous Irreversible Electroporation for Treatment of Locally Recurrent Pancreatic Cancer After Surgical Resection. C. MÅNSSON, A. NILSSON, P. NYGREN, B.-M. KARLSON ( <i>Uppsala, Sweden</i> ) .....	2771
Five Genes Associated With Survival in Patients With Lower-grade Gliomas Were Identified by Information-theoretical Analysis. K. SATO, K. TAHATA, K. AKIMOTO ( <i>Chiba, Japan</i> ) .....	2777
Significance of Quantitative Interferon-gamma Levels in Non-small-cell Lung Cancer Patients' Response to Immune Checkpoint Inhibitors. T. KANAI, H. SUZUKI, H. YOSHIDA, A. MATSUSHITA, H. KAWASUMI, Y. SAMEJIMA, Y. NODA, S. NASU, A. TANAKA, N. MORISHITA, S. HASHIMOTO, K. KAWAHARA, Y. TAMURA, N. OKAMOTO, T. TANAKA, T. HIRASHIMA ( <i>Osaka, Japan</i> ) .....	2787
Inflammatory Liver Tumor Caused by <i>Fasciola hepatica</i> Mimicking Intrahepatic Cholangiocarcinoma. T. KAIDA, T. BEPPU, H. HAYASHI, K. IMAI, K. YAMAMURA, H. OKABE, K. MATSUMURA, D. YOSHII, Y. KOMOHARA, S. AKAHOSHI, K. DOI, Y.-I. YAMASHITA, H. BABA ( <i>Nobeoka; Yamaga; Kumamoto, Japan</i> )..	2795
Impact of the Lysine-urethane Adhesive TissuGlu® on Postoperative Complications and Interventions After Drain-free Mastectomy. R. OHLINGER, R. RUTKOWSKI, T. KOHLMANN, S. PAEPKE, Z. ALWAFI, C. FLIEGER, S. MÖLLER, F. LENZ, M. ZYGMUNT, J. UNGER ( <i>Greifswald; Hamburg; Munich, Germany</i> ) .....	2801
Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient. Q. HAN, Y. TAN, R.M. HOFFMAN ( <i>San Diego, CA, USA</i> ) .....	2813
Two Malignancies With Differential Responses to Immune Checkpoint Inhibitors: A Case Report. S.Y. HAN, B.N. JAHAGIRDAR, A.Z. DUDEK ( <i>Minneapolis; Saint Paul, MN, USA</i> ) .....	2821
Phase II Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Unresectable Esophageal Cancer. K. TAKAHASHI, Y. OSAKA, Y. OTA, T. WATANABE, K. IWASAKI, S. TACHIBANA, Y. NAGAKAWA, K. KATSUMATA, A. TSUCHIDA ( <i>Tokyo, Japan</i> ) .....	2827
The Prognostic Value of the Number of Harvested Negative Lymph Nodes in Patients Treated by Esophagectomy With or Without Neoadjuvant Chemoradiation. M. BRUNNER, S. MERKEL, C. KRAUTZ, S. KERSTING, R. GRÜTZMANN, G.F. WEBER ( <i>Erlangen, Germany</i> ) .....	2833



Extra-cerebral Metastasis – An Independent Predictor of Survival in Older Patients With Brain Metastases Receiving a Local Therapy Plus Whole-Brain Radiotherapy (WBRT). D. RADES, T. NGUYEN, S.E. SCHILD ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ) .....	2841
Evaluation of Five Survival Scores in a Cohort of Elderly Patients With Cerebral Metastasis from Non-small Cell Lung Cancer. D. RADES, T. NGUYEN, M.T. KHOA, S. JANSSEN, S.E. SCHILD ( <i>Lübeck; Hannover, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA</i> ) .....	2847
Outcome and Toxicity of Carbon Ion Radiotherapy for Axial Bone and Soft Tissue Sarcomas. F. CUCCIA, M.R. FIORE, A. BARCELLINI, A. IANNALFI, B. VISCHIONI, S. RONCHI, M. BONORA, G. RIVA, A. VAI, A. FACOETTI, L. PREDA, F. VALVO, V. VITOLO ( <i>Pavia; Verona, Italy</i> ).....	2853
Incidental Testicular Pathologies in Patients With Idiopathic Hydrocele Testis: Is Preoperative Scrotal Ultrasound Justified? M. KAFKA, K. STROHHACKER, F. AIGNER, F. STEINKOHL, W. HORNINGER, R. PICHLER, I. HEIDEGGER ( <i>Innsbruck, Austria</i> ) .....	2861
Impact of Cytoreductive Surgery and HIPEC on Intraoperative Gastrointestinal Wall Thickness and Patient Outcomes. M.Z. CHEN, D.L. CHAN, M.S. ALSHAHRANI, K. ALTOUKHI, N. ALZHRANI, D.L. MORRIS ( <i>Kogarah; Sydney, NSW, Australia; Riyadh, Kingdom of Saudi Arabia</i> ).....	2865
Prognostic Significance of Neutrophil-to-lymphocyte Ratio in Luminal Breast Cancers With Low Levels of Tumour-infiltrating Lymphocytes. A. BUN, Y. FUJIMOTO, T. HIGUCHI, A. SATA, R. FUKUI, H. OZAWA, Y. MIYAGAWA, M. IMAMURA, T. WATANABE, Y. MIYOSHI ( <i>Nishinomiya; Osaka, Japan</i> ) .....	2871
Preoperative Neutrophil-to-lymphocyte Ratio Predicts Tumor-infiltrating CD8 <sup>+</sup> T Cells in Biliary Tract Cancer. R. TANAKA, K. KIMURA, S. EGUCHI, J. TAUCHI, M. SHIBUTANI, H. SHINKAWA, G. OHIRA, S. YAMAZOE, S. TANAKA, R. AMANO, H. TANAKA, M. YASHIRO, S. KUBO, M. OHIRA ( <i>Osaka, Japan</i> ).....	2881
Resection for Internal Jugular Vein Thrombosis and Cervical Lymph Nodes' Involvement from Gastric Cancer. G. ILLUMINATI, R. PASQUA, P. NARDI, C. FRATINI, A. MINNI, C. GIORDANO ( <i>Rome, Italy</i> ) .....	2889
Elderly Age Is Associated With More Conservative Treatment of Invasive Melanoma. SB. BATENI, A.J. JOHNS, A.A. GINGRICH, S. GHOLAMI, R.J. BOLD, R.J. CANTER, A.R. KIRANE ( <i>Sacramento, CA, USA</i> ) .....	2895
Whole-bladder Radiation Therapy for Lymph Node-negative Bladder Cancer With Muscle Invasion in Elderly Patients. A. ADACHI, H. KAWAMURA, D. YOSHIDA, M. KAWAHARA, S. KUDO, T. EBARA, T. NAKANO ( <i>Gunma; Kanagawa; Nagano; Saitama, Japan</i> ) .....	2905
Targeted Therapy Followed by Cytotoxic Chemotherapy in Preoperative Patients With Locally Advanced Lung Adenocarcinoma. M. AOKI, K. UEDA, T. UMEHARA, G. KAMIMURA, T. TOKUNAGA, A. HARADA-TAKEDA, K. MAEDA, T. NAGATA, N. YOKOMAKURA, K. KARIATSUMARI, Y. NONAKA, N. IMAMURA, S. MORIZONO, M. SATO ( <i>Kagoshima, Japan</i> ) .....	2911
Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk. S. KIM, S.-S. YOON, J. HONG, D.-Y. SHIN, Y. KOH, J.M. BYUN, I. KIM ( <i>Seoul, Republic of Korea</i> ) .....	2917
Quantitative Assessment of Contrast Enhancement on Contrast Enhancement Spectral Mammography (CESM) and Comparison With Qualitative Assessment. W. RUDNICKI, S. HEINZE, T. POPIELA, Z. KOJS, E. LUCZYNSKA ( <i>Cracow; Rzeszow, Poland</i> ).....	2925
Primary Peritoneal High-grade Serous Carcinoma Misinterpreted as Metastatic Breast Carcinoma: A Rare Encounter in Peritoneal Fluid Cytology. S. PARK, E.Y. CHO, Y.L. OH, Y.H. PARK, H.-S. KIM ( <i>Seoul, Republic of Korea</i> ) .....	2933

<i>SF3B4</i> Plays an Oncogenic Role in Esophageal Squamous Cell Carcinoma. S. KIDOGAMI, T. IGUCHI, K. SATO, Y. YOSHIKAWA, Q. HU, S. NAMBARA, H. KOMATSU, M. UEDA, Y. KURODA, T. MASUDA, M. MORI, Y. DOKI, K. MIMORI ( <i>Oita; Osaka, Japan</i> ) .....	w2941
Expression of MicroRNA in Locoregional Recurrent Rectal Cancer. N. KOTNIK, N. EL-SOURANI, U. RAAP, H.-R. RAAB, M. BOCKHORN, H. MEYER, A. TROJA ( <i>Oldenburg, Germany</i> ).....	2947
Efficacy and Safety of Weekly Paclitaxel in Breast Cancer With Symptomatic Bone Marrow Infiltration. A. DA SILVA, C. LEVY, D. ALLOUACHE, I. HRAB, A. MOREL, A. FAVEYRIAL, K. GUNZER, A. JOHNSON, C. SEGURA, I. LICAJ, G. DAMAJ, G. EMILE ( <i>Caen, France</i> ) .....	2955
Clinicopathological Significance of MTUS1 Expression in Patients With Renal Cell Carcinoma. J. SIM, Y.C. WI, H.Y. PARK, S.Y. PARK, Y.E. YOON, S. BANG, Y. KIM, K. JANG, S.S. PAIK, S.-J. SHIN ( <i>Daejeon; Seoul; Busan, Republic of Korea</i> ) .....	2961
Defecatory Dysfunction After Colon Cancer Resection: The Role of Inferior Mesenteric Artery Tie. E. FIORI, D. CROCETTI, A. LAMAZZA, F. DE FELICE, G.B. SCOTTI, A.V. STERPETTI, A. MINGOLI, P. SAPIENZA, G. DE TOMA ( <i>Rome, Italy</i> ).....	2969
The Role of Predictive Model Based on Quantitative Basic Magnetic Resonance Imaging in Differentiating Medulloblastoma from Ependymoma. N.M. DUC, H.Q. HUUY, C. NADARAJAN, B. KESERCI ( <i>Ha Noi; Ho Chi Minh City, Vietnam; Kelantan, Malaysia; Istanbul, Turkey</i> ) .....	2975
A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer. H. YOSHIDA, Y.H. KIM, Y. SAKAMORI, H. NAGAI, H. OZASA, T. KANEDA, H. YOSHIOKA, H. NAKAGAWA, K. TOMII, A. OKADA, K. YOSHIMURA, M. HIRABAYASHI, T. HIRAI ( <i>Kyoto; Hirakata; Kobe; Kurashiki; Shiga; Suita; Osaka; Hiroshima; Amagasaki, Japan</i> ) .....	2981
The Role of Magnetic Resonance Imaging in the Pre-operative Evaluation of Women Diagnosed With Atypical Endometrial Hyperplasia. C.G. LIAKOU, M.-C. LA RUSSA, N. AKRIVOS, V. AMES, S. SCOTT-BARRETT, T.J. DUNCAN, J.J. NIETO, N. BURBOS ( <i>Norwich, UK</i> ).....	2989
Building a Nomogram for Prediction of Prostate Cancer in Patients With Preoperatively Suspected Prostate Cancer. Y.C. OU, K.-H. CHANG, M.-C. TUNG, I.-J. TSAI, L.-H. HUANG, W.-C. WENG, C.-Y. HSU, Y.-S. LIN, T.-Y. TSAO ( <i>Taichung; Miaoli, Taiwan, ROC</i> ) .....	2995
Evaluation of the Irradiated Volume of the Heart and Cardiac Substructures After Left Breast Radiotherapy. A. GKANTAIFI, C. PAPAPOPOULOS, D. SPYROPOULOU, M. TOUMPOURLEKA, G. ILIADIS, N. TSOUKALAS, G. KYRGIAS, M. TOLIA ( <i>Thessaloniki; Patras; Athens; Larissa, Greece</i> ).....	3003
Erratum .....	3011

## Number 6, June

### Reviews

Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow. A. RIZZO, A.D. RICCI, N. TOBER, M.C. NIGRO, M. MOSCA, A. PALLONI, F. ABBATI, G. FREGA, S. DE LORENZO, S. TAVOLARI, G. BRANDI ( <i>Bologna, Italy</i> ) .....	3013
Is Perineural Invasion a Novel Prognostic Factor Useful to Tailor Adjuvant Treatment in Patients Treated With Primary Surgery for Cervical and Vulvar Carcinoma? A. GADDUCCI, S. PISTOLESI, S. COSIO, A.G. NACCARATO ( <i>Pisa, Italy</i> ) .....	3031

The Role of MSCs in the Tumor Microenvironment and Tumor Progression. S.Y. AHN ( <i>Seoul, Republic of Korea</i> ) .....	3039
Tumor Handling of Early-stage Cervical Cancer: A Literature Analysis of Villoglandular Adenocarcinoma of the Cervix. A. DIETL, K. AUMANN, M.W. BECKMANN ( <i>Erlangen; Freiburg, Germany</i> ) .....	3049
PARP Inhibitors as Therapeutic Options for Tyrosine Kinase-dependent Leukemia: A Review. C.B. MACHADO, E.L. DA SILVA, M.O. DE MORAES FILHO, M.E. AMARAL DE MORAES, C.A. MOREIRA-NUNES ( <i>Fortaleza, Brazil</i> ) .....	3055
Surgical Versus Conservative Treatment for Endometrial Cancer in Women of Reproductive Age: Incidence of Urinary Tract Symptoms. A. KOUTRAS, A. PETEINARIS, S. DAVAKIS, G. KALINTERAKIS, I. TSILIKIS, N. GARMPIIS, P.-A. ZOTOS, A. CHIONIS, D. SCHIZAS, I. KARAVOKYROS, N. THOMAKOS, E. KONTOMANOLIS, A. SYLLAIOS ( <i>Athens; Patras; Larisa; Alexandroupolis, Greece</i> ).....	3065
<i>Experimental Studies</i>	
Retinoids Augment Thiazolidinedione PPAR $\gamma$ Activation in Oral Cancer Cells. R. ROSAS, S. BURYSKA, R. SILVER, B. WUERTZ, F. ONDREY ( <i>Duluth; Minneapolis, MN, USA</i> ).....	3071
Lack of Correlation Between Immunohistochemical Expression of SPARC and Invasion in Different Grades of Meningiomas. H.K. ROOPRAI, A.J. MARTIN, A. KING, U.D. APPADU, R.W. GULLAN, N.W.M. THOMAS, G.J. PILKINGTON ( <i>London; Portsmouth, UK</i> ) .....	3081
Oncogenic miRNAs Identified in Tear Exosomes From Metastatic Breast Cancer Patients. S. INUBUSHI, H. KAWAGUCHI, S. MIZUMOTO, T. KUNIHISA, M. BABA, Y. KITAYAMA, T. TAKEUCHI, R.M. HOFFMAN, R. SASAKI ( <i>Hyogo, Japan; San Diego, CA, USA</i> ) .....	3091
Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30. R. SCHMIDT-WOLF, G. ZISSEL ( <i>Bonn; Freiburg, Germany</i> ).....	3097
New Pancreatic Cancer Biomarkers eIF1, eIF2D, eIF3C and eIF6 Play a Major Role in Translational Control in Ductal Adenocarcinoma. N. GOLOB-SCHWARZL, P. PUCHAS, M. GOGG-KAMERER, W. WEICHERT, B. GÖPPERT, J. HAYBAECK ( <i>Graz; Innsbruck, Austria; Munich; Heidelberg, Germany</i> ).....	3109
Knockdown of Myoferlin Suppresses Migration and Invasion in Clear-Cell Renal-Cell Carcinoma. A. COX, C. ZHAO, Y. TOLKACH, D. NETTERSHEIM, D. SCHMIDT, G. KRISTIANSEN, S.C. MUELLER, M. RITTER, S. HAUSER, J. ELLINGER ( <i>Bonn; Düsseldorf, Germany</i> ) .....	3119
Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells <i>In Vitro</i> . T. KUITTINEN, P. ROVIO, T. LUUKKAALA, M. LAURILA, S. GRÉNMAN, A. KALLIONIEMI, J. MÄENPÄÄ ( <i>Tampere; Turku, Finland</i> ).....	3129
Anti-infectious and Anti-tumor Activities of $\beta$ -glucans. V. VETVICKA, J. VETVICKOVA ( <i>Louisville, KY, USA</i> ) .....	3139
Six Candidate miRNAs Associated With Early Relapse in Pediatric B-Cell Acute Lymphoblastic Leukemia. E.K. AMANKWAH, M. DEVIDAS, D.T. TEACHEY, K.R. RABIN, P.A. BROWN ( <i>Baltimore, MD; St. Petersburg; Gainesville, FL; Philadelphia, PA; Houston, TX, USA</i> ).....	3147
Sirtuin 1 Activation Suppresses the Growth of T-lymphoblastic Leukemia Cells by Inhibiting NOTCH and NF- $\kappa$ B Pathways. S.M. OKASHA, M. ITOH, S. TOHDA ( <i>Tokyo, Japan</i> ) .....	3155
Oncological Safety of Ultrasonically Activated Surgical Devices During Gastric Cancer Surgery. T. KUBOTA, K. SHODA, S. OGAWA, T. MATSUMOTO, H. KUBO, M. YUBAKAMI, T. OHASHI, T. KOSUGA, H. KONISHI, A. SHIOZAKI, T. ARITA, H. SHIMIZU, Y. YAMAMOTO, R. MORIMURA, H. IKOMA, Y. KURIU, H. FUJIWARA, K. OKAMOTO, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	3163

Investigation of the Involvement of Parkin in Parkinson's Disease and Cancer by Monitoring the Changes in SH-SY5Y Cells at the Nuclear Proteome Level. A. AYIMUGU, M. SARIHAN, M. KASAP, G. AKPINAR ( <i>Kocaeli, Turkey</i> ) .....	3169
Galectin-8 Favors VEGF-Induced Angiogenesis: <i>In Vitro</i> Study in Human Umbilical Vein Endothelial Cells and <i>In Vivo</i> Study in Chick Chorioallantoic Membrane. L. VARINSKÁ, L. FÁBER, E. PETROVOVÁ, L. BALÁŽOVÁ, E. IVANČOVÁ, M. KOLÁŘ, P. GÁL ( <i>Košice, Slovak Republic; Prague, Czech Republic</i> ) ....	3191
Characteristics of Gastric Carcinomas With High ERCC1 Expression and the Prognostic Value of ERCC1 Expression. J.W. YANG, J.-H. LEE, J.S. LEE, D.C. KIM, D.H. SONG, S.M. JANG, H.J. AN, H.M. KOH, M. KIM, J.M. NA, S.-H. JEONG, Y.-J. LEE, G.H. KO ( <i>Jinju; Changwon, Republic of Korea</i> ) .....	3203
Tannic Acid Inhibits Non-small Cell Lung Cancer (NSCLC) Stemness by Inducing G0/G1 Cell Cycle Arrest and Intrinsic Apoptosis. N. SP, D.Y. KANG, D.H. KIM, J.-S. YOO, E.S. JO, A. RUGAMBA, K.-J. JANG, Y.M. YANG ( <i>Seoul, Republic of Korea; Sapporo, Japan</i> ).....	3209
Possible Diagnostic Application of CXCL12 and CXCR4 as Tumor Markers in Breast Cancer Patients. E. DĄBROWSKA, A. PRZYLIPIAK, M. ZAJKOWSKA, B.M. PISKOR, I. SIDORKIEWICZ, M. SZMITKOWSKI, S. LAWICKI ( <i>Bialystok, Poland</i> ) .....	3221
KHYG-1 Cells With EGFRvIII-specific CAR Induced a Pseudoprogession-like Feature in Subcutaneous Tumours Derived from Glioblastoma-like Cells. T. NAKAZAWA, T. MURAKAMI, A. NATSUME, F. NISHIMURA, T. MORIMOTO, R. MATSUDA, M. NAKAMURA, S. YAMADA, I. NAKAGAWA, Y.-S. PARK, Y. MOTOYAMA, T. TSUJIMURA, T. WAKABAYASHI, H. NAKASE ( <i>Kashihara; Uda; Nagoya, Japan</i> ).....	3231
NCAPH Is Required for Proliferation, Migration and Invasion of Non-small-cell Lung Cancer Cells. B. KIM, S.W. KIM, J.-Y. LIM, S.-J. PARK ( <i>Gwangju, Republic of Korea</i> ) .....	3239
Cell Cycle Dysregulation Is Associated With 5-Fluorouracil Resistance in Gastric Cancer Cells. D.S. KIM, K. MIN, S.K. LEE ( <i>Seoul, Republic of Korea</i> ) .....	3247
EBV Rta-induced IL-6 Promotes Migration of Bystander Tumor Cells Through IL-6R/JAK/STAT3 Pathway <i>In Vitro</i> . K.-L. TUNG, Y.-T. WU, C. LIU, S.-C. LIN, C.-H. WU, S.-Y. WU, Y. CHANG, Y.-Y. LAN ( <i>Kaohsiung; Pingtung; Tainan, Taiwan, ROC</i> ).....	3255
Investigation of the Effects of MicroRNA-221 Expression Levels in Glioblastoma Multiforme Tumors. S. OZDOGAN, C.K. YALTIRIK, S.G. YILMAZ, F.T. AKDENIZ, K. SUMERKENT, A.H. DUZKALIR, U. TURE, T. ISBIR ( <i>Istanbul, Turkey</i> ) .....	3265
The Putative Glyoxalase 1 Inhibitor Piceatannol Exhibits Both Anxiolytic-like and Antitumor Effects in Mice. K. YOSHIZAWA, M. TABUCHI, S. UKAI, H. SUZUKI, Y. KAWANO, R. TAKASAWA ( <i>Chiba, Japan</i> ) ....	3271
Induction Chemotherapy in Hypopharyngeal Cancer: Influence of DNA Repair Gene Polymorphisms. H. HIRAKAWA, T. IKEGAMI, S. AZECHI, S. AGENA, J. UEZATO, H. KINJYO, Y. YAMASHITA, A. KIYUNA, K. TANAKA, S. KONDO, H. MAEDA, M. SUZUKI, A. GANAHA ( <i>Okinawa; Miyazaki, Japan</i> ) .....	3277
Tranilast Inhibits TGF- $\beta$ 1-induced Epithelial-mesenchymal Transition and Invasion/Metastasis <i>via</i> the Suppression of Smad4 in Human Lung Cancer Cell Lines. K. TAKAHASHI, T. MENJU, S. NISHIKAWA, R. MIYATA, S. TANAKA, Y. YUTAKA, Y. YAMADA, D. NAKAJIMA, M. HAMAJI, A. OHSUMI, T.F. CHEN-YOSHIKAWA, T. SATO, M. SONOBE, H. DATE ( <i>Kyoto; Aichi; Osaka, Japan</i> ) .....	3287
An Animal Model of Colorectal Cancer Liver Metastasis With a High Metastasis Rate and Clonal Dynamics. K.B. BAE, S.-H. KIM, M.S. KANG, D.-H. KIM ( <i>Busan, Republic of Korea</i> ).....	3297

*Clinical Studies*

Race Does Not Affect Survival in Patients With Prostate Cancer Treated With Radiation Therapy. J. KODIYAN, M. ASHAMALLA, A. GUIRGUIS, H. ASHAMALLA (*New York, NY, USA*)..... 3307

Efficacy of Adjuvant Combination Therapy With Trastuzumab and Chemotherapy in HER2-positive Early Breast Cancer: A Single Institutional Cohort Study from Clinical Practice. M. OKAMOTO, W. TAJIRI, H. UEO, T. MASUDA, H. IJICHI, C. KOGA, Y. NAKAMURA, K. TAGUCHI, S. OHNO, E. TOKUNAGA (*Fukuoka; Tokyo, Japan*) ..... 3315

Melanoma Risk Estimation Based on Objective Measures as a Complement to Self-Assessment. A. CARLSSON, M. FALK (*Linköping, Sweden*) ..... 3325

Symptomatic Intraosseous Vascular Malformation of Infraorbital Rim: A Case Report With Literature Survey. R.E. FRIEDRICH, U. GRZYSKA, F.K. KOHLRUSCH, S. VON KROGE, T. VOLLKOMMER, A.M. LUEBKE (*Hamburg, Germany*) ..... 3333

Validation of Systemic and Local Tumour Immune Response to Eribulin Chemotherapy in the Treatment of Breast Cancer. S. KASHIWAGI, Y. ASANO, W. GOTO, K. TAKADA, T. MORISAKI, R. KOUHASHI, A. YABUMOTO, S. TANAKA, T. TAKASHIMA, M. OHSAWA, K. HIRAKAWA, M. OHIRA (*Osaka, Japan*)..... 3345

Classification Model to Estimate MIB-1 (Ki 67) Proliferation Index in NSCLC Patients Evaluated With <sup>18</sup>F-FDG-PET/CT. B. PALUMBO, R. CAPOZZI, F. BIANCONI, M.L. FRAVOLINI, S. CASCIANELLI, S.G. MESSINA, G. BELLEZZA, A. SIDONI, F. PUMA, M. RAGUSA (*Perugia; Terni, Italy*) ..... 3355

Spleen Volume as a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy. T. MIYATA, H. TAKAMURA, R. KIN, H. NISHIKI, A. HASHIMOTO, Y. FUJII, S. MIURA, J. FUJITA, D. KAIDA, Y. TOMITA, N. NAKAMURA, H. FUJITA, S. KINAMI, N. UEDA, T. KOSAKA (*Ishikawa, Japan*) ..... 3361

The Lymphocyte-to-monocyte Ratio Is an Independent Prognostic Indicator in Pancreatic Head Cancer that Correlates With Obstructive Jaundice. M. TAKEUCHI, M. MITSUYOSHI, K. YOSHIDA, M. ONODA, M. IWAMURA, A. FURUTANI, K. KAWANO, T. KATOH (*Yamaguchi; Fukuoka, Japan*) ..... 3371

The Role of Radiotherapy for Patients With Thyroid Cancer in the Modern Era. L. SAMHOURI, J. KRIZ, K. ELSAYAD, M. CHANNAOUI, A. PASCHER, B. RIEMANN, R. WIEWRODT, U. HAVERKAMP, S. SCOBIOALA, H.T. EICH (*Muenster, Germany*) ..... 3379

Fractionated Stereotactic Sequential Boost in a Selected Cohort of Glioblastoma Patients: A Mono-institutional Analysis. A. MARCHIONNI, I. PALUMBO, G. MONTESI, V. BINI, C. ZUCCHETTI, N. CENCI, P. CHIARINI, S. SACCIA, C. ARISTEI, M. LUPATTELLI (*Perugia; Rovigo, Italy*) ..... 3387

Tumor-infiltrating Lymphocyte Score Based on FDG PET/CT for Predicting the Effect of Neoadjuvant Chemotherapy in Breast Cancer. S. SASADA, Y. KIMURA, A. EMI, N. MASUMOTO, T. KADOYA, K. ARIHIRO, M. OKADA (*Hiroshima, Japan*) ..... 3395

Hydro-MDCT for Gastric Adenocarcinoma Staging. A Comparative Study With Surgical and Histopathological Findings for Selecting Patients for Echo-endoscopy. M. DI GIROLAMO, F. CARBONETTI, P. BONOME, A. GROSSI, F. MAZZUCA, L. MASONI (*Rome, Italy*) ..... 3401

National Comprehensive Analysis of Characteristics of Acral Lentiginous Melanoma. M.T. HUAYLLANI, D.J. RESTREPO, D. BOCZAR, F.R. AVILA, S.P. BAGARIA, A.C. SPAULDING, B.D. RINKER, A.J. FORTE (*Jacksonville, FL, USA*) ..... 3411

Intraluminal Brachytherapy in Unresectable Extrahepatic Biliary Duct Cancer: An Italian Pooled Analysis. R. AUTORINO, S. BISIELLO, B. PAPPALARDI, V. PRIVITERA, M. BUWENGE, F. PICCOLO, C. MASCIOCCHI, L. TAGLIAFERRI, G. MACCHIA, C.D. CURTI, M. LUPPATELI, A. CERROTTA, A.G. MORGANTI, V. VALENTINI, G. MATTIUCCI ( <i>Rome; Bologna; Milan; Campobasso; Perugia, Italy</i> ) .....	3417
Mosaic Neurofibromatosis Type 1 With Multiple Cutaneous Diffuse and Plexiform Neurofibromas of the Lower Leg. R.E. FRIEDRICH, C. HAGEL, F.K. KOHLRUSCH, I. SCHANZE, I. WIELAND, M. ZENKER ( <i>Hamburg; Magdeburg, Germany</i> ).....	3423
Seizures Prior to Whole-brain Irradiation for Metastatic Disease: Prevalence, Risk Factors and Association With Survival. D. RADES, J. WITTELER, L. DZIGGEL, T.W. KJAER, S. TVILSTED, S.E. SCHILD ( <i>Lübeck, Germany; Roskilde; Koege, Denmark; Scottsdale, AZ, USA</i> ).....	3429
Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer. S.M. MOON, J.-H. KIM, S.K. KIM, S. KIM, H.-J. KWON, J.-S. BAE, S. LEE, H.S. LEE, M.-Y. CHOI, B.H. JEON, B.-H. JEONG, K. LEE, H.K. KIM, J. KIM, S.-W. UM ( <i>Seoul; Changwon; Incheon, Republic of Korea</i> ) .....	3435
Umbilical Defunctioning Ileostomy for Rectal Cancer Results in Reduced Risk for Incisional Hernia. K. ETO, M. KOSUGE, M. OHKUMA, D. ITO, Y. TAKEDA, S. YATABE, H. SUGANO, N. TAKADA, T. KUMAMOTO, K. YANAGA ( <i>Tokyo, Japan</i> ).....	3445
Occurrence of Glioma in Pregnant Patients: An Institutional Case Series and Review of the Literature. P. SINGH, E. MANTILLA, J. SEWELL, K.J. HATANPAA, E. PAN ( <i>Irvine, CA; Fort Worth; Dallas, TX, USA</i> ) .....	3453
Correlation of Iodine Quantification and FDG Uptake in Early Therapy Response Assessment of Non-small Cell Lung Cancer: Possible Benefit of Dual-energy CT Scan as an Integral Part of PET/CT Examination. J. BAXA, J. LUDVIK, M. SEDLMAIR, T. FLOHR, B. SCHMIDT, P. HOŠEK, M. PESEK, M. SVATOŇ, J. FERDA ( <i>Pilsen, Czech Republic; Forchheim, Germany</i> ).....	3459
Comparison Between Biweekly and Weekly Cetuximab in Patients With Metastatic Colorectal Cancer: A Meta-analysis. A. MATSUDA, T. YAMADA, S. JAMJITTRONG, S. SHINJI, R. OHTA, H. SONODA, T. KAMONVARAPITAK, K. SEKIGUCHI, M. MIYASHITA, H. SUZUKI, H. YOSHIDA ( <i>Tokyo; Chiba, Japan; Chonburi, Thailand</i> ) .....	3469
Impact of Implementing the Paris System for Reporting Urinary Cytology: A Single-institutional Experience With Emphasis on Diagnostic Yield of High-grade Urothelial Carcinoma and Low-grade Urothelial Neoplasm. H.H. KOH, M.J. LEE, N.J. PARK, H.-S. KIM, Y.L. OH ( <i>Seoul, Republic of Korea</i> ).....	3477
Cytoplasmic Expression of AXL Is Associated With High Risk of Postoperative Relapse of Conventional Renal Cell Carcinoma. L. PETERFI, T. BJERCKE, M.V. YUSENKO, G. KOVACS, D. BANYAI ( <i>Pecs, Hungary; Muenster; Heidelberg, Germany</i> ).....	3485
Classification of Abnormal Findings on Ring-type Dedicated Breast PET for the Detection of Breast Cancer. S. SASADA, N. MASUMOTO, Y. KIMURA, A. EMI, T. KADOYA, M. OKADA ( <i>Hiroshima, Japan</i> ).....	3491
Occurrence of Seizures Prior to Single-fraction Radiosurgery or Multi-fraction Stereotactic Radiotherapy in Patients With Very Few Brain Metastases. D. RADES, J. WITTELER, T.W. KJAER, S. TVILSTED, S.E. SCHILD ( <i>Lübeck, Germany; Roskilde; Koege, Denmark; Scottsdale, AZ, USA</i> ).....	3499
Clinical Significance of Nucleoli Cytomorphology Assessment in Patients With Uveal Melanoma. T. BERUS, A. MARKIEWICZ, P. BIECEK, J. ORŁOWSKA-HEITZMAN, A. HAŁOŃ, B. ROMANOWSKA-DIXON, P. DONIZY ( <i>Wroclaw; Krakow; Warsaw, Poland</i> ) .....	3505

Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy. T. ABE, N. KOBAYASHI, T. AOSHIKA, Y. RYUNO, S. SAITO, M. IGARI, R. HIRAI, Y. KUMAZAKI, Y. MIURA, K. KAIRA, H. KAGAMU, S.-E. NODA, S. KATO ( <i>Hidaka, Japan</i> ) .....	3513
Clinical Features of Treatment-related Neuroendocrine Prostate Cancer: A Case Series. K. SUZUKI, T. TERAOKAWA, N. JIMBO, R. INABA, Y. NAKANO, M. FUJISAWA ( <i>Kobe, Japan</i> ) .....	3519
Diagnostic Reliability, Accuracy and Safety of Ultrasound-guided Biopsy and Ascites Puncture in Primarily Inoperable Ovarian Tumours. P. VLASAK, J. BOUDA, J. KOSTUN, D. BEREZOVSKIY, M. ZIKAN, V. WEINBERGER, O. ONDIC, Z. RUSAVY, R. KUCERA, O. TOPOLCAN, Z. NOVOTNY, J. PRESL ( <i>Pilsen; Prague; Brno, Czech Republic</i> ) .....	3527
Inflammation Caused by Surgical Stress Has a Negative Impact on the Long-term Survival Outcomes in Patients With Colorectal Cancer. M. SHIBUTANI, S. NAKAO, K. MAEDA, H. NAGAHARA, T. FUKUOKA, Y. ISEKI, K. HIRAKAWA, M. OHIRA ( <i>Osaka, Japan</i> ) .....	3535
Tumor-to-nipple Distance Should Not Preclude Nipple-sparing Mastectomy in Breast Cancer Patients. Personal Experience and Literature Review. P. FREGATTI, M. GIPPONI, G. ZOPPOLI, M. LAMBERTINI, E. BLONDEAUX, L. BELGIOIA, R. DEROSA, F. MURELLI, F. DEPAOLI, M. CEPPI, A. GARLASCHI, D. FRIEDMAN ( <i>Genoa, Italy</i> ) .....	3543
Risk Factors for Postoperative Deep Infection After Malignant Bone Tumor Surgery of the Extremities. M.B. LANGIT, S. MIWA, N. YAMAMOTO, K. HAYASHI, A. TAKEUCHI, K. IGARASHI, K. TADA, T. HIGUCHI, H. YONEZAWA, S. MORINAGA, Y. ARAKI, Y. ASANO, H. TSUCHIYA ( <i>Kanazawa, Japan; Manila, Philippines</i> ) .....	3551
Epithelial–Mesenchymal Transition Status of Circulating Tumor Cells Is Associated With Tumor Relapse in Head and Neck Squamous Cell Carcinoma. H. TADA, H. TAKAHASHI, S. IDA, Y. NAGATA, K. CHIKAMATSU ( <i>Gunma, Japan</i> ) .....	3559
A Phase II Study of Neoadjuvant Chemotherapy Followed by Extended Field Concurrent Chemoradiotherapy for Para-aortic Lymph Node Positive Cervical Cancer. Y. SHIMOJI, Y. NAGAI, T. TOITA, T. ARIGA, J. HEIYANNA, T. NAKASONE, Y. TAIRA, Y. ARAKAKI, T. NAKAMOTO, T. OYAMA, W. KUDAKA, I. KANESHIMA, K. NISHIHARA, K. MEKARU, Y. AOKI ( <i>Okinawa, Japan</i> ) .....	3565
Effectiveness of Photodynamic Screening Using 5-Aminolevulinic Acid for the Diagnosis of Pancreatic Cancer. T. IKEURA, Y. HORI, T. MITSUYAMA, H. MIYOSHI, M. SHIMATANI, K. UCHIDA, M. TAKAOKA, U. OTA, A. KAMIYA, K. TAKAHASHI, M. ISHIZUKA, M. KAIBORI, K. OKAZAKI ( <i>Osaka; Kochi; Tokyo; Hirakata, Japan</i> ) .....	3571
Neoadjuvant Treatment in Upper Rectal Cancer Does Not Improve Oncologic Outcomes But Increases Postoperative Morbidity. N. TABCHOURI, Y. EID, G. MANCEAU, A. FRONTALI, Z. LAKKIS, E. SALAME, T. LECOMTE, S. CHAPET, G. CALAIS, B. HEYD, M. KAROUI, A. ALVES, Y. PANIS, M. OUAISSI ( <i>Chambray Les Tours; Caen; Paris; Clichy; Besançon, France</i> ) .....	3579
Erratum .....	3589

**Number 7, July**

*Reviews*

Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests. J. MEKLIN, K. SYRJÄNEN, M. ESKELINEN (Kuopio; Kaarina, Finland; Barretos, Brazil) ..... 3591

Review of the Role of Radiomics in Tumour Risk Classification and Prognosis of Cancer. Y.L. WEN, M. LEECH (Dublin, Ireland; Singapore, Singapore) ..... 3605

Gene Polymorphisms and Circulating Levels of MMP-2 and MMP-9: A Review of Their Role in Breast Cancer Risk. S.G. DOFARA, S.-L. CHANG, C. DIORIO (Quebec City, QC, Canada)..... 3619

Savi Scout® Radar Localisation of Non-palpable Breast Lesions: Systematic Review and Pooled Analysis of 842 Cases. I. KASEM, K. MOKBEL (London, UK) ..... 3633

FGD3 Gene as a New Prognostic Factor in Breast Cancer. T. SUSINI, I. RENDA (Florence, Italy)..... 3645

Minimizing Fertility-sparing Treatment for Low Volume Early Stage Cervical Cancer; Is Less the (R)Evolution? C. THEOFANAKIS, D. HAIDOPOULOS, N. THOMAKOS, A. RODOLAKIS, C. FOTOPOULOU (Athens, Greece; London, UK) ..... 3651

*Experimental Studies*

FOLFIRINOX Versus Gemcitabine-based Therapy for Pancreatic Ductal Adenocarcinoma: Lessons from Patient-derived Cell Lines. S.K.S. BEGG, D.J. BIRNBAUM, J.W. CLARK, M. MINO-KENUDSON, U.F. WELLNER, O. SCHILLING, K.D. LILLEMÖE, A.L. WARSHAW, C. FERNÁNDEZ-DEL CASTILLO, A.S. LISS (Boston, MA, USA; Lübeck; Freiburg, Germany)..... 3659

Modulation of Estrogen  $\alpha$  and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol *In Vitro*. F. NOURIEMAMZADEN, B. WORD, E. COTTON, A. HAWKINS, K. LITTLEJOHN, R. MOORE, G. MIRANDA-CARBON, C.N. ORISH, B. LYN-COOK (Jefferson, AR; White Oak, MD; Memphis, TN, USA; Port Harcourt, Nigeria) ..... 3669

Protection of Bortezomib-induced Neurotoxicity by Antioxidants. Y. IJIMA, K. BANDOW, S. AMANO, M. SANO, S. HINO, T. KANEKO, N. HORIE, H. SAKAGAMI (Kawagoe; Sakado; Tokyo, Japan)..... 3685

Metabolome of Mammary Tumors Differs from Normal Mammary Glands But Is Not Altered by Time-restricted Feeding Under Obesogenic Conditions. L. YAN, S. SUNDARAM, B.M. RUST, M.J. PICKLO, M.R. BUKOWSKI (Grand Forks, ND, USA) ..... 3697

The Contribution of Interleukin-12A Genotypes to Oral Cancer Risk in Taiwanese. C.-H. LI, L.-C. SHIH, C.-L. HSU, H.-T. LEE, Y.-C. WANG, W.-S. CHANG, C.-W. TSAI, C.-Y. LI, D.-T. BAU (Taichung, Taiwan, ROC)..... 3707

MicroRNAs Associated With Biological Pathways of Left- and Right-sided Colorectal Cancer. S. ENEH, S. HEIKKINEN, J.M. HARTIKAINEN, T. KUOPIO, J.-P. MECKLIN, V.-M. KOSMA, A. MANNERMAA (Kuopio; Jyväskylä, Finland) ..... 3713

BNIP3L Is a New Autophagy Related Prognostic Biomarker for Melanoma Patients Treated With AGI-101H. U. KAZIMIERCZAK, T. KOLENDA, D. KOWALCZYK, J. MACKIEWICZ, A. MACKIEWICZ (Poznan, Poland) .. 3723

The Expression Level of *PD-L1* (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer. T. MASUDA, M. NODA, A. KITAGAWA, Q. HU, A. FUJII, S. ITO, K. KOSAI, Y. ANDO, Y. MATSUMOTO, H. OHTSU, H. UCHIDA, S. OHNO, K. MIMORI (Beppu; Tokyo, Japan) ..... 3733



Determination of Immediate vs. Kinetic Growth Retardation in Physically Plasma-treated Cells by Experimental and Modelling Data. L. HARALAMBIEV, A. BANDYOPHADYAY, B. SUCHY, M. WEISS, A. KRAMER, S. BEKESCHUS, A. EKKERNKAMP, A. MUSTEA, L. KADERALI, M.B. STOPE ( <i>Greifswald; Berlin; Tübingen; Bonn, Germany</i> ) .....	3743
Adiponectin Is Inversely Associated With Tumour Grade in Colorectal Cancer Patients. R. POLITO, E. NIGRO, L. FEI, L. DE MAGISTRIS, M.L. MONACO, R. D'AMICO, S. NAVIGLIO, G. SIGNORIELLO, A. DANIELE ( <i>Naples, Italy</i> ) .....	3751
Chromosome 17 <i>In Situ</i> Hybridization Grid-based Analysis in Oral Squamous Cell Carcinoma. A. CHRYSOVERGIS, V. PAPANIKOLAOU, N. MASTRONIKOLIS, E. TSIAMBAS, V. RAGOS, D. PESCHOS, C. RIZIOTIS, C. STAVRAKA, D. ROUKAS, E. KYRODIMOS ( <i>Athens; Patras; Ioannina, Greece; Nicosia, Cyprus; London, UK</i> ) .....	3759
Epigenetic Regulation of APAF-1 Through DNA Methylation in Pancreatic Cancer. A. LUKOSIUTE-URBONIENE, A. MAZEIKE, M. KAZOKAITE, G. SILKUNIENE, M. SILKUNAS, V. BARAUSKAS, G. BARAUSKAS, A. GULBINAS, A. DAUKSA, Z. DAMBRAUSKAS ( <i>Kaunas, Lithuania</i> ) .....	3765
Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma. W. KONG, S. SENDER, S.V. PEREZ, A. SEKORA, B. RUETGEN, C. JUNGHANSS, I. NOLTE, H.M. ESCOBAR ( <i>Rostock; Hannover, Germany; Vienna, Austria</i> ).....	3781
Photosensitizer With Illumination Enhances <i>In Vivo</i> Antitumor Effect of Anti-ROBO1 Immunotoxin on Maxillary Sinus Squamous Cell Carcinoma. N. KOMATSU, M. KOMATSU, R. OHASHI, A. HORII, K. HOSHI, T. TAKATO, T. ABE, T. HAMAKUBO ( <i>Tokyo; Kawasaki; Miyagi; Niigata, Japan</i> ).....	3793
Papillary Thyroid Cancer Tumor Spheres Cultured by Passaging Without Sorting Exhibit Cancer Stemness. J.-M. CHO, H.J. LEE, J.H. CHUNG, W.Y. KIM, M.H. KANG, K.S. HA, S.U. WOO, J.B. LEE ( <i>Seoul, Republic of Korea</i> ) .....	3801
Molecular Characterization of Second Primary Endometrial Cancer. J. HARAGA, K. NAKAMURA, T. HARUMA, A. NYUYA, T. NAGASAKA, H. MASUYAMA ( <i>Okayama; Kurashiki, Japan</i> ).....	3811
Anti-tumor Properties of <i>Picrasma quassioides</i> Extracts in H-Ras <sup>G12V</sup> Liver Cancer Are Mediated Through ROS-dependent Mitochondrial Dysfunction. D.-P. XIE, Y.-X. GONG, Y.-H. JIN, C.-X. REN, Y. LIU, Y.-H. HAN, M.-H. JIN, D. ZHU, Q.-Z. PAN, L.-Y. YU, D.-S. LEE, J. LEE, J. KIM, Y.H. PARK, J.W. HYUN, T. KWON, Y.-D. CUI, H.-N. SUN ( <i>Daqing, PR China; Daegu; Gyeonggi; Seoul; Jeju; Jeonbuk, Republic of Korea</i> ).....	3819
Cytotoxicity of Exogenous Acetoacetate in Lithium Salt Form Is Mediated by Lithium and Not Acetoacetate. R. COHEN-HARAZI, S. HOFMANN, V. KOGAN, H. FULMAN-LEVY, K. ABAEV, O. SHOVMAN, T. BRIDER, I. KOMAN ( <i>Ariel, Israel</i> ) .....	3831
Novel Prognostic Factor for Uveal Melanoma: Bioinformatics Analysis of Three Independent Cohorts. S. CHOI, M. HA, J.S. LEE, H.J. HEO, G.H. KIM, S.-O. OH, J.J. LEE, T.S. GOH, Y.H. KIM ( <i>Yongsan; Busan, Republic of Korea</i> ) .....	3839
Tyrosine Kinase Inhibitors and Everolimus Reduce IGF1R Expression in HPV16-positive and -negative Squamous Cell Carcinoma. B. KRAMER, A. SCHELL, C. ADERHOLD, L. HUBER, C.E. MUELLER, N. ROTTER, R. BIRK ( <i>Mannheim; Marburg, Germany</i> ) .....	3847
Activity of Alcohol Dehydrogenase and Aldehyde Dehydrogenase in Lung Cancer Cells. K. ORYWAL, W. JELSKI, M.D. KOZŁOWSKI, B. MROCZKO ( <i>Bialystok, Poland</i> ) .....	3857
Cytokine-induced Killer T Cells Enhance the Cytotoxicity Against Carboplatin-resistant Ovarian Cancer Cells. Y. PAN, Y.-H. CHIU, S.-C. CHIU, D.-Y. CHO, L.-M. LEE, Y.-C. WEN, J. WHANG-PENG, C.-H. HSIAO, P.-H. SHIH ( <i>Taipei; Taichung, Taiwan, ROC</i> ) .....	3865

*Clinical Studies*

- Pathological Validity of Using Near-infrared Fluorescence Imaging for Securing Surgical Margins During Liver Resection. Y. TASHIRO, T. AOKI, T. HIRAI, T. KOIZUMI, D.A. MANSOU, T. KUSANO, K. MATSUDA, K. YAMADA, K. NOGAKI, T. HAKOZAKI, Y. WADA, H. SHIBATA, K. TOMIOKA, T. YAMAZAKI, K. SAITO, A. FUJIMORI, Y. ENAMI, R.M. HOFFMAN, M. MURAKAMI (*Tokyo, Japan; Cairo, Egypt; San Diego, CA, USA*) ..... 3873
- Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic Syndromes. H.B. ALKHATEEB, M.M. PATNAIK, A. AL-KALI, D.L. ZBLEWSKI, S. WALLERICH, H. MCTAVISH, A.Z. DUDEK (*Rochester; Saint Paul; Minneapolis, MN, USA*) ..... 3883
- Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor. S. KUBO, N. KOBAYASHI, K. SOMEKAWA, M. HIRATA, C. KAMIMAKI, H. AIKO, S. KATAKURA, S. TERANISHI, K. WATANABE, Y. HARA, M. YAMAMOTO, M. KUDO, T. KANEKO (*Yokohama, Japan*) ..... 3889
- Geographical Differences in Likelihood of Home Death Among Palliative Cancer Patients: A National Population-based Register Study. J. NILSSON, B. AXELSSON, G. HOLGERSSON, T. CARLSSON, M. BERGQVIST, S. BERGSTROM (*Gävle; Umeå; Uppsala, Sweden*) ..... 3897
- Real-world Evaluation of Oral Vinorelbine in the Treatment of Metastatic Breast Cancer: An ESME-MBC Study. P. HEUDEL, S. DELALOGUE, D. PARENT, N. MADRANGES, C. LEVY, F. DALENC, E. BRAIN, L. UWER, V. D'HONDT, P. AUGEREAU, A. MAILLIEZ, C. PERRIN, J.-S. FRENEL, M.-P. SABLIN, M.-A. MOURET-REYNIER, T. VERMEULIN, J.-C. EYMARD, T. PETIT, J.-M. FERRERO, S. ILIE, A. GONCALVES, G. CHENUC, M. ROBAIN, G. SIMON, D. PEROL (*Lyon; Villejuif; Reims; Bordeaux; Caen; Toulouse; Paris; Vandoeuvre-lès-Nancy; Montpellier; Saint-Herblain; Lille; Rennes; Clermont-Ferrand; Rouen; Strasbourg; Nice; Dijon; Marseille, France*) ..... 3905
- Reflector-guided Localization of Non-palpable Breast Lesions: The First Reported European Evaluation of the SAVI SCOUT® System. S. TAYEH, S. MUKTAR, J. HEENEY, M.J. MICHELL, N. PERRY, T. SUARIS, D. EVANS, A. MALHOTRA, K. MOKBEL (*London, UK*) ..... 3915
- Primary and Interval Debulking Surgery Provide Similar Survival and Platinum Sensitivity Outcomes in Advanced Ovarian Cancer: A Retrospective Study. O. GLOVER, V. ASHER, A. BALI, S. ABDUL, A. COLLINS, A. PHILLIPS (*Derby; Leicester, UK*) ..... 3925
- The Association Between Extracellular Water-to-Total Body Water Ratio and Therapeutic Durability for Advanced Lung Cancer. Y. NODA, H. SUZUKI, T. KANAI, Y. SAMEJIMA, S. NASU, A. TANAKA, N. MORISHITA, N. OKAMOTO, T. HIRASHIMA (*Osaka, Japan*) ..... 3931
- GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer. F. SELLE, P.-E. HEUDEL, A.-C. HARDY-BESSARD, A. POZET, J. MEUNIER, L. GLADIEFF, J.-P. LOTZ, M. PROVANSAL, P. AUGEREAU, D. BERTON, N. BONICHON-LAMICHHANE, H. ORFEUVRE, P. PAUTIER, E. KALBACHER, Y. TAZI, D. SPAETH (*Paris; Lyon; Plerin; Besançon; Orléans; Toulouse; Marseille; Angers; Saint-Herblain; Bordeaux; Bourg-en-Bresse; Villejuif; Strasbourg; Nancy, France*) ..... 3939
- Evaluating the Platelet Distribution Width-to-Plateletcrit Ratio as a Prognostic Marker for Patients With Breast Cancer. H. TAKEUCHI, D. NODA, M. ABE, K. ANAMI, M. MIYAWAKI, A. OSOEGAWA, K. SUGIO (*Oita, Japan*) ..... 3947
- Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma. M. MORIGUCHI, T. ARAMAKI, R. SATO, K. IWAI, S. TSUCHIYA, K. ASAKURA, A. TAKAHASHI, Y. SEKO, A. UMEMURA, K. YMAGUCHI, M. ENDO, Y. ITOH (*Kyoto; Nagaizumi, Japan*) ..... 3953

Seizures Prior to Radiotherapy of Gliomas: Prevalence, Risk Factors and Survival Prognosis. J. WITTELER, T.W. KJAER, S. TVILSTED, S.E. SCHILD, D. RADES ( <i>Lübeck, Germany; Roskilde; Koege, Denmark; Scottsdale, AZ, USA</i> ) .....	3961
Non-invasive Detection of Bladder Cancer by UBC Rapid Test, Ultrasonography and Cytology. V. BARAK, D. ITZKOVICH, R. EINARSSON, O. GOFRIT, D. PODE ( <i>Jerusalem, Israel; Stockholm, Sweden</i> ) .....	3967
Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer. L.C. HANKER, F. FÖRSTER, J. SCHRÖDER, A. GRAFE, T. HITSCHOLD, T. HESSE, C.R. LATTRICH, A. RODY ( <i>Lübeck; Chemnitz; Mülheim an der Ruhr; Nordhausen; Worms; Rotenburg an der Wümme; Grenzach, Germany</i> ) .....	3973
Features of Hepatocellular Carcinoma With Micro Hepatic Vein Invasion and their Correlation With Hepatitis B and C Virus. Y. SAKURAOKA, K. KUBOTA, G. TANAKA, T. SHIMIZU, K. TAGO, K.H. PARK, T. MATSUMOTO, T. SHIRAKI, S. MORI, Y. ISO, T. AOKI ( <i>Tochigi, Japan</i> ) .....	3983
Russell Body Gastroesophagitis Concurrent With Barrett's Esophagus. J. ARSHI, J. NGUYEN, F. YIN ( <i>Columbia, MO, USA</i> ) .....	3991
Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature. S.T. BURNS, L. DAMON, N. AKAGI, Z. LASZIK, A.H. KO ( <i>San Francisco, CA, USA</i> ) .....	3995
Comprehensive Analysis and Clinical Implication of PD-L1 Expression Considering HPV Status in Oropharyngeal Squamous Cell Carcinoma. J.Y. JEONG, T.-I. PARK, D. AHN ( <i>Daegu, Republic of Korea</i> ) .....	4001
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX. J.-D. FUMET, J. VINCENT, L. BENGRINE, A. HENNEQUIN, L. GRANCONATO, R. PALMIER, F. GHIRINGHELLI ( <i>Dijon, France</i> ) .....	4011
Skin Architecture, Kidney Transplantation, and Their Relationship to Basal and Squamous Cell Carcinomas. A. CAPASSO, G. BILANCIO, M.W. LEE, G. PALLADINO, R.M. POLLASTRO, M. SIMEONI, C. SECONDULFO, A. RONCHI, A. CAPUTO, R. FRANCO, P. ZEPPA, G. CAPASSO, D. VIGGIANO ( <i>Austin, TX, USA; Salerno; Naples; Ariano Irpino, Italy</i> ) .....	4017
Prognostic Impact of a Novel Tumor Marker and Inflammation Index for Patients With Non-small-cell Lung Cancer. M. TOMITA, R. MAEDA, T. AYABE, K. NAKAMURA ( <i>Miyazaki, Japan</i> ) .....	4023
Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma. C. CAO, P. PARIKH, K. MOEZARDALAN, A. ANANTHARAMAN, A. AZARM, J. LAI ( <i>Sacramento, CA; Providence, RI, USA</i> ) .....	4029
Preoperative Scoring System to Predict Prognosis in Patients Who Undergo Neoadjuvant Therapy for Pancreatic Cancer. K.-I. OKADA, M. KAWAI, S. HIRONO, K. TANIOKA, M. MIYAZAWA, Y. KITAHATA, R. KOBAYASI, M. UENO, S. HAYAMI, H. YAMAUE ( <i>Wakayama, Japan</i> ) .....	4033
Radiotherapy Dose and Volume De-escalation in Ocular Adnexal Lymphoma. S. REHN, K. ELSAYAD, M. OERTEL, A. BAEHR, N. ETER, U. HAVERKAMP, G. LENZ, H.T. EICH ( <i>Muenster, Germany</i> ) .....	4041
Low Eosinophil Percentages as a New Predictive Marker for Infusion Reactions Due to Trastuzumab. M. TAKAHASHI, K. TAKAHASHI, S. MATSUMOTO, T. TAKASHIMA, Y. ASANO, T. MORISAKI, S. KASHIWAGI, S. NODA, N. ONODA, M. OHIRA, K. NAGAYAMA ( <i>Osaka, Japan</i> ) .....	4047
Proposal of a Classification System for Adenocarcinoma Involving the Ileocecal Valve (Bauhin's Valve): A Retrospective Study of 689 Right Hemicolectomized Patients. E. VIRGILIO, F. MONTALI, R. COSTI, M. CAVALLINI ( <i>Rome; Parma; Fidenza; L'Aquila, Italy</i> ) .....	4053

Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. B. PULA, E. ISKIERKA-JAZDZEWSKA, M. DLUGOSZ-DANECKA, A. SZYMCZYK, M. HUS, A. SZEREMET, J. DROZD-SOKOLOWSKA, A. WASZCZUK-GAJDA, J.M. ZAUCHA, J. HOLOJDA, W. PISZCZEK, P. STECKIEWICZ, M. WOJCIECHOWSKA, M. OSOWIECKI, W. KNOPINSKA-POSLUSZNY, M. DUDZINSKI, D. ZAWIRSKA, E. SUBOCZ, J. HALKA, A. PLUTA, R. WICHARY, B. KUMIEGA, B.K. BUDZISZEWSKA, W. JURCZAK, E. LECH-MARANDA, K. GIANNOPOULOS, T. ROBAK, K. JAMROZIAK ( <i>Warsaw; Lodz; Krakow; Lublin; Wroclaw; Gdansk; Legnica; Torun; Kielce; Olsztyn; Rzeszow; Brzozow; Katowice; Nowy Sacz, Poland</i> ) .....	4059
The Impact of Severe Infectious Complications on Long-term Prognosis for Gastric Cancer. Y. MAEZAWA, T. AOYAMA, M. JU, K. KOMORI, K. KANO, S. SAWAZAKI, M. NUMATA, T. HAYASHI, T. YAMADA, H. TAMAGAWA, T. SATO, T. OGATA, H. CHO, T. OSHIMA, N. YUKAWA, T. YOSHIKAWA, M. MASUDA, Y. RINO ( <i>Yokohama; Tokyo, Japan</i> ) .....	4067
Retzius-sparing Robotic-assisted Radical Prostatectomy Facilitates Early Continence Regardless of Neurovascular Bundle Sparing. P.-C. LIAO, S.-C. HUNG, J.-C. HU, K.-Y. CHIU ( <i>Taichung; Nantou, Taiwan, ROC</i> ).....	4075
Predicting the Risk of Subsequent Distant Brain Metastases After Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy in Elderly Patients. D. RADES, T. NGUYEN, L. DZIGGEL, O. BLANCK, S.E. SCHILD ( <i>Lübeck; Güstrow, Germany; Scottsdale, AZ, USA</i> ) .....	4081
The Impact of Hypertension on the Clinicopathological Outcome and Progression of Renal Cell Carcinoma. T. MAKINO, K. IZUMI, H. IWAMOTO, S. KADOMOTO, R. NAITO, H. YAEGASHI, K. SHIGEHARA, Y. KADONO, A. MIZOKAMI ( <i>Kanazawa, Japan</i> ) .....	4087
The Promising Treatment Schedule of Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Alternative for Conventional Fractionation Using Mathematical Analysis. Y. UEDA, O. SUZUKI, S. OHIRA, M. YAGI, I. SUMIDA, K. WADA, S. INUI, M. ISONO, M. MIYAZAKI, K. OGAWA, T. TESHIMA ( <i>Osaka, Japan</i> ) .....	4095
Usefulness of Tumor Tissue Biopsy for Predicting the Biological Behavior of Hepatocellular Carcinoma. T. SHIOGA, R. KONDO, S. OGASAWARA, J. AKIBA, S. MIZUOCHI, H. KUSANO, Y. MIHARA, M. TANIGAWA, Y. KINJO, Y. NAITO, R. KUROMATSU, O. NAKASHIMA, H. YANO ( <i>Kurume, Japan</i> ) ...	4105
Magnetic Resonance and Ultrasound Fusion Imaging to Characterise Ovarian Masses: A Feasibility Study. A. CRESTANI, C. THEODORE, J.-M. LEVAILLANT, I. THOMASSIN-NAGGARA, D. SKALLI, G. MIAIHLE, Y. DABI, B. HADDAD, C. TOUBOUL ( <i>Créteil; Paris, France</i> ) .....	4115
Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report. M. NAKAMURA, M. UENO, S. HAYAMI, M. KAWAI, A. MIYAMOTO, N. SUZAKI, S. HIRONO, K.-I. OKADA, M. MIYAZAWA, Y. KITAHATA, R. KOBAYASHI, F. KOJIMA, H. YAMAUE ( <i>Wakayama, Japan</i> ).....	4123
Pembrolizumab and Radiotherapy for Platinum-refractory Recurrent Uterine Carcinosarcoma With an Abscopal Effect: A Case Report. M. YANO, S. ASO, M. SATO, Y. AOYAGI, H. MATSUMOTO, K. NASU ( <i>Oita; Saitama, Japan</i> ).....	4131
Coprevalence and Incidence of Lung Cancer in Patients Screened for Abdominal Aortic Aneurysm. A. HOHNECK, T. SHCHETYNSKA-MARINOVA, G. RUEMENAPF, M. PANCHEVA, R. HOFHEINZ, J. BODA-HEGGEMANN, E. SPERK, P. RIFFEL, J. MICHELS, M. BORGGREFE, I. AKIN, M. SIGL ( <i>Mannheim; Speyer, Germany</i> ) .....	4137
C-Reactive Protein and Absolute Lymphocyte Count Can Predict Overall Survival of Patients Treated With Eribulin. A. SATA, R. FUKUI, Y. MIYAGAWA, A. BUN, H. OZAWA, Y. FUJIMOTO, T. HIGUCHI, M. IMAMURA, Y. MIYOSHI ( <i>Nishinomiya; Yao, Japan</i> ) .....	4147

Combining Bevacizumab With Trifluridine/Thymidine Phosphorylase Inhibitor Improves the Survival Outcomes Regardless of the Usage History of Bevacizumab in Front-line Treatment of Patients With Metastatic Colorectal Cancer. M. SHIBUTANI, H. NAGAHARA, T. FUKUOKA, Y. ISEKI, E. WANG, Y. OKAZAKI, S. KASHIWAGI, K. MAEDA, K. HIRAKAWA, M. OHIRA ( <i>Osaka, Japan</i> ).....	4157
Prognostic Impact of Geriatric Nutritional Risk Index in Patients With Synchronous Colorectal Liver Metastasis. T. IGUCHI, K. SUGIMACHI, Y. MANO, T. MOTOMURA, M. SUGIYAMA, M. OTA, M. IKEBE, T. ESAKI, T. YOSHIKUMI, M. MORITA, M. MORI, Y. TOH ( <i>Fukuoka, Japan</i> ) .....	4165
Sorafenib Might Induce Sarcopenia in Patients With Hepatocellular Carcinoma by Inhibiting Carnitine Absorption. M. AMANUMA, H. NAGAI, Y. IGARASHI ( <i>Tokyo, Japan</i> ) .....	4173
A Single Institution’s Experience of Definitive Radiotherapy Using Volumetric-modulated Arc Therapy for Hypopharyngeal Cancers. K. KUBO, Y. MURAKAMI, N. IMANO, Y. TAKEUCHI, I. NISHIBUCHI, T. KIMURA, D. KAWAHARA, K. MIKI, A. SAITO, T. NAKASHIMA, T. HAMAMOTO, T. UEDA, S. TAKENO, Y. NAGATA ( <i>Hiroshima, Japan</i> ) .....	4183
Radioembolization-induced Tumor Calcifications as a Surrogate Marker of Tumor Response in Patients With Hepatocellular Carcinoma. H.-C. KIM, I. JOO, M. LEE, Y.J. KIM, J.C. PAENG, J.W. CHUNG ( <i>Seoul, Republic of Korea</i> ) .....	4191
Recurrent Leiomyosarcoma of the Small Bowel: A Case Series. C. FERRARI, S. DI DOMENICO, M. MASCHERINI, M. SANTOLIQUIDO, L. MASTRACCI, F. DE CIAN ( <i>Genoa, Italy</i> ) .....	4199
Errata.....	4205

## Number 8, August

### *Clinical Studies*

Detection and Oncologic Outcomes of Head and Neck Squamous Cell Carcinoma of Unknown Primary Origin. M.Y. LEE, N. FOWLER, D. ADELSTEIN, S. KOYFMAN, B. PRENDES, B.B. BURKEY ( <i>Cleveland; South Euclid, OH, USA</i> ) .....	4207
Secretin-induced Duodenal Aspirate of Pancreatic Juice (SIDA): Utility of Commercial Genetic Analysis. R.E. SIMPSON, M. YIP-SCHNEIDER, K.F. FLICK, M. SOUFI, E.P. CEPPA, M.A. AL-HADDAD, J.J. EASLER, S. SHERMAN, J.M. DEWITT, C.M. SCHMIDT ( <i>Indianapolis, IN, USA</i> ) .....	4215
Is Low Inferior Mesenteric Artery Ligation Worthwhile to Prevent Urinary and Sexual Dysfunction After Total Mesorectal Excision for Rectal Cancer? E. FIORI, D. CROCETTI, A. LAMAZZA, F. DE FELICE, A.V. STERPETTI, L. IRACE, A. MINGOLI, P. SAPIENZA, G. DE TOMA ( <i>Rome, Italy</i> ).....	4223
A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer. A. TAMIYA, M. TAMIYA, H. GO, T. INOUE, K. KUNIMASA, K. NAKAHAMA, Y. TANIGUCHI, T. SHIROYAMA, S.-I. ISA, K. NISHINO, T. KUMAGAI, H. SUZUKI, T. HIRASHIMA, S. ATAGI, A. SHINTANI, F. IMAMURA ( <i>Osaka, Japan</i> ).....	4229
Adaptive Radiotherapy for Glioblastoma Multiforme – The Impact on Disease Outcome. Z. VÉGVÁRY, B. DARÁZS, V. PACZONA, Á. DOBI, Z. REISZ, Z. VARGA, E. FODOR, A. CSERHÁTI, J. OLÁH, D. KIS, P. BARZÓ, K. HIDEGHÉTY ( <i>Szeged, Hungary</i> ) .....	4237
Variants of <i>SLC22A16</i> Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer. A. TAKEUCHI, T. OGURI, S. FUKUDA, K. SONE, Y. KAGAWA, T. UEMURA, O. TAKAKUWA, K. MAENO, K. FUKUMITSU, Y. KANEMITSU, T. TAJIRI, H. OHKUBO, M. TAKEMURA, Y. ITO, A. NIIMI ( <i>Nagoya, Japan</i> ).....	4245

Interest for a Systematic Rehabilitation Program Including Physical Exercise and Lifestyle Accompaniment for Women Recently Treated for Early Breast Cancer: A Comparative Study. S. MARECHAL, M.-P. GRAAS, L. COLLARD, M. COLLIN, V. RASKIN, G. BRANDS, P. EVRARD, J.-P. LOBELLE, C. FOCAN ( <i>Liège; Beernem, Belgium</i> ).....	4253
Association of C677T and A1298C <i>MTHFR</i> Polymorphisms and Fluoropyrimidine-induced Toxicity in Mestizo Patients With Metastatic Colorectal Cancer. A. RAMOS-ESQUIVEL, R. CHINCHILLA, M. VALLE ( <i>Barcelona, Spain; San Jose, Costa Rica</i> ) .....	4263
Skeletal Muscle Mass Depletion After Gastrectomy Negatively Affects the Prognosis of Patients With Gastric Cancer. Y. KANAZAWA, T. YAMADA, D. KAKINUMA, K. MATSUNO, F. ANDO, I. FUJITA, H. KANNO, S. KATO, H. YOSHIDA ( <i>Tokyo, Japan</i> ) .....	4271
Interstitial Brachytherapy for Limited (<4 cm) and Large (≥4 cm) Hepatic Metastases from Rare and Less Common Cancers. C. HEINZE, J. OMARI, R. DAMM, P. HASS, T. BRUNNER, A. SUROV, R. SEIDESTICKER, M. SEIDENSTICKER, J. RICKE, M. POWERSKI, M. PECH ( <i>Magdeburg; Munich, Germany</i> ) .....	4281
Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer. Y. SHIMURA, Y. SUGA, S. ITAI, H. IWAMOTO, Y. TAKEZAWA, H. YAEGASHI, K. IZUMI, T. SHIMADA, Y. SAI, R. MATSUSHITA, A. MIZOKAMI ( <i>Kanazawa, Japan</i> ).....	4291
Increase in Circulating Tumor Cells in Invasive Bladder Cancer After Transurethral Resection of Bladder Tumor. N. HAGA, K. TSUBOUCHI, H. MARUTA, T. KOGUCHI, S. HOSHI, S. OGAWA, H. AKAIHATA, J. HATA, Y. KOJIMA ( <i>Fukushima; Fukuoka, Japan</i> ) .....	4299
Ephrin Receptor B2 Expression May Be a Prognostic Marker for Patients With Cancer: A Meta-analysis. H.M. KOH, C.L. HYUN, B.G. JANG, H.J. LEE ( <i>Changwon; Jeju; Cheonan, Republic of Korea</i> ) .....	4309
Borderline Microenvironment Fibrosis Is a Novel Poor Prognostic Marker of Oral Squamous Cell Carcinoma. K. TSUCHIHASHI, M. NAKATSUGAWA, J.-I. KOBAYASHI, T. SASAYA, R. MORITA, T. KUBO, T. KANASEKI, T. TSUKAHARA, H. ASANUMA, T. HASEGAWA, H. HIRANO, A. MIYAZAKI, Y. HIROHASHI, T. TORIGOE ( <i>Hokkaido; Tokyo, Japan</i> ) .....	4319
Correlation of Pathological Complete Response With Tumor Volume Reduction During Neoadjuvant Chemoradiotherapy in Lung Cancer. S. TAKAHASHI, T. GO, M. ANADA, T. KINOSHITA, T. NISHIDE, H. YOKOMISE, T. SHIBATA ( <i>Kagawa, Japan</i> ) .....	4327
Practice Variation in the Adjuvant Treatment of Colon Cancer in the Netherlands: A Population-based Study. L. KEIKES, M. KOOPMAN, V.E.P.P. LEMMENS, M.G.H. VAN OIJEN, C.J.A. PUNT ( <i>Amsterdam; Utrecht; Rotterdam, the Netherlands</i> ) .....	4331
Predictors of Postoperative Ascites After Hepatic Resection in Patients With Hepatocellular Carcinoma. N. HARIMOTO, K. ARAKI, N. ISHII, R. MURANUSHI, K. HOSHINO, K. HAGIWARA, M. TSUKAGOSHI, T. IGARASHI, A. WATANABE, N. KUBO, K. SHIRABE ( <i>Maebashi, Japan</i> ) .....	4343
Diagnostic Role of Contrast-enhanced Ultrasound in the Discrimination of Malignant Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma. J.H. KWON, S.H. YOO, S.W. NAM, Y.J. LEE, Y.R. SHIN ( <i>Incheon; Daejeon; Seoul, Republic of Korea</i> ) .....	4351
Better Cancer-specific Survival in Younger Patients With Stage III Colorectal Cancer: A Propensity Score Matching Study From Japan. L. WANG, Y. HIRANO, G. HENG, T. ISHII, H. KONDO, K. HARA, N. OBARA, M. ASARI, S. YAMAGUCHI ( <i>Saitama, Japan</i> ).....	4365
Giant Cell Tumor of Tendon Sheath With a t(1;1)(p13;p34) Chromosomal Translocation. S. NAKAYAMA, J. NISHIO, K. NAKATANI, K. NABESHIMA, T. YAMAMOTO ( <i>Fukuoka, Japan</i> ) .....	4373
A Model for Predicting DNA Mismatch Repair-deficient Colorectal Cancer. K. CHIKATANI, N. CHIKA, O. SUZUKI, T. SAKIMOTO, K. ISHIBASHI, H. EGUCHI, Y. OKAZAKI, H. ISHIDA ( <i>Saitama; Tokyo, Japan</i> ) .....	4379

Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy. T. KUROKAWA, Y. HAMAI, M. EMI, Y. IBUKI, T. YOSHIKAWA, M. OHSAWA, R. HIROHATA, M. OKADA ( <i>Hiroshima, Japan</i> ) .....	4387
Prognostic Stratification of the IMDC Intermediate Risk Group After Treatment With First-line Molecular-targeted Therapy for Metastatic Renal Cell Carcinoma. K. TAKAHARA, R. ANDO, K. KANAO, T. ITO, H. MIYAKE, M. SUMITOMO, T. YASUI, R. SHIROKI ( <i>Toyoake; Nagoya; Hidaka; Hamamatsu, Japan</i> ) .....	4395
EGFR Mutated Lung Adenocarcinoma Metastasis to the Pancreas Mimicking Primary Pancreatic Ductal Carcinoma. C. CAO, M.X. KONG, M. KAPALI, K. MOEZARDALAN, Q. SHI, A. AZARM, J. LAI ( <i>Sacramento, CA; Providence, RI; Atlanta, GA, USA</i> ) .....	4401
Predictive Factors for Non-sentinel Nodal Metastasis in Patients With Sentinel Lymph Node-positive Breast Cancer. Y. ISHIZUKA, Y. HORIMOTO, M. NAKAMURA, A. ARAKAWA, T. FUJITA, K. IJIMA, M. SAITO ( <i>Tokyo; Urayasu, Japan</i> ).....	4405
Radiotherapy of Prostate Carcinoma: A Comparison of the Predictive Role of EAU Versus NCCN Risk Stratification Systems. M. BUWENGE, F. DEODATO, N. DOMINSKY, M. NTRETA, S. CILLA, G. SIEPE, A.R. ALITTO, S. BISELLO, V. VALENTINI, G. MACCHIA, A.G. MORGANTI ( <i>Bologna; Campobasso; Rome, Italy</i> ).....	4413
Fibrosis or Necrosis in Resected Lymph Node Indicate Metastasis Before Chemoradiotherapy in Lung Cancer Patients. Y. TAKAHASHI, J. SOH, K. SHIEN, H. YAMAMOTO, M. YAMANE, K. KIURA, S. KANAZAWA, H. YANAI, S. TOYOOKA ( <i>Okayama, Japan</i> ).....	4419
<i>Experimental Studies</i>	
Mosaic Recombinant Adeno-associated Virus Vector rAAV/DJ/CAG for Targeted Gene Delivery to Melanoma Cells Metastasized to the Lung. M. CZAJKA, A. ZAJKOWSKA, M. GAWLAK, M. BUJALSKA-ZADROZNY, M. MALECKI ( <i>Warsaw, Poland</i> ).....	4425
Involvement of the Interferon Signaling Pathways in Pancreatic Cancer Cells. M. FUJISAWA, T. KANDA, T. SHIBATA, R. SASAKI, R. MASUZAKI, N. MATSUMOTO, K. NIREI, H. IMAZU, K. KURODA, M. SUGITANI, T. TAKAYAMA, M. MORIYAMA ( <i>Tokyo, Japan</i> ).....	4445
A Novel Anti-inflammatory Phenotype Transformed by Repetitive Low-dose Lipopolysaccharide in Primary Peritoneal Tissue-resident Macrophages. H. MIZOBUCHI, K. YAMAMOTO, M. YAMASHITA, H. INAGAWA, C. KOHCHI, G.-I. SOMA ( <i>Kagawa; Niigata, Japan</i> ) .....	4457
MiR-196a-2 Genotypes Determine the Susceptibility and Early Onset of Childhood Acute Lymphoblastic Leukemia. C.-C. CHEN, P.-C. HSU, L.-C. SHIH, Y.-N. HSU, C.-C. KUO, C.-Y. CHAO, W.-S. CHANG, C.-W. TSAI, D.-T. BAU, J.-S. PEI ( <i>Taoyuan; Taichung, Taiwan, ROC</i> ).....	4465
Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL). R. YOKOTA, S. HASHIMOTO, I. WATANABE, S. KISHIMOTO, M. TOYAMA, M. OKAMOTO, M. YOSHIMITSU, K. ISHITSUKA, Y. ITO, M. BABA ( <i>Kagoshima, Japan</i> ).....	4471
Clinical Implications of Cancer Stem Cell Markers and ABC Transporters as a Predictor of Prognosis in Colorectal Cancer Patients. B.-H. KIM, H.-K. OH, D.-W. KIM, S.-B. KANG, Y. CHOI, E. SHIN ( <i>Seoul; Seongnam; Hwaseong, Republic of Korea</i> ) .....	4481
Peroxiredoxin II Inhibits Alcohol-induced Apoptosis in L02 Hepatocytes Through AKT/ $\beta$ -Catenin Signaling Pathway. Y.-H. HAN, W.-L. LI, M.-H. JIN, Y.-H. JIN, Y.-Q. ZHANG, L.-Z. KONG, L.-Y. YU, J.W. HYUN, J. KWON, H.-N. SUN, T. KWON ( <i>Daqing, PR China; Jeju; Chungbuk; Jeonbuk, Republic of Korea</i> ) .....	4491
Involvement of Corticotropin-releasing Hormone-related Peptides in Cellular Stress Caused by Anticancer Drugs in Colorectal Cancer. G. KUWATA, K. IKEDA, Y. MANOME ( <i>Tokyo, Japan</i> ) .....	4505

Cetyltrimethylammonium Bromide Disrupts the Mesenchymal Characteristics of HA22T/VGH Cells Via Inactivation of c-Met/PI3K/Akt/mTOR Pathway. C.-H. YUE, C.-H. CHEN, W.-T. LEE, T.-F. SU, Y.-R. PAN, Y.-P. CHEN, F.-M. HUANG, C.-J. LEE ( <i>Taichung; Miaoli; Changhua, Taiwan, ROC</i> ).....	4513
The Contribution of <i>MMP-9</i> Genotypes to Pterygium in Taiwan. C.-B. TSAI, N.-Y. HSIA, Z.-H. WANG, J.-S. YANG, Y.-M. HSU, Y.-C. WANG, W.-S. CHANG, D.-T. BAU, M.-C. YIN, C.-W. TSAI ( <i>Chia-Yi; Taichung, Taiwan, ROC</i> ).....	4523
Ginseng Seed Oil Inhibits the Growth of Estrogen Receptor-positive Breast Cancer Cells. T.H. KIM, S.-C. KWON, J.N. KIM, J.-H. YOON, S.-G. CHO ( <i>Chungbuk; Pusan, Republic of Korea</i> ).....	4529
The Roles of Connexin 26, 32, and 43 as Prognostic Factors for Gastric Cancer. E.Y. KIM, K.H. JUN, K. YIM ( <i>Seoul, Republic of Korea</i> ) .....	4537
Exploring Flavonoids for Potential Inhibitors of a Cancer Signaling Protein PI3K $\gamma$ Kinase Using Computational Methods. M. REHAN, M.M. MAHMOUD, S. TABREZ, H.M.A. HASSAN, G.M. ASHRAF ( <i>Jeddah, Kingdom of Saudi Arabia; Cairo, Egypt</i> ).....	4547
Overexpression of Holocarboxylase Synthetase Predicts Lymph Node Metastasis and Unfavorable Prognosis in Breast Cancer. W. SUKJOI, S. SIRITUTSOONTORN, P. CHANSONGKROW, S. WAIWITLIKHIT, S.W. POLYAK, M. WARNNISSORN, V. CHAROENSAWAN, C. THUWAJIT, S. JITRAPAKDEE ( <i>Bangkok; Nakhon Pathom, Thailand; Brighton, UK; Adelaide, Australia</i> ) .....	4557
Molecular Profiles of Breast Cancer in a Single Institution. T. KAMIO, H. KAMIO, T. AOKI, Y. ONDO, T. UCHIYAMA, K. YAMAMOTO-SHIMOJIMA, M. WATANABE, T. OKAMOTO, H. KANNO, T. YAMAMOTO ( <i>Tokyo, Japan</i> ).....	4567
<b>ABSTRACTS OF THE 30th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO).</b> 26 - 29 September 2020 ( <i>Virtual Meeting</i> ) .....	4571-4650
<b>PROCEEDINGS OF THE 23RD ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES.</b> 7 December, 2019 ( <i>Niigata, Japan</i> ) .....	4651-4804
<i>Review</i>	
Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs. Y. HASHIMOTO, Y. YOSHIDA, T. YAMADA, N. AISU, G. YOSHIMATSU, F. YOSHIMURA, S. HASEGAWA ( <i>Fukuoka, Japan</i> ) .....	4655
<i>Experimental Studies</i>	
Mutant <i>KRAS</i> Promotes NKG2D+ T Cell Infiltration and CD155 Dependent Immune Evasion. K. NISHI, S. ISHIKURA, M. UMEBAYASHI, T. MORISAKI, T. INOZUME, T. KINUGASA, M. AOKI, S. NIMURA, A. SWAIN, Y. YOSHIDA, S. HASEGAWA, K. NABESHIMA, T. SAKATA, S. SHIRASAWA, T. TSUNODA ( <i>Fukuoka; Chuo; Chiba; Kurume, Japan</i> ).....	4663
Effect of Isomerization of TX-2036 Derivatives on the Interaction With Tyrosine Kinase Domain of EGF Receptor. K. OHKURA, A. TABATA, Y. UTO, H. HORI ( <i>Suzuka; Tokushima, Japan</i> ).....	4675
Enhanced Effect of Hyaluronan and Elastin Synthesis in Fibroblasts Through Lipopolysaccharide-activated Macrophages. T. HONDA, S. TSUTSUI, C. KOHCHI, H. INAGAWA ( <i>Kanagawa; Kagawa; Niigata, Japan</i> ) .....	4681
MK615 Suppresses Hypoxia Tolerance by Up-regulation of E-cadherin in Colorectal Cancer Cells With Mutant <i>KRAS</i> . K. NISHI, T. TSUNODA, Y. UCHIDA, T. SUETA, M. SAWATSUBASHI, T. YAMANO, Y. HASHIGUCHI, A. SWAIN, S. SHIRASAWA, T. SAKATA ( <i>Fukuoka, Japan</i> ).....	4687
Quercetin Suppresses Proliferation of Liver Cancer Cell Lines <i>In Vitro</i> . T. HISAKA, H. SAKAI, T. SATO, Y. GOTO, Y. NOMURA, S. FUKUTOMI, F. FUJITA, T. MIZOBE, O. NAKASHIMA, M. TANIGAWA, Y. NAITO, J. AKIBA, S. OGASAWARA, K. NAKASHIMA, Y. AKAGI, K. OKUDA, H. YANO ( <i>Kurume, Japan</i> ).....	4695



Therapeutic Effect and Mechanism of Action of Low-molecular-weight Whey Protein Capable of Activating Macrophages in Bovine Mastitis. T. TASAKA, K. MAHASHI, H. YAMADA, A. SHIRAI, H. UNUMA, KEN TOKUNAGA, A. HAYAKAWA, A. GO, K. GO, Y. UTO ( <i>Tokushima; Tokyo, Japan</i> ) .....	4701
Comparison of Macrophage Activation Using $\gamma$ -Globulin and Serum-derived Macrophage Activating Factor. M. AKAMATSU, R. MASHIBA, K. KAWAKATSU, M. ISHIKAWA, T. NISHIKATA ( <i>Kobe, Japan</i> ) .....	4707
Attempt to Construct an <i>In Vitro</i> Model of Enhancement of Macrophage Phagocytosis Via Continuous Administration of LPS. K. YAMAMOTO, H. MIZOBUCHI, M. YAMASHITA, H. INAGAWA, C. KOHCHI, G.-I. SOMA ( <i>Kagawa; Niigata, Japan</i> ).....	4711
Mastication Affects Transcriptomes of Mouse Microglia. M. SEKI, A. HAINO, T. ISHIKAWA, H. INAGAWA, G.-I. SOMA, H. TERADA, M. NASHIMOTO ( <i>Niigata; Kagawa, Japan</i> ) .....	4719
<i>Clinical Studies</i>	
Prognostic Factors for Endometrial and Cervical Cancers of Uterus Treated With Immune-cell Therapy: A Retrospective Study. R. TAKIMOTO, T. KAMIGAKI, S. OKADA, H. IBE, E. OGUMA, K. NAITOH, K. MAKITA, K. YASUMOTO, S. GOTO ( <i>Tokyo; Fukuoka; Osaka, Japan</i> ).....	4729
Adoptive Immune-Cell Therapy for the Treatment of Neuroendocrine Carcinoma of the Uterine Cervix. S. GOTO, Y. TERAU, T. KAMIGAKI, R. TAKIMOTO, K. NAITOH, K. MAKITA, K. YASUMOTO, S. OKADA, K. TAKIZAWA, N. YOKOMICHI, N. SUZUKI, S. TAKEDA ( <i>Tokyo; Kawasaki, Japan</i> ) .....	4741
Prognostic Impact of Desmoplastic Reaction Evaluation for Intrahepatic Cholangiocarcinoma. S. KOJIMA, T. HISAKA, R. MIDORIKAWA, Y. NAITO, J. AKIBA, M. TANIGAWA, H. YANO, Y. AKAGI, K. OKUDA ( <i>Kurume, Japan</i> ).....	4749
Useful Cases of Patients With Developmental Disorders Improved by Oral Administration of LPS Derived from <i>Pantoea agglomerans</i> . A. MORISHIMA, R. ZHANG, T. NAGAOKA, H. INAGAWA ( <i>Osaka; Takamatsu; Niigata, Japan</i> ) .....	4755
Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemotherapy. T. YAMADA, Y. YOSHIDA, T. MAEDA, G. YOSHIMATSU, N. AISU, K. YAMASHITA, A. KOMONO, R. KAJITANI, Y. MATSUMOTO, H. NAGANO, K. NAITO, K. YASUMOTO, R. TAKIMOTO, T. KAMIGAKI, S. GOTO, F. YOSHIMURA, N. SAKATA, S. KODAMA, S. HASEGAWA ( <i>Fukuoka; Tokyo, Japan</i> ) .....	4763
Salvage Surgery for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Downstaged by Hepatic Arterial Infusion Chemotherapy. Y. GOTO, T. HISAKA, H. SAKAI, K. TAKAGI, S. FUKUTOMI, Y. AKAGI, K. OKUDA ( <i>Kurume, Japan</i> ) .....	4773
Pilot Study of Irinotecan and S-1 (IRIS) for Advanced and Metastatic Breast Cancer. T. TANAKA, M. TANAKA, H. FURUSAWA, Y. KAMADA, Y. SAGARA, K. ANAN, K. MIYARA, Y. KAI, T. UGA, K. TAMURA, S. MITSUYAMA ( <i>Fukuoka; Miyazaki; Okinawa; Kagoshima; Oita; Nagasaki, Japan</i> ) .....	4779
The Impact of Histological Variant on Oncological Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. K. TAKEMOTO, J. TEISHIMA, Y. KOHADA, K. IKEDA, H. NAGAMATSU, A. GORIKI, S. INOUE, T. HAYASHI, M. KAJIWARA, A. MATSUBARA ( <i>Hiroshima; Oita, Japan</i> ).....	4787
Artificial Intelligence in Ovarian Cancer Diagnosis. M. AKAZAWA, K. HASHIMOTO ( <i>Tokyo, Japan</i> ).....	4795
Clinical Outcomes of Surgical Resection for Brain Metastases from Non-small Cell Lung Cancer. T. NAKAO, T. OKUDA, H. YOSHIOKA, M. FUJITA ( <i>Osaka, Japan</i> ).....	4801
Errata .....	4805

## Number 9, September

## Reviews

- The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer. A. HALLEY, A. LEONETTI, A. GREGORI, M. TISEO, D.M. DENG, E. GIOVANNETTI, G.J. PETERS (*Amsterdam, the Netherlands; Parma; Pisa, Italy; Gdańsk, Poland*) ..... 4807
- Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: Review of the Literature and Perspectives of Clinical Research. A. GADDUCCI, STEFANIA COSIO (*Pisa, Italy*) ..... 4819
- The Future of ER+/HER2– Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors. A. STRAVODIMOU, I.A. VOUSADAKIS (*Lausanne, Switzerland; Sault Ste Marie; Sudbury, ON, Canada*) ..... 4829
- Inhibitors of Fatty Acid Synthesis and Oxidation as Potential Anticancer Agents in Colorectal Cancer Treatment. P. MOZOLEWSKA, K. DUZOWSKA, A. PAKIET, A. MIKA, T. ŚLEDZIŃSKI (*Gdansk, Poland*) ..... 4843

## Experimental Studies

- Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells. A. THADI, L. LEWIS, E. GOLDSTEIN, A. AGGARWAL, M. KHALILI, L. STEELE, B. POLYAK, S. SEYDAFKAN, M.H. BLUTH, K.A. WARD, M. STYLER, P.M. CAMPBELL, M.R. PINCUS, W.B. BOWNE (*Philadelphia, PA; Brooklyn, NY; Detroit, MI, USA*) ..... 4857
- Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model. N. SUGISAWA, K. HAMADA, Q. HAN, J. YAMAMOTO, Y. SUN, H. NISHINO, K. KAWAGUCHI, M. BOUVET, M. UNNO, R.M. HOFFMAN (*San Diego, CA, USA; Sendai, Japan*) ..... 4869
- A Potential Mechanism of Anticancer Immune Response Coincident With Immune-related Adverse Events in Patients With Renal Cell Carcinoma. T. KATO, E. TOMIYAMA, Y. KOH, M. MATSUSHITA, Y. HAYASHI, K. NAKANO, Y. ISHIZUYA, C. WANG, K. HATANO, A. KAWASHIMA, T. UJIKE, K. KAWASAKI, E. MORII, K. GOTOH, H. EGUCHI, K. KIYOTANI, K. FUJITA, N. NONOMURA, M. UEMURA (*Osaka; Tokyo, Japan*) ..... 4875
- Antitumor Effects and Tumor-specificity of Guaiazulene-3-Carboxylate Derivatives Against Oral Squamous Cell Carcinoma *In Vitro*. M. TERATANI, S. NAKAMURA, H. SAKAGAMI, M. FUJISE, M. HASHIMOTO, N. OKUDAIRA, K. BANDOW, Y. IJIMA, J. NAGAI, Y. UESAWA, H. WAKABAYASHI (*Saitama; Tokyo; Kawagoe, Japan*) ..... 4885
- Effect of Phosphoribosyltransferase Down-regulation on Malignant Glioma Cell Characteristics. M. KAMADA, K. IKEDA, Y. MANOME (*Tokyo, Japan*) ..... 4895
- Luteolin Induces Cytotoxicity in Mix Cellularity Classical Hodgkin's Lymphoma *via* Caspase Activated-cell Death. R. GHARBARAN, E. SHANG, O. ONWUMERE, N. CODRINGTON, E.D. SARPONG, S. REDENTI (*Bronx; New York, NY, USA*) ..... 4907
- New Imidazo[2,1-*b*][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma. G.L. PETRI, C. PECORARO, O. RANDAZZO, S. ZOPPI, S.M. CASCIOFERRO, B. PARRINO, D. CARBONE, B. EL HASSOUNI, A. CAVAZZONI, N. ZAFFARONI, G. CIRRINCIONE, P. DIANA, G.J. PETERS, E. GIOVANNETTI (*Amsterdam, the Netherlands; Palermo; Parma; Milan; Pisa, Italy; Gdansk, Poland*) ..... 4913
- Phenothiazines and Selenocompounds: A Potential Novel Combination Therapy of Multidrug Resistant Cancer. M. GAJDÁCS, M. NOVÉ, Á. CSONKA, B. VARGA, C. SANMARTÍN, E. DOMÍNGUEZ-ÁLVAREZ, G. SPENGLER (*Szeged, Hungary; Pamplona; Madrid, Spain*) ..... 4921

Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1). C.H. KANG, S.U. CHOI, Y.H. SON, H.K. LEE, H.G. JEONG, C.-S. YUN, S. AHN, C.H. PARK ( <i>Daejeon, Republic of Korea</i> ) .....	4929
ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer. K.THRIN FLESCHUTZ, L. WALTER, R. LEISTNER, L. HEINZERLING ( <i>Erlangen; Bamberg, Germany</i> ).....	4937
Effects of Sclareol Against Small Cell Lung Carcinoma and the Related Mechanism: <i>In Vitro</i> and <i>In Vivo</i> Studies. H.L. CHEN, J.Y. GONG, S.-C. LIN, S. LI, Y.-C. CHIANG, J.-H. HUNG, C.-C. YEN, C.-C. LIN ( <i>Taichung; Keelung; New Taipei City; Tainan; Changhua, Taiwan, ROC; Blacksburg, VA, USA; Huanggang, PR China</i> ) .....	4947
Inhibition of Retinoblastoma Cell Growth by CEP1347 Through Activation of the P53 Pathway. K. TOGASHI, M. OKADA, S. SUZUKI, T. SANOMACHI, S. SEINO, M. YAMAMOTO, H. YAMASHITA, C. KITANAKA ( <i>Yamagata, Japan</i> ) .....	4961
<i>Brucea javanica</i> Increases Survival and Enhances Gemcitabine Efficacy in a Patient-derived Orthotopic Xenograft (PDOX) Mouse Model of Pancreatic Cancer. H. YANG, Z. TONG, L. SHEN, Y. SUN, R.M. HOFFMAN, J. HUANG ( <i>Hefei, PR China; San Diego, CA, USA</i> ) .....	4969
<i>CDKN1A</i> Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality. D. HRCKOVA DROZDKOVA, J. GURSKY, J. MINARIK, I. ÜBERALL, Z. KOLAR, K. SMESNY TRTKOVA ( <i>Olomouc, Czech Republic</i> ) .....	4979
Ephemeranthol A Suppresses Epithelial to Mesenchymal Transition and FAK-Akt Signaling in Lung Cancer Cells. N. NONPANYA, O. PRAKHONGCHEEP, K. PETSRI, C. JITJAICHAM, S. TUNGSUKRUTHAI, B. SRITULARAK, P. CHANVORACHOTE ( <i>Bangkok, Thailand</i> ) .....	4989
The Effects of Newly Synthesized Platinum(IV) Complexes on Cytotoxicity and Radiosensitization of Human Tumour Cells <i>In Vitro</i> . M. PETROVIC, S. POPOVIC, D. BASKIC, M. TODOROVIC, P. DJURDJEVIC, A. RISTIC-FIRA, O. KETA, V. PETKOVIC, L. KORICANAC, D. STOJKOVIC, V. JEVTIC, S. TRIFUNOVIC, D. TODOROVIC ( <i>Kragujevac; Belgrade, Serbia</i> ) .....	5001
Assessment of <i>In Vitro</i> Anti-melanoma Potential of <i>Ephedranthus pisocarpus</i> R.E.Fr. L.K. BESERRA SANTOS, M.D. ALVES VERAS, K.K. GADELHA MARQUES, M.M. DE MORAES ALVES, A. NOGUEIRA MENDES, F.A. DE AMORIM CARVALHO, M. VIEIRA SOBRAL, M.H. CHAVES, J.C. RAMOS GONÇALVES ( <i>Teresina; João Pessoa, Brazil</i> ).....	5015
A New Ciprofloxacin-derivative Inhibits Proliferation and Suppresses the Migration Ability of HeLa Cells. M. FATHY, S. SUN, Q.-L. ZHAO, M. ABDEL-AZIZ, G.E.-D.A. ABUO-RAHMA, S. AWALE, T. NIKAIIDO ( <i>Toyama, Japan; Minia, Egypt</i> ) .....	5025
Up-regulation of Death Receptor 5/TRAIL-R2 Mediates Apoptosis Induced by <i>N,N'</i> -[(3,4-dimethoxyphenyl)methylene] Biscinnamide in Cancer Cells. H. II, S. NAKATA, J. UENISHI ( <i>Kyoto; Osaka, Japan</i> ).....	5035
Inhibitory Effect of Eicosapentaenoic Acid on the Migration of the Esophageal Squamous Cell Carcinoma Cell Line TE-1. H. KUBOTA, T. HIRAI, A. YAMAUCHI, A. OGO, H. MATSUMOTO, T. UENO ( <i>Okayama; Hiroshima, Japan</i> ) .....	5043
Anticancer Effect of a Spiro-acridine Compound Involves Immunomodulatory and Anti-angiogenic Actions. S. SOUSA DUARTE, D.K. FRADE SILVA, T.M. HONORATO LISBOA, R. GALDINO GOUVEIA, R.C. FERREIRA, R.O. DE MOURA, J.M. DA SILVA, É. DE ALMEIDA LIMA, S. RODRIGUES-MASCARENHAS, P.M. DA SILVA, D.F. FARIAS, J.A. DA COSTA RIBEIRO SOUZA, K.C. DE PAULA MEDEIROS, J.C. RAMOS GONÇALVES, M. VIEIRA SOBRAL ( <i>João Pessoa; Recife; Natal, Brazil</i> ) .....	5049

Cetyltrimethylammonium Bromide Suppresses the Migration and Invasion of Hepatic Mahlavu Cells by Modulating Fibroblast Growth Factor Signaling. T.-K. WU, C.-H. CHEN, W.-T. LEE, T.-F. SU, Y.-R. PAN, F.-M. HUANG, C.-J. LEE ( <i>Taichung; Miaoli; Changhua, Taiwan, ROC</i> ) .....	5059
Setanaxib as a Potent Hypoxia-specific Therapeutic Agent Against Liver Cancer. S. OWADA, H. ENDO, C. OKADA, K. YOSHIDA, Y. SHIDA, M. TATEMACHI ( <i>Isehara, Japan</i> ) .....	5071
Novel Imidazo[2,1-b]oxazole Derivatives Inhibit Epithelial Cell Transformation and Triple Negative Breast Cancer Tumorigenesis. P.Y. BHATTARAI, C.-H. OH, G. KIM, M.S. KIM, B.S. LEE, H.S. CHOI ( <i>Gwangju; Seoul; Hwaseong, Republic of Korea</i> ) .....	5081
YM155 Reverses Cabazitaxel Resistance in Castration-resistant Prostate Cancer by Reducing Survivin Expression. T. MIYAO, H. KOIKE, Y. SEKINE, A. OHTSU, D. OKA, K. SUZUKI ( <i>Maebashi, Japan</i> ) .....	5091
Assessing the Anti-cancer Therapeutic Mechanism of a Herbal Combination for Breast Cancer on System-level by a Network Pharmacological Approach. H.-S. LEE, D.-S. OH ( <i>Daejeon, Republic of Korea</i> ) .....	5097
Anti-tumor Effect of Hedgehog Signaling Inhibitor, Vismodegib, on Castration-resistant Prostate Cancer. A. ISHII, K. SHIGEMURA, K. KITAGAWA, S.-Y. SUNG, K.-C. CHEN, C. YI-TE, M.-C. LIU, M. FUJISAWA ( <i>Kobe, Japan; Taipei, Taiwan, ROC</i> ) .....	5107
Antitumor Effect of Shikonin, a PKM2 Inhibitor, in Cholangiocarcinoma Cell Lines. U. THONSRI, W. SEUBWAI, S. WARAASAWAPATI, S. WONGKHAM, T. BOONMARS, U. CHA'ON, C. WONGKHAM ( <i>Khon Kaen, Thailand</i> ) .....	5115
Anti-progressive Effects of a Series of Glycinylnyl and Alaninylnyl Triazolyl-oxazolidinones on Kelly Neuroblastoma Cell Line. N.A. AL-HASAWI, O.A. PHILLIPS, F. AL-AWADHI, L.H. SHARAF, S.A. AMINE, L. NOVOTNY ( <i>Kuwait City, Kuwait</i> ) .....	5125
Temozolomide and AZD7762 Induce Synergistic Cytotoxicity Effects on Human Glioma Cells. Y. CHEN, B.-J. TSENG, Y.-H. TSAI, S.-H. TSENG ( <i>New Taipei; Taoyuan; Taipei, Taiwan, ROC</i> ) .....	5141
Static Magnetic Stimulation Induces Cell-type Specific Alterations in the Viability of SH-SY5Y Neuroblastoma Cell Line. H.R. MEDEIROS, J.A.F. ASSUMPCAO, L.F. MEDEIROS, M. STAPENHORST, L. NUNES, N.A.C. HENCKES, C. URIBE CRUZ, F. FREGNI, P.R.S. SANCHES, F.S.O. OLIVEIRA, W. CAUMO, E.O. CIRNE-LIMA, I.L.S. TORRES ( <i>Porto Alegre, RS, Brazil; Boston, MA, USA</i> ) .....	5151
Redox-related Molecular Mechanism of Sensitizing Colon Cancer Cells to Camptothecin Analog SN38. B. NIKOLOVA, S. SEMKOVA, I. TSONEVA, E. STOYANOVA, P. LEFTEROV, D. LAZAROVA, Z. ZHELEV, I. AOKI, T. HIGASHI, R. BAKALOVA ( <i>Sofia, Stara Zagora, Bulgaria; Chiba, Japan</i> ) .....	5159
Inhibitory Effects of Beraprost Sodium in Murine Hepatic Sinusoidal Obstruction Syndrome. M. NAKURA, T. MIYASHITA, Y. YAMAMOTO, S. TAKADA, S. KANOU, H. TAJIMA, H. TAKAMURA, T. OHTA ( <i>Kanazawa; Kahoku, Japan</i> ) .....	5171
Advanced Non-linear Mathematical Model for the Prediction of the Activity of a Putative Anticancer Agent in Human-to-mouse Cancer Xenografts. S.G. LILIOPOULOS, G.S. STAVRAKAKIS, K.S. DIMAS ( <i>Chania; Larissa, Greece</i> ) .....	5181
Methylsulfonylmethane Induces Cell Cycle Arrest and Apoptosis, and Suppresses the Stemness Potential of HT-29 Cells. D.H. KIM, D.Y. KANG, N. SP, E.S. JO, A. RUGAMBA, K.-J. JANG, Y.M. YANG ( <i>Chungju, Republic of Korea</i> ) .....	5191
Total Flavonoids Isolated from <i>Diospyros kaki</i> L. f. Leaves Induced Apoptosis and Oxidative Stress in Human Cancer Cells. L. CHEN, Y. GUO, G. ALSAIF, Y. GAO ( <i>Murfreesboro, TN, USA; Liuzhou; Nanning, PR China</i> ) .....	5201

Anti-tumor Activity of the Small Molecule Inhibitor PRI-724 Against $\beta$ -Catenin-activated Hepatocellular Carcinoma. R. GABATA, K. HARADA, Y. MIZUTANI, H. OUCHI, K. YOSHIMURA, Y. SATO, A. KITAO, K. KIMURA, H. KOUJI, T. MIYASHITA, H. TAJIMA, T. OHTA ( <i>Kanazawa; Tokyo; Oita; Fujisawa, Japan</i> ) .....	5211
Gamma/Delta T-Cells Enhance Carboplatin-induced Cytotoxicity Towards Advanced Bladder Cancer Cells. Y. PAN, Y.-H. CHIU, S.-C. CHIU, D.-Y. CHO, L.-M. LEE, Y.-C. WEN, J. WHANG-PENG, C.-H. HSIAO, P.-H. SHIH ( <i>Taipei; Taichung, Taiwan, ROC</i> ) .....	5221
<i>Clinical Studies</i>	
Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer. H. MINAMI, Y. ANDO, K. TAMURA, T. TAJIMA, R. ISAACS ( <i>Kobe; Nagoya; Tokyo, Japan; East Hanover, NJ, USA</i> ) .....	5229
Mogamulizumab Plus EPOCH Therapy for Patients With Newly Diagnosed Aggressive Adult T-cell Leukemia/Lymphoma. T. JO, K. MATSUZAKA, H. SHIOYA, H. TOMINAGA, T. SAKAI, Y. KANEKO, S. HAYASHI, M. MATSUO, J. TAGUCHI, K. ABE, K. SHIGEMATSU, R. KUBOTA-KOKETSU ( <i>Nagasaki; Osaka, Japan</i> ) .....	5237
Higher BMI, But Not Sarcopenia, Is Associated With Pembrolizumab-related Toxicity in Patients With Advanced Melanoma. J.B. HU, S. RAVICHANDRAN, C. RUSHING, G.M. BEASLEY, B.A. HANKS, S.-H. JUNG, A.K.S. SALAMA, L. HO, P.J. MOSCA ( <i>Durham, NC, USA</i> ) .....	5245
Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer. C. VESTERGAARD MADSEN, P. ADIMI, A. JAKOBSEN, K.D. STEFFENSEN ( <i>Vejle; Odense, Denmark</i> ) .....	5255
Successful Management of Platinum-resistant Ovarian Cancer by Weekly Nedaplatin Followed by Olaparib: Three Case Reports. S. SOEDA, T. WATANABE, N. KAMO, T. SATO, C. OKABE, M. UEDA, Y. ENDO, K. MANABU, S. NOMURA, S. FURUKAWA, H. NISHIGORI, T. TAKAHASHI, K. FUJIMORI ( <i>Fukushima, Japan</i> ) .....	5263
Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma. R. NARITA, K. KOTOH, A. YONEDA, M. MOTOMURA, M. HARADA ( <i>Oita; Kitakyushu; Fukuoka, Japan</i> ) .....	5271
Salvage Chemotherapy After Nivolumab for Recurrent or Metastatic Head and Neck Carcinoma. C. FUSHIMI, I. OKAMOTO, T. MATSUKI, T. MASUBUCHI, T. OKADA, H. SATO, K. TSUKAHARA, T. KONDO, T. YAMASHITA, K. HANYU, G. OMURA, H. TAKAHASHI, Y. TADA, K. MIURA ( <i>Tokyo; Sagami-hara; Hachioji; Yokohama, Japan</i> ) .....	5277
Continuous Administration of Bevacizumab After Disease Progression in Recurrent Ovarian Cancer: A Retrospective Observational Study. T. TANIGAWA, M. MATODA, M. OMI, Y. AOKI, S. NETSU, H. NOMURA, S. OKAMOTO, K. OMATSU, M. YUNOKAWA, H. KANAO, N. TAKESHIMA ( <i>Tokyo, Japan</i> ) .....	5285
Severe Gastrointestinal Mucositis Following Concurrent Palbociclib and Palliative Radiation Therapy. U.M. NASIR, A.M. MOZEIKA, M. SAYAN, I. JAN, N. KOWAL, B. HAFFTY, S. AHLAWAT, N. KOTHARI ( <i>Newark; New Brunswick, NJ, USA</i> ) .....	5291
Randomized Study of Postoperative Single Intravesical Instillation With Pirarubicin and Mitomycin C for Low-risk Bladder Cancer. S. YAMAMOTO, Y. KAGEYAMA, Y. FUJII, T. AIZAWA, S. URAKAMI, I. FUKUI ( <i>Tokyo; Saitama, Japan</i> ) .....	5295
Phase I Study of the Administration of Low-dose Perioperative Human Atrial Natriuretic Peptide in Patients With Resectable Colorectal Cancer. H. TAKAHASHI, T. TAKEDA, Y. NISHIZAWA, T. OGINO, N. MIYOSHI, C. MATSUDA, H. YAMAMOTO, T. MIZUSHIMA, Y. DOKI, H. EGUCHI ( <i>Osaka, Japan</i> ) .....	5301
Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer. K. KOBAYASHI, K. KAIRA, H. KAGAMU ( <i>Saitama, Japan</i> ) .....	5309

Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients. U. MARKOVIC, A. BULLA, S. LEOTTA, S. STELLA, M.L. CONSOLI, L. TAMBÈ, C. CONTICELLO, F. DI RAIMONDO, F. STAGNO ( <i>Catania, Italy</i> ) .....	5313
Clinical Outcome of Surgically Treated Leiomyosarcoma of the Extremities: A Retrospective Overview. A. VAN BEECK, M. VAN DE SANDE, V. VAN PRAAG, D. DAMMERER, J. MICHIENSEN, T. SCHUBERT, B. KAPANCI, F. SHUMELINSKY, J. SOMVILLE, S. DIJKSTRA ( <i>Antwerp; Brussels, Belgium; Leiden, the Netherlands; Innsbruck, Austria</i> ) .....	5319
Erratum .....	5327

## Number 10, October

The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents. Y.M. MORILLON II, A. SABZEVARI, J. SCHLOM, J.W. GREINER ( <i>Bethesda, MD, USA</i> ) .....	5329
Systematic Review on the Controlling Nutritional Status (CONUT) Score in Patients Undergoing Esophagectomy for Esophageal Cancer. K. TAKAGI, S. BUETTNER, J.N.M. IJZERMANS, B.P.L. WIJNHOFEN ( <i>Rotterdam, the Netherlands; Okayama, Japan</i> ) .....	5343
De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe? U. WAZIR, K. MOKBEL ( <i>London, UK; Peshawar, Pakistan</i> ) .....	5351

### *Experimental Studies*

Human NK-92 Cells Function as Target Cells for Human NK Cells – Implications for CAR NK-92 Therapies. H. BERGMAN, N. SISSALA, H. HÄGERSTRAND, C. LINDQVIST ( <i>Turku, Finland</i> ) .....	5355
Activation of Toll-Like Receptor 2 Promotes Proliferation of Human Lung Adenocarcinoma Cells. A.K. GERGEN, P.D. KOHTZ, A.L. HALPERN, A. LI, X. MENG, T.B. REECE, D.A. FULLERTON, M.J. WEYANT ( <i>Aurora, CO, USA</i> ) .....	5361
Novel TSPO-targeted Doxorubicin Prodrug for Colorectal Carcinoma Cells. J.B. JIA, X. LING, M. XING, J.M. LUDWIG, M. BAI, H.S. KIM ( <i>Pittsburgh, PA; Los Angeles, CA; New Haven, CT, USA</i> ) .....	5371
Toll-like Receptor-3 Activation Enhances Malignant Traits in Human Breast Cancer Cells Through Hypoxia-inducible Factor-1 $\alpha$ . F. SCATOZZA, A. D'AMORE, R.A. FONTANELLA, P. DE CESARIS, F. MARAMPON, F. PADULA, E. ZIPARO, A. RICCIOLI, A. FILIPPINI ( <i>Rome; L'Aquila, Italy</i> ) .....	5379
A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy. N. SUGISAWA, H. NISHINO, T. HIGUCHI, J.H. PARK, J. YAMAMOTO, Y. TASHIRO, K. KAWAGUCHI, M. BOUVET, M. UNNO, R.M. HOFFMAN ( <i>San Diego, CA, USA; Sendai, Japan</i> ) .....	5393
Idarubicin, an Anthracycline, Induces Oxidative DNA Damage in the Presence of Copper (II). H. MIZUTANI, C. SHIGA, M. IMAI, K. IKEMURA, Y. KITAMURA, K. OHTA, D. MIYAZAWA, M. SAKANASHI, T. TAHIRA, T. MAEDA, Y. HIRAKU, S. KAWANISHI ( <i>Nagoya; Suita; Eihei-ji; Suzuka, Japan</i> ) .....	5399
Expression of ATP-binding Cassette Transporter 11 (ABCC11) Protein in Colon Cancer. Y. YAMADA, K. YOSHIMATSU, H. YOKOMIZO, S. OKAYAMA, S. SHIOZAWA ( <i>Tokyo, Japan</i> ) .....	5405

Double Negativity for Expression of YAP1 and CDX2 Defines an Aggressive Type of Colitis-associated Cancer. F. YIN, H. XIE, J. LAI, Y. CHEN, J. DONG, X. ZHANG, X. LIU ( <i>Columbia, MO; Tampa; Gainesville, FL; Sacramento, CA; Omaha, NE; Cleveland, OH, USA</i> ) .....	5411
Genomic Database Analysis for Head and Neck Cancer Prevention Targets: MTOR Signal Transduction Pathway. C. KOENIGSBERG, F.G. ONDREY ( <i>Minneapolis, MN, USA</i> ).....	5417
Association Between Pesticide Use and Incidence of Diffuse Large B-Cell Lymphoma. A. ALTAHAN, L.J. HARRIS, J. PORTA, A.L. JAIN, M.G. MARTIN ( <i>Memphis, TN, USA</i> ) .....	5423
DRAQ7 as an Alternative to MTT Assay for Measuring Viability of Glioma Cells Treated With Polyphenols. H.K. ROOPRAI, P. LAWRENCE, S. KESHAVARZ, P. YASHOD, R.W. GULLAN, R.P. SELWAY, D. DAVIES ( <i>London; Sutton, UK</i> ) .....	5427
Expression and Clinical Significance of Neuropilin-1 in Patients With Multiple Myeloma. A. KARCZMARCZYK, S. BILSKA, M. KORPYSZ, J. PURKOT, N. GRZAŚKO, M. HUS, K. GIANNOPOULOS ( <i>Lublin, Poland</i> ) .....	5437
Therapeutic Time-restricted Feeding Reduces Renal Tumor Bioluminescence in Mice But Fails to Improve Anti-CTLA-4 Efficacy. W.J. TURBITT, R.M. ORLANDELLA, J.T. GIBSON, C.M. PETERSON, L.A. NORIAN ( <i>Birmingham, AL, USA</i> ) .....	5445
The Interplay Between Innate Immunity (TLR-4) and sCD40L in the Context of an Animal Model of Colitis-associated Cancer. A. ANGELOU, A.E. PAPALOIS, E. ANTONIOU, J. WANG, N. AMINI, A. PIKOULI, N. ANDREATOS, S. BUETTNER, M. MUNIR, G. THEODOROPOULOS, G.C. ZOGRAFOS, P. SARANTIS, A. PULVIRENTI, C. KAMPHUES, S. THEOCHARIS, E. PIKOULIS, G.A. MARGONIS ( <i>Athens, Greece; Nicosia, Cyprus; Baltimore, MD; New York, NY, USA; Milan, Italy; Berlin, Germany</i> ) .....	5457
Promotion of Chondrosarcoma Cell Survival, Migration and Lymphangiogenesis by Periostin. J.Y. JEONG, W. JEONG, H.-J. KIM ( <i>Daegu, Republic of Korea</i> ).....	5463
MDA-MB-157 Cell Line Presents High Levels of MAD2L2 and Dysregulated Mitosis. N. PERNICONE, L. PERETZ, S. GRINSHPON, T. LISTOVSKY ( <i>Ariel, Israel</i> ) .....	5471
Sphere-derived Prostate Cancer Stem Cells Are Resistant to $\gamma\delta$ T Cell Cytotoxicity. M. MIYASHITA, M. TOMOGANE, Y. NAKAMURA, T. SHIMIZU, A. FUJIHARA, O. UKIMURA, E. ASHIHARA ( <i>Kyoto, Japan</i> ) ..	5481
Presence of the Transmembrane Protein Neuropilin in Cytokine-induced Killer Cells. E.V. DÍEZ GARCÍA DE OLALLA, F. GAROFANO, H. WEIHER, M. MUDERS, S. FÖRSTER, I.G.H. SCHMIDT-WOLF ( <i>Bonn; Rheinbach, Germany</i> ).....	5489
Differences in Linear Energy Transfer Affect Cell-killing and Radiosensitizing Effects of Spread-out Carbon-ion Beams. S. SHIBA, M. WAKATSUKI, T. OHNO, T. NAKANO ( <i>Chiba; Maebashi, Japan</i> ) .....	5497
Association of Caspase-8 Genotypes With the Risk for Nasopharyngeal Carcinoma in Taiwan. L.-C. SHIH, C.-W. TSAI, W.-S. CHANG, T.-C. SHEN, Y.-C. WANG, J.-S. YANG, M.-L. LIN, Z.-H. WANG, D.-T. BAU ( <i>Taichung, Taiwan, ROC</i> ).....	5503
Protein Profiling of Extracellular Vesicles Associated With Cisplatin Resistance in Lung Cancer. H. BALBINOTTI, N.A. CADORE, C.S. DUTRA, E.D. DA SILVA, H.B. FERREIRA, A. ZAHA, K.M. MONTEIRO ( <i>Porto Alegre, Brazil</i> ) .....	5509
Azidothymidine (AZT) Inhibits Proliferation of Human Ovarian Cancer Cells by Regulating Cell Cycle Progression. Y. HSIEH, J.-J. TSENG ( <i>Taichung, Taiwan, ROC</i> ) .....	5517
Curcumol Suppresses Triple-negative Breast Cancer Metastasis by Attenuating Anoikis Resistance via Inhibition of Skp2-mediated Transcriptional Addiction. C.-L. LI, C.-W. HUANG, C.-J. KO, S.-Y. FANG, F. OU-YANG, M.-R. PAN, C.-W. LUO, M.-F. HOU ( <i>Kaohsiung, Taiwan, ROC</i> ).....	5529

Mxi-2 Dependent Regulation of p53 in Prostate Cancer. B. KÖDITZ, J.W.U. FRIES, H. GÖBEL, P. PAFFENHOLZ, K. RICHTER, A. HEIDENREICH, M. VON BRANDENSTEIN ( <i>Rheinbach; Cologne, Germany</i> ).....	5539
Opposing Oncogenic Functions of p38 Mitogen-activated Protein Kinase Alpha and Beta in Human Pancreatic Cancer Cells. X. TIAN, B. TRAUB, X. XIE, S. ZHOU, D. HENNE-BRUNS, U. KNIPPSCHILD, M. KORNMANN ( <i>Ulm, Germany; Beijing, PR China</i> ).....	5545
Differential Expression of E-Cadherin and P-Cadherin in Breast Cancer Molecular Subtypes. M.M. MARGAN, A.M. CIMPEAN, A.R. CEASU, M. RAICA ( <i>Timisoara, Romania</i> ).....	5557
Relationship Between Stage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer. T. YUNO, Y. MIYATA, T. MATSUO, Y. MUKAE, A. OTSUBO, K. MISTUNARI, K. OHBA, T. SUDA, S. SAITO, H. SAKAI ( <i>Nagasaki; Okinawa, Japan</i> ).....	5567
A Novel System to Detect Circulating Tumor Cells Using Two Different Size-selective Microfilters. T. SONODA, N. YANAGITANI, K. SUGA, T. YOSHIKAWA, S. NISHIKAWA, S. KITAZONO, A. HORIIKE, K. SHIBA, T. ISHIZUKA, M. NISHIO, S. MATSUSAKA ( <i>Tokyo; Fukui; Ishikawa; Ibaraki, Japan</i> ).....	5577
A Psychometric Validation of the Decisional Conflict Scale in Italian Cancer Patients Scheduled for Insertion of Central Venous Access Devices. M.R. ESPOSITO, A. GUILLARI, F. GIANCAMILI, T. REA, M. PIREDDA, M. GRAZIA DE MARINIS, A. CHIRICO ( <i>Naples; Rome, Italy; Philadelphia, PA, USA</i> ).....	5583
Prognostic Significance of TYRO3 Receptor Tyrosine Kinase Expression in Gastric Cancer. C. UEJIMA, M. MORIMOTO, M. YAMAMOTO, K. HARA, W. MIYAUCHI, K. SUGEZAWA, Y. TADA, A. TANIO, K. KIHARA, T. MATSUNAGA, N. TOKUYASU, T. SAKAMOTO, S. HONJO, Y. UMEKITA, Y. FUJIWARA ( <i>Yonago, Japan</i> ).....	5593
<i>LRRC17</i> Is Linked to Prognosis of Ovarian Cancer Through a p53-dependent Anti-apoptotic Function. C.-K. OH, J.J. PARK, M. HA, H.J. HEO, J. KANG, E.J. KWON, J.W. KANG, Y. KIM, J.M. KANG, S.Z. YOON, Y. KO, D.S. KO, Y.H. KIM ( <i>Ulsan; Seoul; Yangsan; Incheon; Busan, Republic of Korea; Ann Arbor, MI, USA</i> ).....	5601
Role of PrPC in Cancer Stem Cell Characteristics and Drug Resistance in Colon Cancer Cells. G. GO, C.W. YUN, Y.M. YOON, J.H. LIM, J.H. LEE, S.H. LEE ( <i>Cheonan; Seoul, Republic of Korea</i> ).....	5611
FGF Expression in HPV16-positive and -negative SCC After Treatment With Small-molecule Tyrosine Kinase Inhibitors and Everolimus. L. HUBER, R. BIRK, M. KNUETTEL, N. ROTTER, C. ADERHOLD, C. SCHERL, A. LAMMERT, F. JUNGBAUER, B. KRAMER ( <i>Mannheim; Marburg, Germany</i> ).....	5621
High Expression of p21 as a Potential Therapeutic Target in Ovarian Clear-cell Carcinoma. Y. MINAGAWA, K. ISHINO, R. WADA, M. KUDO, Z. NAITO, T. TAKESHITA, R. OHASHI ( <i>Tokyo, Japan</i> ).....	5631
Mesenchymal Stem Cells Combined With IFN $\gamma$ Induce Apoptosis of Breast Cancer Cells Partially Through TRAIL. E.N. YENILMEZ, D. GENC, A.A. FAROOQI, S. TUNOGLU, U. ZEYBEK, T. AKKOC, İ. YAYLIM ( <i>Istanbul; Muğla, Turkey; Islamabad, Pakistan</i> ).....	5641
The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast. E. YILDIRIM, S. BEKTAS, O. GUNDOGAR, D. FINDIK, S. ALCICEK, K.O. ERDOGAN, M. YILDIZ ( <i>Istanbul; Osmaniye, Turkey</i> ).....	5649
<i>LINE-1</i> Hypomethylation Is Associated With Malignant Traits and Cell Proliferation in Lung Adenocarcinoma. H. KITAHARA, T. OKAMOTO, S. SHIMAMATSU, M. KOHNO, Y. MORODOMI, T. TAGAWA, H. KITAO, S. OKANO, Y. ODA, Y. MAEHARA, M. MORI ( <i>Fukuoka, Japan</i> ).....	5659
Expression Analysis of Tyrosine Phosphatase Genes at Different Stages of Renal Cell Carcinoma. I. LACZMANSKA, L. LACZMANSKI, M.M. SASIADEK ( <i>Wroclaw, Poland</i> ).....	5667



*Clinical Studies*

Minimal Access vs. Open Spine Surgery in Patients With Metastatic Spinal Cord Compression - A One-Center Randomized Controlled Trial. S.S. MORGEN, L.V. HANSEN, T. KARBO, R. SVARDAL-STELMER, M. GEHRCHEN, B. DAHL (*Copenhagen, Denmark; Houston, TX, USA*)..... 5673

Cytopathological Heterogeneity of Circulating Tumor Cells in Non-metastatic Esophageal Adenocarcinoma. J. KUVENDJISKA, M.B. PITMAN, V. MARTINI, C. BRAUN, K. GREBE, S. TIMME, S. FICHTNER-FEIGL, T. GLATZ, C. SCHMOOR, J. GUENZLE, J. HOEPPNER, B. KULEMANN (*Freiburg; Bochum, Germany; Boston, MA, USA*)..... 5679

Highly Activated *Ex Vivo*-expanded Natural Killer Cells in Patients With Solid Tumors in a Phase I/IIa Clinical Study. K. NAGAI, Y. HARADA, H. HARADA, K. YANAGIHARA, Y. YONEMITSU, Y. MIYAZAKI (*Nagasaki; Fukuoka, Japan*) ..... 5687

The Induction of Antioxidant Catalase Enzyme With Decrease of Plasma Malonidialdehyde: An Important Reactive Oxidative Species Inhibiting Mechanism. M. RUOTTINEN, V. KAARONEN, I. SAIMANEN, V. KUOSMANEN, J. KÄRKKÄINEN, T. SELANDER, S. ASPINEN, M. ESKELINEN (*Kuopio, Finland*)..... 5701

Association of *ANRIL* Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. J. LI, N. SELIGSON, X. ZHANG, J. JOHNSON, Z. VANGUNDY, D. WANG, M. PHELPS, C. HOFMEISTER, W. SADEE, M.J. POI (*Columbus, OH; Gainesville, FL; Atlanta, GA, USA*) ..... 5707

Prognostic Significance of Combined Platelet Distribution Width and C-Reactive Protein Score in Esophageal Cancer. Y. KAWAKITA, S. MOTOYAMA, Y. SATO, A. WAKITA, Y. NAGAKI, K. IMAI, Y. MINAMIYA (*Akita, Japan*) ..... 5715

Impact of the Affordable Care Act on Timeliness to Treatment for Patients With Multiple Myeloma. T. JAYAKRISHNAN, V. BAKALOV, N.S. CALLANDER, S. SADASHIV, R. WAGNER, S. AILAWADHI (*Pittsburgh, PA; Madison, WI; Jacksonville, FL, USA*) ..... 5727

Utility of Bone Scintigraphy and PET-CT in the Surgical Staging of Skeletal Chondrosarcoma. J.D. JOHNSON, W.G. RAINER, P.S. ROSE, M.T. HOUDEK (*Rochester, MN, USA*) ..... 5735

Surgical Resection With Pedicled Rotation Flap for Post-mastectomy Locoregional Breast Cancer Recurrence. Y. SHINDEN, A. NAGATA, Y. NOMOTO, H. SAHO, A. NAKAJO, K. MINAMI, T. OWAKI, T. OHTSUKA, Y. KIJIMA (*Kagoshima; Toyoake, Japan*) ..... 5739

Angiosarcomas of Primary Gynecologic Origin – A Case Series and Review of the Literature. L. CHINCZEWSKI, E.T. TAUBE, F.W. FELDHAUS, L.A. DRÖGE, R. CHEKEROV, M.Z. MUALLEM, K. PIETZNER, J. SEHOULI, S. ALAVI (*Berlin, Germany*) ..... 5743

Contribution of Matrix Metalloproteinase-9 rs3918242 Genotypes to Childhood Leukemia Risk. C.-C. KUO, C.-W. TSAI, W.-S. CHANG, T.-C. SHEN, H.-E. TZENG, C. LI, Y.-C. WANG, F.-J. TSAI, D.-T. BAU (*Taichung; Taipei, Taiwan, ROC*) ..... 5751

Treatment of Patients With Non-small-cell Lung Cancer With Uncommon *EGFR* Mutations in Clinical Practice. Y. YAMADA, T. TAMURA, Y. YAMAMOTO, H. ICHIMURA, K. HAYASHIHARA, T. SAITO, H. YAMADA, T. ENDO, R. NAKAMURA, Y. INAGE, H. SATOH, K. IGUCHI, K. SAITO, M. INAGAKI, N. KIKUCHI, K. KURISHIMA, H. ISHIKAWA, M. SAKAI, K. KAMIYAMA, T. SHIOZAWA, N. HIZAWA, I. SEKINE, Y. SATO, Y. FUNAYAMA, K. MIYAZAKI, T. KODAMA, S. HAYASHI, A. NOMURA, H. NAKAMURA, K. FURUKAWA, T. YAMASHITA, H. OKUBO, H. SUZUKI, M. KIYOSHIMA, T. KABURAGI (*Kasama; Hitachi; Tokai; Hitachinaka; Mito; Tsuchiura; Tsukuba; Ryugasaki; Sakai; Ami; Toride, Japan*) ..... 5757

Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial. K. NAGAI, T. ADACHI, H. HARADA, S. EGUCHI, H. SUGIYAMA, Y. MIYAZAKI ( <i>Nagasaki; Osaka, Japan</i> ).....	5765
Expression of Insulin-like Growth Factor II mRNA-binding Protein 3 in Gallbladder Carcinoma. S.J. KIM, S.-W. KIM, C.H. OH, M. HONG, S.-I. DO, Y.W. KIM, H.-S. KIM, K. NA ( <i>Seoul, Republic of Korea</i> ).....	5777
Hypothalamic-Pituitary Axis Dysfunction After Whole Brain Radiotherapy – A Cohort Study. J. GEBAUER, P. MEHTA, F.B. FAHLBUSCH, S.M. SCHMID, D. RADES, S. JANSSEN ( <i>Luebeck; Erlangen; Hannover, Germany</i> ) .....	5787
Preoperative Evaluation of Myxofibrosarcoma: Prognostic Value and Reproducibility of Different Features on MRI. H. MÜHLHOFER, A. GERSING, D. PFEIFFER, K. WÖRTLER, U. LENZE, F. LENZE, V. LALLINGER, B. HALLER, R. BURGKART, R. VON EISENHART-ROTHER, C. KNEBEL ( <i>Munich, Germany</i> ) .....	5793
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma. Y. LIU, M.S. STRAWDERMAN, K.T. WARREN, M. RICHARDSON, J.N. SERVENTI, N.A. MOHILE, M.T. MILANO, K.A. WALTER ( <i>Rochester, NY, USA</i> ) .....	5801
Is it Necessary to Confirm Negative Margins in Gastrectomy for Peritoneal Lavage Cytology-positive Gastric Cancer? S. ENDO, Y. FUJIWARA, T. YAMATSUJI, K. NISHIKAWA, K. FUJITANI, M. IKENAGA, J. KAWADA, Y. OKAMOTO, H. KUBOTA, M. HIGASHIDA, T. UENO ( <i>Okayama; Osaka, Japan</i> ) .....	5807
Clinical Significance of Glioma-associated Oncogene 1 Expression in Patients With Locally Advanced Gastric Cancer Administered Adjuvant Chemotherapy With S-1 After Curative Surgery. I. HASHIMOTO, N. OUE, Y. KIMURA, Y. HIROSHIMA, K. HARA, Y. MAEZAWA, K. KANO, H. FUJIKAWA, T. AOYAMA, M. NUMATA, T. YAMADA, H. TAMAGAWA, N. YAMAMOTO, T. OGATA, M. SHIOZAWA, S. MORINAGA, Y. RINO, W. YASUI, M. MASUDA, Y. MIYAGI, T. OSHIMA ( <i>Yokohama; Hiroshima, Japan</i> ) .....	5815
Complete Removal of Adrenal Metastasis in Hepatocellular Carcinoma Using Indocyanine Green Fluorescent Imaging. K. YAMAMURA, T. BEPPU, N. SATO, K. KINOSHITA, E. ODA, H. YUKI, T. MOTOHARA, H. MIYAMOTO, Y. KOMOHARA, S. AKAHOSHI ( <i>Kumamoto, Japan</i> ) .....	5823
Five-year Outcomes of Chemotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil Followed by Oesophagectomy in Oesophageal Cancer. Y. TANISHIMA, K. NISHIKAWA, Y. ARAKAWA, A. MATSUMOTO, M. YUDA, Y. TANAKA, N. MITSUMORI, K. YANAGA ( <i>Tokyo, Japan</i> ) .....	5829
Radical Nephrectomy and Pulmonary Lobectomy for Renal Cell Carcinoma With Tumor Thrombus Extension into the Inferior Vena Cava and Pulmonary Arteries. A. MANOHARAN, A. LUGO-BARUQUI, G. CIANCIO ( <i>Miami, FL, USA; Guadalajara, Mexico</i> ) .....	5837
Endoscopic Ultrasound-guided Sampling of Solid Pancreatic Lesions: A Comparative Analysis of 25 Gauge Versus 22 Gauge Core Biopsy Needles. D.A. SIDDIQUE, M.A. RAHAL, K. TREVINO, H.H. WU, M.A. AL-HADDAD ( <i>Indianapolis; Carmel, IN, USA</i> ) .....	5845
Upfront Radiotherapy in Patients With Asymptomatic Incurable Rectal Cancer: A Retrospective Cohort Study. G. JONSSON, L. PHILIPSON, K. VILLMAN, A. VALACHIS ( <i>Eskilstuna; Örebro, Sweden</i> ) .....	5853
Bladder-conserving Approach in Radical Treatment of Patients With Bladder Cancer – A Single-institution Experience. W. MAJEWSKI, J. NIECKULA, T. DWORZECKI, L. MISZCZYK ( <i>Gliwice, Poland</i> ) .....	5861
Radical Surgical Procedures in Advanced Ovarian Cancer and Differences Between Primary and Interval Debulking Surgery. V. MITSOPOULOS, A. INNAMAA, J. LIPPIATT, N. PLEVRIS, I. BILIATIS ( <i>Poole, UK</i> ) .....	5869

Diagnostic Accuracy of Pleural Fluid Cytology, Carcinoembryonic Antigen and C-Reactive Protein Together in Patients With Pulmonary Metastases and Malignant Pleural Effusion. S.M.M. BASSO, A. DEL CONTE, U. ZUCCON, S.C. SULFARO, G. FANTI, F. MAFFEIS, P. UBIALI, M. ERMANI, F. LUMACHI ( <i>Pordenone; Padua, Italy</i> ) .....	5877
Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Cancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859]. J.H. PARK, J.-H. AHN, J.E. KIM, K.H. JUNG, G. GONG, H.J. LEE, B.-H. SON, S.-H. AHN, H.-H. KIM, H.J. SHIN, D.-H. MOON, D. KIM, S.-B. KIM ( <i>Seoul, Republic of Korea</i> ).....	5883
Prognostic Significance of Oligometastatic Disease Classification by the ESTRO/EORTC of Cancer for Patients With Lung Cancer Treated With Definitive Radical Radiotherapy. H.-J. CHEN, C.-Y. TU, T.-C. HSIA, H.-Y. FANG, C.-H. CHEN, S.-C. CHEN, C.-H. LI, Y.-M. LIAO, C.-Y. HSIEH, M.-Y. LEIN, J.-A. LIANG, C.-R. CHIEN ( <i>Taichung; Hsinchu, Taiwan, ROC</i> ).....	5895
Predictors of Local Control for Stereotactic Ablative Radiotherapy (SAbR) in Pulmonary Oligometastases from Gastrointestinal Malignancies. N. SIMONI, R. MICERA, G. ROSSI, M.G. GIRI, M. PAVARANA, A. MURAGLIA, N.L.V. CERNUSCO, M. DE LIGUORO, S. GUARIGLIA, C. CAVEDON, M. MILELLA, R. MAZZAROTTO ( <i>Verona, Italy</i> ).....	5901
Incidence of CMV Replication and the Role of Letermovir Primary/Secondary Prophylaxis in the Early Phase After Allogeneic Hematopoietic Stem Cell Transplantation – A Single Centre Study. U. STUDER, N. KHANNA, K. LEUZINGER, H.H. HIRSCH, D. HEIM, C. LENGERKE, D.A. TSAKIRIS, J. HALTER, S. GERULL, J. PASSWEG, M. MEDINGER, M. GWERDER ( <i>Basel, Switzerland</i> ) .....	5909
First Reported Case of Localized Extra-pulmonary Small Cell Carcinoma (EPSC) of the Esophagus Treated With Triple Therapy. A. HAAG, T. JAYAKRISHNAN, D. SHAH, A. SANDHU, D. MONGA ( <i>Pittsburgh, PA, USA</i> ) .....	5919
Characterization of Paired Box 8 (PAX8)-expressing Metastatic Breast Carcinoma. S.-W. KIM, H.-S. KIM, K. NA ( <i>Seoul, Republic of Korea</i> ).....	5925
A Rare Case of Locally Advanced Primary Small Cell Neuroendocrine Carcinoma of the Adrenal Gland. V. LIMONNIK, D. SHAH, A. SANDHU, D.K. MONGA ( <i>Pittsburgh, PA, USA</i> ) .....	5933
Oncological and Reproductive Outcomes of Abdominal Radical Trachelectomy. A. YOSHINO, E. KOBAYASHI, M. KODAMA, K. HASHIMOTO, Y. UEDA, K. SAWADA, T. TOMIMATSU, T. KIMURA ( <i>Osaka, Japan</i> ) .....	5939
Erratum .....	5949

## Number 11, November

### Reviews

EBV Positivity and Programmed Death-ligand 1 Expression in Diffuse Large B-cell Lymphoma: A Systematic Review. G.A. BARZYK, V. SHERIFF ( <i>Coventry; London, UK</i> ).....	5951
Dickkopf-3 in Human Malignant Tumours: A Clinical Viewpoint. E.-J. LEE, Q.T.T. NGUYEN, M. LEE ( <i>Seoul, Republic of Korea</i> ).....	5969
The Role of Zyxin in Carcinogenesis. A. PARTYNSKA, A. GOMULKIEWICZ, P. DZIEGIEL, M. PODHORSKA-OKOLOW ( <i>Wroclaw, Poland</i> ).....	5981

Potential for Treatment of Glioblastoma: New Aspects of Superparamagnetic Iron Oxide Nanoparticles. D. MAREKOVA, K. TURNOVCOVA, T.H. SURSAL, C.D. GANDHI, P. JENDELOVA, M. JHANWAR-UNIYAL ( <i>Prague, Czech Republic; New York, NY, USA</i> ) .....	5989
Estro-progestin Contraceptives and Risk of Cervical Cancer: A Debated Issue. A. GADDUCCI, S. COSIO, F. FRUZZETTI ( <i>Pisa, Italy</i> ) .....	5995
Survival After Primary Surgery Compared With Neoadjuvant Chemotherapy in Early-stage Ovarian Cancer. D. HUFFMAN, R. WEGNER, A. JALIL, T. KRIVAK, E. MILLER ( <i>Pittsburgh, PA, USA</i> ) .....	6003
Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review. E.N. KONTOMANOLIS, A. KOUTRAS, A. SYLLAIOS, D. SCHIZAS, A. MASTORAKI, N. GARMPIIS, M. DIAKOSAVVAS, K. ANGELOU, G. TSATSARIS, A. PAGKALOS, T. NTOUNIS, Z. FASOULAKIS ( <i>Alexandroupolis; Athens; Xanthi, Greece</i> ) .....	6009
<i>Experimental Studies</i>	
WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer. S. LEE, J. JUN, W.J. KIM, P. TAMAYO, S.B. HOWELL ( <i>Seoul, Republic of Korea; San Diego, CA, USA</i> ) .....	6017
Effect of Sex Steroid Hormones on Tongue Cancer Cells <i>In Vitro</i> . J. PELTONEN, K. TUOMAINEN, T. SALLINEN, I. FARESS, I. SULEYMANOVA, A. AL-SAMADI, T. SALO, P. ÅSTRÖM ( <i>Helsinki; Oulu, Finland; Århus, Denmark</i> ) .....	6029
Characterization of a Novel Barbituric Acid and Two Thiobarbituric Acid Compounds for Lung Cancer Treatment. S.Y. LEE, B. SLAGLE-WEBB, A.K. SHARMA, J.R. CONNOR ( <i>Hershey, PA, USA</i> ) .....	6039
<i>In Vitro</i> Effect and Mechanism of Action of Ergot Alkaloid Dihydroergocristine in Chemoresistant Prostate Cancer Cells. L. BAI, X. LI, X. MA, R. ZHAO, D. WU ( <i>Wuhan; Shanghai; Changchun, PR China; Augusta, GA, USA</i> ) .....	6051
<i>In Vitro</i> Analyses of Interactions Between Colonic Myofibroblasts and Colorectal Cancer Cells for Anticancer Study. M. MUSA, D. OUARET, W.F. BODMER ( <i>Kubang Kerian, Malaysia; Oxford, UK</i> ) .....	6063
An Autocrine Role for CXCL1 in Progression of Hepatocellular Carcinoma. K.J.V. DAHLQUIST, L.C. VOTH, A.J. FEE, A.K. STOECKMAN ( <i>Saint Paul, MN, USA</i> ) .....	6075
Oral Recombinant Methioninase Sensitizes a Bladder Cancer Orthotopic Xenograft Mouse Model to Low-dose Cisplatin and Prevents Metastasis. Y. SUN, H. NISHINO, N. SUGISAWA, J. YAMAMOTO, K. HAMADA, G. ZHU, H.I. LIM, R.M. HOFFMAN ( <i>San Diego, CA, USA</i> ) .....	6083
Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells. Y. PAN, Y.-H. CHIU, S.-C. CHIU, D.-Y. CHO, L.-M. LEE, Y.-C. WEN, J. WHANG-PENG, C.-H. HSIAO, P.-H. SHIH ( <i>Taipei; Taichung, Taiwan, ROC</i> ) .....	6093
miR-935 Inhibits Oral Squamous Cell Carcinoma and Targets Inositol Polyphosphate-4-phosphatase Type IA (INPP4A). N. MARUYAMA, M. UMIKAWA, H. MATSUMOTO, T. MARUYAMA, K. NISHIHARA, T. NAKASONE, A. MATAYOSHI, T. GOTO, F. HIRANO, A. ARASAKI, H. NAKAMURA, G. MATSUZAKI, G. TAKAESU ( <i>Nishihara, Japan</i> ) .....	6101
<i>TYRO3</i> Truncation Resulting From at(10;15)(p11;q15) Chromosomal Translocation in Pediatric Acute Myeloid Leukemia. M. BRUNETTI, B. ZELLER, A. TIERENS, S. HEIM, F. MICCI, I. PANAGOPOULOS ( <i>Oslo, Norway; Toronto, ON, Canada</i> ) .....	6115
Dose-dependent Changes After Proton and Photon Irradiation in a Zebrafish Model. S. BRUNNER, T. TÓKÉS, E.R. SZABÓ, R. POLANEK, I.Z. SZABÓ, Z. REISZ, B.K. GUBÁN, A.L. SZIJÁRTÓ, M. BRAND, S. HANS, L. KARSCH, E. LESSMANN, J. PAWELKE, M. SCHÜRER, E. BEYREUTHER, K. HIDEGHÉTY ( <i>Szeged, Hungary; London, UK; Dresden, Germany</i> ) .....	6123

Heat Shock Protein 90 Inhibitors AUY922, BIIB021 and SNX5422 Induce Bim-mediated Death of Thyroid Carcinoma Cells. S.H. KIM, Y.K. CHO, J.H. HUH, J.G. KANG, S.-H. IHM, M.G. CHOI, S.J. LEE ( <i>Chuncheon, Republic of Korea</i> ) .....	6137
Synthetic Betulin Derivatives Inhibit Growth of Glioma Cells <i>In Vitro</i> . S.K. KRÓL, E. BĘBENEK, A. SŁAWIŃSKA-BRYCH, M. DMOŚZYŃSKA-GRANICZKA, S. BORYCZKA, A. STEPULAK ( <i>Lublin; Katowice, Poland</i> ) .....	6151
Novel Two MRT Cell Lines Established from Multiple Sites of a Synchronous MRT Patient. Y. KUWAHARA, T. IEHARA, E. ICHISE, Y. KATSUMI, K. OUCHI, K. TSUCHIYA, M. MIYACHI, E. KONISHI, H. SASAJIMA, S. NAKAMURA, S. FUMINO, T. TAJIRI, P.D. JOHANN, M.C. FRÜHWALD, T. YOSHIDA, T. OKUDA, H. HOSOI ( <i>Kyoto, Japan; Heidelberg; Augsburg, Germany</i> ) .....	6159
A Potential Role of Adhesion Molecules on Lung Metastasis Enhanced by Local Inflammation. H. Horiguchi, H. TSUJIMOTO, N. SHINOMIYA, Y. MATSUMOTO, H. SUGASAWA, T. YAMORI, H. MIYAZAKI, D. SAITOH, Y. KISHI, H. UENO ( <i>Saitama; Tokyo, Japan</i> ) .....	6171
Breast Cancer Cells Induce a Pro-inflammatory Response to Mitigate Immune Mediation in a 3D Culture Model. T.N. AUGUSTINE, R. DUARTE, G.P. CANDY ( <i>Johannesburg, South Africa</i> ) .....	6179
Apoptosis-related Proteins Are Altered by Selective Tyrosine Kinase Inhibitors and Everolimus in HPV-dependent SCC. R. BIRK, A. SCHELL, C. ADERHOLD, S. HOCH, L. HUBER, C.E. MUELLER, A. LAMMERT, C. SCHERL, N. ROTTER, J.U. SOMMER, B. KRAMER ( <i>Marburg; Mannheim; Wuppertal, Germany</i> ) .....	6195
Protherapeutic Effects and Inactivation of Mammary Carcinoma Cells by a Medical Argon Plasma Device. M.B. STOPE, R. BENOVAHI, C. SANDER, L. HARALAMBIEV, A. NITSCH, E. EGGER, A. MUSTEA ( <i>Bonn; Greifswald; Berlin, Germany</i> ) .....	6205
Expression of IGF-IEc Isoform in Renal Cell Carcinoma Tissues. F. MICHALOPOULOU, C. PETRAKI, A. PHILIPPOU, A. ANALITIS, P. MSAOUEL, M. KOUTSILIERIS ( <i>Athens, Greece; Houston, TX, USA</i> ) .....	6213
Frequent MN1 Gene Mutations in Malignant Peripheral Nerve Sheath Tumor. I. KINOSHITA, Y. YAMADA, K. KOHASHI, H. YAMAMOTO, T. IWASAKI, S. ISHIHARA, Y. TODA, Y. ITO, Y. SUSUKI, K. KAWAGUCHI, T. ICHIKI, Y. SATO, M. FURUE, Y. NAKASHIMA, Y. ODA ( <i>Fukuoka, Japan</i> ) .....	6221
Evaluation of an Assay for MGMT Gene Promoter Methylation in Glioblastoma Samples. M. FILIPITS, M. PREUSSER, J.A. HAINFELLNER, S. SPIEGL-KREINECKER, A.S. BERGHOFF, E.W. LAI, K. KOCCOMOND, A. KOHLWAY, J. WEIDLER, M. BATES, C. CORLESS ( <i>Vienna; Linz, Austria; Sunnyvale, CA; Portland, OR, USA</i> ) .....	6229
3EZ, 20Ac-ingenol-induced Apoptosis in Chemoresistant Cancers With Cyclin D1 Accumulation. S. MIYATA, T. NAKAMURA, S. KITANAKA ( <i>Tokyo; Chiba, Japan</i> ) .....	6237
Involvement of the MicroRNA-1-LITAF Axis in Gastric Cancer Cell Growth and Invasion. Y.-C. CHEN, C.-C. WU, Y.-T. TU, Y.-R. CHEN, M.-C. LEE, K.-W. TSAI ( <i>New Taipei City, Taiwan, ROC</i> ) .....	6247
Association of <i>MDM2 T309G</i> (rs2279744) Polymorphism and Expression Changes With Risk of Prostate Cancer in the Slovak Population. M. KMETOVA SIVONOVA, J. JURECEKOVA, P. KAPLAN, M. HIVES, M. GRENDAR, A. TOMASCOVA, R. DUSENKA, H. DROBKOVA, D. EVIN, J. KLIMENT ( <i>Martin, Slovak Republic</i> ) .....	6257
Synergistic Antiproliferative Effect of Ribociclib (LEE011) and 5-Fluorouracil on Human Colorectal Cancer. P.-M. LIN, H.-M. LEE, C.-I HUANG, T.-S. TAI, J.-H. CHEN, C.-I CHEN, Y.-C. SU ( <i>Kaohsiung, Taiwan, ROC</i> ) .....	6265

Use of AKR1C1 and TKTL1 in the Diagnosis of Low-grade Squamous Intraepithelial Lesions from Mexican Women. A. SEQUEDA-JUÁREZ, A. JIMÉNEZ, A. ESPINOSA-MONTESINOS, M.D.C. CARDENAS-AGUAYO, E. RAMÓN-GALLEGOS ( <i>Mexico City, México</i> ).....	6273
Overexpression of Pyruvate Carboxylase Is Correlated With Colorectal Cancer Progression and Supports Growth of Invasive Colon Cancer HT-29 Cell Line. J. NGAMKHAM, C. THUWAJIT, P. THUWAJIT, P. KHAMWACHIRAPITHAK, K. LERTSUWAN, V. CHAROENSAWAN, S. JITRAPAKDEE ( <i>Bangkok; Nakhon Pathom, Thailand</i> ).....	6285
Melatonin Exerts Anticancer Effects in Human Tongue Squamous Cell Carcinoma Cells by Promoting Autophagy. E.-S. SUNG, J.-Y. KIM, Y.T. AHN, I.-W. LEE, S.-W. CHOI, H.-B. JANG, J.-C. LEE, W.G. AN ( <i>Yangsan; Busan, Republic of Korea</i> ).....	6295
High Expression of UBE2B as a Poor Prognosis Factor in Patients With Rectal Cancer Following Chemoradiotherapy. W.-L. HUANG, C.-W. LUO, C.-L. CHOU, C.-C. YANG, T.-J. CHEN, C.-F. LI, M.-R. PAN ( <i>Kaohsiung; Tainan, Taiwan, ROC</i> ).....	6305
Development of an Oncolytic Recombinant Vesicular Stomatitis Virus Encoding a Tumor-suppressor MicroRNA. T. SAKUDA, T. KUBO, M.P. JOHAN, T. FURUTA, T. SAKAGUCHI, N. ADACHI ( <i>Hiroshima, Japan; Makassar, Indonesia</i> ).....	6319
Cofilin-1 Maintains Prosurvival Signaling in Chronic Lymphocytic Leukemia Cells. M. KARP, A. KARCZMARCZYK, A. BOJARSKA-JUNAK, J. PURKOT, M. CHOJNACKI, M. ZAJĄC, M. KORPYSZ, W. TOMCZAK, M. HUS, M. MORAWSKA, K. GIANNOPOULOS ( <i>Lublin, Poland</i> ).....	6327
Expression Profile of S100A2 and its Clinicopathological Significance in Renal Cell Carcinoma. T. SUGIYAMA, S. OZONO, H. MIYAKE ( <i>Hamamatsu, Japan</i> ).....	6337
Potential of Differentiation and Apoptosis in a Human Promyelocytic Leukemia Cell Line by Garlic Essential Oil and Its Organosulfur Compounds. S.F.T. AGASSI, T.-M. YEH, C.-D. CHANG, J.-L. HSU, W.-L. SHIH ( <i>Pingtung, Taiwan, ROC</i> ).....	6345
Significance of <i>P16<sup>INK4A</sup></i> Expression and <i>PTEN</i> Loss of Heterozygosity in Human Papilloma Virus-related Oral Squamous Cell Carcinoma. V.D.J. OLIVEIRA KATO, M. CARVALHO DE ABREU, A.M. DE BRITO KATO, L.L. DE SOUZA, F.S. CORREA PONTES, C. DE CASTRO SANT'ANNA, A. GONÇALVES JUNIOR, H.A. REBELO PONTES, A.S. KHAYAT, R.M. RODRIGUEZ BURBANO ( <i>Belém; Piracicaba, Brazil</i> ).....	6355
<i>Clinical Studies</i>	
Tertiary Lymphoid Structures in Colorectal Cancer Liver Metastases: Association With Immunological and Clinical Parameters and Chemotherapy Response. A. AHMED, N. HALAMA ( <i>Heidelberg; Mainz, Germany</i> ).....	6367
Sequencing of Sclerosing Microcystic Adenocarcinoma Identifies Mutational Burden and Somatic Variants Associated With Tumorigenesis. R. JIANG, J. MARQUEZ, J.I. TOWER, D. JACOBS, W. CHEN, S. MEHRA, M.L. PRASAD, B.L. JUDSON ( <i>New Haven, CT, USA</i> ).....	6375
Gastric Cancer Disparities Among Asian American Subpopulations. D. TRUMBULL, R. LEMINI, K. ATTWOOD, M. KUKAR, E. GABRIEL ( <i>Gainesville; Jacksonville, FL; Buffalo, NY, USA</i> ).....	6381
<i>Helicobacter pylori</i> (Hp) IgG ELISA of the New-Generation GastroPanel® Is Highly Accurate in Diagnosis of Hp-Infection in Gastroscopy Referral Patients. M. MÄKI, D. SÖDERSTRÖM, L. PALOHEIMO, P. HENDOLIN, O. SUOVANIEMI, K. SYRJÄNEN ( <i>Helsinki; Kaarina, Finland</i> ).....	6387
Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer. K. SJØGREN, K.A. JACOBSEN, B.H. GRØNBERG, T.O. HALVORSEN ( <i>Trondheim, Norway</i> ).....	6399

Clinical Significance of Tumour CD44v and MIST1 Expression in Patients With Non-small-cell Lung Cancer. T. NAGASHIMA, T. OSHIMA, Y. HIROSHIMA, T. YOKOSE, T. WOO, Y. RINO, M. MASUDA, Y. MIYAGI, H. ITO, H. NAKAYAMA ( <i>Yokohama, Japan</i> ) .....	6407
Thyroid Hormones, Silencing Mediator for Retinoid and Thyroid Receptors and Prognosis in Primary Breast Cancer. B. NISMAN, T.M. ALLWEIS, E. CARMON, L. KADOURI, B. MALY, O. MAIMON, T. PERETZ ( <i>Jerusalem; Rehovot, Israel</i> ).....	6417
Unresectable Chondrosarcomas Treated With Carbon Ion Radiotherapy: Relationship Between Dose-averaged Linear Energy Transfer and Local Recurrence. S. MATSUMOTO, S.H. LEE, R. IMAI, T. INANIWA, N. MATSUFUJI, M. FUKAHORI, R. KOHNO, S. YONAI, N. OKONOJI, S. YAMADA, N. KANEMATSU ( <i>Chiba, Japan</i> ) .....	6429
Effect of Computer-aided Detection System Use on the Duration of MRI-guided Biopsy of the Breast. M. SHIMODA, S.J. KIM, Y. TOKUDA, Y. SOTA, T. MIYAKE, T. TANEI, N. KAGARA, Y. NAOI, S. NOGUCHI, K. SHIMAZU ( <i>Osaka, Japan</i> ).....	6437
Longitudinal Changes in Health-related Quality of Life After <sup>125</sup> I Low-dose-rate Brachytherapy for Localized Prostate Cancer. N. OGASAWARA, M. NAKIRI, H. KUROSE, K. UEDA, K. CHIKUI, K. NISHIHARA, M. MATSUO, S. SUEKANE, K. MUROTANI, K. MURAKI, C. HATTORI, E. OGO, T. IGAWA, T. ISHITAKE ( <i>Kurume, Japan</i> ) .....	6443
Protective Desmoplasia in Pancreatic Adenocarcinoma: High Vitamin D Receptor Expression and Collagen Content. A.V. BAHAT, S. BAR-DAVID, A. BROOKS, A. AIZIC, O. GREENBERG, I. WOLF, J.M. KLAUSNER, G. LAHAT, E. NIZRI ( <i>Tel-Aviv, Israel</i> ) .....	6457
Hepatocellular Carcinoma With Extensive Cancer-associated Thrombosis Successfully Treated With Liver Resection and Direct Oral Anticoagulant: A Case Report. K. YAMAMURA, T. BEPPU, K. KINOSHITA, E. ODA, N. SATO, H. YUKI, T. MOTOHARA, H. MIYAMOTO, H. KAWAGUCHI, Y. KOMOHARA, S. AKAHOSHI ( <i>Kumamoto, Japan</i> ).....	6465
Alpha-type-1 Polarized Dendritic Cell-based Vaccination in Newly Diagnosed High-grade Glioma: A Phase II Clinical Trial. K. MITSUYA, Y. AKIYAMA, A. IIZUKA, H. MIYATA, S. DEGUCHI, N. HAYASHI, C. MAEDA, R. KONDOU, A. KANEMATSU, K. WATANABE, T. ASHIZAWA, Y. ABE, I. ITO, T. OISHI, T. SUGINO, Y. NAKASU, K. YAMAGUCHI ( <i>Shizuoka; Nagano, Japan</i> ) .....	6473
Efficacy of Electrochemotherapy in the Treatment of Cutaneous Melanoma Metastases and Rare Non-melanoma Skin Cancer. L. BORGOGNONI, L. PESCIPELLI, G. GERLINI, P. BRANDANI, R. GELLI, V. GIANNOTTI, F. BELLUCCI, S. SESTINI ( <i>Florence, Italy</i> ) .....	6485
Efficacy and Safety of Axitinib Therapy After Nivolumab for Patients With Metastatic Renal Cell Cancer. S. YASUOKA, T. YUASA, R. FUJIWARA, Y. KOMAI, N. NUMAO, S. YAMAMOTO, Y. KONDO, J. YONESE ( <i>Tokyo, Japan</i> ) .....	6493
Simultaneous Integrated Radiotherapy Boost to the Dominant Intraprostatic Lesion: Final Results of a Phase I/II Trial. M. BUWENGE, A.R. ALITTO, S. CILLA, I. CAPOCACCIA, E. MAZZEO, E. IPPOLITO, G. MANTINI, G. SIEPE, L. CAVALLINI, V. VALENTINI, F. DEODATO, A.G. MORGANTI, G. MACCHIA ( <i>Bologna; Rome; Campobasso; Modena, Italy</i> ) .....	6499
Using the Bolus in Post-mastectomy Radiation Therapy (PMRT): A National Survey on Behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Breast Cancer Group. M. NUZZO, L.A. URSINI, F. PATANI, C. ROSA, M. TRIGNANI, M. DI TOMMASO, I. MEATTINI, F. GREGUCCI, A. CIABATTONI, D. GENOVESI, L. CARAVATTA ( <i>Chieti; Florence; Acquaviva delle Fonti; Rome, Italy</i> ).....	6505
Re-Evaluation of Prognostic Factors for Survival After Radiotherapy of Cerebral Gliomas: A Supplementary Analysis to a Previous Study. J. WITTELER, T.W. KJAER, S. TVILSTED, S.E. SCHILD, D. RADES ( <i>Lübeck, Germany; Roskilde; Koege, Denmark; Scottsdale, AZ, USA</i> ).....	6513

Usefulness of Preoperative Endoscopic Fluorescent Clip Marking in Laparoscopic Gastrointestinal Surgery. S. RYU, A. OKAMOTO, K. NAKASHIMA, K. HARA, K. ISHIDA, R. ITO, Y. NAKABAYASHI, K. ETO, T. IKEGAMI ( <i>Kawaguchi; Tokyo, Japan</i> ) .....	6517
Impaired Vitamin D Signaling Is Associated With Frequent Development of Renal Cell Tumor in End-stage Kidney Disease. J. DOCS, D. BANYAI, T. FLASKO, A. SZANTO, G. KOVACS ( <i>Pecs; Debrecen, Hungary; Heidelberg, Germany</i> ) .....	6525
Impact of Palifermin on Transplant Outcomes in Children and Adolescents Undergoing Allogeneic Hematopoietic Cell Transplantation. K. CZYŻEWSKI, R. DĘBSKI, N. BARTOSZEWICZ, E. DEMIDOWICZ, M. RICHERT-PRZYGOŃSKA, M. ŁĘCKA, S. TARASENKO, J. STYCZYŃSKI ( <i>Bydgoszcz, Poland</i> ) .....	6531
Usefulness of Omentoplasty to Reduce Perineal Wound Complications in Abdominoperineal Resection After Neoadjuvant Chemoradiotherapy. M. NAGATA, T. MATSUDA, H. HASEGAWA, M. UTSUMI, K. YAMASHITA, M. YAMAMOTO, S. KANAJI, T. OSHIKIRI, T. NAKAMURA, S. SUZUKI, Y. KAKEJI ( <i>Kobe, Japan</i> ) .....	6539
Usefulness of a Transumbilical Incision for Organ Removal in Laparoscopic Hepatectomy. K. TOMIOKA, T. AOKI, K. MATSUDA, A. FUJIMORI, T. KOIZUMI, T. KUSANO, K. NOGAKI, Y. TASHIRO, Y. WADA, T. HAKOZAKI, H. SHIBATA, T. HIRAI, T. YAMAZAKI, K. SAITO, Y. ENAMI, M. MURAKAMI ( <i>Tokyo, Japan</i> ).....	6545
A Blood-based Gene-expression Scoring System for Cancer Screening in Patients With Branch-duct Intraductal Papillary Mucinous Neoplasms. R. SUZUKI, H. TAMURA, R. HONMA, N. KONNO, H. IRIE, T. TAKAGI, M. SUGIMOTO, H. ASAMA, Y. SATO, O. YOSHINORI, J. NAKAMURA, M. TAKASUMI, T. KATO, M. HASHIMOTO, T. HIKICHI, J.-I. IMAI, S. WATANABE, H. OHIRA ( <i>Fukushima; Tokyo, Japan</i> ).....	6551
Structural Origin and Surgical Complications of Peripheral Schwannomas. H. YONEZAWA, S. MIWA, N. YAMAMOTO, K. HAYASHI, A. TAKEUCHI, K. IGARASHI, K. TADA, M.B. LANGIT, T. HIGUCHI, K. ABE, Y. TANIGUCHI, S. MORINAGA, Y. ARAKI, Y. ASANO, H. TSUCHIYA ( <i>Kanazawa, Japan; Manila, Philippines</i> ).....	6563
Erratum .....	6571

## Number 12, December

### Reviews

Alternative Biomarkers to Predict Tumor Biology in Hepatocellular Carcinoma. P. ABREU, R. FERREIRA, V. MINELI, M. ALVES RIBEIRO, F. GONÇALVES FERREIRA, R. MARTINEZ DE MELLO VIANNA, F.D. SAAVEDRA TOMASICH, L.A. SZUTAN ( <i>Miami, FL, USA; Sao Paulo, SP; Curitiba, PR, Brazil</i> ) .....	6573
Application of Pharmacometrics of 5-Fluorouracil to Personalized Medicine: A Tool for Predicting Pharmacokinetic–Pharmacodynamic/Toxicodynamic Responses. S. KOBUCHI, Y. ITO ( <i>Kyoto, Japan</i> ) .....	6585
Animal Models for the Calculation of Circulating Tumor Cells for Experimental Demonstration. N. GARMPI, C. DAMASKOS, A. ANGELOU, A. GARMPI, V.E. GEORGAKOPOULOU, S. VALSAMI, D. SCHIZAS, E. VOUTYRITSA, A. SYLLAIOS, E. DIAMANTIS, P. FARMAKI, G. KYRIAKOS, A. PATSOURAS, M. PSIFIS, E.A. ANTONIOU, K. KONTZOGLU, N. TRAKAS, D. DIMITROULIS ( <i>Athens; Piraeus; Heraklion, Greece; Cartagena, Spain</i> ) .....	6599



Younger Age as a Risk Factor for Gynecologic Cancer-related Lymphedema: A Systematic Review. G. GULIYEVA, M.T. HUAYLLANI, F.R. AVILA, D. BOCZAR, X. LU, A.J. FORTE ( <i>Jacksonville, FL; New Haven, CT, USA</i> ) .....	6609
<i>Experimental Studies</i>	
Role of LLT1 and PCNA as Natural Killer Cell Immune Evasion Strategies of HCT 116 Cells. J.D. MALAER, P.A. MATHEW ( <i>Fort Worth, TX, USA</i> ) .....	6613
Combinatorial Cytotoxic Effects of 2,3-Dichloro-5,8-dimethoxy-1,4-naphthoquinone and 4-hydroxytamoxifen in Triple-negative Breast Cancer Cell Lines. A.G.J. ROBINSON, Y.M. KANAAN, R.L. COPELAND ( <i>Washington, DC, USA</i> ) .....	6623
Apoptosis Induced by (+)-Betulin Through NF- $\kappa$ B Inhibition in MDA-MB-231 Breast Cancer Cells. G.D. ANAYA-EUGENIO, N.A. EGGERS, Y. REN, J. RIVERA-CHÁVEZ, A.D. KINGHORN, E.J. CARCACHE DE BLANCO ( <i>Columbus, OH, USA; Ciudad Universitaria, Mexico</i> ) .....	6637
Mir-139 Regulates Autophagy in Prostate Cancer Cells Through Beclin-1 and mTOR Signaling Proteins. R.K. NAM, T. BENATAR, Y. AMEMIYA, C. SHERMAN, A. SETH ( <i>Toronto, ON, Canada</i> ) .....	6649
Novel Prognostic Implications of Methylated RNA and Demethylases in Resected HCC and Background Liver Tissue. N. NAKAGAWA, K. TANAKA, F. SONOHARA, R. KANDIMALLA, Y. SUNAGAWA, Y. INOKAWA, H. TAKAMI, M. HAYASHI, S. YAMADA, M. KANDA, C. TANAKA, G. NAKAYAMA, M. KOIKE, Y. KODERA ( <i>Nagoya, Japan; Dallas, TX, USA</i> ) .....	6665
The Biological Role of the Long Non-coding RNA <i>LINK-A</i> in Ovarian Carcinoma. N. FILIPPOV-LEVY, B. DAVIDSON, R. REICH ( <i>Jerusalem, Israel; Oslo, Norway</i> ) .....	6677
EZH2 Expression in Follicular Lymphoma Is Variable and Independent from the Progression of Disease Within 24 Months of First Treatment. A. SZUMERA-CIEĆKIEWICZ, J. POLESZCZUK, E. PASZKIEWICZ-KOZIK, G. RYMKIEWICZ, K. SOKÓŁ, A. BORYSIUK, M. KOTARSKA, D. OWCZAREK, M. KAWECKA, B. PYTLAK, J. WALEWSKI, M. PROCHOREC-SOBIESZEK ( <i>Warsaw, Poland</i> ) .....	6685
Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models. Y. NIWA, M. ASANO, T. NAKAGAWA, D. FRANCE, T. SEMBA, Y. FUNAHASHI ( <i>Ibaraki, Japan; Dijon, France</i> ) .....	6699
AMIGO2 Expression as a Potential Prognostic Biomarker for Gastric Cancer. S. NAKAMURA, M. KANDA, D. SHIMIZU, C. TANAKA, Y. INOKAWA, N. HATTORI, M. HAYASHI, S. YAMADA, G. NAKAYAMA, K. OMAE, M. KOIKE, Y. KODERA ( <i>Nagoya; Fukushima, Japan</i> ) .....	6713
Anticancer Efficacy and Mechanism of Amentoflavone for Sensitizing Oral Squamous Cell Carcinoma to Cisplatin. C.-H. CHEN, Y.-C. HUANG, Y.-H. LEE, Z.-L. TAN, C.-J. TSAI, Y.-C. CHUANG, H.-F. TU, T.-C. LIU, F.-T. HSU ( <i>Changhua; Taichung; Kaohsiung; Yilan; Taipei, Taiwan, ROC; Houston, TX, USA; Macau SAR, P.R. China</i> ) .....	6723
Aldehyde Dehydrogenase 1-related Genes in Triple-negative Breast Cancer Investigated Using Network Analysis. A. YAMADA, C. SUZUKI, H. SHIMA, K. KIDA, S. ADACHI, S. YAMAMOTO, K. NARUI, M. TANABE, D. SHIMIZU, R. TANIGUCHI, M. OSHI, K. TAKABE, Y. MIYAGI, Y. ICHIKAWA, T. ISHIKAWA, I. ENDO ( <i>Kanagawa; Tokyo, Japan; Buffalo, NY, USA</i> ) .....	6733
Interleukin-13 Promoter Genotypes and Taiwanese Breast Cancer Susceptibility. C.-L. TSAI, C.-W. TSAI, W.-S. CHANG, C.-H. SU, L.-C. LIU, H.-C. WANG, H.-T. LEE, C.-M. YEN, J.-C. CHEN, Y.-C. WANG, C.-H. CHEN, D.-T. BAU ( <i>Taichung; Changhua, Taiwan, ROC</i> ) .....	6743
Nitric Oxide Inhibits NF- $\kappa$ B-mediated Survival Signaling: Possible Role in Overcoming TRAIL Resistance. J.A. BAUER, J.A. LUPICA, J.A. DIDONATO, D.J. LINDNER ( <i>North Canton; Cleveland, OH, USA</i> ) .....	6751

A Universal Gelfoam 3-D Histoculture Method to Establish Patient-derived Cancer Cells (3D-PDCC) Without Fibroblasts from Patient-derived Xenografts. J. YAMAMOTO, N. SUGISAWA, K. HAMADA, H. NISHINO, K. MIYAKE, R. MATSUYAMA, S. INUBUSHI, H. TANINO, M. BOUVET, I. ENDO, R.M. HOFFMAN ( <i>San Diego; La Jolla, CA, USA; Yokohama; Hyogo, Japan</i> ) .....	6765
Hyperthermia During Intraperitoneal Chemotherapy With Paclitaxel or Docetaxel for Ovarian Cancer: Is There Any Benefit? E. DE BREE, D. KATSOUKRI, H. POLIOUDAKI, E. TSANGARIDOU, D. MICHELAKIS, O. ZORAS, P. THEODOROPOULOS ( <i>Heraklion, Greece</i> ) .....	6769
Cytology-based Detection of Circulating Tumour Cells in Human Pancreatic Cancer Xenograft Models With KRAS Mutation. Y. ITO, E. INOUE, Y. MATSUI, S. KOBUCHI, C. MOYAMA, K. AMAGASE, M. YOSHIMURA, Y. IKEHARA, S. NAKATA, H. NAKANISHI ( <i>Kyoto; Shiga; Aichi; Chiba, Japan</i> ).....	6781
Hypoxia-inducible Factor-1 $\alpha$ Suppression in Ovarian Clear-cell Carcinoma Cells by Silibinin Administration. M. MIYAZAWA, M. YASUDA, M. MIYAZAWA, N. OGANE, T. KATOH, M. YANO, T. HIRASAWA, M. MIKAMI, H. ISHIMOTO ( <i>Kanagawa; Saitama; Oita, Japan</i> ) .....	6791
Anti-cancer Effects of Fucoxanthin on Human Glioblastoma Cell Line. F. GARCIA LOPES, K. ANDRINEIA OLIVEIRA, R. GARCIA LOPES, G. GODOY POLUCENO, C. SIMIONI, G. DA SILVA PESCADOR, C.M. BAUER, M. MARASCHIN, R.B. DERNER, R. CASTILHO GARCEZ, C. INES TASCA, C.B. NEDEL ( <i>Florianópolis, SC, Brazil</i> ) .....	6799
Influence of Mesenchymal Stem Cell Administration on The Outcome of Partial Liver Resection in a Porcine Model of Sinusoidal Obstruction Syndrome. R. PALEK, J. ROSENDORF, A. MALECKOVA, L. VISTEJNOVA, K. BAJCUROVA, H. MIRKA, V. TEGL, O. BRZON, A. KUMAR, L. BEDNAR, Z. TONAR, P. HOSEK, V. MOULISOVA, L. EBERLOVA, V. TRESKA, V. LISKA ( <i>Pilsen, Czech Republic</i> ).....	6817
ADGRF4 Regulates Non-small Cell Lung Cancer Cell Invasiveness. J.-H. YOON, S.-G. CHO ( <i>Chungbuk, Republic of Korea</i> ) .....	6835
Hypoxia and CD11b+ Cell Influx Are Strongly Associated With Lymph Node Metastasis of Oral Cancer. K. SUGIURA, S. NAKAJIMA, I. KATO, M. OKUBO-SATO, Y. NAKAZAWA, K. MITSUDO, M. KIOI ( <i>Yokohama; Tokyo; Tsukuba, Japan</i> ).....	6845
Oxidative and Nitrosative Pattern in Circulating Leukocytes of Very Early/Early Hepatocellular Carcinoma Patients. P. LLUCH, G. SEGARRA, J. TOSCA, L. NAVARRO, J. NAVARRETE-NAVARRO, G. HERRERA, A. SANAHUJA, S. HERNANDEZ, S. LLUCH, P. MEDINA ( <i>Valencia, Spain</i> ) .....	6853
The Role of Genetic Analysis in Correct Diagnosis of Eosinophilic Variant of Chromophobe Renal Cell Carcinoma. A. MOLNAR, M.V. YUSENKO, G. KOVACS, D. BANYAI ( <i>Pecs, Hungary; Muenster; Heidelberg, Germany</i> ).....	6863
Maslinic Acid Induces DNA Damage and Impairs DNA Repair in Human Cervical Cancer HeLa Cells. K.-W. LU, M.-D. YANG, S.-F. PENG, J.-C. CHEN, P.-Y. CHEN, H.-Y. CHEN, T.-J. LU, F.-S. CHUEH, J.-C. LIEN, K.-C. LAI, K.-C. LIU, Y.-Y. TAI ( <i>Taichung; Changhua; Yunlin; Tainan, Taiwan, ROC</i> ) .....	6869
Chloride Intracellular Channel Protein 1 (CLIC1) Is Over-expressed in Muscle Invasive Urinary Bladder Cancer. T.G. ADELMANN, T.C. CAMEROTA, A.R. CEAUSU, A.M. CIMPEAN, M. MAZZANTI, M. RAICA ( <i>Timisoara, Romania; Pavia; Milan, Italy</i> ).....	6879
Distribution and Expression of the Adhesion Molecule CD44 on Human Corneal Grafts Is Not Altered by Chemotherapy. G.S. DIMTSAS, X. GRAMMATOGLU, T. CHOREFTAKI, M. DETTORAKI, A. KARATHANOU, N. GOULIOPOULOS, C. DAMASKOS, M.M. MOSCHOS ( <i>Athens; Larissa, Greece</i> ).....	6885
Mitochondrial Glutamine Metabolism Determines Senescence Induction After Chemotherapy. B. KIM, J. GWAK, E.K. LEE, S.M. JEONG ( <i>Seoul, Republic of Korea</i> ).....	6891

Expression of FOXO4 Inhibits Cholangiocarcinoma Cell Proliferation <i>In Vitro</i> via Induction of G <sub>0</sub> /G <sub>1</sub> Arrest. K. INTUYOD, S. CHOMWONG, P. THONGPON, K. VAETEEWOOTTACHARN, C. PAIROJKUL, P. PINLAOR, S. PINLAOR ( <i>Khon Kaen, Thailand</i> ) .....	6899
Flavopereirine Inhibits Hepatocellular Carcinoma Cell Growth by Inducing Cell-cycle Arrest, Apoptosis, and Autophagy-related Protein Expression. S.-Y. CHEN, C.-N. CHAO, H.-Y. HUANG, C.-Y. FANG ( <i>Chiayi; Tainan City; Taichung, Taiwan, ROC</i> ) .....	6907
<i>Clinical Studies</i>	
Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel – A Final Analysis of the Prosty II Trial. P.-L. KELLOKUMPU-LEHTINEN, T. MARTTILA, A. JEKUNEN, P. HERVONEN, K. KLINTRUP, V. KATAJA, T. UTRIAINEN, M. LUUKKAA, M. LESKINEN, K. PULKKANEN, A.-L. KAUTIO, T. HUTTUNEN ( <i>Tampere; Seinäjoki; Vaasa; Oulu; Kuopio; Helsinki; Turku, Finland</i> ) .....	6915
Microvessels in Epithelial Ovarian Tumors: High Microvessel Density Is a Significant Feature of Malignant Ovarian Tumors. M. SOPO, M. ANTTILA, O.-T. MUUKKONEN, S. YLÄ-HERTTUALA, V.-M. KOSMA, L. KESKI-NISULA, H. SALLINEN ( <i>Kuopio, Finland</i> ) .....	6923
Differential Analyses of Peripheral Blood Parameters in CCR5 Inhibition-treated Colorectal Cancer Patients Reveal Dynamic Changes Linked to Clinical Outcomes. A. AHMED, N. HALAMA ( <i>Heidelberg; Mainz, Germany</i> ) .....	6933
Outcome of Soft-tissue Reconstruction in the Setting of Combined Preoperative and Intraoperative Radiotherapy for Extremity Soft-tissue Sarcomas. R.L. HONIG, M.E. TIBBO, K.E. MALLETT, K. BAKRI, S.K. AHMED, I.A. PETERSEN, P.S. ROSE, S.L. MORAN, M.T. HOUDEK ( <i>Rochester, MN, USA</i> ) .....	6941
Performance of a Diagnostic Score in Confirming Acute Cholecystitis Among Patients With Acute Abdominal Pain. M. ESKELINEN, J. MEKLIN, K. SYRJÄNEN, M. ESKELINEN ( <i>Kuopio; Kaarina, Finland; Barretos, Brazil</i> ) .....	6947
Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy After Definitive Chemoradiotherapy. M. MORIMOTO, K. NISHINO, K. WADA, F. IMAMURA, K. KONISHI, H. KUHARA, M. TAMIYA, T. INOUE, K. KUNIMASA, M. KIMURA, T. HIRATA, N. KANAYAMA, M. TORATANI, H. KAWACHI, K. OHIRA, E. NAKANISHI, S. OHIRA, T. SAGAWA, M. MIYAZAKI, T. MATSUNAGA, T. KUMAGAI, T. TESHIMA ( <i>Osaka, Japan</i> ) .....	6957
Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors. T. HIRASHIMA, T. KANAI, H. SUZUKI, H. YOSHIDA, A. MATSUSITA, H. KAWASUMI, S. NASU, A. TANAKA, N. MORISHITA, K. KAWAHARA, Y. TAMURA, N. OKAMOTO ( <i>Osaka, Japan</i> ) .....	6971
Survival and Surgical Complications in Anaplastic Thyroid Cancer Patients After Completed Multimodal Treatment. B. LORNTZSEN, A.-B. JACOBSEN, K.K. GRØHOLT, E. SIGSTAD, T. OSNES ( <i>Oslo, Norway</i> ) .....	6979
Rediscovering the Role of Traditional Risk Factors in Young Adults With Oral Squamous Cell Carcinoma. N. NECKEL, M. MICHAEL, D. TROELTZSCH, J. WÜSTER, S. KOERDT, C. DOLL, K. JÖHRENS, K. NEUMANN, M. HEILAND, J.-D. RAGUSE ( <i>Berlin; Dresden; Münster, Germany</i> ) .....	6987
Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life. J.H. CHECK, D. CHECK, M.D. SRIVASTAVA, T. PORETTA, J.K. AIKINS ( <i>Camden; Mt. Laurel; Sewell, NJ; Buffalo, NY, USA</i> ) .....	6997
Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. E. COJOCARU, K. THWAY, C. FISHER, C. MESSIOU, S. ZAIDI, A.B. MIAH, C. BENSON, S. GENNATAS, P. HUANG, R.L. JONES ( <i>London; Birmingham, UK</i> ) .....	7003

Delayed Initiation of Treatment Is Associated With Metastasis of Soft-tissue Sarcoma. Y. ARAKI, N. YAMAMOTO, K. HAYASHI, A. TAKEUCHI, S. MIWA, K. IGARASHI, H. TAKASHI, A. KENSAKU, Y. TANIGUCHI, H. YONEZAWA, S. MORINAGA, Y. ASANO, H. TSUCHIYA ( <i>Kanazawa, Japan</i> ) .....	7009
Prognostic Significance of Plasma Fibrinogen/Serum Albumin Ratio in the Postoperative Outcome of Pancreatic Ductal Adenocarcinoma. K. TOMITA, S. OCHIAI, T. GUNJI, K. HIKITA, T. KOBAYASHI, T. SANO, N. CHIBA, S. KAWACHI ( <i>Tokyo, Japan</i> ) .....	7017
Prognostic Factors of Local Control and Survival in Patients Irradiated for Glioblastoma Multiforme (GBM). J. WITTELER, S.E. SCHILD, D. RADES ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ) .....	7025
Innominate Grooves of the Colon: Histological Reappraisal. C.A. RUBIO ( <i>Stockholm, Sweden</i> ) .....	7031
Interleukin-13 Promoter Genotypes and Taiwanese Breast Cancer Susceptibility. C.-L. TSAI, C.-W. TSAI, W.-S. CHANG, C.-H. SU, L.-C. LIU, H.-C. WANG, H.-T. LEE, C.-M. YEN, J.-C. CHEN, Y.-C. WANG, C.-H. CHEN, D.-T. BAU ( <i>Taichung; Changhua, Taiwan, ROC</i> ) .....	7037
Outcomes and Prognostic Factors Following Surgical Treatment of Pulmonary Metastases from Colorectal Carcinoma. J. VODIČKA, J. FICHTL, J. ŠEBEK, K. PROCHÁZKOVÁ, M. SKÁLA, V. TŘEŠKA, S. KORMUNDA, B. VAŇKOVÁ, M. SVATOŇ, O. TOPOLČAN, R. KUČERA ( <i>Pilsen, Czech Republic</i> ).....	7045
Small Cell Lung Carcinoma and Synchronous Rectal Adenocarcinoma and Jejunal Gastrointestinal Stromal Tumor Present in a Patient With History of Laryngeal Squamous Cell Carcinoma. B. LIU, S. SHIRAGA, M.M. MORTENSON, J. LAI ( <i>Sacramento, CA; Grenada, West Indies, USA</i> ) .....	7053
Genetic Alterations Detected by Targeted Next-generation Sequencing and Their Clinical Implications in Neuroblastoma. K.-N. KOH, J.-Y. LEE, J. LIM, J. SHIN, S.H. KANG, J.K. SUH, H. KIM, H.J. IM, J.-M. NAMGOONG, D.Y. KIM, S.J. JANG, S.-M. CHUN ( <i>Seoul, Republic of Korea</i> ).....	7057
Cancer Cachexia Reduces the Efficacy of Nivolumab Treatment in Patients With Advanced Gastric Cancer. H. FUJII, A. MAKIYAMA, H. IIHARA, N. OKUMURA, S. YAMAMOTO, T. IMAI, S. ARAKAWA, R. KOBAYASHI, Y. TANAKA, K. YOSHIDA, A. SUZUKI ( <i>Gifu, Japan</i> ) .....	7067
Re-Irradiation for Recurrent Glioblastoma Multiforme. D. RADES, J. WITTELER, J. LEPPERT, S.E. SCHILD ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ) .....	7077
Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer. I. MACAIONE, A. GALVANO, G. GRACEFFA, S. LUPO, M. LATTERI, A. RUSSO, S. VIENI, C. CIPOLLA ( <i>Palermo, Italy</i> ) .....	7083
Clustered Circulating Tumor Cells in Lung Adenocarcinoma: Implications of Test Results of Continuous Variables. T. WATANABE, N. SAWABATA, T. KAWAGUCHI, D. YOSHIKAWA, K. KUSHIBE, S. NAKANE, S. TANIGUCHI ( <i>Nara; Kashihara; Osaka, Japan</i> ) .....	7089
Nivolumab for the Treatment of Advanced Pediatric Malignancies. A. MARJAŃSKA, M. DROGOSIEWICZ, B. DEMBOWSKA-BAGIŃSKA, K. PAWIŃSKA-WĄSIKOWSKA, W. BALWIERZ, K. BOBEFF, W. MŁYNARSKI, A. MIZIA-MALARZ, A. RACIBORSKA, M. WYSOCKI, J. STYCZYŃSKI ( <i>Bydgoszcz; Warsaw; Cracow; Lodz; Katowice, Poland</i> ) .....	7095
Efficacy and Safety of Enzalutamide in a Real-World Cohort of Japanese Patients With Castration-resistant Prostate Cancer. A. HORI, H. SAHASHI, S. SANO, E. MATSUMIYA, M. ARIGA, A. ASANO, M. SODA, C. GOTO, T. MIZUI, H. KOMEDA, K. KITAICHI ( <i>Gifu, Japan</i> ).....	7101
Differences Between Laparoscopic and Open Gastrectomy on the Impact of Postoperative Infectious Complications on Prognosis. H. NAGATA, H. TSUJIMOTO, K. KOUZU, Y. ITAZAKI, Y. ISHIBASHI, S. TSUCHIYA, T. SUGIHARA, N. ITO, M. HARADA, S. NOMURA, Y. KISHI, H. UENO ( <i>Tokorozawa, Japan</i> ) .....	7109

Delay in Breast Cancer Treatments During the First COVID-19 Lockdown. A Multicentric Analysis of 432 Patients. G. VANNI, G. TAZZIOLI, M. PELLICCIARO, M. MATERAZZO, O. PAOLO, F. CATTADORI, F. COMBI, S. PAPI, C.A. PISTOLESE, M. COTESTA, F. SANTORI, J. CASPI, A. CHIARAVALLI, S. MUSCOLI, V. LOMBARDO, A. GRASSO, L. CAGGIATI, R. RASELLI, D. PALLI, V. ALTOMARE, R.M. MARIA D'ANGELILLO, L. PALOMBI, O.C. BUONOMO ( <i>Rome; Modena; Piacenza; Pozzilli; Messina, Italy</i> ).....	7119
Stage III and Metastatic Lymph Node Ratio Are the only Independent Prognostic Factors in Colorectal Signet-ring Cell Carcinoma Patients. A. ANNICCHIARICO, A. MORINI, A. ROMBOLI, M. RICCÒ, F. LEONARDI, P. CRAFA, E. VIRGILIO, P. DELL'ABATE, R. COSTI ( <i>Parma; Reggio Emilia; Fidenza, Italy</i> ) .....	7127
Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal Cancer. M. KIMURA, E. USAMI, T. YOSHIMURA ( <i>Gifu, Japan</i> ) .....	7135
Factors Influencing Social Isolation and Loneliness Among Lung Cancer Patients: A Cross-sectional Study. N. ASHI, Y. KATAOKA, T. TAKEMURA, C. SHIRAKAWA, K. OKAZAKI, A. SAKURAI, T. IMAKITA, S. IKEGAKI, H. MATSUMOTO, E. SAITO, H. TAKATA, S. KAKU, N. WADA, M. SHINOMIYA, T. OTOSHI, M. SHIMADA, J. NIKAIDO, R. IKI, K. HIRANO, T. HIRAI, K. ENDO, M. HIRABAYASHI, T. NAGANUMA ( <i>Hyogo; Kyoto; Tokyo; Fukushima, Japan</i> ) .....	7141
Cholangiolocarcinoma With Multiple Recurrences Successfully Treated With Repeated Liver Resection and Radiofrequency Ablation. N. SATO, K. YAMAMURA, E. ODA, S. AKAHOSHI, H. YUKI, T. MOTOHARA, H. MIYAMOTO, D. YOSHII, Y. KOMOHARA, T. BEPPU ( <i>Kumamoto, Japan</i> ) .....	7147
Errata .....	7155
Index 2020 .....	7157

## Subject Index

(Figures refer to page numbers)

- (+)-betulin, NF- $\kappa$ B, MDA-MB-231, zebrafish, apoptosis, 6637
- 1-b][1, mesothelioma, imidazo[2, 3, 4]thiadiazole compounds, FAK, gemcitabine, human equilibrative nucleoside transporter-1, 4913
- 1-b]oxazole derivatives, imidazo[2, RAF inhibitors, TNBC, chemotherapy, 5081
- 1, oral squamous cell carcinoma, vitamin D, sonic Hedgehog signaling, SHH, wNT/ $\beta$ -catenin signaling, 20-hydroxyvitamin D<sub>3</sub>, 20-dihydroxyvitamin D<sub>3</sub>, 2467
- 1, TNBC, tamoxifen, 4 naphthoquinone, breast cancer cell lines, 6623
- 1, vitamin D, 25-D<sub>3</sub>, ovarian cancer, *in vitro*, paclitaxel, carboplatin, growth inhibition, VDR, 3129
- 16S rRNA gene sequencing, gut microbiota, gene mutations, colorectal cancer, stool DNA, 1325
- <sup>18</sup>F-FDG PET/CT, non-small-cell lung cancer, MIB-1, artificial intelligence, 3355
- 2-hydroxyglutarate, isocitrate dehydrogenase 1, mutation, IDH1 R132H, high-throughput screening, 4929
- 20-dihydroxyvitamin D<sub>3</sub>, oral squamous cell carcinoma, vitamin D, sonic Hedgehog signaling, SHH, wNT/ $\beta$ -catenin signaling, 20-hydroxyvitamin D<sub>3</sub>, 1, 2467
- 20-hydroxyvitamin D<sub>3</sub>, oral squamous cell carcinoma, vitamin D, sonic Hedgehog signaling, SHH, wNT/ $\beta$ -catenin signaling, 1, 20-dihydroxyvitamin D<sub>3</sub>, 2467
- 25-D<sub>3</sub>, vitamin D, 1, ovarian cancer, *in vitro*, paclitaxel, carboplatin, growth inhibition, VDR, 3129
- 25-hydroxycholesterol, apoptosis, cholesterol, head and neck squamous cell carcinoma, oxysterol, 779
- 25-hydroxyvitamin D, *vitamin D*<sub>3</sub>, *vitamin D*<sub>3</sub> supplementation, gut microbiota, randomized clinical trial, 551
- 25-hydroxyvitamin D, breast, cancer, colon, colorectal, ecological, mendelian randomization, prostate, ultraviolet B, UVB, review, 491
- 25-hydroxyvitamin D, vitamin D, supplementation, metabolomics, genomics, broad gene expression, metabolomic profile, individual response, personalized medicine, 535
- 25(OH)D, sunscreen, photoprotection, vitamin D, UVR exposure, review, 511
- 2D gel electrophoresis, parkin, nuclear proteome, phosphoproteome, neuroblastoma cancer, 3169
- 3-D culture, histoculture, gelfoam, patient-derived cancer cells, PDCC, patient-derived xenograft, PDX, 6765
- 3-methyladenine, areca nut, autophagy, nude mice, chloroquine, cisplatin, 221
- 3-Styrylchromones, methoxy group, cytotoxicity, tumor-specificity, QSAR analysis, cell cycle analysis, molecular shape, 87
- 3, mesothelioma, imidazo[2, 1-b][1, 4]thiadiazole compounds, FAK, gemcitabine, human equilibrative nucleoside transporter-1, 4913
- 3D culture, breast cancer, cytokines, regulatory T-lymphocytes, natural killer cells, 6179
- 3D culture, CD155, CAK cells, KRAS, TNK cells, PD-1, TIGIT, 4663
- 3D reconstruction, vascular malformation, intraosseous, haemangioma, orbit, cone beam computed tomography, bone mineral density, immunohistochemistry, differential diagnosis, 3333
- 3PO, melanoma, BRAF<sup>V600E</sup>, A375, inhibitor, PFKFB3, 2613
- 4 naphthoquinone, TNBC, tamoxifen, 1, breast cancer cell lines, 6623
- 5-aminolevulinic acid, pancreatic cancer, photodynamic screening, biomarker, 3571
- 5-fluorouracil, chemotherapy, calcitriol, vitamin D analogs, tacalcitol, 837
- 5-fluorouracil, colon cancer, aTP-binding cassette transporter 11, prognosis, 5405
- 5-fluorouracil, colorectal cancer, anti-cancer drug resistance, cK2 $\alpha$ , ER stress, 1419
- 5-fluorouracil, gastric cancer, liver metastasis, patient-derived orthotopic xenograft (PDOX), nude mice, oxaliplatin, gemcitabine, 5393
- 5-fluorouracil, ribociclib, human colorectal cancer, 6265
- 5-FU prodrug, modelling and simulation, chronopharmacokinetics, translational research, cancer chemotherapy, therapeutic drug monitoring, pharmacometrics, review, 6585
- 5-FU prodrugs, therapeutic drug monitoring, personalized treatment, capecitabine, review, 4655
- 5-FU, cisplatin, chemoresponsive, chemorefractory, chemoresistance, apex1-Jagged-1 cascade, 1897
- 5-FU, drug resistance, gastric cancer, EMT, cell cycle, p57, cyclin D1, 3247
- 53BP1, oesophageal squamous cell carcinoma, PARP inhibitor, DNA damaging agents, REV7, 813
- 8-hydroxy-2'-deoxyguanosine, previtamin D<sub>3</sub>, DNA damage, nitric oxide, vitamin D, nitrite, human skin, 565
- 9-cis-retinoic acid, pPAR $\gamma$ , ciglitazone, thiazolidinedione, retinoids, head and neck squamous carcinoma, 3071
- A $\beta$  T cell therapy, colorectal cancer, chemotherapy, immunotherapy, immunological status, 4763
- A $\beta$  T cell therapy, immune-cell therapy, cervical cancer, endometrial cancer, prognostic factors, dendritic cell vaccine, 4729
- A375, melanoma, BRAF<sup>V600E</sup>, 3PO, inhibitor, PFKFB3, 2613

- A549 lung adenocarcinoma cell line, methylsulfonylmethane, intrinsic apoptosis, cell-cycle arrest, 1905
- B-carboline alkaloid, flavopereirine, hepatocarcinoma, apoptosis, autophagy, cell-cycle arrest, 6907
- B-catenin, chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII), colorectal cancer, akt, forkhead box C1 (FOXC1), 177
- B-catenin, hepatocellular carcinoma, wnt, CBP, inhibitor, PRI-724, 5211
- B-catenin, peroxisome proliferator activated receptor  $\gamma$  coactivator-1 $\alpha$  (PGC-1 $\alpha$ ), colorectal cancer, AKT, glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ), 653
- $\Gamma$ -globulin, THP-1 macrophages, serum-MAF, talin-1, calpain, time-lapse imaging, morphological change, 4707
- $\Gamma\delta$  T cell, immunotherapy, prostate cancer, cancer stem cell, sphere, prostasphere, CD133, NANOG, SOX2, OCT4, 5481
- A-to-I RNA editing, ADAR, 1307
- ABC transporter, colorectal cancer, cancer stem cell, prognosis, 4481
- ABCG2, HNSCC, CSC, cisplatin, piCa, faDu, 1277
- Abdominal aortic aneurysm, screening, high cardiovascular risk profile, lung cancer, 4137
- Abdominal radical trachelectomy, cervical cancer, fertility-sparing, fertility preservation, radical hysterectomy, 5939
- Abdominoperineal resection, omentoplasty, perineal wound complication, NACRT, 6539
- ABHD12, breast cancer, proliferation, migration, invasion, 2601
- Abiraterone, androgen receptor, cabazitaxel, docetaxel, enzalutamide, prostate cancer, 335
- Abnormal uptake, breast cancer, dedicated breast PET, FDG, classification, 3491
- Abscopal effect, carcinosarcoma, endometrial neoplasms, microsatellite instability, pembrolizumab, radiotherapy, 4131
- Absolute lymphocyte count, breast cancer, c-reactive protein, eribulin, overall survival, 4147
- Accelerated hyperfractionated thoracic radiotherapy (AHTRT), volumetric modulated arc therapy (VMAT), intensity modulated radiation therapy (IMRT), involved field radiotherapy irradiation (IFR-IFI), twice-daily thoracic radiotherapy (BID-TRT), anti-programmed cell death ligand-1 immune checkpoint inhibitor (ICIs), 6957
- Accelerated radiotherapy, stage III non-small cell lung cancer (NSCLC), tumor control probability (TCP), normal tissue complication probability (NTCP), concomitant boost, 4095
- Acetoacetate, ketogenic diet, ketone bodies, lithium, breast cancer, 3831
- Acetylenic synthetic betulin derivatives, betulin, chemotherapy, glioma, 6151
- Acral lentiginous melanoma, malignant melanoma, National Cancer Database, tumor characteristics, 3411
- Acriflavine, hIF1 $\alpha$ , vasculogenic mimicry, HIF1 inhibitors, apoptosis, 5379
- ACTB-GLI1* fusion gene, pericytoma, t(7;12), GLI1 isoform 2 protein, unbalanced chromosome translocation, 1239
- Activated dendritic cell, immunotherapy, high-grade glioma, HLA-A24, phase II trial, 6473
- Activating transcription factor 4, breast cancer, cysteine, hypoxia, sulfasalazine, tumor necrosis factor-related apoptosis-inducing ligand, 1387
- Actual 5-year survivor, colorectal liver metastasis, CRLM, modern chemotherapy, 1107
- Acute abdominal pain, acute cholecystitis, diagnostic score, ROC, HSROC, diagnostic accuracy, 6947
- Acute cholecystitis, acute abdominal pain, diagnostic score, ROC, HSROC, diagnostic accuracy, 6947
- Acute kidney injury, apela, iodinated contrast agent, 635
- Acute lung injury (ALI), lung metastasis, pneumonia, intercellular adhesion molecule-1 (ICAM-1), e-selectin, 6171
- Acute lymphocytic leukemia, case-control study, childhood, genotype, *MMP-9*, polymorphism, Taiwan, 5751
- Acute myeloid leukemia, anthracycline, consolidation, 357
- Acute myeloid leukemia, pediatric, chromosome translocation, RNA sequencing, tYRO3gene, 6115
- Acute myeloid leukemia, secondary, therapy related, survival, mutations, 2917
- ADAMTS6, AGR2, NSCLC, mutant NSCLC, gefitinib resistance, yuanhuadine, 1855
- Adaptive radiotherapy, replanning, gliomas, brain tumor, 4237
- Adaptive tumor growth short-term prediction, pharmacokinetic (PK)-Pharmacodynamic (PD), tumor growth inhibition (TGI) mathematical model, deep learning neural networks (DLNN), nonlinear optimization, TGI model parameter estimation, xenografted mice (PDX), pancreatic ductal adenocarcinoma (PDAC) xenograft, 5181
- ADAR, a-to-I RNA editing, 1307
- Adenocarcinoma, EGFR-TKI, pleurodesis, malignant pleural effusions, hypoalbuminemia, 1117
- Adenoviral vector, GPR87, shRNA, gene therapy, cell surface marker, NSCLC, 733
- Adenovirus, oncolytic virus, CUL4A, shRNA, virotherapy, 161
- ADGRF4, GPR115, PPP4C, lung cancer, cell invasiveness, 6835
- Adherence, adjuvant aromatase inhibitor, breast cancer, postmenopausal, 857

- Adhesion, oxazolidinones, neuroblastoma, kelly cell line, proliferation, progression, BSA heat denaturation, fibronectin, 5125
- Adiponectin, colorectal cancer, high-molecular weight oligomers, adipoR1, adipoR2, t-cadherin, 3751
- ADIPOQ*, colorectal cancer, genotype, polymorphism, Taiwan, 1297
- AdipoR1, colorectal cancer, adiponectin, high-molecular weight oligomers, adipoR2, t-cadherin, 3751
- AdipoR2, colorectal cancer, adiponectin, high-molecular weight oligomers, adipoR1, t-cadherin, 3751
- Adjuvant aromatase inhibitor, breast cancer, postmenopausal, adherence, 857
- Adjuvant chemotherapy, chemoradiotherapy, esophageal squamous cell carcinoma, radiotherapy dose escalation, 1771
- Adjuvant chemotherapy, colon cancer, practice variation, quality of care, population-based study, 4331
- Adjuvant chemotherapy, gastric cancer, glioma-associated oncogene 1, S-1, prognostic factor, 5815
- Adjuvant chemotherapy, gastric cancer, postoperative complication, recurrence, 1683
- Adjuvant chemotherapy, high-risk factor, mucinous adenocarcinoma, stage II, 1651
- Adjuvant therapy, breast cancer, surgical resection, recurrence, methionine restriction, recombinant methioninase, lung metastasis, inhibition, 4869
- Adjuvant therapy, perineural invasion, cervical cancer, vulvar cancer, surgery, review, 3031
- Adnexal masses, magnetic resonance, ultrasound, MR-US fusion, iOTA simple rules, O-RADS MRI scoring system, ovarian cancer, 4115
- Adoptive immunotherapy, neuroendocrine carcinoma, carcinoma of the uterine cervix, immunotherapy, cellular immunotherapy, t-cells, 4741
- Adrenal gland cancer adrenal gland, small cell neuroendocrine carcinoma, SCNEC, extrapulmonary small cell carcinoma, chemotherapy, radiation therapy, chemoradiation, 5933
- Adrenal insufficiency, secondary adrenal insufficiency, steroid dependence, glioma, glioblastoma, 2059
- Adrenal metastasis, hepatocellular carcinoma, indocyanine green fluorescent imaging, 5823
- Adult T-cell leukemia/lymphoma, mogamulizumab, EPOCH, 5237
- Adult, lymphangioma, oropharynx, 1631
- Advanced gastric cancer, *HER2*, trastuzumab, chemotherapy, 75
- Advanced non-squamous non-small cell lung cancer, amrubicin, bevacizumab, efficacy, prospective study, 1571
- Advanced urothelial carcinoma, second-line chemotherapy, paclitaxel, gemcitabine, cisplatin, 1613
- Adverse effects, immunotherapy, checkpoint inhibitor, outcome, efficacy, review, 1219
- Adverse event, ethinylestradiol, castration resistant prostate cancer, prostate-specific antigen, 2291
- Adverse event, ramucirumab, third-line treatment, overall survival, drug cost, metastatic colorectal cancer, 1605
- Adverse events, oxaliplatin, creatinine clearance, colorectal cancer, nausea, 299
- Adverse reactions, melanoma, sarcopenia, body mass index, pembrolizumab, monoclonal antibodies, retrospective studies, clinical decision-making, drug-related side effects, 5245
- Afatinib, PDGF, PDGFR, head and neck squamous cell carcinoma, drug resistance, nilotinib, dasatinib, erlotinib, gefitinib, 825
- Affordable Care Act, multiple myeloma, social determinants of health, disparity, 5727
- AFP, yolk sac tumour, primitive germ cell tumour, stem cell, 759
- African-American, single nucleotide polymorphisms, interleukin 10, prostate cancer, smoking, inflammation, 27
- Age, gender, genotype, *MMP-1*, polymorphism, pterygium, Taiwan, 703
- Age, gender, genotype, *MMP-9*, polymorphism, pterygium, Taiwan, 4523
- Age, gynecologic cancer-related lymphedema, secondary lymphedema, iatrogenic lymphedema, lymphedema, plastic surgery, review, 6609
- Age, salvage surgery, differentiated thyroid carcinoma, distant metastasis, survival, 11292
- Age, vitamin D, gynaecological cancers, seasonal influence, menopause status, nicotine abuse, grade, 545
- Aggressiveness, tumour budding, squamous-cell carcinoma, skin, 2695
- Ago2, prostate cancer, endothelin-1, mxi-2, p53, 5539
- AGR2, NSCLC, mutant NSCLC, gefitinib resistance, yuanhuadine, ADAMTS6, 1855
- Akt, catalytic topo I inhibitor, cyclin D1 accumulation, ATR, PTEN, gSK-3 $\beta$ , 6237
- Akt, chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII), colorectal cancer,  $\beta$ -catenin, forkhead box C1 (FOXC1), 177
- AKT, peroxisome proliferator activated receptor  $\gamma$  coactivator-1 $\alpha$  (PGC-1 $\alpha$ ), colorectal cancer, glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ),  $\beta$ -catenin, 653
- ALBI grade, postoperative ascites, m2BPGi, VTQ, hepatic resection, HCC, 4343
- Albumin, FA score, fibrinogen, pancreatic ductal adenocarcinoma, surgical resection, prognostic index, 7017
- ALC, breast cancer, eribulin, tGF- $\beta$ , tILs, tumour microenvironment, 3345



- Alcohol consumption, oral squamous cell carcinoma, OSCC, risk factors, young adults, case-control study, survival analysis, smoking, 6987
- Alcohol dehydrogenase isoenzymes, aldehyde dehydrogenase, intrahepatic cholestasis of pregnancy, 1997
- Alcohol dehydrogenase isoenzymes, aldehyde dehydrogenase, lung cancer, carcinogenesis, 3857
- Alcohol drinking, betel quid, genotype, interleukin-12A, oral cancer, polymorphism, smoking, Taiwan, 3707
- Aldehyde dehydrogenase 1, triple-negative breast cancer, microarray analysis, network analysis, 6733
- Aldehyde dehydrogenase, alcohol dehydrogenase isoenzymes, intrahepatic cholestasis of pregnancy, 1997
- Aldehyde dehydrogenase, alcohol dehydrogenase isoenzymes, lung cancer, carcinogenesis, 3857
- ALDH1A3, cancer stem cell, breast cancer, c-Met, pKCl, 35
- Alectinib, clinical practice, non-small cell lung cancer, anaplastic lymphoma kinase fusion gene mutation, chemotherapy, 957
- Alectinib, NSCLC, *ALK* inhibitors, ceritinib, crizotinib, anaplastic lymphoma kinase, radiation, 4937
- ALK* inhibitors, NSCLC, ceritinib, crizotinib, alectinib, anaplastic lymphoma kinase, radiation, 4937
- ALK*, neuroblastoma, children, next-generation sequencing, prognosis, 7057
- Alkaline diet, pancreatic cancer, alkalization therapy, tumor microenvironment, bicarbonate, urine pH, 873
- Alkalization therapy, pancreatic cancer, tumor microenvironment, alkaline diet, bicarbonate, urine pH, 873
- Alkaloid, papuamine, anticancer, mitochondria, 323
- ALL, pediatric, miRNA, relapse, epigenetic, 3147
- Allogeneic hematopoietic stem cell transplantation, *ANRIL*, single nucleotide polymorphism, *ARF-INK4* locus, hematologic malignancies, 5707
- Allogeneic hematopoietic stem cell transplantation, cytomegalovirus, letermovir, 5909
- Alpha fetoprotein, hepatocellular carcinoma, lenvatinib, ramucirumab, second-line therapy, 2089
- Amentoflavone, cisplatin, oral squamous cell carcinoma, NF- $\kappa$ B, apoptosis, 6723
- AMIGO2*, gastric cancer, prognosis, biomarker, 6713
- Aminonaphthoquinone, curcumin, combination, cytotoxic, anti-angiogenic, anti-metastatic, 229
- AMPK/AKT/mTOR pathway, niclosamide, caspase-independent pathway, autophagy, NSCLC, 1405
- Amrubicin, advanced non-squamous non-small cell lung cancer, bevacizumab, efficacy, prospective study, 1571
- Analysis of survival, immunotherapy, melanoma, pembrolizumab, S100, 2157
- Anaplastic large cell lymphoma (ALCL), non-Hodgkin's lymphoma (NHL), t-cell lymphomas, anaplastic lymphoma kinase (*ALK*), mammalian target of rapamycin (mTOR), drug combination therapy, 1395
- Anaplastic lymphoma kinase (*ALK*), non-Hodgkin's lymphoma (NHL), t-cell lymphomas, anaplastic large cell lymphoma (ALCL), mammalian target of rapamycin (mTOR), drug combination therapy, 1395
- Anaplastic lymphoma kinase fusion gene mutation, clinical practice, alectinib, non-small cell lung cancer, chemotherapy, 957
- Anaplastic lymphoma kinase, NSCLC, *ALK* inhibitors, ceritinib, crizotinib, alectinib, radiation, 4937
- Anaplastic thyroid cancer, thyroid surgery, multimodal treatment, radiotherapy, hyperfractionated accelerated radiotherapy, 6979
- Anaplerotic enzyme, pyruvate carboxylase, colorectal cancer, 6285
- Anastomosis leak, esophageal cancer, overall survival, recurrence, 443
- Anastomosis, indocyanine green fluorescence, colorectal cancer, intestinal blood flow, 373
- Anastomotic leakage, gastric cancer, disease-free survival, overall survival, review, 619
- Anastomotic leakage, rectal cancer, robotic surgery, laparoscopic surgery, 2337
- And rhabdomyosarcoma, primary hepatic carcinosarcoma, collision tumor, hepatocellular carcinoma, HCC, cholangiocarcinoma, CC, osteosarcoma, 2225
- Androgen receptor, abiraterone, cabazitaxel, docetaxel, enzalutamide, prostate cancer, 335
- Androgen receptor, hepatocellular carcinoma, epCAM, sorafenib, 1285
- Androgen stimulation, polycomb and Trithorax genes, prostate cancer cells, quantitative RT-PCR, 2559
- Anemia, olaparib, meta-analysis, randomized clinical trial, fatigue, PARP, review, 597
- Angiogenesis, endothelial cells, glioblastoma, cell crosstalk, *MMP-9*, *CXCR4*, 2725
- Angiogenesis, glioblastoma, fucoxanthin, apoptosis, migration, invasion, 6799
- Angiogenesis, leiomyosarcoma, tumor stem cell, hematogenous metastasis, 1255
- Angiogenesis, locoregional recurrent rectal cancer, microRNA, expression, colorectal cancer, 2947
- Angiogenesis, ovarian cancer, immunohistochemistry, lymphangiogenesis, CD105, CD34, 6923
- Angiogenesis, periostin, carcinoma, stemness, metastasis, lymphangiogenesis, chondrosarcoma, 5463
- Angiosarcoma, hemangiosarcoma, gynaecology, cancer, uterine sarcoma, ovarian sarcoma, chemotherapy, paclitaxel, laparotomy, osseous metastasis, 5743
- Angiosarcoma, proton beam radiotherapy, hadrontherapy, 1645
- Animal model, AOM/DSS, IBD, colitis associated cancer, carcinogenesis, colorectal cancer, 5457
- Animal model, colorectal cancer, liver metastasis, clonal dynamics, splenic injection, orthotopic implantation, 3297

- Animal model, head and neck cancer, saliva, recurrence, metastasis, circulating DNA, 191
- Animal models, circulating tumor cells, animal study, neoplasia, cancer detection, review, 6599
- Animal models, vitamin D, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, review, 527
- Animal study, circulating tumor cells, animal models, neoplasia, cancer detection, review, 6599
- Anogenital warts, high-risk HPV, smoking, sexually transmitted infection, *Mycoplasma genitalium*, *Mycoplasma hominis*, *Ureaplasma* spp, 2219
- Anoikis, triple-negative breast cancer, curcumol, skp2, 5529
- Anorectal function, rectal cancer, chemoradiotherapy, neoadjuvant, manometry, 2199
- ANRIL*, single nucleotide polymorphism, *ARF-INK4* locus, hematologic malignancies, allogeneic hematopoietic stem cell transplantation, 5707
- Anthracycline, acute myeloid leukemia, consolidation, 357
- Anti PD-1 inhibitor, older patients, non-small cell lung cancer, immune checkpoint inhibitor, overall survival, 923
- Anti-angiogenic activity, spiro-acridine, antitumor activity, immunomodulation, zebrafish, Ehrlich ascites carcinoma model, 5049
- Anti-angiogenic, aminonaphthoquinone, curcumin, combination, cytotoxic, anti-metastatic, 229
- Anti-beta glucan antibody, BTH1677, imprime PGG, immunoglobulin, immunotherapy, 1467
- Anti-cancer drug resistance, colorectal cancer, 5-fluorouracil, cK2 $\alpha$ , ER stress, 1419
- Anti-cancer drug resistance, prion protein, prPC, cancer stem cell characteristics, colorectal cancer, 5611
- Anti-cancer, flavonoid, PI3K, inhibitor, protein kinase, virtual screening, 4547
- Anti-diabetic medication, pancreatic ductal adenocarcinoma, cancer metabolism, combination therapy, polytherapy, 153
- Anti-hypertensive agent, hypertension, renal cell carcinoma, 4087
- Anti-inflammation, repetitive low-dose lipopolysaccharide, tissue-resident macrophages, phagocytosis, 4457
- Anti-metastatic, aminonaphthoquinone, curcumin, combination, cytotoxic, anti-angiogenic, 229
- Anti-migration, benzoxazine dimer analogue, non-small cell lung cancer, integrins, 2583
- Anti-PD-(L)1, chemotherapy, gastric cancer, immune checkpoint inhibitor, 2247
- Anti-PD-1 blockade, defective mismatch repair, colorectal cancer, microsatellite instability, Lynch syndrome, 4379
- Anti-PD-1, nivolumab, ipilimumab, pediatric cancer, malignant melanoma, brain tumor, 7095
- Anti-PDI/PD-L1 therapy, KRAS, NSCLC, immunotherapy, 427
- Anti-programmed cell death ligand-1 immune checkpoint inhibitor (ICIs), volumetric modulated arc therapy (VMAT), intensity modulated radiation therapy (IMRT), involved field radiotherapy irradiation (IFR-IFI), twice-daily thoracic radiotherapy (BID-TRT), accelerated hyperfractionated thoracic radiotherapy (AHTRT), 6957
- Antibiotics, nivolumab, non-small cell lung cancer, corticoids, proton pump inhibitors, NSAID, statins, metformin, 2209
- Antibody drug conjugate, ATL, HTLV-1, cancer chemotherapy, immunotherapy, 4471
- Anticancer drug target, proto-oncogene, c-Myc, lung cancer, review, 609
- Anticancer drug, colorectal cancer, corticotropin-releasing hormone, stress, 4505
- Anticancer drugs, bortezomib, neurotoxicity, PC12, differentiation, overlay method, NGF, protection, antioxidant, 3685
- Anticancer effect, breast cancer, hormone, calcium, src, 1989
- Anticancer, papuamine, alkaloid, mitochondria, 323
- Anticancer, persimmon leaf flavonoids, reactive oxygen species, apoptosis, antioxidant, 5201
- Anticoagulation treatment, esophageal cancer, bleeding, antiplatelet treatment, 2359
- Antimutagenic properties, grape stem extracts, greek vine varieties, antioxidants, polyphenols, bio-functional foods, 2025
- Antioxidant, anticancer drugs, bortezomib, neurotoxicity, PC12, differentiation, overlay method, NGF, protection, 3685
- Antioxidant, persimmon leaf flavonoids, anticancer, reactive oxygen species, apoptosis, 5201
- Antioxidants, grape stem extracts, greek vine varieties, antimutagenic properties, polyphenols, bio-functional foods, 2025
- Antiplatelet treatment, esophageal cancer, bleeding, anticoagulation treatment, 2359
- Antiproliferation effect, quercetin, apoptosis, hepatocellular carcinoma, 4695
- Antiproliferative effect, cold atmospheric plasma, cell growth inhibition, growth rate, 3743
- Antitumor activity, spiro-acridine, anti-angiogenic activity, immunomodulation, zebrafish, Ehrlich ascites carcinoma model, 5049
- Antitumor effect, glyoxalase 1, piceatannol, anxiolytic effect, 3271
- Anxiolytic effect, glyoxalase 1, piceatannol, antitumor effect, 3271
- AOM/DSS, IBD, colitis associated cancer, animal model, carcinogenesis, colorectal cancer, 5457
- Aortic reconstruction, retroperitoneal sarcoma, major vascular resection, 1049

- APAF-1, pancreatic cancer, DNA methylation, decitabine, 3765
- APC/C, MAD2L2, TNBC, 5471
- Apela, iodinated contrast agent, acute kidney injury, 635
- Apex1-Jagged-1 cascade, cisplatin, 5-FU, chemoresponsive, chemorefractory, chemoresistance, 1897
- Apo2L/TRAIL, nitric oxide, nuclear factor kappa B, inhibitor kappa B kinase, apoptosis, 6751
- Apoptosis, (+)-betulin, NF- $\kappa$ B, MDA-MB-231, zebrafish, 6637
- Apoptosis, amentoflavone, cisplatin, oral squamous cell carcinoma, NF- $\kappa$ B, 6723
- Apoptosis, apo2L/TRAIL, nitric oxide, nuclear factor kappa B, inhibitor kappa B kinase, 6751
- Apoptosis, breast cancer, methoxy poly(ethylene glycol)-poly(lactic-co-glycolic) acid, piperine, thin-film hydration, 689
- Apoptosis, cancer, cell cycle, cytotoxicity, gamma rays, platinum(IV) complexes, 5001
- Apoptosis, CARD14, proliferation, migration, breast cancer, 1953
- Apoptosis, cholesterol, head and neck squamous cell carcinoma, oxysterol, 25-hydroxycholesterol, 779
- Apoptosis, ciprofloxacin, cell cycle arrest, colorectal cancer, lung cancer, 2739
- Apoptosis, ciprofloxacin, colony formation, HeLa cells, migration ability, 5025
- Apoptosis, CLL, cofilin-1, CFL1, chemotaxis, migration, cell cycle, 6327
- Apoptosis, differentiation, human promyelocytic leukemia, HL-60 cells, garlic, diallyl sulfide, gas chromatography-mass spectrometry, 6345
- Apoptosis, ephemeranthol A, lung cancer, epithelial to mesenchymal transition (EMT), 4989
- Apoptosis, epithelial-to-mesenchymal transition, breast cancer, cancer epigenetics, DNMT inhibitors, HDAC inhibitors, phytochemicals, 9
- Apoptosis, FAS CD95, FAS ligand, caspase-3, TKI, nilotinib, dasatinib, erlotinib, gefitinib, everolimus, 6195
- Apoptosis, flavopereirine,  $\beta$ -carboline alkaloid, hepatocarcinoma, autophagy, cell-cycle arrest, 6907
- Apoptosis, glioblastoma, fucoxanthin, migration, invasion, angiogenesis, 6799
- Apoptosis, HIF1 $\alpha$ , vasculogenic mimicry, HIF1 inhibitors, acriflavine, 5379
- Apoptosis, LC3B-II, SQSTM1, chloroquine, miR-139, autophagy, beclin-1, mTOR, prostate cancer, 6649
- Apoptosis, melanoma, natural products, *E. piscocarpus*, photoprotection, spathulenol, 5015
- Apoptosis, melatonin, tongue squamous cell carcinoma, MTT, migration, invasion, autophagy, 6295
- Apoptosis, methylsulfonylmethane, cell cycle arrest, stemness, HT-29 cells, 5191
- Apoptosis, multiple myeloma, gene expression, myeloma cell lines, 4979
- Apoptosis, myeloid cell leukemia-1, non-small cell lung cancer, prognosis, survival, 1007
- Apoptosis, N, n'-(arylmethylene)biscinnamide, caspase, death receptor 5, cancer cells, 5035
- Apoptosis, nitric oxide, HNSCC human head and neck cell, isogenic cell lines, cell proliferation, invasiveness, matrix metalloproteinases, 2657
- Apoptosis, ovarian epithelial cancer, LRRC17, survival analysis, zebrafish, gene expression omnibus, TCGA, 5601
- Apoptosis, pancreatic neuroendocrine tumor, metformin, cell cycle, microRNA, 121
- Apoptosis, peroxisome proliferator-activated receptor  $\gamma$ , troglitazone, oral SCC, G1 arrest, 1247
- Apoptosis, persimmon leaf flavonoids, anticancer, reactive oxygen species, antioxidant, 5201
- Apoptosis, quercetin, antiproliferation effect, hepatocellular carcinoma, 4695
- Apoptosis, small cell lung carcinoma, sclareol, cell cycle, DNA damage, xenograft, 4947
- Apoptotic death, cell death mode, lipid rafts, necrotic death, 2573
- Apparent diffusion coefficient, neoadjuvant therapy, score, multimodality, 4033
- Appleby procedure, distal pancreatectomy, outcome, 387
- Areca nut, autophagy, nude mice, 3-methyladenine, chloroquine, cisplatin, 221
- ARF-INK4* locus, *ANRIL*, single nucleotide polymorphism, hematologic malignancies, allogeneic hematopoietic stem cell transplantation, 5707
- Array comparative genomic hybridisation, chromophobe renal cell carcinoma, eosinophilic variant, chromosome alteration, 6863
- Artificial intelligence, <sup>18</sup>F-FDG PET/CT, non-small-cell lung cancer, MIB-1, 3355
- Artificial intelligence, deep learning, machine learning, neural network, ovarian cancers, ovarian tumor, blood test, 4795
- Aryl hydrocarbon receptor, bladder cancer, carcinogenesis, 1345
- Ascites, tru-Cut biopsy, ovarian cancer, puncture, 3527
- Ascorbate, menadione, cancer, mitochondria, superoxide, succinate, 1963
- Asian Americans, gastric cancer, survival outcomes, 6381
- Assay development, cancer prevention, vitamin D metabolites, stereoselective synthesis, review, 519
- Asymptomatic, endometrial polyps, postmenopausal, malignancy, PTEN, 789
- ATL, HTLV-1, antibody drug conjugate, cancer chemotherapy, immunotherapy, 4471

- ATP-binding cassette transporter 11, colon cancer, 5-fluorouracil, prognosis, 5405
- ATR, catalytic topo I inhibitor, cyclin D1 accumulation, PTEN, akt, gSK-3 $\beta$ , 6237
- Attention deficit hyperactivity disorder, autism spectrum disorder, *Pantoea agglomerans* bacteria derived LPS, oral administration, 4755
- Atypical endometrial hyperplasia, endometrial cancer, hysterectomy, magnetic resonance imaging, preoperative procedure, 2989
- Atypical urothelial cell, urine, cytology, the Paris System, high-grade urothelial carcinoma, low-grade urothelial neoplasm, 3477
- Autism spectrum disorder, attention deficit hyperactivity disorder, *Pantoea agglomerans* bacteria derived LPS, oral administration, 4755
- Auto-delineation, positron emission tomography, radiotherapy planning, gross tumour volume, digital positron emission tomography, 2567
- Autophagy, areca nut, nude mice, 3-methyladenine, chloroquine, cisplatin, 221
- Autophagy, flavopereirine,  $\beta$ -carboline alkaloid, hepatocarcinoma, apoptosis, cell-cycle arrest, 6907
- Autophagy, LC3B-II, SQSTM1, apoptosis, chloroquine, miR-139, beclin-1, mTOR, prostate cancer, 6649
- Autophagy, melanoma, biomarker, BNIP3L, melanoma vaccine, 3723
- Autophagy, melatonin, tongue squamous cell carcinoma, MTT, migration, invasion, apoptosis, 6295
- Autophagy, niclosamide, caspase-independent pathway, aMPK/AKT/mTOR pathway, NSCLC, 1405
- Autophagy, non-small cell lung cancer, radiotherapy, histone modification, GABARAPL1, 2537
- AUY922, thyroid carcinoma, HSP90 inhibitor, BIIB021, SNX5422, bim, 6137
- Axial bone sarcomas, carbon ion radiotherapy, soft tissue sarcomas, hadrontherapy, 2853
- Axillary disease, breast cancer, neo-adjuvant chemotherapy, sentinel node biopsy, review, 5351
- Axillary ultrasound, BMI, breast cancer, predictive value, 7083
- Axitinib, nivolumab, metastatic renal cell carcinoma, immune checkpoint inhibitor, 6493
- AXL expression, conventional RCC, immunohistochemistry, tumor progression, 3485
- AZD7762, temozolomide, cytotoxicity, glioma, 5141
- AZT, ovarian cancer, cell cycle arrest, chemotherapy, p21, p16, 5517
- Barbituric acid, cytotoxicity, *in vivo* tumor model, lung cancer, thiobarbituric acid, 6039
- Barrett's esophagus, russell body esophagitis, russell body gastritis, Mott cells, 3991
- Barrier, sarcoma, extraskeletal myxoid chondrosarcoma, 1035
- Basic magnetic resonance imaging, medulloblastoma, ependymoma, predictive model, 2975
- Bauhin's valve, ileocecal valve, colorectal cancer, small bowel adenocarcinoma, 4053
- BcR gene recombinations, IGK, lung adenocarcinoma, tumor specimen exomes, CD19, CD20, CD79 B-cell markers, survival rates, 2043
- BCR-ABL1*, CML, TKI, resistance, efficacy, review, 2457
- BCR-ABL1*, imatinib, chronic myeloid leukemia, dasatinib, second-line treatment, TKI, 5313
- BCR, bromodomain (BRD), BET inhibitor, sYK inhibitor, lymphoma, canine DLBCL, 3781
- Beclin-1, LC3B-II, SQSTM1, apoptosis, chloroquine, miR-139, autophagy, mTOR, prostate cancer, 6649
- Benign disease, cancer, lipid peroxidation, plasma malonaldehyde, pain following surgery, 253
- Benzoxazine dimer analogue, anti-migration, non-small cell lung cancer, integrins, 2583
- Beraprost sodium, liver sinusoidal endothelial cells, liver transplantation, oxaliplatin based chemotherapy, sinusoidal obstruction syndrome, veno-occlusive disease, 5171
- Best supportive care, salvage chemotherapy, immune checkpoint inhibitor, nivolumab, head and neck carcinoma, recurrent or metastatic, 5277
- BET inhibitor, BCR, bromodomain (BRD), sYK inhibitor, lymphoma, canine DLBCL, 3781
- Betel quid, alcohol drinking, genotype, interleukin-12A, oral cancer, polymorphism, smoking, Taiwan, 3707
- Betulin, acetylenic synthetic betulin derivatives, chemotherapy, glioma, 6151
- Bevacizumab, advanced non-squamous non-small cell lung cancer, amrubicin, efficacy, prospective study, 1571
- Bevacizumab, disease progression, continuous administration, recurrent ovarian cancer, progression-free survival, 5285
- Bevacizumab, epithelial ovarian cancer; primary debulking surgery, chemotherapy, paclitaxel; carboplatin, complete response, recurrence, 1543
- Bevacizumab, erlotinib, tumor metrics, non-small cell lung cancer, Hellenic Cooperative Oncology Group, 2095
- Bevacizumab, FTD/TPI, TAS-102, 4157
- Bevacizumab, maintenance therapy, nonsquamous non-small cell lung cancer, pemetrexed, bevacizumab+pemetrexed, 2981
- Bevacizumab+pemetrexed, maintenance therapy, nonsquamous non-small cell lung cancer, pemetrexed, bevacizumab, 2981
- Bicarbonate, pancreatic cancer, alkalization therapy, tumor microenvironment, alkaline diet, urine pH, 873
- BIIB021, thyroid carcinoma, HSP90 inhibitor, AUY922, SNX5422, bim, 6137
- Bile leakage, complication, liver surgery, 401
- Biliary tract cancer, cholangiocarcinoma, targeted therapy, chemotherapy, second-line, review, 3013

- Biliary tract cancer, neutrophil-to-lymphocyte ratio, tumor infiltrating lymphocytes, 2881
- Biliary tract cancers, radiotherapy, chemoradiation, brachytherapy, cholangiocarcinoma, 3417
- Biliary tract carcinoma, gemcitabine, pazopanib, phase II study, 929
- Bim, thyroid carcinoma, HSP90 inhibitor, AUY922, BIIB021, SNX5422, 6137
- Bio-functional foods, grape stem extracts, greek vine varieties, antioxidants, antimutagenic properties, polyphenols, 2025
- Biochemical recurrence, SSEA-4, neoadjuvant hormonal therapy, histological effect, prostate cancer, 5567
- Bioelectrical impedance analysis, lung cancer, ECW/TBW, prognostic factor, 3931
- Bioinformatics, uveal melanoma, the Cancer Genome Atlas, gene Expression Omnibus, prognosis, 3839
- Biological pathways, left-sided colorectal cancer, right-sided colorectal cancer, microRNA, 3713
- Biomarker test, *Helicobacter pylori*, hp IgG ELISA, gastroPanel, new-generation, clinical validation, non-invasive, gastroscopy, biopsy, pepsinogen I, pepsinogen II, gastrin-17, 6387
- Biomarker, breast cancer, platelet–lymphocyte ratio, sentinel lymph node biopsy, blood test, 2343
- Biomarker, gastric cancer, *AMIGO2*, prognosis, 6713
- Biomarker, glial tumors, glioblastoma, microRNA, miRNA-221, 3265
- Biomarker, immunohistochemistry, knockdown, myoferlin, renal cell carcinoma, 3119
- Biomarker, integration, fusion gene, HBV S, human ESPL1, hepatocellular carcinoma, 245
- Biomarker, interferon-gamma release, immune checkpoint inhibitor, non-small-cell lung cancer, time to treatment failure, 6971
- Biomarker, intraductal papillary mucinous neoplasms, iPMN-derived carcinoma, pancreatic ductal adenocarcinoma, microarray, 6551
- Biomarker, lung cancer, pulmonary metastases, colorectal carcinoma, surgery, prognosis, 7045
- Biomarker, melanoma, BNIP3L, autophagy, melanoma vaccine, 3723
- Biomarker, OSCC, fibrosis, bMF, tumor microenvironment, 4319
- Biomarker, pancreatic cancer, 5-aminolevulinic acid, photodynamic screening, 3571
- Biomarker, pancreatic cancer, eukaryotic translation initiation factors, pI3K/AKT/mTOR pathway, 3109
- Biomarker, PD-L1, breast cancer, liquid biopsy, recurrence, 3733
- Biomarker, proteomics, squamous intraepithelial lesion, specificity, sensitivity, 6273
- Biomarker, *SLC22A16*, *rs714368*, cytotoxic chemotherapy, 4245
- Biomarkers, exosomes, extracellular vesicles, miRNA, breast cancer, tears, 3091
- Biomarkers, hepatocellular carcinoma, surveillance, screening, diagnosis, tumor biology, liver tumors, review, 6573
- Biomarkers, immune checkpoint inhibition, immunotherapy, 2821
- Biomarkers, inflammatory cytokines, rhenium, selenium, cancer cells, 1915
- Biophoton, chemo brain, tryptophan, kynurenine, NAD, tubulin, cognition, review, 1189
- Biopsy, fine-needle, large-core needle, pancreatic neoplasms, endosonography, 5845
- Biopsy, *Helicobacter pylori*, hp IgG ELISA, gastroPanel, new-generation, clinical validation, non-invasive, biomarker test, gastroscopy, pepsinogen I, pepsinogen II, gastrin-17, 6387
- Biosynthesis, n-farnesyl-norcantharimide, jurkat T cells, next-generation sequencing, tumor suppressor gene, 2675
- Biotin-dependent carboxylases, holocarboxylase synthetase, biotin, breast cancer, metabolism, 4557
- Biotin, holocarboxylase synthetase, biotin-dependent carboxylases, breast cancer, metabolism, 4557
- Biweekly dosing, mCRPC, cabazitaxel, postdocetaxel, 6915
- Biweekly, cetuximab, metastatic colorectal cancer, weekly, 3469
- Bladder cancer, aryl hydrocarbon receptor, carcinogenesis, 1345
- Bladder cancer, bruton’s tyrosine kinase, chemotherapy, drug resistance, cytotoxicity, 6093
- Bladder cancer, case–control study, genotype, *NBS1*, polymorphism, 2011
- Bladder cancer, chloride intracellular channel protein 1 (CLIC1), immunohistochemistry, potential therapeutic target, prognosis, 6879
- Bladder cancer, circulating tumor cells, transurethral resection of bladder tumor, 4299
- Bladder cancer, immunocellular therapy, gamma/delta T-cell, chemotherapy, cytotoxicity, 5221
- Bladder cancer, orthotopic, nude mice, GFP, cisplatin, oral recombinant methioninase, combination, sensitize, efficacy, 6083
- Bladder cancer, radiotherapy, chemoradiotherapy, neoadjuvant chemotherapy, bladder sparing, 5861
- Bladder cancer, tumor-associated macrophages, cell growth, cell migration, cell invasion, cytokines, tumor microenvironment, 2715
- Bladder cancer, UBC Rapid, tumor markers, 3967
- Bladder sparing, bladder cancer, radiotherapy, chemoradiotherapy, neoadjuvant chemotherapy, 5861
- Bladder, large cell neuroendocrine carcinoma, kidney, ureter, review, 2439

- Bleeding, esophageal cancer, antiplatelet treatment, anticoagulation treatment, 2359
- Bleeding, metastatic spinal cord compression, spinal surgery, spinal metastases, vertebral metastases, operation time, minimal access surgery, 5673
- Blood parameters, NSCLC, chemoradiotherapy, survival, prognostic factor, 2319
- Blood test, artificial intelligence, deep learning, machine learning, neural network, ovarian cancers, ovarian tumor, 4795
- Blood test, breast cancer, platelet–lymphocyte ratio, sentinel lymph node biopsy, biomarker, 2343
- Blood, EWAS, normal breast tissue, DNA methylation, obesity, body mass index, breast cancer, epigenetic biomarkers, review, 1797
- BMF, OSCC, fibrosis, biomarker, tumor microenvironment, 4319
- BMI, breast cancer, axillary ultrasound, predictive value, 7083
- BMI1, PTC209, inhibition, cervical cancer, cancer stem cell, 133
- BNIP3L, melanoma, biomarker, autophagy, melanoma vaccine, 3723
- Body mass index, EWAS, normal breast tissue, blood, DNA methylation, obesity, breast cancer, epigenetic biomarkers, review, 1797
- Body mass index, melanoma, sarcopenia, pembrolizumab, monoclonal antibodies, retrospective studies, clinical decision-making, drug-related side effects, adverse reactions, 5245
- Bolus, breast cancer, clinical practice, mastectomy, radiotherapy, 6505
- Bone marrow infiltration, breast cancer, weekly paclitaxel, erythroblastic blood smear, 2955
- Bone metastases, breast cancer, survival probability, radiotherapy, scoring instrument, 367
- Bone metastases, colorectal cancer, radiotherapy, survival, prognostic score, 287
- Bone mineral density, vascular malformation, intraosseous, haemangioma, orbit, cone beam computed tomography, 3D reconstruction, immunohistochemistry, differential diagnosis, 3333
- Bone scintigraphy, chondrosarcoma, skeletal metastases, PET-CT, staging, 5735
- Bone tumor, extremity, postoperative deep infection, risk factor, multivariate analysis, 3551
- Bone tumor, sarcoma, chondrosarcoma, chest wall, sternum, 1519
- Boost, glioblastoma, fractionated stereotactic radiotherapy, toxicity, survival, 3387
- Bortezomib, anticancer drugs, neurotoxicity, PC12, differentiation, overlay method, NGF, protection, antioxidant, 3685
- Bovine mastitis, low-molecular-weight whey protein, macrophages, cytokines, 4701
- Bowel cancer, colorectal cancer, polyps, NICE Guidelines, colonoscopy, 1705
- Brachytherapy, prostate cancer, HDR-BT, daily replanning, 1677
- Brachytherapy, prostate cancer, health-related quality of life, 6443
- Brachytherapy, radiotherapy, biliary tract cancers, chemoradiation, cholangiocarcinoma, 3417
- BRAFmutation, pan-RAF inhibitor, LY3009120, non-small cell lung cancer, 2667
- BRAFV600E, melanoma, 3PO, A375, inhibitor, PFKFB3, 2613
- Brain metastases, cancer of unknown primary, patients aged  $\geq 65$  years, whole-brain irradiation, remaining lifespan, 2261
- Brain metastases, elderly patients, esophageal cancer, whole-brain irradiation, survival, scoring tool, 1661
- Brain metastases, non-small cell lung cancer, surgical resection, molecularly targeted therapy, 4801
- Brain metastases, older patients, local therapies, whole-brain radiotherapy, overall survival, extra-cerebral metastasis, 2841
- Brain metastases, palliative radiotherapy, whole-brain radiotherapy, supportive care, prognostic factors, 977
- Brain metastases, radiosurgery, stereotactic radiotherapy, seizures, 3499
- Brain metastases, seizures, whole-brain irradiation, prevalence, risk factors, survival, 3429
- Brain metastasis, breast cancer, survival, prognosis, surgical resection, molecular subtype, 1759
- Brain metastasis, gynecological cancer, elderly, whole-brain irradiation, survival prognosis, 2257
- Brain tumor, adaptive radiotherapy, replanning, gliomas, 4237
- Brain tumor, cognition, DNA microarray, neuroimmunity, regulation of actin cytoskeleton, 4719
- Brain tumor, glioblastoma, kisspeptin, KISS1, KISS1R, 213
- Brain tumor, neuropilin, cytokine-induced killer cells, immunology, lung cancer, flow cytometry, 5489
- Brain tumor, nivolumab, ipilimumab, anti-PD-1, pediatric cancer, malignant melanoma, 7095
- Breast cancer cell lines, TNBC, tamoxifen, 1, 4 naphthoquinone, 6623
- Breast cancer risk, matrix metalloproteinases, gelatinases, polymorphisms, circulating levels, review, 3619
- Breast cancer therapy, seroma formation, drainage, drain-free mastectomy, surgical adhesive, tissuGlu<sup>®</sup>, dead space reduction, 2801
- Breast cancer, ABHD12, proliferation, migration, invasion, 2601
- Breast cancer, absolute lymphocyte count, c-reactive protein, eribulin, overall survival, 4147

- Breast cancer, activating transcription factor 4, cysteine, hypoxia, sulfasalazine, tumor necrosis factor-related apoptosis-inducing ligand, 1387
- Breast cancer, adjuvant aromatase inhibitor, postmenopausal, adherence, 857
- Breast cancer, apoptosis, epithelial-to-mesenchymal transition, cancer epigenetics, DNMT inhibitors, HDAC inhibitors, phytochemicals, 9
- Breast cancer, apoptosis, methoxy poly(ethylene glycol)-poly(lactic-co-glycolic) acid, piperine, thin-film hydration, 689
- Breast cancer, BMI, axillary ultrasound, predictive value, 7083
- Breast cancer, bolus, clinical practice, mastectomy, radiotherapy, 6505
- Breast cancer, bone marrow infiltration, weekly paclitaxel, erythroblastic blood smear, 2955
- Breast cancer, brain metastasis, survival, prognosis, surgical resection, molecular subtype, 1759
- Breast cancer, C-X-C motif chemokine ligand 12, C-X-C motif chemokine receptor 4, tumor marker, 3221
- Breast cancer, cancer stem cell, ALDH1A3, c-Met, pKCL, 35
- Breast cancer, CARD14, proliferation, apoptosis, migration, 1953
- Breast cancer, contrast-enhanced spectral mammography (CESM), mammography (MG), 2925
- Breast cancer, COVID-19, screening suspension, lockdown, oncological treatments delay, 7119
- Breast cancer, cytokines, regulatory T-lymphocytes, natural killer cells, 3D culture, 6179
- Breast cancer, dedicated breast PET, FDG, abnormal uptake, classification, 3491
- Breast cancer, e-cadherin, p-cadherin, molecular subtypes, 5557
- Breast cancer, eosinophil percentages, infusion reaction, trastuzumab, 4047
- Breast cancer, ER positive, ER targeting, elacestrant, FGFR inhibitors, venetoclax, review, 4829
- Breast cancer, eribulin, tGF- $\beta$ , tILs, ALC, tumour microenvironment, 3345
- Breast cancer, EWAS, normal breast tissue, blood, DNA methylation, obesity, body mass index, epigenetic biomarkers, review, 1797
- Breast cancer, exosomes, extracellular vesicles, miRNA, biomarkers, tears, 3091
- Breast cancer, fGD<sub>3</sub> gene, prognostic factor, precision medicine, review, 3645
- Breast cancer, genotype, interleukin-13, polymorphism, Taiwan, 6743
- Breast cancer, ginseng seed oil, oleic acid, ER+, tamoxifen, 4529
- Breast cancer, *HER2* gene amplification, *TP53* mutation, estrogen receptor, early recurrence, 645
- Breast cancer, *HER2*, trastuzumab, 3315
- Breast cancer, holocarboxylase synthetase, biotin-dependent carboxylases, biotin, metabolism, 4557
- Breast cancer, hormone, calcium, src, anticancer effect, 1989
- Breast cancer, kallikreins, kallikrein-related peptidases, gene expression, cluster analysis, 2487
- Breast cancer, ketogenic diet, ketone bodies, acetoacetate, lithium, 3831
- Breast cancer, MCF-7, mesenchymal stem cells, TRAIL, 5641
- Breast cancer, molecular subtypes, immunohistochemistry, IGF1R, 1555
- Breast cancer, neo-adjuvant chemotherapy, sentinel node biopsy, axillary disease, review, 5351
- Breast cancer, neoadjuvant chemotherapy, complete pathological response, MRI accuracy, histological examination, 281
- Breast cancer, neoadjuvant chemotherapy, predict pCR, 2303
- Breast cancer, neoadjuvant chemotherapy, tumor-infiltrating lymphocyte, 1883
- Breast cancer, neutrophil-to-lymphocyte ratio, tumour-infiltrating lymphocytes, prognosis, 2871
- Breast cancer, nipple discharge, galactoscopy, mammary ductoscopy, endoscopic classification, 2185
- Breast cancer, nipple-sparing mastectomy, breast MRI, 3543
- Breast cancer, PAX8, immunohistochemistry, 5925
- Breast cancer, PD-L1, biomarker, liquid biopsy, recurrence, 3733
- Breast cancer, pedicled rotation flap, locoregional recurrence, 5739
- Breast cancer, pegfilgrastim, relative dose intensity, febrile neutropenia, FEC-100, 915
- Breast cancer, PET, SUV, tumor-infiltrating lymphocyte, neoadjuvant chemotherapy, pathological complete response, 3395
- Breast cancer, physical exercise, oncological rehabilitation, quality of life, fatigue, 4253
- Breast cancer, platelet distribution width, plateletcrit, prognostic factor, 3947
- Breast cancer, platelet-lymphocyte ratio, sentinel lymph node biopsy, biomarker, blood test, 2343
- Breast cancer, prognostic parameters, GATA3, ki-67, 5649
- Breast cancer, prolactin receptor, prostate cancer, 5229
- Breast cancer, radiotherapy, cardiotoxicity, mean heart dose, LAD, LV, echocardiography, 3003
- Breast cancer, SAVI SCOUT, reflector localization, non-wire localization, 3915
- Breast cancer, savi Scout<sup>®</sup>, reflector-guided localisation, radar localisation, non-wire localisation, non-palpable breast lesions, review, 3633
- Breast cancer, sentinel lymph node, intraoperative frozen section, 1711
- Breast cancer, sentinel node biopsy, metastasis, platelet-to-lymphocyte ratio, 4405

- Breast cancer, surgical resection, recurrence, methionine restriction, recombinant methioninase, lung metastasis, inhibition, adjuvant therapy, 4869
- Breast cancer, survival probability, radiotherapy, bone metastases, scoring instrument, 367
- Breast cancer, systems biology, network pharmacology, herbal, combination, pharmacological mechanism, 5097
- Breast cancer, thyroid gland, TSH, FT3, FT4, silencing mediator for retinoid and thyroid receptors, prognosis, 6417
- Breast cancer, triple negative breast cancer, TNBC subtypes, ultrasound, clinical imaging, 2125
- Breast cancer, tumor infiltrating lymphocytes, FOXP3, CD8, 2141
- Breast cancer, vacuum-assisted excision, vacuum-assisted breast biopsy, ultrasound, breast lesions, lesions of uncertain malignant potential, 1719
- Breast conserving surgery, neoadjuvant chemotherapy, long-term outcome, down-staging, tumor shrinkage, recurrence, 1079
- Breast lesions, vacuum-assisted excision, vacuum-assisted breast biopsy, ultrasound, lesions of uncertain malignant potential, breast cancer, 1719
- Breast MRI, breast cancer, nipple-sparing mastectomy, 3543
- Breast neoplasm, healthcare use, second primary neoplasms, treatment, 1041
- Breast surgery, pecs block, regional anesthesia, modified radical mastectomy, postoperative pain, nonphysician anesthesia provider, 2231
- Breast, cancer, colon, colorectal, ecological, mendelian randomization, prostate, ultraviolet B, UVB, 25-hydroxyvitamin D, review, 491
- Breast, triple-negative breast carcinoma, programmed death ligand 1, intratumoral immune cells, 1487
- Broad gene expression, vitamin D, supplementation, metabolomics, genomics, metabolomic profile, individual response, personalized medicine, 25-hydroxyvitamin D, 535
- Bromodomain (BRD), BCR, BET inhibitor, SYK inhibitor, lymphoma, canine DLBCL, 3781
- Bruton's tyrosine kinase, bladder cancer, chemotherapy, drug resistance, cytotoxicity, 6093
- BSA heat denaturation, oxazolidinones, neuroblastoma, kelly cell line, proliferation, progression, adhesion, fibronectin, 5125
- BTH1677, imprime PGG, anti-beta glucan antibody, immunoglobulin, immunotherapy, 1467
- Bursting pressure, stapled anastomosis, triangulating anastomosis, 1891
- C-Met, cancer stem cell, breast cancer, ALDH1A3, pKCL, 35
- C-Myc, proto-oncogene, lung cancer, anticancer drug target, review, 609
- C-reactive protein to albumin ratio, esophageal cancer, overall survival, recurrence, 2365
- C-reactive protein, breast cancer, absolute lymphocyte count, eribulin, overall survival, 4147
- C-reactive protein, platelet distribution width, esophageal cancer, 5715
- C-reactive protein, tumor marker, inflammation index, carcinoembryonic antigen, novel index, non-small cell lung cancer, surgery, prognosis, 4023
- C-X-C motif chemokine ligand 12, breast cancer, C-X-C motif chemokine receptor 4, tumor marker, 3221
- C-X-C motif chemokine receptor 4, breast cancer, C-X-C motif chemokine ligand 12, tumor marker, 3221
- Ca 72.4, gastric cancer, tumor antigen, gastric juice, gastrectomy, 1691
- Cabazitaxel, abiraterone, androgen receptor, docetaxel, enzalutamide, prostate cancer, 335
- Cabazitaxel, castration-resistant prostate cancer, inhibitor of apoptosis proteins, drug therapy, YM155, survivin, 5091
- Cabazitaxel, mCRPC, postdocetaxel, biweekly dosing, 6915
- Cabazitaxel, platinum-resistance, recurrent ovarian cancer, chemotherapy, phase II randomized study, 5255
- Cabozantinib, Ewing sarcoma, metastatic, 2265
- Cabozantinib, metastatic renal cell carcinoma, RCC, polycystic liver disease, liver cyst, pazopanib, 1527
- CAK cells, CD155, KRAS, TNK cells, PD-1, TIGIT, 3D culture, 4663
- Calcitriol, chemotherapy, 5-fluorouracil, vitamin D analogs, tacalcitol, 837
- Calcium, breast cancer, hormone, src, anticancer effect, 1989
- Calpain, THP-1 macrophages, serum-MAF,  $\gamma$ -globulin, talin-1, time-lapse imaging, morphological change, 4707
- CAML, esophageal cancer adenocarcinoma, circulating tumor cells, cytopathology, heterogeneity, 5679
- Cancer cachexia, nivolumab, gastric cancer, overall survival, time to treatment failure, 7067
- Cancer cell membrane, leukemia, PNC-27, HDM-2, 4857
- Cancer cells, inflammatory cytokines, biomarkers, rhenium, selenium, 1915
- Cancer cells, N, n'-(arylmethylene)biscinnamide, apoptosis, caspase, death receptor 5, 5035
- Cancer chemotherapy, ATL, HTLV-1, antibody drug conjugate, immunotherapy, 4471
- Cancer chemotherapy, modelling and simulation, chronopharmacokinetics, translational research, therapeutic drug monitoring, 5-FU prodrug, pharmacometrics, review, 6585
- Cancer detection, circulating tumor cells, animal models, animal study, neoplasia, review, 6599
- Cancer epigenetics, apoptosis, epithelial-to-mesenchymal transition, breast cancer, DNMT inhibitors, HDAC inhibitors, phytochemicals, 9
- Cancer immunotherapy, time-restricted feeding, high-fat diet, 5445



- Cancer metabolism, pancreatic ductal adenocarcinoma, combination therapy, polytherapy, anti-diabetic medication, 153
- Cancer of unknown primary, brain metastases, patients aged  $\geq 65$  years, whole-brain irradiation, remaining lifespan, 2261
- Cancer patient donors, cornea, corneal transplantation, CD44, chemotherapy, 6885
- Cancer patients, methioninase, oral, methionine, methionine restriction prostate cancer, PSA, ovarian cancer, supplement, 2813
- Cancer prevention, vitamin D metabolites, assay development, stereoselective synthesis, review, 519
- Cancer stem cell characteristics, prion protein, prPC, anti-cancer drug resistance, colorectal cancer, 5611
- Cancer stem cell,  $\gamma\delta$  T cell, immunotherapy, prostate cancer, sphere, prostasphere, CD133, NANOG, SOX2, OCT4, 5481
- Cancer stem cell, breast cancer, ALDH1A3, c-Met, pKCl, 35
- Cancer stem cell, colorectal cancer, ABC transporter, prognosis, 4481
- Cancer stem cell, non-small-cell lung cancer, prognostic marker, 6407
- Cancer stem cell, PTC209, BMI1, inhibition, cervical cancer, 133
- Cancer stem cells eradication, RLS lymphosarcoma, cyclophosphamide, double-stranded DNA, secondary ascites, 795
- Cancer stem cells, colorectal cancer, stemness, COLO 201 cells, cD44-positive cancer cells, 169
- Cancer stem cells, natural killer cells, immunotherapy, colorectal cancer, immune evasion, 6613
- Cancer stem cells, pancreatic cancer, cancer-associated fibroblasts, tumor dissociation, FACS, 1267
- Cancer survivor, whole brain radiotherapy, hypothalamic-pituitary dysfunction, endocrine late effects, 5787
- Cancer therapy, microbiome, lung cancer, carcinogenesis, review, 4807
- Cancer treatment-induced pain, pancreatic cancer, pain, pancreatic cancer treatment, pancreatic cancer pain, 1789
- Cancer treatment, hypoxia, setanaxib, oxidative stress, liver cancer, 5071
- Cancer-associated fibroblasts, pancreatic cancer, cancer stem cells, tumor dissociation, FACS, 1267
- Cancer-associated thrombosis, hepatocellular carcinoma, superior mesenteric vein thrombosis, direct oral anticoagulant, liver resection, 6465
- Cancer-associated thrombosis, thrombosis, low molecular weight heparin, LMWH, CAT, incidental CAT, symptomatic CAT, 305
- Cancer-specific survival, younger colorectal cancer, propensity score matching, 4365
- Cancer, angiosarcoma, hemangiosarcoma, gynaecology, uterine sarcoma, ovarian sarcoma, chemotherapy, paclitaxel, laparotomy, osseous metastasis, 5743
- Cancer, apoptosis, cell cycle, cytotoxicity, gamma rays, platinum(IV) complexes, 5001
- Cancer, benign disease, lipid peroxidation, plasma malonidialdehyde, pain following surgery, 253
- Cancer, breast, colon, colorectal, ecological, mendelian randomization, prostate, ultraviolet B, UVB, 25-hydroxyvitamin D, review, 491
- Cancer, ccl18 protein, gpr30, epithelial-mesenchymal transition (EMT), metastasis, 3097
- Cancer, ephrin receptor B2, meta-analysis, prognosis, 4309
- Cancer, gallstone disease, surgery, plasma MDA, plasma CAT, NRS pain score, 5701
- Cancer, glucan, phagocytosis, IL-2, infection, 3139
- Cancer, hybrid, minimally-invasive, esophagectomy, esophageal, 1753
- Cancer, luteolin, Hodgkin's lymphoma, mix cellularity classical Hodgkin's lymphoma, 4907
- Cancer, menadione, ascorbate, mitochondria, superoxide, succinate, 1963
- Cancer, multidrug resistance, t-lymphoma, phenothiazines, selenoesters, selenoanhydride, combination chemotherapy, 4921
- Cancer, multiple myeloma, interleukin-8, sRAGE, oxidative stress, gender, 1443
- Cancer, muscle mass loss, sarcopenia, skeletal muscle index, meta-analysis, review, 2409
- Cancer, nasopharyngeal, CT, MRI, sNPs, polymorphism, variations, genotype, VEGFA, EDNRA *NBS1*, FAS, 677
- Cancer, pBMCs, humanized mice, immunotherapy, immunoncology, review, 5329
- Cancer, radiotherapy, palliative treatment, oligometastases, symptom score, 1551
- Cancer, zenithal natural killer cells, immune cell therapy, phase I/IIa study, 5687
- Cancer, zyxin, LIM domain proteins, review, 5981
- Canine DLBCL, BCR, bromodomain (BRD), BET inhibitor, sYK inhibitor, lymphoma, 3781
- Capecitabine, 5-FU prodrugs, therapeutic drug monitoring, personalized treatment, review, 4655
- Capecitabine, pancreatic cancer, chemotherapy, cisplatin, gemcitabine, docetaxel, 4011
- Carbon ion radiotherapy, axial bone sarcomas, soft tissue sarcomas, hadrontherapy, 2853
- Carbon ion radiotherapy, intensity-modulated radiotherapy, hepatocellular carcinoma, vascular invasion, 459
- Carbon-ion beams, linear energy transfer, cell-killing effect, radiosensitizing effect, HeLa cells, 5497
- Carbon-ion radiotherapy, non-small-cell lung cancer, effectiveness, stage III, toxicity, 379

- Carboplatin, vitamin D, 1, 25-D<sub>3</sub>, ovarian cancer, *in vitro*, paclitaxel, growth inhibition, VDR, 3129
- Carcinoembryonic antigen, tumor marker, inflammation index, c-reactive protein, novel index, non-small cell lung cancer, surgery, prognosis, 4023
- Carcinogenesis, alcohol dehydrogenase isoenzymes, aldehyde dehydrogenase, lung cancer, 3857
- Carcinogenesis, AOM/DSS, IBD, colitis associated cancer, animal model, colorectal cancer, 5457
- Carcinogenesis, bladder cancer, aryl hydrocarbon receptor, 1345
- Carcinogenesis, microbiome, lung cancer, cancer therapy, review, 4807
- Carcinogenesis, oncogenes, tumor-suppressor genes, signaling pathways, review, 6009
- Carcinogenesis, ulcerative colitis, mtDNA, 101
- Carcinogenicity, pesticide, lymphoma, ecologic, 5423
- Carcinoma of the breast, secondary brain lesions, older persons, radiation therapy, survival analyses, 2271
- Carcinoma of the uterine cervix, neuroendocrine carcinoma, immunotherapy, cellular immunotherapy, adoptive immunotherapy, t-cells, 4741
- Carcinoma, gallbladder, IMP3, immunohistochemistry, prognosis, 5777
- Carcinoma, larynx, topoisomerase, immunohistochemistry, digital image analysis, 807
- Carcinoma, oral, chromosome, polysomy, grid, microscopy, 3759
- Carcinoma, periostin, stemness, metastasis, angiogenesis, lymphangiogenesis, chondrosarcoma, 5463
- Carcinosarcoma, endometrial neoplasms, microsatellite instability, pembrolizumab, radiotherapy, abscopal effect, 4131
- CARD14, proliferation, apoptosis, migration, breast cancer, 1953
- Cardiotoxicity, breast cancer, radiotherapy, mean heart dose, LAD, LV, echocardiography, 3003
- Carnitine, HCC, sorafenib, sarcopenia, liver cirrhosis, 4173
- Case-control study, oral squamous cell carcinoma, OSCC, risk factors, young adults, survival analysis, smoking, alcohol consumption, 6987
- Case-control study, acute lymphocytic leukemia, childhood, genotype, *MMP-9*, polymorphism, Taiwan, 5751
- Case-control study, bladder cancer, genotype, *NBS1*, polymorphism, 2011
- Case-control study, caspase-8, genotype, nasopharyngeal carcinoma, polymorphism, Taiwan, 5503
- Caspase-3, FAS CD95, FAS ligand, TKI, apoptosis, nilotinib, dasatinib, erlotinib, gefitinib, everolimus, 6195
- Caspase-8, case-control study, genotype, nasopharyngeal carcinoma, polymorphism, Taiwan, 5503
- Caspase-8, miRNA-301-3p, pancreatic cancer, TRAIL, luteolin, combination effect, 723
- Caspase-independent pathway, niclosamide, autophagy, aMPK/AKT/mTOR pathway, NSCLC, 1405
- Caspase, N, n<sup>'</sup>-(arylmethylene)biscinnamide, apoptosis, death receptor 5, cancer cells, 5035
- Caspases, mast cells, mastocytosis, histones, demethylase, 2525
- Castration resistant prostate cancer, ethinylestradiol, prostate-specific antigen, adverse event, 2291
- Castration-resistant prostate cancer, cabazitaxel, inhibitor of apoptosis proteins, drug therapy, YM155, survivin, 5091
- Castration-resistant prostate cancer, enzalutamide, n-desmethyl enzalutamide, pharmacokinetics, reduced dose, 7101
- Castration-resistant prostate cancer, non-metastatic, disease progression, 1101
- Castration-resistant prostate cancer, vismodegib, Hedgehog signaling, sonic Hedgehog, epithelial-mesenchymal transition, 5107
- CAT, thrombosis, low molecular weight heparin, LMWH, cancer-associated thrombosis, incidental CAT, symptomatic CAT, 305
- Catalytic topo I inhibitor, cyclin D1 accumulation, ATR, PTEN, akt, gSK-3 $\beta$ , 6237
- CBP, hepatocellular carcinoma,  $\beta$ -catenin, wnt, inhibitor, PRI-724, 5211
- CC, primary hepatic carcinosarcoma, collision tumor, hepatocellular carcinoma, HCC, cholangiocarcinoma, osteosarcoma, and rhabdomyosarcoma, 2225
- Ccl18 protein, gpr30, epithelial-mesenchymal transition (EMT), cancer, metastasis, 3097
- CCR5 inhibition, colorectal cancer, immunotherapy, microsatellite stability, chemokine, innate immunity, macrophages, monocytes, 6933
- CCRT, UBE2B, rectal cancer, radioresistance, 6305
- CD105, ovarian cancer, immunohistochemistry, angiogenesis, lymphangiogenesis, CD<sub>34</sub>, 6923
- CD11b+ cell, oral cancer, LN metastasis, lymphangiogenesis, hypoxia, 6845
- CD133,  $\gamma\delta$  T cell, immunotherapy, prostate cancer, cancer stem cell, sphere, prostasphere, NANOG, SOX2, OCT4, 5481
- CD155, CAK cells, KRAS, TNK cells, PD-1, TIGIT, 3D culture, 4663
- CD19, bcR gene recombinations, IGK, lung adenocarcinoma, tumor specimen exomes, CD20, CD79 B-cell markers, survival rates, 2043
- CD20, bcR gene recombinations, IGK, lung adenocarcinoma, tumor specimen exomes, CD19, CD79 B-cell markers, survival rates, 2043
- CD<sub>34</sub>, ovarian cancer, immunohistochemistry, angiogenesis, lymphangiogenesis, CD105, 6923
- CD4, pulmonary pleomorphic carcinoma, tumor immunity, CD8, PD-L1, prognosis, 261

- CD40 agonist, tongue cancer, PD-1 antagonist, postoperative adjuvant treatment, 2707
- CD44-positive cancer cells, cancer stem cells, colorectal cancer, stemness, COLO 201 cells, 169
- CD44, cornea, corneal transplantation, chemotherapy, cancer patient donors, 6885
- CD58, WEE1, EMP3, E2F7, NSUN7, lower-grade gliomas, information-theoretical approach, 2777
- CD79 B-cell markers, bcR gene recombinations, IGK, lung adenocarcinoma, tumor specimen exomes, CD19, CD20, survival rates, 2043
- CD8, breast cancer, tumor infiltrating lymphocytes, FOXP3, 2141
- CD8, MMR, PD-L1, endometrial cancer, 1669
- CD8, pulmonary pleomorphic carcinoma, tumor immunity, CD4, PD-L1, prognosis, 261
- CDA, non-small cell lung carcinoma, gemcitabine, pharmacogenomics, messenger RNA, RRM1, RRM2, dCK, hENT1, 901
- CDK4/6 inhibitor, eribulin mesylate, luminal-type breast cancer, patient-derived xenograft model, reversal of epithelial-mesenchymal transition, preclinical trial, 6699
- CDKN1A*, drug repositioning, repurposing, *MDM2*, *MDMX*, *P21<sup>WAF1/CIP1</sup>*, 4961
- Cdt1, DNA replication, DNA repair, chromatin, cell cycle, genome stability, review, 2449
- CDX2, colitis-associated colorectal cancer, YAP1, prognosis, 5411
- CEA, pleural effusion, pulmonary metastases, pleural cytology, CRP, LDH, predictive model, 5877
- Celecoxib, COX2, immune checkpoint inhibitor, PD-1, lung cancer, 5309
- Cell adhesion, cell–matrix interactions, migration, tumor spheroids, tGF $\beta$ , ILK, MIC1, PARVA, LIMS1, RSU1, 1375
- Cell apoptosis, peroxiredoxin II, PRDX2; ROS, liver injury, 4491
- Cell biology, margins of excision, stomach neoplasms, 5807
- Cell crosstalk, angiogenesis, endothelial cells, glioblastoma, *MMP-9*, *CXCR4*, 2725
- Cell cycle analysis, 3-Styrylchromones, methoxy group, cytotoxicity, tumor-specificity, QSAR analysis, molecular shape, 87
- Cell cycle arrest, AZT, ovarian cancer, chemotherapy, p21, p16, 5517
- Cell cycle arrest, ciprofloxacin, apoptosis, colorectal cancer, lung cancer, 2739
- Cell cycle arrest, methylsulfonylmethane, apoptosis, stemness, HT-29 cells, 5191
- Cell cycle, apoptosis, cancer, cytotoxicity, gamma rays, platinum(IV) complexes, 5001
- Cell cycle, CLL, cofilin-1, CFL1, chemotaxis, migration, apoptosis, 6327
- Cell cycle, DNA replication, DNA repair, chromatin, genome stability, cdt1, review, 2449
- Cell cycle, drug resistance, 5-FU, gastric cancer, EMT, p57, cyclin D1, 3247
- Cell cycle, FOXO4, cholangiocarcinoma, G<sub>0</sub>/G<sub>1</sub> arrest, 6899
- Cell cycle, NCAPH, condensin, chromosome, NSCLC, 3239
- Cell cycle, pancreatic neuroendocrine tumor, metformin, apoptosis, microRNA, 121
- Cell cycle, small cell lung carcinoma, sclareol, apoptosis, DNA damage, xenograft, 4947
- Cell cycle, static magnetic stimulation, neuroblastoma, cell viability, cell death, 5151
- Cell death mode, lipid rafts, apoptotic death, necrotic death, 2573
- Cell death, static magnetic stimulation, neuroblastoma, cell viability, cell cycle, 5151
- Cell growth inhibition, cold atmospheric plasma, antiproliferative effect, growth rate, 3743
- Cell growth, tumor-associated macrophages, bladder cancer, cell migration, cell invasion, cytokines, tumor microenvironment, 2715
- Cell invasion, tumor-associated macrophages, bladder cancer, cell growth, cell migration, cytokines, tumormicroenvironment, 2715
- Cell invasiveness, ADGRF4, GPR115, PPP4C, lung cancer, 6835
- Cell line, synchronous rhabdoid tumor, germline mutation, DNA methylation analysis, 6159
- Cell migration, Epstein-Barr virus, rta, nasopharyngeal carcinoma, interleukin-6, 3255
- Cell migration, tumor-associated macrophages, bladder cancer, cell growth, cell invasion, cytokines, tumor microenvironment, 2715
- Cell permeabilisation, cold atmospheric plasma, osteosarcoma, 841
- Cell proliferation, colon, sessile serrated polyps, non-dysplastic, p53 up-regulated cells, 1535
- Cell proliferation, nitric oxide, HNSCC human head and neck cell, isogenic cell lines, apoptosis, invasiveness, matrix metalloproteinases, 2657
- Cell surface marker, GPR87, shRNA, gene therapy, adenoviral vector, NSCLC, 733
- Cell viability, static magnetic stimulation, neuroblastoma, cell death, cell cycle, 5151
- Cell-cycle arrest, flavopereirine,  $\beta$ -carboline alkaloid, hepatocarcinoma, apoptosis, autophagy, 6907
- Cell-cycle arrest, methylsulfonylmethane, intrinsic apoptosis, A549 lung adenocarcinoma cell line, 1905
- Cell-killing effect, carbon-ion beams, linear energy transfer, radiosensitizing effect, HeLa cells, 5497
- Cell–matrix interactions, cell adhesion, migration, tumor spheroids, tGF $\beta$ , ILK, MIC1, PARVA, LIMS1, RSU1, 1375

- Cellular immunotherapy, neuroendocrine carcinoma, carcinoma of the uterine cervix, immunotherapy, adoptive immunotherapy, t-cells, 4741
- Central vascular access devices, decisional conflict scale, psychometrics, validation study, 5583
- Cerebral glioma, radiotherapy, survival, prognostic factors, re-evaluation, 6513
- Cerebral metastases, prostate cancer, elderly patients, radiotherapy, performance status, 1665
- Cerebral metastasis, non-small cell lung cancer, elderly, radiation therapy, survival scores, 2847
- Ceritinib, NSCLC, *ALK* inhibitors, crizotinib, alectinib, anaplastic lymphoma kinase, radiation, 4937
- Cervical cancer, abdominal radical trachelectomy, fertility-sparing, fertility preservation, radical hysterectomy, 5939
- Cervical cancer, high-dose-rate brachytherapy, pre-brachytherapy magnetic resonance imaging, radiotherapy, 999
- Cervical cancer, HPV, self-sampling, ethiopia, screening, 1513
- Cervical cancer, immune-cell therapy, endometrial cancer, prognostic factors,  $\alpha\beta$ T cell therapy, dendritic cell vaccine, 4729
- Cervical cancer, *miR-187*, siHa cells, 1427
- Cervical cancer, oral contraception, estrogen, progesterone, human papilloma virus (HPV), review, 5995
- Cervical cancer, para-aortic node metastasis, neoadjuvant chemotherapy, extended-field concurrent chemoradiotherapy, phase II study, 3565
- Cervical cancer, perineural invasion, vulvar cancer, surgery, adjuvant therapy, review, 3031
- Cervical cancer, PTC209, BMI1, inhibition, cancer stem cell, 133
- Cervical cancer, radiotherapy, concurrent chemoradiation, neoadjuvant chemotherapy, radical surgery, review, 4819
- Cervical cancer, small volume, simple trachelectomy, conization, parametrial involvement, pelvic lymphadenectomy, review, 3651
- Cetuximab, metastatic colorectal cancer, biweekly, weekly, 3469
- Cetuximab, panitumumab, first-line treatment, overall survival, metastatic colorectal cancer, hypomagnesemia, 7135
- Cetyltrimethylammonium bromide (CTAB), hepatic cancer, HA22T/VGH, mesenchymal to epithelial transition, 4513
- Cetyltrimethylammonium bromide, CTAB, hepatic cancer, mahlavu, fibroblast growth factor, FGF, 5059
- CFL1, CLL, cofilin-1, chemotaxis, migration, apoptosis, cell cycle, 6327
- Checkpoint inhibitor, immunotherapy, adverse effects, outcome, efficacy, review, 1219
- Chemerin, hypertension, fibrosis, tumor marker, 143
- Chemo brain, tryptophan, kynurenine, NAD, tubulin, cognition, biophoton, review, 1189
- Chemo resistance, NSCLC, Hedgehog pathway, pemetrexed, gant61, 1451
- Chemo-radiotherapy, endometrial cancer, surgical treatment, progestins, urinary tract symptoms, 3065
- Chemokine, colorectal cancer, immunotherapy, microsatellite stability, CCR5 inhibition, innate immunity, macrophages, monocytes, 6933
- Chemoprevention, MTOR, head and neck squamous carcinoma, 5417
- Chemoradiation therapy, upper rectal cancer, neoadjuvant treatment, recurrence-free and overall survival, long-term functional results, 3579
- Chemoradiation, esophagus, neoadjuvant therapy, recurrence-free survival, tumor response, prognostic factors, 4387
- Chemoradiation, mucositis, palbociclib, chemotherapy, palliative, radiation therapy, ibrance, 5291
- Chemoradiation, radiotherapy, biliary tract cancers, brachytherapy, cholangiocarcinoma, 3417
- Chemoradiation, rectal cancer, pathologic response, clinical predictor, prediction nomogram, 2171
- Chemoradiation, small cell neuroendocrine carcinoma, SCNEC, adrenal gland cancer adrenal gland, extrapulmonary small cell carcinoma, chemotherapy, radiation therapy, 5933
- Chemoradiotherapy, bladder cancer, radiotherapy, neoadjuvant chemotherapy, bladder sparing, 5861
- Chemoradiotherapy, esophageal cancer, docetaxel, unresectable advanced cancer, 2827
- Chemoradiotherapy, esophageal squamous cell carcinoma, adjuvant chemotherapy, radiotherapy dose escalation, 1771
- Chemoradiotherapy, fibrosis, necrosis, non-small cell lung cancer, lymph node, 4419
- Chemoradiotherapy, NSCLC, survival, prognostic factor, blood parameters, 2319
- Chemoradiotherapy, rectal cancer, anorectal function, neoadjuvant, manometry, 2199
- Chemorefractory, cisplatin, 5-FU, chemoresponsive, chemoresistance, apex1-Jagged-1 cascade, 1897
- Chemoresistance, cisplatin, 5-FU, chemoresponsive, chemorefractory, apex1-Jagged-1 cascade, 1897
- Chemoresistance, cisplatin, oral cancer, transcriptional upregulation, *SEI1*, 67
- Chemoresistance, prostate cancer, dihydroergocristine mesylate, dopamine receptor agonist, 6051
- Chemoresponsive, cisplatin, 5-FU, chemorefractory, chemoresistance, apex1-Jagged-1 cascade, 1897
- Chemosensitivity, PDAC, pancreatic cancer, FOLFIRINOX, gemcitabine, paclitaxel, 3659
- Chemotaxis, CLL, cofilin-1, CFL1, migration, apoptosis, cell cycle, 6327

- Chemotaxis, tE1-cells, eicosatetraenoic acids, squamous cell carcinoma, 5043
- Chemotherapy complications, gemcitabine, thrombotic microangiopathy, eculizumab, pancreatic cancer, 3995
- Chemotherapy-induced neurotoxicity, oxaliplatin, colorectal cancer, gastrointestinal cancer, 865
- Chemotherapy, 5-fluorouracil, calcitriol, vitamin D analogs, tacalcitol, 837
- Chemotherapy, acetylenic synthetic betulin derivatives, betulin, glioma, 6151
- Chemotherapy, angiosarcoma, hemangiosarcoma, gynaecology, cancer, uterine sarcoma, ovarian sarcoma, paclitaxel, laparotomy, osseous metastasis, 5743
- Chemotherapy, anti-PD-(L)1, gastric cancer, immune checkpoint inhibitor, 2247
- Chemotherapy, AZT, ovarian cancer, cell cycle arrest, p21, p16, 5517
- Chemotherapy, biliary tract cancer, cholangiocarcinoma, targeted therapy, second-line, review, 3013
- Chemotherapy, bruton's tyrosine kinase, bladder cancer, drug resistance, cytotoxicity, 6093
- Chemotherapy, clear cell sarcoma, gemcitabine, EWSR1 translocation, 7003
- Chemotherapy, clinical practice, alectinib, non-small cell lung cancer, anaplastic lymphoma kinase fusion gene mutation, 957
- Chemotherapy, colorectal cancer, immunotherapy,  $\alpha\beta$  T cell therapy, immunological status, 4763
- Chemotherapy, cornea, corneal transplantation, CD44, cancer patient donors, 6885
- Chemotherapy, EGFR gene, non-small cell lung cancer, osimertinib, 2239
- Chemotherapy, endometriosis-associated intestinal malignancies, endometriosis-associated malignancies of urinary tract, endometriosis-associated malignancies of surgical scars, immunohistochemistry, surgery, review, 2429
- Chemotherapy, epithelial ovarian cancer; primary debulking surgery, paclitaxel; carboplatin, bevacizumab, complete response, recurrence, 1543
- Chemotherapy, esophageal squamous cell carcinoma, FDG-PET, sUVmax, 1153
- Chemotherapy, extra pulmonary small cell carcinoma, high grade neuro-endocrine tumor, esophageal cancer, thoracic surgery, 5919
- Chemotherapy, *HER2*, advanced gastric cancer, trastuzumab, 75
- Chemotherapy, imidazo[2, 1-*b*]oxazole derivatives, RAF inhibitors, TNBC, 5081
- Chemotherapy, immunocellular therapy, gamma/delta T-cell, bladder cancer, cytotoxicity, 5221
- Chemotherapy, lung cancer, toxicity, predictive, prognostic, 6399
- Chemotherapy, mucositis, palbociclib, palliative, radiation therapy, ibrance, chemoradiation, 5291
- Chemotherapy, oral mucositis, rat model, immunosuppression, 2701
- Chemotherapy, ovarian cancer, cytokine-induced killer cell, peripheral blood mononuclear cell, flow cytometry, 3865
- Chemotherapy, pancreatic cancer, cisplatin, capecitabine, gemcitabine, docetaxel, 4011
- Chemotherapy, pancreatic cancer, stereotactic body radiotherapy, dose effect, 465
- Chemotherapy, platinum-resistance, recurrent ovarian cancer, cabazitaxel, phase II randomized study, 5255
- Chemotherapy, sarcoma, synovial sarcoma, 1029
- Chemotherapy, sentinel lymph node biopsy (SLNB), lymphadenectomy, immunotherapy, radiation, 2895
- Chemotherapy, small cell neuroendocrine carcinoma, SCNEC, adrenal gland cancer adrenal gland, extrapulmonary small cell carcinoma, radiation therapy, chemoradiation, 5933
- Chemotherapy, sophageal cancer, esophageal stricture, radiotherapy, risk factor, 1071
- Chemotherapy, stage IV rectal cancer, radiotherapy, local complication, 5853
- Chemotherapy, synchronous primary malignancy, colonic adenocarcinoma, pancreatic ductal carcinoma, immunohistochemistry, microsatellite stable, 4029
- Chemotherapy, synchronous primary malignancy, rectal adenocarcinoma; small cell lung carcinoma, gastrointestinal stromal tumor (GIST), immunohistochemistry; microsatellite stable, 7053
- Chemotherapy, tertiary lymphoid structure, colorectal cancer metastases, 6367
- Chemotherapy, upper gastrointestinal tract, gastric cancer, esophageal cancer, *HER2*, 965
- Chest wall, sarcoma, chondrosarcoma, bone tumor, sternum, 1519
- Chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII), colorectal cancer, akt,  $\beta$ -catenin, forkhead box C1 (FOXC1), 177
- Chicken ovalbumin upstream promoter-transcription factor II, colorectal cancer, p53, PTEN, p-Akt, 767
- Childhood cancer, medulloblastoma, PI3K inhibitors, FGFR inhibitors, 53
- Childhood leukemia, genotype, miR-196a-2, polymorphism, Taiwan, 4465
- Childhood, acute lymphocytic leukemia, case-control study, genotype, *MMP-9*, polymorphism, Taiwan, 5751
- Children, hematopoietic cell transplantation, mucositis, palifermin, risk factors analysis, keratinocyte growth factor, 6531
- Children, neuroblastoma, next-generation sequencing, *ALK*, prognosis, 7057

- Chimeric antigen receptor, natural killer cells, glioblastoma, epidermal growth factor receptor variant III, 3231
- Chloride intracellular channel protein 1 (CLIC1), bladder cancer, immunohistochemistry, potential therapeutic target, prognosis, 6879
- Chloroquine, areca nut, autophagy, nude mice, 3-methyladenine, cisplatin, 221
- Chloroquine, LC3B-II, SQSTM1, apoptosis, miR-139, autophagy, beclin-1, mTOR, prostate cancer, 6649
- Cholangiocarcinoma, biliary tract cancer, targeted therapy, chemotherapy, second-line, review, 3013
- Cholangiocarcinoma, FOXO4, cell cycle, G<sub>0</sub>/G<sub>1</sub> arrest, 6899
- Cholangiocarcinoma, *miR-146a*, *rs2910164*, single nucleotide polymorphism, esophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, gallbladder cancer, pancreatic cancer, 1495
- Cholangiocarcinoma, primary hepatic carcinosarcoma, collision tumor, hepatocellular carcinoma, HCC, CC, osteosarcoma, and rhabdomyosarcoma, 2225
- Cholangiocarcinoma, pyruvate kinase M2, shikonin, reactive oxygen species, 5115
- Cholangiocarcinoma, radiotherapy, biliary tract cancers, chemoradiation, brachytherapy, 3417
- Cholangiolocarcinoma, liver resection, radio-frequency ablation, 7147
- Cholecystectomy, ovarian cancer, cytoreductive surgery, 2331
- Cholesterol, apoptosis, head and neck squamous cell carcinoma, oxysterol, 25-hydroxycholesterol, 779
- Chondrosarcoma, periostin, carcinoma, stemness, metastasis, angiogenesis, lymphangiogenesis, 5463
- Chondrosarcoma, radiotherapy, linear energy transfer, sarcoma, 6429
- Chondrosarcoma, sarcoma, chest wall, bone tumor, sternum, 1519
- Chondrosarcoma, skeletal metastases, bone scintigraphy, PET-CT, staging, 5735
- Chromatin, DNA replication, DNA repair, cell cycle, genome stability, *cdt1*, review, 2449
- Chromophobe renal cell carcinoma, eosinophilic variant, array comparative genomic hybridisation, chromosome alteration, 6863
- Chromosome alteration, chromophobe renal cell carcinoma, eosinophilic variant, array comparative genomic hybridisation, 6863
- Chromosome translocation, chronic expanding hematoma, cytogenetics, 97
- Chromosome translocation, giant cell tumor of tendon sheath, cytogenetics, CSF1, 4373
- Chromosome translocation, pediatric, acute myeloid leukemia, RNA sequencing, *TYRO3* gene, 6115
- Chromosome, carcinoma, oral, polysomy, grid, microscopy, 3759
- Chromosome, NCAPH, condensin, cell cycle, NSCLC, 3239
- Chronic disease, colorectal liver metastases, resectability, surgery, 1
- Chronic expanding hematoma, cytogenetics, chromosome translocation, 97
- Chronic lymphocytic leukemia, ibrutinib, therapy, 4059
- Chronic myeloid leukemia, imatinib, dasatinib, second-line treatment, TKI, *BCR-ABL1*, 5313
- Chronic myelomonocytic leukemia, IGF-1R, IGF-MTX, phase I study, myelodysplastic syndrome, oligoblastic acute myeloid leukemia, 3883
- Chronopharmacokinetics, modelling and simulation, translational research, cancer chemotherapy, therapeutic drug monitoring, 5-FU prodrug, pharmacometrics, review, 6585
- Ciglitazone, pPAR $\gamma$ , thiazolidinedione, 9-cis-retinoic acid, retinoids, head and neck squamous carcinoma, 3071
- Ciprofloxacin, apoptosis, colony formation, HeLa cells, migration ability, 5025
- Ciprofloxacin, cell cycle arrest, apoptosis, colorectal cancer, lung cancer, 2739
- Circulating DNA, head and neck cancer, saliva, recurrence, metastasis, animal model, 191
- Circulating leukocytes, hepatocellular carcinoma, cirrhosis, oxidative stress, nitric oxide, glutathione, 6853
- Circulating levels, matrix metalloproteinases, gelatinases, polymorphisms, breast cancer risk, review, 3619
- Circulating tumor cell cluster, size-selective microfilters, circulating tumor cell, non-small cell lung cancer, 5577
- Circulating tumor cell, epithelial–mesenchymal transition, head and neck squamous cell carcinoma, recurrence, metastasis, 3559
- Circulating tumor cell, liquid biopsy, circulating tumor DNA, primary lung cancer, diagnosis, 3435
- Circulating tumor cell, pulmonary adenocarcinoma, clinical stage I, surgery, recurrence, 7089
- Circulating tumor cell, size-selective microfilters, circulating tumor cell cluster, non-small cell lung cancer, 5577
- Circulating tumor cells, animal models, animal study, neoplasia, cancer detection, review, 6599
- Circulating tumor cells, bladder cancer, transurethral resection of bladder tumor, 4299
- Circulating tumor cells, esophageal cancer adenocarcinoma, CAML, cytopathology, heterogeneity, 5679
- Circulating tumor DNA, liquid biopsy, circulating tumor cell, primary lung cancer, diagnosis, 3435
- Cirrhosis, hepatocellular carcinoma, oxidative stress, circulating leukocytes, nitric oxide, glutathione, 6853
- Cisplatin resistance, doxorubicin, ovarian carcinoma, oxaliplatin, spectrin  $\alpha$ II, 2497
- Cisplatin sensitivity, HNSCC, lncRNA, *MALAT1*, radiation sensitivity, 2645

- Cisplatin, 5-FU, chemoresponsive, chemorefractory, chemoresistance, apex1-Jagged-1 cascade, 1897
- Cisplatin, ABCG2, HNSCC, CSC, piCa, faDu, 1277
- Cisplatin, advanced urothelial carcinoma, second-line chemotherapy, paclitaxel, gemcitabine, 1613
- Cisplatin, amentoflavone, oral squamous cell carcinoma, NF- $\kappa$ B, apoptosis, 6723
- Cisplatin, areca nut, autophagy, nude mice, 3-methyladenine, chloroquine, 221
- Cisplatin, extracellular vesicles, lung cancer, drug resistance, mass spectrometry, 5509
- Cisplatin, hyperthermic intraperitoneal intraoperative chemotherapy, HIPEC, ovarian cancer, side effects, 1481
- Cisplatin, nSAIDs, nephrotoxicity, meta-analysis, 1747
- Cisplatin, oral cancer, transcriptional upregulation, *SEI1*, chemoresistance, 67
- Cisplatin, ovarian clear-cell carcinoma, DNA damage response, p21, 5631
- Cisplatin, pancreatic cancer, chemotherapy, capecitabine, gemcitabine, docetaxel, 4011
- Cisplatin, stomach, ERCC1, human gastric carcinoma, 3203
- Cisplatin, bladder cancer, orthotopic, nude mice, GFP, oral recombinant methioninase, combination, sensitize, efficacy, 6083
- Cisplatin, PDOX, patient-derived orthotopic xenograft, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, tumor regression, 2475
- CK2 $\alpha$ , colorectal cancer, 5-fluorouracil, anti-cancer drug resistance, ER stress, 1419
- Classification, breast cancer, dedicated breast PET, FDG, abnormal uptake, 3491
- Classification, radiomics, prediction, tumour risk, prognosis, review, 3605
- Clear cell RCC, insulin-like growth factor-I, IGF-I, iGF-IEc, renal cancer, 6213
- Clear cell sarcoma, gemcitabine, chemotherapy, EWSR1 translocation, 7003
- Clinical biomarker, dickkopf-3, malignant tumour, therapeutics, review, 5969
- Clinical data, melanoma, vitamin D, pigmentation, experimental models, review, 473
- Clinical decision-making, melanoma, sarcopenia, body mass index, pembrolizumab, monoclonal antibodies, retrospective studies, drug-related side effects, adverse reactions, 5245
- Clinical features, primary renal angiosarcoma, diagnostic approach, therapeutic management, review, 625
- Clinical imaging, triple negative breast cancer, TNBC subtypes, ultrasound, breast cancer, 2125
- Clinical outcomes, sarcopenia, esophageal cancer, neoadjuvant therapy, 1175
- Clinical outcomes, urothelial carcinoma, histological variant, radical cystectomy, 4787
- Clinical practice, alectinib, non-small cell lung cancer, anaplastic lymphoma kinase fusion gene mutation, chemotherapy, 957
- Clinical practice, breast cancer, bolus, mastectomy, radiotherapy, 6505
- Clinical practice, non-small cell lung cancer, uncommon mutation, *EGFR*, epidermal growth factor receptor, 5757
- Clinical predictor, rectal cancer, chemoradiation, pathologic response, prediction nomogram, 2171
- Clinical stage I, pulmonary adenocarcinoma, surgery, circulating tumor cell, recurrence, 7089
- Clinical validation, *Helicobacter pylori*, hp IgG ELISA, gastroPanel, new-generation, non-invasive, biomarker test, gastroscopy, biopsy, pepsinogen I, pepsinogen II, gastrin-17, 6387
- CLL, cofilin-1, CFL1, chemotaxis, migration, apoptosis, cell cycle, 6327
- Clonal dynamics, colorectal cancer, liver metastasis, animal model, splenic injection, orthotopic implantation, 3297
- Cluster analysis, kallikreins, kallikrein-related peptidases, breast cancer, gene expression, 2487
- Cluster analysis, lung cancer, metastasis, metastatic pattern, 413
- Cluster analysis, prognosis, lung cancer, metastatic pattern, 421
- CML, *BCR-ABL1*, TKI, resistance, efficacy, review, 2457
- Cofilin-1, CLL, CFL1, chemotaxis, migration, apoptosis, cell cycle, 6327
- Cognition, brain tumor, DNA microarray, neuroimmunity, regulation of actin cytoskeleton, 4719
- Cognition, chemo brain, tryptophan, kynurenine, NAD, tubulin, biophoton, review, 1189
- Cold atmospheric plasma, antiproliferative effect, cell growth inhibition, growth rate, 3743
- Cold atmospheric plasma, cell permeabilisation, osteosarcoma, 841
- Cold atmospheric plasma, physical plasma, plasma medicine, radiation, nitrogen oxides, occupational health and safety, 2591
- Cold atmospheric plasma, plasma oncology, plasma surgery, mammary carcinoma, physical therapy, 6205
- Colitis associated cancer, AOM/DSS, IBD, animal model, carcinogenesis, colorectal cancer, 5457
- Colitis-associated colorectal cancer, YAP1, CDX2, prognosis, 5411
- Collagen, pancreatic ductal adenocarcinoma, desmoplasia, vitamin D receptor, 6457
- Collision tumor, primary hepatic carcinosarcoma, hepatocellular carcinoma, HCC, cholangiocarcinoma, CC, osteosarcoma, and rhabdomyosarcoma, 2225
- COLO 201 cells, cancer stem cells, colorectal cancer, stemness, cD44-positive cancer cells, 169
- Colon 26, ultrasound, nanomedicine, poly-ethylene glycol-modified carbon nanotubes, sonodynamic therapy, sarcoma 180, 2549

- Colon cancer, adjuvant chemotherapy, practice variation, quality of care, population-based study, 4331
- Colon cancer, aTP-binding cassette transporter 11, 5-fluorouracil, prognosis, 5405
- Colon cancer, KRAS, MK615, HIF, e-cadherin, prunus mume, 4687
- Colon cancer, methylation, p53, prognosis, sidedness, 201
- Colon, breast, cancer, colorectal, ecological, mendelian randomization, prostate, ultraviolet B, UVB, 25-hydroxyvitamin D, review, 491
- Colon, innominate grooves, tributary crypts, frequency, ulcerative colitis, 7031
- Colon, neoplasms, tumour microenvironment, tumour heterogeneity, 6063
- Colon, sessile serrated polyps, non-dysplastic, cell proliferation, p53 up-regulated cells, 1535
- Colonic adenocarcinoma, synchronous primary malignancy, pancreatic ductal carcinoma, immunohistochemistry, microsatellite stable, chemotherapy, 4029
- Colonoscopy, colorectal cancer, polyps, NICE Guidelines, bowel cancer, 1705
- Colony formation, apoptosis, ciprofloxacin, HeLa cells, migration ability, 5025
- Colorectal cancer metastases, tertiary lymphoid structure, chemotherapy, 6367
- Colorectal cancer screening, fecal occult blood, guaiac-based test, fecal immunochemical test, gFOBT, iFOBT, FIT, meta-analysis, sensitivity, specificity, false negative, false positive, ROC, HSROC, 3591
- Colorectal cancer, 5-fluorouracil, anti-cancer drug resistance, cK2 $\alpha$ , ER stress, 1419
- Colorectal cancer, adiponectin, high-molecular weight oligomers, adipoR1, adipoR2, t-cadherin, 3751
- Colorectal cancer, *ADIPOQ*, genotype, polymorphism, Taiwan, 1297
- Colorectal cancer, AOM/DSS, IBD, colitis associated cancer, animal model, carcinogenesis, 5457
- Colorectal cancer, bone metastases, radiotherapy, survival, prognostic score, 287
- Colorectal cancer, cancer stem cell, ABC transporter, prognosis, 4481
- Colorectal cancer, cancer stem cells, stemness, COLO 201 cells, cD44-positive cancer cells, 169
- Colorectal cancer, chemotherapy-induced neurotoxicity, oxaliplatin, gastrointestinal cancer, 865
- Colorectal cancer, chemotherapy, immunotherapy,  $\alpha\beta$  T cell therapy, immunological status, 4763
- Colorectal cancer, chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII), akt,  $\beta$ -catenin, forkhead box C1 (FOXC1), 177
- Colorectal cancer, chicken ovalbumin upstream promoter-transcription factor II, p53, PTEN, p-Akt, 767
- Colorectal cancer, ciprofloxacin, cell cycle arrest, apoptosis, lung cancer, 2739
- Colorectal cancer, corticotropin-releasing hormone, stress, anticancer drug, 4505
- Colorectal cancer, defective mismatch repair, anti-PD-1 blockade, microsatellite instability, Lynch syndrome, 4379
- Colorectal cancer, diagnosis, screening, fecal occult blood test, FOBT, fecal immunochemical test, FIT, false-negative, false-positive, review, 575
- Colorectal cancer, dialysis, laparoscopic surgery, short-term outcome, overall survival, 2165
- Colorectal cancer, fatty acid synthesis, fatty acid oxidation, inhibitors, review, 4843
- Colorectal cancer, fluorescence, preoperative marking, gastric cancer, 6517
- Colorectal cancer, gut microbiota, gene mutations, stool DNA, 16S rRNA gene sequencing, 1325
- Colorectal cancer, human natriuretic peptide, prevention of metastasis, feasibility, 5301
- Colorectal cancer, ileocecal valve, bauhin's valve, small bowel adenocarcinoma, 4053
- Colorectal cancer, immunotherapy, microsatellite stability, CCR5 inhibition, chemokine, innate immunity, macrophages, monocytes, 6933
- Colorectal cancer, indocyanine green fluorescence, anastomosis, intestinal blood flow, 373
- Colorectal cancer, inflammation, surgical stress, survival, 3535
- Colorectal cancer, liver metastasis, clonal dynamics, animal model, splenic injection, orthotopic implantation, 3297
- Colorectal cancer, locoregional recurrent rectal cancer, microRNA, angiogenesis, expression, 2947
- Colorectal cancer, *miR-146a*, *rs2910164*, single nucleotide polymorphism, esophageal cancer, gastric cancer, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, pancreatic cancer, 1495
- Colorectal cancer, natural killer cells, immunotherapy, immune evasion, cancer stem cells, 6613
- Colorectal cancer, neutrophils-lymphocyte ratio, dynamic change of NLR, prognosis, perioperative nutrition management, 2311
- Colorectal cancer, oxaliplatin, creatinine clearance, adverse events, nausea, 299
- Colorectal cancer, peroxisome proliferator activated receptor  $\gamma$  coactivator-1 $\alpha$  (PGC-1 $\alpha$ ), AKT, glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ),  $\beta$ -catenin, 653
- Colorectal cancer, polyps, NICE Guidelines, colonoscopy, bowel cancer, 1705
- Colorectal cancer, prion protein, prPC, cancer stem cell characteristics, anti-cancer drug resistance, 5611
- Colorectal cancer, pyruvate carboxylase, anaplerotic enzyme, 6285
- Colorectal cancer, signet-ring cell carcinoma, survival, 7127



- Colorectal cancer, sinusoidal obstruction syndrome, liver metastases, liver resection, mesenchymal stem cells, monocrotaline, 6817
- Colorectal cancer, SN38, redox-status, oxidative stress, ferroptosis, electroporation, multidrug resistance, 5159
- Colorectal carcinoma, lung cancer, pulmonary metastases, surgery, biomarker, prognosis, 7045
- Colorectal carcinoma, targeted therapy, doxorubicin, TSPO, prodrug, 5371
- Colorectal liver metastases, resectability, chronic disease, surgery, 1
- Colorectal liver metastasis, CRLM, actual 5-year survivor, modern chemotherapy, 1107
- Colorectal liver metastasis, geriatric nutritional risk index, prognosis, 4165
- Colorectal liver metastasis, parenchymal-sparing liver resection, surgical margin, spray diathermy, 1359
- Colorectal neoplasms, oxaliplatin. renal function, peripheral neuropathy, survival, 2379
- Colorectal, breast, cancer, colon, ecological, mendelian randomization, prostate, ultraviolet B, UVB, 25-hydroxyvitamin D, review, 491
- Combination chemotherapy, cancer, multidrug resistance, t-lymphoma, phenothiazines, selenoesters, selenoanhydride, 4921
- Combination chemotherapy, urothelial carcinoma, second-line chemotherapy, 1141
- Combination effect, miRNA-301-3p, pancreatic cancer, caspase-8, TRAIL, luteolin, 723
- Combination therapy, pancreatic ductal adenocarcinoma, cancer metabolism, polytherapy, anti-diabetic medication, 153
- Combination, aminonaphthoquinone, curcumin, cytotoxic, anti-angiogenic, anti-metastatic, 229
- Combination, bladder cancer, orthotopic, nude mice, GFP, cisplatin, oral recombinant methioninase, sensitize, efficacy, 6083
- Combination, dedifferentiated liposarcoma, PDOX, nude mice, recombinant methioninase, *S. typhimurium* A1-R, tumor regression, 2515
- Combination, systems biology, network pharmacology, herbal, breast cancer, pharmacological mechanism, 5097
- Combinational treatment, EGFR inhibitor resistance, patient-derived model, *MET* signaling, tumor microenvironment, 109
- Complete cytoreduction, debulking for ovarian cancer, primary debulking, upper abdominal surgery, morbidity, interval debulking surgery, 5869
- Complete pathological response, breast cancer, neoadjuvant chemotherapy, MRI accuracy, histological examination, 281
- Complete response, epithelial ovarian cancer; primary debulking surgery, chemotherapy, paclitaxel; carboplatin, bevacizumab, recurrence, 1543
- Complication, bile leakage, liver surgery, 401
- Complication, schwannoma, neurological deficit, distribution, sensory nerve, motor nerve, 6563
- Computed tomography, head and neck squamous cell carcinoma, texture analysis, machine learning, 271
- Computer-aided detection, magnetic resonance imaging, vacuum-assisted biopsy, 6437
- Concomitant boost, stage III non-small cell lung cancer (NSCLC), tumor control probability (TCP), normal tissue complication probability (NTCP), accelerated radiotherapy, 4095
- Concurrent chemo-radiotherapy, local failure, locally advanced non-small cell lung cancer, 3513
- Concurrent chemoradiation, cervical cancer, radiotherapy, neoadjuvant chemotherapy, radical surgery, review, 4819
- Concurrent chemoradiotherapy, locally advanced cervical cancer, post-treatment hematological parameters, prognosis, neutrophil-to-lymphocyte, 451
- Condensin, NCAPH, chromosome, cell cycle, NSCLC, 3239
- Cone beam computed tomography, vascular malformation, intraosseous, haemangioma, orbit, 3D reconstruction, bone mineral density, immunohistochemistry, differential diagnosis, 3333
- Conization, cervical cancer, small volume, simple trachelectomy, parametrial involvement, pelvic lymphadenectomy, review, 3651
- Connexins, prognosis, gastric cancer, 4537
- Consolidation, acute myeloid leukemia, anthracycline, 357
- Continence, robotic-assisted radical prostatectomy, retzius-sparing approach, retropubic approach, 4075
- Continuous administration, bevacizumab, disease progression, recurrent ovarian cancer, progression-free survival, 5285
- Contrast media, stomach neoplasms, neoplasm staging, multidetector computed tomography, echo-endoscopy, 3401
- Contrast media, ultrasonography, portal vein, hepatocellular carcinoma, 4351
- Contrast-enhanced spectral mammography (CESM), breast cancer, mammography (MG), 2925
- Controlling nutritional status score, esophagectomy, esophageal cancer, outcome, review, 5343
- Conventional RCC, AXL expression, immunohistochemistry, tumor progression, 3485
- Conversion surgery, gastric cancer, itraconazole, repurposing, 991
- Copper, idarubicin, DNA damage, ROS, 5399
- Cornea, corneal transplantation, CD44, chemotherapy, cancer patient donors, 6885
- Corneal transplantation, cornea, CD44, chemotherapy, cancer patient donors, 6885
- Corticoids, nivolumab, non-small cell lung cancer, antibiotics, proton pump inhibitors, NSAID, statins, metformin, 2209

- Corticotropin-releasing hormone, colorectal cancer, stress, anticancer drug, 4505
- COVID-19, breast cancer, screening suspension, lockdown, oncological treatments delay, 7119
- COX2, celecoxib, immune checkpoint inhibitor, PD-1, lung cancer, 5309
- Creatinine clearance, oxaliplatin, adverse events, colorectal cancer, nausea, 299
- CRISPR/Cas9, *LINK-A*, long non-coding RNA, high-grade serous carcinoma, tumorigenesis, *in vitro*, 6677
- Crizotinib, NSCLC, *ALK* inhibitors, ceritinib, alectinib, anaplastic lymphoma kinase, radiation, 4937
- CRLM, colorectal liver metastasis, actual 5-year survivor, modern chemotherapy, 1107
- CRP, pleural effusion, pulmonary metastases, pleural cytology, CEA, LDH, predictive model, 5877
- Cryopreservation, xenograft model, pancreatic ductal carcinoma, 2637
- CSC, ABCG2, HNSCC, cisplatin, piCa, faDu, 1277
- CSF1, giant cell tumor of tendon sheath, cytogenetics, chromosome translocation, 4373
- CT, nasopharyngeal, cancer, MRI, sNPs, polymorphism, variations, genotype, VEGFA, EDNRA *NBS1*, FAS, 677
- CT, systemic mastocytosis, hounsfield units, 1015
- CTAB, cetyltrimethylammonium bromide, hepatic cancer, mahlavu, fibroblast growth factor, FGF, 5059
- CTC detection platform, CTC, pancreatic cancer, KRAS mutation, mouse model, cytology, 6781
- CTC, pancreatic cancer, KRAS mutation, mouse model, cytology, CTC detection platform, 6781
- CUL4A, oncolytic virus, adenovirus, shRNA, virotherapy, 161
- Curative, thyroid cancer, palliative setting, stereotactic radiotherapy, 3379
- Curcumin, aminonaphthoquinone, combination, cytotoxic, anti-angiogenic, anti-metastatic, 229
- Curcumol, triple-negative breast cancer, anoikis, *skp2*, 5529
- CXCL1, hepatocellular carcinoma, CXCR2, palmitate, 6075
- CXCR2, hepatocellular carcinoma, CXCL1, palmitate, 6075
- CXCR4, angiogenesis, endothelial cells, glioblastoma, cell crosstalk, *MMP-9*, 2725
- CyberKnife, SBRT, prostate cancer, 2053
- Cyclin D1 accumulation, catalytic topo I inhibitor, ATR, PTEN, akt, gSK-3 $\beta$ , 6237
- Cyclin D1, drug resistance, 5-FU, gastric cancer, EMT, cell cycle, p57, 3247
- Cyclooxygenase 2, stomach neoplasms, immunohistochemistry, prognosis, 341
- Cyclophosphamide, RLS lymphosarcoma, double-stranded DNA, secondary ascites, cancer stem cells eradication, 795
- CYP24A1, end-stage kidney disease, VDR, CYP27B1, tumor development, 6525
- CYP27B1, end-stage kidney disease, VDR, CYP24A1, tumor development, 6525
- Cysteine, activating transcription factor 4, breast cancer, hypoxia, sulfasalazine, tumor necrosis factor-related apoptosis-inducing ligand, 1387
- Cytogenetics, chronic expanding hematoma, chromosome translocation, 97
- Cytogenetics, giant cell tumor of tendon sheath, chromosome translocation, CSF1, 4373
- Cytokine-induced killer cell, ovarian cancer, peripheral blood mononuclear cell, chemotherapy, flow cytometry, 3865
- Cytokine-induced killer cells, neuropilin, immunology, lung cancer, brain tumor, flow cytometry, 5489
- Cytokines, breast cancer, regulatory T-lymphocytes, natural killer cells, 3D culture, 6179
- Cytokines, low-molecular-weight whey protein, bovine mastitis, macrophages, 4701
- Cytokines, tumor-associated macrophages, bladder cancer, cell growth, cell migration, cell invasion, tumor microenvironment, 2715
- Cytology, CTC, pancreatic cancer, KRAS mutation, mouse model, CTC detection platform, 6781
- Cytology, peritoneum, high-grade serous carcinoma, metastatic breast carcinoma, 2933
- Cytology, urine, the Paris System, atypical urothelial cell, high-grade urothelial carcinoma, low-grade urothelial neoplasm, 3477
- Cytomegalovirus, letermovir, allogeneic hematopoietic stem cell transplantation, 5909
- Cytopathology, esophageal cancer adenocarcinoma, circulating tumor cells, CAML, heterogeneity, 5679
- Cytoreductive surgery, gastric cancer, peritoneal carcinomatosis, HIPEC, 2151
- Cytoreductive surgery, heated intraperitoneal chemotherapy, ileus, length of stay, small intestine, 2865
- Cytoreductive surgery, ovarian cancer, cholecystectomy, 2331
- Cytotoxic chemotherapy, *SLC22A16*, *rs714368*, biomarker, 4245
- Cytotoxic, aminonaphthoquinone, curcumin, combination, anti-angiogenic, anti-metastatic, 229
- Cytotoxicity, 3-Styrylchromones, methoxy group, tumor-specificity, QSAR analysis, cell cycle analysis, molecular shape, 87
- Cytotoxicity, apoptosis, cancer, cell cycle, gamma rays, platinum(IV) complexes, 5001
- Cytotoxicity, barbituric acid, *in vivo* tumor model, lung cancer, thiobarbituric acid, 6039
- Cytotoxicity, bruton's tyrosine kinase, bladder cancer, chemotherapy, drug resistance, 6093
- Cytotoxicity, immunocellular therapy, gamma/delta T-cell, bladder cancer, chemotherapy, 5221

- Cytotoxicity, temozolomide, AZD7762, glioma, 5141
- D<sub>3</sub> dissection, laparoscopic colectomy, descending colon cancer, long-term outcomes, short-term outcomes, 1731
- Daily replanning, prostate cancer, brachytherapy, HDR-BT, 1677
- Dasatinib, FAS CD95, FAS ligand, caspase-3, TKI, apoptosis, nilotinib, erlotinib, gefitinib, everolimus, 6195
- Dasatinib, IGF1R, insulin-like growth factor 1 receptor, TKI, head and neck squamous cell carcinoma (HNSCC), nilotinib, erlotinib, gefitinib, everolimus, 3847
- Dasatinib, imatinib, chronic myeloid leukemia, second-line treatment, TKI, *BCR-ABL1*, 5313
- Dasatinib, PDGF, PDGFR, head and neck squamous cell carcinoma, drug resistance, afatinib, nilotinib, erlotinib, gefitinib, 825
- Day-case, mastectomy, patient satisfaction, questionnaire, 2179
- DCK, non-small cell lung carcinoma, gemcitabine, pharmacogenomics, messenger RNA, RRM1, RRM2, CDA, hENT1, 901
- Dead space reduction, seroma formation, drainage, drain-free mastectomy, surgical adhesive, TissuGlu<sup>®</sup>, breast cancer therapy, 2801
- Death receptor 5, N, N<sup>2</sup>-(arylmethylene)biscinnamide, apoptosis, caspase, cancer cells, 5035
- Debulking for ovarian cancer, primary debulking, complete cytoreduction, upper abdominal surgery, morbidity, interval debulking surgery, 5869
- Debulking surgery, ovarian cancer, PDS, IDS, surgical complexity, 3925
- Decisional conflict scale, central vascular access devices, psychometrics, validation study, 5583
- Decitabine, pancreatic cancer, APAF-1, DNA methylation, 3765
- Dedicated breast PET, breast cancer, FDG, abnormal uptake, classification, 3491
- Dedifferentiated liposarcoma, PDOX, nudemice, recombinant methioninase, *S. typhimurium* A1-R, combination, tumor regression, 2515
- Deep learning neural networks (DLNN), pharmacokinetic (PK)–Pharmacodynamic (PD), tumor growth inhibition (TGI) mathematical model, nonlinear optimization, TGI model parameter estimation, adaptive tumor growth short-term prediction, xenografted mice (PDX), pancreatic ductal adenocarcinoma (PDAC) xenograft, 5181
- Deep learning, artificial intelligence, machine learning, neural network, ovarian cancers, ovarian tumor, blood test, 4795
- Deep venous thrombosis, prognostic nutritional index, pancreatic surgery, 2297
- Defecatory dysfunction, high inferior mesenteric artery tie, low inferior mesenteric artery tie, sigmoidal cancer, 2969
- Defective mismatch repair, colorectal cancer, anti-PD-1 blockade, microsatellite instability, Lynch syndrome, 4379
- Dementia, lung cancer, social determinants of health, social isolation, loneliness, 7141
- Demethylase, mast cells, mastocytosis, histones, caspases, 2525
- Dendritic cell vaccination, pancreatic ductal adenocarcinoma, WT1, MUC1, phase I/IIa study, 5765
- Dendritic cell vaccine, immune-cell therapy, cervical cancer, endometrial cancer, prognostic factors,  $\alpha\beta$ T cell therapy, 4729
- Descending colon cancer, laparoscopic colectomy, D<sub>3</sub> dissection, long-term outcomes, short-term outcomes, 1731
- Desmoplasia, pancreatic ductal adenocarcinoma, vitamin D receptor, collagen, 6457
- Desmoplastic reaction, intrahepatic cholangiocarcinoma, microenvironment, 4749
- Diagnosis, colorectal cancer, screening, fecal occult blood test, FOBT, fecal immunochemical test, FIT, false-negative, false-positive, review, 575
- Diagnosis, hepatocellular carcinoma, surveillance, screening, biomarkers, tumor biology, liver tumors, review, 6573
- Diagnosis, liquid biopsy, circulating tumor cell, circulating tumor DNA, primary lung cancer, 3435
- Diagnostic accuracy, acute cholecystitis, acute abdominal pain, diagnostic score, ROC, HSROC, 6947
- Diagnostic approach, primary renal angiosarcoma, clinical features, therapeutic management, review, 625
- Diagnostic score, acute cholecystitis, acute abdominal pain, ROC, HSROC, diagnostic accuracy, 6947
- Diallyl sulfide, differentiation, apoptosis, human promyelocytic leukemia, HL-60 cells, garlic, gas chromatography-mass spectrometry, 6345
- Dialysis, colorectal cancer, laparoscopic surgery, short-term outcome, overall survival, 2165
- Dickkopf-3, clinical biomarker, malignant tumour, therapeutics, review, 5969
- Diet, metabolomics, plasma, time-restricted feeding, Lewis lung carcinoma, mice, 1833
- Differential diagnosis, malignant pleural effusion, pleural-fluid cytology, lung cancer, pulmonary metastases, 1135
- Differential diagnosis, vascular malformation, intraosseous, haemangioma, orbit, cone beam computed tomography, 3D reconstruction, bone mineral density, immunohistochemistry, 3333
- Differentiated thyroid carcinoma, salvage surgery, age, distant metastasis, survival, 11292
- Differentiation, anticancer drugs, bortezomib, neurotoxicity, PC12, overlay method, NGF, protection, antioxidant, 3685
- Differentiation, apoptosis, human promyelocytic leukemia, HL-60 cells, garlic, diallyl sulfide, gas chromatography-mass spectrometry, 6345

- Diffuse large b-cell lymphoma, EBV, Epstein-Barr virus positive diffuse large b-cell lymphoma, programmed death-ligand 1, tumour immunology, non-Hodgkin lymphoma, review, 5951
- Digital image analysis, larynx, carcinoma, topoisomerase, immunohistochemistry, 807
- Digital positron emission tomography, positron emission tomography, radiotherapy planning, gross tumour volume, auto-delineation, 2567
- Dihydroergocristine mesylate, prostate cancer, chemoresistance, dopamine receptor agonist, 6051
- Direct oral anticoagulant, hepatocellular carcinoma, cancer-associated thrombosis, superior mesenteric vein thrombosis, liver resection, 6465
- Disease progression, bevacizumab, continuous administration, recurrent ovarian cancer, progression-free survival, 5285
- Disease progression, non-metastatic, castration-resistant prostate cancer, 1101
- Disease-free survival, gastric cancer, overall survival, anastomotic leakage, review, 619
- Disparities, gastric cancer, outcomes, race, 881
- Disparity, multiple myeloma, social determinants of health, affordable Care Act, 5727
- Dissemination, ultrasonically-activated surgical device, gastric cancer, 3163
- Distal pancreatectomy, appleby procedure, outcome, 387
- Distant brain metastases, stereotactic radiosurgery, fractionated stereotactic radiotherapy, elderly patients, prognostic instrument, 4081
- Distant metastasis, salvage surgery, differentiated thyroid carcinoma, age, survival, 11292
- Distribution, schwannoma, neurological deficit, sensory nerve, motor nerve, complication, 6563
- DLL1, metastasis, suppressor, pancreatic cancer, src, p38, 1335
- DNA condensation and fragmentation, maslinic acid, human cervical cancer, HeLa cells, DNA damage, 6869
- DNA damage response, ovarian clear-cell carcinoma, cisplatin, p21, 5631
- DNA damage, idarubicin, ROS, copper, 5399
- DNA damage, maslinic acid, human cervical cancer, HeLa cells, DNA condensation and fragmentation, 6869
- DNA damage, previtamin D<sub>3</sub>, 8-hydroxy-2'-deoxyguanosine, nitric oxide, vitamin D, nitrite, human skin, 565
- DNA damage, senescence, glutamine metabolism, mTOR, 6891
- DNA damage, small cell lung carcinoma, sclareol, cell cycle, apoptosis, xenograft, 4947
- DNA damaging agents, oesophageal squamous cell carcinoma, PARP inhibitor, 53BP1, REV7, 813
- DNA methylation analysis, synchronous rhabdoid tumor, cell line, germline mutation, 6159
- DNA methylation, EWAS, normal breast tissue, blood, obesity, body mass index, breast cancer, epigenetic biomarkers, review, 1797
- DNA methylation, pancreatic cancer, APAF-1, decitabine, 3765
- DNA microarray, brain tumor, cognition, neuroimmunity, regulation of actin cytoskeleton, 4719
- DNA mismatch repair, temozolomide, resistance, G2 checkpoint, glioblastoma, 1315
- DNA repair gene, single nucleotide polymorphism, overall survival, hypopharyngeal cancer, japanese, 3277
- DNA repair, DNA replication, chromatin, cell cycle, genome stability, cdt1, review, 2449
- DNA replication, DNA repair, chromatin, cell cycle, genome stability, cdt1, review, 2449
- DNA-DSB, proton, photon, zebrafish embryo model, morphological malformations, histological changes, 6123
- DNMT inhibitors, apoptosis, epithelial-to-mesenchymal transition, breast cancer, cancer epigenetics, HDAC inhibitors, phytochemicals, 9
- Docetaxel, abiraterone, androgen receptor, cabazitaxel, enzalutamide, prostate cancer, 335
- Docetaxel, esophageal cancer, chemoradiotherapy, unresectable advanced cancer, 2827
- Docetaxel, leukopenia, febrile neutropenia, time to treatment failure, prostate cancer, 4291
- Docetaxel, paclitaxel, hyperthermia, ovarian cancer, *in vitro* study, intraperitoneal chemotherapy, HIPEC, 6769
- Docetaxel, pancreatic cancer, chemotherapy, cisplatin, capecitabine, gemcitabine, 4011
- Docetaxel/cisplatin/5-fluorouracil, oesophageal cancer, oesophagectomy, five-year survival, preoperative chemotherapy, 5829
- Dominant intraprostatic lesion, prostate neoplasms, intensity-modulated radiotherapy, simultaneous integrated boost, phase I-II, 6499
- Dopamine receptor agonist, prostate cancer, chemoresistance, dihydroergocristine mesylate, 6051
- Dose effect, pancreatic cancer, stereotactic body radiotherapy, chemotherapy, 465
- Double-stranded DNA, RLS lymphosarcoma, cyclophosphamide, secondary ascites, cancer stem cells eradication, 795
- Down-staging, neoadjuvant chemotherapy, long-term outcome, tumor shrinkage, breast conserving surgery, recurrence, 1079
- Downstaging, hepatocellular carcinoma, low dose FP, salvage surgery, 4773
- Doxorubicin, cisplatin resistance, ovarian carcinoma, oxaliplatin, spectrin  $\alpha$ II, 2497
- Doxorubicin, targeted therapy, colorectal carcinoma, TSPO, prodrug, 5371

- Drain-free mastectomy, seroma formation, drainage, surgical adhesive, tissuGlu<sup>®</sup>, breast cancer therapy, dead space reduction, 2801
- Drainage, seroma formation, drain-free mastectomy, surgical adhesive, tissuGlu<sup>®</sup>, breast cancer therapy, dead space reduction, 2801
- DRAQ7, glioma, viability, polyphenols, flow cytometry, MTT, 5427
- Drug combination therapy, non-Hodgkin's lymphoma (NHL), t-cell lymphomas, anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (*ALK*), mammalian target of rapamycin (mTOR), 1395
- Drug cost, ramucirumab, third-line treatment, overall survival, adverse event, metastatic colorectal cancer, 1605
- Drug delivery system, ROBO1, HNSCC, photochemical internalization, immunotoxin, 3793
- Drug repositioning, repurposing, *MDM2*, *MDMX*, *CDKN1A*, *P21*<sup>WAF1/CIP1</sup>, 4961
- Drug resistance, 5-FU, gastric cancer, EMT, cell cycle, p57, cyclin D1, 3247
- Drug resistance, bruton's tyrosine kinase, bladder cancer, chemotherapy, cytotoxicity, 6093
- Drug resistance, extracellular vesicles, lung cancer, cisplatin, mass spectrometry, 5509
- Drug resistance, PDGF, PDGFR, head and neck squamous cell carcinoma, afatinib, nilotinib, dasatinib, erlotinib, gefitinib, 825
- Drug therapy, castration-resistant prostate cancer, cabazitaxel, inhibitor of apoptosis proteins, YM155, survivin, 5091
- Drug-delivery, superparamagnetic iron oxide nanoparticles, SPION, glioblastoma, review, 5989
- Drug-related side effects, melanoma, sarcopenia, body mass index, pembrolizumab, monoclonal antibodies, retrospective studies, clinical decision-making, adverse reactions, 5245
- Dual-energy, multidetector computed tomography, positron-emission tomography, iodine, fluorodeoxyglucose, lung cancer, 3459
- Dynamic change of NLR, colorectal cancer, neutrophils-lymphocyte ratio, prognosis, perioperative nutrition management, 2311
- E-cadherin, breast cancer, p-cadherin, molecular subtypes, 5557
- E-cadherin, KRAS, MK615, colon cancer, HIF, prunus mume, 4687
- E-selectin, lung metastasis, acute lung injury (ALI), pneumonia, intercellular adhesion molecule-1 (ICAM-1), 6171
- E. piscocarpus*, melanoma, natural products, photoprotection, spathulenol, apoptosis, 5015
- E2F7, WEE1, EMP3, CD58, NSUN7, lower-grade gliomas, information-theoretical approach, 2777
- E3 ubiquitin ligase, RNF126, gastric cancer, 1367
- Early and late stage survival, p16 prognostic value, ki-67, resected lung cancer, 983
- Early consultation, soft-tissue sarcoma, metastasis, histological grade, tumor site, early referral, 7009
- Early recurrence, breast cancer, *HER2* gene amplification, *TP53* mutation, estrogen receptor, 645
- Early referral, soft-tissue sarcoma, metastasis, histological grade, tumor site, early consultation, 7009
- Early-stage cervical cancer, villoglandular adenocarcinoma of the uterine cervix, minimal invasive surgery, minimal handling, review, 3049
- EAU, risk stratification systems, NCCN, radiotherapy, prostate neoplasms, 4413
- EBV, diffuse large b-cell lymphoma, Epstein-Barr virus positive diffuse large b-cell lymphoma, programmed death-ligand 1, tumour immunology, non-Hodgkin lymphoma, review, 5951
- Echo-endoscopy, stomach neoplasms, neoplasm staging, multidetector computed tomography, contrast media, 3401
- Echocardiography, breast cancer, radiotherapy, cardiotoxicity, mean heart dose, LAD, LV, 3003
- Ecologic, pesticide, lymphoma, carcinogenicity, 5423
- Ecological, breast, cancer, colon, colorectal, mendelian randomization, prostate, ultraviolet B, UVB, 25-hydroxyvitamin D, review, 491
- Eculizumab, gemcitabine, thrombotic microangiopathy, chemotherapy complications, pancreatic cancer, 3995
- ECW/TBW, lung cancer, bioelectrical impedance analysis, prognostic factor, 3931
- EDNRA *NBS1*, nasopharyngeal, cancer, CT, MRI, sNPs, polymorphism, variations, genotype, VEGFA, FAS, 677
- Effectiveness, carbon-ion radiotherapy, non-small-cell lung cancer, stage III, toxicity, 379
- Efficacy, advanced non-squamous non-small cell lung cancer, amrubicin, bevacizumab, prospective study, 1571
- Efficacy, *BCR-ABL1*, CML, TKI, resistance, review, 2457
- Efficacy, bladder cancer, orthotopic, nude mice, GFP, cisplatin, oral recombinant methioninase, combination, sensitize, 6083
- Efficacy, immunotherapy, checkpoint inhibitor, adverse effects, outcome, review, 1219
- EGF receptor, head and neck cancer, phytochemicals, light, oxidative stress, 751
- EGF receptor, molecular design, structure, tX-2036 derivatives, 4675
- EGFR gene, non-small cell lung cancer, chemotherapy, osimertinib, 2239
- EGFR inhibitor resistance, patient-derived model, *MET* signaling, combinational treatment, tumor microenvironment, 109
- EGFR-TKI, adenocarcinoma, pleurodesis, malignant pleural effusions, hypoalbuminemia, 1117

- EGFR*, clinical practice, non-small cell lung cancer, uncommon mutation, epidermal growth factor receptor, 5757
- EGFR*, lung cancer, tyrosine kinase inhibitor, induction treatment, 2911
- Ehrlich ascites carcinoma model, spiro-acridine, antitumor activity, anti-angiogenic activity, immunomodulation, zebrafish, 5049
- Eicosatetraenoic acids, chemotaxis, tE1-cells, squamous cell carcinoma, 5043
- EIF4E, hIF-1 $\alpha$ , silibinin, RPS6, ovarian clear-cell carcinoma, 6791
- Elacestrant, ER positive, breast cancer, ER targeting, FGFR inhibitors, venetoclax, review, 4829
- Elastin, monocyte, macrophage, fibroblast, hyaluronan, lipopolysaccharide, 4681
- Elderly patients, brain metastases, esophageal cancer, whole-brain irradiation, survival, scoring tool, 1661
- Elderly patients, esophageal cancer, esophagectomy, 1087
- Elderly patients, muscle invasive bladder cancer, radiation therapy, whole-bladder, 2905
- Elderly patients, prostate cancer, cerebral metastases, radiotherapy, performance status, 1665
- Elderly patients, stereotactic radiosurgery, fractionated stereotactic radiotherapy, distant brain metastases, prognostic instrument, 4081
- Elderly, brain metastasis, gynecological cancer, whole-brain irradiation, survival prognosis, 2257
- Elderly, non-small cell lung cancer, cerebral metastasis, radiation therapy, survival scores, 2847
- Electrochemotherapy, melanoma, rare non-melanoma skin cancer, metastases, 6485
- Electroporation, colorectal cancer, SN38, redox-status, oxidative stress, ferroptosis, multidrug resistance, 5159
- EMP3, WEE1, E2F7, CD58, NSUN7, lower-grade gliomas, information-theoretical approach, 2777
- EMT, drug resistance, 5-FU, gastric cancer, cell cycle, p57, cyclin D1, 3247
- EMT, tranilast, smad4, tGF- $\beta$ 1, 3287
- End-stage kidney disease, VDR, CYP27B1, CYP24A1, tumor development, 6525
- Endocrine late effects, whole brain radiotherapy, hypothalamic-pituitary dysfunction, cancer survivor, 5787
- Endoglin, prostate cancer, prostate biopsy, high-grade prostate cancer, sCD105, 1459
- Endometrial cancer, atypical endometrial hyperplasia, hysterectomy, magnetic resonance imaging, preoperative procedure, 2989
- Endometrial cancer, immune-cell therapy, cervical cancer, prognostic factors,  $\alpha\beta$ T cell therapy, dendritic cell vaccine, 4729
- Endometrial cancer, MMR, PD-L1, CD8, 1669
- Endometrial cancer, pelvic lymphadenectomy, survival, para aortic lymphadenectomy, 1563
- Endometrial cancer, second primary cancer, molecular characterization, interval from first primary cancer to second primary cancer, 3811
- Endometrial cancer, surgical treatment, chemo-radiotherapy, progestins, urinary tract symptoms, 3065
- Endometrial neoplasms, carcinosarcoma, microsatellite instability, pembrolizumab, radiotherapy, abscopal effect, 4131
- Endometrial polyps, asymptomatic, postmenopausal, malignancy, PTEN, 789
- Endometriosis-associated intestinal malignancies, endometriosis-associated malignancies of urinary tract, endometriosis-associated malignancies of surgical scars, immunohistochemistry, surgery, chemotherapy, review, 2429
- Endometriosis-associated malignancies of surgical scars, endometriosis-associated intestinal malignancies, endometriosis-associated malignancies of urinary tract, immunohistochemistry, surgery, chemotherapy, review, 2429
- Endometriosis-associated malignancies of urinary tract, endometriosis-associated intestinal malignancies, endometriosis-associated malignancies of surgical scars, immunohistochemistry, surgery, chemotherapy, review, 2429
- Endoscopic classification, breast cancer, nipple discharge, galactoscopy, mammary ductoscopy, 2185
- Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) and biopsy (FNB), epidermal growth factor receptor (EGFR) mutation, lung adenocarcinoma, pancreatic ductal carcinoma, immunohistochemistry, 4401
- Endosonography, biopsy, fine-needle, large-core needle, pancreatic neoplasms, 5845
- Endothelial cells, angiogenesis, glioblastoma, cell crosstalk, *MMP-9*, CXCR4, 2725
- Endothelin-1, prostate cancer, mxi-2, ago2, p53, 5539
- Environmental carcinogen, tGF $\beta$  signaling, functional loss, mammary cancer, 2687
- Enzalutamide, abiraterone, androgen receptor, cabazitaxel, docetaxel, prostate cancer, 335
- Enzalutamide, n-desmethyl enzalutamide, castration-resistant prostate cancer, pharmacokinetics, reduced dose, 7101
- EORTC, ESTRO, oligometastatic disease, 5895
- Eosinophil percentages, infusion reaction, trastuzumab, breast cancer, 4047
- Eosinophilic variant, chromophobe renal cell carcinoma, array comparative genomic hybridisation, chromosome alteration, 6863
- EpCAM, hepatocellular carcinoma, androgen receptor, sorafenib, 1285
- Ependymoma, medulloblastoma, basic magnetic resonance imaging, predictive model, 2975
- Ephemeranthol A, lung cancer, epithelial to mesenchymal transition (EMT), apoptosis, 4989

- Ephrin receptor B2, cancer, meta-analysis, prognosis, 4309
- Epidemiology, pulmonary sarcoma, prognostic factors, survival, 1697
- Epidermal growth factor receptor (EGFR) mutation, lung adenocarcinoma, pancreatic ductal carcinoma, endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) and biopsy (FNB), immunohistochemistry, 4401
- Epidermal growth factor receptor variant III, chimeric antigen receptor, natural killer cells, glioblastoma, 3231
- Epidermal growth factor receptor, clinical practice, non-small cell lung cancer, uncommon mutation, *EGFR*, 5757
- Epigenetic biomarkers, EWAS, normal breast tissue, blood, DNA methylation, obesity, body mass index, breast cancer, review, 1797
- Epigenetic, pediatric, miRNA, ALL, relapse, 3147
- Epigenetics, metaplastic breast carcinoma, EZH2, MMSET, 2133
- Epithelial ovarian cancer, secondary cytoreductive surgery, platinum-sensitive recurrence, positron-emission tomography/computed tomography, 2191
- Epithelial ovarian cancer; primary debulking surgery, chemotherapy, paclitaxel; carboplatin, bevacizumab, complete response, recurrence, 1543
- Epithelial to mesenchymal transition (EMT), ephemeranthol A, lung cancer, apoptosis, 4989
- Epithelial-mesenchymal transition (EMT), ccl18 protein, gpr30, cancer, metastasis, 3097
- Epithelial-mesenchymal transition, pancreatic cancer, exosomes, micro RNA, 1843
- Epithelial-mesenchymal transition, vismodegib, castration-resistant prostate cancer, Hedgehog signaling, sonic Hedgehog, 5107
- Epithelial-to-mesenchyma transition, periostin, radioresistance, head and neck cancer, 2627
- Epithelial-to-mesenchymal transition, apoptosis, breast cancer, cancer epigenetics, DNMT inhibitors, HDAC inhibitors, phytochemicals, 9
- Epithelial-mesenchymal transition, circulating tumor cell, head and neck squamous cell carcinoma, recurrence, metastasis, 3559
- EPOCH, adult T-cell leukemia/lymphoma, mogamulizumab, 5237
- Epstein-Barr virus positive diffuse large b-cell lymphoma, EBV, diffuse large b-cell lymphoma, programmed death-ligand 1, tumour immunology, non-Hodgkin lymphoma, review, 5951
- Epstein-Barr virus, rta, nasopharyngeal carcinoma, interleukin-6, cell migration, 3255
- ER positive, breast cancer, ER targeting, elacestrant, FGFR inhibitors, venetoclax, review, 4829
- ER stress, colorectal cancer, 5-fluorouracil, anti-cancer drug resistance, cK2 $\alpha$ , 1419
- ER targeting, ER positive, breast cancer, elacestrant, FGFR inhibitors, venetoclax, review, 4829
- ER+, ginseng seed oil, oleic acid, breast cancer, tamoxifen, 4529
- ER+/*HER2*+, triple-positive breast cancer, next-generation sequencing, neo-ALL-IN, *MLL2*, *PIK3CA*, 5883
- ERCC1, stomach, cisplatin, human gastric carcinoma, 3203
- Eribulin mesylate, CDK4/6 inhibitor, luminal-type breast cancer, patient-derived xenograft model, reversal of epithelial-mesenchymal transition, preclinical trial, 6699
- Eribulin, breast cancer, absolute lymphocyte count, c-reactive protein, overall survival, 4147
- Eribulin, breast cancer, tGF- $\beta$ , tILs, ALC, tumour microenvironment, 3345
- Eribulin, PDOX, patient-derived orthotopic xenograft, nude mice, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, olaparib, regression, resistance, 2509
- Eribulin, PDOX, patient-derived orthotopic xenograft, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, cisplatin, tumor regression, 2475
- Erlotinib, bevacizumab, tumor metrics, non-small cell lung cancer, Hellenic Cooperative Oncology Group, 2095
- Erlotinib, FAS CD95, FAS ligand, caspase-3, TKI, apoptosis, nilotinib, dasatinib, gefitinib, everolimus, 6195
- Erlotinib, IGF1R, insulin-like growth factor 1 receptor, TKI, head and neck squamous cell carcinoma (HNSCC), nilotinib, dasatinib, gefitinib, everolimus, 3847
- Erlotinib, PDGF, PDGFR, head and neck squamous cell carcinoma, drug resistance, afatinib, nilotinib, dasatinib, gefitinib, 825
- Erythroblastic blood smear, breast cancer, bone marrow infiltration, weekly paclitaxel, 2955
- ESME, vinorelbine, metastatic breast cancer, real-world data, retrospective study, 3905
- Esophageal cancer adenocarcinoma, circulating tumor cells, CAML, cytopathology, heterogeneity, 5679
- Esophageal cancer, anastomosis leak, overall survival, recurrence, 443
- Esophageal cancer, bleeding, antiplatelet treatment, anticoagulation treatment, 2359
- Esophageal cancer, c-reactive protein to albumin ratio, overall survival, recurrence, 2365
- Esophageal cancer, chemoradiotherapy, docetaxel, unresectable advanced cancer, 2827
- Esophageal cancer, controlling nutritional status score, esophagectomy, outcome, review, 5343
- Esophageal cancer, elderly patients, brain metastases, whole-brain irradiation, survival, scoring tool, 1661
- Esophageal cancer, elderly patients, esophagectomy, 1087
- Esophageal cancer, extra pulmonary small cell carcinoma, high grade neuro-endocrine tumor, thoracic surgery, chemotherapy, 5919

- Esophageal cancer, minimally invasive esophagectomy, thoracoscope, 1587
- Esophageal cancer, *miR-146a*, *rs2910164*, single nucleotide polymorphism, gastric cancer, colorectal cancer, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, pancreatic cancer, 1495
- Esophageal cancer, platelet distribution width, c-reactive protein, 5715
- Esophageal cancer, sarcopenia, clinical outcomes, neoadjuvant therapy, 1175
- Esophageal cancer, stereotactic body radiotherapy (SBRT), oligometastases, oligo-recurrence, prognostic factor, 2065
- Esophageal cancer, upper gastrointestinal tract, gastric cancer, chemotherapy, *HER2*, 965
- Esophageal carcinoma, oncological esophagectomy, neoadjuvant chemoradiation, lymphadenectomy, survival, prognosis, 2833
- Esophageal squamous cell carcinoma, chemoradiotherapy, adjuvant chemotherapy, radiotherapy dose escalation, 1771
- Esophageal squamous cell carcinoma, chemotherapy, FDG-PET, sUVmax, 1153
- Esophageal squamous cell carcinoma, *FOXO3A*, *HER2*, trastuzumab, 1921
- Esophageal squamous cell carcinoma, oligo-recurrence, radical re-irradiation, 2387
- Esophageal squamous cell carcinoma, *SF3B4*, poor prognostic biomarker, 2941
- Esophageal stricture, esophageal cancer, chemotherapy, radiotherapy, risk factor, 1071
- Esophageal, hybrid, minimally-invasive, esophagectomy, cancer, 1753
- Esophagectomy, controlling nutritional status score, esophageal cancer, outcome, review, 5343
- Esophagectomy, esophageal cancer, elderly patients, 1087
- Esophagectomy, hybrid, minimally-invasive, esophageal, cancer, 1753
- Esophagectomy, muscle mass loss, oesophageal cancer, 2275
- Esophagus, chemoradiation, neoadjuvant therapy, recurrence-free survival, tumor response, prognostic factors, 4387
- Estradiol, oral tongue squamous cell carcinoma, sex hormones, *MMP8*, 6029
- ESTRO, EORTC, oligometastatic disease, 5895
- Estrogen receptor, breast cancer, *HER2* gene amplification, *TP53* mutation, early recurrence, 645
- Estrogen receptor, vorinostat, I3C, triple negative breast cancer, progesterone receptor, HDAC activity, HDAC7, 3669
- Estrogen, oral contraception, progesterone, human papilloma virus (HPV), cervical cancer, review, 5995
- Ethinylestradiol, castration resistant prostate cancer, prostate-specific antigen, adverse event, 2291
- Ethiopia, HPV, self-sampling, screening, cervical cancer, 1513
- Eukaryotic translation initiation factors, pancreatic cancer, pI3K/AKT/mTOR pathway, biomarker, 3109
- Everolimus, FAS CD95, FAS ligand, caspase-3, TKI, apoptosis, nilotinib, dasatinib, erlotinib, gefitinib, 6195
- Everolimus, fibroblast growth factor, HPV, FGF, head and neck squamous cell carcinoma, HNSCC, tyrosine kinase inhibitors, mTOR inhibitors, 5621
- Everolimus, IGF1R, insulin-like growth factor 1 receptor, TKI, head and neck squamous cell carcinoma (HNSCC), nilotinib, dasatinib, erlotinib, gefitinib, 3847
- EWAS, normal breast tissue, blood, DNA methylation, obesity, body mass index, breast cancer, epigenetic biomarkers, review, 1797
- Ewing Sarcoma, metastatic, cabozantinib, 2265
- Ewing Sarcoma, stereotactic body radiation therapy, metastasis, 951
- EWSR1 translocation, clear cell sarcoma, gemcitabine, chemotherapy, 7003
- Excisional margins, invasive melanoma, wide excisional surgery, NCDB, 1065
- Excisional margins, invasive melanoma, wide excisional surgery, residual tumor, NCDB, 1059
- Exosomes, epithelial-mesenchymal transition, pancreatic cancer, micro RNA, 1843
- Exosomes, extracellular vesicles, miRNA, breast cancer, biomarkers, tears, 3091
- Experimental models, melanoma, vitamin D, pigmentation, clinical data, review, 473
- Expression profile, follicular lymphoma, EZH2, POD24, time to first systemic therapy, prognostic factors, 6685
- Expression, locoregional recurrent rectal cancer, microRNA, angiogenesis, colorectal cancer, 2947
- Expression, *MDM2*, polymorphism, prostate cancer, slovak population, 6257
- Expression, protein tyrosine phosphatases, pTPs, renal cell carcinoma, RCC, 5667
- Extended-field concurrent chemoradiotherapy, cervical cancer, para-aortic node metastasis, neoadjuvant chemotherapy, phase II study, 3565
- Extra pulmonary small cell carcinoma, high grade neuroendocrine tumor, esophageal cancer, thoracic surgery, chemotherapy, 5919
- Extra-cerebral metastasis, older patients, brain metastases, local therapies, whole-brain radiotherapy, overall survival, 2841
- Extracellular vesicles, exosomes, miRNA, breast cancer, biomarkers, tears, 3091
- Extracellular vesicles, lung cancer, drug resistance, cisplatin, mass spectrometry, 5509
- Extracorporeally-irradiated autograft, vascularized bone graft, reconstruction, sarcoma, 1637



- Extranodal extension, head and neck cancer, squamous cell carcinoma, positron emission tomography, lymph node metastasis, 2073
- Extrapulmonary small cell carcinoma, small cell neuroendocrine carcinoma, SCNEC, adrenal gland cancer adrenal gland, chemotherapy, radiation therapy, chemoradiation, 5933
- Extraskelatal myxoid chondrosarcoma, sarcoma, barrier, 1035
- Extravascular-migratory-metastasis, melanoma sentinel lymph node, melanoma metastases, melanoma progression, 891
- Extremity, bone tumor, postoperative deep infection, risk factor, multivariate analysis, 3551
- EZH2, follicular lymphoma, POD24, time to first systemic therapy, prognostic factors, expression profile, 6685
- EZH2, metaplastic breast carcinoma, epigenetics, MMSET, 2133
- FA score, fibrinogen, albumin, pancreatic ductal adenocarcinoma, surgical resection, prognostic index, 7017
- FACS, pancreatic cancer, cancer stem cells, cancer-associated fibroblasts, tumor dissociation, 1267
- FaDu, ABCG2, HNSCC, CSC, cisplatin, piCa, 1277
- FAK, mesothelioma, imidazo[2, 1-*b*][1, 3, 4]thiadiazole compounds, gemcitabine, human equilibrative nucleoside transporter-1, 4913
- False negative, fecal occult blood, guaiac-based test, fecal immunochemical test, gFOBT, iFOBT, FIT, colorectal cancer screening, meta-analysis, sensitivity, specificity, false positive, ROC, HSROC, 3591
- False positive, fecal occult blood, guaiac-based test, fecal immunochemical test, gFOBT, iFOBT, FIT, colorectal cancer screening, meta-analysis, sensitivity, specificity, false negative, ROC, HSROC, 3591
- False-negative, colorectal cancer, diagnosis, screening, fecal occult blood test, FOBT, fecal immunochemical test, FIT, false-positive, review, 575
- False-positive, colorectal cancer, diagnosis, screening, fecal occult blood test, FOBT, fecal immunochemical test, FIT, false-negative, review, 575
- FAS CD95, FAS ligand, caspase-3, TKI, apoptosis, nilotinib, dasatinib, erlotinib, gefitinib, everolimus, 6195
- FAS ligand, FAS CD95, caspase-3, TKI, apoptosis, nilotinib, dasatinib, erlotinib, gefitinib, everolimus, 6195
- FAS, nasopharyngeal, cancer, CT, MRI, sNPs, polymorphism, variations, genotype, VEGFA, EDNRA *NBS1*, 677
- Fasciola hepatica*, inflammatory liver tumor, intrahepatic cholangiocarcinoma, 2795
- Fatigue, breast cancer, physical exercise, oncological rehabilitation, quality of life, 4253
- Fatigue, olaparib, meta-analysis, randomized clinical trial, anemia, PARP, review, 597
- Fatty acid oxidation, colorectal cancer, fatty acid synthesis, inhibitors, review, 4843
- Fatty acid synthesis, colorectal cancer, fatty acid oxidation, inhibitors, review, 4843
- FDG-PET, chemotherapy, esophageal squamous cell carcinoma, sUVM<sub>ax</sub>, 1153
- FDG, breast cancer, dedicated breast PET, abnormal uptake, classification, 3491
- Feasibility, colorectal cancer, human natriuretic peptide, prevention of metastasis, 5301
- Febrile neutropenia, leukopenia, time to treatment failure, docetaxel, prostate cancer, 4291
- Febrile neutropenia, pegfilgrastim, relative dose intensity, breast cancer, FEC-100, 915
- FEC-100, pegfilgrastim, relative dose intensity, febrile neutropenia, breast cancer, 915
- Fecal immunochemical test, colorectal cancer, diagnosis, screening, fecal occult blood test, FOBT, FIT, false-negative, false-positive, review, 575
- Fecal immunochemical test, fecal occult blood, guaiac-based test, gFOBT, iFOBT, FIT, colorectal cancer screening, meta-analysis, sensitivity, specificity, false negative, false positive, ROC, HSROC, 3591
- Fecal occult blood test, colorectal cancer, diagnosis, screening, FOBT, fecal immunochemical test, FIT, false-negative, false-positive, review, 575
- Fecal occult blood, guaiac-based test, fecal immunochemical test, gFOBT, iFOBT, FIT, colorectal cancer screening, meta-analysis, sensitivity, specificity, false negative, false positive, ROC, HSROC, 3591
- Ferroptosis, colorectal cancer, SN38, redox-status, oxidative stress, electroporation, multidrug resistance, 5159
- Fertility preservation, abdominal radical trachelectomy, cervical cancer, fertility-sparing, radical hysterectomy, 5939
- Fertility-sparing, abdominal radical trachelectomy, cervical cancer, fertility preservation, radical hysterectomy, 5939
- FGD<sub>3</sub>gene, breast cancer, prognostic factor, precision medicine, review, 3645
- FGF, cetyltrimethylammonium bromide, CTAB, hepatic cancer, mahlavu, fibroblast growth factor, 5059
- FGF, fibroblast growth factor, HPV, head and neck squamous cell carcinoma, HNSCC, everolimus, tyrosine kinase inhibitors, mTOR inhibitors, 5621
- FGFR inhibitors, childhood cancer, medulloblastoma, PI3K inhibitors, 53
- FGFR inhibitors, ER positive, breast cancer, ER targeting, elacestrant, venetoclax, review, 4829
- Fibrinogen, FA score, albumin, pancreatic ductal adenocarcinoma, surgical resection, prognostic index, 7017
- Fibroadenoma, fibroepithelial lesions, phyllodes tumors, score, 1095
- Fibroblast growth factor, cetyltrimethylammonium bromide, CTAB, hepatic cancer, mahlavu, FGF, 5059

- Fibroblast growth factor, HPV, FGF, head and neck squamous cell carcinoma, HNSCC, everolimus, tyrosine kinase inhibitors, mTOR inhibitors, 5621
- Fibroblast, monocyte, macrophage, hyaluronan, elastin, lipopolysaccharide, 4681
- Fibroepithelial lesions, phyllodes tumors, fibroadenoma, score, 1095
- Fibrolamellar, hepatocellular carcinoma, prognosis, outcome, 847
- Fibronectin, oxazolindiones, neuroblastoma, kelly cell line, proliferation, progression, BSA heat denaturation, adhesion, 5125
- Fibrosis, hypertension, chemerin, tumor marker, 143
- Fibrosis, necrosis, non-small cell lung cancer, lymph node, chemoradiotherapy, 4419
- Fibrosis, OSCC, bMF, biomarker, tumor microenvironment, 4319
- Fine-needle, biopsy, large-core needle, pancreatic neoplasms, endosonography, 5845
- First-line treatment, cetuximab, panitumumab, overall survival, metastatic colorectal cancer, hypomagnesemia, 7135
- FIT, colorectal cancer, diagnosis, screening, fecal occult blood test, FOBT, fecal immunochemical test, false-negative, false-positive, review, 575
- FIT, fecal occult blood, guaiac-based test, fecal immunochemical test, gFOBT, iFOBT, colorectal cancer screening, meta-analysis, sensitivity, specificity, false negative, false positive, ROC, HSROC, 3591
- Five-year survival, docetaxel/cisplatin/5-fluorouracil, oesophageal cancer, oesophagectomy, preoperative chemotherapy, 5829
- Flap, intraoperative radiotherapy, IORT, limb salvage, soft-tissue reconstruction, 6941
- Flavonoid, PI3K, inhibitor, protein kinase, anti-cancer, virtual screening, 4547
- Flavopereirine,  $\beta$ -carboline alkaloid, hepatocarcinoma, apoptosis, autophagy, cell-cycle arrest, 6907
- Flow cytometry, glioma, viability, polyphenols, DRAQ7, MTT, 5427
- Flow cytometry, igG4-related ophthalmic disease, lymphoma, 2019
- Flow cytometry, neuropilin, cytokine-induced killer cells, immunology, lung cancer, brain tumor, 5489
- Flow cytometry, ovarian cancer, cytokine-induced killer cell, peripheral blood mononuclear cell, chemotherapy, 3865
- Fluorescence imaging, indocyanine green, mediastinal lymphatic metastasis, orthotopic implantation, squamous lung carcinoma, 1875
- Fluorescence pattern, surgical margin, ICG fluorescence-guided surgery, fluorescence width, laparoscopic liver resection, 3873
- Fluorescence width, surgical margin, ICG fluorescence-guided surgery, fluorescence pattern, laparoscopic liver resection, 3873
- Fluorescence, preoperative marking, colorectal cancer, gastric cancer, 6517
- Fluorodeoxyglucose, multidetector computed tomography, positron-emission tomography, iodine, lung cancer, dual-energy, 3459
- Fluoropyrimidine-based chemotherapy, metastatic colorectal cancer, methylenetetrahydrofolate reductase, sNPs, side effects, mestizo population, 4263
- FOBT, colorectal cancer, diagnosis, screening, fecal occult blood test, fecal immunochemical test, FIT, false-negative, false-positive, review, 575
- FOLFIRINOX, PDAC, pancreatic cancer, chemosensitivity, gemcitabine, paclitaxel, 3659
- Follicular lymphoma, EZH2, POD24, time to first systemic therapy, prognostic factors, expression profile, 6685
- Follow-up, MRI, rectal cancer, lymph node, neoadjuvant therapy, metastases, 2757
- Forkhead box C1 (FOXC1), chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII), colorectal cancer, akt,  $\beta$ -catenin, 177
- FOXO3A, *HER2*, trastuzumab, esophageal squamous cell carcinoma, 1921
- FOXO4, cholangiocarcinoma, cell cycle,  $G_0/G_1$  arrest, 6899
- FOXP3, breast cancer, tumor infiltrating lymphocytes, CD8, 2141
- Fractionated stereotactic radiotherapy, glioblastoma, boost, toxicity, survival, 3387
- Fractionated stereotactic radiotherapy, stereotactic radiosurgery, distant brain metastases, elderly patients, prognostic instrument, 4081
- Free vascularized fibula flap, upper extremity, limb salvage, oncologic resection, 2751
- Frequency, colon, innominate grooves, tributary crypts, ulcerative colitis, 7031
- FSHr, HNSCC, neoangiogenesis, histopathology, immunohistochemistry, 349
- FT3, breast cancer, thyroid gland, TSH, FT4, silencing mediator for retinoid and thyroid receptors, prognosis, 6417
- FT4, breast cancer, thyroid gland, TSH, FT3, silencing mediator for retinoid and thyroid receptors, prognosis, 6417
- FTD/TPI, TAS-102, bevacizumab, 4157
- Fucoxanthin, glioblastoma, apoptosis, migration, invasion, angiogenesis, 6799
- Functional loss, tGF $\beta$  signaling, mammary cancer, environmental carcinogen, 2687
- Fusion gene, integration, HBV S, human ESPL1, hepatocellular carcinoma, biomarker, 245
- $G_0/G_1$  arrest, FOXO4, cholangiocarcinoma, cell cycle, 6899

- G<sub>0</sub>/G<sub>1</sub> cell cycle arrest, lung cancer, tannic acid, intrinsic apoptosis, 3209
- G1 arrest, peroxisome proliferator-activated receptor  $\gamma$ , troglitazone, oral SCC, apoptosis, 1247
- G2 checkpoint, temozolomide, resistance, DNA mismatch repair, glioblastoma, 1315
- GABARAPL1, non-small cell lung cancer, radiotherapy, autophagy, histone modification, 2537
- Galactoscopy, breast cancer, nipple discharge, mammary ductoscopy, endoscopic classification, 2185
- Gallbladder cancer, *miR-146a*, *rs2910164*, single nucleotide polymorphism, esophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, cholangiocarcinoma, pancreatic cancer, 1495
- Gallbladder, carcinoma, IMP3, immunohistochemistry, prognosis, 5777
- Gallstone disease, cancer, surgery, plasma MDA, plasma CAT, NRS pain score, 5701
- Gamma rays, apoptosis, cancer, cell cycle, cytotoxicity, platinum(IV) complexes, 5001
- Gamma/delta T-cell, immunocellular therapy, bladder cancer, chemotherapy, cytotoxicity, 5221
- Gant61, NSCLC, Hedgehog pathway, pemetrexed, chemo resistance, 1451
- Garlic, differentiation, apoptosis, human promyelocytic leukemia, HL-60 cells, diallyl sulfide, gas chromatography-mass spectrometry, 6345
- Gas chromatography-mass spectrometry, differentiation, apoptosis, human promyelocytic leukemia, HL-60 cells, garlic, diallyl sulfide, 6345
- Gastrectomy, ca 72.4, gastric cancer, tumor antigen, gastric juice, 1691
- Gastrectomy, gastric cancer, psoas muscle, survival rate, 4271
- Gastrectomy, systemic inflammation score, gastric cancer, 1503
- Gastric cancer, *AMIGO2*, prognosis, biomarker, 6713
- Gastric cancer, anti-PD-(L)1, chemotherapy, immune checkpoint inhibitor, 2247
- Gastric cancer, asian Americans, survival outcomes, 6381
- Gastric cancer, ca 72.4, tumor antigen, gastric juice, gastrectomy, 1691
- Gastric cancer, connexins, prognosis, 4537
- Gastric cancer, conversion surgery, itraconazole, repurposing, 991
- Gastric cancer, disease-free survival, overall survival, anastomotic leakage, review, 619
- Gastric cancer, disparities, outcomes, race, 881
- Gastric cancer, drug resistance, 5-FU, EMT, cell cycle, p57, cyclin D1, 3247
- Gastric cancer, fluorescence, preoperative marking, colorectal cancer, 6517
- Gastric cancer, genotype, *MMP7*, polymorphism, Taiwan, 695
- Gastric cancer, glioma-associated oncogene 1, adjuvant chemotherapy, S-1, prognostic factor, 5815
- Gastric cancer, intraoperative blood loss, overall survival, prognosticator, 405
- Gastric cancer, liver metastasis, patient-derived orthotopic xenograft (PDOX), nude mice, 5-fluorouracil, oxaliplatin, gemcitabine, 5393
- Gastric cancer, microRNAs, microRNA-449a, miR-449a, 239
- Gastric cancer, minimal invasive surgery, postoperative infectious complications, surgical stress, prognosis, 7109
- Gastric cancer, miR-1, LITAF, 6247
- Gastric cancer, *miR-146a*, *rs2910164*, single nucleotide polymorphism, esophageal cancer, colorectal cancer, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, pancreatic cancer, 1495
- Gastric cancer, nivolumab, cancer cachexia, overall survival, time to treatment failure, 7067
- Gastric cancer, peritoneal carcinomatosis, HIPEC, cytoreductive surgery, 2151
- Gastric cancer, postoperative complication, recurrence, adjuvant chemotherapy, 1683
- Gastric cancer, postoperative infectious complications, prognostic factor, 4067
- Gastric cancer, psoas muscle, gastrectomy, survival rate, 4271
- Gastric cancer, RNF126, E3 ubiquitin ligase, 1367
- Gastric cancer, systemic inflammation score, gastrectomy, 1503
- Gastric cancer, TAM, TYRO3, prognostic factor, 5593
- Gastric cancer, Trousseau' syndrome, neoplastic venous thrombosis, internal jugular vein, 2889
- Gastric cancer, ultrasonically-activated surgical device, dissemination, 3163
- Gastric cancer, upper gastrointestinal tract, esophageal cancer, chemotherapy, *HER2*, 965
- Gastric cancer, ZKSCAN3 (ZNF306), prognosis, 81
- Gastric juice, ca 72.4, gastric cancer, tumor antigen, gastrectomy, 1691
- Gastrin-17, *Helicobacter pylori*, hp IgG ELISA, gastroPanel, new-generation, clinical validation, non-invasive, biomarker test, gastroscopy, biopsy, pepsinogen I, pepsinogen II, 6387
- Gastrointestinal cancer, chemotherapy-induced neurotoxicity, oxaliplatin, colorectal cancer, 865
- Gastrointestinal stromal tumor (GIST), synchronous primary malignancy, rectal adenocarcinoma; small cell lung carcinoma, immunohistochemistry; microsatellite stable, chemotherapy, 7053
- Gastrointestinal stromal tumor, imatinib mesylate, neoadjuvant treatment, giant tumor, 1147
- Gastrointestinal stromal tumour, GIST, imatinib, real-world, survival, safety, 435

- Gastrointestinal tumors, sAbR, lung metastases, oligometastatic disease, 5901
- GastroPanel, *Helicobacter pylori*, hp IgG ELISA, new-generation, clinical validation, non-invasive, biomarker test, gastroscopy, biopsy, pepsinogen I, pepsinogen II, gastrin-17, 6387
- Gastroscopy, *Helicobacter pylori*, hp IgG ELISA, gastroPanel, new-generation, clinical validation, non-invasive, biomarker test, biopsy, pepsinogen I, pepsinogen II, gastrin-17, 6387
- Gastrostomy, PEG, RPG, head and neck cancer, nutrition, 1167
- GATA3, breast cancer, prognostic parameters, ki-67, 5649
- Gefitinib resistance, AGR2, NSCLC, mutant NSCLC, yuanhuadine, ADAMTS6, 1855
- Gefitinib, FAS CD95, FAS ligand, caspase-3, TKI, apoptosis, nilotinib, dasatinib, erlotinib, everolimus, 6195
- Gefitinib, IGF1R, insulin-like growth factor 1 receptor, TKI, head and neck squamous cell carcinoma (HNSCC), nilotinib, dasatinib, erlotinib, everolimus, 3847
- Gefitinib, PDGF, PDGFR, head and neck squamous cell carcinoma, drug resistance, afatinib, nilotinib, dasatinib, erlotinib, 825
- Gelatinases, matrix metalloproteinases, polymorphisms, circulating levels, breast cancer risk, review, 3619
- Gelfoam, 3-D culture, histoculture, patient-derived cancer cells, PDCC, patient-derived xenograft, PDX, 6765
- Gemcitabine, advanced urothelial carcinoma, second-line chemotherapy, paclitaxel, cisplatin, 1613
- Gemcitabine, biliary tract carcinoma, pazopanib, phase II study, 929
- Gemcitabine, clear cell sarcoma, chemotherapy, EWSR1 translocation, 7003
- Gemcitabine, gastric cancer, liver metastasis, patient-derived orthotopic xenograft (PDOX), nude mice, 5-fluorouracil, oxaliplatin, 5393
- Gemcitabine, mesothelioma, imidazo[2, 1-*b*][1, 3, 4]thiadiazole compounds, FAK, human equilibrative nucleoside transporter-1, 4913
- Gemcitabine, non-small cell lung carcinoma, pharmacogenomics, messenger RNA, RRM1, RRM2, CDA, dCK, hENT1, 901
- Gemcitabine, pancreatic cancer, chemotherapy, cisplatin, capecitabine, docetaxel, 4011
- Gemcitabine, PDAC, pancreatic cancer, chemosensitivity, FOLFIRINOX, paclitaxel, 3659
- Gemcitabine, thrombotic microangiopathy, eculizumab, chemotherapy complications, pancreatic cancer, 3995
- Gender, age, genotype, *MMP-1*, polymorphism, pterygium, Taiwan, 703
- Gender, age, genotype, *MMP-9*, polymorphism, pterygium, Taiwan, 4523
- Gender, multiple myeloma, interleukin-8, sRAGE, oxidative stress, cancer, 1443
- Gene expression omnibus, ovarian epithelial cancer, LRRC17, survival analysis, zebrafish, apoptosis, TCGA, 5601
- Gene Expression Omnibus, uveal melanoma, the Cancer Genome Atlas, prognosis, bioinformatics, 3839
- Gene expression, kallikreins, kallikrein-related peptidases, breast cancer, cluster analysis, 2487
- Gene expression, multiple myeloma, apoptosis, myeloma cell lines, 4979
- Gene mutations, gut microbiota, colorectal cancer, stool DNA, 16S rRNA gene sequencing, 1325
- Gene polymorphism, malignant melanoma, melanoma risk, meta-analysis, vitamin D receptor, review, 583
- Gene therapy, GPR87, shRNA, adenoviral vector, cell surface marker, NSCLC, 733
- GeneXpert, MGMT promoter methylation, glioblastoma, pyrosequencing, 6229
- Genome stability, DNA replication, DNA repair, chromatin, cell cycle, cdt1, review, 2449
- Genomics, vitamin D, supplementation, metabolomics, broad gene expression, metabolomic profile, individual response, personalized medicine, 25-hydroxyvitamin D, 535
- Genotype, acute lymphocytic leukemia, case-control study, childhood, *MMP-9*, polymorphism, Taiwan, 5751
- Genotype, *ADIPOQ*, colorectal cancer, polymorphism, Taiwan, 1297
- Genotype, age, gender, *MMP-1*, polymorphism, pterygium, Taiwan, 703
- Genotype, age, gender, *MMP-9*, polymorphism, pterygium, Taiwan, 4523
- Genotype, alcohol drinking, betel quid, interleukin-12A, oral cancer, polymorphism, smoking, Taiwan, 3707
- Genotype, bladder cancer, case-control study, *NBS1*, polymorphism, 2011
- Genotype, breast cancer, interleukin-13, polymorphism, Taiwan, 6743
- Genotype, case-control study, caspase-8, nasopharyngeal carcinoma, polymorphism, Taiwan, 5503
- Genotype, childhood leukemia, miR-196a-2, polymorphism, Taiwan, 4465
- Genotype, gastric cancer, *MMP7*, polymorphism, Taiwan, 695
- Genotype, nasopharyngeal, cancer, CT, MRI, sNPs, polymorphism, variations, VEGFA, EDNRA *NBS1*, FAS, 677
- Geographical, home death, palliative cancer patients, register study, 3897
- Geriatric nutritional risk index, colorectal liver metastasis, prognosis, 4165
- Germline mutation, synchronous rhabdoid tumor, cell line, DNA methylation analysis, 6159
- Germline mutation, tumor mutation burden, tumor neoantigen, 4567

- GFOBT, fecal occult blood, guaiac-based test, fecal immunochemical test, iFOBT, FIT, colorectal cancer screening, meta-analysis, sensitivity, specificity, false negative, false positive, ROC, HSROC, 3591
- GFP, bladder cancer, orthotopic, nude mice, cisplatin, oral recombinant methioninase, combination, sensitize, efficacy, 6083
- Giant cell tumor of tendon sheath, cytogenetics, chromosome translocation, CSF1, 4373
- Giant tumor, gastrointestinal stromal tumor, imatinib mesylate, neoadjuvant treatment, 1147
- Ginseng seed oil, oleic acid, ER+, breast cancer, tamoxifen, 4529
- GIST, gastrointestinal stromal tumour, imatinib, real-world, survival, safety, 435
- Gleason grade, nucleolar proteins, prostate cancer, local spread, neoplasm invasiveness, 1973
- GLI1 isoform 2 protein, pericytoma, t(7;12), *ACTB-GLI1* fusion gene, unbalanced chromosome translocation, 1239
- Glial tumors, glioblastoma, microRNA, miRNA-221, biomarker, 3265
- Glioblastoma multiforme, longer-course radiotherapy, local control, survival, prognostic factors, 7025
- Glioblastoma, adrenal insufficiency, secondary adrenal insufficiency, steroid dependence, glioma, 2059
- Glioblastoma, angiogenesis, endothelial cells, cell crosstalk, *MMP-9*, *CXCR4*, 2725
- Glioblastoma, chimeric antigen receptor, natural killer cells, epidermal growth factor receptor variant III, 3231
- Glioblastoma, fractionated stereotactic radiotherapy, boost, toxicity, survival, 3387
- Glioblastoma, fucoxanthin, apoptosis, migration, invasion, angiogenesis, 6799
- Glioblastoma, glial tumors, microRNA, miRNA-221, biomarker, 3265
- Glioblastoma, inflammation, routine laboratory parameter, 1161
- Glioblastoma, kisspeptin, *KISS1*, *KISS1R*, brain tumor, 213
- Glioblastoma, MGMT promoter methylation, pyrosequencing, geneXpert, 6229
- Glioblastoma, superparamagnetic iron oxide nanoparticles, SPION, drug-delivery, review, 5989
- Glioblastoma, temozolomide, resistance, G2 checkpoint, DNA mismatch repair, 1315
- Glioma-associated oncogene 1, gastric cancer, adjuvant chemotherapy, S-1, prognostic factor, 5815
- Glioma, acetylenic synthetic betulin derivatives, betulin, chemotherapy, 6151
- Glioma, adrenal insufficiency, secondary adrenal insufficiency, steroid dependence, glioblastoma, 2059
- Glioma, nicotinamide phosphoribosyltransferase, shRNA, 4895
- Glioma, pregnancy, iDHmutated, radiation, 3453
- Glioma, seizures, radiation therapy, prevalence, risk factors, survival, 3961
- Glioma, temozolomide, AZD7762, cytotoxicity, 5141
- Glioma, viability, polyphenols, flow cytometry, DRAQ7, MTT, 5427
- Gliomas, adaptive radiotherapy, replanning, brain tumor, 4237
- Glucan, cancer, phagocytosis, IL-2, infection, 3139
- Glutamine metabolism, senescence, mTOR, DNA damage, 6891
- Glutathione, hepatocellular carcinoma, cirrhosis, oxidative stress, circulating leukocytes, nitric oxide, 6853
- Glycobiology, tumor growth, wound healing, vessel sprouting, sugar code, 3191
- Glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ), peroxisome proliferator activated receptor  $\gamma$  coactivator-1 $\alpha$  (PGC-1 $\alpha$ ), colorectal cancer, AKT,  $\beta$ -catenin, 653
- Glyoxalase 1, piceatannol, anxiolytic effect, antitumor effect, 3271
- GNAS, pancreatic juice, pancreatic neoplasms, pancreatic cyst, KRAS, secretin-induced duodenal aspiration, 4215
- GPR115, ADGRF4, PPP4C, lung cancer, cell invasiveness, 6835
- Gpr30, ccl18 protein, epithelial-mesenchymal transition (EMT), cancer, metastasis, 3097
- GPR87, shRNA, gene therapy, adenoviral vector, cell surface marker, NSCLC, 733
- Grade Groups, prostate cancer, thyroid hormones, triiodothyronine, prostatectomy, pathological T stage, tumor percentage involvement, 2323
- Grade, vitamin D, gynaecological cancers, seasonal influence, menopause status, age, nicotine abuse, 545
- Grape stem extracts, greek vine varieties, antioxidants, antimutagenic properties, polyphenols, bio-functional foods, 2025
- Greek vine varieties, grape stem extracts, antioxidants, antimutagenic properties, polyphenols, bio-functional foods, 2025
- Grid, carcinoma, oral, chromosome, polysomy, microscopy, 3759
- Gross tumour volume, positron emission tomography, radiotherapy planning, auto-delineation, digital positron emission tomography, 2567
- Growth inhibition, vitamin D, 1, 25-D<sub>3</sub>, ovarian cancer, *in vitro*, paclitaxel, carboplatin, VDR, 3129
- Growth rate, cold atmospheric plasma, antiproliferative effect, cell growth inhibition, 3743
- GSK-3 $\beta$ , catalytic topo I inhibitor, cyclin D1 accumulation, ATR, PTEN, akt, 6237
- Guaiac-based test, fecal occult blood, fecal immunochemical test, gFOBT, iFOBT, FIT, colorectal cancer screening, meta-analysis, sensitivity, specificity, false negative, false positive, ROC, HSROC, 3591

- Guaiazulene-3-carboxylate, QSAR, OSCC, tumor-specificity, molecular shape, ionization potential, 4885
- Gut microbiota, gene mutations, colorectal cancer, stool DNA, 16S rRNA gene sequencing, 1325
- Gut microbiota, *vitamin D<sub>3</sub>*, 25-hydroxyvitamin D, *vitamin D<sub>3</sub>* supplementation, randomized clinical trial, 551
- Gynaecological cancers, vitamin D, seasonal influence, menopause status, age, nicotine abuse, grade, 545
- Gynaecology, angiosarcoma, hemangiosarcoma, cancer, uterine sarcoma, ovarian sarcoma, chemotherapy, paclitaxel, laparotomy, osseous metastasis, 5743
- Gynecologic cancer-related lymphedema, age, secondary lymphedema, iatrogenic lymphedema, lymphedema, plastic surgery, review, 6609
- Gynecological cancer, brain metastasis, elderly, whole-brain irradiation, survival prognosis, 2257
- H&E staining, nucleolus, uveal melanoma, prognosis, 3505
- HA22T/VGH, cetyltrimethylammonium bromide (CTAB), hepatic cancer, mesenchymal to epithelial transition, 4513
- Hadrontherapy, carbon ion radiotherapy, axial bone sarcomas, soft tissue sarcomas, 2853
- Hadrontherapy, proton beam radiotherapy, angiosarcoma, 1645
- Haemangioma, vascular malformation, intraosseous, orbit, cone beam computed tomography, 3D reconstruction, bone mineral density, immunohistochemistry, differential diagnosis, 3333
- Hand, outcome, soft tissue sarcoma, radiotherapy, 1463
- HBc antibody, hepatitis B virus, head and neck cancer, multivariate analysis, 2393
- HBV S, integration, fusion gene, human ESPL1, hepatocellular carcinoma, biomarker, 245
- HCC, postoperative ascites, m2BPGi, VTQ, hepatic resection, ALBI grade, 4343
- HCC, primary hepatic carcinosarcoma, collision tumor, hepatocellular carcinoma, cholangiocarcinoma, CC, osteosarcoma, and rhabdomyosarcoma, 2225
- HCC, RSF3, *SF3B4*, mRNA stability, SNU-368, 2033
- HCC, sorafenib, sarcopenia, carnitine, liver cirrhosis, 4173
- HDAC activity, vorinostat, I3C, triple negative breast cancer, estrogen receptor, progesterone receptor, HDAC7, 3669
- HDAC inhibitors, apoptosis, epithelial-to-mesenchymal transition, breast cancer, cancer epigenetics, DNMT inhibitors, phytochemicals, 9
- HDAC7, vorinostat, I3C, triple negative breast cancer, estrogen receptor, progesterone receptor, HDAC activity, 3669
- HDM-2, cancer cell membrane, leukemia, PNC-27, 4857
- HDR-BT, prostate cancer, brachytherapy, daily replanning, 1677
- Head and neck cancer, hepatitis B virus, hBc antibody, multivariate analysis, 2393
- Head and neck cancer, PEG, RPG, gastrostomy, nutrition, 1167
- Head and neck cancer, periostin, radioresistance, epithelial-to-mesenchyma transition, 2627
- Head and neck cancer, phytochemicals, light, EGF receptor, oxidative stress, 751
- Head and neck cancer, saliva, recurrence, metastasis, circulating DNA, animal model, 191
- Head and neck cancer, squamous cell carcinoma, positron emission tomography, extranodal extension, lymph node metastasis, 2073
- Head and neck cancer, unknown primary, human papillomavirus, oropharyngeal cancer, survival, 4207
- Head and neck carcinoma, salvage chemotherapy, immune checkpoint inhibitor, nivolumab, recurrent or metastatic, best supportive care, 5277
- Head and neck neoplasms, ulcerated melanoma, NCDB, united States/epidemiology, 1055
- Head and neck squamous carcinoma, MTOR, chemoprevention, 5417
- Head and neck squamous carcinoma, pPAR $\gamma$ , ciglitazone, thiazolidinedione, 9-cis-retinoic acid, retinoids, 3071
- Head and neck squamous cell carcinoma (HNSCC), IGF1R, insulin-like growth factor 1 receptor, TKI, nilotinib, dasatinib, erlotinib, gefitinib, everolimus, 3847
- Head and neck squamous cell carcinoma, apoptosis, cholesterol, oxysterol, 25-hydroxycholesterol, 779
- Head and neck squamous cell carcinoma, computed tomography, texture analysis, machine learning, 271
- Head and neck squamous cell carcinoma, epithelial-mesenchymal transition, circulating tumor cell, recurrence, metastasis, 3559
- Head and neck squamous cell carcinoma, fibroblast growth factor, HPV, FGF, HNSCC, everolimus, tyrosine kinase inhibitors, mTOR inhibitors, 5621
- Head and neck squamous cell carcinoma, PDGF, PDGFR, drug resistance, afatinib, nilotinib, dasatinib, erlotinib, gefitinib, 825
- Head and neck, HPV, p16, PTEN, oral squamous cell carcinoma, 6355
- Health-related quality of life, prostate cancer, brachytherapy, 6443
- Healthcare use, breast neoplasm, second primary neoplasms, treatment, 1041
- Healthy population, oral HPV prevalence, HPV antibodies, oropharyngeal cancer, 1597
- Heated intraperitoneal chemotherapy, cytoreductive surgery, ileus, length of stay, small intestine, 2865
- Hedgehog pathway, NSCLC, pemetrexed, chemo resistance, gant61, 1451
- Hedgehog signaling, vismodegib, castration-resistant prostate cancer, sonic Hedgehog, epithelial-mesenchymal transition, 5107
- HeLa cells, apoptosis, ciprofloxacin, colony formation, migration ability, 5025

- HeLa cells, carbon-ion beams, linear energy transfer, cell-killing effect, radiosensitizing effect, 5497
- HeLa cells, maslinic acid, human cervical cancer, DNA damage, DNA condensation and fragmentation, 6869
- Helicobacter pylori*, hp IgG ELISA, gastroPanel, new-generation, clinical validation, non-invasive, biomarker test, gastroscopy, biopsy, pepsinogen I, pepsinogen II, gastrin-17, 6387
- Hellenic Cooperative Oncology Group, bevacizumab, erlotinib, tumor metrics, non-small cell lung cancer, 2095
- Hemangiosarcoma, angiosarcoma, gynaecology, cancer, uterine sarcoma, ovarian sarcoma, chemotherapy, paclitaxel, laparotomy, osseous metastasis, 5743
- Hematogenous metastasis, leiomyosarcoma, tumor stem cell, angiogenesis, 1255
- Hematogenous metastasis, microvascular invasion, hepatocellular carcinoma, prognosis, 3983
- Hematologic malignancies, *ANRIL*, single nucleotide polymorphism, *ARF-INK4* locus, allogeneic hematopoietic stem cell transplantation, 5707
- Hematopoietic cell transplantation, mucositis, palifermin, children, risk factors analysis, keratinocyte growth factor, 6531
- HENT1, non-small cell lung carcinoma, gemcitabine, pharmacogenomics, messenger RNA, RRM1, RRM2, CDA, dCK, 901
- Hepatectomy, laparoscopic, transumbilical incision, 6545
- Hepatic cancer, cetyltrimethylammonium bromide (CTAB), HA22T/VGH, mesenchymal to epithelial transition, 4513
- Hepatic cancer, cetyltrimethylammonium bromide, CTAB, mahlavu, fibroblast growth factor, FGF, 5059
- Hepatic encephalopathy, hepatocellular carcinoma, lenvatinib, portal vein flow velocity, 5271
- Hepatic resection, postoperative ascites, m2BPGi, VTQ, HCC, ALBI grade, 4343
- Hepatic stellate cell, hepatocellular carcinoma, interleukin-6, 743
- Hepatitis B virus, head and neck cancer, hBc antibody, multivariate analysis, 2393
- Hepatocarcinoma, flavopereirine,  $\beta$ -carboline alkaloid, apoptosis, autophagy, cell-cycle arrest, 6907
- Hepatocellular carcinoma,  $\beta$ -catenin, wnt, CBP, inhibitor, PRI-724, 5211
- Hepatocellular carcinoma, adrenal metastasis, indocyanine green fluorescent imaging, 5823
- Hepatocellular carcinoma, alpha fetoprotein, lenvatinib, ramucirumab, second-line therapy, 2089
- Hepatocellular carcinoma, androgen receptor, epCAM, sorafenib, 1285
- Hepatocellular carcinoma, cancer-associated thrombosis, superior mesenteric vein thrombosis, direct oral anticoagulant, liver resection, 6465
- Hepatocellular carcinoma, carbon ion radiotherapy, intensity-modulated radiotherapy, vascular invasion, 459
- Hepatocellular carcinoma, cirrhosis, oxidative stress, circulating leukocytes, nitric oxide, glutathione, 6853
- Hepatocellular carcinoma, contrast media, ultrasonography, portal vein, 4351
- Hepatocellular carcinoma, CXCL1, CXCR2, palmitate, 6075
- Hepatocellular carcinoma, downstaging, low dose FP, salvage surgery, 4773
- Hepatocellular carcinoma, fibrolamellar, prognosis, outcome, 847
- Hepatocellular carcinoma, hepatic stellate cell, interleukin-6, 743
- Hepatocellular carcinoma, immunohistochemistry, tumor morphology, 4105
- Hepatocellular carcinoma, integration, fusion gene, HBV S, human ESPL1, biomarker, 245
- Hepatocellular carcinoma, lenvatinib, portal vein flow velocity, hepatic encephalopathy, 5271
- Hepatocellular carcinoma, methylation of N6 adenosine, RNA demethylase, prognosis, 6665
- Hepatocellular carcinoma, microbiome, sorafenib, tyrosine kinase inhibitors, 665
- Hepatocellular carcinoma, microvascular invasion, hematogenous metastasis, prognosis, 3983
- Hepatocellular carcinoma, *miR-146a*, *rs2910164*, single nucleotide polymorphism, esophageal cancer, gastric cancer, colorectal cancer, cholangiocarcinoma, gallbladder cancer, pancreatic cancer, 1495
- Hepatocellular carcinoma, primary hepatic carcinosarcoma, collision tumor, HCC, cholangiocarcinoma, CC, osteosarcoma, and rhabdomyosarcoma, 2225
- Hepatocellular carcinoma, quercetin, antiproliferation effect, apoptosis, 4695
- Hepatocellular carcinoma, radioembolization, tumor calcification, 4191
- Hepatocellular carcinoma, sorafenib, lenvatinib, portal vein tumor thrombosis, 2283
- Hepatocellular carcinoma, sorafenib, second-line therapy, sequential therapy, tumor burden, 3953
- Hepatocellular carcinoma, surveillance, screening, diagnosis, biomarkers, tumor biology, liver tumors, review, 6573
- HER2* gene amplification, breast cancer, *TP53* mutation, estrogen receptor, early recurrence, 645
- HER2*-positive, metastatic breast cancer, re-therapy, trastuzumab, 3973
- HER2*, advanced gastric cancer, trastuzumab, chemotherapy, 75
- HER2*, breast cancer, trastuzumab, 3315
- HER2*, FOXO3A, trastuzumab, esophageal squamous cell carcinoma, 1921
- HER2*, upper gastrointestinal tract, gastric cancer, esophageal cancer, chemotherapy, 965

- Herbal, systems biology, network pharmacology, combination, breast cancer, pharmacological mechanism, 5097
- Heterogeneity, esophageal cancer adenocarcinoma, circulating tumor cells, CAML, cytopathology, 5679
- HIF-1 $\alpha$ , silibinin, eIF4E, RPS6, ovarian clear-cell carcinoma, 6791
- HIF, KRAS, MK615, colon cancer, e-cadherin, prunus mume, 4687
- HIF1 inhibitors, HIF1 $\alpha$ , vasculogenic mimicry, apoptosis, acriflavine, 5379
- HIF1 $\alpha$ , vasculogenic mimicry, HIF1 inhibitors, apoptosis, acriflavine, 5379
- High cardiovascular risk profile, abdominal aortic aneurysm, screening, lung cancer, 4137
- High grade neuro-endocrine tumor, extra pulmonary small cell carcinoma, esophageal cancer, thoracic surgery, chemotherapy, 5919
- High inferior mesenteric artery tie, defecatory dysfunction, low inferior mesenteric artery tie, sigmoidal cancer, 2969
- High inferior mesenteric artery tie, urinary dysfunction, sexual dysfunction, low inferior mesenteric artery tie, rectal cancer, 4223
- High-dose-rate brachytherapy, cervical cancer, pre-brachytherapy magnetic resonance imaging, radiotherapy, 999
- High-fat diet, metabolomics, mammary tumor, mMTV-PyMT, mice, 3697
- High-fat diet, time-restricted feeding, cancer immunotherapy, 5445
- High-grade glioma, activated dendritic cell, immunotherapy, HLA-A24, phase II trial, 6473
- High-grade prostate cancer, prostate cancer, prostate biopsy, endoglin, sCD105, 1459
- High-grade serous carcinoma, *LINK-A*, long non-coding RNA, cRISPR/Cas9, tumorigenesis, *in vitro*, 6677
- High-grade serous carcinoma, peritoneum, cytology, metastatic breast carcinoma, 2933
- High-grade urothelial carcinoma, urine, cytology, the Paris System, atypical urothelial cell, low-grade urothelial neoplasm, 3477
- High-molecular weight oligomers, colorectal cancer, adiponectin, adipoR1, adipoR2, t-cadherin, 3751
- High-risk factor, adjuvant chemotherapy, mucinous adenocarcinoma, stage II, 1651
- High-risk HPV, smoking, anogenital warts, sexually transmitted infection, *Mycoplasma genitalium*, *Mycoplasma hominis*, *Ureaplasma spp*, 2219
- High-throughput screening, isocitrate dehydrogenase 1, mutation, IDH1 R132H, 2-hydroxyglutarate, 4929
- Hill criteria, sunbeds, melanoma, solarium, tanning, 501
- HIPEC, gastric cancer, peritoneal carcinomatosis, cytoreductive surgery, 2151
- HIPEC, hyperthermic intraperitoneal intraoperative chemotherapy, ovarian cancer, side effects, cisplatin, 1481
- HIPEC, paclitaxel, docetaxel, hyperthermia, ovarian cancer, *in vitro* study, intraperitoneal chemotherapy, 6769
- Histoculture, 3-D culture, gelfoam, patient-derived cancer cells, PDCC, patient-derived xenograft, PDX, 6765
- Histological changes, proton, photon, zebrafish embryo model, DNA-DSB, morphological malformations, 6123
- Histological effect, SSEA-4, neoadjuvant hormonal therapy, biochemical recurrence, prostate cancer, 5567
- Histological examination, breast cancer, neoadjuvant chemotherapy, complete pathological response, MRI accuracy, 281
- Histological grade, soft-tissue sarcoma, metastasis, tumor site, early consultation, early referral, 7009
- Histological variant, urothelial carcinoma, radical cystectomy, clinical outcomes, 4787
- Histone modification, non-small cell lung cancer, radiotherapy, autophagy, GABARAPL1, 2537
- Histones, mast cells, mastocytosis, demethylase, caspases, 2525
- Histopathology, fShr, HNSCC, neoangiogenesis, immunohistochemistry, 349
- HL-60 cells, differentiation, apoptosis, human promyelocytic leukemia, garlic, diallyl sulfide, gas chromatography-mass spectrometry, 6345
- HLA-A24, activated dendritic cell, immunotherapy, high-grade glioma, phase II trial, 6473
- HNSCC human head and neck cell, nitric oxide, isogenic cell lines, cell proliferation, apoptosis, invasiveness, matrix metalloproteinases, 2657
- HNSCC, ABCG2, CSC, cisplatin, piCa, faDu, 1277
- HNSCC, fibroblast growth factor, HPV, FGF, head and neck squamous cell carcinoma, everolimus, tyrosine kinase inhibitors, mTOR inhibitors, 5621
- HNSCC, fShr, neoangiogenesis, histopathology, immunohistochemistry, 349
- HNSCC, lncRNA, *MALAT1*, radiation sensitivity, cisplatin sensitivity, 2645
- HNSCC, ROBO1, photochemical internalization, immunotoxin, drug delivery system, 3793
- Hodgkin's lymphoma, luteolin, cancer, mix cellularity classical Hodgkin's lymphoma, 4907
- Holocarboxylase synthetase, biotin-dependent carboxylases, biotin, breast cancer, metabolism, 4557
- Home death, geographical, palliative cancer patients, register study, 3897
- Hormone, breast cancer, calcium, src, anticancer effect, 1989
- Hospital volume, textbook outcome, retroperitoneal sarcoma, National Cancer Database, survival, 2107
- Hounsfield units, CT, systemic mastocytosis, 1015



- Hp IgG ELISA, *Helicobacter pylori*, gastroPanel, new-generation, clinical validation, non-invasive, biomarker test, gastroscopy, biopsy, pepsinogen I, pepsinogen II, gastrin-17, 6387
- HPV antibodies, oral HPV prevalence, healthy population, oropharyngeal cancer, 1597
- HPV, fibroblast growth factor, FGF, head and neck squamous cell carcinoma, HNSCC, everolimus, tyrosine kinase inhibitors, mTOR inhibitors, 5621
- HPV, head and neck, p16, PTEN, oral squamous cell carcinoma, 6355
- HPV, self-sampling, ethiopia, screening, cervical cancer, 1513
- HSP90 inhibitor, thyroid carcinoma, AUY922, BIIB021, SNX5422, bim, 6137
- HSROC, acute cholecystitis, acute abdominal pain, diagnostic score, ROC, diagnostic accuracy, 6947
- HSROC, fecal occult blood, guaiac-based test, fecal immunochemical test, gFOBT, iFOBT, FIT, colorectal cancer screening, meta-analysis, sensitivity, specificity, false negative, false positive, ROC, 3591
- HT-29 cells, methylsulfonylmethane, apoptosis, cell cycle arrest, stemness, 5191
- HTLV-1, ATL, antibody drug conjugate, cancer chemotherapy, immunotherapy, 4471
- Human cervical cancer, maslinic acid, HeLa cells, DNA damage, DNA condensation and fragmentation, 6869
- Human colorectal cancer, ribociclib, 5-fluorouracil, 6265
- Human equilibrative nucleoside transporter-1, mesothelioma, imidazo[2, 1-*b*][1, 3, 4]thiadiazole compounds, FAK, gemcitabine, 4913
- Human ESPL1, integration, fusion gene, HBV S, hepatocellular carcinoma, biomarker, 245
- Human gastric carcinoma, stomach, cisplatin, ERCC1, 3203
- Human natriuretic peptide, colorectal cancer, prevention of metastasis, feasibility, 5301
- Human papilloma virus (HPV), oral contraception, estrogen, progesterone, cervical cancer, review, 5995
- Human papillomavirus, head and neck cancer, unknown primary, oropharyngeal cancer, survival, 4207
- Human papillomavirus, programmed cell death ligand 1, oropharyngeal squamous cell carcinoma, 4001
- Human promyelocytic leukemia, differentiation, apoptosis, HL-60 cells, garlic, diallyl sulfide, gas chromatography-mass spectrometry, 6345
- Human skin, previtamin D<sub>3</sub>, DNA damage, 8-hydroxy-2'-deoxyguanosine, nitric oxide, vitamin D, nitrite, 565
- Human skin, previtamin D<sub>3</sub>, ultraviolet radiation light emitting diode (LED), *vitamin D*<sub>3</sub>, ultraviolet B radiation, 719
- Humanized mice, pBMCs, immunotherapy, cancer, immunoncology, review, 5329
- Hyaluronan, monocyte, macrophage, fibroblast, elastin, lipopolysaccharide, 4681
- Hybrid, minimally-invasive, esophagectomy, esophageal, cancer, 1753
- Hydrocele testis, testicular cancer, ultrasound, scrotal malignancies, 2861
- Hyperfractionated accelerated radiotherapy, anaplastic thyroid cancer, thyroid surgery, multimodal treatment, radiotherapy, 6979
- Hypertension, anti-hypertensive agent, renal cell carcinoma, 4087
- Hypertension, chemerin, fibrosis, tumor marker, 143
- Hyperthermia, paclitaxel, docetaxel, ovarian cancer, *in vitro* study, intraperitoneal chemotherapy, HIPEC, 6769
- Hyperthermic intraperitoneal intraoperative chemotherapy, HIPEC, ovarian cancer, side effects, cisplatin, 1481
- Hypoalbuminemia, adenocarcinoma, EGFR-TKI, pleurodesis, malignant pleural effusions, 1117
- Hypomagnesemia, cetuximab, panitumumab, first-line treatment, overall survival, metastatic colorectal cancer, 7135
- Hypopharyngeal cancer, DNA repair gene, single nucleotide polymorphism, overall survival, japanese, 3277
- Hypopharyngeal cancer, volumetric-modulated arc therapy, laryngoesophageal dysfunction-free survival, 4183
- Hypothalamic-pituitary dysfunction, whole brain radiotherapy, endocrine late effects, cancer survivor, 5787
- Hypoxia inducible factor-1 $\alpha$ , malignant pleural mesothelioma, von Hippel Lindau mutation, molecular targeted therapy, 1867
- Hypoxia, activating transcription factor 4, breast cancer, cysteine, sulfasalazine, tumor necrosis factor-related apoptosis-inducing ligand, 1387
- Hypoxia, cancer treatment, setanaxib, oxidative stress, liver cancer, 5071
- Hypoxia, oral cancer, LN metastasis, cD11b+ cell, lymphangiogenesis, 6845
- Hysterectomy, atypical endometrial hyperplasia, endometrial cancer, magnetic resonance imaging, preoperative procedure, 2989
- I3C, vorinostat, triple negative breast cancer, estrogen receptor, progesterone receptor, HDAC activity, HDAC7, 3669
- Iatrogenic lymphedema, age, gynecologic cancer-related lymphedema, secondary lymphedema, lymphedema, plastic surgery, review, 6609
- IBD, AOM/DSS, colitis associated cancer, animal model, carcinogenesis, colorectal cancer, 5457
- Ibrance, mucositis, palbociclib, chemotherapy, palliative, radiation therapy, chemoradiation, 5291
- Ibrutinib, chronic lymphocytic leukemia, therapy, 4059
- ICE chemotherapy, neurofibromatosis type I, NF1, malignant peripheral nerve sheath tumor, MPNST, 1619
- ICG fluorescence-guided surgery, surgical margin, fluorescence width, fluorescence pattern, laparoscopic liver resection, 3873

- Idarubicin, DNA damage, ROS, copper, 5399
- IDH1 R132H, isocitrate dehydrogenase 1, mutation, 2-hydroxyglutarate, high-throughput screening, 4929
- IDHmutated, pregnancy, glioma, radiation, 3453
- IDS, ovarian cancer, debulking surgery, PDS, surgical complexity, 3925
- IFOBT, fecal occult blood, guaiac-based test, fecal immunochemical test, gFOBT, FIT, colorectal cancer screening, meta-analysis, sensitivity, specificity, false negative, false positive, ROC, HSROC, 3591
- IGF-1R, IGF-MTX, phase 1 study, myelodysplastic syndrome, chronic myelomonocytic leukemia, oligoblastic acute myeloid leukemia, 3883
- IGF-I, insulin-like growth factor-I, iGF-IEc, renal cancer, clear cell RCC, 6213
- IGF-IEc, insulin-like growth factor-I, IGF-I, renal cancer, clear cell RCC, 6213
- IGF-MTX, IGF-1R, phase 1 study, myelodysplastic syndrome, chronic myelomonocytic leukemia, oligoblastic acute myeloid leukemia, 3883
- IGF1R, breast cancer, molecular subtypes, immunohistochemistry, 1555
- IGF1R, insulin-like growth factor 1 receptor, TKI, head and neck squamous cell carcinoma (HNSCC), nilotinib, dasatinib, erlotinib, gefitinib, everolimus, 3847
- IgG4-related ophthalmic disease, flow cytometry, lymphoma, 2019
- IGK, bcR gene recombinations, lung adenocarcinoma, tumor specimen exomes, CD19, CD20, CD79 B-cell markers, survival rates, 2043
- IHCCC, pembrolizumab, mSI-high, 4123
- IL-2, glucan, cancer, phagocytosis, infection, 3139
- Ileocecal valve, bauhin's valve, colorectal cancer, small bowel adenocarcinoma, 4053
- Ileus, cytoreductive surgery, heated intraperitoneal chemotherapy, length of stay, small intestine, 2865
- ILK, cell-matrix interactions, cell adhesion, migration, tumor spheroids, tGF $\beta$ , MIC1, PARVA, LIMS1, RSU1, 1375
- Image-guided intervention, liver metastases, oligometastases, interventional oncology, local ablation, interstitial brachytherapy, 4281
- Imatinib mesylate, gastrointestinal stromal tumor, neoadjuvant treatment, giant tumor, 1147
- Imatinib, chronic myeloid leukemia, dasatinib, second-line treatment, TKI, *BCR-ABL1*, 5313
- Imatinib, gastrointestinal stromal tumour, GIST, real-world, survival, safety, 435
- Imidazo[2, 1-*b*]oxazole derivatives, RAF inhibitors, TNBC, chemotherapy, 5081
- Imidazo[2, mesothelioma, 1-*b*][1, 3, 4]thiadiazole compounds, FAK, gemcitabine, human equilibrative nucleoside transporter-1, 4913
- Immune cell therapy, zenithal natural killer cells, cancer, phase I/IIa study, 5687
- Immune checkpoint inhibition, immunotherapy, biomarkers, 2821
- Immune checkpoint inhibitor, anti-PD-(L)1, chemotherapy, gastric cancer, 2247
- Immune checkpoint inhibitor, celecoxib, COX2, PD-1, lung cancer, 5309
- Immune checkpoint inhibitor, interferon-gamma release, non-small-cell lung cancer, biomarker, time to treatment failure, 6971
- Immune checkpoint inhibitor, interferon-gamma, non-small-cell lung cancer, immune-related adverse event, 2787
- Immune checkpoint inhibitor, nivolumab, metastatic renal cell carcinoma, axitinib, 6493
- Immune checkpoint inhibitor, non-small-cell lung carcinoma, predictive factor, neutrophil counts, tumor-associated neutrophils, 3889
- Immune checkpoint inhibitor, older patients, non-small cell lung cancer, anti PD-1 inhibitor, overall survival, 923
- Immune checkpoint inhibitor, salvage chemotherapy, nivolumab, head and neck carcinoma, recurrent or metastatic, best supportive care, 5277
- Immune checkpoint inhibitors, immune-related adverse events (irAEs), t-cell receptor, renal cell carcinoma, next-generation sequencing, immune response, 4875
- Immune evasion, natural killer cells, immunotherapy, colorectal cancer, cancer stem cells, 6613
- Immune response, immune checkpoint inhibitors, immune-related adverse events (irAEs), t-cell receptor, renal cell carcinoma, next-generation sequencing, 4875
- Immune-cell therapy, cervical cancer, endometrial cancer, prognostic factors,  $\alpha\beta$ T cell therapy, dendritic cell vaccine, 4729
- Immune-related adverse event, interferon-gamma, immune checkpoint inhibitor, non-small-cell lung cancer, 2787
- Immune-related adverse events (irAEs), immune checkpoint inhibitors, t-cell receptor, renal cell carcinoma, next-generation sequencing, immune response, 4875
- Immuno-histochemistry, conventional RCC, AXL expression, tumor progression, 3485
- Immuno-oncology, pBMCs, humanized mice, immunotherapy, cancer, review, 5329
- Immunocellular therapy, gamma/delta T-cell, bladder cancer, chemotherapy, cytotoxicity, 5221
- Immunoglobulin, BTH1677, imprime PGG, anti-beta glucan antibody, immunotherapy, 1467
- Immunohistochemistry, biomarker, knockdown, myoferlin, renal cell carcinoma, 3119
- Immunohistochemistry, bladder cancer, chloride intracellular channel protein 1 (CLIC1), potential therapeutic target, prognosis, 6879

- Immunohistochemistry, breast cancer, molecular subtypes, IGF1R, 1555
- Immunohistochemistry, breast cancer, PAX8, 5925
- Immunohistochemistry, endometriosis-associated intestinal malignancies, endometriosis-associated malignancies of urinary tract, endometriosis-associated malignancies of surgical scars, surgery, chemotherapy, review, 2429
- Immunohistochemistry, epidermal growth factor receptor (EGFR) mutation, lung adenocarcinoma, pancreatic ductal carcinoma, endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) and biopsy (FNB), 4401
- Immunohistochemistry, fShr, HNSCC, neoangiogenesis, histopathology, 349
- Immunohistochemistry, gallbladder, carcinoma, IMP3, prognosis, 5777
- Immunohistochemistry, hepatocellular carcinoma, tumor morphology, 4105
- Immunohistochemistry, larynx, carcinoma, topoisomerase, digital image analysis, 807
- Immunohistochemistry, merkel cell carcinoma, nasal vestibule, traumatic suture scar, *TP53* mutation, 1123
- Immunohistochemistry, MTUS1, renal cell carcinoma, public data, prognosis, 2961
- Immunohistochemistry, ovarian cancer, angiogenesis, lymphangiogenesis, CD105, CD34, 6923
- Immunohistochemistry, SPARC, invasion, meningioma, malignant, recurrence, 3081
- Immunohistochemistry, stomach neoplasms, cyclooxygenase 2, prognosis, 341
- Immunohistochemistry, synchronous primary malignancy, colonic adenocarcinoma, pancreatic ductal carcinoma, microsatellite stable, chemotherapy, 4029
- Immunohistochemistry, vascular malformation, intraosseous, haemangioma, orbit, cone beam computed tomography, 3D reconstruction, bone mineral density, differential diagnosis, 3333
- Immunohistochemistry; microsatellite stable, synchronous primary malignancy, rectal adenocarcinoma; small cell lung carcinoma, gastrointestinal stromal tumor (GIST), chemotherapy, 7053
- Immunological status, colorectal cancer, chemotherapy, immunotherapy,  $\alpha\beta$  T cell therapy, 4763
- Immunology, neuropilin, cytokine-induced killer cells, lung cancer, brain tumor, flow cytometry, 5489
- Immunomodulation, spiro-acridine, antitumor activity, anti-angiogenic activity, zebrafish, Ehrlich ascites carcinoma model, 5049
- Immunosuppression, kidney transplantation, skin, onconeurology, 4017
- Immunosuppression, next-generation sequencing, sclerosing microcystic adenocarcinoma, oral cancer, 6375
- Immunosuppression, oral mucositis, rat model, chemotherapy, 2701
- Immunosurveillance, pancreatic cancer, progesterone receptor antagonists, progesterone induced blocking factor, palliation, natural killer cells, 6997
- Immunotherapy,  $\gamma\delta$  T cell, prostate cancer, cancer stem cell, sphere, prostasphere, CD133, NANOG, SOX2, OCT4, 5481
- Immunotherapy, activated dendritic cell, high-grade glioma, HLA-A24, phase II trial, 6473
- Immunotherapy, analysis of survival, melanoma, pembrolizumab, S100, 2157
- Immunotherapy, ATL, HTLV-1, antibody drug conjugate, cancer chemotherapy, 4471
- Immunotherapy, BTH1677, imprime PGG, anti-beta glucan antibody, immunoglobulin, 1467
- Immunotherapy, checkpoint inhibitor, adverse effects, outcome, efficacy, review, 1219
- Immunotherapy, colorectal cancer, chemotherapy,  $\alpha\beta$  T cell therapy, immunological status, 4763
- Immunotherapy, colorectal cancer, microsatellite stability, CCR5 inhibition, chemokine, innate immunity, macrophages, monocytes, 6933
- Immunotherapy, immune checkpoint inhibition, biomarkers, 2821
- Immunotherapy, KRAS, NSCLC, anti-PDI/PD-L1 therapy, 427
- Immunotherapy, natural killer cells, colorectal cancer, immune evasion, cancer stem cells, 6613
- Immunotherapy, neuroendocrine carcinoma, carcinoma of the uterine cervix, cellular immunotherapy, adoptive immunotherapy, t-cells, 4741
- Immunotherapy, pBMCs, humanized mice, cancer, immunoncology, review, 5329
- Immunotherapy, sentinel lymph node biopsy (SLNB), lymphadenectomy, radiation, chemotherapy, 2895
- Immunotoxin, ROBO1, HNSCC, photochemical internalization, drug delivery system, 3793
- IMP3, gallbladder, carcinoma, immunohistochemistry, prognosis, 5777
- Imprime PGG, BTH1677, anti-beta glucan antibody, immunoglobulin, immunotherapy, 1467
- In vitro* study, paclitaxel, docetaxel, hyperthermia, ovarian cancer, intraperitoneal chemotherapy, HIPEC, 6769
- In vitro*, *LINK-A*, long non-coding RNA, cRISPR/Cas9, high-grade serous carcinoma, tumorigenesis, 6677
- In vitro*, LPS, macrophage, oral administration, phagocytosis, 4711
- In vitro*, vitamin D, 1, 25-D<sub>3</sub>, ovarian cancer, paclitaxel, carboplatin, growth inhibition, VDR, 3129
- In vivo* tumor model, barbituric acid, cytotoxicity, lung cancer, thiobarbituric acid, 6039
- Incidental CAT, thrombosis, low molecular weight heparin, LMWH, cancer-associated thrombosis, CAT, symptomatic CAT, 305

- Incisional hernia, umbilical defunctioning ileostomy, rectal cancer, laparoscopic surgery, 3445
- Individual response, vitamin D, supplementation, metabolomics, genomics, broad gene expression, metabolomic profile, personalized medicine, 25-hydroxyvitamin D, 535
- Indocyanine green fluorescence, anastomosis, colorectal cancer, intestinal blood flow, 373
- Indocyanine green fluorescent imaging, adrenal metastasis, hepatocellular carcinoma, 5823
- Indocyanine green, fluorescence imaging, mediastinal lymphatic metastasis, orthotopic implantation, squamous lung carcinoma, 1875
- Induction treatment, lung cancer, tyrosine kinase inhibitor, *EGFR*, 2911
- Infection, glucan, cancer, phagocytosis, IL-2, 3139
- Inferior vena cava, renal cell carcinoma, thrombus, pulmonary embolism, radical nephrectomy, lung metastasis, 5837
- Inflammation index, tumor marker, carcinoembryonic antigen, c-reactive protein, novel index, non-small cell lung cancer, surgery, prognosis, 4023
- Inflammation, glioblastoma, routine laboratory parameter, 1161
- Inflammation, single nucleotide polymorphisms, interleukin 10, prostate cancer, smoking, African-American, 27
- Inflammation, surgical stress, survival, colorectal cancer, 3535
- Inflammatory cytokines, biomarkers, rhenium, selenium, cancer cells, 1915
- Inflammatory liver tumor, *Fasciola hepatica*, intrahepatic cholangiocarcinoma, 2795
- Inflammatory marker, renal cell carcinoma, molecular targeted therapy, 1739
- Information-theoretical approach, *WEE1*, *EMP3*, *E2F7*, *CD58*, *NSUN7*, lower-grade gliomas, 2777
- Infusion rate systematic review, monoclonal antibody, infusion reaction, infusion time, review, 1201
- Infusion reaction, eosinophil percentages, trastuzumab, breast cancer, 4047
- Infusion reaction, monoclonal antibody, infusion time, infusion rate systematic review, review, 1201
- Infusion time, monoclonal antibody, infusion reaction, infusion rate systematic review, review, 1201
- Inhibition, breast cancer, surgical resection, recurrence, methionine restriction, recombinant methioninase, lung metastasis, adjuvant therapy, 4869
- Inhibition, *PTC209*, *BMI1*, cervical cancer, cancer stem cell, 133
- Inhibitor kappa B kinase, apo2L/TRAIL, nitric oxide, nuclear factor kappa B, apoptosis, 6751
- Inhibitor of apoptosis proteins, castration-resistant prostate cancer, cabazitaxel, drug therapy, YM155, survivin, 5091
- Inhibitor, flavonoid, PI3K, protein kinase, anti-cancer, virtual screening, 4547
- Inhibitor, hepatocellular carcinoma,  $\beta$ -catenin, wnt, CBP, PRI-724, 5211
- Inhibitor, melanoma, BRAF<sup>V600E</sup>, 3PO, A375, PFKFB3, 2613
- Inhibitors, colorectal cancer, fatty acid synthesis, fatty acid oxidation, review, 4843
- Innate immunity, colorectal cancer, immunotherapy, microsatellite stability, CCR5 inhibition, chemokine, macrophages, monocytes, 6933
- Innominate grooves, colon, tributary crypts, frequency, ulcerative colitis, 7031
- INPP4A, microarray, microRNA, miR-935, oral squamous cell carcinoma, 6101
- Insulin-like growth factor 1 receptor, IGF1R, TKI, head and neck squamous cell carcinoma (HNSCC), nilotinib, dasatinib, erlotinib, gefitinib, everolimus, 3847
- Insulin-like growth factor-I, IGF-I, iGF-Iec, renal cancer, clear cell RCC, 6213
- Integration, fusion gene, HBV S, human ESPL1, hepatocellular carcinoma, biomarker, 245
- Integrins, anti-migration, benzoxazine dimer analogue, non-small cell lung cancer, 2583
- Intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy (VMAT), involved field radiotherapy irradiation (IFR-IFI), twice-daily thoracic radiotherapy (BID-TRT), accelerated hyperfractionated thoracic radiotherapy (AHTRT), anti-programmed cell death ligand-1 immune checkpoint inhibitor (ICIs), 6957
- Intensity-modulated radiotherapy, carbon ion radiotherapy, hepatocellular carcinoma, vascular invasion, 459
- Intensity-modulated radiotherapy, low-dose, ultra-low, toxicity, moderate-dose RT, 4041
- Intensity-modulated radiotherapy, prostate neoplasms, simultaneous integrated boost, dominant intraprostatic lesion, phase I-II, 6499
- Intercellular adhesion molecule-1 (ICAM-1), lung metastasis, acute lung injury (ALI), pneumonia, e-selectin, 6171
- Interferon-gamma release, immune checkpoint inhibitor, non-small-cell lung cancer, biomarker, time to treatment failure, 6971
- Interferon-gamma, immune checkpoint inhibitor, non-small-cell lung cancer, immune-related adverse event, 2787
- Interferon, pancreatic cancer, rNA-Seq, TKI, toll-like receptor, 4445
- Interleukin 10, single nucleotide polymorphisms, prostate cancer, smoking, inflammation, African-American, 27
- Interleukin-12A, alcohol drinking, betel quid, genotype, oral cancer, polymorphism, smoking, Taiwan, 3707
- Interleukin-13, breast cancer, genotype, polymorphism, Taiwan, 6743

- Interleukin-6, Epstein-Barr virus, rta, nasopharyngeal carcinoma, cell migration, 3255
- Interleukin-6, hepatocellular carcinoma, hepatic stellate cell, 743
- Interleukin-8, multiple myeloma, sRAGE, oxidative stress, cancer, gender, 1443
- Internal jugular vein, gastric cancer, Trousseau' syndrome, neoplastic venous thrombosis, 2889
- International Metastatic Renal Cell Carcinoma Database Consortium, metastatic renal cell carcinoma, novel stratification system, japanese patients, 4395
- Interstitial brachytherapy, liver metastases, oligometastases, interventional oncology, local ablation, image-guided intervention, 4281
- Interval debulking surgery, debulking for ovarian cancer, primary debulking, complete cytoreduction, upper abdominal surgery, morbidity, 5869
- Interval from first primary cancer to second primary cancer, endometrial cancer, second primary cancer, molecular characterization, 3811
- Interventional oncology, liver metastases, oligometastases, local ablation, image-guided intervention, interstitial brachytherapy, 4281
- Interventional ultrasonography, irreversible electroporation, pancreatic cancer, recurrence, 2771
- Intestinal blood flow, indocyanine green fluorescence, anastomosis, colorectal cancer, 373
- Intraductal papillary mucinous neoplasms, iPMN-derived carcinoma, pancreatic ductal adenocarcinoma, biomarker, microarray, 6551
- Intrahepatic cholangiocarcinoma, desmoplastic reaction, microenvironment, 4749
- Intrahepatic cholangiocarcinoma, inflammatory liver tumor, *Fasciola hepatica*, 2795
- Intrahepatic cholestasis of pregnancy, alcohol dehydrogenase isoenzymes, aldehyde dehydrogenase, 1997
- Intranasal delivery, melanoma, metastatic melanoma, rAAV, lungs, 4425
- Intraoperative blood loss, overall survival, prognosticator, gastric cancer, 405
- Intraoperative frozen section, breast cancer, sentinel lymph node, 1711
- Intraoperative radiotherapy, IORT, limb salvage, soft-tissue reconstruction, flap, 6941
- Intraosseous, vascular malformation, haemangioma, orbit, cone beam computed tomography, 3D reconstruction, bone mineral density, immunohistochemistry, differential diagnosis, 3333
- Intraperitoneal chemotherapy, paclitaxel, docetaxel, hyperthermia, ovarian cancer, *in vitro* study, HIPEC, 6769
- Intratumoral immune cells, breast, triple-negative breast carcinoma, programmed death ligand 1, 1487
- Intrinsic apoptosis, lung cancer, tannic acid, g0/G1 cell cycle arrest, 3209
- Intrinsic apoptosis, methylsulfonylmethane, cell-cycle arrest, A549 lung adenocarcinoma cell line, 1905
- Invasion, ABHD12, breast cancer, proliferation, migration, 2601
- Invasion, glioblastoma, fucoxanthin, apoptosis, migration, angiogenesis, 6799
- Invasion, melatonin, tongue squamous cell carcinoma, MTT, migration, apoptosis, autophagy, 6295
- Invasion, p38 mitogen-activated protein kinase, isoforms, pancreatic cancer, metastasis, 5545
- Invasion, SPARC, meningioma, immunohistochemistry, malignant, recurrence, 3081
- Invasive melanoma, wide excisional surgery, excisional margins, NCDB, 1065
- Invasive melanoma, wide excisional surgery, excisional margins, residual tumor, NCDB, 1059
- Invasiveness, nitric oxide, HNSCC human head and neck cell, isogenic cell lines, cell proliferation, apoptosis, matrix metalloproteinases, 2657
- Involved field radiotherapy irradiation (IFR-IFI), volumetric modulated arc therapy (VMAT), intensity modulated radiation therapy (IMRT), twice-daily thoracic radiotherapy (BID-TRT), accelerated hyperfractionated thoracic radiotherapy (AHTRT), anti-programmed cell death ligand-1 immune checkpoint inhibitor (ICIs), 6957
- Iodinated contrast agent, apela, acute kidney injury, 635
- Iodine, multidetector computed tomography, positron-emission tomography, fluorodeoxyglucose, lung cancer, dual-energy, 3459
- Ionization potential, QSAR, guaiazulene-3-carboxylate, OSCC, tumor-specificity, molecular shape, 4885
- IORT, intraoperative radiotherapy, limb salvage, soft-tissue reconstruction, flap, 6941
- IOTA simple rules, magnetic resonance, ultrasound, MR-US fusion, O-RADS MRI scoring system, adnexal masses, ovarian cancer, 4115
- Ipilimumab, nivolumab, anti-PD-1, pediatric cancer, malignant melanoma, brain tumor, 7095
- iPMN-derived carcinoma, intraductal papillary mucinous neoplasms, pancreatic ductal adenocarcinoma, biomarker, microarray, 6551
- Irinotecan, S-1, IRIS, pilot study, metastatic breast cancer, 4779
- IRIS, S-1, pilot study, irinotecan, metastatic breast cancer, 4779
- Irreversible electroporation, pancreatic cancer, recurrence, interventional ultrasonography, 2771
- Isocitrate dehydrogenase 1, mutation, IDH1 R132H, 2-hydroxyglutarate, high-throughput screening, 4929
- Isoforms, p38 mitogen-activated protein kinase, pancreatic cancer, invasion, metastasis, 5545

- Iso-genic cell lines, nitric oxide, HNSCC human head and neck cell, cell proliferation, apoptosis, invasiveness, matrix metalloproteinases, 2657
- Itraconazole, gastric cancer, conversion surgery, repurposing, 991
- Japanese patients, metastatic renal cell carcinoma, international Metastatic Renal Cell Carcinoma Database Consortium, novel stratification system, 4395
- Japanese, DNA repair gene, single nucleotide polymorphism, overall survival, hypopharyngeal cancer, 3277
- Jurkat T cells, n-farnesyl-norcantharimide, next-generation sequencing, tumor suppressor gene, biosynthesis, 2675
- K562, natural killer cells, lysis, NK-92, PBMC, 5355
- Kallikrein-related peptidases, kallikreins, breast cancer, gene expression, cluster analysis, 2487
- Kallikreins, kallikrein-related peptidases, breast cancer, gene expression, cluster analysis, 2487
- Kaplan–Meier analysis, ROCK1, ROCK2, melanoma, tumor-infiltrating lymphocytes, prognosis, 1931
- Kelly cell line, oxazolindiones, neuroblastoma, proliferation, progression, BSA heat denaturation, adhesion, fibronectin, 5125
- Keratinocyte growth factor, hematopoietic cell transplantation, mucositis, palifermin, children, risk factors analysis, 6531
- Ketogenic diet, ketone bodies, acetoacetate, lithium, breast cancer, 3831
- Ketone bodies, ketogenic diet, acetoacetate, lithium, breast cancer, 3831
- Ki-67, breast cancer, prognostic parameters, GATA3, 5649
- Ki-67, p16 prognostic value, resected lung cancer, early and late stage survival, 983
- Kidney transplantation, immunosuppression, skin, onconeurology, 4017
- Kidney, large cell neuroendocrine carcinoma, bladder, ureter, review, 2439
- KISS1, glioblastoma, kisspeptin, KISS1R, brain tumor, 213
- KISS1, KISS1R, prostate cancer, metastasis suppression, 709
- KISS1R, glioblastoma, kisspeptin, KISS1, brain tumor, 213
- KISS1R, KISS1, prostate cancer, metastasis suppression, 709
- Kisspeptin, glioblastoma, KISS1, KISS1R, brain tumor, 213
- Knockdown, biomarker, immunohistochemistry, myoferlin, renal cell carcinoma, 3119
- KRAS mutation, CTC, pancreatic cancer, mouse model, cytology, CTC detection platform, 6781
- KRAS, CD155, CAK cells, TNK cells, PD-1, TIGIT, 3D culture, 4663
- KRAS, MK615, colon cancer, HIF, e-cadherin, prunus mume, 4687
- KRAS, NSCLC, anti-PDI/PD-L1 therapy, immunotherapy, 427
- KRAS, pancreatic juice, pancreatic neoplasms, pancreatic cyst, GNAS, secretin-induced duodenal aspiration, 4215
- Kynurenine, chemo brain, tryptophan, NAD, tubulin, cognition, biophoton, review, 1189
- LAD, breast cancer, radiotherapy, cardiotoxicity, mean heart dose, LV, echocardiography, 3003
- Laparoscopic colectomy, descending colon cancer, D<sub>3</sub> dissection, long-term outcomes, short-term outcomes, 1731
- Laparoscopic liver resection, surgical margin, ICG fluorescence-guided surgery, fluorescence width, fluorescence pattern, 3873
- Laparoscopic surgery, dialysis, colorectal cancer, short-term outcome, overall survival, 2165
- Laparoscopic surgery, rectal cancer, robotic surgery, anastomotic leakage, 2337
- Laparoscopic surgery, staging laparoscopy, pancreatic cancer, prognosis, 1023
- Laparoscopic surgery, umbilical defunctioning ileostomy, incisional hernia, rectal cancer, 3445
- Laparoscopic, transumbilical incision, hepatectomy, 6545
- Laparoscopy, nomogram, suspected prostate cancer, radical prostatectomy, robotics, 2995
- Laparoscopy, predictive score, locally advanced rectal cancer, total mesorectal excision, 2079
- Laparotomy, angiosarcoma, hemangiosarcoma, gynaecology, cancer, uterine sarcoma, ovarian sarcoma, chemotherapy, paclitaxel, osseous metastasis, 5743
- Large cell neuroendocrine carcinoma, bladder, kidney, ureter, review, 2439
- Large-core needle, biopsy, fine-needle, pancreatic neoplasms, endosonography, 5845
- Laryngeal squamous cell carcinoma, matrix metalloproteinases, matrix metalloproteinase 8, MMP8, single nucleotide polymorphism, rs11225395, rs2155052, 2003
- Laryngoesophageal dysfunction-free survival, hypopharyngeal cancer, volumetric-modulated arc therapy, 4183
- Larynx, carcinoma, topoisomerase, immunohistochemistry, digital image analysis, 807
- LC3B-II, SQSTM1, apoptosis, chloroquine, miR-139, autophagy, beclin-1, mTOR, prostate cancer, 6649
- LDH, pleural effusion, pulmonary metastases, pleural cytology, CEA, CRP, predictive model, 5877
- Left-sided colorectal cancer, right-sided colorectal cancer, microRNA, biological pathways, 3713
- Leiomyosarcoma, small bowel, oncological surgery, sarcoma, 4199
- Leiomyosarcoma, tumor stem cell, angiogenesis, hematogenous metastasis, 1255
- Length of stay, cytoreductive surgery, heated intraperitoneal chemotherapy, ileus, small intestine, 2865
- Lenvatinib, alpha fetoprotein, hepatocellular carcinoma, ramucirumab, second-line therapy, 2089

- Lenvatinib, hepatocellular carcinoma, portal vein flow velocity, hepatic encephalopathy, 5271
- Lenvatinib, hepatocellular carcinoma, sorafenib, portal vein tumor thrombosis, 2283
- Lesions of uncertain malignant potential, vacuum-assisted excision, vacuum-assisted breast biopsy, ultrasound, breast lesions, breast cancer, 1719
- Letermovir, cytomegalovirus, allogeneic hematopoietic stem cell transplantation, 5909
- Leukemia, cancer cell membrane, PNC-27, HDM-2, 4857
- Leukemia, PARP inhibitors, tyrosine kinase, review, 3055
- Leukemia, sirtuin1, NOTCH, NF- $\kappa$ B, p53, 3155
- Leukopenia, febrile neutropenia, time to treatment failure, docetaxel, prostate cancer, 4291
- Lewis lung carcinoma, metabolomics, plasma, diet, time-restricted feeding, mice, 1833
- Light, head and neck cancer, phytochemicals, EGF receptor, oxidative stress, 751
- LIM domain proteins, zyxin, cancer, review, 5981
- Limb salvage, intraoperative radiotherapy, IORT, soft-tissue reconstruction, flap, 6941
- Limb salvage, upper extremity, free vascularized fibula flap, oncologic resection, 2751
- LIMS1, cell–matrix interactions, cell adhesion, migration, tumor spheroids, tGF $\beta$ , ILK, MIC1, PARVA, RSU1, 1375
- Linear energy transfer, carbon-ion beams, cell-killing effect, radiosensitizing effect, HeLa cells, 5497
- Linear energy transfer, radiotherapy, chondrosarcoma, sarcoma, 6429
- LINK-A*, long non-coding RNA, CRISPR/Cas9, high-grade serous carcinoma, tumorigenesis, *in vitro*, 6677
- Lipid peroxidation, benign disease, cancer, plasma malondialdehyde, pain following surgery, 253
- Lipid rafts, cell death mode, apoptotic death, necrotic death, 2573
- Lipopolysaccharide, monocyte, macrophage, fibroblast, hyaluronan, elastin, 4681
- Liquid biopsy, circulating tumor cell, circulating tumor DNA, primary lung cancer, diagnosis, 3435
- Liquid biopsy, PD-L1, breast cancer, biomarker, recurrence, 3733
- LITAF, gastric cancer, miR-1, 6247
- Lithium, ketogenic diet, ketone bodies, acetoacetate, breast cancer, 3831
- Liver cancer, cancer treatment, hypoxia, setanaxib, oxidative stress, 5071
- Liver cancer, mitochondria, ROS, *Picrasma quassioides*, 3819
- Liver cirrhosis, HCC, sorafenib, sarcopenia, carnitine, 4173
- Liver cyst, metastatic renal cell carcinoma, RCC, polycystic liver disease, cabozantinib, pazopanib, 1527
- Liver injury, peroxiredoxin II, PRDX2; ROS, cell apoptosis, 4491
- Liver metastases, oligometastases, interventional oncology, local ablation, image-guided intervention, interstitial brachytherapy, 4281
- Liver metastases, sinusoidal obstruction syndrome, colorectal cancer, liver resection, mesenchymal stem cells, monocrotaline, 6817
- Liver metastasis, colorectal cancer, clonal dynamics, animal model, splenic injection, orthotopic implantation, 3297
- Liver metastasis, gastric cancer, patient-derived orthotopic xenograft (PDOX), nude mice, 5-fluorouracil, oxaliplatin, gemcitabine, 5393
- Liver resection, cholangiolocarcinoma, radio-frequency ablation, 7147
- Liver resection, hepatocellular carcinoma, cancer-associated thrombosis, superior mesenteric vein thrombosis, direct oral anticoagulant, 6465
- Liver resection, sinusoidal obstruction syndrome, colorectal cancer, liver metastases, mesenchymal stem cells, monocrotaline, 6817
- Liver sinusoidal endothelial cells, beraprost sodium, liver transplantation, oxaliplatin based chemotherapy, sinusoidal obstruction syndrome, veno-occlusive disease, 5171
- Liver surgery, bile leakage, complication, 401
- Liver transplantation, beraprost sodium, liver sinusoidal endothelial cells, oxaliplatin based chemotherapy, sinusoidal obstruction syndrome, veno-occlusive disease, 5171
- Liver tumors, hepatocellular carcinoma, surveillance, screening, diagnosis, biomarkers, tumor biology, review, 6573
- LMWH, thrombosis, low molecular weight heparin, cancer-associated thrombosis, CAT, incidental CAT, symptomatic CAT, 305
- LN metastasis, oral cancer, cD11b+ cell, lymphangiogenesis, hypoxia, 6845
- LncRNA, HNSCC, *MALAT1*, radiation sensitivity, cisplatin sensitivity, 2645
- Local ablation, liver metastases, oligometastases, interventional oncology, image-guided intervention, interstitial brachytherapy, 4281
- Local complication, stage IV rectal cancer, radiotherapy, chemotherapy, 5853
- Local control, glioblastoma multiforme, longer-course radiotherapy, survival, prognostic factors, 7025
- Local failure, locally advanced non-small cell lung cancer, concurrent chemo-radiotherapy, 3513
- Local spread, nucleolar proteins, prostate cancer, gleason grade, neoplasm invasiveness, 1973
- Local therapies, older patients, brain metastases, whole-brain radiotherapy, overall survival, extra-cerebral metastasis, 2841
- Localisation, magseed, pooled analysis, wireless, review, 1809

- Locally advanced cervical cancer, post-treatment hematological parameters, prognosis, neutrophil-to-lymphocyte, concurrent chemoradiotherapy, 451
- Locally advanced non-small cell lung cancer, local failure, concurrent chemo-radiotherapy, 3513
- Locally advanced rectal cancer, predictive score, laparoscopy, total mesorectal excision, 2079
- Lockdown, COVID-19, breast cancer, screening suspension, oncological treatments delay, 7119
- Locoregional recurrence, pedicled rotation flap, breast cancer, 5739
- Locoregional recurrent rectal cancer, microRNA, angiogenesis, expression, colorectal cancer, 2947
- Loneliness, lung cancer, social determinants of health, social isolation, dementia, 7141
- Long interspersed nuclear element-1, non-small cell lung cancer, methylation, maximum standardized uptake value, p53, 5659
- Long non-coding RNA, *LINK-A*, CRISPR/Cas9, high-grade serous carcinoma, tumorigenesis, *in vitro*, 6677
- Long-term functional results, upper rectal cancer, neoadjuvant treatment, chemoradiation therapy, recurrence-free and overall survival, 3579
- Long-term outcome, neoadjuvant chemotherapy, downstaging, tumor shrinkage, breast conserving surgery, recurrence, 1079
- Long-term outcomes, laparoscopic colectomy, descending colon cancer, D<sub>3</sub> dissection, short-term outcomes, 1731
- Long-term survival, metastatic spinal cord compression, spinal metastasis, surgical treatment, prognostic factor, sex, 1475
- Longer-course radiotherapy, glioblastoma multiforme, local control, survival, prognostic factors, 7025
- Low dose FP, downstaging, hepatocellular carcinoma, salvage surgery, 4773
- Low inferior mesenteric artery tie, defecatory dysfunction, high inferior mesenteric artery tie, sigmoidal cancer, 2969
- Low inferior mesenteric artery tie, urinary dysfunction, sexual dysfunction, high inferior mesenteric artery tie, rectal cancer, 4223
- Low molecular weight heparin, thrombosis, LMWH, cancer-associated thrombosis, CAT, incidental CAT, symptomatic CAT, 305
- Low-dose, ultra-low, intensity-modulated radiotherapy, toxicity, moderate-dose RT, 4041
- Low-grade urothelial neoplasm, urine, cytology, the Paris System, atypical urothelial cell, high-grade urothelial carcinoma, 3477
- Low-molecular-weight whey protein, bovine mastitis, macrophages, cytokines, 4701
- Low-risk bladder cancer, single intravesical instillation, pirarubicin, mitomycin C, 5295
- Lower-grade gliomas, WEE1, EMP3, E2F7, CD58, NSUN7, information-theoretical approach, 2777
- LPS, *in vitro*, macrophage, oral administration, phagocytosis, 4711
- LRRC17, ovarian epithelial cancer, survival analysis, zebrafish, apoptosis, gene expression omnibus, TCGA, 5601
- Luminal-type breast cancer, CDK4/6 inhibitor, eribulin mesylate, patient-derived xenograft model, reversal of epithelial-mesenchymal transition, preclinical trial, 6699
- Lung adenocarcinoma, bcR gene recombinations, IGK, tumor specimen exomes, CD19, CD20, CD79 B-cell markers, survival rates, 2043
- Lung adenocarcinoma, epidermal growth factor receptor (EGFR) mutation, pancreatic ductal carcinoma, endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) and biopsy (FNB), immunohistochemistry, 4401
- Lung adenocarcinoma, lung cancer, non-small cell lung cancer, toll-like receptor 2, nuclear factor-kappa B, proliferation, 5361
- Lung cancer, abdominal aortic aneurysm, screening, high cardiovascular risk profile, 4137
- Lung cancer, ADGRF4, GPR115, PPP4C, cell invasiveness, 6835
- Lung cancer, alcohol dehydrogenase isoenzymes, aldehyde dehydrogenase, carcinogenesis, 3857
- Lung cancer, barbituric acid, cytotoxicity, *in vivo* tumor model, thiobarbituric acid, 6039
- Lung cancer, bioelectrical impedance analysis, ECW/TBW, prognostic factor, 3931
- Lung cancer, celecoxib, COX2, immune checkpoint inhibitor, PD-1, 5309
- Lung cancer, chemotherapy, toxicity, predictive, prognostic, 6399
- Lung cancer, ciprofloxacin, cell cycle arrest, apoptosis, colorectal cancer, 2739
- Lung cancer, cluster analysis, prognosis, metastatic pattern, 421
- Lung cancer, ephemeranthol A, epithelial to mesenchymal transition (EMT), apoptosis, 4989
- Lung cancer, extracellular vesicles, drug resistance, cisplatin, mass spectrometry, 5509
- Lung cancer, malignant pleural effusion, differential diagnosis, pleural-fluid cytology, pulmonary metastases, 1135
- Lung cancer, metastasis, metastatic pattern, cluster analysis, 413
- Lung cancer, microbiome, carcinogenesis, cancer therapy, review, 4807
- Lung cancer, multidetector computed tomography, positron-emission tomography, iodine, fluorodeoxyglucose, dual-energy, 3459
- Lung cancer, neuropilin, cytokine-induced killer cells, immunology, brain tumor, flow cytometry, 5489



- Lung cancer, non-small cell lung cancer, lung adenocarcinoma, toll-like receptor 2, nuclear factor-kappa B, proliferation, 5361
- Lung cancer, proto-oncogene, c-Myc, anticancer drug target, review, 609
- Lung cancer, pulmonary metastases, colorectal carcinoma, surgery, biomarker, prognosis, 7045
- Lung cancer, social determinants of health, social isolation, loneliness, dementia, 7141
- Lung cancer, tannic acid, intrinsic apoptosis, G0/G1 cell cycle arrest, 3209
- Lung cancer, tyrosine kinase inhibitor, induction treatment, *EGFR*, 2911
- Lung metastases, sAbR, oligometastatic disease, gastrointestinal tumors, 5901
- Lung metastasis, acute lung injury (ALI), pneumonia, intercellular adhesion molecule-1 (ICAM-1), e-selectin, 6171
- Lung metastasis, breast cancer, surgical resection, recurrence, methionine restriction, recombinant methioninase, inhibition, adjuvant therapy, 4869
- Lung metastasis, renal cell carcinoma, inferior vena cava, thrombus, pulmonary embolism, radical nephrectomy, 5837
- Lung squamous cell carcinoma, neoadjuvant therapy, sarcomatoid transformation, 1625
- Lungs, melanoma, metastatic melanoma, rAAV, intranasal delivery, 4425
- Luteolin, Hodgkin's lymphoma, cancer, mix cellularity classical Hodgkin's lymphoma, 4907
- Luteolin, miRNA-301-3p, pancreatic cancer, caspase-8, TRAIL, combination effect, 723
- LV, breast cancer, radiotherapy, cardiotoxicity, mean heart dose, LAD, echocardiography, 3003
- LY3009120, pan-RAF inhibitor, non-small cell lung cancer, BRAF mutation, 2667
- Lymph node metastasis, head and neck cancer, squamous cell carcinoma, positron emission tomography, extranodal extension, 2073
- Lymph node, fibrosis, necrosis, non-small cell lung cancer, chemoradiotherapy, 4419
- Lymph node, MRI, rectal cancer, neoadjuvant therapy, metastases, follow-up, 2757
- Lymphadenectomy, esophageal carcinoma, oncological esophagectomy, neoadjuvant chemoradiation, survival, prognosis, 2833
- Lymphadenectomy, sentinel lymph node biopsy (SLNB), immunotherapy, radiation, chemotherapy, 2895
- Lymphangiogenesis, oral cancer, LN metastasis, CD11b+ cell, hypoxia, 6845
- Lymphangiogenesis, ovarian cancer, immunohistochemistry, angiogenesis, CD105, CD34, 6923
- Lymphangiogenesis, periostin, carcinoma, stemness, metastasis, angiogenesis, chondrosarcoma, 5463
- Lymphangioma, adult, oropharynx, 1631
- Lymphedema, age, gynecologic cancer-related lymphedema, secondary lymphedema, iatrogenic lymphedema, plastic surgery, review, 6609
- Lymphocyte-to-monocyte ratio, pancreatic head cancer, prognosis, obstructive jaundice, 3371
- Lymphoma, BCR, bromodomain (BRD), BET inhibitor, sYK inhibitor, canine DLBCL, 3781
- Lymphoma, flow cytometry, IgG4-related ophthalmic disease, 2019
- Lymphoma, pesticide, ecologic, carcinogenicity, 5423
- Lynch syndrome, defective mismatch repair, colorectal cancer, anti-PD-1 blockade, microsatellite instability, 4379
- Lysis, natural killer cells, NK-92, K562, PBMC, 5355
- M2BPGi, postoperative ascites, VTQ, hepatic resection, HCC, ALBI grade, 4343
- Machine learning, artificial intelligence, deep learning, neural network, ovarian cancers, ovarian tumor, blood test, 4795
- Machine learning, head and neck squamous cell carcinoma, computed tomography, texture analysis, 271
- Macrophage, *in vitro*, LPS, oral administration, phagocytosis, 4711
- Macrophage, monocyte, fibroblast, hyaluronan, elastin, lipopolysaccharide, 4681
- Macrophages, colorectal cancer, immunotherapy, microsatellite stability, CCR5 inhibition, chemokine, innate immunity, monocytes, 6933
- Macrophages, low-molecular-weight whey protein, bovine mastitis, cytokines, 4701
- MAD2L2, APC/C, TNBC, 5471
- Magnetic resonance imaging, atypical endometrial hyperplasia, endometrial cancer, hysterectomy, preoperative procedure, 2989
- Magnetic resonance imaging, computer-aided detection, vacuum-assisted biopsy, 6437
- Magnetic resonance, ultrasound, MR-US fusion, iOTA simple rules, O-RADS MRI scoring system, adnexal masses, ovarian cancer, 4115
- Magnetic seeds, radiofrequency identification tags, non-wire localisation, 315
- Magseed, pooled analysis, wireless, localisation, review, 1809
- Mahlavu, cetyltrimethylammonium bromide, CTAB, hepatic cancer, fibroblast growth factor, FGF, 5059
- Maintenance therapy, nonsquamous non-small cell lung cancer, pemetrexed, bevacizumab, bevacizumab+pemetrexed, 2981
- Major vascular resection, aortic reconstruction, retroperitoneal sarcoma, 1049
- MALAT1*, HNSCC, lncRNA, radiation sensitivity, cisplatin sensitivity, 2645
- Malignancy, asymptomatic, endometrial polyps, postmenopausal, PTEN, 789

- Malignant melanoma, acral lentiginous melanoma, National Cancer Database, tumor characteristics, 3411
- Malignant melanoma, gene polymorphism, melanoma risk, meta-analysis, vitamin D receptor, review, 583
- Malignant melanoma, nivolumab, ipilimumab, anti-PD-1, pediatric cancer, brain tumor, 7095
- Malignant melanoma, tailored advice, questionnaire, sun habits, ultraviolet radiation, 3325
- Malignant peripheral nerve sheath tumor, neurofibromatosis type I, NF1, ICE chemotherapy, MPNST, 1619
- Malignant peripheral nerve sheath tumor, von Recklinghausen's disease, MN1, NF1, next-generation sequencing, 6221
- Malignant pleural effusion, differential diagnosis, pleural-fluid cytology, lung cancer, pulmonary metastases, 1135
- Malignant pleural effusions, adenocarcinoma, EGFR-TKI, pleurodesis, hypoalbuminemia, 1117
- Malignant pleural mesothelioma, von Hippel Lindau mutation, hypoxia inducible factor-1 $\alpha$ , molecular targeted therapy, 1867
- Malignant tumour, dickkopf-3, clinical biomarker, therapeutics, review, 5969
- Malignant, SPARC, invasion, meningioma, immunohistochemistry, recurrence, 3081
- Mammalian target of rapamycin (mTOR), non-Hodgkin's lymphoma (NHL), t-cell lymphomas, anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (ALK), drug combination therapy, 1395
- Mammary cancer, tGF $\beta$  signaling, functional loss, environmental carcinogen, 2687
- Mammary carcinoma, plasma oncology, plasma surgery, cold atmospheric plasma, physical therapy, 6205
- Mammary ductoscopy, breast cancer, nipple discharge, galactoscopy, endoscopic classification, 2185
- Mammary tumor, metabolomics, mMTV-PyMT, high-fat diet, mice, 3697
- Mammography (MG), breast cancer, contrast-enhanced spectral mammography (CESM), 2925
- Manometry, rectal cancer, anorectal function, chemoradiotherapy, neoadjuvant, 2199
- Margins of excision, cell biology, stomach neoplasms, 5807
- Maslinic acid, human cervical cancer, HeLa cells, DNA damage, DNA condensation and fragmentation, 6869
- Mass spectrometry, extracellular vesicles, lung cancer, drug resistance, cisplatin, 5509
- Mast cells, mastocytosis, histones, demethylase, caspases, 2525
- Mastectomy, breast cancer, bolus, clinical practice, radiotherapy, 6505
- Mastectomy, day-case, patient satisfaction, questionnaire, 2179
- Mastocytosis, mast cells, histones, demethylase, caspases, 2525
- Matrix metalloproteinase 8, laryngeal squamous cell carcinoma, matrix metallo-proteinases, MMP8, single nucleotide polymorphism, rs11225395, rs2155052, 2003
- Matrix metalloproteinases, gelatinases, polymorphisms, circulating levels, breast cancer risk, review, 3619
- Matrix metallo-proteinases, laryngeal squamous cell carcinoma, matrix metalloproteinase 8, MMP8, single nucleotide polymorphism, rs11225395, rs2155052, 2003
- Matrix metalloproteinases, nitric oxide, HNSCC human head and neck cell, isogenic cell lines, cell proliferation, apoptosis, invasiveness, 2657
- Matrix-producing breast carcinoma, PDOX, patient-derived orthotopic xenograft, TNBC, triple-negative breast cancer, eribulin, cisplatin, tumor regression, 2475
- Matrix-producing breast carcinoma, PDOX, patient-derived orthotopic xenograft, nude mice, TNBC, triple-negative breast cancer, eribulin, olaparib, regression, resistance, 2509
- Maximum standardized uptake value, non-small cell lung cancer, long interspersed nuclear element-1, methylation, p53, 5659
- MCF-7, breast cancer, mesenchymal stem cells, TRAIL, 5641
- MCRPC, cabazitaxel, postdocetaxel, biweekly dosing, 6915
- MDA-MB-231, (+)-betulin, NF- $\kappa$ B, zebrafish, apoptosis, 6637
- MDM2*, drug repositioning, repurposing, *MDMX*, *CDKN1A*, P21<sup>WAF1/CIP1</sup>, 4961
- MDM2*, polymorphism, expression, prostate cancer, slovak population, 6257
- MDMX*, drug repositioning, repurposing, *MDM2*, *CDKN1A*, P21<sup>WAF1/CIP1</sup>, 4961
- Mean heart dose, breast cancer, radiotherapy, cardiotoxicity, LAD, LV, echocardiography, 3003
- Mediastinal lymphatic metastasis, indocyanine green, fluorescence imaging, orthotopic implantation, squamous lung carcinoma, 1875
- Medulloblastoma, childhood cancer, PI3K inhibitors, FGFR inhibitors, 53
- Medulloblastoma, ependymoma, basic magnetic resonance imaging, predictive model, 2975
- MEK inhibitors, peripheral nerve sheath tumor, plexiform neurofibroma, MPNST, neurofibromatosis type 1, NF1, review, 1817
- Melanoma metastases, melanoma sentinel lymph node, melanoma progression, extravascular-migratory-metastasis, 891
- Melanoma progression, melanoma sentinel lymph node, melanoma metastases, extravascular-migratory-metastasis, 891
- Melanoma risk, gene polymorphism, malignant melanoma, meta-analysis, vitamin D receptor, review, 583
- Melanoma sentinel lymph node, melanoma metastases, melanoma progression, extravascular-migratory-metastasis, 891

- Melanoma vaccine, melanoma, biomarker, BNIP3L, autophagy, 3723
- Melanoma, analysis of survival, immunotherapy, pembrolizumab, S100, 2157
- Melanoma, biomarker, BNIP3L, autophagy, melanoma vaccine, 3723
- Melanoma, BRAF<sup>V600E</sup>, 3PO, A375, inhibitor, PFKFB3, 2613
- Melanoma, electrochemotherapy, rare non-melanoma skin cancer, metastases, 6485
- Melanoma, metastatic melanoma, rAAV, intranasal delivery, lungs, 4425
- Melanoma, natural products, *E. piscocarpus*, photoprotection, spathulenol, apoptosis, 5015
- Melanoma, ROCK1, ROCK2, tumor-infiltrating lymphocytes, prognosis, Kaplan–Meier analysis, 1931
- Melanoma, sarcopenia, body mass index, pembrolizumab, monoclonal antibodies, retrospective studies, clinical decision-making, drug-related side effects, adverse reactions, 5245
- Melanoma, sunbeds, solarium, tanning, hill criteria, 501
- Melanoma, vitamin D, pigmentation, clinical data, experimental models, review, 473
- Melatonin, tongue squamous cell carcinoma, MTT, migration, invasion, apoptosis, autophagy, 6295
- Menadione, ascorbate, cancer, mitochondria, superoxide, succinate, 1963
- Mendelian randomization, breast, cancer, colon, colorectal, ecological, prostate, ultraviolet B, UVB, 25-hydroxyvitamin D, review, 491
- Meningioma, SPARC, invasion, immunohistochemistry, malignant, recurrence, 3081
- Menopause status, vitamin D, gynaecological cancers, seasonal influence, age, nicotine abuse, grade, 545
- Merkel cell carcinoma, nasal vestibule, traumatic suture scar, immunohistochemistry, TP53 mutation, 1123
- Mesenchymal stem cells, MCF-7, breast cancer, TRAIL, 5641
- Mesenchymal stem cells, sinusoidal obstruction syndrome, colorectal cancer, liver metastases, liver resection, monocrotaline, 6817
- Mesenchymal stem cells, tumor progression, tumor microenvironment, review, 3039
- Mesenchymal to epithelial transition, cetyltrimethylammonium bromide (CTAB), hepatic cancer, HA22T/VGH, 4513
- Mesothelioma, imidazo[2, 1-*b*][1, 3, 4]thiadiazole compounds, FAK, gemcitabine, human equilibrative nucleoside transporter-1, 4913
- Messenger RNA, non-small cell lung carcinoma, gemcitabine, pharmacogenomics, RRM1, RRM2, CDA, dCK, hENT1, 901
- Mestizo population, metastatic colorectal cancer, methylenetetrahydrofolate reductase, sNPs, fluoropyrimidine-based chemotherapy, side effects, 4263
- MET* signaling, EGFR inhibitor resistance, patient-derived model, combinational treatment, tumor microenvironment, 109
- Meta-analysis, cancer, ephrin receptor B2, prognosis, 4309
- Meta-analysis, cisplatin, nSAIDs, nephrotoxicity, 1747
- Meta-analysis, fecal occult blood, guaiac-based test, fecal immunochemical test, gFOBT, iFOBT, FIT, colorectal cancer screening, sensitivity, specificity, false negative, false positive, ROC, HSROC, 3591
- Meta-analysis, gene polymorphism, malignant melanoma, melanoma risk, vitamin D receptor, review, 583
- Meta-analysis, muscle mass loss, sarcopenia, cancer, skeletal muscle index, review, 2409
- Meta-analysis, olaparib, randomized clinical trial, anemia, fatigue, PARP, review, 597
- Metabolism, holocarboxylase synthetase, biotin-dependent carboxylases, biotin, breast cancer, 4557
- Metabolomic profile, vitamin D, supplementation, metabolomics, genomics, broad gene expression, individual response, personalized medicine, 25-hydroxyvitamin D, 535
- Metabolomics, mammary tumor, mMTV-PyMT, high-fat diet, mice, 3697
- Metabolomics, plasma, diet, time-restricted feeding, Lewis lung carcinoma, mice, 1833
- Metabolomics, vitamin D, supplementation, genomics, broad gene expression, metabolomic profile, individual response, personalized medicine, 25-hydroxyvitamin D, 535
- Metaplastic breast carcinoma, epigenetics, EZH2, MMSET, 2133
- Metastases, electrochemotherapy, melanoma, rare non-melanoma skin cancer, 6485
- Metastases, MRI, rectal cancer, lymph node, neoadjuvant therapy, follow-up, 2757
- Metastasis suppression, KISS1, KISS1R, prostate cancer, 709
- Metastasis, breast cancer, sentinel node biopsy, platelet-to-lymphocyte ratio, 4405
- Metastasis, ccl18 protein, gpr30, epithelial-mesenchymal transition (EMT), cancer, 3097
- Metastasis, DLL1, suppressor, pancreatic cancer, src, p38, 1335
- Metastasis, epithelial–mesenchymal transition, circulating tumor cell, head and neck squamous cell carcinoma, recurrence, 3559
- Metastasis, Ewing sarcoma, stereotactic body radiation therapy, 951
- Metastasis, head and neck cancer, saliva, recurrence, circulating DNA, animal model, 191
- Metastasis, lung cancer, metastatic pattern, cluster analysis, 413
- Metastasis, p38 mitogen-activated protein kinase, isoforms, pancreatic cancer, invasion, 5545
- Metastasis, periostin, carcinoma, stemness, angiogenesis, lymphangiogenesis, chondrosarcoma, 5463

- Metastasis, renal cell carcinoma, pazopanib, stereotactic radiotherapy, tyrosine kinase inhibitors, 7037
- Metastasis, soft-tissue sarcoma, histological grade, tumor site, early consultation, early referral, 7009
- Metastatic breast cancer, hER2-positive, re-therapy, trastuzumab, 3973
- Metastatic breast cancer, S-1, IRIS, pilot study, irinotecan, 4779
- Metastatic breast cancer, vinorelbine, real-world data, ESME, retrospective study, 3905
- Metastatic breast carcinoma, peritoneum, cytology, high-grade serous carcinoma, 2933
- Metastatic colorectal cancer, cetuximab, biweekly, weekly, 3469
- Metastatic colorectal cancer, cetuximab, panitumumab, first-line treatment, overall survival, hypomagnesemia, 7135
- Metastatic colorectal cancer, methylenetetrahydrofolate reductase, sNPs, fluoropyrimidine-based chemotherapy, side effects, mestizo population, 4263
- Metastatic colorectal cancer, ramucirumab, third-line treatment, overall survival, drug cost, adverse event, 1605
- Metastatic melanoma, melanoma, rAAV, intranasal delivery, lungs, 4425
- Metastatic pattern, cluster analysis, prognosis, lung cancer, 421
- Metastatic pattern, lung cancer, metastasis, cluster analysis, 413
- Metastatic renal cell carcinoma, international Metastatic Renal Cell Carcinoma Database Consortium, novel stratification system, japanese patients, 4395
- Metastatic renal cell carcinoma, nivolumab, axitinib, immune checkpoint inhibitor, 6493
- Metastatic renal cell carcinoma, RCC, polycystic liver disease, liver cyst, cabozantinib, pazopanib, 1527
- Metastatic spinal cord compression, spinal metastasis, long-term survival, surgical treatment, prognostic factor, sex, 1475
- Metastatic spinal cord compression, spinal surgery, spinal metastases, vertebral metastases, operation time, bleeding, minimal access surgery, 5673
- Metastatic, Ewing sarcoma, cabozantinib, 2265
- Metformin, nivolumab, non-small cell lung cancer, corticoids, antibiotics, proton pump inhibitors, NSAID, statins, 2209
- Metformin, pancreatic neuroendocrine tumor, cell cycle, apoptosis, microRNA, 121
- Methioninase, oral, methionine, methionine restriction prostate cancer, PSA, ovarian cancer, supplement, cancer patients, 2813
- Methionine restriction prostate cancer, methioninase, oral, methionine, PSA, ovarian cancer, supplement, cancer patients, 2813
- Methionine restriction, breast cancer, surgical resection, recurrence, recombinant methioninase, lung metastasis, inhibition, adjuvant therapy, 4869
- Methionine, methioninase, oral, methionine restriction prostate cancer, PSA, ovarian cancer, supplement, cancer patients, 2813
- Methoxy group, 3-Styrylchromones, cytotoxicity, tumor-specificity, QSAR analysis, cell cycle analysis, molecular shape, 87
- Methoxy poly(ethylene glycol)-poly(lactic-co-glycolic) acid, apoptosis, breast cancer, piperine, thin-film hydration, 689
- Methylation of N6 adenosine, hepatocellular carcinoma, RNA demethylase, prognosis, 6665
- Methylation, non-small cell lung cancer, long interspersed nuclear element-1, maximum standardized uptake value, p53, 5659
- Methylation, p53, prognosis, sidedness, colon cancer, 201
- Methylenetetrahydrofolate reductase, metastatic colorectal cancer, sNPs, fluoropyrimidine-based chemotherapy, side effects, mestizo population, 4263
- Methylsulfonylmethane, apoptosis, cell cycle arrest, stemness, HT-29 cells, 5191
- Methylsulfonylmethane, intrinsic apoptosis, cell-cycle arrest, A549 lung adenocarcinoma cell line, 1905
- MGMT promoter methylation, glioblastoma, pyrosequencing, geneXpert, 6229
- MIB-1, <sup>18</sup>F-FDG PET/CT, non-small-cell lung cancer, artificial intelligence, 3355
- MIC1, cell-matrix interactions, cell adhesion, migration, tumor spheroids, tGFβ, ILK, PARVA, LIMS1, RSU1, 1375
- Mice, metabolomics, mammary tumor, mMTV-PyMT, high-fat diet, 3697
- Mice, metabolomics, plasma, diet, time-restricted feeding, Lewis lung carcinoma, 1833
- Micro RNA, epithelial-mesenchymal transition, pancreatic cancer, exosomes, 1843
- Microarray analysis, triple-negative breast cancer, aldehyde dehydrogenase 1, network analysis, 6733
- Microarray, intraductal papillary mucinous neoplasms, iPMN-derived carcinoma, pancreatic ductal adenocarcinoma, biomarker, 6551
- Microarray, microRNA, miR-935, INPP4A, oral squamous cell carcinoma, 6101
- Microbiome, lung cancer, carcinogenesis, cancer therapy, review, 4807
- Microbiome, sorafenib, hepatocellular carcinoma, tyrosine kinase inhibitors, 665
- Microenvironment, desmoplastic reaction, intrahepatic cholangiocarcinoma, 4749
- MicroRNA-449a, gastric cancer, microRNAs, miR-449a, 239
- MicroRNA, glial tumors, glioblastoma, miRNA-221, biomarker, 3265

- MicroRNA, left-sided colorectal cancer, right-sided colorectal cancer, biological pathways, 3713
- MicroRNA, locoregional recurrent rectal cancer, angiogenesis, expression, colorectal cancer, 2947
- MicroRNA, microarray, miR-935, INPP4A, oral squamous cell carcinoma, 6101
- MicroRNA, pancreatic neuroendocrine tumor, metformin, cell cycle, apoptosis, 121
- MicroRNAs, gastric cancer, microRNA-449a, miR-449a, 239
- Microsatellite instability, carcinosarcoma, endometrial neoplasms, pembrolizumab, radiotherapy, abscopal effect, 4131
- Microsatellite instability, defective mismatch repair, colorectal cancer, anti-PD-1 blockade, Lynch syndrome, 4379
- Microsatellite stability, colorectal cancer, immunotherapy, CCR5 inhibition, chemokine, innate immunity, macrophages, monocytes, 6933
- Microsatellite stable, synchronous primary malignancy, colonic adenocarcinoma, pancreatic ductal carcinoma, immunohistochemistry, chemotherapy, 4029
- Microscopy, carcinoma, oral, chromosome, polysomy, grid, 3759
- Microvascular invasion, hepatocellular carcinoma, hematogenous metastasis, prognosis, 3983
- Migration ability, apoptosis, ciprofloxacin, colony formation, HeLa cells, 5025
- Migration, ABHD12, breast cancer, proliferation, invasion, 2601
- Migration, CARD14, proliferation, apoptosis, breast cancer, 1953
- Migration, cell–matrix interactions, cell adhesion, tumor spheroids, tGF $\beta$ , ILK, MIC1, PARVA, LIMS1, RSU1, 1375
- Migration, CLL, cofilin-1, CFL1, chemotaxis, apoptosis, cell cycle, 6327
- Migration, glioblastoma, fucoxanthin, apoptosis, invasion, angiogenesis, 6799
- Migration, melatonin, tongue squamous cell carcinoma, MTT, invasion, apoptosis, autophagy, 6295
- Minimal access surgery, metastatic spinal cord compression, spinal surgery, spinal metastases, vertebral metastases, operation time, bleeding, 5673
- Minimal handling, early-stage cervical cancer, villoglandular adenocarcinoma of the uterine cervix, minimal invasive surgery, review, 3049
- Minimal invasive surgery, early-stage cervical cancer, villoglandular adenocarcinoma of the uterine cervix, minimal handling, review, 3049
- Minimal invasive surgery, gastric cancer, postoperative infectious complications, surgical stress, prognosis, 7109
- Minimally invasive esophagectomy, esophageal cancer, thoracoscope, 1587
- Minimally-invasive, hybrid, esophagectomy, esophageal, cancer, 1753
- MiR-1, gastric cancer, LITAF, 6247
- MiR-139, LC3B-II, SQSTM1, apoptosis, chloroquine, autophagy, beclin-1, mTOR, prostate cancer, 6649
- MiR-146a, *rs2910164*, single nucleotide polymorphism, esophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, pancreatic cancer, 1495
- MiR-187, cervical cancer, siHa cells, 1427
- MiR-196a-2, childhood leukemia, genotype, polymorphism, Taiwan, 4465
- MiR-449a, gastric cancer, microRNAs, microRNA-449a, 239
- MiR-935, microarray, microRNA, INPP4A, oral squamous cell carcinoma, 6101
- MiRNA-221, glial tumors, glioblastoma, microRNA, biomarker, 3265
- MiRNA-301-3p, pancreatic cancer, caspase-8, TRAIL, luteolin, combination effect, 723
- MiRNA, exosomes, extracellular vesicles, breast cancer, biomarkers, tears, 3091
- MiRNA, pediatric, ALL, relapse, epigenetic, 3147
- Mitochondria, liver cancer, ROS, *Picrasma quassoides*, 3819
- Mitochondria, menadione, ascorbate, cancer, superoxide, succinate, 1963
- Mitochondria, papuamine, alkaloid, anticancer, 323
- Mitomycin C, single intravesical instillation, low-risk bladder cancer, pirarubicin, 5295
- Mix cellularity classical Hodgkin's lymphoma, luteolin, Hodgkin's lymphoma, cancer, 4907
- MK615, KRAS, colon cancer, HIF, e-cadherin, prunus mume, 4687
- MLL2, ER+/*HER2*+, triple-positive breast cancer, next-generation sequencing, neo-ALL-IN, *PIK3CA*, 5883
- MMP-1*, age, gender, genotype, polymorphism, pterygium, Taiwan, 703
- MMP7*, gastric cancer, genotype, polymorphism, Taiwan, 695
- MMP8*, laryngeal squamous cell carcinoma, matrix metallo–proteinases, matrix metalloproteinase 8, single nucleotide polymorphism, rs11225395, rs2155052, 2003
- MMP8*, oral tongue squamous cell carcinoma, sex hormones, estradiol, 6029
- MMP-9*, acute lymphocytic leukemia, case–control study, childhood, genotype, polymorphism, Taiwan, 5751
- MMP-9*, age, gender, genotype, polymorphism, pterygium, Taiwan, 4523
- MMP-9*, angiogenesis, endothelial cells, glioblastoma, cell crosstalk, CXCR4, 2725
- MMR, PD-L1, CD8, endometrial cancer, 1669
- MMSET, metaplastic breast carcinoma, epigenetics, EZH2, 2133

- MMTV-PyMT, metabolomics, mammary tumor, high-fat diet, mice, 3697
- MN1, malignant peripheral nerve sheath tumor, von Recklinghausen's disease, NF1, next-generation sequencing, 6221
- Modelling and simulation, chronopharmacokinetics, translational research, cancer chemotherapy, therapeutic drug monitoring, 5-FU prodrug, pharmacometrics, review, 6585
- Moderate-dose RT, low-dose, ultra-low, intensity-modulated radiotherapy, toxicity, 4041
- Modern chemotherapy, colorectal liver metastasis, CRLM, actual 5-year survivor, 1107
- Modified radical mastectomy, pecs block, regional anesthesia, breast surgery, postoperative pain, nonphysician anesthesia provider, 2231
- Mogamulizumab, adult T-cell leukemia/lymphoma, EPOCH, 5237
- Molecular characterization, endometrial cancer, second primary cancer, interval from first primary cancer to second primary cancer, 3811
- Molecular design, structure, EGF receptor, tX-2036 derivatives, 4675
- Molecular shape, 3-Styrylchromones, methoxy group, cytotoxicity, tumor-specificity, QSAR analysis, cell cycle analysis, 87
- Molecular shape, QSAR, guaiiazulene-3-carboxylate, OSCC, tumor-specificity, ionization potential, 4885
- Molecular subtype, breast cancer, brain metastasis, survival, prognosis, surgical resection, 1759
- Molecular subtypes, breast cancer, e-cadherin, p-cadherin, 5557
- Molecular subtypes, breast cancer, immunohistochemistry, IGF1R, 1555
- Molecular targeted therapy, malignant pleural mesothelioma, von Hippel Lindau mutation, hypoxia inducible factor-1 $\alpha$ , 1867
- Molecular targeted therapy, renal cell carcinoma, inflammatory marker, 1739
- Molecularly targeted therapy, brain metastases, non-small cell lung cancer, surgical resection, 4801
- Monoclonal antibodies, melanoma, sarcopenia, body mass index, pembrolizumab, retrospective studies, clinical decision-making, drug-related side effects, adverse reactions, 5245
- Monoclonal antibody, infusion reaction, infusion time, infusion rate systematic review, review, 1201
- Monocrotaline, sinusoidal obstruction syndrome, colorectal cancer, liver metastases, liver resection, mesenchymal stem cells, 6817
- Monocyte, macrophage, fibroblast, hyaluronan, elastin, lipopolysaccharide, 4681
- Monocytes, colorectal cancer, immunotherapy, microsatellite stability, CCR5 inhibition, chemokine, innate immunity, macrophages, 6933
- Monotherapy, small-cell lung cancer, relapsed, refractory, nab-paclitaxel, 1579
- Morbidity, debulking for ovarian cancer, primary debulking, complete cytoreduction, upper abdominal surgery, interval debulking surgery, 5869
- Morphological change, THP-1 macrophages, serum-MAF,  $\gamma$ -globulin, talin-1, calpain, time-lapse imaging, 4707
- Morphological malformations, proton, photon, zebrafish embryo model, DNA-DSB, histological changes, 6123
- Mosaicism, neurofibromatosis type 1, tumour predisposition syndrome, plexiform neurofibroma, 3423
- Motor nerve, schwannoma, neurological deficit, distribution, sensory nerve, complication, 6563
- Mott cells, russell body esophagitis, russell body gastritis, barrett's esophagus, 3991
- Mouse model, CTC, pancreatic cancer, KRAS mutation, cytology, CTC detection platform, 6781
- MPNST, neurofibromatosis type I, NF1, ICE chemotherapy, malignant peripheral nerve sheath tumor, 1619
- MPNST, peripheral nerve sheath tumor, plexiform neurofibroma, neurofibromatosis type 1, NF1, MEK inhibitors, review, 1817
- MR imaging, myxofibrosarcoma, reproducibility, prognosis, survival, 5793
- MR-US fusion, magnetic resonance, ultrasound, iOTA simple rules, O-RADS MRI scoring system, adnexal masses, ovarian cancer, 4115
- MRI accuracy, breast cancer, neoadjuvant chemotherapy, complete pathological response, histological examination, 281
- MRI, nasopharyngeal, cancer, CT, sNPs, polymorphism, variations, genotype, VEGFA, EDNRA *NBS1*, FAS, 677
- MRI, rectal cancer, lymph node, neoadjuvant therapy, metastases, follow-up, 2757
- MRNA stability, RSF3, *SF3B4*, HCC, SNU-368, 2033
- MSI-high, pembrolizumab, IHCCC, 4123
- MtDNA, ulcerative colitis, carcinogenesis, 101
- MTOR inhibitors, fibroblast growth factor, HPV, FGF, head and neck squamous cell carcinoma, HNSCC, everolimus, tyrosine kinase inhibitors, 5621
- MTOR, chemoprevention, head and neck squamous carcinoma, 5417
- MTOR, LC3B-II, SQSTM1, apoptosis, chloroquine, miR-139, autophagy, beclin-1, prostate cancer, 6649
- MTOR, senescence, glutamine metabolism, DNA damage, 6891
- MTT, glioma, viability, polyphenols, flow cytometry, DRAQ7, 5427
- MTT, melatonin, tongue squamous cell carcinoma, migration, invasion, apoptosis, autophagy, 6295
- MTUS1, renal cell carcinoma, immunohistochemistry, public data, prognosis, 2961
- MUC1, pancreatic ductal adenocarcinoma, dendritic cell vaccination, WT1, phase I/IIa study, 5765

- Mucinous adenocarcinoma, adjuvant chemotherapy, high-risk factor, stage II, 1651
- Mucositis, hematopoietic cell transplantation, palifermin, children, risk factors analysis, keratinocyte growth factor, 6531
- Mucositis, palbociclib, chemotherapy, palliative, radiation therapy, ibrance, chemoradiation, 5291
- Multidetector computed tomography, positron-emission tomography, iodine, fluorodeoxyglucose, lung cancer, dual-energy, 3459
- Multidetector computed tomography, stomach neoplasms, neoplasm staging, contrast media, echo-endoscopy, 3401
- Multidrug resistance, cancer, t-lymphoma, phenothiazines, selenoesters, selenoanhydride, combination chemotherapy, 4921
- Multidrug resistance, colorectal cancer, SN38, redox-status, oxidative stress, ferroptosis, electroporation, 5159
- Multimodal treatment, anaplastic thyroid cancer, thyroid surgery, radiotherapy, hyperfractionated accelerated radiotherapy, 6979
- Multimodality, apparent diffusion coefficient, neoadjuvant therapy, score, 4033
- Multiple myeloma, gene expression, apoptosis, myeloma cell lines, 4979
- Multiple myeloma, interleukin-8, sRAGE, oxidative stress, cancer, gender, 1443
- Multiple myeloma, neuropilin-1, pDCs, tregs, 5437
- Multiple myeloma, social determinants of health, disparity, affordable Care Act, 5727
- Multivariate analysis, bone tumor, extremity, postoperative deep infection, risk factor, 3551
- Multivariate analysis, hepatitis B virus, head and neck cancer, hBc antibody, 2393
- Muscle invasive bladder cancer, radiation therapy, whole-bladder, elderly patients, 2905
- Muscle mass loss, oesophageal cancer, esophagectomy, 2275
- Muscle mass loss, sarcopenia, cancer, skeletal muscle index, meta-analysis, review, 2409
- Mutant NSCLC, AGR2, NSCLC, gefitinib resistance, yuanguadine, ADAMTS6, 1855
- Mutation, isocitrate dehydrogenase 1, IDH1 R132H, 2-hydroxyglutarate, high-throughput screening, 4929
- Mutations, acute myeloid leukemia, secondary, therapy related, survival, 2917
- Mxi-2, prostate cancer, endothelin-1, ago2, p53, 5539
- Mycoplasma genitalium*, high-risk HPV, smoking, anogenital warts, sexually transmitted infection, *Mycoplasma hominis*, *Ureaplasma spp*, 2219
- Mycoplasma hominis*, high-risk HPV, smoking, anogenital warts, sexually transmitted infection, *Mycoplasma genitalium*, *Ureaplasma spp*, 2219
- Myelodysplastic syndrome, IGF-1R, IGF-MTX, phase 1 study, chronic myelomonocytic leukemia, oligoblastic acute myeloid leukemia, 3883
- Myeloid cell leukemia-1, apoptosis, non-small cell lung cancer, prognosis, survival, 1007
- Myeloma cell lines, multiple myeloma, gene expression, apoptosis, 4979
- Myoferlin, biomarker, immunohistochemistry, knockdown, renal cell carcinoma, 3119
- Myxofibrosarcoma, MR imaging, reproducibility, prognosis, survival, 5793
- N-desmethyl enzalutamide, enzalutamide, castration-resistant prostate cancer, pharmacokinetics, reduced dose, 7101
- N-farnesyl-norcantharimide, jurkat T cells, next-generation sequencing, tumor suppressor gene, biosynthesis, 2675
- N, n'-(arylmethylene)biscinnamide, apoptosis, caspase, death receptor 5, cancer cells, 5035
- N'-(arylmethylene)biscinnamide, N, apoptosis, caspase, death receptor 5, cancer cells, 5035
- Nab-paclitaxel, small-cell lung cancer, relapsed, refractory, monotherapy, 1579
- NACRT, omentoplasty, perineal wound complication, abdominoperineal resection, 6539
- NAD, chemo brain, tryptophan, kynurenine, tubulin, cognition, biophoton, review, 1189
- NANOG,  $\gamma\delta$  T cell, immunotherapy, prostate cancer, cancer stem cell, sphere, prostasphere, CD133, SOX2, OCT4, 5481
- Nanomedicine, ultrasound, poly-ethylene glycol-modified carbon nanotubes, sonodynamic therapy, sarcoma 180, colon 26, 2549
- Nasal vestibule, merkel cell carcinoma, traumatic suture scar, immunohistochemistry, *TP53* mutation, 1123
- Nasopharyngeal carcinoma, case-control study, caspase-8, genotype, polymorphism, Taiwan, 5503
- Nasopharyngeal carcinoma, Epstein-Barr virus, rta, interleukin-6, cell migration, 3255
- Nasopharyngeal, cancer, CT, MRI, sNPs, polymorphism, variations, genotype, VEGFA, EDNRA *NBS1*, FAS, 677
- National Cancer Database, acral lentiginous melanoma, malignant melanoma, tumor characteristics, 3411
- National Cancer Database, textbook outcome, retroperitoneal sarcoma, hospital volume, survival, 2107
- Nationwide study, pulmonary oligometastases, pulmonary oligo-recurrence, pulmonary sync-oligometastases, SBRT, 393
- Natural killer cells, breast cancer, cytokines, regulatory T-lymphocytes, 3D culture, 6179
- Natural killer cells, chimeric antigen receptor, glioblastoma, epidermal growth factor receptor variant III, 3231
- Natural killer cells, immunotherapy, colorectal cancer, immune evasion, cancer stem cells, 6613
- Natural killer cells, lysis, NK-92, K562, PBMC, 5355

- Natural killer cells, pancreatic cancer, progesterone receptor antagonists, progesterone induced blocking factor, immunosurveillance, palliation, 6997
- Natural products, melanoma, *E. piscocarpus*, photoprotection, spathulenol, apoptosis, 5015
- Nausea, oxaliplatin, creatinine clearance, adverse events, colorectal cancer, 299
- NBS1*, bladder cancer, case-control study, genotype, polymorphism, 2011
- NCAPH, condensin, chromosome, cell cycle, NSCLC, 3239
- NCCN, risk stratification systems, EAU, radiotherapy, prostate neoplasms, 4413
- NCDB, head and neck neoplasms, ulcerated melanoma, united States/epidemiology, 1055
- NCDB, invasive melanoma, wide excisional surgery, excisional margins, residual tumor, 1059
- NCDB, invasive melanoma, wide excisional surgery, excisional margins, 1065
- Necrosis, fibrosis, non-small cell lung cancer, lymph node, chemoradiotherapy, 4419
- Necrotic death, cell death mode, lipid rafts, apoptotic death, 2573
- Neo-adjuvant chemotherapy, breast cancer, sentinel node biopsy, axillary disease, review, 5351
- Neo-ALL-IN, ER+/*HER2*+, triple-positive breast cancer, next-generation sequencing, *MLL2*, *PIK3CA*, 5883
- Neoadjuvant chemoradiation, esophageal carcinoma, oncological esophagectomy, lymphadenectomy, survival, prognosis, 2833
- Neoadjuvant chemotherapy, bladder cancer, radiotherapy, chemoradiotherapy, bladder sparing, 5861
- Neoadjuvant chemotherapy, breast cancer, complete pathological response, MRI accuracy, histological examination, 281
- Neoadjuvant chemotherapy, breast cancer, PET, SUV, tumor-infiltrating lymphocyte, pathological complete response, 3395
- Neoadjuvant chemotherapy, breast cancer, predict pCR, 2303
- Neoadjuvant chemotherapy, breast cancer, tumor-infiltrating lymphocyte, 1883
- Neoadjuvant chemotherapy, cervical cancer, para-aortic node metastasis, extended-field concurrent chemoradiotherapy, phase II study, 3565
- Neoadjuvant chemotherapy, cervical cancer, radiotherapy, concurrent chemoradiation, radical surgery, review, 4819
- Neoadjuvant chemotherapy, long-term outcome, down-staging, tumor shrinkage, breast conserving surgery, recurrence, 1079
- Neoadjuvant chemotherapy, ovarian cancer, primary debulking surgery, review, 6003
- Neoadjuvant chemotherapy, ovarian cancer, treatment-free interval, platinum resistance, 2765
- Neoadjuvant chemotherapy, para-aortic lymph node excision, stomach neoplasms, 2351
- Neoadjuvant hormonal therapy, SSEA-4, biochemical recurrence, histological effect, prostate cancer, 5567
- Neoadjuvant therapy, apparent diffusion coefficient, score, multimodality, 4033
- Neoadjuvant therapy, chemoradiation, esophagus, recurrence-free survival, tumor response, prognostic factors, 4387
- Neoadjuvant therapy, lung squamous cell carcinoma, sarcomatoid transformation, 1625
- Neoadjuvant therapy, MRI, rectal cancer, lymph node, metastases, follow-up, 2757
- Neoadjuvant therapy, sarcopenia, clinical outcomes, esophageal cancer, 1175
- Neoadjuvant treatment, gastrointestinal stromal tumor, imatinib mesylate, giant tumor, 1147
- Neoadjuvant treatment, upper rectal cancer, chemoradiation therapy, recurrence-free and overall survival, long-term functional results, 3579
- Neoadjuvant, rectal cancer, anorectal function, chemoradiotherapy, manometry, 2199
- Neoangiogenesis, fSHr, HNSCC, histopathology, immunohistochemistry, 349
- Neoplasia, circulating tumor cells, animal models, animal study, cancer detection, review, 6599
- Neoplasm invasiveness, nucleolar proteins, prostate cancer, gleason grade, local spread, 1973
- Neoplasm staging, stomach neoplasms, multidetector computed tomography, contrast media, echo-endoscopy, 3401
- Neoplasms, colon, tumour microenvironment, tumour heterogeneity, 6063
- Neoplastic venous thrombosis, gastric cancer, Trousseau' syndrome, internal jugular vein, 2889
- Nephrotoxicity, cisplatin, nSAIDs, meta-analysis, 1747
- Network analysis, triple-negative breast cancer, aldehyde dehydrogenase 1, microarray analysis, 6733
- Network pharmacology, systems biology, herbal, combination, breast cancer, pharmacological mechanism, 5097
- Neural network, artificial intelligence, deep learning, machine learning, ovarian cancers, ovarian tumor, blood test, 4795
- Neuroblastoma cancer, parkin, nuclear proteome, phosphoproteome, 2D gel electrophoresis, 3169
- Neuroblastoma, children, next-generation sequencing, *ALK*, prognosis, 7057
- Neuroblastoma, oxazolidinones, kelly cell line, proliferation, progression, BSA heat denaturation, adhesion, fibronectin, 5125
- Neuroblastoma, static magnetic stimulation, cell viability, cell death, cell cycle, 5151



- Neuroendocrine carcinoma, carcinoma of the uterine cervix, immunotherapy, cellular immunotherapy, adoptive immunotherapy, t-cells, 4741
- Neuroendocrine differentiation, neuron-specific enolase, platinum-based chemotherapy, treatment-related neuroendocrine prostate cancer, small-cell prostate cancer, 3519
- Neurofibromatosis type 1, tumour predisposition syndrome, mosaicism, plexiform neurofibroma, 3423
- Neurofibromatosis type 1, peripheral nerve sheath tumor, plexiform neurofibroma, MPNST, NF1, MEK inhibitors, review, 1817
- Neurofibromatosis type I, NF1, ICE chemotherapy, malignant peripheral nerve sheath tumor, MPNST, 1619
- Neuroimmunity, brain tumor, cognition, DNA microarray, regulation of actin cytoskeleton, 4719
- Neurological deficit, schwannoma, distribution, sensory nerve, motor nerve, complication, 6563
- Neuron-specific enolase, neuroendocrine differentiation, platinum-based chemotherapy, treatment-related neuroendocrine prostate cancer, small-cell prostate cancer, 3519
- Neuropilin-1, multiple myeloma, pDCs, tregs, 5437
- Neuropilin, cytokine-induced killer cells, immunology, lung cancer, brain tumor, flow cytometry, 5489
- Neurotoxicity, anticancer drugs, bortezomib, PC12, differentiation, overlay method, NGF, protection, antioxidant, 3685
- Neutrophil counts, immune checkpoint inhibitor, non-small-cell lung carcinoma, predictive factor, tumor-associated neutrophils, 3889
- Neutrophil-to-lymphocyte ratio, breast cancer, tumour-infiltrating lymphocytes, prognosis, 2871
- Neutrophil-to-lymphocyte ratio, tumor infiltrating lymphocytes, biliary tract cancer, 2881
- Neutrophil-to-lymphocyte, locally advanced cervical cancer, post-treatment hematological parameters, prognosis, concurrent chemoradiotherapy, 451
- Neutrophils-lymphocyte ratio, colorectal cancer, dynamic change of NLR, prognosis, perioperative nutrition management, 2311
- New-generation, *Helicobacter pylori*, hp IgG ELISA, gastroPanel, clinical validation, non-invasive, biomarker test, gastroscopy, biopsy, pepsinogen I, pepsinogen II, gastrin-17, 6387
- Newly diagnosed glioblastoma, tumor treating fields, the Stupp protocol, survival, selection bias, 5801
- Next-generation sequencing, ER+/HER2+, triple-positive breast cancer, neo-ALL-IN, MLL2, *PIK3CA*, 5883
- Next-generation sequencing, immune checkpoint inhibitors, immune-related adverse events (irAEs), t-cell receptor, renal cell carcinoma, immune response, 4875
- Next-generation sequencing, malignant peripheral nerve sheath tumor, von Recklinghausen's disease, MN1, NF1, 6221
- Next-generation sequencing, n-farnesyl-norcantharimide, jurkat T cells, tumor suppressor gene, biosynthesis, 2675
- Next-generation sequencing, neuroblastoma, children, *ALK*, prognosis, 7057
- Next-generation sequencing, sclerosing microcystic adenocarcinoma, immunosuppression, oral cancer, 6375
- NF- $\kappa$ B, (+)-betulin, MDA-MB-231, zebrafish, apoptosis, 6637
- NF- $\kappa$ B, amentoflavone, cisplatin, oral squamous cell carcinoma, apoptosis, 6723
- NF- $\kappa$ B, sirtuin1, leukemia, NOTCH, p53, 3155
- NF1, malignant peripheral nerve sheath tumor, von Recklinghausen's disease, MN1, next-generation sequencing, 6221
- NF1, neurofibromatosis type I, ICE chemotherapy, malignant peripheral nerve sheath tumor, MPNST, 1619
- NF1, peripheral nerve sheath tumor, plexiform neurofibroma, MPNST, neurofibromatosis type 1, MEK inhibitors, review, 1817
- NGF, anticancer drugs, bortezomib, neurotoxicity, PC12, differentiation, overlay method, protection, antioxidant, 3685
- NICE Guidelines, colorectal cancer, polyps, colonoscopy, bowel cancer, 1705
- Niclosamide, caspase-independent pathway, autophagy, aMPK/AKT/mTOR pathway, NSCLC, 1405
- Nicotinamide phosphoribosyltransferase, glioma, shRNA, 4895
- Nicotine abuse, vitamin D, gynaecological cancers, seasonal influence, menopause status, age, grade, 545
- Nilotinib, FAS CD95, FAS ligand, caspase-3, TKI, apoptosis, dasatinib, erlotinib, gefitinib, everolimus, 6195
- Nilotinib, IGF1R, insulin-like growth factor 1 receptor, TKI, head and neck squamous cell carcinoma (HNSCC), dasatinib, erlotinib, gefitinib, everolimus, 3847
- Nilotinib, PDGF, PDGFR, head and neck squamous cell carcinoma, drug resistance, afatinib, dasatinib, erlotinib, gefitinib, 825
- Nipple discharge, breast cancer, galactoscopy, mammary ductoscopy, endoscopic classification, 2185
- Nipple-sparing mastectomy, breast cancer, breast MRI, 3543
- Nitric oxide, apo2L/TRAIL, nuclear factor kappa B, inhibitor kappa B kinase, apoptosis, 6751
- Nitric oxide, hepatocellular carcinoma, cirrhosis, oxidative stress, circulating leukocytes, glutathione, 6853
- Nitric oxide, HNSCC human head and neck cell, isogenic cell lines, cell proliferation, apoptosis, invasiveness, matrix metalloproteinases, 2657
- Nitric oxide, previtamin D<sub>3</sub>, DNA damage, 8-hydroxy-2'-deoxyguanosine, vitamin D, nitrite, human skin, 565

- Nitrite, previtamin D<sub>3</sub>, DNA damage, 8-hydroxy-2'-deoxyguanosine, nitric oxide, vitamin D, human skin, 565
- Nitrogen oxides, physical plasma, cold atmospheric plasma, plasma medicine, radiation, occupational health and safety, 2591
- Nivolumab, cancer cachexia, gastric cancer, overall survival, time to treatment failure, 7067
- Nivolumab, ipilimumab, anti-PD-1, pediatric cancer, malignant melanoma, brain tumor, 7095
- Nivolumab, metastatic renal cell carcinoma, axitinib, immune checkpoint inhibitor, 6493
- Nivolumab, non-small cell lung cancer, corticoids, antibiotics, proton pump inhibitors, NSAID, statins, metformin, 2209
- Nivolumab, non-small-cell lung cancer, nomogram, 4229
- Nivolumab, salvage chemotherapy, immune checkpoint inhibitor, head and neck carcinoma, recurrent or metastatic, best supportive care, 5277
- NK-92, natural killer cells, lysis, K562, PBMC, 5355
- Nomogram, laparoscopy, suspected prostate cancer, radical prostatectomy, robotics, 2995
- Nomogram, non-small-cell lung cancer, nivolumab, 4229
- Non-alcoholic fatty liver disease, animal models, vitamin D, non-alcoholic steatohepatitis, review, 527
- Non-alcoholic steatohepatitis, animal models, vitamin D, non-alcoholic fatty liver disease, review, 527
- Non-clear cell carcinoma, S100A2, renal cell carcinoma, p53, 6337
- Non-dysplastic, colon, sessile serrated polyps, cell proliferation, p53 up-regulated cells, 1535
- Non-Hodgkin lymphoma, EBV, diffuse large b-cell lymphoma, Epstein-Barr virus positive diffuse large b-cell lymphoma, programmed death-ligand 1, tumour immunology, review, 5951
- Non-Hodgkin's lymphoma (NHL), t-cell lymphomas, anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (*ALK*), mammalian target of rapamycin (mTOR), drug combination therapy, 1395
- Non-invasive, *Helicobacter pylori*, hp IgG ELISA, gastroPanel, new-generation, clinical validation, biomarker test, gastroscopy, biopsy, pepsinogen I, pepsinogen II, gastrin-17, 6387
- Non-metastatic, castration-resistant prostate cancer, disease progression, 1101
- Non-palpable breast lesions, savi Scout<sup>®</sup>, reflector-guided localisation, radar localisation, non-wire localisation, breast cancer, review, 3633
- Non-small cell lung cancer, anti-migration, benzoxazine dimer analogue, integrins, 2583
- Non-small cell lung cancer, apoptosis, myeloid cell leukemia-1, prognosis, survival, 1007
- Non-small cell lung cancer, bevacizumab, erlotinib, tumor metrics, Hellenic Cooperative Oncology Group, 2095
- Non-small cell lung cancer, brain metastases, surgical resection, molecularly targeted therapy, 4801
- Non-small cell lung cancer, cerebral metastasis, elderly, radiation therapy, survival scores, 2847
- Non-small cell lung cancer, clinical practice, alectinib, anaplastic lymphoma kinase fusion gene mutation, chemotherapy, 957
- Non-small cell lung cancer, clinical practice, uncommon mutation, *EGFR*, epidermal growth factor receptor, 5757
- Non-small cell lung cancer, EGFR gene, chemotherapy, osimertinib, 2239
- Non-small cell lung cancer, fibrosis, necrosis, lymph node, chemoradiotherapy, 4419
- Non-small cell lung cancer, long interspersed nuclear element-1, methylation, maximum standardized uptake value, p53, 5659
- Non-small cell lung cancer, lung cancer, lung adenocarcinoma, toll-like receptor 2, nuclear factor-kappa B, proliferation, 5361
- Non-small cell lung cancer, nivolumab, corticoids, antibiotics, proton pump inhibitors, NSAID, statins, metformin, 2209
- Non-small cell lung cancer, older patients, immune checkpoint inhibitor, anti PD-1 inhibitor, overall survival, 923
- Non-small cell lung cancer, pan-RAF inhibitor, LY3009120, BRAF mutation, 2667
- Non-small cell lung cancer, radiotherapy, autophagy, histone modification, GABARAPL1, 2537
- Non-small cell lung cancer, size-selective microfilters, circulating tumor cell, circulating tumor cell cluster, 5577
- Non-small cell lung cancer, tumor marker, inflammation index, carcinoembryonic antigen, c-reactive protein, novel index, surgery, prognosis, 4023
- Non-small cell lung carcinoma, gemcitabine, pharmacogenomics, messenger RNA, RRM1, RRM2, CDA, dCK, hENT1, 901
- Non-small-cell lung cancer, <sup>18</sup>F-FDG PET/CT, MIB-1, artificial intelligence, 3355
- Non-small-cell lung cancer, cancer stem cell, prognostic marker, 6407
- Non-small-cell lung cancer, carbon-ion radiotherapy, effectiveness, stage III, toxicity, 379
- Non-small-cell lung cancer, interferon-gamma release, immune checkpoint inhibitor, biomarker, time to treatment failure, 6971
- Non-small-cell lung cancer, interferon-gamma, immune checkpoint inhibitor, immune-related adverse event, 2787
- Non-small-cell lung cancer, nivolumab, nomogram, 4229
- Non-wire localisation, magnetic seeds, radiofrequency identification tags, 315

- Non-wire localisation, savi Scout<sup>®</sup>, reflector-guided localisation, radar localisation, non-palpable breast lesions, breast cancer, review, 3633
- Non-wire localization, SAVI SCOUT, reflector localization, breast cancer, 3915
- Non-small-cell lung carcinoma, immune checkpoint inhibitor, predictive factor, neutrophil counts, tumor-associated neutrophils, 3889
- Nonlinear optimization, pharmacokinetic (PK)–Pharmacodynamic (PD), tumor growth inhibition (TGI) mathematical model, deep learning neural networks (DLNN), TGI model parameter estimation, adaptive tumor growth short-term prediction, xenografted mice (PDX), pancreatic ductal adenocarcinoma (PDAC) xenograft, 5181
- Nonphysician anesthesia provider, pecs block, regional anesthesia, modified radical mastectomy, breast surgery, postoperative pain, 2231
- Nonsquamous non-small cell lung cancer, maintenance therapy, pemetrexed, bevacizumab, bevacizumab+pemetrexed, 2981
- Normal breast tissue, EWAS, blood, DNA methylation, obesity, body mass index, breast cancer, epigenetic biomarkers, review, 1797
- Normal tissue complication probability (NTCP), stage III non-small cell lung cancer (NSCLC), tumor control probability (TCP), concomitant boost, accelerated radiotherapy, 4095
- Normal tissue, re-irradiation, re-treatment, recurrence, stereotactic body radiation therapy, radiation biology, 1981
- NOTCH, sirtuin1, leukemia, NF- $\kappa$ B, p53, 3155
- Novel index, tumor marker, inflammation index, carcinoembryonic antigen, c-reactive protein, non-small cell lung cancer, surgery, prognosis, 4023
- Novel stratification system, metastatic renal cell carcinoma, international Metastatic Renal Cell Carcinoma Database Consortium, japanese patients, 4395
- NRS pain score, gallstone disease, cancer, surgery, plasma MDA, plasma CAT, 5701
- NSAID, nivolumab, non-small cell lung cancer, corticoids, antibiotics, proton pump inhibitors, statins, metformin, 2209
- NSAIDs, cisplatin, nephrotoxicity, meta-analysis, 1747
- NSCLC, AGR2, mutant NSCLC, gefitinib resistance, yuanhuadine, ADAMTS6, 1855
- NSCLC, *ALK* inhibitors, ceritinib, crizotinib, alectinib, anaplastic lymphoma kinase, radiation, 4937
- NSCLC, chemoradiotherapy, survival, prognostic factor, blood parameters, 2319
- NSCLC, GPR87, shRNA, gene therapy, adenoviral vector, cell surface marker, 733
- NSCLC, Hedgehog pathway, pemetrexed, chemo resistance, gant61, 1451
- NSCLC, KRAS, anti-PDI/PD-L1 therapy, immunotherapy, 427
- NSCLC, NCAPH, condensin, chromosome, cell cycle, 3239
- NSCLC, niclosamide, caspase-independent pathway, autophagy, aMPK/AKT/mTOR pathway, 1405
- NSUN7, WEE1, EMP3, E2F7, CD58, lower-grade gliomas, information-theoretical approach, 2777
- Nuclear factor kappa B, apo2L/TRAIL, nitric oxide, inhibitor kappa B kinase, apoptosis, 6751
- Nuclear factor-kappa B, lung cancer, non-small cell lung cancer, lung adenocarcinoma, toll-like receptor 2, proliferation, 5361
- Nuclear proteome, parkin, phosphoproteome, neuroblastoma cancer, 2D gel electrophoresis, 3169
- Nucleolar proteins, prostate cancer, gleason grade, local spread, neoplasm invasiveness, 1973
- Nucleolus, uveal melanoma, H&E staining, prognosis, 3505
- Nude mice, areca nut, autophagy, 3-methyladenine, chloroquine, cisplatin, 221
- Nude mice, bladder cancer, orthotopic, GFP, cisplatin, oral recombinant methioninase, combination, sensitize, efficacy, 6083
- Nude mice, gastric cancer, liver metastasis, patient-derived orthotopic xenograft (PDOX), 5-fluorouracil, oxaliplatin, gemcitabine, 5393
- Nude mice, PDOX, patient-derived orthotopic xenograft, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, olaparib, regression, resistance, 2509
- Nudemice, dedifferentiated liposarcoma, PDOX, recombinant methioninase, *S. typhimurium* A1-R, combination, tumor regression, 2515
- Nutrition, PEG, RPG, gastrostomy, head and neck cancer, 1167
- O-RADS MRI scoring system, magnetic resonance, ultrasound, MR-US fusion, iOTA simple rules, adnexal masses, ovarian cancer, 4115
- Obesity, EWAS, normal breast tissue, blood, DNA methylation, body mass index, breast cancer, epigenetic biomarkers, review, 1797
- Obstructive jaundice, pancreatic head cancer, prognosis, lymphocyte-to-monocyte ratio, 3371
- Occupational health and safety, physical plasma, cold atmospheric plasma, plasma medicine, radiation, nitrogen oxides, 2591
- OCT4,  $\gamma\delta$  T cell, immunotherapy, prostate cancer, cancer stem cell, sphere, prostasphere, CD133, NANOG, SOX2, 5481
- Oesophageal cancer, docetaxel/cisplatin/5-fluorouracil, oesophagectomy, five-year survival, preoperative chemotherapy, 5829
- Oesophageal cancer, muscle mass loss, esophagectomy, 2275
- Oesophageal squamous cell carcinoma, PARP inhibitor, DNA damaging agents, 53BP1, REV7, 813

- Oesophagectomy, docetaxel/cisplatin/5-fluorouracil, oesophageal cancer, five-year survival, preoperative chemotherapy, 5829
- Olaparib, meta-analysis, randomized clinical trial, anemia, fatigue, PARP, review, 597
- Olaparib, ovarian cancer, platinum resistance, weekly nedaplatin, 5263
- Olaparib, PDOX, patient-derived orthotopic xenograft, nude mice, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, regression, resistance, 2509
- Older patients, brain metastases, local therapies, whole-brain radiotherapy, overall survival, extra-cerebral metastasis, 2841
- Older patients, non-small cell lung cancer, immune checkpoint inhibitor, anti PD-1 inhibitor, overall survival, 923
- Older persons, secondary brain lesions, carcinoma of the breast, radiation therapy, survival analyses, 2271
- Oleic acid, ginseng seed oil, ER+, breast cancer, tamoxifen, 4529
- Oligo-recurrence, esophageal squamous cell carcinoma, radical re-irradiation, 2387
- Oligo-recurrence, stereotactic body radiotherapy (SBRT), oligometastases, esophageal cancer, prognostic factor, 2065
- Oligoblastic acute myeloid leukemia, IGF-1R, IGF-MTX, phase I study, myelodysplastic syndrome, chronic myelomonocytic leukemia, 3883
- Oligometastases, liver metastases, interventional oncology, local ablation, image-guided intervention, interstitial brachytherapy, 4281
- Oligometastases, radiotherapy, cancer, palliative treatment, symptom score, 1551
- Oligometastases, stereotactic body radiotherapy (SBRT), oligo-recurrence, esophageal cancer, prognostic factor, 2065
- Oligometastatic disease, EORTC, ESTRO, 5895
- Oligometastatic disease, sAbR, lung metastases, gastrointestinal tumors, 5901
- Oligometastatic prostate cancer, stereotactic body radiation therapy, prostate neoplasm, SBRT, SRT, review, 2419
- Omentoplasty, perineal wound complication, abdominoperineal resection, NACRT, 6539
- Oncogenes, tumor-suppressor genes, carcinogenesis, signaling pathways, review, 6009
- Oncologic resection, upper extremity, free vascularized fibula flap, limb salvage, 2751
- Oncological esophagectomy, esophageal carcinoma, neoadjuvant chemoradiation, lymphadenectomy, survival, prognosis, 2833
- Oncological rehabilitation, breast cancer, physical exercise, quality of life, fatigue, 4253
- Oncological surgery, leiomyosarcoma, small bowel, sarcoma, 4199
- Oncological treatments delay, COVID-19, breast cancer, screening suspension, lockdown, 7119
- Oncolytic virus, adenovirus, CUL4A, shRNA, virotherapy, 161
- Onconeurology, immunosuppression, kidney transplantation, skin, 4017
- Operation time, metastatic spinal cord compression, spinal surgery, spinal metastases, vertebral metastases, bleeding, minimal access surgery, 5673
- Oral administration, autism spectrum disorder, attention deficit hyperactivity disorder, *Pantoea agglomerans* bacteria derived LPS, 4755
- Oral administration, *in vitro*, LPS, macrophage, phagocytosis, 4711
- Oral cancer, alcohol drinking, betel quid, genotype, interleukin-12A, polymorphism, smoking, Taiwan, 3707
- Oral cancer, cisplatin, transcriptional upregulation, *SEI1*, chemoresistance, 67
- Oral cancer, LN metastasis, cD11b+ cell, lymphangiogenesis, hypoxia, 6845
- Oral cancer, next-generation sequencing, sclerosing microcystic adenocarcinoma, immunosuppression, 6375
- Oral contraception, estrogen, progesterone, human papilloma virus (HPV), cervical cancer, review, 5995
- Oral HPV prevalence, HPV antibodies, healthy population, oropharyngeal cancer, 1597
- Oral mucositis, rat model, chemotherapy, immunosuppression, 2701
- Oral recombinant methioninase, bladder cancer, orthotopic, nude mice, GFP, cisplatin, combination, sensitize, efficacy, 6083
- Oral SCC, peroxisome proliferator-activated receptor  $\gamma$ , troglitazone, apoptosis, G1 arrest, 1247
- Oral squamous cell carcinoma, amentoflavone, cisplatin, NF- $\kappa$ B, apoptosis, 6723
- Oral squamous cell carcinoma, head and neck, HPV, p16, PTEN, 6355
- Oral squamous cell carcinoma, microarray, microRNA, miR-935, INPP4A, 6101
- Oral squamous cell carcinoma, OSCC, risk factors, young adults, case-control study, survival analysis, smoking, alcohol consumption, 6987
- Oral squamous cell carcinoma, vitamin D, sonic Hedgehog signaling, SHH, wNT/ $\beta$ -catenin signaling, 20-hydroxyvitamin D<sub>3</sub>, 1, 20-dihydroxyvitamin D<sub>3</sub>, 2467
- Oral tongue squamous cell carcinoma, sex hormones, estradiol, MMP8, 6029
- Oral, carcinoma, chromosome, polysomy, grid, microscopy, 3759
- Oral, methioninase, methionine, methionine restriction prostate cancer, PSA, ovarian cancer, supplement, cancer patients, 2813

- Orbit, vascular malformation, intraosseous, haemangioma, cone beam computed tomography, 3D reconstruction, bone mineral density, immunohistochemistry, differential diagnosis, 3333
- Oropharyngeal cancer, head and neck cancer, unknown primary, humanpapillomavirus, survival, 4207
- Oropharyngeal cancer, oral HPV prevalence, HPV antibodies, healthy population, 1597
- Oropharyngeal squamous cell carcinoma, programmed cell death ligand 1, human papillomavirus, 4001
- Oropharynx, adult, lymphangioma, 1631
- Orthotopic implantation, colorectal cancer, liver metastasis, clonal dynamics, animal model, splenic injection, 3297
- Orthotopic implantation, indocyanine green, fluorescence imaging, mediastinal lymphatic metastasis, squamous lung carcinoma, 1875
- Orthotopic, bladder cancer, nude mice, GFP, cisplatin, oral recombinant methioninase, combination, sensitize, efficacy, 6083
- OSCC, fibrosis, BMF, biomarker, tumor microenvironment, 4319
- OSCC, oral squamous cell carcinoma, risk factors, young adults, case-control study, survival analysis, smoking, alcohol consumption, 6987
- OSCC, QSAR, guaiazulene-3-carboxylate, tumor-specificity, molecular shape, ionization potential, 4885
- Osimertinib, EGFR gene, non-small cell lung cancer, chemotherapy, 2239
- Osseous metastasis, angiosarcoma, hemangiosarcoma, gynaecology, cancer, uterine sarcoma, ovarian sarcoma, chemotherapy, paclitaxel, laparotomy, 5743
- Osteosarcoma, cell permeabilisation, cold atmospheric plasma, 841
- Osteosarcoma, primary hepatic carcinosarcoma, collision tumor, hepatocellular carcinoma, HCC, cholangiocarcinoma, CC, and rhabdomyosarcoma, 2225
- Osteosarcoma, vesicular stomatitis virus, tumor-suppressor microRNA, systemic therapy, 6319
- Outcome, controlling nutritional status score, esophagectomy, esophageal cancer, review, 5343
- Outcome, distal pancreatectomy, appleby procedure, 387
- Outcome, fibrolamellar, hepatocellular carcinoma, prognosis, 847
- Outcome, hand, soft tissue sarcoma, radiotherapy, 1463
- Outcome, immunotherapy, checkpoint inhibitor, adverse effects, efficacy, review, 1219
- Outcomes, gastric cancer, disparities, race, 881
- Ovarian cancer, AZT, cell cycle arrest, chemotherapy, p21, p16, 5517
- Ovarian cancer, cytokine-induced killer cell, peripheral blood mononuclear cell, chemotherapy, flow cytometry, 3865
- Ovarian cancer, cytoreductive surgery, cholecystectomy, 2331
- Ovarian cancer, debulking surgery, PDS, IDS, surgical complexity, 3925
- Ovarian cancer, hyperthermic intraperitoneal intraoperative chemotherapy, HIPEC, side effects, cisplatin, 1481
- Ovarian cancer, immunohistochemistry, angiogenesis, lymphangiogenesis, CD105, CD34, 6923
- Ovarian cancer, magnetic resonance, ultrasound, MR-US fusion, iOTA simple rules, O-RADS MRI scoring system, adnexal masses, 4115
- Ovarian cancer, methioninase, oral, methionine, methionine restriction prostate cancer, PSA, supplement, cancer patients, 2813
- Ovarian cancer, neoadjuvant chemotherapy, treatment-free interval, platinum resistance, 2765
- Ovarian cancer, paclitaxel, docetaxel, hyperthermia, *in vitro* study, intraperitoneal chemotherapy, HIPEC, 6769
- Ovarian cancer, platinum resistance, weekly nedaplatin, olaparib, 5263
- Ovarian cancer, primary debulking surgery, neoadjuvant chemotherapy, review, 6003
- Ovarian cancer, r-spondin 1, spondins, wnt signaling, 6017
- Ovarian cancer, trabectedin, pegylated liposomal doxorubicin, platinum-sensitive, 3939
- Ovarian cancer, tru-Cut biopsy, ascites, puncture, 3527
- Ovarian cancer, vitamin D, 1, 25-D<sub>3</sub>, *in vitro*, paclitaxel, carboplatin, growth inhibition, VDR, 3129
- Ovarian cancers, artificial intelligence, deep learning, machine learning, neural network, ovarian tumor, blood test, 4795
- Ovarian carcinoma, cisplatin resistance, doxorubicin, oxaliplatin, spectrin  $\alpha$ II, 2497
- Ovarian clear-cell carcinoma, DNA damage response, cisplatin, p21, 5631
- Ovarian clear-cell carcinoma, HIF-1 $\alpha$ , silibinin, eIF4E, RPS6, 6791
- Ovarian epithelial cancer, LRRC17, survival analysis, zebrafish, apoptosis, gene expression omnibus, TCGA, 5601
- Ovarian sarcoma, angiosarcoma, hemangiosarcoma, gynaecology, cancer, uterine sarcoma, chemotherapy, paclitaxel, laparotomy, osseous metastasis, 5743
- Ovarian tumor, artificial intelligence, deep learning, machine learning, neural network, ovarian cancers, blood test, 4795
- Overall survival, breast cancer, absolute lymphocyte count, c-reactive protein, eribulin, 4147
- Overall survival, cetuximab, panitumumab, first-line treatment, metastatic colorectal cancer, hypomagnesemia, 7135
- Overall survival, dialysis, colorectal cancer, laparoscopic surgery, short-term outcome, 2165
- Overall survival, DNA repair gene, single nucleotide polymorphism, hypopharyngeal cancer, japanese, 3277
- Overall survival, esophageal cancer, anastomosis leak, recurrence, 443

- Overall survival, esophageal cancer, c-reactive protein to albumin ratio, recurrence, 2365
- Overall survival, gastric cancer, disease-free survival, anastomotic leakage, review, 619
- Overall survival, intraoperative blood loss, prognosticator, gastric cancer, 405
- Overall survival, nivolumab, cancer cachexia, gastric cancer, time to treatment failure, 7067
- Overall survival, older patients, brain metastases, local therapies, whole-brain radiotherapy, extra-cerebral metastasis, 2841
- Overall survival, older patients, non-small cell lung cancer, immune checkpoint inhibitor, anti PD-1 inhibitor, 923
- Overall survival, ramucirumab, third-line treatment, drug cost, adverse event, metastatic colorectal cancer, 1605
- Overlay method, anticancer drugs, bortezomib, neurotoxicity, PC12, differentiation, NGF, protection, antioxidant, 3685
- Oxaliplatin based chemotherapy, beraprost sodium, liver sinusoidal endothelial cells, liver transplantation, sinusoidal obstruction syndrome, veno-occlusive disease, 5171
- Oxaliplatin, chemotherapy-induced neurotoxicity, colorectal cancer, gastrointestinal cancer, 865
- Oxaliplatin, cisplatin resistance, doxorubicin, ovarian carcinoma, spectrin  $\alpha$ II, 2497
- Oxaliplatin, creatinine clearance, adverse events, colorectal cancer, nausea, 299
- Oxaliplatin, spleen volume, sinusoidal obstruction syndrome, 3361
- Oxaliplatin. renal function, colorectal neoplasms, peripheral neuropathy, survival, 2379
- Oxaliplatinum, gastric cancer, liver metastasis, patient-derived orthotopic xenograft (PDOX), nude mice, 5-fluorouracil, gemcitabine, 5393
- Oxazolindiones, neuroblastoma, kelly cell line, proliferation, progression, BSA heat denaturation, adhesion, fibronectin, 5125
- Oxidative stress, cancer treatment, hypoxia, setanaxib, liver cancer, 5071
- Oxidative stress, colorectal cancer, SN38, redox-status, ferroptosis, electroporation, multidrug resistance, 5159
- Oxidative stress, head and neck cancer, phytochemicals, light, EGF receptor, 751
- Oxidative stress, hepatocellular carcinoma, cirrhosis, circulating leukocytes, nitric oxide, glutathione, 6853
- Oxidative stress, multiple myeloma, interleukin-8, sRAGE, cancer, gender, 1443
- Oxysterol, apoptosis, cholesterol, head and neck squamous cell carcinoma, 25-hydroxycholesterol, 779
- P-Akt, chicken ovalbumin upstream promoter-transcription factor II, colorectal cancer, p53, PTEN, 767
- P-cadherin, breast cancer, e-cadherin, molecular subtypes, 5557
- P16 prognostic value, ki-67, resected lung cancer, early and late stage survival, 983
- P16, AZT, ovarian cancer, cell cycle arrest, chemotherapy, p21, 5517
- P16, head and neck, HPV, PTEN, oral squamous cell carcinoma, 6355
- P21, AZT, ovarian cancer, cell cycle arrest, chemotherapy, p16, 5517
- P21, ovarian clear-cell carcinoma, DNA damage response, cisplatin, 5631
- P21<sup>WAF1/CIP1</sup>, drug repositioning, repurposing, *MDM2*, *MDMX*, *CDKN1A*, 4961
- P38 mitogen-activated protein kinase, isoforms, pancreatic cancer, invasion, metastasis, 5545
- P38, *DLL1*, metastasis, suppressor, pancreatic cancer, src, 1335
- P53 up-regulated cells, colon, sessile serrated polyps, non-dysplastic, cell proliferation, 1535
- P53, chicken ovalbumin upstream promoter-transcription factor II, colorectal cancer, PTEN, p-Akt, 767
- P53, methylation, prognosis, sidedness, colon cancer, 201
- P53, non-small cell lung cancer, long interspersed nuclear element-1, methylation, maximum standardized uptake value, 5659
- P53, prostate cancer, endothelin-1, mxi-2, ago2, 5539
- P53, S100A2, renal cell carcinoma, non-clear cell carcinoma, 6337
- P53, sirtuin1, leukemia, NOTCH, NF- $\kappa$ B, 3155
- P57, drug resistance, 5-FU, gastric cancer, EMT, cell cycle, cyclin D1, 3247
- Paclitaxel, advanced urothelial carcinoma, second-line chemotherapy, gemcitabine, cisplatin, 1613
- Paclitaxel, angiosarcoma, hemangiosarcoma, gynaecology, cancer, uterine sarcoma, ovarian sarcoma, chemotherapy, laparotomy, osseous metastasis, 5743
- Paclitaxel, docetaxel, hyperthermia, ovarian cancer, *in vitro* study, intraperitoneal chemotherapy, HIPEC, 6769
- Paclitaxel, PDAC, pancreatic cancer, chemosensitivity, FOLFIRINOX, gemcitabine, 3659
- Paclitaxel, vitamin D, 1, 25-D<sub>3</sub>, ovarian cancer, *in vitro*, carboplatin, growth inhibition, VDR, 3129
- Paclitaxel; carboplatin, epithelial ovarian cancer; primary debulking surgery, chemotherapy, bevacizumab, complete response, recurrence, 1543
- Pain following surgery, benign disease, cancer, lipid peroxidation, plasma malonaldehyde, 253
- Pain, pancreatic cancer, cancer treatment-induced pain, pancreatic cancer treatment, pancreatic cancer pain, 1789
- Palbociclib, mucositis, chemotherapy, palliative, radiation therapy, ibrance, chemoradiation, 5291
- Palifermin, hematopoietic cell transplantation, mucositis, children, risk factors analysis, keratinocyte growth factor, 6531

- Palliation, pancreatic cancer, progesterone receptor antagonists, progesterone induced blocking factor, immunosurveillance, natural killer cells, 6997
- Palliative cancer patients, geographical, home death, register study, 3897
- Palliative radiotherapy, whole-brain radiotherapy, supportive care, brain metastases, prognostic factors, 977
- Palliative setting, thyroid cancer, curative, stereotactic radiotherapy, 3379
- Palliative treatment, radiotherapy, cancer, oligometastases, symptom score, 1551
- Palliative, mucositis, palbociclib, chemotherapy, radiation therapy, ibrance, chemoradiation, 5291
- Palmitate, hepatocellular carcinoma, CXCL1, CXCR2, 6075
- Pan-RAF inhibitor, LY3009120, non-small cell lung cancer, BRAFmutation, 2667
- Pancreatic cancer pain, pancreatic cancer, pain, cancer treatment-induced pain, pancreatic cancer treatment, 1789
- Pancreatic cancer treatment, pancreatic cancer, pain, cancer treatment-induced pain, pancreatic cancer pain, 1789
- Pancreatic cancer, 5-aminolevulinic acid, photodynamic screening, biomarker, 3571
- Pancreatic cancer, alkalization therapy, tumor microenvironment, alkaline diet, bicarbonate, urine pH, 873
- Pancreatic cancer, APAF-1, DNA methylation, decitabine, 3765
- Pancreatic cancer, cancer stem cells, cancer-associated fibroblasts, tumor dissociation, FACS, 1267
- Pancreatic cancer, chemotherapy, cisplatin, capecitabine, gemcitabine, docetaxel, 4011
- Pancreatic cancer, CTC, KRAS mutation, mouse model, cytology, CTC detection platform, 6781
- Pancreatic cancer, DLL1, metastasis, suppressor, src, p38, 1335
- Pancreatic cancer, epithelial-mesenchymal transition, exosomes, micro RNA, 1843
- Pancreatic cancer, eukaryotic translation initiation factors, pI3K/AKT/mTOR pathway, biomarker, 3109
- Pancreatic cancer, gemcitabine, thrombotic microangiopathy, eculizumab, chemotherapy complications, 3995
- Pancreatic cancer, interferon, rNA-Seq, TKI, toll-like receptor, 4445
- Pancreatic cancer, irreversible electroporation, recurrence, interventional ultrasonography, 2771
- Pancreatic cancer, *miR-146a*, *rs2910164*, single nucleotide polymorphism, esophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, 1495
- Pancreatic cancer, miRNA-301-3p, caspase-8, TRAIL, luteolin, combination effect, 723
- Pancreatic cancer, p38 mitogen-activated protein kinase, isoforms, invasion, metastasis, 5545
- Pancreatic cancer, pain, cancer treatment-induced pain, pancreatic cancer treatment, pancreatic cancer pain, 1789
- Pancreatic cancer, PDAC, chemosensitivity, FOLFIRINOX, gemcitabine, paclitaxel, 3659
- Pancreatic cancer, progesterone receptor antagonists, progesterone induced blocking factor, immunosurveillance, palliation, natural killer cells, 6997
- Pancreatic cancer, staging laparoscopy, prognosis, laparoscopic surgery, 1023
- Pancreatic cancer, stereotactic body radiotherapy, chemotherapy, dose effect, 465
- Pancreatic cyst, pancreatic juice, pancreatic neoplasms, KRAS, GNAS, secretin-induced duodenal aspiration, 4215
- Pancreatic ductal adenocarcinoma (PDAC) xenograft, pharmacokinetic (PK)–Pharmacodynamic (PD), tumor growth inhibition (TGI) mathematical model, deep learning neural networks (DLNN), nonlinear optimization, TGI model parameter estimation, adaptive tumor growth short-term prediction, xenografted mice (PDX), 5181
- Pancreatic ductal adenocarcinoma, cancer metabolism, combination therapy, polytherapy, anti-diabetic medication, 153
- Pancreatic ductal adenocarcinoma, dendritic cell vaccination, WT1, MUC1, phase I/IIa study, 5765
- Pancreatic ductal adenocarcinoma, desmoplasia, vitamin D receptor, collagen, 6457
- Pancreatic ductal adenocarcinoma, FA score, fibrinogen, albumin, surgical resection, prognostic index, 7017
- Pancreatic ductal adenocarcinoma, intraductal papillary mucinous neoplasms, iPMN-derived carcinoma, biomarker, microarray, 6551
- Pancreatic ductal carcinoma, epidermal growth factor receptor (EGFR) mutation, lung adenocarcinoma, endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) and biopsy (FNB), immunohistochemistry, 4401
- Pancreatic ductal carcinoma, synchronous primary malignancy, colonic adenocarcinoma, immunohistochemistry, microsatellite stable, chemotherapy, 4029
- Pancreatic ductal carcinoma, xenograft model, cryopreservation, 2637
- Pancreatic head cancer, prognosis, lymphocyte-to-monocyte ratio, obstructive jaundice, 3371
- Pancreatic juice, pancreatic neoplasms, pancreatic cyst, KRAS, GNAS, secretin-induced duodenal aspiration, 4215
- Pancreatic neoplasms, biopsy, fine-needle, large-core needle, endosonography, 5845
- Pancreatic neoplasms, pancreatic juice, pancreatic cyst, KRAS, GNAS, secretin-induced duodenal aspiration, 4215
- Pancreatic neuroendocrine tumor, metformin, cell cycle, apoptosis, microRNA, 121

- Pancreatic surgery, prognostic nutritional index, deep venous thrombosis, 2297
- Panitumumab, cetuximab, first-line treatment, overall survival, metastatic colorectal cancer, hypomagnesemia, 7135
- Pantoea agglomerans* bacteria derived LPS, autism spectrum disorder, attention deficit hyperactivity disorder, oral administration, 4755
- Papillary, thyroid cancer, tumor stem cells, 3801
- Papillary, thyroid cancer, ultrasonography, thyroid nodule, 1779
- Papuamine, alkaloid, anticancer, mitochondria, 323
- Para aortic lymphadenectomy, endometrial cancer, pelvic lymphadenectomy, survival, 1563
- Para-aortic lymph node excision, neoadjuvant chemotherapy, stomach neoplasms, 2351
- Para-aortic node metastasis, cervical cancer, neoadjuvant chemotherapy, extended-field concurrent chemoradiotherapy, phase II study, 3565
- Parametrial involvement, cervical cancer, small volume, simple trachelectomy, conization, pelvic lymphadenectomy, review, 3651
- Parenchymal-sparing liver resection, colorectal liver metastasis, surgical margin, spray diathermy, 1359
- Parkin, nuclear proteome, phosphoproteome, neuroblastoma cancer, 2D gel electrophoresis, 3169
- PARP inhibitor, oesophageal squamous cell carcinoma, DNA damaging agents, 53BP1, REV7, 813
- PARP inhibitors, leukemia, tyrosine kinase, review, 3055
- PARP, olaparib, meta-analysis, randomized clinical trial, anemia, fatigue, review, 597
- PARVA, cell-matrix interactions, cell adhesion, migration, tumor spheroids, tGF $\beta$ , ILK, MIC1, LIMS1, RSU1, 1375
- Pathologic complete response, tumor volume, radiochemotherapy, 4327
- Pathologic response, rectal cancer, chemoradiation, clinical predictor, prediction nomogram, 2171
- Pathological complete response, breast cancer, PET, SUV, tumor-infiltrating lymphocyte, neoadjuvant chemotherapy, 3395
- Pathological T stage, prostate cancer, thyroid hormones, triiodothyronine, grade Groups, prostatectomy, tumor percentage involvement, 2323
- Patient satisfaction, day-case, mastectomy, questionnaire, 2179
- Patient-derived cancer cells, 3-D culture, histoculture, gelfoam, PDCC, patient-derived xenograft, PDX, 6765
- Patient-derived model, EGFR inhibitor resistance, *MET* signaling, combinational treatment, tumor microenvironment, 109
- Patient-derived orthotopic xenograft (PDOX), gastric cancer, liver metastasis, nude mice, 5-fluorouracil, oxaliplatin, gemcitabine, 5393
- Patient-derived orthotopic xenograft, PDOX, nude mice, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, olaparib, regression, resistance, 2509
- Patient-derived orthotopic xenograft, PDOX, patient-derived xenograft, PDX, TNBC, triple-negative breast cancer, 2481
- Patient-derived orthotopic xenograft, PDOX, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, cisplatin, tumor regression, 2475
- Patient-derived xenograft model, CDK4/6 inhibitor, eribulin mesylate, luminal-type breast cancer, reversal of epithelial-mesenchymal transition, preclinical trial, 6699
- Patient-derived xenograft, 3-D culture, histoculture, gelfoam, patient-derived cancer cells, PDCC, PDX, 6765
- Patient-derived xenograft, PDOX, patient-derived orthotopic xenograft, PDX, TNBC, triple-negative breast cancer, 2481
- Patients aged  $\geq 65$  years, cancer of unknown primary, brain metastases, whole-brain irradiation, remaining lifespan, 2261
- PAX8, breast cancer, immunohistochemistry, 5925
- Pazopanib, biliary tract carcinoma, gemcitabine, phase II study, 929
- Pazopanib, metastatic renal cell carcinoma, RCC, polycystic liver disease, liver cyst, cabozantinib, 1527
- Pazopanib, renal cell carcinoma, metastasis, stereotactic radiotherapy, tyrosine kinase inhibitors, 7037
- PBMC, natural killer cells, lysis, NK-92, K562, 5355
- PBMCs, humanized mice, immunotherapy, cancer, immunoncology, review, 5329
- PC12, anticancer drugs, bortezomib, neurotoxicity, differentiation, overlay method, NGF, protection, antioxidant, 3685
- PD-1 antagonist, tongue cancer, CD40 agonist, postoperative adjuvant treatment, 2707
- PD-1, CD155, CAK cells, KRAS, TNK cells, TIGIT, 3D culture, 4663
- PD-1, celecoxib, COX2, immune checkpoint inhibitor, lung cancer, 5309
- PD-L1, breast cancer, biomarker, liquid biopsy, recurrence, 3733
- PD-L1, MMR, CD8, endometrial cancer, 1669
- PD-L1, pulmonary pleomorphic carcinoma, tumor immunity, CD4, CD8, prognosis, 261
- PDAC, pancreatic cancer, chemosensitivity, FOLFIRINOX, gemcitabine, paclitaxel, 3659
- PDCC, 3-D culture, histoculture, gelfoam, patient-derived cancer cells, patient-derived xenograft, PDX, 6765
- PDCs, multiple myeloma, neuropilin-1, tregs, 5437
- PDGF, PDGFR, head and neck squamous cell carcinoma, drug resistance, afatinib, nilotinib, dasatinib, erlotinib, gefitinib, 825
- PDGFR, PDGF, head and neck squamous cell carcinoma, drug resistance, afatinib, nilotinib, dasatinib, erlotinib, gefitinib, 825



- PDOX, dedifferentiated liposarcoma, nude mice, recombinant methioninase, *S. typhimurium* A1-R, combination, tumor regression, 2515
- PDOX, patient-derived orthotopic xenograft, nude mice, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, olaparib, regression, resistance, 2509
- PDOX, patient-derived orthotopic xenograft, patient-derived xenograft, PDX, TNBC, triple-negative breast cancer, 2481
- PDOX, patient-derived orthotopic xenograft, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, cisplatin, tumor regression, 2475
- PDS, ovarian cancer, debulking surgery, IDS, surgical complexity, 3925
- PDX, 3-D culture, histoculture, gelfoam, patient-derived cancer cells, PDCC, patient-derived xenograft, 6765
- PDX, PDOX, patient-derived orthotopic xenograft, patient-derived xenograft, TNBC, triple-negative breast cancer, 2481
- Pecs block, regional anesthesia, modified radical mastectomy, breast surgery, postoperative pain, nonphysician anesthesia provider, 2231
- Pediatric cancer, nivolumab, ipilimumab, anti-PD-1, malignant melanoma, brain tumor, 7095
- Pediatric, acute myeloid leukemia, chromosome translocation, RNA sequencing, tYRO3 gene, 6115
- Pediatric, miRNA, ALL, relapse, epigenetic, 3147
- Pedicled rotation flap, locoregional recurrence, breast cancer, 5739
- PEG, RPG, gastrostomy, head and neck cancer, nutrition, 1167
- Pegfilgrastim, relative dose intensity, febrile neutropenia, breast cancer, FEC-100, 915
- Pegylated liposomal doxorubicin, ovarian cancer, trabectedin, platinum-sensitive, 3939
- Pelvic lymphadenectomy, cervical cancer, small volume, simple trachelectomy, conization, parametrial involvement, review, 3651
- Pelvic lymphadenectomy, endometrial cancer, survival, para-aortic lymphadenectomy, 1563
- Pembrolizumab, analysis of survival, immunotherapy, melanoma, S100, 2157
- Pembrolizumab, carcinosarcoma, endometrial neoplasms, microsatellite instability, radiotherapy, abscopal effect, 4131
- Pembrolizumab, melanoma, sarcopenia, body mass index, monoclonal antibodies, retrospective studies, clinical decision-making, drug-related side effects, adverse reactions, 5245
- Pembrolizumab, mSI-high, IHCCC, 4123
- Pemetrexed, maintenance therapy, nonsquamous non-small cell lung cancer, bevacizumab, bevacizumab+pemetrexed, 2981
- Pemetrexed, NSCLC, Hedgehog pathway, chemo resistance, gant61, 1451
- Pepsinogen I, *Helicobacter pylori*, hp IgG ELISA, gastroPanel, new-generation, clinical validation, non-invasive, biomarker test, gastroscopy, biopsy, pepsinogen II, gastrin-17, 6387
- Pepsinogen II, *Helicobacter pylori*, hp IgG ELISA, gastroPanel, new-generation, clinical validation, non-invasive, biomarker test, gastroscopy, biopsy, pepsinogen I, gastrin-17, 6387
- Performance status, prostate cancer, elderly patients, cerebral metastases, radiotherapy, 1665
- Pericytoma, t(7;12), *ACTB-GLI1* fusion gene, GLI1 isoform 2 protein, unbalanced chromosome translocation, 1239
- Perineal wound complication, omentoplasty, abdominoperineal resection, NACRT, 6539
- Perineural invasion, cervical cancer, vulvar cancer, surgery, adjuvant therapy, review, 3031
- Perioperative nutrition management, colorectal cancer, neutrophils-lymphocyte ratio, dynamic change of NLR, prognosis, 2311
- Periostin, carcinoma, stemness, metastasis, angiogenesis, lymphangiogenesis, chondrosarcoma, 5463
- Periostin, radioresistance, head and neck cancer, epithelial-to-mesenchyma transition, 2627
- Peripheral blood mononuclear cell, ovarian cancer, cytokine-induced killer cell, chemotherapy, flow cytometry, 3865
- Peripheral nerve sheath tumor, plexiform neurofibroma, MPNST, neurofibromatosis type 1, NF1, MEK inhibitors, review, 1817
- Peripheral neuropathy, oxaliplatin, renal function, colorectal neoplasms, survival, 2379
- Peritoneal carcinomatosis, gastric cancer, HIPEC, cytoreductive surgery, 2151
- Peritoneal recurrence, prognostic factor, recurrent pancreatic cancer, 293
- Peritoneum, cytology, high-grade serous carcinoma, metastatic breast carcinoma, 2933
- Peroxiredoxin II, PRDX2; ROS, liver injury, cell apoptosis, 4491
- Peroxisome proliferator activated receptor  $\gamma$  coactivator-1 $\alpha$  (PGC-1 $\alpha$ ), colorectal cancer, AKT, glycogen synthase kinase-3 $\beta$  (GSK-3 $\beta$ ),  $\beta$ -catenin, 653
- Peroxisome proliferator-activated receptor  $\gamma$ , troglitazone, oral SCC, apoptosis, G1 arrest, 1247
- Persimmon leaf flavonoids, anticancer, reactive oxygen species, apoptosis, antioxidant, 5201
- Personalized medicine, vitamin D, supplementation, metabolomics, genomics, broad gene expression, metabolomic profile, individual response, 25-hydroxyvitamin D, 535
- Personalized treatment, 5-FU prodrugs, therapeutic drug monitoring, capecitabine, review, 4655

- Pesticide, lymphoma, ecologic, carcinogenicity, 5423
- PET-CT, chondrosarcoma, skeletal metastases, bone scintigraphy, staging, 5735
- PET, breast cancer, SUV, tumor-infiltrating lymphocyte, neoadjuvant chemotherapy, pathological complete response, 3395
- PFKFB3, melanoma, BRAF<sup>V600E</sup>, 3PO, A375, inhibitor, 2613
- Phagocytosis, glucan, cancer, IL-2, infection, 3139
- Phagocytosis, *in vitro*, LPS, macrophage, oral administration, 4711
- Phagocytosis, repetitive low-dose lipopolysaccharide, tissue-resident macrophages, anti-inflammation, 4457
- Pharmacogenomics, non-small cell lung carcinoma, gemcitabine, messenger RNA, RRM1, RRM2, CDA, dCK, hENT1, 901
- Pharmacokinetic (PK)–Pharmacodynamic (PD), tumor growth inhibition (TGI) mathematical model, deep learning neural networks (DLNN), nonlinear optimization, TGI model parameter estimation, adaptive tumor growth short-term prediction, xenografted mice (PDX), pancreatic ductal adenocarcinoma (PDAC) xenograft, 5181
- Pharmacokinetics, enzalutamide, n-desmethyl enzalutamide, castration-resistant prostate cancer, reduced dose, 7101
- Pharmacological mechanism, systems biology, network pharmacology, herbal, combination, breast cancer, 5097
- Pharmacometrics, modelling and simulation, chronopharmacokinetics, translational research, cancer chemotherapy, therapeutic drug monitoring, 5-FU prodrug, review, 6585
- Phase I study, IGF-1R, IGF-MTX, myelodysplastic syndrome, chronic myelomonocytic leukemia, oligoblastic acute myeloid leukemia, 3883
- Phase I-II, prostate neoplasms, intensity-modulated radiotherapy, simultaneous integrated boost, dominant intraprostatic lesion, 6499
- Phase I/IIa study, pancreatic ductal adenocarcinoma, dendritic cell vaccination, WT1, MUC1, 5765
- Phase I/IIa study, zenithal natural killer cells, immune cell therapy, cancer, 5687
- Phase II randomized study, platinum-resistance, recurrent ovarian cancer, chemotherapy, cabazitaxel, 5255
- Phase II study, biliary tract carcinoma, gemcitabine, pazopanib, 929
- Phase II study, cervical cancer, para-aortic node metastasis, neoadjuvant chemotherapy, extended-field concurrent chemoradiotherapy, 3565
- Phase II trial, activated dendritic cell, immunotherapy, high-grade glioma, HLA-A24, 6473
- Phenothiazines, cancer, multidrug resistance, t-lymphoma, selenoesters, selenoanhydride, combination chemotherapy, 4921
- Phosphoproteome, parkin, nuclear proteome, neuroblastoma cancer, 2D gel electrophoresis, 3169
- Photochemical internalization, ROBO1, HNSCC, immunotoxin, drug delivery system, 3793
- Photodynamic screening, pancreatic cancer, 5-aminolevulinic acid, biomarker, 3571
- Photon, proton, zebrafish embryo model, DNA-DSB, morphological malformations, histological changes, 6123
- Photoprotection, melanoma, natural products, *E. pisciparus*, spathulenol, apoptosis, 5015
- Photoprotection, sunscreen, 25(OH)D, vitamin D, UVR exposure, review, 511
- Phyllodes tumors, fibroepithelial lesions, fibroadenoma, score, 1095
- Physical exercise, breast cancer, oncological rehabilitation, quality of life, fatigue, 4253
- Physical plasma, cold atmospheric plasma, plasma medicine, radiation, nitrogen oxides, occupational health and safety, 2591
- Physical therapy, plasma oncology, plasma surgery, cold atmospheric plasma, mammary carcinoma, 6205
- Phytochemicals, apoptosis, epithelial-to-mesenchymal transition, breast cancer, cancer epigenetics, DNMT inhibitors, HDAC inhibitors, 9
- Phytochemicals, head and neck cancer, light, EGF receptor, oxidative stress, 751
- PI3K inhibitors, childhood cancer, medulloblastoma, FGFR inhibitors, 53
- PI3K, flavonoid, inhibitor, protein kinase, anti-cancer, virtual screening, 4547
- PI3K/AKT/mTOR pathway, pancreatic cancer, eukaryotic translation initiation factors, biomarker, 3109
- PiCa, ABCG2, HNSCC, CSC, cisplatin, faDu, 1277
- Piceatannol, glyoxalase 1, anxiolytic effect, antitumor effect, 3271
- Picrasma quassioides*, liver cancer, mitochondria, ROS, 3819
- Pigmentation, melanoma, vitamin D, clinical data, experimental models, review, 473
- PIK3CA*, ER+/HER2+, triple-positive breast cancer, next-generation sequencing, neo-ALL-IN, MLL2, 5883
- Pilot study, S-1, IRIS, irinotecan, metastatic breast cancer, 4779
- Piperine, apoptosis, breast cancer, methoxy poly(ethylene glycol)-poly(lactic-co-glycolic) acid, thin-film hydration, 689
- Pirarubicin, single intravesical instillation, low-risk bladder cancer, mitomycin C, 5295
- PKC $\lambda$ , cancer stem cell, breast cancer, ALDH1A3, c-Met, 35
- Plasma CAT, gallstone disease, cancer, surgery, plasma MDA, NRS pain score, 5701
- Plasma malonaldehyde, benign disease, cancer, lipid peroxidation, pain following surgery, 253
- Plasma MDA, gallstone disease, cancer, surgery, plasma CAT, NRS pain score, 5701
- Plasma medicine, physical plasma, cold atmospheric plasma, radiation, nitrogen oxides, occupational health and safety, 2591

- Plasma oncology, plasma surgery, cold atmospheric plasma, mammary carcinoma, physical therapy, 6205
- Plasma surgery, plasma oncology, cold atmospheric plasma, mammary carcinoma, physical therapy, 6205
- Plasma, metabolomics, diet, time-restricted feeding, Lewis lung carcinoma, mice, 1833
- Plastic surgery, age, gynecologic cancer-related lymphedema, secondary lymphedema, iatrogenic lymphedema, lymphedema, review, 6609
- Platelet distribution width, breast cancer, plateletcrit, prognostic factor, 3947
- Platelet distribution width, c-reactive protein, esophageal cancer, 5715
- Platelet-to-lymphocyte ratio, breast cancer, sentinel node biopsy, metastasis, 4405
- Platelet–lymphocyte ratio, breast cancer, sentinel lymph node biopsy, biomarker, blood test, 2343
- Plateletcrit, breast cancer, platelet distribution width, prognostic factor, 3947
- Platinum resistance, ovarian cancer, neoadjuvant chemotherapy, treatment-free interval, 2765
- Platinum resistance, ovarian cancer, weekly nedaplatin, olaparib, 5263
- Platinum-based chemotherapy, neuroendocrine differentiation, neuron-specific enolase, treatment-related neuroendocrine prostate cancer, small-cell prostate cancer, 3519
- Platinum-resistance, recurrent ovarian cancer, chemotherapy, cabazitaxel, phase II randomized study, 5255
- Platinum-sensitive recurrence, epithelial ovarian cancer, secondary cytoreductive surgery, positron-emission tomography/computed tomography, 2191
- Platinum-sensitive, ovarian cancer, trabectedin, pegylated liposomal doxorubicin, 3939
- Platinum(IV) complexes, apoptosis, cancer, cell cycle, cytotoxicity, gamma rays, 5001
- Pleural cytology, pleural effusion, pulmonary metastases, CEA, CRP, LDH, predictive model, 5877
- Pleural effusion, pulmonary metastases, pleural cytology, CEA, CRP, LDH, predictive model, 5877
- Pleural-fluid cytology, malignant pleural effusion, differential diagnosis, lung cancer, pulmonary metastases, 1135
- Pleurodesis, adenocarcinoma, EGFR-TKI, malignant pleural effusions, hypoalbuminemia, 1117
- Plexiform neurofibroma, neurofibromatosis type 1, tumour predisposition syndrome, mosaicism, 3423
- Plexiform neurofibroma, peripheral nerve sheath tumor, MPNST, neurofibromatosis type 1, NF1, MEK inhibitors, review, 1817
- PNC-27, cancer cell membrane, leukemia, HDM-2, 4857
- Pneumonia, lung metastasis, acute lung injury (ALI), intercellular adhesion molecule-1 (ICAM-1), e-selectin, 6171
- POD24, follicular lymphoma, EZH2, time to first systemic therapy, prognostic factors, expression profile, 6685
- Poly-ethylene glycol-modified carbon nanotubes, ultrasound, nanomedicine, sonodynamic therapy, sarcoma 180, colon 26, 2549
- Polyamine analogues, polyamines, polyamine oxidase, tumour, 1437
- Polyamine oxidase, polyamines, tumour, polyamine analogues, 1437
- Polyamines, polyamine oxidase, tumour, polyamine analogues, 1437
- Polycomb and Trithorax genes, prostate cancer cells, androgen stimulation, quantitative RT-PCR, 2559
- Polycystic liver disease, metastatic renal cell carcinoma, RCC, liver cyst, cabozantinib, pazopanib, 1527
- Polymorphism, acute lymphocytic leukemia, case–control study, childhood, genotype, *MMP-9*, Taiwan, 5751
- Polymorphism, *ADIPOQ*, colorectal cancer, genotype, Taiwan, 1297
- Polymorphism, age, gender, genotype, *MMP-1*, pterygium, Taiwan, 703
- Polymorphism, age, gender, genotype, *MMP-9*, pterygium, Taiwan, 4523
- Polymorphism, alcohol drinking, betel quid, genotype, interleukin-12A, oral cancer, smoking, Taiwan, 3707
- Polymorphism, bladder cancer, case–control study, genotype, *NBS1*, 2011
- Polymorphism, breast cancer, genotype, interleukin-13, Taiwan, 6743
- Polymorphism, case–control study, caspase-8, genotype, nasopharyngeal carcinoma, Taiwan, 5503
- Polymorphism, childhood leukemia, genotype, miR-196a-2, Taiwan, 4465
- Polymorphism, gastric cancer, genotype, *MMP7*, Taiwan, 695
- Polymorphism, *MDM2*, expression, prostate cancer, slovak population, 6257
- Polymorphism, nasopharyngeal, cancer, CT, MRI, sNPs, variations, genotype, VEGFA, EDNRA *NBS1*, FAS, 677
- Polymorphisms, matrix metalloproteinases, gelatinases, circulating levels, breast cancer risk, review, 3619
- Polyphenols, glioma, viability, flow cytometry, DRAQ7, MTT, 5427
- Polyphenols, grape stem extracts, greek vine varieties, antioxidants, antimutagenic properties, bio-functional foods, 2025
- Polyps, colorectal cancer, NICE Guidelines, colonoscopy, bowel cancer, 1705
- Polysomy, carcinoma, oral, chromosome, grid, microscopy, 3759
- Polytherapy, pancreatic ductal adenocarcinoma, cancer metabolism, combination therapy, anti-diabetic medication, 153

- Pooled analysis, magseed, wireless, localisation, review, 1809
- Poor prognostic biomarker, *SF3B4*, esophageal squamous cell carcinoma, 2941
- Population-based study, colon cancer, adjuvant chemotherapy, practice variation, quality of care, 4331
- Portal vein flow velocity, hepatocellular carcinoma, lenvatinib, hepatic encephalopathy, 5271
- Portal vein tumor thrombosis, hepatocellular carcinoma, sorafenib, lenvatinib, 2283
- Portal vein, contrast media, ultrasonography, hepatocellular carcinoma, 4351
- Positron emission tomography, head and neck cancer, squamous cell carcinoma, extranodal extension, lymph node metastasis, 2073
- Positron emission tomography, radiotherapy planning, gross tumour volume, auto-delineation, digital positron emission tomography, 2567
- Positron-emission tomography, multidetector computed tomography, iodine, fluorodeoxyglucose, lung cancer, dual-energy, 3459
- Positron-emission tomography/computed tomography, epithelial ovarian cancer, secondary cytoreductive surgery, platinum-sensitive recurrence, 2191
- Post-treatment hematological parameters, locally advanced cervical cancer, prognosis, neutrophil-to-lymphocyte, concurrent chemoradiotherapy, 451
- Postdocetaxel, mCRPC, cabazitaxel, biweekly dosing, 6915
- Postmenopausal, adjuvant aromatase inhibitor, breast cancer, adherence, 857
- Postmenopausal, asymptomatic, endometrial polyps, malignancy, PTEN, 789
- Postoperative adjuvant treatment, tongue cancer, CD40 agonist, PD-1 antagonist, 2707
- Postoperative ascites, m2BPGi, VTQ, hepatic resection, HCC, ALBI grade, 4343
- Postoperative complication, gastric cancer, recurrence, adjuvant chemotherapy, 1683
- Postoperative deep infection, bone tumor, extremity, risk factor, multivariate analysis, 3551
- Postoperative infectious complications, gastric cancer, prognostic factor, 4067
- Postoperative infectious complications, minimal invasive surgery, gastric cancer, surgical stress, prognosis, 7109
- Postoperative pain, pecs block, regional anesthesia, modified radical mastectomy, breast surgery, nonphysician anesthesia provider, 2231
- Potential therapeutic target, bladder cancer, chloride intracellular channel protein 1 (CLIC1), immunohistochemistry, prognosis, 6879
- PPAR $\gamma$ , ciglitazone, thiazolidinedione, 9-cis-retinoic acid, retinoids, head and neck squamous carcinoma, 3071
- PPP4C, ADGRF4, GPR115, lung cancer, cell invasiveness, 6835
- Practice variation, colon cancer, adjuvant chemotherapy, quality of care, population-based study, 4331
- PRDX2; ROS, peroxiredoxin II, liver injury, cell apoptosis, 4491
- Pre-brachytherapy magnetic resonance imaging, cervical cancer, high-dose-rate brachytherapy, radiotherapy, 999
- Precision medicine, breast cancer, fGD3gene, prognostic factor, review, 3645
- Preclinical trial, CDK4/6 inhibitor, eribulin mesylate, luminal-type breast cancer, patient-derived xenograft model, reversal of epithelial-mesenchymal transition, 6699
- Predict pCR, breast cancer, neoadjuvant chemotherapy, 2303
- Prediction nomogram, rectal cancer, chemoradiation, pathologic response, clinical predictor, 2171
- Prediction, radiomics, classification, tumour risk, prognosis, review, 3605
- Predictive factor, immune checkpoint inhibitor, non-small-cell lung carcinoma, neutrophil counts, tumor-associated neutrophils, 3889
- Predictive model, medulloblastoma, ependymoma, basic magnetic resonance imaging, 2975
- Predictive model, pleural effusion, pulmonary metastases, pleural cytology, CEA, CRP, LDH, 5877
- Predictive score, locally advanced rectal cancer, laparoscopy, total mesorectal excision, 2079
- Predictive value, BMI, breast cancer, axillary ultrasound, 7083
- Predictive, lung cancer, chemotherapy, toxicity, prognostic, 6399
- Pregnancy, glioma, iDHmutated, radiation, 3453
- Preoperative chemotherapy, docetaxel/cisplatin/5-fluorouracil, oesophageal cancer, oesophagectomy, five-year survival, 5829
- Preoperative marking, fluorescence, colorectal cancer, gastric cancer, 6517
- Preoperative procedure, atypical endometrial hyperplasia, endometrial cancer, hysterectomy, magnetic resonance imaging, 2989
- Prevalence, glioma, seizures, radiation therapy, risk factors, survival, 3961
- Prevalence, seizures, brain metastases, whole-brain irradiation, risk factors, survival, 3429
- Prevention of metastasis, colorectal cancer, human natriuretic peptide, feasibility, 5301
- Prevention of perforation, small intestinal lymphoma, 2373
- Previtamin D<sub>3</sub>, DNA damage, 8-hydroxy-2'-deoxyguanosine, nitric oxide, vitamin D, nitrite, human skin, 565
- Previtamin D<sub>3</sub>, ultraviolet radiation light emitting diode (LED), vitamin D<sub>3</sub>, human skin, ultraviolet B radiation, 719
- PRI-724, hepatocellular carcinoma,  $\beta$ -catenin, wnt, CBP, inhibitor, 5211

- Primary debulking surgery, ovarian cancer, neoadjuvant chemotherapy, review, 6003
- Primary debulking, debulking for ovarian cancer, complete cytoreduction, upper abdominal surgery, morbidity, interval debulking surgery, 5869
- Primary hepatic carcinosarcoma, collision tumor, hepatocellular carcinoma, HCC, cholangiocarcinoma, CC, osteosarcoma, and rhabdomyosarcoma, 2225
- Primary lung cancer, liquid biopsy, circulating tumor cell, circulating tumor DNA, diagnosis, 3435
- Primary renal angiosarcoma, clinical features, diagnostic approach, therapeutic management, review, 625
- Primitive germ cell tumour, yolk sac tumour, AFP, stem cell, 759
- Prion protein, prPC, cancer stem cell characteristics, anti-cancer drug resistance, colorectal cancer, 5611
- Prodrug, targeted therapy, colorectal carcinoma, doxorubicin, TSPO, 5371
- Progesterone induced blocking factor, pancreatic cancer, progesterone receptor antagonists, immunosurveillance, palliation, natural killer cells, 6997
- Progesterone receptor antagonists, pancreatic cancer, progesterone induced blocking factor, immunosurveillance, palliation, natural killer cells, 6997
- Progesterone receptor, vorinostat, I3C, triple negative breast cancer, estrogen receptor, HDAC activity, HDAC7, 3669
- Progesterone, oral contraception, estrogen, human papilloma virus (HPV), cervical cancer, review, 5995
- Progestins, endometrial cancer, surgical treatment, chemoradiotherapy, urinary tract symptoms, 3065
- Prognosis, apoptosis, myeloid cell leukemia-1, non-small cell lung cancer, survival, 1007
- Prognosis, bladder cancer, chloride intracellular channel protein 1 (CLIC1), immunohistochemistry, potential therapeutic target, 6879
- Prognosis, breast cancer, brain metastasis, survival, surgical resection, molecular subtype, 1759
- Prognosis, breast cancer, neutrophil-to-lymphocyte ratio, tumour-infiltrating lymphocytes, 2871
- Prognosis, breast cancer, thyroid gland, TSH, FT3, FT4, silencing mediator for retinoid and thyroid receptors, 6417
- Prognosis, cancer, ephrin receptor B2, meta-analysis, 4309
- Prognosis, cluster analysis, lung cancer, metastatic pattern, 421
- Prognosis, colitis-associated colorectal cancer, YAP1, CDX2, 5411
- Prognosis, colon cancer, aTP-binding cassette transporter 11, 5-fluorouracil, 5405
- Prognosis, colorectal cancer, cancer stem cell, ABC transporter, 4481
- Prognosis, colorectal cancer, neutrophils-lymphocyte ratio, dynamic change of NLR, perioperative nutrition management, 2311
- Prognosis, connexins, gastric cancer, 4537
- Prognosis, esophageal carcinoma, oncological esophagectomy, neoadjuvant chemoradiation, lymphadenectomy, survival, 2833
- Prognosis, fibrolamellar, hepatocellular carcinoma, outcome, 847
- Prognosis, gallbladder, carcinoma, IMP3, immunohistochemistry, 5777
- Prognosis, gastric cancer, *AMIGO2*, biomarker, 6713
- Prognosis, geriatric nutritional risk index, colorectal liver metastasis, 4165
- Prognosis, hepatocellular carcinoma, methylation of N6 adenosine, RNA demethylase, 6665
- Prognosis, locally advanced cervical cancer, post-treatment hematological parameters, neutrophil-to-lymphocyte, concurrent chemoradiotherapy, 451
- Prognosis, lung cancer, pulmonary metastases, colorectal carcinoma, surgery, biomarker, 7045
- Prognosis, methylation, p53, sidedness, colon cancer, 201
- Prognosis, microvascular invasion, hepatocellular carcinoma, hematogenous metastasis, 3983
- Prognosis, minimal invasive surgery, gastric cancer, postoperative infectious complications, surgical stress, 7109
- Prognosis, MTUS1, renal cell carcinoma, immunohistochemistry, public data, 2961
- Prognosis, myxofibrosarcoma, MR imaging, reproducibility, survival, 5793
- Prognosis, neuroblastoma, children, next-generation sequencing, *ALK*, 7057
- Prognosis, nucleolus, uveal melanoma, H&E staining, 3505
- Prognosis, pancreatic head cancer, lymphocyte-to-monocyte ratio, obstructive jaundice, 3371
- Prognosis, pulmonary pleomorphic carcinoma, tumor immunity, CD4, CD8, PD-L1, 261
- Prognosis, radiomics, prediction, classification, tumour risk, review, 3605
- Prognosis, ROCK1, ROCK2, melanoma, tumor-infiltrating lymphocytes, Kaplan–Meier analysis, 1931
- Prognosis, staging laparoscopy, pancreatic cancer, laparoscopic surgery, 1023
- Prognosis, stomach neoplasms, immunohistochemistry, cyclooxygenase 2, 341
- Prognosis, tumor marker, inflammation index, carcinoembryonic antigen, c-reactive protein, novel index, non-small cell lung cancer, surgery, 4023
- Prognosis, uveal melanoma, the Cancer Genome Atlas, gene Expression Omnibus, bioinformatics, 3839
- Prognosis, ZKSCAN3 (ZNF306), gastric cancer, 81
- Prognostic factor, breast cancer, fGD3gene, precision medicine, review, 3645
- Prognostic factor, breast cancer, platelet distribution width, plateletcrit, 3947

- Prognostic factor, gastric cancer, glioma-associated oncogene 1, adjuvant chemotherapy, S-1, 5815
- Prognostic factor, gastric cancer, postoperative infectious complications, 4067
- Prognostic factor, lung cancer, bioelectrical impedance analysis, ECW/TBW, 3931
- Prognostic factor, metastatic spinal cord compression, spinal metastasis, long-term survival, surgical treatment, sex, 1475
- Prognostic factor, NSCLC, chemoradiotherapy, survival, blood parameters, 2319
- Prognostic factor, recurrent pancreatic cancer, peritoneal recurrence, 293
- Prognostic factor, stereotactic body radiotherapy (SBRT), oligometastases, oligo-recurrence, esophageal cancer, 2065
- Prognostic factor, TAM, TYRO3, gastric cancer, 5593
- Prognostic factors, cerebral glioma, radiotherapy, survival, re-evaluation, 6513
- Prognostic factors, chemoradiation, esophagus, neoadjuvant therapy, recurrence-free survival, tumor response, 4387
- Prognostic factors, follicular lymphoma, EZH2, POD24, time to first systemic therapy, expression profile, 6685
- Prognostic factors, glioblastoma multiforme, longer-course radiotherapy, local control, survival, 7025
- Prognostic factors, immune-cell therapy, cervical cancer, endometrial cancer,  $\alpha\beta$ T cell therapy, dendritic cell vaccine, 4729
- Prognostic factors, palliative radiotherapy, whole-brain radiotherapy, supportive care, brain metastases, 977
- Prognostic factors, pulmonary sarcoma, epidemiology, survival, 1697
- Prognostic factors, recurrent glioblastoma, re-irradiation, survival, 7077
- Prognostic index, FA score, fibrinogen, albumin, pancreatic ductal adenocarcinoma, surgical resection, 7017
- Prognostic instrument, stereotactic radiosurgery, fractionated stereotactic radiotherapy, distant brain metastases, elderly patients, 4081
- Prognostic marker, non-small-cell lung cancer, cancer stem cell, 6407
- Prognostic nutritional index, deep venous thrombosis, pancreatic surgery, 2297
- Prognostic parameters, breast cancer, GATA3, ki-67, 5649
- Prognostic score, colorectal cancer, bone metastases, radiotherapy, survival, 287
- Prognostic, lung cancer, chemotherapy, toxicity, predictive, 6399
- Prognosticator, intraoperative blood loss, overall survival, gastric cancer, 405
- Programmed cell death ligand 1, human papillomavirus, oropharyngeal squamous cell carcinoma, 4001
- Programmed death ligand 1, breast, triple-negative breast carcinoma, intratumoral immune cells, 1487
- Programmed death-ligand 1, EBV, diffuse large b-cell lymphoma, Epstein-Barr virus positive diffuse large b-cell lymphoma, tumour immunology, non-Hodgkin lymphoma, review, 5951
- Progression-free survival, bevacizumab, disease progression, continuous administration, recurrent ovarian cancer, 5285
- Progression, oxazolidinones, neuroblastoma, kelly cell line, proliferation, BSA heat denaturation, adhesion, fibronectin, 5125
- Prolactin receptor, breast cancer, prostate cancer, 5229
- Proliferation, ABHD12, breast cancer, migration, invasion, 2601
- Proliferation, CARD14, apoptosis, migration, breast cancer, 1953
- Proliferation, lung cancer, non-small cell lung cancer, lung adenocarcinoma, toll-like receptor 2, nuclear factor-kappa B, 5361
- Proliferation, oxazolidinones, neuroblastoma, kelly cell line, progression, BSA heat denaturation, adhesion, fibronectin, 5125
- P propensity score matching, younger colorectal cancer, cancer-specific survival, 4365
- Prospective study, advanced non-squamous non-small cell lung cancer, amrubicin, bevacizumab, efficacy, 1571
- Prostasphere,  $\gamma\delta$  T cell, immunotherapy, prostate cancer, cancer stem cell, sphere, CD133, NANOG, SOX2, OCT4, 5481
- Prostate biopsy, prostate cancer, endoglin, high-grade prostate cancer, sCD105, 1459
- Prostate cancer cells, polycomb and Trithorax genes, androgen stimulation, quantitative RT-PCR, 2559
- Prostate cancer,  $\gamma\delta$  T cell, immunotherapy, cancer stem cell, sphere, prostasphere, CD133, NANOG, SOX2, OCT4, 5481
- Prostate cancer, abiraterone, androgen receptor, cabazitaxel, docetaxel, enzalutamide, 335
- Prostate cancer, brachytherapy, HDR-BT, daily replanning, 1677
- Prostate cancer, brachytherapy, health-related quality of life, 6443
- Prostate cancer, chemoresistance, dihydroergocristine mesylate, dopamine receptor agonist, 6051
- Prostate cancer, elderly patients, cerebral metastases, radiotherapy, performance status, 1665
- Prostate cancer, endothelin-1, mxi-2, ago2, p53, 5539
- Prostate cancer, KISS1, KISS1R, metastasis suppression, 709
- Prostate cancer, LC3B-II, SQSTM1, apoptosis, chloroquine, miR-139, autophagy, beclin-1, mTOR, 6649
- Prostate cancer, leukopenia, febrile neutropenia, time to treatment failure, docetaxel, 4291
- Prostate cancer, *MDM2*, polymorphism, expression, slovak population, 6257

- Prostate cancer, nucleolar proteins, gleason grade, local spread, neoplasm invasiveness, 1973
- Prostate cancer, prolactin receptor, breast cancer, 5229
- Prostate cancer, prostate biopsy, endoglin, high-grade prostate cancer, sCD105, 1459
- Prostate cancer, SBRT, cyberKnife, 2053
- Prostate cancer, single nucleotide polymorphisms, interleukin 10, smoking, inflammation, African-American, 27
- Prostate cancer, SSEA-4, neoadjuvant hormonal therapy, biochemical recurrence, histological effect, 5567
- Prostate cancer, thyroid hormones, triiodothyronine, grade Groups, prostatectomy, pathological T stage, tumor percentage involvement, 2323
- Prostate neoplasm, stereotactic body radiation therapy, oligometastatic prostate cancer, SBRT, SRT, review, 2419
- Prostate neoplasms, intensity-modulated radiotherapy, simultaneous integrated boost, dominant intraprostatic lesion, phase I-II, 6499
- Prostate neoplasms, risk stratification systems, NCCN, EAU, radiotherapy, 4413
- Prostate-specific antigen, ethinylestradiol, castration resistant prostate cancer, adverse event, 2291
- Prostate, breast, cancer, colon, colorectal, ecological, mendelian randomization, ultraviolet B, UVB, 25-hydroxyvitamin D, review, 491
- Prostate, radiation, race, survival, 3307
- Prostatectomy, prostate cancer, thyroid hormones, triiodothyronine, grade Groups, pathological T stage, tumor percentage involvement, 2323
- Protection, anticancer drugs, bortezomib, neurotoxicity, PC12, differentiation, overlay method, NGF, antioxidant, 3685
- Protein kinase, flavonoid, PI3K, inhibitor, anti-cancer, virtual screening, 4547
- Protein tyrosine phosphatases, pTPs, expression, renal cell carcinoma, RCC, 5667
- Proteomics, biomarker, squamous intraepithelial lesion, specificity, sensitivity, 6273
- Proto-oncogene, c-Myc, lung cancer, anticancer drug target, review, 609
- Proton beam radiotherapy, angiosarcoma, hadrontherapy, 1645
- Proton pump inhibitors, nivolumab, non-small cell lung cancer, corticoids, antibiotics, NSAID, statins, metformin, 2209
- Proton, photon, zebrafish embryo model, DNA-DSB, morphological malformations, histological changes, 6123
- PrPC, prion protein, cancer stem cell characteristics, anti-cancer drug resistance, colorectal cancer, 5611
- Prunus mume, KRAS, MK615, colon cancer, HIF, e-cadherin, 4687
- PSA, methioninase, oral, methionine, methionine restriction prostate cancer, ovarian cancer, supplement, cancer patients, 2813
- Psoas muscle, gastric cancer, gastrectomy, survival rate, 4271
- Psychometrics, decisional conflict scale, central vascular access devices, validation study, 5583
- PTC209, BMI1, inhibition, cervical cancer, cancer stem cell, 133
- PTEN, asymptomatic, endometrial polyps, postmenopausal, malignancy, 789
- PTEN, catalytic topo I inhibitor, cyclin D1 accumulation, ATR, akt, gSK-3 $\beta$ , 6237
- PTEN, chicken ovalbumin upstream promoter-transcription factor II, colorectal cancer, p53, p-Akt, 767
- PTEN, head and neck, HPV, p16, oral squamous cell carcinoma, 6355
- PTEN, renal cell carcinoma, spheroid, sunitinib, sorafenib, 1943
- Pterygium, age, gender, genotype, *MMP-1*, polymorphism, Taiwan, 703
- Pterygium, age, gender, genotype, *MMP-9*, polymorphism, Taiwan, 4523
- PTPs, protein tyrosine phosphatases, expression, renal cell carcinoma, RCC, 5667
- Public data, MTUS1, renal cell carcinoma, immunohistochemistry, prognosis, 2961
- Pulmonary adenocarcinoma, clinical stage I, surgery, circulating tumor cell, recurrence, 7089
- Pulmonary embolism, renal cell carcinoma, inferior vena cava, thrombus, radical nephrectomy, lung metastasis, 5837
- Pulmonary metastases, lung cancer, colorectal carcinoma, surgery, biomarker, prognosis, 7045
- Pulmonary metastases, malignant pleural effusion, differential diagnosis, pleural-fluid cytology, lung cancer, 1135
- Pulmonary metastases, pleural effusion, pleural cytology, CEA, CRP, LDH, predictive model, 5877
- Pulmonary oligo-recurrence, pulmonary oligometastases, pulmonary sync-oligometastases, SBRT, nationwide study, 393
- Pulmonary oligometastases, pulmonary oligo-recurrence, pulmonary sync-oligometastases, SBRT, nationwide study, 393
- Pulmonary pleomorphic carcinoma, tumor immunity, CD4, CD8, PD-L1, prognosis, 261
- Pulmonary sarcoma, epidemiology, prognostic factors, survival, 1697
- Pulmonary sync-oligometastases, pulmonary oligometastases, pulmonary oligo-recurrence, SBRT, nationwide study, 393
- Puncture, tru-Cut biopsy, ovarian cancer, ascites, 3527
- Pyrosequencing, MGMT promoter methylation, glioblastoma, geneXpert, 6229

- Pyruvate carboxylase, colorectal cancer, anaplerotic enzyme, 6285
- Pyruvate kinase M2, cholangiocarcinoma, shikonin, reactive oxygen species, 5115
- QSAR analysis, 3-Styrylchromones, methoxy group, cytotoxicity, tumor-specificity, cell cycle analysis, molecular shape, 87
- QSAR, guaiazulene-3-carboxylate, OSCC, tumor-specificity, molecular shape, ionization potential, 4885
- Quality of care, colon cancer, adjuvant chemotherapy, practice variation, population-based study, 4331
- Quality of life, breast cancer, physical exercise, oncological rehabilitation, fatigue, 4253
- Quantitative RT-PCR, polycomb and Trithorax genes, prostate cancer cells, androgen stimulation, 2559
- Quercetin, antiproliferation effect, apoptosis, hepatocellular carcinoma, 4695
- Questionnaire, day-case, mastectomy, patient satisfaction, 2179
- Questionnaire, malignant melanoma, tailored advice, sun habits, ultraviolet radiation, 3325
- R-spondin 1, spondins, ovarian cancer, wnt signaling, 6017
- RAAV, melanoma, metastatic melanoma, intranasal delivery, lungs, 4425
- Race, gastric cancer, disparities, outcomes, 881
- Race, prostate, radiation, survival, 3307
- Radar localisation, savi Scout<sup>®</sup>, reflector-guided localisation, non-wire localisation, non-palpable breast lesions, breast cancer, review, 3633
- Radiation biology, re-irradiation, re-treatment, recurrence, normal tissue, stereotactic body radiation therapy, 1981
- Radiation sensitivity, HNSCC, lncRNA, *MALAT1*, cisplatin sensitivity, 2645
- Radiation therapy, glioma, seizures, prevalence, risk factors, survival, 3961
- Radiation therapy, mucositis, palbociclib, chemotherapy, palliative, ibrance, chemoradiation, 5291
- Radiation therapy, muscle invasive bladder cancer, whole-bladder, elderly patients, 2905
- Radiation therapy, non-small cell lung cancer, cerebral metastasis, elderly, survival scores, 2847
- Radiation therapy, secondary brain lesions, carcinoma of the breast, older persons, survival analyses, 2271
- Radiation therapy, small cell neuroendocrine carcinoma, SCNEC, adrenal gland cancer adrenal gland, extrapulmonary small cell carcinoma, chemotherapy, chemoradiation, 5933
- Radiation, NSCLC, *ALK* inhibitors, ceritinib, crizotinib, alectinib, anaplastic lymphoma kinase, 4937
- Radiation, physical plasma, cold atmospheric plasma, plasma medicine, nitrogen oxides, occupational health and safety, 2591
- Radiation, pregnancy, glioma, iDHmutated, 3453
- Radiation, prostate, race, survival, 3307
- Radiation, sentinel lymph node biopsy (SLNB), lymphadenectomy, immunotherapy, chemotherapy, 2895
- Radical cystectomy, urothelial carcinoma, histological variant, clinical outcomes, 4787
- Radical hysterectomy, abdominal radical trachelectomy, cervical cancer, fertility-sparing, fertility preservation, 5939
- Radical nephrectomy, renal cell carcinoma, inferior vena cava, thrombus, pulmonary embolism, lung metastasis, 5837
- Radical prostatectomy, laparoscopy, nomogram, suspected prostate cancer, robotics, 2995
- Radical re-irradiation, esophageal squamous cell carcinoma, oligo-recurrence, 2387
- Radical surgery, cervical cancer, radiotherapy, concurrent chemoradiation, neoadjuvant chemotherapy, review, 4819
- Radio-frequency ablation, cholangiolocarcinoma, liver resection, 7147
- Radiochemotherapy, tumor volume, pathologic complete response, 4327
- Radioembolization, hepatocellular carcinoma, tumor calcification, 4191
- Radiofrequency identification tags, magnetic seeds, non-wire localisation, 315
- Radiomics, prediction, classification, tumour risk, prognosis, review, 3605
- Radioreistance, periostin, head and neck cancer, epithelial-to-mesenchyma transition, 2627
- Radioreistance, UBE2B, CCRT, rectal cancer, 6305
- Radiosensitizing effect, carbon-ion beams, linear energy transfer, cell-killing effect, HeLa cells, 5497
- Radiosurgery, brain metastases, stereotactic radiotherapy, seizures, 3499
- Radiotherapy dose escalation, chemoradiotherapy, esophageal squamous cell carcinoma, adjuvant chemotherapy, 1771
- Radiotherapy planning, positron emission tomography, gross tumour volume, auto-delineation, digital positron emission tomography, 2567
- Radiotherapy, anaplastic thyroid cancer, thyroid surgery, multimodal treatment, hyperfractionated accelerated radiotherapy, 6979
- Radiotherapy, biliary tract cancers, chemoradiation, brachytherapy, cholangiocarcinoma, 3417
- Radiotherapy, bladder cancer, chemoradiotherapy, neoadjuvant chemotherapy, bladder sparing, 5861
- Radiotherapy, breast cancer, bolus, clinical practice, mastectomy, 6505
- Radiotherapy, breast cancer, cardiotoxicity, mean heart dose, LAD, LV, echocardiography, 3003
- Radiotherapy, breast cancer, survival probability, bone metastases, scoring instrument, 367
- Radiotherapy, cancer, palliative treatment, oligometastases, symptom score, 1551



- Radiotherapy, carcinosarcoma, endometrial neoplasms, microsatellite instability, pembrolizumab, abscopal effect, 4131
- Radiotherapy, cerebral glioma, survival, prognostic factors, re-evaluation, 6513
- Radiotherapy, cervical cancer, concurrent chemoradiation, neoadjuvant chemotherapy, radical surgery, review, 4819
- Radiotherapy, cervical cancer, high-dose-rate brachytherapy, pre-brachytherapy magnetic resonance imaging, 999
- Radiotherapy, colorectal cancer, bone metastases, survival, prognostic score, 287
- Radiotherapy, hand, outcome, soft tissue sarcoma, 1463
- Radiotherapy, linear energy transfer, chondrosarcoma, sarcoma, 6429
- Radiotherapy, non-small cell lung cancer, autophagy, histone modification, GABARAPL1, 2537
- Radiotherapy, prostate cancer, elderly patients, cerebral metastases, performance status, 1665
- Radiotherapy, risk stratification systems, NCCN, EAU, prostate neoplasms, 4413
- Radiotherapy, sophageal cancer, esophageal stricture, chemotherapy, risk factor, 1071
- Radiotherapy, stage IV rectal cancer, chemotherapy, local complication, 5853
- RAF inhibitors, imidazo[2, 1-*b*]oxazole derivatives, TNBC, chemotherapy, 5081
- Ramucirumab, alpha fetoprotein, hepatocellular carcinoma, lenvatinib, second-line therapy, 2089
- Ramucirumab, third-line treatment, overall survival, drug cost, adverse event, metastatic colorectal cancer, 1605
- Randomized clinical trial, olaparib, meta-analysis, anemia, fatigue, PARP, review, 597
- Randomized clinical trial, *vitamin D<sub>3</sub>*, 25-hydroxyvitamin D, *vitamin D<sub>3</sub>* supplementation, gut microbiota, 551
- Rare non-melanoma skin cancer, electrochemotherapy, melanoma, metastases, 6485
- Rat model, oral mucositis, chemotherapy, immunosuppression, 2701
- RCC, metastatic renal cell carcinoma, polycystic liver disease, liver cyst, cabozantinib, pazopanib, 1527
- RCC, protein tyrosine phosphatases, pTPs, expression, renal cell carcinoma, 5667
- Re-evaluation, cerebral glioma, radiotherapy, survival, prognostic factors, 6513
- Re-irradiation, re-treatment, recurrence, normal tissue, stereotactic body radiation therapy, radiation biology, 1981
- Re-irradiation, recurrent glioblastoma, survival, prognostic factors, 7077
- Re-therapy, hER2-positive, metastatic breast cancer, trastuzumab, 3973
- Re-treatment, re-irradiation, recurrence, normal tissue, stereotactic body radiation therapy, radiation biology, 1981
- Reactive oxygen species, cholangiocarcinoma, pyruvate kinase M2, shikonin, 5115
- Reactive oxygen species, persimmon leaf flavonoids, anticancer, apoptosis, antioxidant, 5201
- Real-world data, vinorelbine, metastatic breast cancer, ESME, retrospective study, 3905
- Real-world, gastrointestinal stromal tumour, GIST, imatinib, survival, safety, 435
- Recombinant methioninase, breast cancer, surgical resection, recurrence, methionine restriction, lung metastasis, inhibition, adjuvant therapy, 4869
- Recombinant methioninase, dedifferentiated liposarcoma, PDOX, nudemice, *S. typhimurium* A1-R, combination, tumor regression, 2515
- Reconstruction, extracorporeally-irradiated autograft, vascularized bone graft, sarcoma, 1637
- Rectal adenocarcinoma; small cell lung carcinoma, synchronous primary malignancy, gastrointestinal stromal tumor (GIST), immunohistochemistry; microsatellite stable, chemotherapy, 7053
- Rectal cancer, anorectal function, chemoradiotherapy, neoadjuvant, manometry, 2199
- Rectal cancer, chemoradiation, pathologic response, clinical predictor, prediction nomogram, 2171
- Rectal cancer, MRI, lymph node, neoadjuvant therapy, metastases, follow-up, 2757
- Rectal cancer, robotic surgery, laparoscopic surgery, anastomotic leakage, 2337
- Rectal cancer, UBE2B, CCRT, radioresistance, 6305
- Rectal cancer, umbilical defunctioning ileostomy, incisional hernia, laparoscopic surgery, 3445
- Rectal cancer, urinary dysfunction, sexual dysfunction, high inferior mesenteric artery tie, low inferior mesenteric artery tie, 4223
- Recurrence-free and overall survival, upper rectal cancer, neoadjuvant treatment, chemoradiation therapy, long-term functional results, 3579
- Recurrence-free survival, chemoradiation, esophagus, neoadjuvant therapy, tumor response, prognostic factors, 4387
- Recurrence, breast cancer, surgical resection, methionine restriction, recombinant methioninase, lung metastasis, inhibition, adjuvant therapy, 4869
- Recurrence, epithelial ovarian cancer; primary debulking surgery, chemotherapy, paclitaxel; carboplatin, bevacizumab, complete response, 1543
- Recurrence, epithelial–mesenchymal transition, circulating tumor cell, head and neck squamous cell carcinoma, metastasis, 3559
- Recurrence, esophageal cancer, anastomosis leak, overall survival, 443
- Recurrence, esophageal cancer, c-reactive protein to albumin ratio, overall survival, 2365

- Recurrence, gastric cancer, postoperative complication, adjuvant chemotherapy, 1683
- Recurrence, head and neck cancer, saliva, metastasis, circulating DNA, animal model, 191
- Recurrence, irreversible electroporation, pancreatic cancer, interventional ultrasonography, 2771
- Recurrence, neoadjuvant chemotherapy, long-term outcome, down-staging, tumor shrinkage, breast conserving surgery, 1079
- Recurrence, PD-L1, breast cancer, biomarker, liquid biopsy, 3733
- Recurrence, pulmonary adenocarcinoma, clinical stage I, surgery, circulating tumor cell, 7089
- Recurrence, re-irradiation, re-treatment, normal tissue, stereotactic body radiation therapy, radiation biology, 1981
- Recurrence, smooth-muscle tumors of uncertain malignant potential, uterine malignancies, uterine smooth-muscle neoplasms, STUMP, review, 1229
- Recurrence, SPARC, invasion, meningioma, immunohistochemistry, malignant, 3081
- Recurrent glioblastoma, re-irradiation, survival, prognostic factors, 7077
- Recurrent or metastatic, salvage chemotherapy, immune checkpoint inhibitor, nivolumab, head and neck carcinoma, best supportive care, 5277
- Recurrent ovarian cancer, bevacizumab, disease progression, continuous administration, progression-free survival, 5285
- Recurrent ovarian cancer, platinum-resistance, chemotherapy, cabazitaxel, phase II randomized study, 5255
- Recurrent pancreatic cancer, prognostic factor, peritoneal recurrence, 293
- Redox-status, colorectal cancer, SN38, oxidative stress, ferroptosis, electroporation, multidrug resistance, 5159
- Reduced dose, enzalutamide, n-desmethyl enzalutamide, castration-resistant prostate cancer, pharmacokinetics, 7101
- Reflector localization, SAVI SCOUT, non-wire localization, breast cancer, 3915
- Reflector-guided localisation, savi Scout<sup>®</sup>, radar localisation, non-wire localisation, non-palpable breast lesions, breast cancer, review, 3633
- Refractory, small-cell lung cancer, relapsed, nab-paclitaxel, monotherapy, 1579
- Regional anesthesia, pecs block, modified radical mastectomy, breast surgery, postoperative pain, nonphysician anesthesia provider, 2231
- Register study, geographical, home death, palliative cancer patients, 3897
- Regression, PDOX, patient-derived orthotopic xenograft, nude mice, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, olaparib, resistance, 2509
- Regulation of actin cytoskeleton, brain tumor, cognition, DNA microarray, neuroimmunity, 4719
- Regulatory T-lymphocytes, breast cancer, cytokines, natural killer cells, 3D culture, 6179
- Relapse, pediatric, miRNA, ALL, epigenetic, 3147
- Relapsed, small-cell lung cancer, refractory, nab-paclitaxel, monotherapy, 1579
- Relative dose intensity, pegfilgrastim, febrile neutropenia, breast cancer, FEC-100, 915
- Remaining lifespan, cancer of unknown primary, brain metastases, patients aged  $\geq 65$  years, whole-brain irradiation, 2261
- Renal cancer, insulin-like growth factor-I, IGF-I, iGF-IEc, clear cell RCC, 6213
- Renal cell carcinoma, anti-hypertensive agent, hypertension, 4087
- Renal cell carcinoma, biomarker, immunohistochemistry, knockdown, myoferlin, 3119
- Renal cell carcinoma, immune checkpoint inhibitors, immune-related adverse events (irAEs), t-cell receptor, next-generation sequencing, immune response, 4875
- Renal cell carcinoma, inferior vena cava, thrombus, pulmonary embolism, radical nephrectomy, lung metastasis, 5837
- Renal cell carcinoma, metastasis, pazopanib, stereotactic radiotherapy, tyrosine kinase inhibitors, 7037
- Renal cell carcinoma, molecular targeted therapy, inflammatory marker, 1739
- Renal cell carcinoma, MTUS1, immunohistochemistry, public data, prognosis, 2961
- Renal cell carcinoma, protein tyrosine phosphatases, pTPs, expression, RCC, 5667
- Renal cell carcinoma, PTEN, spheroid, sunitinib, sorafenib, 1943
- Renal cell carcinoma, S100A2, p53, non-clear cell carcinoma, 6337
- Repetitive low-dose lipopolysaccharide, tissue-resident macrophages, anti-inflammation, phagocytosis, 4457
- Replanning, adaptive radiotherapy, gliomas, brain tumor, 4237
- Reproducibility, myxofibrosarcoma, MR imaging, prognosis, survival, 5793
- Repurposing, drug repositioning, *MDM2*, *MDMX*, *CDKN1A*, P21<sup>WAF1/CIP1</sup>, 4961
- Repurposing, gastric cancer, conversion surgery, itraconazole, 991
- Resectability, colorectal liver metastases, chronic disease, surgery, 1
- Resected lung cancer, p16 prognostic value, ki-67, early and late stage survival, 983
- Residual tumor, invasive melanoma, wide excisional surgery, excisional margins, NCDB, 1059
- Resistance, *BCR-ABLI*, CML, TKI, efficacy, review, 2457

- Resistance, PDOX, patient-derived orthotopic xenograft, nude mice, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, olaparib, regression, 2509
- Resistance, temozolomide, G2 checkpoint, DNA mismatch repair, glioblastoma, 1315
- Retinoids, pPAR $\gamma$ , ciglitazone, thiazolidinedione, 9-cis-retinoic acid, head and neck squamous carcinoma, 3071
- Retroperitoneal sarcoma, aortic reconstruction, major vascular resection, 1049
- Retroperitoneal sarcoma, textbook outcome, hospital volume, National Cancer Database, survival, 2107
- Retropubic approach, robotic-assisted radical prostatectomy, retzius-sparing approach, continence, 4075
- Retrospective studies, melanoma, sarcopenia, body mass index, pembrolizumab, monoclonal antibodies, clinical decision-making, drug-related side effects, adverse reactions, 5245
- Retrospective study, vinorelbine, metastatic breast cancer, real-world data, ESME, 3905
- Retzius-sparing approach, robotic-assisted radical prostatectomy, retropubic approach, continence, 4075
- REV7, oesophageal squamous cell carcinoma, PARP inhibitor, DNA damaging agents, 53BP1, 813
- Reversal of epithelial-mesenchymal transition, CDK4/6 inhibitor, eribulin mesylate, luminal-type breast cancer, patient-derived xenograft model, preclinical trial, 6699
- Review, 5-FU prodrugs, therapeutic drug monitoring, personalized treatment, capecitabine, 4655
- Review, age, gynecologic cancer-related lymphedema, secondary lymphedema, iatrogenic lymphedema, lymphedema, plastic surgery, 6609
- Review, animal models, vitamin D, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, 527
- Review, *BCR-ABL1*, CML, TKI, resistance, efficacy, 2457
- Review, biliary tract cancer, cholangiocarcinoma, targeted therapy, chemotherapy, second-line, 3013
- Review, breast cancer, fGD3gene, prognostic factor, precision medicine, 3645
- Review, breast cancer, neo-adjuvant chemotherapy, sentinel node biopsy, axillary disease, 5351
- Review, breast, cancer, colon, colorectal, ecological, mendelian randomization, prostate, ultraviolet B, UVB, 25-hydroxyvitamin D, 491
- Review, cancer prevention, vitamin D metabolites, assay development, stereoselective synthesis, 519
- Review, cervical cancer, radiotherapy, concurrent chemoradiation, neoadjuvant chemotherapy, radical surgery, 4819
- Review, cervical cancer, small volume, simple trachelectomy, conization, parametrial involvement, pelvic lymphadenectomy, 3651
- Review, chemo brain, tryptophan, kynurenine, NAD, tubulin, cognition, biophoton, 1189
- Review, circulating tumor cells, animal models, animal study, neoplasia, cancer detection, 6599
- Review, colorectal cancer, diagnosis, screening, fecal occult blood test, FOBT, fecal immunochemical test, FIT, false-negative, false-positive, 575
- Review, colorectal cancer, fatty acid synthesis, fatty acid oxidation, inhibitors, 4843
- Review, controlling nutritional status score, esophagectomy, esophageal cancer, outcome, 5343
- Review, dickkopf-3, clinical biomarker, malignant tumour, therapeutics, 5969
- Review, DNA replication, DNA repair, chromatin, cell cycle, genome stability, cdt1, 2449
- Review, early-stage cervical cancer, villoglandular adenocarcinoma of the uterine cervix, minimal invasive surgery, minimal handling, 3049
- Review, EBV, diffuse large b-cell lymphoma, Epstein-Barr virus positive diffuse large b-cell lymphoma, programmed death-ligand 1, tumour immunology, non-Hodgkin lymphoma, 5951
- Review, endometriosis-associated intestinal malignancies, endometriosis-associated malignancies of urinary tract, endometriosis-associated malignancies of surgical scars, immunohistochemistry, surgery, chemotherapy, 2429
- Review, ER positive, breast cancer, ER targeting, elacestrant, FGFR inhibitors, venetoclax, 4829
- Review, EWAS, normal breast tissue, blood, DNA methylation, obesity, body mass index, breast cancer, epigenetic biomarkers, 1797
- Review, gastric cancer, disease-free survival, overall survival, anastomotic leakage, 619
- Review, gene polymorphism, malignant melanoma, melanoma risk, meta-analysis, vitamin D receptor, 583
- Review, hepatocellular carcinoma, surveillance, screening, diagnosis, biomarkers, tumor biology, liver tumors, 6573
- Review, immunotherapy, checkpoint inhibitor, adverse effects, outcome, efficacy, 1219
- Review, large cell neuroendocrine carcinoma, bladder, kidney, ureter, 2439
- Review, leukemia, PARP inhibitors, tyrosine kinase, 3055
- Review, magseed, pooled analysis, wireless, localisation, 1809
- Review, matrix metalloproteinases, gelatinases, polymorphisms, circulating levels, breast cancer risk, 3619
- Review, melanoma, vitamin D, pigmentation, clinical data, experimental models, 473
- Review, mesenchymal stem cells, tumor progression, tumor microenvironment, 3039
- Review, microbiome, lung cancer, carcinogenesis, cancer therapy, 4807
- Review, modelling and simulation, chronopharmacokinetics, translational research, cancer chemotherapy, therapeutic drug monitoring, 5-FU prodrug, pharmacometrics, 6585

- Review, monoclonal antibody, infusion reaction, infusion time, infusion rate systematic review, 1201
- Review, muscle mass loss, sarcopenia, cancer, skeletal muscle index, meta-analysis, 2409
- Review, olaparib, meta-analysis, randomized clinical trial, anemia, fatigue, PARP, 597
- Review, oncogenes, tumor-suppressor genes, carcinogenesis, signaling pathways, 6009
- Review, oral contraception, estrogen, progesterone, human papilloma virus (HPV), cervical cancer, 5995
- Review, ovarian cancer, primary debulking surgery, neoadjuvant chemotherapy, 6003
- Review, pBMCs, humanized mice, immunotherapy, cancer, immuno-oncology, 5329
- Review, perineural invasion, cervical cancer, vulvar cancer, surgery, adjuvant therapy, 3031
- Review, peripheral nerve sheath tumor, plexiform neurofibroma, MPNST, neurofibromatosis type 1, NF1, MEK inhibitors, 1817
- Review, primary renal angiosarcoma, clinical features, diagnostic approach, therapeutic management, 625
- Review, proto-oncogene, c-Myc, lung cancer, anticancer drug target, 609
- Review, radiomics, prediction, classification, tumour risk, prognosis, 3605
- Review, savi Scout<sup>®</sup>, reflector-guided localisation, radar localisation, non-wire localisation, non-palpable breast lesions, breast cancer, 3633
- Review, smooth-muscle tumors of uncertain malignant potential, recurrence, uterine malignancies, uterine smooth-muscle neoplasms, STUMP, 1229
- Review, stereotactic body radiation therapy, oligometastatic prostate cancer, prostate neoplasm, SBRT, SRT, 2419
- Review, sunscreen, photoprotection, 25(OH)D, vitamin D, UVR exposure, 511
- Review, superparamagnetic iron oxide nanoparticles, SPION, glioblastoma, drug-delivery, 5989
- Review, zyxin, LIM domain proteins, cancer, 5981
- Rhenium, inflammatory cytokines, biomarkers, selenium, cancer cells, 1915
- Ribociclib, 5-fluorouracil, human colorectal cancer, 6265
- Right-sided colorectal cancer, left-sided colorectal cancer, microRNA, biological pathways, 3713
- Risk factor, bone tumor, extremity, postoperative deep infection, multivariate analysis, 3551
- Risk factor, sophageal cancer, esophageal stricture, chemotherapy, radiotherapy, 1071
- Risk factors analysis, hematopoietic cell transplantation, mucositis, palifermin, children, keratinocyte growth factor, 6531
- Risk factors, glioma, seizures, radiation therapy, prevalence, survival, 3961
- Risk factors, oral squamous cell carcinoma, OSCC, young adults, case-control study, survival analysis, smoking, alcohol consumption, 6987
- Risk factors, seizures, brain metastases, whole-brain irradiation, prevalence, survival, 3429
- Risk stratification systems, NCCN, EAU, radiotherapy, prostate neoplasms, 4413
- RLS lymphosarcoma, cyclophosphamide, double-stranded DNA, secondary ascites, cancer stem cells eradication, 795
- RNA demethylase, hepatocellular carcinoma, methylation of N6 adenosine, prognosis, 6665
- RNA sequencing, pediatric, acute myeloid leukemia, chromosome translocation, tYRO3gene, 6115
- RNA-Seq, interferon, pancreatic cancer, TKI, toll-like receptor, 4445
- RNF126, E3 ubiquitin ligase, gastric cancer, 1367
- ROBO1, HNSCC, photochemical internalization, immunotoxin, drug delivery system, 3793
- Robotic surgery, rectal cancer, laparoscopic surgery, anastomotic leakage, 2337
- Robotic-assisted radical prostatectomy, retzius-sparing approach, retropubic approach, continence, 4075
- Robotics, laparoscopy, nomogram, suspected prostate cancer, radical prostatectomy, 2995
- ROC, acute cholecystitis, acute abdominal pain, diagnostic score, HSROC, diagnostic accuracy, 6947
- ROC, fecal occult blood, guaiac-based test, fecal immunochemical test, gFOBT, iFOBT, FIT, colorectal cancer screening, meta-analysis, sensitivity, specificity, false negative, false positive, HSROC, 3591
- ROCK1, ROCK2, melanoma, tumor-infiltrating lymphocytes, prognosis, Kaplan–Meier analysis, 1931
- ROCK2, ROCK1, melanoma, tumor-infiltrating lymphocytes, prognosis, Kaplan–Meier analysis, 1931
- ROS, idarubicin, DNA damage, copper, 5399
- ROS, liver cancer, mitochondria, *Picrasma quassioides*, 3819
- Routine laboratory parameter, glioblastoma, inflammation, 1161
- RPG, PEG, gastrostomy, head and neck cancer, nutrition, 1167
- RPS6, hIF-1 $\alpha$ , silibinin, eIF4E, ovarian clear-cell carcinoma, 6791
- RRM1, non-small cell lung carcinoma, gemcitabine, pharmacogenomics, messenger RNA, RRM2, CDA, dCK, hENT1, 901
- RRM2, non-small cell lung carcinoma, gemcitabine, pharmacogenomics, messenger RNA, RRM1, CDA, dCK, hENT1, 901
- Rs11225395, laryngeal squamous cell carcinoma, matrix metallo-proteinases, matrix metalloproteinase 8, MMP8, single nucleotide polymorphism, rs2155052, 2003
- Rs2155052, laryngeal squamous cell carcinoma, matrix metallo-proteinases, matrix metalloproteinase 8, MMP8, single nucleotide polymorphism, rs11225395, 2003

- Rs2910164, *miR-146a*, single nucleotide polymorphism, esophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, pancreatic cancer, 1495
- Rs714368, *SLC22A16*, biomarker, cytotoxic chemotherapy, 4245
- RSF3, *SF3B4*, mRNA stability, HCC, SNU-368, 2033
- RSU1, cell–matrix interactions, cell adhesion, migration, tumor spheroids, tGF $\beta$ , ILK, MIC1, PARVA, LIMS1, 1375
- Rta, Epstein-Barr virus, nasopharyngeal carcinoma, interleukin-6, cell migration, 3255
- Russell body esophagitis, russell body gastritis, Mott cells, barrett’s esophagus, 3991
- Russell body gastritis, russell body esophagitis, Mott cells, barrett’s esophagus, 3991
- S-1, gastric cancer, glioma-associated oncogene 1, adjuvant chemotherapy, prognostic factor, 5815
- S-1, IRIS, pilot study, irinotecan, metastatic breast cancer, 4779
- S. typhimurium* A1-R, dedifferentiated liposarcoma, PDOX, nude mice, recombinant methioninase, combination, tumor regression, 2515
- S100, analysis of survival, immunotherapy, melanoma, pembrolizumab, 2157
- S100A2, renal cell carcinoma, p53, non-clear cell carcinoma, 6337
- SAbR, lung metastases, oligometastatic disease, gastrointestinal tumors, 5901
- Safety, gastrointestinal stromal tumour, GIST, imatinib, real-world, survival, 435
- Saliva, head and neck cancer, recurrence, metastasis, circulating DNA, animal model, 191
- Salvage chemotherapy, immune checkpoint inhibitor, nivolumab, head and neck carcinoma, recurrent or metastatic, best supportive care, 5277
- Salvage surgery, differentiated thyroid carcinoma, age, distant metastasis, survival, 11292
- Salvage surgery, downstaging, hepatocellular carcinoma, low dose FP, 4773
- Sarcoma 180, ultrasound, nanomedicine, poly-ethylene glycol-modified carbon nanotubes, sonodynamic therapy, colon 26, 2549
- Sarcoma, chondrosarcoma, chest wall, bone tumor, sternum, 1519
- Sarcoma, extracorporeally-irradiated autograft, vascularized bone graft, reconstruction, 1637
- Sarcoma, extraskeletal myxoid chondrosarcoma, barrier, 1035
- Sarcoma, leiomyosarcoma, small bowel, oncological surgery, 4199
- Sarcoma, radiotherapy, linear energy transfer, chondrosarcoma, 6429
- Sarcoma, synovial sarcoma, chemotherapy, 1029
- Sarcomatoid transformation, lung squamous cell carcinoma, neoadjuvant therapy, 1625
- Sarcopenia, clinical outcomes, esophageal cancer, neoadjuvant therapy, 1175
- Sarcopenia, HCC, sorafenib, carnitine, liver cirrhosis, 4173
- Sarcopenia, melanoma, body mass index, pembrolizumab, monoclonal antibodies, retrospective studies, clinical decision-making, drug-related side effects, adverse reactions, 5245
- Sarcopenia, muscle mass loss, cancer, skeletal muscle index, meta-analysis, review, 2409
- SAVI SCOUT, reflector localization, non-wire localization, breast cancer, 3915
- Savi Scout<sup>®</sup>, reflector-guided localisation, radar localisation, non-wire localisation, non-palpable breast lesions, breast cancer, review, 3633
- SBRT, cyberKnife, prostate cancer, 2053
- SBRT, pulmonary oligometastases, pulmonary oligo-recurrence, pulmonary sync-oligometastases, nationwide study, 393
- SBRT, stereotactic body radiation therapy, oligometastatic prostate cancer, prostate neoplasm, SRT, review, 2419
- SCD105, prostate cancer, prostate biopsy, endoglin, high-grade prostate cancer, 1459
- Schwannoma, neurological deficit, distribution, sensory nerve, motor nerve, complication, 6563
- Sclareol, small cell lung carcinoma, cell cycle, apoptosis, DNA damage, xenograft, 4947
- Sclerosing microcystic adenocarcinoma, next-generation sequencing, immunosuppression, oral cancer, 6375
- SCNEC, small cell neuroendocrine carcinoma, adrenal gland cancer adrenal gland, extrapulmonary small cell carcinoma, chemotherapy, radiation therapy, chemoradiation, 5933
- Score, apparent diffusion coefficient, neoadjuvant therapy, multimodality, 4033
- Score, fibroepithelial lesions, phyllodes tumors, fibroadenoma, 1095
- Scoring instrument, breast cancer, survival probability, radiotherapy, bone metastases, 367
- Scoring tool, elderly patients, brain metastases, esophageal cancer, whole-brain irradiation, survival, 1661
- Screening suspension, COVID-19, breast cancer, lockdown, oncological treatments delay, 7119
- Screening, abdominal aortic aneurysm, high cardiovascular risk profile, lung cancer, 4137
- Screening, colorectal cancer, diagnosis, fecal occult blood test, FOBT, fecal immunochemical test, FIT, false-negative, false-positive, review, 575
- Screening, hepatocellular carcinoma, surveillance, diagnosis, biomarkers, tumor biology, liver tumors, review, 6573
- Screening, HPV, self-sampling, ethiopia, cervical cancer, 1513

- Scrotal malignancies, testicular cancer, hydrocele testis, ultrasound, 2861
- Seasonal influence, vitamin D, gynaecological cancers, menopause status, age, nicotine abuse, grade, 545
- Second primary cancer, endometrial cancer, molecular characterization, interval from first primary cancer to second primary cancer, 3811
- Second primary neoplasms, breast neoplasm, healthcare use, treatment, 1041
- Second-line chemotherapy, advanced urothelial carcinoma, paclitaxel, gemcitabine, cisplatin, 1613
- Second-line chemotherapy, urothelial carcinoma, combination chemotherapy, 1141
- Second-line therapy, alpha fetoprotein, hepatocellular carcinoma, lenvatinib, ramucirumab, 2089
- Second-line therapy, hepatocellular carcinoma, sorafenib, sequential therapy, tumor burden, 3953
- Second-line treatment, imatinib, chronic myeloid leukemia, dasatinib, TKI, *BCR-ABL1*, 5313
- Second-line, biliary tract cancer, cholangiocarcinoma, targeted therapy, chemotherapy, review, 3013
- Secondary adrenal insufficiency, adrenal insufficiency, steroid dependence, glioma, glioblastoma, 2059
- Secondary ascites, RLS lymphosarcoma, cyclophosphamide, double-stranded DNA, cancer stem cells eradication, 795
- Secondary brain lesions, carcinoma of the breast, older persons, radiation therapy, survival analyses, 2271
- Secondary cytoreductive surgery, epithelial ovarian cancer, platinum-sensitive recurrence, positron-emission tomography/computed tomography, 2191
- Secondary lymphedema, age, gynecologic cancer-related lymphedema, iatrogenic lymphedema, lymphedema, plastic surgery, review, 6609
- Secondary, acute myeloid leukemia, therapy related, survival, mutations, 2917
- Secretin-induced duodenal aspiration, pancreatic juice, pancreatic neoplasms, pancreatic cyst, KRAS, GNAS, 4215
- SEI1*, cisplatin, oral cancer, transcriptional upregulation, chemoresistance, 67
- Seizures, brain metastases, radiosurgery, stereotactic radiotherapy, 3499
- Seizures, brain metastases, whole-brain irradiation, prevalence, risk factors, survival, 3429
- Seizures, glioma, radiation therapy, prevalence, risk factors, survival, 3961
- Selection bias, tumor treating fields, the Stupp protocol, newly diagnosed glioblastoma, survival, 5801
- Selenium, inflammatory cytokines, biomarkers, rhenium, cancer cells, 1915
- Selenoanhydride, cancer, multidrug resistance, t-lymphoma, phenothiazines, selenoesters, combination chemotherapy, 4921
- Selenoesters, cancer, multidrug resistance, t-lymphoma, phenothiazines, selenoanhydride, combination chemotherapy, 4921
- Self-sampling, HPV, ethiopia, screening, cervical cancer, 1513
- Senescence, glutamine metabolism, mTOR, DNA damage, 6891
- Sensitivity, biomarker, proteomics, squamous intraepithelial lesion, specificity, 6273
- Sensitivity, fecal occult blood, guaiac-based test, fecal immunochemical test, gFOBT, iFOBT, FIT, colorectal cancer screening, meta-analysis, specificity, false negative, false positive, ROC, HSROC, 3591
- Sensitize, bladder cancer, orthotopic, nude mice, GFP, cisplatin, oral recombinant methioninase, combination, efficacy, 6083
- Sensory nerve, schwannoma, neurological deficit, distribution, motor nerve, complication, 6563
- Sentinel lymph node biopsy (SLNB), lymphadenectomy, immunotherapy, radiation, chemotherapy, 2895
- Sentinel lymph node biopsy, breast cancer, platelet-lymphocyte ratio, biomarker, blood test, 2343
- Sentinel lymph node, breast cancer, intraoperative frozen section, 1711
- Sentinel node biopsy, breast cancer, metastasis, platelet-lymphocyte ratio, 4405
- Sentinel node biopsy, breast cancer, neo-adjuvant chemotherapy, axillary disease, review, 5351
- Sequential therapy, hepatocellular carcinoma, sorafenib, second-line therapy, tumor burden, 3953
- Seroma formation, drainage, drain-free mastectomy, surgical adhesive, tissuGlu<sup>®</sup>, breast cancer therapy, dead space reduction, 2801
- Serum-MAF, THP-1 macrophages,  $\gamma$ -globulin, talin-1, calpain, time-lapse imaging, morphological change, 4707
- Sessile serrated polyps, colon, non-dysplastic, cell proliferation, p53 up-regulated cells, 1535
- Setanaxib, cancer treatment, hypoxia, oxidative stress, liver cancer, 5071
- Sex hormones, oral tongue squamous cell carcinoma, estradiol, MMP8, 6029
- Sex, metastatic spinal cord compression, spinal metastasis, long-term survival, surgical treatment, prognostic factor, 1475
- Sexual dysfunction, urinary dysfunction, high inferior mesenteric artery tie, low inferior mesenteric artery tie, rectal cancer, 4223
- Sexually transmitted infection, high-risk HPV, smoking, anogenital warts, *Mycoplasma genitalium*, *Mycoplasma hominis*, *Ureaplasma spp*, 2219
- SF3B4*, esophageal squamous cell carcinoma, poor prognostic biomarker, 2941
- SF3B4*, RSF3, mRNA stability, HCC, SNU-368, 2033

- SHH, oral squamous cell carcinoma, vitamin D, sonic Hedgehog signaling, wNT/ $\beta$ -catenin signaling, 20-hydroxyvitamin D<sub>3</sub>, 1, 20-dihydroxyvitamin D<sub>3</sub>, 2467
- Shikonin, cholangiocarcinoma, pyruvate kinase M2, reactive oxygen species, 5115
- Short-term outcome, dialysis, colorectal cancer, laparoscopic surgery, overall survival, 2165
- Short-term outcomes, laparoscopic colectomy, descending colon cancer, D<sub>3</sub> dissection, long-term outcomes, 1731
- ShRNA, GPR87, gene therapy, adenoviral vector, cell surface marker, NSCLC, 733
- ShRNA, nicotinamide phosphoribosyltransferase, glioma, 4895
- ShRNA, oncolytic virus, adenovirus, CUL4A, virotherapy, 161
- Side effects, hyperthermic intraperitoneal intraoperative chemotherapy, HIPEC, ovarian cancer, cisplatin, 1481
- Side effects, metastatic colorectal cancer, methylenetetrahydrofolate reductase, sNPs, fluoropyrimidine-based chemotherapy, mestizo population, 4263
- Sidedness, methylation, p53, prognosis, colon cancer, 201
- Sigmoidal cancer, defecatory dysfunction, high inferior mesenteric artery tie, low inferior mesenteric artery tie, 2969
- Signaling pathways, oncogenes, tumor-suppressor genes, carcinogenesis, review, 6009
- Signet-ring cell carcinoma, colorectal cancer, survival, 7127
- SiHa cells, *miR-187*, cervical cancer, 1427
- Silencing mediator for retinoid and thyroid receptors, breast cancer, thyroid gland, TSH, FT3, FT4, prognosis, 6417
- Silibinin, HIF-1 $\alpha$ , eIF4E, RPS6, ovarian clear-cell carcinoma, 6791
- Simple trachelectomy, cervical cancer, small volume, conization, parametrial involvement, pelvic lymphadenectomy, review, 3651
- Simultaneous integrated boost, prostate neoplasms, intensity-modulated radiotherapy, dominant intraprostatic lesion, phase I-II, 6499
- Single intravesical instillation, low-risk bladder cancer, pirarubicin, mitomycin C, 5295
- Single nucleotide polymorphism, *ANRIL*, *ARF-INK4* locus, hematologic malignancies, allogeneic hematopoietic stem cell transplantation, 5707
- Single nucleotide polymorphism, DNA repair gene, overall survival, hypopharyngeal cancer, Japanese, 3277
- Single nucleotide polymorphism, laryngeal squamous cell carcinoma, matrix metallo-proteinases, matrix metalloproteinase 8, MMP8, rs11225395, rs2155052, 2003
- Single nucleotide polymorphism, *miR-146a*, *rs2910164*, esophageal cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, pancreatic cancer, 1495
- Single nucleotide polymorphisms, interleukin 10, prostate cancer, smoking, inflammation, African-American, 27
- Sinusoidal obstruction syndrome, beraprost sodium, liver sinusoidal endothelial cells, liver transplantation, oxaliplatin based chemotherapy, veno-occlusive disease, 5171
- Sinusoidal obstruction syndrome, colorectal cancer, liver metastases, liver resection, mesenchymal stem cells, monocrotaline, 6817
- Sinusoidal obstruction syndrome, spleen volume, oxaliplatin, 3361
- Sirtuin1, leukemia, NOTCH, NF- $\kappa$ B, p53, 3155
- Size-selective microfilters, circulating tumor cell, circulating tumor cell cluster, non-small cell lung cancer, 5577
- Skeletal metastases, chondrosarcoma, bone scintigraphy, PET-CT, staging, 5735
- Skeletal muscle index, muscle mass loss, sarcopenia, cancer, meta-analysis, review, 2409
- Skin cancer, UVR, solar lentigines, skin phototype, 557
- Skin phototype, skin cancer, UVR, solar lentigines, 557
- Skin, immunosuppression, kidney transplantation, onconeurology, 4017
- Skin, tumour budding, squamous-cell carcinoma, aggressiveness, 2695
- Skp2, triple-negative breast cancer, curcumin, anoikis, 5529
- SLC22A16*, *rs714368*, biomarker, cytotoxic chemotherapy, 4245
- Slovak population, *MDM2*, polymorphism, expression, prostate cancer, 6257
- Smad4, EMT, tranilast, tGF- $\beta$ 1, 3287
- Small bowel adenocarcinoma, ileocecal valve, Bauhin's valve, colorectal cancer, 4053
- Small bowel, leiomyosarcoma, oncological surgery, sarcoma, 4199
- Small cell lung carcinoma, sclerol, cell cycle, apoptosis, DNA damage, xenograft, 4947
- Small cell neuroendocrine carcinoma, SCNEC, adrenal gland cancer adrenal gland, extrapulmonary small cell carcinoma, chemotherapy, radiation therapy, chemoradiation, 5933
- Small intestinal lymphoma, prevention of perforation, 2373
- Small intestine, cytoreductive surgery, heated intraperitoneal chemotherapy, ileus, length of stay, 2865
- Small volume, cervical cancer, simple trachelectomy, conization, parametrial involvement, pelvic lymphadenectomy, review, 3651
- Small-cell lung cancer, relapsed, refractory, nab-paclitaxel, monotherapy, 1579
- Small-cell prostate cancer, neuroendocrine differentiation, neuron-specific enolase, platinum-based chemotherapy, treatment-related neuroendocrine prostate cancer, 3519
- Smoking, alcohol drinking, betel quid, genotype, interleukin-12A, oral cancer, polymorphism, Taiwan, 3707

- Smoking, high-risk HPV, anogenital warts, sexually transmitted infection, *Mycoplasma genitalium*, *Mycoplasma hominis*, *Ureaplasma spp*, 2219
- Smoking, oral squamous cell carcinoma, OSCC, risk factors, young adults, case-control study, survival analysis, alcohol consumption, 6987
- Smoking, single nucleotide polymorphisms, interleukin 10, prostate cancer, inflammation, African-American, 27
- Smooth-muscle tumors of uncertain malignant potential, recurrence, uterine malignancies, uterine smooth-muscle neoplasms, STUMP, review, 1229
- SN38, colorectal cancer, redox-status, oxidative stress, ferroptosis, electroporation, multidrug resistance, 5159
- SNPs, metastatic colorectal cancer, methylenetetrahydrofolate reductase, fluoropyrimidine-based chemotherapy, side effects, mestizo population, 4263
- SNPs, nasopharyngeal, cancer, CT, MRI, polymorphism, variations, genotype, VEGFA, EDNRA *NBS1*, FAS, 677
- SNU-368, RSF3, *SF3B4*, mRNA stability, HCC, 2033
- SNX5422, thyroid carcinoma, HSP90 inhibitor, AUY922, BIIB021, bim, 6137
- Social determinants of health, lung cancer, social isolation, loneliness, dementia, 7141
- Social determinants of health, multiple myeloma, disparity, affordable Care Act, 5727
- Social isolation, lung cancer, social determinants of health, loneliness, dementia, 7141
- Soft tissue sarcoma, hand, outcome, radiotherapy, 1463
- Soft tissue sarcomas, carbon ion radiotherapy, axial bone sarcomas, hadrontherapy, 2853
- Soft-tissue reconstruction, intraoperative radiotherapy, IORT, limb salvage, flap, 6941
- Soft-tissue sarcoma, metastasis, histological grade, tumor site, early consultation, early referral, 7009
- Solar lentigines, skin cancer, UVR, skin phototype, 557
- Solarium, sunbeds, melanoma, tanning, hill criteria, 501
- Sonic Hedgehog signaling, oral squamous cell carcinoma, vitamin D, SHH, wNT/ $\beta$ -catenin signaling, 20-hydroxyvitamin D<sub>3</sub>, 1, 20-dihydroxyvitamin D<sub>3</sub>, 2467
- Sonic Hedgehog, vismodegib, castration-resistant prostate cancer, Hedgehog signaling, epithelial-mesenchymal transition, 5107
- Sonodynamic therapy, ultrasound, nanomedicine, polyethylene glycol-modified carbon nanotubes, sarcoma 180, colon 26, 2549
- Sophageal cancer, esophageal stricture, chemotherapy, radiotherapy, risk factor, 1071
- Sorafenib, HCC, sarcopenia, carnitine, liver cirrhosis, 4173
- Sorafenib, hepatocellular carcinoma, androgen receptor, epCAM, 1285
- Sorafenib, hepatocellular carcinoma, lenvatinib, portal vein tumor thrombosis, 2283
- Sorafenib, hepatocellular carcinoma, second-line therapy, sequential therapy, tumor burden, 3953
- Sorafenib, microbiome, hepatocellular carcinoma, tyrosine kinase inhibitors, 665
- Sorafenib, renal cell carcinoma, PTEN, spheroid, sunitinib, 1943
- SOX2,  $\gamma\delta$  T cell, immunotherapy, prostate cancer, cancer stem cell, sphere, prostasphere, CD133, NANOG, OCT4, 5481
- SPARC, invasion, meningioma, immunohistochemistry, malignant, recurrence, 3081
- Spathulenol, melanoma, natural products, *E. pisocarpus*, photoprotection, apoptosis, 5015
- Specificity, biomarker, proteomics, squamous intraepithelial lesion, sensitivity, 6273
- Specificity, fecal occult blood, guaiac-based test, fecal immunochemical test, gFOBT, iFOBT, FIT, colorectal cancer screening, meta-analysis, sensitivity, false negative, false positive, ROC, HSROC, 3591
- Spectrin  $\alpha$ II, cisplatin resistance, doxorubicin, ovarian carcinoma, oxaliplatin, 2497
- Sphere,  $\gamma\delta$  T cell, immunotherapy, prostate cancer, cancer stem cell, prostasphere, CD133, NANOG, SOX2, OCT4, 5481
- Spheroid, renal cell carcinoma, PTEN, sunitinib, sorafenib, 1943
- Spinal metastases, metastatic spinal cord compression, spinal surgery, vertebral metastases, operation time, bleeding, minimal access surgery, 5673
- Spinal metastasis, metastatic spinal cord compression, long-term survival, surgical treatment, prognostic factor, sex, 1475
- Spinal surgery, metastatic spinal cord compression, spinal metastases, vertebral metastases, operation time, bleeding, minimal access surgery, 5673
- SPION, superparamagnetic iron oxide nanoparticles, glioblastoma, drug-delivery, review, 5989
- Spiro-acridine, antitumor activity, anti-angiogenic activity, immunomodulation, zebrafish, Ehrlich ascites carcinoma model, 5049
- Spleen volume, oxaliplatin, sinusoidal obstruction syndrome, 3361
- Splenic injection, colorectal cancer, liver metastasis, clonal dynamics, animal model, orthotopic implantation, 3297
- Spondins, r-spondin 1, ovarian cancer, wnt signaling, 6017
- Spray diathermy, colorectal liver metastasis, parenchymal-sparing liver resection, surgical margin, 1359
- SQSTM1, LC3B-II, apoptosis, chloroquine, miR-139, autophagy, beclin-1, mTOR, prostate cancer, 6649
- Squamous cell carcinoma, chemotaxis, tE1-cells, eicosatetraenoic acids, 5043
- Squamous cell carcinoma, head and neck cancer, positron emission tomography, extranodal extension, lymph node metastasis, 2073



- Squamous intraepithelial lesion, biomarker, proteomics, specificity, sensitivity, 6273
- Squamous lung carcinoma, indocyanine green, fluorescence imaging, mediastinal lymphatic metastasis, orthotopic implantation, 1875
- Squamous-cell carcinoma, tumour budding, skin, aggressiveness, 2695
- SRAGE, multiple myeloma, interleukin-8, oxidative stress, cancer, gender, 1443
- Src, breast cancer, hormone, calcium, anticancer effect, 1989
- Src, DLL1, metastasis, suppressor, pancreatic cancer, p38, 1335
- SRT, stereotactic body radiation therapy, oligometastatic prostate cancer, prostate neoplasm, SBRT, review, 2419
- SSEA-4, neoadjuvant hormonal therapy, biochemical recurrence, histological effect, prostate cancer, 5567
- Stage III, carbon-ion radiotherapy, non-small-cell lung cancer, effectiveness, toxicity, 379
- Stage II, adjuvant chemotherapy, high-risk factor, mucinous adenocarcinoma, 1651
- Stage III non-small cell lung cancer (NSCLC), tumor control probability (TCP), normal tissue complication probability (NTCP), concomitant boost, accelerated radiotherapy, 4095
- Stage IV rectal cancer, radiotherapy, chemotherapy, local complication, 5853
- Staging laparoscopy, pancreatic cancer, prognosis, laparoscopic surgery, 1023
- Staging, chondrosarcoma, skeletal metastases, bone scintigraphy, PET-CT, 5735
- Stapled anastomosis, bursting pressure, triangulating anastomosis, 1891
- Static magnetic stimulation, neuroblastoma, cell viability, cell death, cell cycle, 5151
- Statins, nivolumab, non-small cell lung cancer, corticoids, antibiotics, proton pump inhibitors, NSAID, metformin, 2209
- Stem cell, yolk sac tumour, primitive germ cell tumour, AFP, 759
- Stemness, cancer stem cells, colorectal cancer, COLO 201 cells, cD44-positive cancer cells, 169
- Stemness, methylsulfonylmethane, apoptosis, cell cycle arrest, HT-29 cells, 5191
- Stemness, periostin, carcinoma, metastasis, angiogenesis, lymphangiogenesis, chondrosarcoma, 5463
- Stereoselective synthesis, cancer prevention, vitamin D metabolites, assay development, review, 519
- Stereotactic body radiation therapy, Ewing sarcoma, metastasis, 951
- Stereotactic body radiation therapy, oligometastatic prostate cancer, prostate neoplasm, SBRT, SRT, review, 2419
- Stereotactic body radiation therapy, re-irradiation, re-treatment, recurrence, normal tissue, radiation biology, 1981
- Stereotactic body radiotherapy (SBRT), oligometastases, oligo-recurrence, esophageal cancer, prognostic factor, 2065
- Stereotactic body radiotherapy, pancreatic cancer, chemotherapy, dose effect, 465
- Stereotactic radiosurgery, fractionated stereotactic radiotherapy, distant brain metastases, elderly patients, prognostic instrument, 4081
- Stereotactic radiotherapy, brain metastases, radiosurgery, seizures, 3499
- Stereotactic radiotherapy, renal cell carcinoma, metastasis, pazopanib, tyrosine kinase inhibitors, 7037
- Stereotactic radiotherapy, thyroid cancer, curative, palliative setting, 3379
- Sternum, sarcoma, chondrosarcoma, chest wall, bone tumor, 1519
- Steroid dependence, adrenal insufficiency, secondary adrenal insufficiency, glioma, glioblastoma, 2059
- Stomach neoplasms, cell biology, margins of excision, 5807
- Stomach neoplasms, immunohistochemistry, cyclooxygenase 2, prognosis, 341
- Stomach neoplasms, neoadjuvant chemotherapy, para-aortic lymph node excision, 2351
- Stomach neoplasms, neoplasm staging, multidetector computed tomography, contrast media, echo-endoscopy, 3401
- Stomach, cisplatin, ERCC1, human gastric carcinoma, 3203
- Stool DNA, gut microbiota, gene mutations, colorectal cancer, 16S rRNA gene sequencing, 1325
- Stress, colorectal cancer, corticotropin-releasing hormone, anticancer drug, 4505
- Structure, molecular design, EGF receptor, tX-2036 derivatives, 4675
- STUMP, smooth-muscle tumors of uncertain malignant potential, recurrence, uterine malignancies, uterine smooth-muscle neoplasms, review, 1229
- Succinate, menadione, ascorbate, cancer, mitochondria, superoxide, 1963
- Sugar code, tumor growth, wound healing, vessel sprouting, glycobiology, 3191
- Sulfasalazine, activating transcription factor 4, breast cancer, cysteine, hypoxia, tumor necrosis factor-related apoptosis-inducing ligand, 1387
- Sun habits, malignant melanoma, tailored advice, questionnaire, ultraviolet radiation, 3325
- Sunbeds, melanoma, solarium, tanning, hill criteria, 501
- Sunitinib, renal cell carcinoma, PTEN, spheroid, sorafenib, 1943
- Sunscreen, photoprotection, 25(OH)D, vitamin D, UVR exposure, review, 511
- Superior mesenteric vein thrombosis, hepatocellular carcinoma, cancer-associated thrombosis, direct oral anticoagulant, liver resection, 6465

- Superoxide, menadione, ascorbate, cancer, mitochondria, succinate, 1963
- Superparamagnetic iron oxide nanoparticles, SPION, glioblastoma, drug-delivery, review, 5989
- Supplement, methioninase, oral, methionine, methionine restriction prostate cancer, PSA, ovarian cancer, cancer patients, 2813
- Supplementation, vitamin D, metabolomics, genomics, broad gene expression, metabolomic profile, individual response, personalized medicine, 25-hydroxyvitamin D, 535
- Supportive care, palliative radiotherapy, whole-brain radiotherapy, brain metastases, prognostic factors, 977
- Suppressor, DLL1, metastasis, pancreatic cancer, src, p38, 1335
- Surgery, colorectal liver metastases, resectability, chronic disease, 1
- Surgery, endometriosis-associated intestinal malignancies, endometriosis-associated malignancies of urinary tract, endometriosis-associated malignancies of surgical scars, immunohistochemistry, chemotherapy, review, 2429
- Surgery, gallstone disease, cancer, plasma MDA, plasma CAT, NRS pain score, 5701
- Surgery, lung cancer, pulmonary metastases, colorectal carcinoma, biomarker, prognosis, 7045
- Surgery, perineural invasion, cervical cancer, vulvar cancer, adjuvant therapy, review, 3031
- Surgery, pulmonary adenocarcinoma, clinical stage I, circulating tumor cell, recurrence, 7089
- Surgery, tumor marker, inflammation index, carcinoembryonic antigen, c-reactive protein, novel index, non-small cell lung cancer, prognosis, 4023
- Surgical adhesive, seroma formation, drainage, drain-free mastectomy, tissuGlu<sup>®</sup>, breast cancer therapy, dead space reduction, 2801
- Surgical complexity, ovarian cancer, debulking surgery, PDS, IDS, 3925
- Surgical margin, colorectal liver metastasis, parenchymal-sparing liver resection, spray diathermy, 1359
- Surgical margin, ICG fluorescence-guided surgery, fluorescence width, fluorescence pattern, laparoscopic liver resection, 3873
- Surgical resection, brain metastases, non-small cell lung cancer, molecularly targeted therapy, 4801
- Surgical resection, breast cancer, brain metastasis, survival, prognosis, molecular subtype, 1759
- Surgical resection, breast cancer, recurrence, methionine restriction, recombinant methioninase, lung metastasis, inhibition, adjuvant therapy, 4869
- Surgical resection, FA score, fibrinogen, albumin, pancreatic ductal adenocarcinoma, prognostic index, 7017
- Surgical stress, inflammation, survival, colorectal cancer, 3535
- Surgical stress, minimal invasive surgery, gastric cancer, postoperative infectious complications, prognosis, 7109
- Surgical treatment, endometrial cancer, chemo-radiotherapy, progestins, urinary tract symptoms, 3065
- Surgical treatment, metastatic spinal cord compression, spinal metastasis, long-term survival, prognostic factor, sex, 1475
- Surveillance, hepatocellular carcinoma, screening, diagnosis, biomarkers, tumor biology, liver tumors, review, 6573
- Survival analyses, secondary brain lesions, carcinoma of the breast, older persons, radiation therapy, 2271
- Survival analysis, oral squamous cell carcinoma, OSCC, risk factors, young adults, case-control study, smoking, alcohol consumption, 6987
- Survival analysis, ovarian epithelial cancer, LRRC17, zebrafish, apoptosis, gene expression omnibus, TCGA, 5601
- Survival outcomes, asian Americans, gastric cancer, 6381
- Survival probability, breast cancer, radiotherapy, bone metastases, scoring instrument, 367
- Survival prognosis, brain metastasis, gynecological cancer, elderly, whole-brain irradiation, 2257
- Survival rate, gastric cancer, psoas muscle, gastrectomy, 4271
- Survival rates, bcR gene recombinations, IGK, lung adenocarcinoma, tumor specimen exomes, CD19, CD20, CD79 B-cell markers, 2043
- Survival scores, non-small cell lung cancer, cerebral metastasis, elderly, radiation therapy, 2847
- Survival, acute myeloid leukemia, secondary, therapy related, mutations, 2917
- Survival, apoptosis, myeloid cell leukemia-1, non-small cell lung cancer, prognosis, 1007
- Survival, breast cancer, brain metastasis, prognosis, surgical resection, molecular subtype, 1759
- Survival, cerebral glioma, radiotherapy, prognostic factors, re-evaluation, 6513
- Survival, colorectal cancer, bone metastases, radiotherapy, prognostic score, 287
- Survival, colorectal cancer, signet-ring cell carcinoma, 7127
- Survival, elderly patients, brain metastases, esophageal cancer, whole-brain irradiation, scoring tool, 1661
- Survival, endometrial cancer, pelvic lymphadenectomy, para aortic lymphadenectomy, 1563
- Survival, esophageal carcinoma, oncological esophagectomy, neoadjuvant chemoradiation, lymphadenectomy, prognosis, 2833
- Survival, gastrointestinal stromal tumour, GIST, imatinib, real-world, safety, 435
- Survival, glioblastoma multiforme, longer-course radiotherapy, local control, prognostic factors, 7025
- Survival, glioblastoma, fractionated stereotactic radiotherapy, boost, toxicity, 3387
- Survival, glioma, seizures, radiation therapy, prevalence, risk factors, 3961

- Survival, head and neck cancer, unknown primary, human papillomavirus, oropharyngeal cancer, 4207
- Survival, inflammation, surgical stress, colorectal cancer, 3535
- Survival, myxofibrosarcoma, MR imaging, reproducibility, prognosis, 5793
- Survival, NSCLC, chemoradiotherapy, prognostic factor, blood parameters, 2319
- Survival, oxaliplatin. renal function, colorectal neoplasms, peripheral neuropathy, 2379
- Survival, prostate, radiation, race, 3307
- Survival, pulmonary sarcoma, epidemiology, prognostic factors, 1697
- Survival, recurrent glioblastoma, re-irradiation, prognostic factors, 7077
- Survival, salvage surgery, differentiated thyroid carcinoma, age, distant metastasis, 11292
- Survival, seizures, brain metastases, whole-brain irradiation, prevalence, risk factors, 3429
- Survival, textbook outcome, retroperitoneal sarcoma, hospital volume, National Cancer Database, 2107
- Survival, tumor treating fields, the Stupp protocol, newly diagnosed glioblastoma, selection bias, 5801
- Survivin, castration-resistant prostate cancer, cabazitaxel, inhibitor of apoptosis proteins, drug therapy, YM155, 5091
- Suspected prostate cancer, laparoscopy, nomogram, radical prostatectomy, robotics, 2995
- SUV, breast cancer, PET, tumor-infiltrating lymphocyte, neoadjuvant chemotherapy, pathological complete response, 3395
- SUV<sub>max</sub>, chemotherapy, esophageal squamous cell carcinoma, FDG-PET, 1153
- SYK inhibitor, BCR, bromodomain (BRD), BET inhibitor, lymphoma, canine DLBCL, 3781
- Symptom score, radiotherapy, cancer, palliative treatment, oligometastases, 1551
- Symptomatic CAT, thrombosis, low molecular weight heparin, LMWH, cancer-associated thrombosis, CAT, incidental CAT, 305
- Synchronous primary malignancy, colonic adenocarcinoma, pancreatic ductal carcinoma, immunohistochemistry, microsatellite stable, chemotherapy, 4029
- Synchronous primary malignancy, rectal adenocarcinoma; small cell lung carcinoma, gastrointestinal stromal tumor (GIST), immunohistochemistry; microsatellite stable, chemotherapy, 7053
- Synchronous rhabdoid tumor, cell line, germline mutation, DNA methylation analysis, 6159
- Synovial sarcoma, sarcoma, chemotherapy, 1029
- Systemic inflammation score, gastric cancer, gastrectomy, 1503
- Systemic mastocytosis, CT, hounsfield units, 1015
- Systemic therapy, vesicular stomatitis virus, tumor-suppressor microRNA, osteosarcoma, 6319
- Systems biology, network pharmacology, herbal, combination, breast cancer, pharmacological mechanism, 5097
- T-cadherin, colorectal cancer, adiponectin, high-molecular weight oligomers, adipoR1, adipoR2, 3751
- T-cell lymphomas, non-Hodgkin's lymphoma (NHL), anaplastic large cell lymphoma (ALCL), anaplastic lymphoma kinase (*ALK*), mammalian target of rapamycin (mTOR), drug combination therapy, 1395
- T-cell receptor, immune checkpoint inhibitors, immune-related adverse events (irAEs), renal cell carcinoma, next-generation sequencing, immune response, 4875
- T-cells, neuroendocrine carcinoma, carcinoma of the uterine cervix, immunotherapy, cellular immunotherapy, adoptive immunotherapy, 4741
- T-lymphoma, cancer, multidrug resistance, phenothiazines, selenoesters, selenoanhydride, combination chemotherapy, 4921
- T(7;12), pericytoma, *ACTB-GLI1* fusion gene, *GLI1* isoform 2 protein, unbalanced chromosome translocation, 1239
- Tacalcitol, chemotherapy, 5-fluorouracil, calcitriol, vitamin D analogs, 837
- Tailored advice, malignant melanoma, questionnaire, sun habits, ultraviolet radiation, 3325
- Taiwan, acute lymphocytic leukemia, case-control study, childhood, genotype, *MMP-9*, polymorphism, 5751
- Taiwan, *ADIPOQ*, colorectal cancer, genotype, polymorphism, 1297
- Taiwan, age, gender, genotype, *MMP-1*, polymorphism, pterygium, 703
- Taiwan, age, gender, genotype, *MMP-9*, polymorphism, pterygium, 4523
- Taiwan, alcohol drinking, betel quid, genotype, interleukin-12A, oral cancer, polymorphism, smoking, 3707
- Taiwan, breast cancer, genotype, interleukin-13, polymorphism, 6743
- Taiwan, case-control study, caspase-8, genotype, nasopharyngeal carcinoma, polymorphism, 5503
- Taiwan, childhood leukemia, genotype, miR-196a-2, polymorphism, 4465
- Taiwan, gastric cancer, genotype, *MMP7*, polymorphism, 695
- Talin-1, THP-1 macrophages, serum-MAF,  $\gamma$ -globulin, calpain, time-lapse imaging, morphological change, 4707
- TAM, TYRO3, gastric cancer, prognostic factor, 5593
- Tamoxifen, ginseng seed oil, oleic acid, ER+, breast cancer, 4529
- Tamoxifen, TNBC, 1, 4 naphthoquinone, breast cancer cell lines, 6623
- Tannic acid, lung cancer, intrinsic apoptosis, g0/G1cell cycle arrest, 3209
- Tanning, sunbeds, melanoma, solarium, hill criteria, 501
- Targeted therapy, biliary tract cancer, cholangiocarcinoma, chemotherapy, second-line, review, 3013

- Targeted therapy, colorectal carcinoma, doxorubicin, TSPO, prodrug, 5371
- TAS-102, FTD/TPI, bevacizumab, 4157
- TCGA, ovarian epithelial cancer, LRRC17, survival analysis, zebrafish, apoptosis, gene expression omnibus, 5601
- TE1-cells, chemotaxis, eicosatetraenoic acids, squamous cell carcinoma, 5043
- Tears, exosomes, extracellular vesicles, miRNA, breast cancer, biomarkers, 3091
- Temozolomide, AZD7762, cytotoxicity, glioma, 5141
- Temozolomide, resistance, G2 checkpoint, DNA mismatch repair, glioblastoma, 1315
- Tertiary lymphoid structure, colorectal cancer metastases, chemotherapy, 6367
- Testicular cancer, hydrocele testis, ultrasound, scrotal malignancies, 2861
- Textbook outcome, retroperitoneal sarcoma, hospital volume, National Cancer Database, survival, 2107
- Texture analysis, head and neck squamous cell carcinoma, computed tomography, machine learning, 271
- TGF- $\beta$ , breast cancer, eribulin, tILs, ALC, tumour microenvironment, 3345
- TGF- $\beta$ 1, EMT, tranilast, smad4, 3287
- TGF $\beta$  signaling, functional loss, mammary cancer, environmental carcinogen, 2687
- TGF $\beta$ , cell–matrix interactions, cell adhesion, migration, tumor spheroids, ILK, MIC1, PARVA, LIMS1, RSU1, 1375
- TGI model parameter estimation, pharmacokinetic (PK)–Pharmacodynamic (PD), tumor growth inhibition (TGI) mathematical model, deep learning neural networks (DLNN), nonlinear optimization, adaptive tumor growth short-term prediction, xenografted mice (PDX), pancreatic ductal adenocarcinoma (PDAC) xenograft, 5181
- The Cancer Genome Atlas, uveal melanoma, gene Expression Omnibus, prognosis, bioinformatics, 3839
- The Paris System, urine, cytology, atypical urothelial cell, high-grade urothelial carcinoma, low-grade urothelial neoplasm, 3477
- The Stupp protocol, tumor treating fields, newly diagnosed glioblastoma, survival, selection bias, 5801
- Therapeutic drug monitoring, 5-FU prodrugs, personalized treatment, capecitabine, review, 4655
- Therapeutic drug monitoring, modelling and simulation, chronopharmacokinetics, translational research, cancer chemotherapy, 5-FU prodrug, pharmacometrics, review, 6585
- Therapeutic management, primary renal angiosarcoma, clinical features, diagnostic approach, review, 625
- Therapeutics, dickkopf-3, clinical biomarker, malignant tumour, review, 5969
- Therapy related, acute myeloid leukemia, secondary, survival, mutations, 2917
- Therapy, ibrutinib, chronic lymphocytic leukemia, 4059
- Thiazolidinedione, pPAR $\gamma$ , ciglitazone, 9-cis-retinoic acid, retinoids, head and neck squamous carcinoma, 3071
- Thin-film hydration, apoptosis, breast cancer, methoxy poly(ethylene glycol)-poly(lactic-co-glycolic) acid, piperine, 689
- Thiobarbituric acid, barbituric acid, cytotoxicity, *in vivo* tumor model, lung cancer, 6039
- Third-line treatment, ramucirumab, overall survival, drug cost, adverse event, metastatic colorectal cancer, 1605
- Thoracic surgery, extra pulmonary small cell carcinoma, high grade neuro-endocrine tumor, esophageal cancer, chemotherapy, 5919
- Thoracoscope, esophageal cancer, minimally invasive esophagectomy, 1587
- THP-1 macrophages, serum-MAF,  $\gamma$ -globulin, talin-1, calpain, time-lapse imaging, morphological change, 4707
- Thrombosis, low molecular weight heparin, LMWH, cancer-associated thrombosis, CAT, incidental CAT, symptomatic CAT, 305
- Thrombotic microangiopathy, gemcitabine, eculizumab, chemotherapy complications, pancreatic cancer, 3995
- Thrombus, renal cell carcinoma, inferior vena cava, pulmonary embolism, radical nephrectomy, lung metastasis, 5837
- Thyroid cancer, curative, palliative setting, stereotactic radiotherapy, 3379
- Thyroid cancer, papillary, tumor stem cells, 3801
- Thyroid cancer, papillary, ultrasonography, thyroid nodule, 1779
- Thyroid carcinoma, HSP90 inhibitor, AUY922, BIIB021, SNX5422, bim, 6137
- Thyroid gland, breast cancer, TSH, FT3, FT4, silencing mediator for retinoid and thyroid receptors, prognosis, 6417
- Thyroid hormones, prostate cancer, triiodothyronine, grade Groups, prostatectomy, pathological T stage, tumor percentage involvement, 2323
- Thyroid nodule, thyroid cancer, papillary, ultrasonography, 1779
- Thyroid surgery, anaplastic thyroid cancer, multimodal treatment, radiotherapy, hyperfractionated accelerated radiotherapy, 6979
- TIGIT, CD155, CAK cells, KRAS, TNK cells, PD-1, 3D culture, 4663
- TILs, breast cancer, eribulin, tGF- $\beta$ , ALC, tumour microenvironment, 3345
- Time to first systemic therapy, follicular lymphoma, EZH2, POD24, prognostic factors, expression profile, 6685
- Time to treatment failure, interferon-gamma release, immune checkpoint inhibitor, non-small-cell lung cancer, biomarker, 6971
- Time to treatment failure, leukopenia, febrile neutropenia, docetaxel, prostate cancer, 4291

- Time to treatment failure, nivolumab, cancer cachexia, gastric cancer, overall survival, 7067
- Time-lapse imaging, THP-1 macrophages, serum-MAF,  $\gamma$ -globulin, talin-1, calpain, morphological change, 4707
- Time-restricted feeding, cancer immunotherapy, high-fat diet, 5445
- Time-restricted feeding, metabolomics, plasma, diet, Lewis lung carcinoma, mice, 1833
- Tissue-resident macrophages, repetitive low-dose lipopolysaccharide, anti-inflammation, phagocytosis, 4457
- TissuGlu<sup>®</sup>, seroma formation, drainage, drain-free mastectomy, surgical adhesive, breast cancer therapy, dead space reduction, 2801
- TKI, *BCR-ABL1*, CML, resistance, efficacy, review, 2457
- TKI, FAS CD95, FAS ligand, caspase-3, apoptosis, nilotinib, dasatinib, erlotinib, gefitinib, everolimus, 6195
- TKI, IGF1R, insulin-like growth factor 1 receptor, head and neck squamous cell carcinoma (HNSCC), nilotinib, dasatinib, erlotinib, gefitinib, everolimus, 3847
- TKI, imatinib, chronic myeloid leukemia, dasatinib, second-line treatment, *BCR-ABL1*, 5313
- TKI, interferon, pancreatic cancer, rNA-Seq, toll-like receptor, 4445
- TNBC subtypes, triple negative breast cancer, ultrasound, clinical imaging, breast cancer, 2125
- TNBC, imidazo[2, 1-*b*]oxazole derivatives, RAF inhibitors, chemotherapy, 5081
- TNBC, MAD2L2, APC/C, 5471
- TNBC, PDOX, patient-derived orthotopic xenograft, nude mice, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, olaparib, regression, resistance, 2509
- TNBC, PDOX, patient-derived orthotopic xenograft, patient-derived xenograft, PDX, triple-negative breast cancer, 2481
- TNBC, PDOX, patient-derived orthotopic xenograft, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, cisplatin, tumor regression, 2475
- TNBC, tamoxifen, 1, 4 naphthoquinone, breast cancer cell lines, 6623
- TNK cells, CD155, CAK cells, KRAS, PD-1, TIGIT, 3D culture, 4663
- Toll-like receptor 2, lung cancer, non-small cell lung cancer, lung adenocarcinoma, nuclear factor-kappa B, proliferation, 5361
- Toll-like receptor, interferon, pancreatic cancer, rNA-Seq, TKI, 4445
- Tongue cancer, CD40 agonist, PD-1 antagonist, postoperative adjuvant treatment, 2707
- Tongue squamous cell carcinoma, melatonin, MTT, migration, invasion, apoptosis, autophagy, 6295
- Topoisomerase, larynx, carcinoma, immunohistochemistry, digital image analysis, 807
- Total mesorectal excision, predictive score, locally advanced rectal cancer, laparoscopy, 2079
- Toxicity, carbon-ion radiotherapy, non-small-cell lung cancer, effectiveness, stage III, 379
- Toxicity, glioblastoma, fractionated stereotactic radiotherapy, boost, survival, 3387
- Toxicity, low-dose, ultra-low, intensity-modulated radiotherapy, moderate-dose RT, 4041
- Toxicity, lung cancer, chemotherapy, predictive, prognostic, 6399
- TP53* mutation, breast cancer, *HER2* gene amplification, estrogen receptor, early recurrence, 645
- TP53* mutation, merkel cell carcinoma, nasal vestibule, traumatic suture scar, immunohistochemistry, 1123
- Trabectedin, ovarian cancer, pegylated liposomal doxorubicin, platinum-sensitive, 3939
- TRAIL, MCF-7, breast cancer, mesenchymal stem cells, 5641
- TRAIL, miRNA-301-3p, pancreatic cancer, caspase-8, luteolin, combination effect, 723
- Tranilast, EMT, smad4, tGF- $\beta$ 1, 3287
- Transcriptional upregulation, cisplatin, oral cancer, *SEI1*, chemoresistance, 67
- Translational research, modelling and simulation, chronopharmacokinetics, cancer chemotherapy, therapeutic drug monitoring, 5-FU prodrug, pharmacometrics, review, 6585
- Transumbilical incision, laparoscopic, hepatectomy, 6545
- Transurethral resection of bladder tumor, circulating tumor cells, bladder cancer, 4299
- Trastuzumab, breast cancer, *HER2*, 3315
- Trastuzumab, eosinophil percentages, infusion reaction, breast cancer, 4047
- Trastuzumab, FOXO3A, *HER2*, esophageal squamous cell carcinoma, 1921
- Trastuzumab, hER2-positive, metastatic breast cancer, re-therapy, 3973
- Trastuzumab, *HER2*, advanced gastric cancer, chemotherapy, 75
- Traumatic suture scar, merkel cell carcinoma, nasal vestibule, immunohistochemistry, *TP53* mutation, 1123
- Treatment-free interval, ovarian cancer, neoadjuvant chemotherapy, platinum resistance, 2765
- Treatment-related neuroendocrine prostate cancer, neuroendocrine differentiation, neuron-specific enolase, platinum-based chemotherapy, small-cell prostate cancer, 3519
- Treatment, breast neoplasm, healthcare use, second primary neoplasms, 1041
- Tregs, multiple myeloma, neuropilin-1, pDCs, 5437
- Triangulating anastomosis, stapled anastomosis, bursting pressure, 1891
- Tributary crypts, colon, innominate grooves, frequency, ulcerative colitis, 7031

- Triiodothyronine, prostate cancer, thyroid hormones, grade Groups, prostatectomy, pathological T stage, tumor percentage involvement, 2323
- Triple negative breast cancer, TNBC subtypes, ultrasound, clinical imaging, breast cancer, 2125
- Triple negative breast cancer, vorinostat, I3C, estrogen receptor, progesterone receptor, HDAC activity, HDAC7, 3669
- Triple-negative breast cancer, aldehyde dehydrogenase 1, microarray analysis, network analysis, 6733
- Triple-negative breast cancer, curcumol, anoikis, skp2, 5529
- Triple-negative breast cancer, PDOX, patient-derived orthotopic xenograft, TNBC, matrix-producing breast carcinoma, eribulin, cisplatin, tumor regression, 2475
- Triple-negative breast cancer, PDOX, patient-derived orthotopic xenograft, patient-derived xenograft, PDX, TNBC, 2481
- Triple-negative breast cancer, PDOX, patient-derived orthotopic xenograft, nude mice, TNBC, matrix-producing breast carcinoma, eribulin, olaparib, regression, resistance, 2509
- Triple-negative breast carcinoma, breast, programmed death ligand 1, intratumoral immune cells, 1487
- Triple-positive breast cancer, ER+/HER2+, next-generation sequencing, neo-ALL-IN, MLL2, *PIK3CA*, 5883
- Troglitazone, peroxisome proliferator-activated receptor  $\gamma$ , oral SCC, apoptosis, G1 arrest, 1247
- Trousseau' syndrome, gastric cancer, neoplastic venous thrombosis, internal jugular vein, 2889
- Tru-Cut biopsy, ovarian cancer, ascites, puncture, 3527
- Tryptophan, chemo brain, kynurenine, NAD, tubulin, cognition, biophoton, review, 1189
- TSH, breast cancer, thyroid gland, FT3, FT4, silencing mediator for retinoid and thyroid receptors, prognosis, 6417
- TSPO, targeted therapy, colorectal carcinoma, doxorubicin, prodrug, 5371
- Tubulin, chemo brain, tryptophan, kynurenine, NAD, cognition, biophoton, review, 1189
- Tumor antigen, ca 72.4, gastric cancer, gastric juice, gastrectomy, 1691
- Tumor biology, hepatocellular carcinoma, surveillance, screening, diagnosis, biomarkers, liver tumors, review, 6573
- Tumor burden, hepatocellular carcinoma, sorafenib, second-line therapy, sequential therapy, 3953
- Tumor calcification, hepatocellular carcinoma, radioembolization, 4191
- Tumor characteristics, acral lentiginous melanoma, malignant melanoma, National Cancer Database, 3411
- Tumor control probability (TCP), stage III non-small cell lung cancer (NSCLC), normal tissue complication probability (NTCP), concomitant boost, accelerated radiotherapy, 4095
- Tumor development, end-stage kidney disease, VDR, CYP27B1, CYP24A1, 6525
- Tumor dissociation, pancreatic cancer, cancer stem cells, cancer-associated fibroblasts, FACS, 1267
- Tumor growth inhibition (TGI) mathematical model, pharmacokinetic (PK)–Pharmacodynamic (PD), deep learning neural networks (DLNN), nonlinear optimization, TGI model parameter estimation, adaptive tumor growth short-term prediction, xenografted mice (PDX), pancreatic ductal adenocarcinoma (PDAC) xenograft, 5181
- Tumor growth, wound healing, vessel sprouting, glycobiology, sugar code, 3191
- Tumor immunity, pulmonary pleomorphic carcinoma, CD4, CD8, PD-L1, prognosis, 261
- Tumor infiltrating lymphocytes, breast cancer, FOXP3, CD8, 2141
- Tumor infiltrating lymphocytes, neutrophil-to-lymphocyte ratio, biliary tract cancer, 2881
- Tumor marker, breast cancer, C-X-C motif chemokine ligand 12, C-X-C motif chemokine receptor 4, 3221
- Tumor marker, hypertension, chemerin, fibrosis, 143
- Tumor marker, inflammation index, carcinoembryonic antigen, c-reactive protein, novel index, non-small cell lung cancer, surgery, prognosis, 4023
- Tumor markers, bladder cancer, UBC Rapid, 3967
- Tumor metrics, bevacizumab, erlotinib, non-small cell lung cancer, Hellenic Cooperative Oncology Group, 2095
- Tumor microenvironment, EGFR inhibitor resistance, patient-derived model, *MET* signaling, combinational treatment, 109
- Tumor microenvironment, mesenchymal stem cells, tumor progression, review, 3039
- Tumor microenvironment, OSCC, fibrosis, bMF, biomarker, 4319
- Tumor microenvironment, pancreatic cancer, alkalization therapy, alkaline diet, bicarbonate, urine pH, 873
- Tumor microenvironment, tumor-associated macrophages, bladder cancer, cell growth, cell migration, cell invasion, cytokines, 2715
- Tumor morphology, hepatocellular carcinoma, immunohistochemistry, 4105
- Tumor mutation burden, germline mutation, tumor neoantigen, 4567
- Tumor necrosis factor-related apoptosis-inducing ligand, activating transcription factor 4, breast cancer, cysteine, hypoxia, sulfasalazine, 1387
- Tumor neoantigen, tumor mutation burden, germline mutation, 4567
- Tumor percentage involvement, prostate cancer, thyroid hormones, triiodothyronine, grade Groups, prostatectomy, pathological T stage, 2323
- Tumor progression, conventional RCC, AXL expression, immuno-histochemistry, 3485

- Tumor progression, mesenchymal stem cells, tumor microenvironment, review, 3039
- Tumor regression, dedifferentiated liposarcoma, PDOX, nude mice, recombinant methioninase, *S. typhimurium* A1-R, combination, 2515
- Tumor regression, PDOX, patient-derived orthotopic xenograft, TNBC, triple-negative breast cancer, matrix-producing breast carcinoma, eribulin, cisplatin, 2475
- Tumor response, chemoradiation, esophagus, neoadjuvant therapy, recurrence-free survival, prognostic factors, 4387
- Tumor shrinkage, neoadjuvant chemotherapy, long-term outcome, down-staging, breast conserving surgery, recurrence, 1079
- Tumor site, soft-tissue sarcoma, metastasis, histological grade, early consultation, early referral, 7009
- Tumor specimen exomes, bcR gene recombinations, IGK, lung adenocarcinoma, CD19, CD20, CD79 B-cell markers, survival rates, 2043
- Tumor spheroids, cell–matrix interactions, cell adhesion, migration, tGF $\beta$ , ILK, MIC1, PARVA, LIMS1, RSU1, 1375
- Tumor stem cell, leiomyosarcoma, angiogenesis, hematogenous metastasis, 1255
- Tumor stem cells, thyroid cancer, papillary, 3801
- Tumor suppressor gene, n-farnesyl-norcantharimide, jurkat T cells, next-generation sequencing, biosynthesis, 2675
- Tumor treating fields, the Stupp protocol, newly diagnosed glioblastoma, survival, selection bias, 5801
- Tumor volume, radiochemotherapy, pathologic complete response, 4327
- Tumor-associated macrophages, bladder cancer, cell growth, cell migration, cell invasion, cytokines, tumor microenvironment, 2715
- Tumor-associated neutrophils, immune checkpoint inhibitor, non–small-cell lung carcinoma, predictive factor, neutrophil counts, 3889
- Tumor-infiltrating lymphocyte, breast cancer, neoadjuvant chemotherapy, 1883
- Tumor-infiltrating lymphocyte, breast cancer, PET, SUV, neoadjuvant chemotherapy, pathological complete response, 3395
- Tumor-infiltrating lymphocytes, ROCK1, ROCK2, melanoma, prognosis, Kaplan–Meier analysis, 1931
- Tumor-specificity, 3-Styrylchromones, methoxy group, cytotoxicity, QSAR analysis, cell cycle analysis, molecular shape, 87
- Tumor-specificity, QSAR, guaiiazulene-3-carboxylate, OSCC, molecular shape, ionization potential, 4885
- Tumor-suppressor genes, oncogenes, carcinogenesis, signaling pathways, review, 6009
- Tumor-suppressor microRNA, vesicular stomatitis virus, osteosarcoma, systemic therapy, 6319
- Tumorigenesis, *LINK-A*, long non-coding RNA, CRISPR/Cas9, high-grade serous carcinoma, *in vitro*, 6677
- Tumour budding, squamous-cell carcinoma, skin, aggressiveness, 2695
- Tumour heterogeneity, neoplasms, colon, tumour microenvironment, 6063
- Tumour immunology, EBV, diffuse large b-cell lymphoma, Epstein-Barr virus positive diffuse large b-cell lymphoma, programmed death-ligand 1, non-Hodgkin lymphoma, review, 5951
- Tumour microenvironment, breast cancer, eribulin, tGF- $\beta$ , tILs, ALC, 3345
- Tumour microenvironment, neoplasms, colon, tumour heterogeneity, 6063
- Tumour predisposition syndrome, neurofibromatosis type 1, mosaicism, plexiform neurofibroma, 3423
- Tumour risk, radiomics, prediction, classification, prognosis, review, 3605
- Tumour-infiltrating lymphocytes, breast cancer, neutrophil-to-lymphocyte ratio, prognosis, 2871
- Tumour, polyamines, polyamine oxidase, polyamine analogues, 1437
- Twice-daily thoracic radiotherapy (BID-TRT), volumetric modulated arc therapy (VMAT), intensity modulated radiation therapy (IMRT), involved field radiotherapy irradiation (IFR-IFI), accelerated hyperfractionated thoracic radiotherapy (AHTRT), anti-programmed cell death ligand-1 immune checkpoint inhibitor (ICIs), 6957
- TX-2036 derivatives, molecular design, structure, EGF receptor, 4675
- TYRO3, TAM, gastric cancer, prognostic factor, 5593
- TYRO3 gene, pediatric, acute myeloid leukemia, chromosome translocation, RNA sequencing, 6115
- Tyrosine kinase inhibitor, lung cancer, induction treatment, *EGFR*, 2911
- Tyrosine kinase inhibitors, fibroblast growth factor, HPV, FGF, head and neck squamous cell carcinoma, HNSCC, everolimus, mTOR inhibitors, 5621
- Tyrosine kinase inhibitors, microbiome, sorafenib, hepatocellular carcinoma, 665
- Tyrosine kinase inhibitors, renal cell carcinoma, metastasis, pazopanib, stereotactic radiotherapy, 7037
- Tyrosine kinase, leukemia, PARP inhibitors, review, 3055
- UBC Rapid, bladder cancer, tumor markers, 3967
- UBE2B, CCRT, rectal cancer, radioresistance, 6305
- Ulcerated melanoma, head and neck neoplasms, NCDB, United States/epidemiology, 1055
- Ulcerative colitis, carcinogenesis, mtDNA, 101
- Ulcerative colitis, colon, innominate grooves, tributary crypts, frequency, 7031
- Ultra-low, low-dose, intensity-modulated radiotherapy, toxicity, moderate-dose RT, 4041
- Ultrasonically-activated surgical device, gastric cancer, dissemination, 3163

- Ultrasonography, contrast media, portal vein, hepatocellular carcinoma, 4351
- Ultrasonography, thyroid cancer, papillary, thyroid nodule, 1779
- Ultrasound, magnetic resonance, MR-US fusion, iOTA simple rules, O-RADS MRI scoring system, adnexal masses, ovarian cancer, 4115
- Ultrasound, nanomedicine, poly-ethylene glycol-modified carbon nanotubes, sonodynamic therapy, sarcoma 180, colon 26, 2549
- Ultrasound, testicular cancer, hydrocele testis, scrotal malignancies, 2861
- Ultrasound, triple negative breast cancer, TNBC subtypes, clinical imaging, breast cancer, 2125
- Ultrasound, vacuum-assisted excision, vacuum-assisted breast biopsy, breast lesions, lesions of uncertain malignant potential, breast cancer, 1719
- Ultraviolet B radiation, previtamin D<sub>3</sub>, ultraviolet radiation light emitting diode (LED), *vitamin D<sub>3</sub>*, human skin, 719
- Ultraviolet B, breast, cancer, colon, colorectal, ecological, mendelian randomization, prostate, UVB, 25-hydroxyvitamin D, review, 491
- Ultraviolet radiation light emitting diode (LED), previtamin D<sub>3</sub>, *vitamin D<sub>3</sub>*, human skin, ultraviolet B radiation, 719
- Ultraviolet radiation, malignant melanoma, tailored advice, questionnaire, sun habits, 3325
- Umbilical defunctioning ileostomy, incisional hernia, rectal cancer, laparoscopic surgery, 3445
- Unbalanced chromosome translocation, pericytoma, t(7;12), *ACTB-GLI1* fusion gene, GLI1 isoform 2 protein, 1239
- Uncommon mutation, clinical practice, non-small cell lung cancer, *EGFR*, epidermal growth factor receptor, 5757
- United States/epidemiology, head and neck neoplasms, ulcerated melanoma, NCDB, 1055
- Unknown primary, head and neck cancer, human papillomavirus, oropharyngeal cancer, survival, 4207
- Unresectable advanced cancer, esophageal cancer, chemoradiotherapy, docetaxel, 2827
- Upper abdominal surgery, debulking for ovarian cancer, primary debulking, complete cytoreduction, morbidity, interval debulking surgery, 5869
- Upper extremity, free vascularized fibula flap, limb salvage, oncologic resection, 2751
- Upper gastrointestinal tract, gastric cancer, esophageal cancer, chemotherapy, *HER2*, 965
- Upper rectal cancer, neoadjuvant treatment, chemoradiation therapy, recurrence-free and overall survival, long-term functional results, 3579
- Ureaplasma spp*, high-risk HPV, smoking, anogenital warts, sexually transmitted infection, *Mycoplasma genitalium*, *Mycoplasma hominis*, 2219
- Ureter, large cell neuroendocrine carcinoma, bladder, kidney, review, 2439
- Urinary dysfunction, sexual dysfunction, high inferior mesenteric artery tie, low inferior mesenteric artery tie, rectal cancer, 4223
- Urinary tract symptoms, endometrial cancer, surgical treatment, chemo-radiotherapy, progestins, 3065
- Urine pH, pancreatic cancer, alkalization therapy, tumor microenvironment, alkaline diet, bicarbonate, 873
- Urine, cytology, the Paris System, atypical urothelial cell, high-grade urothelial carcinoma, low-grade urothelial neoplasm, 3477
- Urothelial carcinoma, histological variant, radical cystectomy, clinical outcomes, 4787
- Urothelial carcinoma, second-line chemotherapy, combination chemotherapy, 1141
- Uterine malignancies, smooth-muscle tumors of uncertain malignant potential, recurrence, uterine smooth-muscle neoplasms, STUMP, review, 1229
- Uterine sarcoma, angiosarcoma, hemangiosarcoma, gynaecology, cancer, ovarian sarcoma, chemotherapy, paclitaxel, laparotomy, osseous metastasis, 5743
- Uterine smooth-muscle neoplasms, smooth-muscle tumors of uncertain malignant potential, recurrence, uterine malignancies, STUMP, review, 1229
- UVB, breast, cancer, colon, colorectal, ecological, mendelian randomization, prostate, ultraviolet B, 25-hydroxyvitamin D, review, 491
- Uveal melanoma, nucleolus, H&E staining, prognosis, 3505
- Uveal melanoma, the Cancer Genome Atlas, gene Expression Omnibus, prognosis, bioinformatics, 3839
- UVR exposure, sunscreen, photoprotection, 25(OH)D, vitamin D, review, 511
- UVR, skin cancer, solar lentigines, skin phototype, 557
- Vacuum-assisted biopsy, magnetic resonance imaging, computer-aided detection, 6437
- Vacuum-assisted breast biopsy, vacuum-assisted excision, ultrasound, breast lesions, lesions of uncertain malignant potential, breast cancer, 1719
- Vacuum-assisted excision, vacuum-assisted breast biopsy, ultrasound, breast lesions, lesions of uncertain malignant potential, breast cancer, 1719
- Validation study, decisional conflict scale, central vascular access devices, psychometrics, 5583
- Variations, nasopharyngeal, cancer, CT, MRI, SNPs, polymorphism, genotype, VEGFA, EDNRA *NBS1*, FAS, 677
- Vascular invasion, carbon ion radiotherapy, intensity-modulated radiotherapy, hepatocellular carcinoma, 459
- Vascular malformation, intraosseous, haemangioma, orbit, cone beam computed tomography, 3D reconstruction, bone mineral density, immunohistochemistry, differential diagnosis, 3333
- Vascularized bone graft, extracorporeally-irradiated autograft, reconstruction, sarcoma, 1637



- Vasculogenic mimicry, HIF1 $\alpha$ , HIF1 inhibitors, apoptosis, acriflavine, 5379
- VDR, end-stage kidney disease, CYP27B1, CYP24A1, tumor development, 6525
- VDR, vitamin D, 1, 25-D<sub>3</sub>, ovarian cancer, *in vitro*, paclitaxel, carboplatin, growth inhibition, 3129
- VEGFA, nasopharyngeal, cancer, CT, MRI, sNPs, polymorphism, variations, genotype, EDNRA *NBSI*, FAS, 677
- Venetoclax, ER positive, breast cancer, ER targeting, elacestrant, FGFR inhibitors, review, 4829
- Veno-occlusive disease, beraprost sodium, liver sinusoidal endothelial cells, liver transplantation, oxaliplatin based chemotherapy, sinusoidal obstruction syndrome, 5171
- Vertebral metastases, metastatic spinal cord compression, spinal surgery, spinal metastases, operation time, bleeding, minimal access surgery, 5673
- Vesicular stomatitis virus, tumor-suppressor microRNA, osteosarcoma, systemic therapy, 6319
- Vessel sprouting, tumor growth, wound healing, glycobiology, sugar code, 3191
- Viability, glioma, polyphenols, flow cytometry, DRAQ7, MTT, 5427
- Villoglandular adenocarcinoma of the uterine cervix, early-stage cervical cancer, minimal invasive surgery, minimal handling, review, 3049
- Vinorelbine, metastatic breast cancer, real-world data, ESME, retrospective study, 3905
- Virotherapy, oncolytic virus, adenovirus, CUL4A, shRNA, 161
- Virtual screening, flavonoid, PI3K, inhibitor, protein kinase, anti-cancer, 4547
- Vismodegib, castration-resistant prostate cancer, Hedgehog signaling, sonic Hedgehog, epithelial-mesenchymal transition, 5107
- Vitamin D analogs, chemotherapy, 5-fluorouracil, calcitriol, tacalcitol, 837
- Vitamin D metabolites, cancer prevention, assay development, stereoselective synthesis, review, 519
- Vitamin D receptor, gene polymorphism, malignant melanoma, melanoma risk, meta-analysis, review, 583
- Vitamin D receptor, pancreatic ductal adenocarcinoma, desmoplasia, collagen, 6457
- Vitamin D, 1, 25-D<sub>3</sub>, ovarian cancer, *in vitro*, paclitaxel, carboplatin, growth inhibition, VDR, 3129
- Vitamin D, animal models, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, review, 527
- Vitamin D, gynaecological cancers, seasonal influence, menopause status, age, nicotine abuse, grade, 545
- Vitamin D, melanoma, pigmentation, clinical data, experimental models, review, 473
- Vitamin D, oral squamous cell carcinoma, sonic Hedgehog signaling, SHH, wNT/ $\beta$ -catenin signaling, 20-hydroxyvitamin D<sub>3</sub>, 1, 20-dihydroxyvitamin D<sub>3</sub>, 2467
- Vitamin D, previtamin D<sub>3</sub>, DNA damage, 8-hydroxy-2'-deoxyguanosine, nitric oxide, nitrite, human skin, 565
- Vitamin D, sunscreen, photoprotection, 25(OH)D, UVR exposure, review, 511
- Vitamin D, supplementation, metabolomics, genomics, broad gene expression, metabolomic profile, individual response, personalized medicine, 25-hydroxyvitamin D, 535
- Vitamin D<sub>3</sub> supplementation, *vitamin D*<sub>3</sub>, 25-hydroxyvitamin D, gut microbiota, randomized clinical trial, 551
- Vitamin D<sub>3</sub>, 25-hydroxyvitamin D, *vitamin D*<sub>3</sub> supplementation, gut microbiota, randomized clinical trial, 551
- Vitamin D*<sub>3</sub>, previtamin D<sub>3</sub>, ultraviolet radiation light emitting diode (LED), human skin, ultraviolet B radiation, 719
- Volumetric modulated arc therapy (VMAT), intensity modulated radiation therapy (IMRT), involved field radiotherapy irradiation (IFR-IFI), twice-daily thoracic radiotherapy (BID-TRT), accelerated hyperfractionated thoracic radiotherapy (AHTRT), anti-programmed cell death ligand-1 immune checkpoint inhibitor (ICIs), 6957
- Volumetric-modulated arc therapy, hypopharyngeal cancer, laryngoesophageal dysfunction-free survival, 4183
- Von Hippel Lindau mutation, malignant pleural mesothelioma, hypoxia inducible factor-1 $\alpha$ , molecular targeted therapy, 1867
- Von Recklinghausen's disease, malignant peripheral nerve sheath tumor, MN1, NF1, next-generation sequencing, 6221
- Vorinostat, I3C, triple negative breast cancer, estrogen receptor, progesterone receptor, HDAC activity, HDAC7, 3669
- VTQ, postoperative ascites, m2BPGi, hepatic resection, HCC, ALBI grade, 4343
- Vulvar cancer, perineural invasion, cervical cancer, surgery, adjuvant therapy, review, 3031
- WEE1, EMP3, E2F7, CD58, NSUN7, lower-grade gliomas, information-theoretical approach, 2777
- Weekly nedaplatin, ovarian cancer, platinum resistance, olaparib, 5263
- Weekly paclitaxel, breast cancer, bone marrow infiltration, erythroblastic blood smear, 2955
- Weekly, cetuximab, metastatic colorectal cancer, biweekly, 3469
- Whole brain radiotherapy, hypothalamic-pituitary dysfunction, endocrine late effects, cancer survivor, 5787
- Whole-bladder, muscle invasive bladder cancer, radiation therapy, elderly patients, 2905
- Whole-brain irradiation, brain metastasis, gynecological cancer, elderly, survival prognosis, 2257
- Whole-brain irradiation, cancer of unknown primary, brain metastases, patients aged  $\geq 65$  years, remaining lifespan, 2261

- Whole-brain irradiation, elderly patients, brain metastases, esophageal cancer, survival, scoring tool, 1661
- Whole-brain irradiation, seizures, brain metastases, prevalence, risk factors, survival, 3429
- Whole-brain radiotherapy, older patients, brain metastases, local therapies, overall survival, extra-cerebral metastasis, 2841
- Whole-brain radiotherapy, palliative radiotherapy, supportive care, brain metastases, prognostic factors, 977
- Wide excisional surgery, invasive melanoma, excisional margins, NCDB, 1065
- Wide excisional surgery, invasive melanoma, excisional margins, residual tumor, NCDB, 1059
- Wireless, magseed, pooled analysis, localisation, review, 1809
- Wnt signaling, r-spondin 1, spondins, ovarian cancer, 6017
- Wnt, hepatocellular carcinoma,  $\beta$ -catenin, CBP, inhibitor, PRI-724, 5211
- WNT/ $\beta$ -catenin signaling, oral squamous cell carcinoma, vitamin D, sonic Hedgehog signaling, SHH, 20-hydroxyvitamin D<sub>3</sub>, 1, 20-dihydroxyvitamin D<sub>3</sub>, 2467
- Wound healing, tumor growth, vessel sprouting, glycobiology, sugar code, 3191
- WT1, pancreatic ductal adenocarcinoma, dendritic cell vaccination, MUC1, phase I/IIa study, 5765
- Xenograft model, pancreatic ductal carcinoma, cryopreservation, 2637
- Xenograft, small cell lung carcinoma, sclareol, cell cycle, apoptosis, DNA damage, 4947
- Xenografted mice (PDX), pharmacokinetic (PK)–Pharmacodynamic (PD), tumor growth inhibition (TGI) mathematical model, deep learning neural networks (DLNN), nonlinear optimization, TGI model parameter estimation, adaptive tumor growth short-term prediction, pancreatic ductal adenocarcinoma (PDAC) xenograft, 5181
- YAP1, colitis-associated colorectal cancer, CDX2, prognosis, 5411
- YM155, castration-resistant prostate cancer, cabazitaxel, inhibitor of apoptosis proteins, drug therapy, survivin, 5091
- Yolk sac tumour, primitive germ cell tumour, AFP, stem cell, 759
- Young adults, oral squamous cell carcinoma, OSCC, risk factors, case-control study, survival analysis, smoking, alcohol consumption, 6987
- Younger colorectal cancer, cancer-specific survival, propensity score matching, 4365
- Yuanhuadine, AGR2, NSCLC, mutant NSCLC, gefitinib resistance, ADAMTS6, 1855
- Zebrafish embryo model, proton, photon, DNA-DSB, morphological malformations, histological changes, 6123
- Zebrafish, (+)-betulin, NF- $\kappa$ B, MDA-MB-231, apoptosis, 6637
- Zebrafish, ovarian epithelial cancer, LRRC17, survival analysis, apoptosis, gene expression omnibus, TCGA, 5601
- Zebrafish, spiro-acridine, antitumor activity, anti-angiogenic activity, immunomodulation, Ehrlich ascites carcinoma model, 5049
- Zenithal natural killer cells, immune cell therapy, cancer, phase I/IIa study, 5687
- ZKSCAN3 (ZNF306), gastric cancer, prognosis, 81
- Zyxin, LIM domain proteins, cancer, review, 5981

## Authors Index

(Figures refer to page numbers)

- Abaev K, 3831  
 Abbas M, 27  
 Abbati F, 597, 3013  
 Abdel-Aziz M, 2739, 5025  
 Abdul S, 3925  
 Abe K, 5237, 6563  
 Abe M, 3947  
 Abe T, 3513, 3793  
 Abe Y, 6473  
 Abramowitz J, 2059  
 Abreu DE, 6355  
 Abreu P, 6573  
 Abuo-Rahma A, 5025  
 Abuo-Rahma GE-DA, 2739  
 Aburatani H, 1255  
 Abusnana S, 1555  
 Adachi A, 2905  
 Adachi N, 6319  
 Adachi S, 6733  
 Adachi T, 5765  
 Adelman TG, 6879  
 Adelstein D, 4207  
 Aderhold C, 825, 3847, 5621, 6195  
 Adimi P, 5255  
 Adomaitiene L, 789  
 Adorni M, 1543  
 Ae K, 1029, 1035  
 Agassi SFT, 6345  
 Agemi Y, 923  
 Agena S, 3277  
 Aggarwal A, 4857  
 Agrò FE, 2231  
 Aguilera R, 857  
 Ahlawat S, 5291  
 Ahmadipour Y, 1161  
 Ahmed A, 6367, 6933  
 Ahmed SK, 1463, 6941  
 Ahn D, 4001  
 Ahn E, 2225  
 Ahn J-H, 5883  
 Ahn S, 4929  
 Ahn S-H, 2707, 5883  
 Ahn SY, 3039  
 Ahn YT, 6295  
 Aigner F, 2861  
 Aikins JK, 6997  
 Aiko H, 3889  
 Aiko N, 923  
 Ailawadhi S, 5727  
 Ain Q, 1705  
 Ainsworth R, 2179  
 Aisu N, 4655, 4763  
 Aizawa M, 373  
 Aizawa T, 5295  
 Aizic A, 6457  
 Akagi N, 3995  
 Akagi Y, 4695, 4749, 4773  
 Akahoshi S, 2795, 5823, 6465, 7147  
 Akaihata H, 4299  
 Akaike H, 2311  
 Akamatsu M, 4707  
 Akazawa M, 4795  
 Akdeniz FT, 3265  
 Akiba J, 4105, 4695, 4749  
 Akimoto K, 35, 2777  
 Akin I, 4137  
 Akino Y, 1677  
 Akiyama H, 1587  
 Akiyama Y, 6473  
 Akkoc T, 5641  
 Akpınar G, 3169  
 Akrivos N, 2331, 2989  
 Alaaeldin R, 2739  
 Alanazi S, 2525  
 Alavi S, 5743  
 Al-Awadhi F, 5125  
 Alcicek S, 5649  
 Aldoescu S, 1049  
 Al-Haddad MA, 4215, 5845  
 Al-Hasawi NA, 5125  
 Alitto AR, 4413, 6499  
 Al-Kali A, 3883  
 Alkhateeb HB, 3883  
 Alkhayyal N, 1555  
 Allegra A, 1443  
 Allegra AG, 1443  
 Allen R, 535  
 Allen RH, 719  
 Allouache D, 2955  
 Allweis TM, 6417  
 Almercy T, 881  
 Almlöv K, 2757  
 Al-Reefy S, 1809  
 Alsaif G, 5201  
 Al-Samadi A, 6029  
 Alshahrani MS, 2865  
 Altahan A, 5423  
 Altomare M, 2231  
 Altomare V, 2231, 7119  
 Altoukhi K, 2865  
 Alves A, 3579  
 Alves Ribeiro M, 6573  
 Alves Veras MD, 5015  
 Alwafai Z, 2185, 2801  
 Alzahrani N, 2865  
 Amagase K, 6781  
 Amankwah EK, 3147  
 Amano R, 2637, 2881  
 Amano S, 3685  
 Amanuma M, 4173  
 Amaral ME, 3055  
 Amemiya H, 2311  
 Amemiya Y, 6649  
 Ames V, 2989  
 Amine SA, 5125  
 Amini N, 5457  
 An HJ, 3203  
 An WG, 6295  
 Anada M, 4327  
 Analitis A, 6213  
 Anami K, 3947  
 Anan K, 4779  
 Anantharaman A, 4029  
 Anastasiou I, 625  
 Anaya-Eugenio GD, 6637  
 Andersen K, 1239  
 Anderson P, 951  
 Ando F, 4271  
 Ando M, 2247  
 Ando R, 4395  
 Ando Y, 3733, 5229  
 Andonova T, 53  
 Andreadis C, 305  
 Andreatos N, 5457  
 Andrineia Oliveira K, 6799  
 Androulakis N, 435  
 Anemona L, 281, 939  
 Angelini A, 1519  
 Angelou A, 5457, 6599  
 Angelou K, 6009  
 Angelov L, 951  
 Annicchiarico A, 7127  
 Antolino L, 619  
 Antoniou E, 5457  
 Antoniou EA, 6599  
 Anttila M, 6923  
 Anzai M, 379  
 Aoki I, 1963, 5159  
 Aoki M, 393, 2065, 2911, 4663  
 Aoki T, 3873, 3983, 4567, 6545  
 Aoki Y, 3565, 5285  
 Aoshika T, 3513  
 Aoyagi Y, 4131  
 Aoyama T, 405, 443, 915, 1087, 1503, 1683, 2337, 2359, 2365, 4067, 5815  
 Appadu UD, 3081  
 Apple S, 1487  
 Apprey V, 27  
 Arakaki Y, 3565  
 Arakawa A, 4405  
 Arakawa S, 1579, 7067  
 Arakawa Y, 5829  
 Araki K, 2667, 4343  
 Araki Y, 3559, 6563, 7009  
 Aramaki T, 3953  
 Arasaki A, 6101  
 Araujo N, 1041  
 Aravantinos G, 305, 435, 929  
 Arcelli A, 465  
 Ardavanis A, 305  
 Ariga M, 7101  
 Ariga T, 3565  
 Arigami T, 75  
 Arihiro K, 3395  
 Arima K, 1023  
 Arimura H, 2073  
 Aristei C, 3387  
 Arita T, 3163  
 Árkosy P, 1759  
 Armakolas A, 709  
 Arshi J, 1625, 3991  
 Asakura K, 3953  
 Asama H, 6551  
 Asano A, 7101  
 Asano M, 6699  
 Asano Y, 2343, 3345, 3559, 4047, 6563, 7009  
 Asanuma H, 4319  
 Asao T, 261  
 Asari M, 1651, 4365

- Ashamalla H, 3307  
 Ashamalla M, 3307  
 Asher V, 3925  
 Ashi N, 7141  
 Ashihara E, 5481  
 Ashizawa N, 2311  
 Ashizawa T, 6473  
 Ashraf GM, 4547  
 Aso S, 4131  
 Aspinen S, 5701  
 Asproдини E, 2025  
 Assi HA, 847  
 Assumpcao JAF, 5151  
 Åström P, 6029  
 Atagi S, 4229  
 Athanasiadis A, 305  
 Athar M, 2467  
 Atreya CE, 865  
 Atsumi Y, 405, 443, 1087, 2337, 2359, 2365  
 Attwood K, 881, 6381  
 Augereau P, 3905, 3939  
 Augustine TN, 6179  
 Aumann K, 3049  
 Aurello P, 619  
 Autorino R, 3417  
 Aygerinos A, 435  
 Avila FR, 3411, 6609  
 Awale S, 5025  
 Awano N, 2239  
 Axelsson B, 3897  
 Ayabe T, 4023  
 Ayimugu A, 3169  
 Azarm A, 4029, 4401  
 Azechi S, 3277  
 Baba H, 1023, 2795  
 Baba M, 3091, 4471  
 Babasaki T, 1943  
 Bacalbasa N, 1049  
 Bach D-H, 1855  
 Bae H, 1771  
 Bae J-S, 3435  
 Bae KB, 3297  
 Baehr A, 4041  
 Bagaria SP, 881, 1055, 1059, 1065, 3411  
 Bahat AV, 6457  
 Bahra M, 387, 1267  
 Bai L, 6051  
 Bai L-Y, 2387  
 Bai M, 5371  
 Bajcurova K, 6817  
 Bajwa A, 1705  
 Bakalov V, 5727  
 Bakalova R, 1963, 5159  
 Bakri K, 1463, 2751, 6941  
 Balážová L, 3191  
 Balbinotti H, 5509  
 Balducci G, 1691  
 Balescu I, 1049  
 Bali A, 3925  
 Balwierz W, 7095  
 Bandow K, 87, 3685, 4885  
 Bandyophadyay A, 3743  
 Bang S, 2961  
 Bang S-M, 357  
 Banyai D, 3485, 6525, 6863  
 Barak V, 3967  
 Barauskas G, 3765  
 Barauskas V, 3765  
 Barberis M, 427  
 Barcellini A, 1645, 2853  
 Bar-David S, 6457  
 Barinova M, 2209  
 Barnhill RL, 891  
 Bartels M, 1  
 Bartosik W, 2613  
 Bartoszewicz N, 6531  
 Bartscht T, 1661, 1665  
 Barzó P, 4237  
 Barzyk GA, 5951  
 Baskic D, 5001  
 Basso SMM, 1135, 5877  
 Bateni SB, 2895  
 Bates M, 6229  
 Bau D-T, 695, 703, 1297, 1631, 2011, 3707, 4465, 4523, 5503, 5751, 6743, 7037  
 Bauer CM, 6799  
 Bauer JA, 6751  
 Baumeister P, 1277, 2117  
 Baumgartner R, 965  
 Baxa J, 3459  
 Beasley GM, 5245  
 Bębenek E, 6151  
 Becker S, 1277  
 Beckmann MW, 3049  
 Bednar L, 6817  
 Begg SKS, 3659  
 Bekeschus S, 2591, 3743  
 Bektas S, 5649  
 Belgioia L, 465, 3543  
 Belka C, 2319  
 Bellezza G, 3355  
 Bellucci F, 6485  
 Benatar T, 6649  
 Bendardaf R, 1555  
 Benes J, 349  
 Bengrine L, 4011  
 Benifla J-L, 1095  
 Beninati E, 1719  
 Benoit L, 1563  
 Benouahi R, 6205  
 Benson C, 7003  
 Beppu S, 1127  
 Beppu T, 2795, 5823, 6465, 7147  
 Béres E, 1759  
 Berezovskiy D, 3527  
 Berghoff AS, 6229  
 Bergman H, 5355  
 Bergqvist M, 3897  
 Bergstrom S, 3897  
 Berizzi A, 1519  
 Berton D, 3939  
 Berus T, 3505  
 Beserra Santos LK, 5015  
 Beyreuther E, 6123  
 Bhattarai PY, 5081  
 Bhowmick NA, 1459  
 Bhutani G, 1527  
 Bianchi S, 1079  
 Bianconi F, 3355  
 Biecek P, 1931, 3505  
 Bilancio G, 4017  
 Bilek O, 2209  
 Biliatis I, 5869  
 Bilska S, 5437  
 Bini V, 3387  
 Birk R, 825, 3847, 5621, 6195  
 Birke M, 583  
 Birnbaum DJ, 3659  
 Bisello S, 4413  
 Bisiello S, 3417  
 Bjelic-Radisic V, 2125  
 Bjercke T, 3485  
 Bjerkehagen B, 97  
 Blagonravov ML, 1437  
 Blanck G, 2043  
 Blanck O, 4081  
 Blanco DE, 6637  
 Blazek J, 2209  
 Blazer 3rd DG, 2107  
 Blažičević K, 2157  
 Blohmer J-U, 2185  
 Blondeaux E, 3543  
 Bluth MH, 4857  
 Bobeff K, 7095  
 Bobos M, 677  
 Bocheva G, 2467  
 Bockhorn M, 2947  
 Boczar D, 1055, 1059, 1065, 3411, 6609  
 Boda-Heggemann J, 4137  
 Bodmer WF, 6063  
 Bogachev SS, 795  
 Bojarska-Junak A, 6327  
 Bokas A, 305  
 Boku N, 1071  
 Bold RJ, 2895  
 Bonichon-Lamichane N, 3939  
 Bonome P, 3401  
 Bonomo P, 465  
 Bonora M, 1645, 2853  
 Boonmars T, 5115  
 Borges M, 1041  
 Borgfeldt C, 1513  
 Borggreffe M, 4137  
 Borgognoni L, 6485  
 Boryczka S, 6151  
 Borysiuk A, 6685  
 Bosak Butković M, 2323  
 Bose N, 1467  
 Boucek J, 349  
 Bouda J, 3527  
 Boukovinas I, 305, 435  
 Bournakis E, 305  
 Bouvet M, 2475, 2481, 2509, 4869, 5393, 6765  
 Bowne WB, 4857  
 Braeuer F, 2151  
 Brain E, 3905  
 Brammen L, 2151  
 Brand M, 6123  
 Brandani P, 6485  
 Brandao M, 1041  
 Brandi G, 597, 3013  
 Brands G, 4253  
 Brasoveanu V, 1049  
 Braun C, 5679  
 Brezan I, 1049  
 Brider T, 3831  
 Brim H, 27  
 Brooks A, 6457  
 Brothers SP, 1789  
 Brown PA, 3147  
 Brożyna AA, 473, 2467  
 Brugnattelli S, 1645  
 Brunetti A, 271

- Brunetti F, 2079  
 Brunetti M, 6115  
 Brunner M, 2833  
 Brunner S, 6123  
 Brunner T, 4281  
 Brzon O, 6817  
 Buchholz I, 2185  
 Budziszewska BK, 4059  
 Buechler C, 143  
 Buettner S, 5343, 5457  
 Bujalska-Zadrozny M, 4425  
 Bukowski MR, 3697  
 Bulla A, 5313  
 Bun A, 2141, 2871, 4147  
 Buonomo OC, 281, 939, 1719, 2231, 7119  
 Burbos N, 2331, 2989  
 Burchardt M, 841  
 Burgkart R, 5793  
 Burkey BB, 4207  
 Burns ST, 3995  
 Burycka S, 3071  
 Buwenge M, 465, 3417, 4413, 6499  
 Byun JM, 357, 2917  
 Cabibi D, 1711  
 Cadore NA, 5509  
 Caggiati L, 7119  
 Calais G, 3579  
 Callahan BM, 2043  
 Callander NS, 5727  
 Calò B, 2439  
 Camara O, 2185  
 Camerota TC, 6879  
 Cammelli S, 465  
 Campbell A, 857  
 Campbell K, 2225  
 Campbell PM, 4857  
 Campbell SR, 951  
 Candy GP, 6179  
 Canter RJ, 2895  
 Cao B, 245  
 Cao C, 4029, 4401  
 Capasso A, 4017  
 Capasso G, 4017  
 Capocaccia I, 6499  
 Capozzi R, 3355  
 Cappuzzo F, 983  
 Caputo A, 4017  
 Caravatta L, 6505  
 Carbone D, 4913  
 Carbonetti F, 3401  
 Carcache EJ, 6637  
 Cardelli P, 1691  
 Cardenas-Aguayo MDC, 6273  
 Caredda E, 2231  
 Carico E, 983  
 Carino R, 2231  
 Carlsson A, 3325  
 Carlsson T, 3897  
 Carmon E, 6417  
 Carrieri G, 2439  
 Carvalho M, 6355  
 Casadei R, 465  
 Cascianelli S, 3355  
 Cascioferro SM, 4913  
 Caspi J, 7119  
 Castilho Garcez R, 6799  
 Castillo B, 857  
 Castillo-Tong DC, 2487  
 Catania CM, 427  
 Catrina E, 1049  
 Cattadori F, 7119  
 Caumo W, 5151  
 Cavallini L, 6499  
 Cavallini M, 1691, 4053  
 Cavazzoni A, 4913  
 Cavedon C, 5901  
 Ceausu AR, 5557, 6879  
 Cellini F, 465  
 Cenci N, 3387  
 Censi M, 939  
 Ceppa EP, 4215  
 Ceppi M, 3543  
 Cernovska M, 2209  
 Cernusco NLV, 5901  
 Cerrotta A, 3417  
 Cerullo M, 2107  
 Cevik MB, 719  
 Cha'on U, 5115  
 Chai W-H, 1405  
 Chairoungdua A, 2645  
 Chan DL, 2865  
 Chan P-C, 1405  
 Chang AR, 1771  
 Chang C-D, 6345  
 Chang C-M, 1285  
 Chang HW, 2627  
 Chang K-H, 2995  
 Chang S-L, 1797, 3619  
 Chang SS, 733  
 Chang W-C, 1285  
 Chang W-S, 695, 703, 1297, 2011, 3707, 4465, 4523, 5503, 5751, 6743, 7037  
 Chang Y, 3255  
 Changkaew P, 2645  
 Channaoui M, 3379  
 Chansongkrow P, 4557  
 Chanvorachote P, 609, 2583, 4989  
 Chao C-N, 6907  
 Chao C-Y, 4465  
 Chao ST, 951  
 Chao Y-H, 1405  
 Chapet S, 3579  
 Charalabopoulos A, 1753  
 Charitandi A, 2095  
 Charoengam N, 535, 551  
 Charoensawan V, 4557, 6285  
 Chaves MH, 5015  
 Check D, 6997  
 Check JH, 6997  
 Chekerov R, 5743  
 Chen C-C, 1297, 2387, 4465  
 Chen C-H, 1405, 2011, 4513, 5059, 5895, 6723, 6743, 7037  
 Chen C-I, 6265  
 Chen C-P, 1297  
 Chen C-Y, 1427  
 Chen F-S, 2549  
 Chen H-J, 5895  
 Chen H-K, 1631  
 Chen HL, 4947  
 Chen H-Y, 6869  
 Chen J-C, 695, 6743, 6869, 7037  
 Chen J-H, 6265  
 Chen K-C, 5107  
 Chen L, 5201  
 Chen M, 2011  
 Chen MZ, 2865  
 Chen P-Y, 6869  
 Chen S-C, 5895  
 Chen S-Y, 6907  
 Chen T-J, 6305  
 Chen W, 6375  
 Chen Y, 5141, 5411  
 Chen Y-C, 6247  
 Chen Y-J, 2675  
 Chen Y-P, 4513  
 Chen Y-R, 6247  
 Chenuc G, 3905  
 Chen-Yoshikawa TF, 3287  
 Cheon SY, 2627  
 Chereil P, 1095  
 Chernych ER, 795  
 Chiang Y-C, 4947  
 Chiaravalloti A, 7119  
 Chiarini P, 3387  
 Chiba N, 7017  
 Chien C-R, 2387, 5895  
 Chien Y-C, 695  
 Chih M, 1161  
 Chika N, 4379  
 Chikamatsu K, 3559  
 Chikatani K, 4379  
 Chikui K, 1739, 6443  
 Chin YJ, 451  
 Chin Y-T, 703  
 Chinchilla R, 4263  
 Chinczewski L, 5743  
 Chionis A, 3065  
 Chirico A, 5583  
 Chirico M, 2439  
 Chiu C-T, 221  
 Chiu K-Y, 4075  
 Chiu S-C, 3865, 5221, 6093  
 Chiu Y-H, 3865, 5221, 6093  
 Cho D-Y, 3865, 5221, 6093  
 Cho EY, 2933  
 Cho H, 1683, 2275, 4067  
 Cho HY, 2627  
 Cho J-M, 3801  
 Cho S-G, 213, 4529, 6835  
 Cho SH, 1779  
 Cho YK, 6137  
 Chobrutskiy BI, 2043  
 Choi HJ, 2481  
 Choi HS, 5081  
 Choi MG, 6137  
 Choi M-Y, 3435  
 Choi S, 3839  
 Choi SU, 4929  
 Choi S-W, 6295  
 Choi Y, 4481  
 Chojnacki M, 6327  
 Chomwong S, 6899  
 Chong GO, 451  
 Choreftaki T, 6885  
 Chou A-K, 1297  
 Chou C-H, 1427  
 Chou C-L, 6305  
 Christodoulou C, 435  
 Christopoulou A, 305  
 Chrysovergis A, 807, 3759  
 Chuang F-J, 1427  
 Chuang H-Y, 695  
 Chuang Y-C, 6723  
 Chueh F-S, 6869

- Chun S-M, 7057  
 Chung JH, 3801  
 Chung JW, 4191  
 Chung W-M, 1285  
 Ciabattoni A, 6505  
 Ciancio G, 5837  
 Ciccozzi M, 983  
 Cilla S, 465, 4413, 6499  
 Cimpean AM, 5557, 6879  
 Cinar P, 865  
 Cinquepalmi M, 619  
 Cipolla C, 1711, 7083  
 Cirne-Lima EO, 5151  
 Cirrincione G, 4913  
 Cizauskas A, 789  
 Clark JW, 3659  
 Claxton MR, 2751  
 Cochuyt JJ, 1059, 1065  
 Cocozza S, 271  
 Codrington N, 4907  
 Cohen-Harazi R, 3831  
 Cojocar E, 7003  
 Colibaseanu DT, 881  
 Collard L, 4253  
 Collery P, 1915  
 Collin M, 4253  
 Collins A, 3925  
 Collura A, 939  
 Combi F, 7119  
 Connor JR, 6039  
 Conrad A, 891  
 Consoli ML, 5313  
 Constantinidis J, 677  
 Conticello C, 5313  
 Copeland RL, 6623  
 Corless C, 6229  
 Cormio L, 2439  
 Cornelis F, 1095  
 Correa Pontes FS, 6355  
 Cosio S, 1543, 2191, 3031, 4819, 5995  
 Costa AR, 1041  
 Costa F, 2231  
 Costi R, 4053, 7135  
 Cotesta M, 7119  
 Cotton E, 3669  
 Cox A, 3119  
 Crafa P, 7127  
 Crestani A, 4115  
 Crocetti D, 2969, 4223  
 Crul M, 1201  
 Cserháti A, 4237  
 Csonka Á, 4921  
 Cuccia F, 2853  
 Cui Y-D, 3819  
 Cuocolo R, 271  
 Curti CD, 3417  
 Czajka M, 4425  
 Czyżewski K, 6531  
 D'Amico R, 3751  
 D'Amore A, 5379  
 D'Angelillo RM, 7119  
 D'Angelo F, 619  
 D'Arcangelo M, 983  
 D'Ascanio M, 983  
 D'Avino V, 2231  
 D'Hondt V, 3905  
 D'Urso R, 1691  
 Da Costa Ribeiro Souza JA, 5049  
 Da Rosa BG, 2725  
 Da Silva A, 2955  
 Da Silva ED, 5509  
 Da Silva EL, 3055  
 Da Silva JM, 5049  
 Da Silva Pescador G, 6799  
 Da Silva PM, 5049  
 Dabi Y, 4115  
 Dąbrowska E, 3221  
 Dahl B, 1475, 5673  
 Dahlquist KJV, 6075  
 Dalenc F, 3905  
 Dalhaug A, 977  
 Dalianis T, 53  
 Damaj G, 2955  
 Damaskos C, 6599, 6885  
 Dambrauskas Z, 3765  
 Damm R, 4281  
 Dammerer D, 5319  
 Damon L, 3995  
 Dan T, 2059  
 Daniele A, 3751  
 Dannecker C, 2117  
 Darázs B, 4237  
 Date H, 3287  
 Dauksa A, 3765  
 Davakis S, 1753, 3065  
 Davey S, 2179  
 Davids H, 229  
 Davidson B, 6677  
 Davies D, 5427  
 De Almeida Lima É, 5049  
 De Amorim Carvalho FA, 5015  
 De Bree E, 6769  
 De Brito Kato AM, 6355  
 De Castro Sant'Anna C, 6355  
 De Cesaris P, 5379  
 De Cian F, 4199  
 De Felice F, 2969, 4223  
 De Gruijl FR, 501  
 De Iaco P, 1229  
 De Koning CB, 229  
 De Leo A, 1229  
 De Liguoro M, 5901  
 De Lorenzo S, 597, 3013  
 De Magistris L, 3751  
 De Marinis F, 427  
 De Moraes Alves MM, 5015  
 De Moraes Filho MO, 3055  
 De Moura RO, 5049  
 De Oliveira Rosario LV, 2725  
 De Paula Medeiros KC, 5049  
 De Souza LL, 6355  
 De Stasio V, 1719  
 De Toma G, 2969, 4223  
 De'Angelis N, 2079  
 Dębski R, 6531  
 Deguchi S, 6473  
 Deiana C, 281  
 Deichert U, 2185  
 Dekura Y, 2065  
 Del Conte A, 1135, 5877  
 Del Signore E, 427  
 Delalogue S, 3905  
 Dell'Abate P, 7127  
 Dembowska-Bagińska B, 7095  
 Demidowicz E, 6531  
 Demiri S, 929  
 Deng D, 245  
 Deng DM, 4807  
 Deng J-L, 221  
 Deodato F, 465, 4413, 6499  
 Depaoli F, 3543  
 Derner RB, 6799  
 Derosa R, 3543  
 Desmaele D, 1915  
 Dettoraki M, 6885  
 Devidas M, 3147  
 Dewitt JM, 4215  
 Di Domenico S, 4199  
 Di Girolamo M, 3401  
 Di Giuliano F, 939  
 Di Gregorio S, 2457  
 Di Marco M, 465, 597  
 Di Raimondo F, 2457, 5313  
 Di Salvo E, 1443  
 Di Stefano C, 1719  
 Di Tommaso M, 6505  
 Di Tosto F, 1719  
 Diakosavvas M, 6009  
 Diamantis E, 6599  
 Diana P, 4913  
 Dias T, 1041  
 Didonato JA, 6751  
 Dietl A, 3049  
 Díez García De Olalla EV, 5489  
 Digkila A, 1697  
 Dijkstra S, 5319  
 Dimas KS, 5181  
 Dimitrakopoulos F-I, 677  
 Dimitroulis D, 6599  
 Dimtsas GS, 6885  
 Diorio C, 1797, 3619  
 Djurdjevic P, 5001  
 Dlugosz-Danecka M, 4059  
 Dmoszyńska-Graniczka M, 6151  
 Do S-I, 1487, 5777  
 Dobak E, 1973  
 Dobi Á, 4237  
 Docs J, 6525  
 Dofara SG, 3619  
 Doi H, 1981  
 Doi K, 2795  
 Doki Y, 2941, 5301  
 Dolgova EV, 795  
 Doll C, 6987  
 Domínguez-Álvarez E, 4921  
 Dominsky N, 4413  
 Dong J, 5411  
 Donizy P, 1931, 3505  
 Doorenbos AZ, 2409  
 Dörr NM, 1  
 Doulgeraki T, 1669  
 Dragic D, 1797  
 Dług-Zalesińska M, 2613  
 Drobkova H, 6257  
 Dröge LA, 5743  
 Drogosiewicz M, 7095  
 Drozd-Sokolowska J, 4059  
 Dry SM, 2515  
 Duarte R, 6179  
 Dubatolova TD, 795  
 Duc NM, 2975  
 Dudek AZ, 1467, 2821, 3883  
 Dudzinski M, 4059  
 Duncan TJ, 2331, 2989

- Dunston G, 27  
 Duong F, 1459  
 Duran-Moreno J, 1697  
 Durocher F, 1797  
 Dusenka R, 6257  
 Dutra CS, 5509  
 Duzkalir AH, 3265  
 Duzowska K, 4843  
 Dwivedi AK, 857  
 Dworzecki T, 5861  
 Dziegiel P, 5981  
 Dziggel L, 3429, 4081  
 Easler JJ, 4215  
 Ebara T, 2905  
 Eberle F, 1167  
 Eberlova L, 6817  
 Eertwegh DEN, 1201  
 Efremov YR, 795  
 Egger E, 6205  
 Eggers NA, 6637  
 Eggersmann TK, 2117  
 Eguchi H, 4379, 4875, 5301  
 Eguchi S, 2303, 2637, 2881, 5765  
 Eich HT, 3379, 4041  
 Eid Y, 3579  
 Einarsson R, 3967  
 Einkenkel R, 841  
 Eino D, 1677  
 Ekkernkamp A, 841, 3743  
 Ekmann-Gade AW, 2765  
 El Hassouni B, 4913  
 Elander NO, 2757  
 El-Din G, 5025  
 Elefante A, 271  
 Elfgen C, 2125  
 Elli EF, 881  
 Ellinger J, 3119  
 Elsayad K, 3379, 4041  
 El-Sourani N, 2947  
 Enamekhoo H, 1527  
 Emi A, 3395, 3491  
 Emi M, 1153, 4387  
 Emile G, 2955  
 Emoto S, 101, 2199, 2373  
 Enami Y, 3873, 6545  
 Endo H, 5071  
 Endo I, 1587, 2475, 2509, 6733, 6765  
 Endo K, 7141  
 Endo M, 3953  
 Endo S, 2351, 5807  
 Endo T, 957, 5757  
 Endo Y, 5263  
 Endoh H, 261  
 Eneh S, 3713  
 Engelholm SA, 2765  
 Ennour-Idrissi K, 1797  
 Erdogan KO, 5649  
 Ermani M, 5877  
 Esaki T, 4165  
 Escobar HM, 3781  
 Eskelinen Maaret, 6947  
 Eskelinen Matti, 253, 3591, 5701, 6947  
 Espin E, 2079  
 Espinosa-Montesinos A, 6273  
 Esposito MR, 5583  
 Eter N, 4041  
 Eto K, 373, 1891, 3445, 6517  
 Eto M, 335  
 Eto T, 1023  
 Eun Y-G, 191  
 Evans CFM, 1705  
 Evans D, 3915  
 Everaert H, 2265  
 Evin D, 6257  
 Evrard P, 4253  
 Eymard J-C, 3905  
 Eze C, 2319  
 Fáber L, 3191  
 Facchetti A, 1645, 2853  
 Fago-Olsen CL, 2765  
 Fahlbusch FB, 5787  
 Falk M, 3325  
 Fang C-Y, 6907  
 Fang H-Y, 2387, 5895  
 Fang S-Y, 5529  
 Fanti G, 5877  
 Fanucchi A, 2191  
 Faress I, 6029  
 Farias DF, 5049  
 Farmaki P, 6599  
 Farooqi AA, 5641  
 Fasoulakis Z, 6009  
 Fathy M, 2739, 5025  
 Faveyrial A, 2955  
 Feder S, 143  
 Fee AJ, 6075  
 Fei L, 3751  
 Feldhaus FW, 5743  
 Felli F, 619  
 Ferda J, 3459  
 Fernández-Del Castillo C, 3659  
 Ferrari C, 4199  
 Ferrari D, 1719  
 Ferraro M, 1443  
 Ferreira HB, 5509  
 Ferreira R, 6573  
 Ferreira RC, 5049  
 Ferrero AM, 1543  
 Ferrero J-M, 3905  
 Fiala O, 1219  
 Fichtl J, 7045  
 Fichtner-Feigl S, 5679  
 Fikru S, 1513  
 Filipits M, 6229  
 Filippini A, 5379  
 Filippov-Levy N, 6677  
 Fincsur A, 1359  
 Findik D, 5649  
 Finek J, 1219  
 Fiore MR, 1645, 2853  
 Fiori E, 2969, 4223  
 Fischer I, 2151  
 Fischer O, 2209  
 Fisher C, 7003  
 Flasko T, 6525  
 Fleisch M, 2125  
 Fleschutz K, 4937  
 Flick KF, 4215  
 Flieger C, 2185, 2801  
 Flieger R, 2185  
 Flohr T, 3459  
 Focan C, 4253  
 Fodor E, 4237  
 Fontanella RA, 5379  
 Fontes F, 1041  
 Forslund O, 1513  
 Förster F, 3973  
 Förster S, 5489  
 Forte AJ, 1055, 1059, 1065, 3411, 6609  
 Fotopoulou C, 3651  
 Fountzilias G, 677, 929, 2095  
 Fowler N, 4207  
 Frade Silva DK, 5049  
 France D, 6699  
 Franceschi M, 2323  
 Franco R, 4017  
 Fratini C, 2889  
 Fravolini ML, 3355  
 Freedland SJ, 1459  
 Frega G, 3013  
 Fregatti P, 3543  
 Fregni F, 5151  
 Freitas C, 2725  
 Frenel J-S, 3905  
 Friedman D, 3543  
 Friedrich M, 545, 1481  
 Friedrich RE, 3333, 3423  
 Fries JWU, 5539  
 Fröbe A, 2323  
 Frontali A, 3579  
 Fruergaard S, 1475  
 Frühwald MC, 6159  
 Fruzzetti F, 5995  
 Fu C-K, 695  
 Fuegger R, 2151  
 Fuji S, 1117  
 Fujihara A, 5481  
 Fujihara S, 121  
 Fujii A, 3733  
 Fujii H, 299, 2379, 7067  
 Fujii Y, 3361, 5295  
 Fujikawa H, 1683, 2275, 5815  
 Fujikawa M, 2165  
 Fujimori A, 3873, 6545  
 Fujimori K, 5263  
 Fujimoto Y, 2141, 2871, 4147  
 Fujisaki M, 81  
 Fujisawa M, 3519, 4445, 5107  
 Fujise M, 4885  
 Fujishiro M, 665, 2089, 2283  
 Fujita A, 261  
 Fujita F, 4695  
 Fujita H, 2343, 3361  
 Fujita I, 4271  
 Fujita J, 3361  
 Fujita K, 121, 1579, 1677, 2053, 4875  
 Fujita M, 4801  
 Fujita N, 121  
 Fujita T, 4405  
 Fujita Y, 1247  
 Fujitani K, 5807  
 Fujiwara H, 3163  
 Fujiwara M, 201, 1843  
 Fujiwara R, 6493  
 Fujiwara T, 161  
 Fujiwara Y, 293, 5593, 5807  
 Fukahori M, 6429  
 Fukuda K, 1921  
 Fukuda S, 4245  
 Fukui I, 1613, 5295  
 Fukui R, 2141, 2871, 4147  
 Fukumitsu K, 4245

- Fukumoto C, 1247  
 Fukuoka T, 3535, 4157  
 Fukushima Komori M, 2393  
 Fukutomi S, 4695, 4773  
 Fullerton DA, 5361  
 Fulman-Levy H, 3831  
 Fumagalli C, 427  
 Fumet J-D, 4011  
 Fumino S, 6159  
 Funahashi Y, 6699  
 Funauchi Y, 1029, 1035  
 Funayama Y, 957, 5757  
 Furue M, 6221  
 Furugen A, 1747  
 Furukawa K, 957, 293, 5757  
 Furukawa S, 5263  
 Furusawa H, 4779  
 Furuta T, 6319  
 Furutani A, 3371  
 Furuya S, 2311  
 Fushimi C, 5277  
 Gabata R, 5211  
 Gabriel E, 881, 6381  
 Gabriel EM, 1059  
 Gadducci A, 1543, 2191, 2429, 3031, 4819, 5995  
 Gadelha Marques KK, 5015  
 Gajdács M, 4921  
 Gakiopoulou H, 1669  
 Gál P, 3191  
 Galanos A, 2219  
 Galazka P, 1817  
 Galdino Gouveia R, 5049  
 Gallwas JKS, 2117  
 Galvano A, 7083  
 Ganaha A, 3277  
 Gandhi CD, 5989  
 Gangemi S, 1443  
 Gangi G, 1711  
 Gao Y, 5201  
 Garcia Lopes F, 6799  
 Garcia Lopes R, 6799  
 Gargano M, 1467  
 Garlaschi A, 3543  
 Garmpi A, 6599  
 Garmpis N, 3065, 6009, 6599  
 Garofano F, 5489  
 Gaur S, 857  
 Gawlak M, 4425  
 Gebauer J, 5787  
 Gehrchen M, 1475, 5673  
 Geisel D, 387  
 Gelbrich N, 841  
 Gelli R, 6485  
 Genc D, 5641  
 Gennatas S, 7003  
 Genovesi D, 6505  
 Georgakopoulou VE, 6599  
 Georgoulas V, 901  
 Gera R, 315, 1809  
 Gergen AK, 5361  
 Gerlini G, 6485  
 Gersing A, 5793  
 Gerull S, 5909  
 Gharbaran R, 4907  
 Ghiringhelli F, 4011  
 Gholami S, 2895  
 Giakoumakis NN, 2449  
 Giancamilli F, 5583  
 Giani M, 1079  
 Giannakas T, 625  
 Giannikaki E, 1669  
 Giannopoulos K, 4059, 5437, 6327  
 Giannotti V, 6485  
 Gianoncelli L, 427  
 Giarnieri E, 1691  
 Gibson JT, 5445  
 Gingrich AA, 2895  
 Giordano C, 2889  
 Giovagnoli MR, 1691  
 Giovannetti E, 4807, 4913  
 Gipponi M, 3543  
 Gires O, 1277  
 Giri MG, 5901  
 Giulitti D, 619  
 Gkantaifi A, 3003  
 Gkretsi V, 1375  
 Gladieff L, 3939  
 Glas M, 1161  
 Glatz T, 5679  
 Glover O, 3925  
 Go A, 4701  
 Go G, 5611  
 Go H, 4229  
 Go K, 4701  
 Go T, 733, 1007, 4327  
 Göbel H, 5539  
 Godai T, 2337  
 Godoy Poluceno G, 6799  
 Gofrit O, 3967  
 Gogg-Kamerer M, 3109  
 Gogolak J, 1267  
 Goh TS, 3839  
 Golčić M, 2157  
 Goldstein E, 4857  
 Golob-Schwarzl N, 3109  
 Gomulkiewicz A, 5981  
 Goncalves A, 3905  
 Gonçalves Ferreira F, 6573  
 Gonçalves Junior A, 6355  
 Gong C-L, 2011  
 Gong G, 1883, 5883  
 Gong J, 1459  
 Gong JY, 4947  
 Gong Y-X, 3819  
 Gonzalez A, 865  
 Göppert B, 3109  
 Gorden K, 1467  
 Goriki A, 4787  
 Gorunova L, 97, 1239  
 Goto C, 7101  
 Goto K, 1943  
 Goto S, 4729, 4741, 4763  
 Goto T, 6101  
 Goto W, 2343, 3345  
 Goto Y, 4695, 4773  
 Gotoh K, 4875  
 Gouliopoulos N, 6885  
 Graas M-P, 4253  
 Graceffa G, 1711, 7083  
 Grafe A, 3973  
 Grammatoglou X, 6885  
 Granconato L, 4011  
 Grant WB, 491, 501  
 Grassi E, 465  
 Grasso A, 281, 2231, 7119  
 Grazia M, 5583  
 Grebe K, 5679  
 Greenberg O, 6457  
 Gregori A, 4807  
 Gregoriou S, 2219  
 Gregucci F, 6505  
 Greiner JW, 5329  
 Grendar M, 6257  
 Grénman S, 3129  
 Gress TM, 1167  
 Grigorakis A, 709  
 Grinshpon S, 5471  
 Grivas A, 305  
 Grøholt KK, 6979  
 Grønberg BH, 6399  
 Grossi A, 3401  
 Grunwald S, 2185  
 Grützmann R, 2833  
 Grząsko N, 5437  
 Grzyska U, 3333  
 Gu C, 1875  
 Guariglia S, 5901  
 Gubán BK, 6123  
 Guenzle J, 5679  
 Guerini-Rocco E, 427  
 Guerra C, 751  
 Guerrini S, 983  
 Guido A, 465  
 Guidoccio F, 2191  
 Guillari A, 5583  
 Guirguis A, 3307  
 Gulbinas A, 3765  
 Guliyeva G, 6609  
 Gullan RW, 3081, 5427  
 Gumbel D, 841  
 Gundermann P, 1015  
 Gundogar O, 5649  
 Gunji T, 7017  
 Gunzer K, 2955  
 Guo X, 1875  
 Guo Y, 5201  
 Gursky J, 4979  
 Gütth U, 2125  
 Gwak J, 6891  
 Gwerder M, 5909  
 Ha KS, 3801  
 Ha M, 3839, 5601  
 Haag A, 5919  
 Haddad B, 4115  
 Haffty B, 5291  
 Haga N, 4299  
 Hagel C, 3423  
 Hägerstrand H, 5355  
 Hagio K, 645  
 Hagiwara K, 4343  
 Hagura T, 1943  
 Hah Y-S, 2627  
 Hahn M, 2185  
 Hahndorf W, 2185  
 Haidopoulos D, 3651  
 Hainfellner JA, 6229  
 Haino A, 4719  
 Hakozaiki T, 3873, 6545  
 Halama N, 6367, 6933  
 Halka J, 4059  
 Hallböök O, 2757  
 Haller B, 5793  
 Halley A, 4807  
 Hałoń A, 1931, 3505  
 Halpern AL, 5361  
 Halter J, 5909  
 Halvorsen TO, 6399  
 Hama T, 915  
 Hamada J-I, 1307



- Hamada K, 4869, 6083, 6765  
 Hamaguchi R, 873  
 Hamaguchi T, 1071  
 Hamai Y, 1153, 4387  
 Hamaji M, 3287  
 Hamakubo T, 3793  
 Hamamoto T, 4183  
 Hamsikova E, 1597  
 Hamura R, 293  
 Han Q, 2481, 2515, 2813, 4869  
 Han S-H, 177  
 Han SI, 2573  
 Han SY, 2821  
 Han X, 1943  
 Han Y-H, 3819, 4491  
 Han Y-S, 1419  
 Hanai N, 1127  
 Hanaoka M, 1731  
 Hanawa T, 35  
 Hanker LC, 3973  
 Hanks BA, 5245  
 Hans S, 6123  
 Hansen LV, 5673  
 Hanyu K, 5277  
 Hara K, 405, 443, 1087, 1503, 1651, 1683, 2337, 2359, 2365, 4365, 5593, 5815, 6517  
 Hara Y, 35, 3889  
 Harada H, 5687, 5765  
 Harada K, 5211  
 Harada M, 5271, 7109  
 Harada Y, 35, 5687  
 Harada-Takeda A, 2911  
 Haraga J, 3811  
 Haralambiev L, 841, 2591, 3743, 6205  
 Harano M, 335  
 Hardy-Bessard A-C, 3939  
 Harikrishnan A, 1915  
 Harimoto N, 4343  
 Haroutounian S, 2025  
 Harris LJ, 5423  
 Harrison B, 1467  
 Hartikainen JM, 3713  
 Haruki K, 293, 1891  
 Haruma T, 3811  
 Hasegawa H, 2165, 6539  
 Hasegawa S, 335, 4655, 4663, 4763  
 Hasegawa T, 1247, 4319  
 Hashiguchi Y, 4687  
 Hashimoto A, 3361  
 Hashimoto D, 1023  
 Hashimoto I, 405, 1087, 2359, 5815  
 Hashimoto K, 4795, 5939  
 Hashimoto M, 4885, 6551  
 Hashimoto S, 2787, 4471  
 Hashimoto T, 1637  
 Hashimoto Y, 4655  
 Hass P, 4281  
 Hassan HMA, 4547  
 Hata J, 4299  
 Hata K, 101, 2199, 2373  
 Hatanaka KC, 645  
 Hatanaka Y, 645  
 Hatano K, 1677, 2053, 4875  
 Hatanpaa KJ, 3453  
 Hatoum H, 847  
 Hattori C, 6443  
 Hattori N, 201, 6713  
 Haus R, 287, 367  
 Hauser S, 3119  
 Haverkamp U, 3379, 4041  
 Hawkins A, 3669  
 Hayakawa A, 4701  
 Hayakawa K, 1029, 1035  
 Hayami S, 4033, 4123  
 Hayashi H, 2795  
 Hayashi I, 813  
 Hayashi K, 379, 2515, 3551, 6563, 7009  
 Hayashi M, 201, 1843, 6665, 6713  
 Hayashi N, 6473  
 Hayashi S, 957, 5237, 5757  
 Hayashi T, 1255, 1503, 1683, 1943, 2275, 4067, 4787  
 Hayashi Y, 4875  
 Hayashihara K, 957, 5757  
 Haybaeck J, 3109  
 Hazboun A, 2231  
 He S, 635  
 Heeney J, 3915  
 Hegenscheid K, 2185  
 Heianna J, 3565  
 Heidegger I, 2861  
 Heidenreich A, 5539  
 Heikkinen S, 3713  
 Heiland M, 6987  
 Heim D, 5909  
 Heim S, 97, 1239, 6115  
 Heinze C, 4281  
 Heinze S, 2925  
 Heinzerling L, 4937  
 Hejtmankova A, 1597  
 Henckes NAC, 5151  
 Hendolin P, 6387  
 Heng G, 1651, 4365  
 Henne-Bruns D, 5545  
 Hennequin A, 4011  
 Henson B, 751  
 Heo HJ, 3839, 5601  
 Herceg D, 2157  
 Hernandez S, 6853  
 Herrera G, 6853  
 Hervonen P, 6915  
 Hesse T, 3973  
 Heudel P, 3905  
 Heudel P-E, 3939  
 Heyd B, 3579  
 Heydarian R, 857  
 Hideghéty K, 4237, 6123  
 Higashi T, 1963, 5159  
 Higashida M, 5807  
 Higashijima J, 239  
 Higashino N, 2165  
 Higuchi T, 2141, 2475, 2509, 2515, 2871, 3559, 4147, 5393, 6563  
 Hikichi T, 6551  
 Hikita K, 7017  
 Hilal A, 1437  
 Hino H, 1731  
 Hino S, 3685  
 Hirabayashi M, 2981, 7141  
 Hirabayashi S, 201  
 Hirai R, 3513  
 Hirai T, 2981, 3873, 5043, 6545, 7141  
 Hirakawa H, 3277  
 Hirakawa K, 2343, 3345, 3535, 4157  
 Hiraki T, 75  
 Hiraku Y, 5399  
 Hirano F, 6101  
 Hirano H, 1071, 4319  
 Hirano K, 7141  
 Hirano S, 813  
 Hirano Y, 1651, 4365  
 Hirasawa T, 6791  
 Hirashima T, 2787, 3931, 4229, 6971  
 Hirata M, 3889  
 Hirata T, 1677, 2053, 6957  
 Hirata Y, 2199  
 Hirohashi Y, 4319  
 Hirohata R, 4387  
 Hirono S, 4033, 4123  
 Hirose Y, 1315  
 Hiroshima Y, 5815, 6407  
 Hirota S, 2141  
 Hirsch HH, 5909  
 Hisada T, 1571, 4695, 4749, 4773  
 Hitschold T, 3973  
 Hives M, 6257  
 Hiyoshi M, 101  
 Hizawa N, 413, 957, 421, 5757  
 Ho L, 5245  
 Hoch S, 6195  
 Hoepfner J, 5679  
 Hoffman RM, 473, 635, 2475, 2481, 2509, 2515, 2813, 3091, 3873, 4869, 4969, 5393, 6083, 6765  
 Hoffmann M, 2319  
 Hofheinz R, 4137  
 Hofmann S, 3831  
 Hofmeister C, 5707  
 Hogdall CK, 2765  
 Hohnneck A, 4137  
 Hokuto D, 1107  
 Holgersson G, 3897  
 Holick MF, 501, 535, 551, 565, 719  
 Holland C, 789  
 Holm-Schou A-SS, 557  
 Holojda J, 4059  
 Holopainen A, 253  
 Holzhauser S, 53  
 Holzmann D, 891  
 Honda K, 2247  
 Honda T, 665, 2089, 2283, 4681  
 Hong DG, 451  
 Hong J, 357, 2917  
 Hong M, 5777  
 Hong S, 1771, 2409  
 Hong S-E, 1387  
 Hongo A, 2509  
 Honig RL, 6941  
 Honjo S, 5593  
 Honma R, 6551  
 Honma Y, 1071  
 Honorato Lisboa TM, 5049  
 Hori A, 7101  
 Hori H, 4675  
 Hori Y, 3571

- Horie N, 3685  
Horie S, 1345  
Horiguchi H, 6171  
Horii A, 3793  
Horiike A, 5577  
Horimoto Y, 4405  
Horninger W, 2861  
Hošek P, 3459, 6817  
Hoshi K, 87, 3793  
Hoshi S, 4299  
Hoshino K, 4343  
Hoshino R, 1739  
Hoskin DW, 689  
Hosoi H, 6159  
Hosomura N, 2311  
Hou M-F, 5529  
Houdek MT, 1463, 2751, 5735, 6941  
Howard LE, 1459  
Howell SB, 6017  
Hozumi C, 2475, 2481, 2509  
Hrab I, 2955  
Hrczkova Drozdkova D, 4979  
Hrnciarik M, 2209  
Hsia N-Y, 703, 4523  
Hsia T-C, 5895  
Hsiao C-H, 3865, 5221, 6093  
Hsiao Y-C, 1297  
Hsieh C-Y, 5895  
Hsieh H-H, 1631  
Hsieh T-C, 1175, 2387  
Hsieh Y, 5517  
Hsu C-L, 3707  
Hsu C-Y, 2995  
Hsu F-T, 6723  
Hsu J-L, 6345  
Hsu P-C, 4465  
Hsu Y-M, 4523  
Hsu Y-N, 4465  
Hu B, 245  
Hu JB, 5245  
Hu J-C, 4075  
Hu Q, 2941, 3733  
Hu R, 1855  
Hua C-H, 1631  
Huang C-H, 1175  
Huang C-I, 6265  
Huang C-P, 2715  
Huang C-W, 5529  
Huang F-M, 4513, 5059  
Huang H-Y, 6907  
Huang J, 635, 4969  
Huang L-H, 2995  
Huang P, 7003  
Huang T-L, 703  
Huang W, 245  
Huang W-L, 6305  
Huang Y-C, 6723  
Huayllani MT, 1055, 1059, 1065, 3411, 6609  
Huber L, 825, 3847, 5621, 6195  
Huber RM, 1451  
Huellner M, 891  
Huffman D, 6003  
Huh JH, 6137  
Hui DD, 751  
Hung J-H, 4947  
Hung P-S, 1427  
Hung S-C, 4075  
Hung Y-C, 1297  
Hur W, 2033  
Hurdalkova K, 2209  
Hurley PJ, 1467  
Hus M, 4059, 5437, 6327  
Huttunen T, 6915  
Huy HQ, 2975  
Hwa JS, 2627  
Hwang J-J, 695  
Hyun CL, 4309  
Hyun JW, 3819, 4491  
Iannalfi A, 1645, 2853  
Ibad A, 27  
Ibe H, 4729  
Ibrahim A, 2179  
Ibuki Y, 1153, 4387  
Ichikawa D, 2311  
Ichikawa Y, 6733  
Ichiki T, 6221  
Ichimura H, 957, 5757  
Ichimura T, 1255  
Ichise E, 6159  
Ida S, 3559  
Ide H, 1345  
Idorn LW, 557  
Iehara T, 6159  
Igarashi K, 2515, 3551, 6563, 7009  
Igarashi T, 4343  
Igarashi Y, 4173  
Igari M, 3513  
Igawa T, 1739, 6443  
Iguchi K, 1587, 5757  
Iguchi T, 2297, 2941, 4165  
Ihara K, 1637  
Ihm S-H, 6137  
Ii H, 5035  
Iida S, 2393  
Iida T, 2373  
Iihara H, 299, 2379, 7067  
Iijima K, 4405  
Iijima M, 2291  
Iijima Y, 3685, 4885  
Iizasa H, 1307  
Iizuka A, 6473  
Ijichi H, 3315  
Ijzermans JNM, 5343  
Ikebe M, 2297, 4165  
Ikeda K, 4505, 4787, 4895  
Ikegaki S, 7141  
Ikegami T, 3277, 6517  
Ikehara Y, 6781  
Ikemoto T, 743  
Ikemura K, 5399  
Ikenaga M, 2351, 5807  
Ikeura T, 3571  
Iki R, 7141  
Ikoma H, 3163  
Ilhan-Mutlu A, 965  
Iliadis G, 3003  
Ilie S, 3905  
Illuminati G, 2889  
Im HJ, 7057  
Imai H, 261, 1571  
Imai J-I, 6551  
Imai K, 2795, 5715  
Imai M, 5399  
Imai R, 6429  
Imai T, 7067  
Imaizumi K, 261  
Imaizumi Y, 1891  
Imakita T, 7141  
Imamura F, 4229, 6957  
Imamura M, 2141, 2871, 4147  
Imamura N, 2911  
Imamura R, 1677, 2053  
Imano N, 4183  
Imazu H, 4445  
Improta G, 271  
Imura S, 743  
Inaba R, 3519  
Inagaki M, 957, 5757  
Inagawa H, 4457, 4681, 4711, 4719, 4755  
Inage Y, 957, 5757  
Inaniwa T, 6429  
Ines Tasca C, 6799  
Innamaa A, 5869  
Innao V, 1443  
Inokawa Y, 6665, 6713  
Inomata M, 2239  
Inoue E, 6781  
Inoue N, 2141  
Inoue S, 1943, 2311, 4787  
Inoue T, 393, 1613, 4229, 6957  
Inozume T, 4663  
Insodaite R, 2003  
Intuyod K, 6899  
Inubushi S, 2475, 2481, 2509, 3091, 6765  
Inui S, 4095  
Ioannidis G, 901  
Ippolito E, 6499  
Irace L, 4223  
Irie H, 6551  
Isa S-I, 4229  
Isaacs R, 5229  
Isbir T, 3265  
Iseki K, 1747  
Iseki Y, 3535, 4157  
Ishi M, 923  
Ishibashi K, 4379  
Ishibashi Y, 7109  
Ishida H, 4379  
Ishida K, 6517  
Ishida N, 645  
Ishida S, 2019  
Ishigami M, 665, 2089, 2283  
Ishigami S, 75  
Ishihara S, 101, 2199, 2373, 6221  
Ishihara T, 299, 2379  
Ishii A, 5107  
Ishii H, 2373  
Ishii N, 4343  
Ishii T, 1651, 4365  
Ishijima K, 2019  
Ishikawa D, 239  
Ishikawa H, 957, 999, 5757  
Ishikawa M, 4707  
Ishikawa T, 2089, 2283, 4719, 6733  
Ishikura S, 4663  
Ishimoto H, 6791  
Ishino K, 5631  
Ishitake T, 6443  
Ishitsuka K, 4471  
Ishizu Y, 665, 2089, 2283  
Ishizuka M, 3571  
Ishizuka T, 5577

- Ishizuka Y, 4405  
 Ishizuya Y, 4875  
 Iskierka-Jazdzewska E, 4059  
 Iso Y, 3983  
 Isono M, 4095  
 Itai S, 4291  
 Itami J, 1071  
 Itazaki Y, 7109  
 Ito D, 3445  
 Ito H, 1683, 6407  
 Ito I, 6473  
 Ito N, 7109  
 Ito R, 6517  
 Ito S, 3733  
 Ito T, 665, 1101, 2089, 2283, 4395  
 Ito Y, 915, 1071, 4245, 4471, 6221, 6585, 6781  
 Itoh M, 3155  
 Itoh Y, 3953  
 Itzkovich D, 3967  
 Ivančová E, 3191  
 Iwahasi S, 743  
 Iwai K, 3953  
 Iwama H, 121  
 Iwamoto H, 1141, 2291, 4087, 4291  
 Iwamura M, 3371  
 Iwanaga R, 1637  
 Iwasa S, 1071  
 Iwasaki K, 2827  
 Iwasaki T, 759, 6221  
 Iwase Y, 2549  
 Iwata T, 2303  
 Izumi K, 1141, 2291, 4087, 4291  
 Izumo T, 2239  
 Jabbarli R, 1161  
 Jacobs D, 6375  
 Jacobsen A-B, 6979  
 Jacobsen KA, 6399  
 Jahagirdar BN, 2821  
 Jain AL, 5423  
 Jakobsen A, 5255  
 Jakovčević D, 2323  
 Jakubikova L, 2209  
 Jalil A, 6003  
 Jamjitrong S, 3469  
 Jamroziak K, 4059  
 Jan I, 5291  
 Jang BG, 4309  
 Jang H-B, 6295  
 Jang K, 2961  
 Jang K-J, 1905, 3209, 5191  
 Jang MK, 2409  
 Jang SJ, 109, 7057  
 Jang S-K, 1387  
 Jang SM, 3203  
 Janjetovic Z, 2467  
 Janssen S, 287, 367, 2257, 2261, 2271, 2847, 5787  
 Jayakrishnan T, 5727, 5919  
 Jekunen A, 6915  
 Jelski W, 1997, 3857  
 Jendelova P, 5989  
 Jeng L-B, 1285  
 Jeon BH, 3435  
 Jeong B-H, 3435  
 Jeong HG, 4929  
 Jeong JY, 4001, 5463  
 Jeong K-Y, 1989  
 Jeong S-H, 3203  
 Jeong SM, 6891  
 Jeong W, 5463  
 Jerkeman M, 1513  
 Jeschke U, 2117  
 Jevtic V, 5001  
 Jha G, 1467  
 Jhanwar-Uniyal M, 5989  
 Jia JB, 5371  
 Jiang J, 245  
 Jiang P, 1123  
 Jiang R, 6375  
 Jimbo N, 3519  
 Jiménez A, 6273  
 Jin H-O, 1387  
 Jin M-H, 3819, 4491  
 Jin Y-H, 3819, 4491  
 Jingu K, 393, 2065  
 Jirousek M, 2209  
 Jitjaicham C, 4989  
 Jitrapakdee S, 4557, 6285  
 Jo ES, 1905, 3209, 5191  
 Jo S-Y, 109  
 Jo T, 2239, 5229  
 Johan MP, 6319  
 Johann PD, 6159  
 Johns AJ, 2895  
 Johnson A, 2955  
 Johnson J, 5707  
 Johnson JD, 5735  
 Jöhrens K, 6987  
 Jomrich G, 965  
 Jones RL, 7003  
 Jonsson G, 5853  
 Joo I, 4191  
 Jordan HR, 9  
 Jorgensen MS, 881  
 Ju M, 4067  
 Judson BL, 6375  
 Jukić T, 2323  
 Jun J, 6017  
 Jun KH, 4537  
 Jun S, 2601  
 Jung JH, 1779  
 Jung KH, 5883  
 Jung S-H, 5245  
 Jung Y, 323  
 Jungbauer F, 825, 5621  
 Junghanss C, 3781  
 Jurczak W, 4059  
 Jurecekova J, 6257  
 Kaaronen V, 253, 5701  
 Kabesova M, 349  
 Kaburagi T, 957, 5757  
 Kaczorowski M, 1931  
 Kaderali L, 3743  
 Kadomoto S, 1141, 4087  
 Kadono Y, 1141, 2291, 4087  
 Kadouri L, 6417  
 Kadowaki S, 2247  
 Kadoya T, 3395, 3491  
 Kafka M, 2861  
 Kagamu H, 3513, 5309  
 Kagara N, 6437  
 Kagawa H, 1731  
 Kagawa M, 2297  
 Kagawa Y, 4245  
 Kageyama K, 2637  
 Kageyama Y, 5295  
 Kai N, 2053  
 Kai Y, 2073, 2567, 4779  
 Kaibori M, 3571  
 Kaida D, 3361  
 Kaida T, 2795  
 Kaira K, 261, 1571, 3513, 5309  
 Kajitani R, 4763  
 Kajiwara M, 4787  
 Kajiyama H, 2497  
 Kakeji Y, 2165, 6539  
 Kakinuma D, 4271  
 Kaku S, 7141  
 Kakuda Y, 1619  
 Kakuwara H, 393, 2065  
 Kakuno A, 991  
 Kalajian TA, 535, 551  
 Kalbacher E, 3939  
 Kalinterakis G, 3065  
 Kalli M, 1375  
 Kallioniemi A, 3129  
 Kalofonos C, 305  
 Kalogera-Fountzila A, 677, 2095  
 Kamada H, 121  
 Kamada M, 4895  
 Kamada Y, 4779  
 Kamide Y, 1571  
 Kamigaki T, 4729, 4741, 4763  
 Kamimaki C, 3889  
 Kamimura G, 2911  
 Kaminuma T, 459  
 Kamio H, 4567  
 Kamio T, 4567  
 Kamitani N, 1107  
 Kamiya A, 3571  
 Kamiyama K, 957, 5757  
 Kamiyoshihara M, 261  
 Kamo N, 5263  
 Kamonvarapitak T, 3469  
 Kämpe TA, 1551  
 Kamphues C, 5457  
 Kanaan Y, 27  
 Kanaan YM, 6623  
 Kanai S, 35  
 Kanai T, 2787, 3931, 6971  
 Kanai Y, 1255  
 Kanaji S, 2165, 6539  
 Kanao H, 5285  
 Kanao K, 4395  
 Kanaseki T, 4319  
 Kanayama N, 6957  
 Kanazawa S, 4419  
 Kanazawa Y, 4271  
 Kanda M, 201, 1843, 6665, 6713  
 Kanda T, 4445  
 Kandimalla R, 6665  
 Kandulski A, 143  
 Kaneda T, 2981  
 Kaneko M, 101, 2199, 2373  
 Kaneko T, 3685, 3889  
 Kaneko Y, 5237  
 Kanellou A, 2449  
 Kanematsu A, 6473  
 Kanematsu N, 6429  
 Kanemitsu Y, 4245  
 Kaneshima I, 3565  
 Kanetaka K, 2303  
 Kang B-H, 2171  
 Kang CH, 4929

- Kang DY, 1905, 3209, 5191  
 Kang J, 5601  
 Kang JG, 6137  
 Kang JM, 5601  
 Kang JW, 5601  
 Kang MH, 3801  
 Kang MS, 3297  
 Kang S-B, 2171, 4481  
 Kang SH, 7057  
 Kangboonruang K, 2645  
 Kanitakis J, 2695  
 Kanno H, 4271, 4567  
 Kanno-Okada H, 645  
 Kano K, 405, 443, 1087,  
 1683, 2275, 2359, 2365,  
 4067, 5815  
 Kanou S, 5171  
 Kapali M, 4401  
 Kapanci B, 5319  
 Kaplan P, 6257  
 Karatayli E, 527  
 Karathanou A, 6885  
 Karavokyros I, 3065  
 Karayannopoulou G, 2695  
 Karbo T, 5673  
 Karczmarczyk A, 5437, 6327  
 Kariatsumari K, 2911  
 Karimi AM, 951  
 Karimi D, 1475  
 Karin M, 2319  
 Kariya S, 2393  
 Kärkkäinen J, 5701  
 Karla T, 1325  
 Karlson B-M, 2771  
 Karoui M, 3579  
 Karp M, 6327  
 Karsch L, 6123  
 Kasahara N, 1571  
 Kasap M, 3169  
 Kase S, 2019  
 Kasem I, 3633  
 Kashihara H, 239  
 Kashiwabara K, 1117  
 Kashiwagi S, 2343, 3345,  
 4047, 4157  
 Käsman L, 2319  
 Katagiri H, 1619  
 Kataja V, 6915  
 Katakura S, 3889  
 Kataoka Y, 7141  
 Kato I, 6845  
 Kato K, 121, 1071, 2247  
 Kato S, 1731, 3513, 4271  
 Kato T, 1651, 4875, 6551  
 Katoh T, 3371, 6791  
 Katsougkri D, 6769  
 Katsui K, 393  
 Katsumata K, 2275, 2827  
 Katsumi Y, 6159  
 Katsutoshi S, 2311  
 Kattner L, 519  
 Kauffmann-Guerrero D, 1451  
 Kaur P, 751  
 Kautio A-L, 6915  
 Kavoura E, 1669  
 Kawachi H, 6957  
 Kawachi K, 2133  
 Kawachi S, 7017  
 Kawada J, 5807  
 Kawaguchi H, 3091, 6465  
 Kawaguchi K, 2515, 4869,  
 5393, 6221  
 Kawaguchi S, 2291  
 Kawaguchi T, 7089  
 Kawaguchi Y, 2311  
 Kawahara D, 4183  
 Kawahara K, 2787, 6971  
 Kawahara M, 2905  
 Kawai K, 101, 2199, 2373  
 Kawai M, 4033, 4123  
 Kawaida H, 2311  
 Kawakami K, 915  
 Kawakatsu K, 4707  
 Kawakita Y, 5715  
 Kawakubo H, 1921  
 Kawamata H, 1247  
 Kawamata R, 2701  
 Kawamura H, 2905  
 Kawanishi S, 5399  
 Kawano K, 3371  
 Kawano Y, 3271  
 Kawasaki K, 4875  
 Kawashima A, 4875  
 Kawashima H, 665  
 Kawashima M, 459  
 Kawashima O, 261  
 Kawasumi H, 2787, 6971  
 Kawecka M, 6685  
 Kazama K, 405, 443, 1087,  
 2337, 2359, 2365  
 Kazimierczak U, 3723  
 Kazokaite M, 3765  
 Kebir S, 1161  
 Keikes L, 4331  
 Kellokumpu-Lehtinen P-L,  
 6915  
 Kensaku A, 7009  
 Kersting S, 2833  
 Keserci B, 2975  
 Keshavarz S, 5427  
 Keski-Nisula L, 6923  
 Keta O, 5001  
 Khachonkham S, 2645  
 Khalili M, 4857  
 Khamwachirapithak P, 6285  
 Khanna N, 5909  
 Khanna S, 1915  
 Khayat AS, 6355  
 Khoa MT, 2261, 2271, 2847  
 Khraiwesh M, 27  
 Kida K, 6733  
 Kidogami S, 2941  
 Kiefl R, 1451  
 Kihara K, 5593  
 Kijima T, 75  
 Kijima Y, 5739  
 Kikkawa F, 2497  
 Kikuchi N, 957, 5757  
 Kim B, 1953, 3239, 6891  
 Kim B-H, 4481  
 Kim CH, 2537  
 Kim CK, 723  
 Kim CS, 779  
 Kim D, 1395, 1855, 5883  
 Kim DC, 3203  
 Kim DH, 1335, 1905, 3209,  
 5191  
 Kim D-H, 1487, 3297  
 Kim DJ, 341  
 Kim DK, 779  
 Kim DS, 3247  
 Kim D-W, 4481  
 Kim DY, 7057  
 Kim EY, 4537  
 Kim G, 5081  
 Kim G-B, 1897  
 Kim GH, 3839  
 Kim H, 2537, 7057  
 Kim H-A, 1387  
 Kim H-B, 1897  
 Kim H-C, 4191  
 Kim H-H, 5883  
 Kim HJ, 1419, 1779  
 Kim H-J, 779, 5463  
 Kim HK, 3435  
 Kim HM, 1989  
 Kim H-R, 2537  
 Kim H-S, 1487, 2933, 3477,  
 5777, 5925  
 Kim HS, 5371  
 Kim I, 357, 2917  
 Kim J, 3435, 3819  
 Kim JE, 5883  
 Kim JH, 1335  
 Kim J-H, 3435  
 Kim JM, 451  
 Kim JN, 4529  
 Kim JP, 2627  
 Kim J-S, 779, 2171  
 Kim J-Y, 6295  
 Kim M, 3203  
 Kim MB, 2481  
 Kim M-R, 1387  
 Kim MS, 5081  
 Kim S, 2707, 2917, 3435  
 Kim S-B, 5883  
 Kim S-H, 3297  
 Kim SH, 6137  
 Kim SJ, 5777, 6437  
 Kim SK, 3435  
 Kim SW, 1953, 2601, 3239  
 Kim S-W, 5777, 5925  
 Kim SY, 2537, 2627  
 Kim T-H, 213, 779  
 Kim TH, 4529  
 Kim TJ, 341  
 Kim T-K, 2467  
 Kim W, 341  
 Kim WH, 1779  
 Kim WJ, 6017  
 Kim WW, 1779  
 Kim WY, 3801  
 Kim Y, 2961, 5601  
 Kim YH, 2981, 3839, 5601  
 Kim YJ, 4191  
 Kim YW, 5777  
 Kimata Y, 2393  
 Kimura H, 2515  
 Kimura K, 2637, 2881, 5211  
 Kimura M, 957, 1605, 6957,  
 7135  
 Kimura T, 2393, 4183, 5939  
 Kimura Y, 3395, 3491, 5815  
 Kin R, 3361  
 Kinami S, 3361  
 King A, 3081  
 Kinghorn AD, 6637  
 Kinjyo H, 3277  
 Kinjyo Y, 4105  
 Kinoshita I, 6221  
 Kinoshita K, 5823, 6465  
 Kinoshita T, 4327

- Kinugasa T, 4663  
 Kioi M, 6845  
 Kirane AR, 2895  
 Kirikovich SS, 795  
 Kis D, 4237  
 Kisaretova PE, 795  
 Kishi Y, 6171, 7109  
 Kishimoto S, 4471  
 Kiss I, 1359  
 Kita Y, 733  
 Kitagawa A, 3733  
 Kitagawa K, 5107  
 Kitagawa T, 373  
 Kitagawa Y, 1307, 1921  
 Kitahara H, 5659  
 Kitahata Y, 4033, 4123  
 Kitaichi K, 7101  
 Kitamura Y, 5399  
 Kitanaka C, 4961  
 Kitanaka S, 6237  
 Kitano Y, 1023  
 Kitao A, 5211  
 Kitao H, 5659  
 Kitayama Y, 3091  
 Kitazono S, 5577  
 Kiura K, 4419  
 Kiyoshima M, 957, 5757  
 Kiyotani K, 4875  
 Kiyuna A, 3277  
 Kiyuna T, 2515  
 Kjaer TW, 3429, 3499, 3961, 6513  
 Klausner JM, 6457  
 Klein F, 387  
 Klekner A, 1759  
 Kletschkus K, 2591  
 Kliment J, 6257  
 Klinkmann G, 2591  
 Klintrup K, 6915  
 Klopotowska D, 837  
 Klozar J, 1597  
 Kmetova Sivonova M, 6257  
 Knebel C, 1519, 5793  
 Knippschild U, 5545  
 Knopinska-Posluszny W, 4059  
 Knuettel M, 5621  
 Knuutila S, 1325  
 Ko AH, 3995  
 Ko C-J, 5529  
 Ko DS, 5601  
 Ko GH, 3203  
 Ko Y, 5601  
 Kobara H, 121  
 Kobayashi D, 201, 1843  
 Kobayashi E, 5939  
 Kobayashi J-I, 4319  
 Kobayashi Kazuo, 915  
 Kobayashi Kokoro, 915  
 Kobayashi Kunihiko 5309  
 Kobayashi M, 393, 1747  
 Kobayashi N, 3513, 3889  
 Kobayashi R, 4123, 7067  
 Kobayashi T, 7017  
 Kobayashi R, 4033  
 Kobuchi S, 6585, 6781  
 Kobunai T, 101  
 Kocmond K, 6229  
 Kodama M, 5939  
 Kodama S, 4763  
 Kodama T, 413, 657, 421, 5757  
 Koder Y, 201, 1843, 6665, 6713  
 Köditz B, 5539  
 Kodiyan J, 3307  
 Koenigsberg C, 5417  
 Koerdt S, 6987  
 Koga C, 3315  
 Kogan V, 3831  
 Koguchi T, 4299  
 Kogure Y, 261  
 Koh HH, 3477  
 Koh HK, 1771  
 Koh HM, 3203, 4309  
 Koh K-N, 7057  
 Koh Y, 357, 1395, 1867, 2917, 4875  
 Kohada Y, 4787  
 Kohagura K, 2133  
 Kohashi K, 759, 6221  
 Kohchi C, 4457, 4681, 4711  
 Kohlmann T, 2185, 2801  
 Kohlrusch FK, 3333, 3423  
 Kohlway A, 6229  
 Kohno M, 5659  
 Kohno R, 6429  
 Kohtz PD, 5361  
 Koike H, 5091  
 Koike M, 201, 1843, 6665, 6713  
 Koizumi T, 3873, 6545  
 Kojima F, 4123  
 Kojima S, 4749  
 Kojima T, 1731  
 Kojima Y, 4299  
 Kojs Z, 2925  
 Kokkali S, 1697  
 Kokki H, 253  
 Kokki M, 253  
 Kokkinakis M, 2025  
 Kokkola A, 1325  
 Kolář M, 3191  
 Kolar Z, 4979  
 Kolenda T, 3723  
 Koliou G-A, 929, 2095, 677  
 Kolnsberg L, 545, 1481  
 Komai Y, 6493  
 Koman I, 3831  
 Komatsu H, 2941  
 Komatsu M, 3793  
 Komatsu N, 3793  
 Komeda H, 7101  
 Komiyama Y, 1247  
 Komohara Y, 2795, 5823, 6465, 7147  
 Komono A, 4763  
 Komori K, 443, 1087, 1683, 2275, 2359, 2365, 4067  
 Kondo H, 1651, 4365  
 Kondo K, 1875  
 Kondo R, 4105  
 Kondo S, 3277  
 Kondo T, 5277  
 Kondo Y, 2687, 6493  
 Kondou R, 6473  
 Kong L-Z, 4491  
 Kong MX, 4401  
 Kong W, 3781  
 Konishi E, 6159  
 Konishi H, 3163  
 Konishi I, 1255  
 Konishi K, 6957  
 Konno N, 6551  
 Kono H, 2311  
 Kono M, 2297  
 Kontomanolis E, 3065  
 Kontomanolis EN, 6009  
 Kontzoglou K, 6599  
 Koo T, 1771  
 Koontongkaew S, 2657  
 Koopman M, 4331  
 Koricanac L, 5001  
 Kormunda S, 7045  
 Kornmann M, 5545  
 Korpysz M, 5437, 6327  
 Korshunova AY, 1437  
 Kosai K, 3733  
 Kosaka T, 1587, 3361  
 Koskas M, 1563  
 Kosma V-M, 3713, 6923  
 Kosmidis P, 435, 2095  
 Kosmidis PA, 677  
 Kostolomov I, 97  
 Kostopoulou ON, 53  
 Kostun J, 3527  
 Kosuga T, 3163  
 Kosuge M, 3445  
 Kotarska M, 6685  
 Kothari N, 5291  
 Kotnik N, 2947  
 Kotoh K, 5271  
 Kotowski K, 2613  
 Kotsakis A, 435  
 Koufopoulos N, 1697  
 Kouhashi R, 2343, 3345  
 Kouji H, 5211  
 Koumakis G, 305  
 Koumariou A, 1697  
 Koumori K, 405  
 Kouretas D, 2025  
 Kousidou O, 435  
 Koutras A, 3065, 6009  
 Koutsilieris M, 709, 6213  
 Kouzu K, 7109  
 Kovacs G, 3485, 6525, 6863  
 Kowal N, 5291  
 Kowalczyk D, 3723  
 Koyama F, 1107  
 Koyfman S, 4207  
 Kozłowski MD, 3857  
 Kraft C, 1481  
 Kraft M, 2079  
 Kramer A, 2591, 3743  
 Kramer B, 825, 3847, 5621, 6195  
 Krautz C, 2833  
 Krejci D, 2209  
 Krejci J, 2209  
 Krilić D, 2323  
 Kristiansen G, 3119  
 Krivak T, 6003  
 Kriz J, 3379  
 Król SK, 6151  
 Krušlin B, 2323  
 Kuba S, 2303  
 Kubo H, 3163  
 Kubo K, 4183  
 Kubo N, 4343  
 Kubo S, 2637, 2881, 3889  
 Kubo T, 1307, 4319, 6319  
 Kubota H, 5043, 5807

- Kubota K, 3983  
 Kubota T, 3163  
 Kubota Y, 459  
 Kubota-Koketsu R, 5237  
 Kucera R, 1219, 3527, 7045  
 Kudaka W, 3565  
 Kudo M, 3889, 5631  
 Kudo S, 2905  
 Kuge H, 1107  
 Kuh HJ, 723  
 Kuhara H, 6957  
 Kuhn W, 1481  
 Kuittinen T, 3129  
 Kukar M, 6381  
 Kulbacka J, 2613  
 Kulemann B, 5679  
 Kultan J, 2209  
 Kumagai T, 4229, 6957  
 Kumamoto T, 1891, 3445  
 Kumar A, 6817  
 Kumar B, 2331  
 Kumazaki Y, 3513  
 Kumazu Y, 1503  
 Kumbrink J, 2117  
 Kumiega B, 4059  
 Kunihisa T, 3091  
 Kunimasa K, 4229, 6957  
 Kunisaki C, 1587  
 Kunishige T, 1367  
 Kuo C-C, 4465, 5751  
 Kuo C-D, 2675  
 Kuopio T, 3713  
 Kuosmanen V, 253, 5701  
 Kuraoka K, 1943  
 Kurebayashi J, 2475  
 Kuribayashi N, 1247  
 Kurihara E, 2667  
 Kurihima K, 957  
 Kurishima K, 5757  
 Kuriu Y, 3163  
 Kuroda D, 1023  
 Kuroda K, 4445  
 Kuroda Y, 2941  
 Kuroiwa K, 335  
 Kurokawa M, 2373  
 Kurokawa T, 4387  
 Kuromatsu R, 4105  
 Kurose H, 1739, 6443  
 Kusano H, 4105  
 Kusano T, 3873, 6545  
 Kuse N, 2239  
 Kushibe K, 7089  
 Kuvendjiska J, 5679  
 Kuwahara Y, 6159  
 Kuwata G, 4505  
 Kuzuya T, 665, 2089, 2283  
 Kwabi-Addo B, 2559  
 Kwon EJ, 5601  
 Kwon H-J, 3435  
 Kwon J, 4491  
 Kwon JH, 4351  
 Kwon S-C, 4529  
 Kwon T, 3819, 4491  
 Kyrgias G, 3003  
 Kyriakopoulos CE, 1527  
 Kyriakos G, 6599  
 Kyrodimos E, 807, 3759  
 La Russa M-C, 2989  
 Laczmanska I, 5667  
 Laczmanski L, 5667  
 Lagoudaki E, 901  
 Lahat G, 6457  
 Lahti L, 1325  
 Lai EW, 6229  
 Lai H-C, 1285  
 Lai J, 1123, 2225, 4029, 4401, 5411, 7053  
 Lai K-C, 6869  
 Lakkis Z, 3579  
 Lakshmi B, 1915  
 Lallinger V, 5793  
 Lamacchia F, 939, 1719  
 Lamazza A, 2969, 4223  
 Lambertini M, 3543  
 Lammert A, 825, 5621, 6195  
 Lammert F, 527  
 Lampropoulou DI, 929  
 Lan Y-Y, 3255  
 Landoni F, 1543  
 Langit MB, 3551, 6563  
 Laszik Z, 3995  
 Latteri M, 1711, 7083  
 Lattrich CR, 3973  
 Laurila M, 3129  
 Lawicki S, 3221  
 Lawrence P, 5427  
 Lazarova D, 5159  
 Le B, 751  
 Lech-Maranda E, 4059  
 Łęcka M, 6531  
 Lecomte T, 3579  
 Lee A, 109  
 Lee B, 109  
 Lee BS, 5081  
 Lee C-H, 109  
 Lee C-J, 4513, 5059  
 Lee D-S, 3819  
 Lee E-J, 5969  
 Lee EK, 6891  
 Lee G-J, 779  
 Lee H, 1883  
 Lee HJ, 1779, 1883  
 Lee H-J, 1897  
 Lee HJ, 451, 3801, 4309, 5883  
 Lee HK, 4929  
 Lee H-M, 6265  
 Lee HS, 2171, 3435  
 Lee H-S, 5097  
 Lee H-T, 3707, 6743, 7037  
 Lee H-Y, 323  
 Lee I-W, 6295  
 Lee J, 357, 2033, 3819  
 Lee JB, 3801  
 Lee J-C, 6295  
 Lee JH, 1419  
 Lee J-H, 2033, 3203  
 Lee JH, 5611  
 Lee JJ, 3839  
 Lee JK, 1989  
 Lee J-O, 357  
 Lee JS, 723, 2481, 2627, 3203, 3839  
 Lee Jungsul, 1335  
 Lee Jungwhoi, 1335  
 Lee J-Y, 7057  
 Lee K, 3435  
 Lee K-W, 2171  
 Lee L-M, 3865, 5221, 6093  
 Lee M, 1883, 4191, 5969  
 Lee M-C, 6247  
 Lee MJ, 3477  
 Lee MW, 4017  
 Lee MY, 1771, 4207  
 Lee S, 1147, 3435, 6017  
 Lee S-H, 109  
 Lee SH, 1419, 5611, 6429  
 Lee SJ, 6137  
 Lee SK, 1855, 3247  
 Lee SY, 6039  
 Lee T-G, 2537  
 Lee W-T, 4513, 5059  
 Lee YC, 191  
 Lee YH, 451  
 Lee Y-H, 6723  
 Lee Y-J, 3203  
 Lee YJ, 4351  
 Lee YS, 451  
 Leech M, 2419, 3605  
 Lefterov P, 5159  
 Lein M-Y, 2387, 5895  
 Leistner R, 4937  
 Lemini R, 881, 6381  
 Lemmens VEPP, 4331  
 Lengerke C, 5909  
 Lenz F, 2801  
 Lenz G, 4041  
 Lenze F, 5793  
 Lenze U, 1519, 5793  
 Leonardi F, 7127  
 Leonetti A, 4807  
 Leotta S, 5313  
 Leppert J, 7077  
 Lertsuwan K, 2645, 6285  
 Lesfevre P, 2265  
 Leskinen M, 6915  
 Lessmann E, 6123  
 Leuzinger K, 5909  
 Levailant J-M, 4115  
 Levy C, 2955, 3905  
 Lewanczuk R, 535  
 Lewandowska M, 1973  
 Lewis J, 751  
 Lewis L, 4857  
 Li A, 5361  
 Li C, 5751  
 Li C-C, 2387  
 Li C-F, 6305  
 Li C-H, 3707, 5895  
 Li C-L, 5529  
 Li C-Y, 3707  
 Li H, 245, 2409  
 Li J, 67, 133, 5701  
 Li QQ, 245  
 Li S, 4947  
 Li W-L, 4491  
 Li X, 635, 6051  
 Li Y, 635, 2515  
 Li Y-R, 1405  
 Liakakos T, 625  
 Liakou CG, 2331, 2989  
 Liang J-A, 2387, 5895  
 Liang S, 1307  
 Liao H-F, 2675  
 Liao P-C, 4075  
 Liao P-Y, 1285  
 Liao Y-M, 5895  
 Licaj I, 2955  
 Lien J-C, 6869  
 Liliopoulos SG, 5181  
 Lillemoe KD, 3659  
 Lim H, 779, 2475, 2509

- Lim HI, 2481, 6083  
 Lim H-J, 1897  
 Lim J, 7057  
 Lim JH, 5611  
 Lim J-Y, 1953, 2601, 3239  
 Lim S-C, 2573  
 Limonnik V, 5933  
 Lin C-C, 2387, 4947  
 Lin C-H, 1405  
 Lin C-Y, 2387  
 Lin J-F, 2675  
 Lin M-H, 221  
 Lin M-L, 2011, 5503  
 Lin P-M, 6265  
 Lin S-C, 3255, 4947  
 Lin S-H, 1405  
 Lin Y-S, 2995  
 Linardou H, 2095  
 Lindenblatt N, 891  
 Lindner DJ, 6751  
 Lindqvist C, 5355  
 Lindqvist PG, 501  
 Ling X, 5371  
 Lippiatt J, 5869  
 Liska V, 6817  
 Liss AS, 3659  
 Lissoni AA, 1543  
 Listovsky T, 5471  
 Littlejohn K, 3669  
 Liu B, 7053  
 Liu B-Y, 221  
 Liu C, 3255  
 Liu D, 733, 1007  
 Liu K-C, 6869  
 Liu L, 2225  
 Liu L-C, 6743, 7037  
 Liu L-X, 2715  
 Liu M-C, 5107  
 Liu S-H, 1175  
 Liu S-Y, 221  
 Liu T-C, 6723  
 Liu X, 5411  
 Liu Y, 1451, 3819, 5801  
 Liu Y-C, 221  
 Liutkevicius V, 2003  
 Lluch P, 6853  
 Lluch S, 6853  
 Lo S-S, 1427  
 Lobelle J-P, 4253  
 Lobmaier I, 97  
 Loftås P, 2757  
 Logli AL, 1463  
 Lohse I, 1789  
 Lombardo V, 7119  
 Lopes Goncalves T, 2725  
 Lopes L, 1495  
 Lopes-Conceicao L, 1041  
 Lorenzi B, 1753  
 Lorntzsen B, 6979  
 Lotz J-P, 3939  
 Louca M, 1375  
 Louizou E, 2219  
 Lourenco Matias DI, 2725  
 Lu K-W, 6869  
 Lu T-J, 6869  
 Lu X, 1055, 6609  
 Lu Y, 1345  
 Lu Z, 635  
 Luciani A, 2079  
 Luczynska E, 2925  
 Ludvik J, 3459  
 Ludwig JM, 5371  
 Lue K-H, 1175  
 Luebke AM, 3333  
 Lugassy C, 891  
 Lugo-Baruqui A, 5837  
 Lukoseviciute M, 53  
 Lukosiute-Urboniene A, 3765  
 Lumachi F, 1135, 5877  
 Lunet N, 1041  
 Luo C-W, 5529, 6305  
 Lupattelli M, 3387  
 Lupica JA, 6751  
 Lupo S, 7083  
 Luppatteli M, 3417  
 Luu T-T-T, 1855  
 Luukka M, 6915  
 Luukkaala T, 3129  
 Lygerou Z, 2449  
 Lyn-Cook B, 3669  
 Ma W-L, 1285  
 Ma X, 6051  
 Macaione I, 7083  
 Macchia G, 465, 3417, 4413, 6499  
 Machado CB, 3055  
 Machida D, 443, 1087  
 Machiorlatti M, 847  
 Mackiewicz A, 3723  
 Mackiewicz J, 3723  
 Madranges N, 3905  
 Maeda C, 6473  
 Maeda H, 3277  
 Maeda K, 1307, 2911, 3535, 4157  
 Maeda O, 2497  
 Maeda R, 4023  
 Maeda S, 2303  
 Maeda T, 4763, 5399  
 Maehara Y, 5659  
 Maehashi K, 4701  
 Maemura K, 75  
 Maeno K, 4245  
 Mäenpää J, 3129  
 Maezawa Y, 405, 443, 1087, 1683, 2359, 2365, 4067, 5815  
 Maffeis F, 1135, 5877  
 Maghazachi A, 1555  
 Mahmoud MM, 4547  
 Mahner S, 2117  
 Mahnken AH, 1167  
 Mailliez A, 3905  
 Maimon O, 6417  
 Majewski W, 5861  
 Majoulet L, 1095  
 Mäki M, 6387  
 Makino K, 2701  
 Makino T, 1141, 4087  
 Makita K, 4729, 4741  
 Makiyama A, 7067  
 Makrantonakis P, 305  
 Malaer JD, 6613  
 Malecki M, 4425  
 Maleckova A, 6817  
 Malerova S, 1597  
 Malhotra A, 315, 3915  
 Malinka T, 387  
 Mallett KE, 6941  
 Maly B, 6417  
 Manabe S, 1731  
 Manabe Y, 393  
 Manabu K, 5263  
 Manapov F, 2319  
 Manca G, 2191  
 Manceau G, 3579  
 Mangana J, 891  
 Mannermaa A, 3713  
 Mano Y, 35, 2297, 4165  
 Manoharan A, 5837  
 Manome Y, 4505, 4895  
 Manrique OJ, 1055  
 Mansou DA, 3873  
 Månsson C, 2771  
 Mantilla E, 3453  
 Mantilla Jr. EC, 2059  
 Mantini G, 6499  
 Manzella L, 2457  
 Marampon F, 5379  
 Maraschin M, 6799  
 Marchand E, 1095  
 Marchionni A, 3387  
 Marechal S, 4253  
 Marekova D, 5989  
 Margan MM, 5557  
 Margonis GA, 5457  
 Marinis DE, 5583  
 Marjanska A, 1817, 7095  
 Markiewicz A, 3505  
 Markovic U, 5313  
 Marquez J, 6375  
 Martí-Martínez E, 2079  
 Martin AJ, 3081  
 Martin MG, 5423  
 Martinez De Mello Vianna R, 6573  
 Martínez-Pérez A, 2079  
 Martini V, 5679  
 Marttila T, 6915  
 Maruta H, 4299  
 Maruyama N, 6101  
 Maruyama T, 6101  
 März W, 501  
 Masaki T, 121  
 Mascherini M, 4199  
 Masciocchi C, 3417  
 Mashiba R, 4707  
 Masiuk M, 1973  
 Mason T, 27  
 Masoni L, 3401  
 Massimino M, 2457  
 Mastoraki A, 625, 6009  
 Mastracci L, 4199  
 Mastronikolis N, 807, 3759  
 Masubuchi T, 5277  
 Masuda H, 1613  
 Masuda M, 405, 443, 1087, 1503, 1587, 1683, 2133, 2337, 2359, 2365, 4067, 5815, 6407  
 Masuda T, 1571, 2941, 3315, 3733  
 Masuishi T, 2247  
 Masumoto N, 3395, 3491  
 Masuyama H, 3811  
 Masuzaki R, 4445  
 Matayoshi A, 6101  
 Materazzo M, 281, 939, 7119  
 Mathew PA, 6613  
 Matkowski R, 1931

- Matkowskyj KA, 1527  
 Matoda M, 5285  
 Matono R, 401  
 Matsubara A, 1943, 4787  
 Matsubara Y, 2133  
 Matsuda A, 3469  
 Matsuda C, 5301  
 Matsuda K, 3873, 6545  
 Matsuda R, 3231  
 Matsuda T, 2165, 6539  
 Matsufuji N, 6429  
 Matsuhashi N, 299, 2379  
 Matsui Y, 6781  
 Matsuki T, 5277  
 Matsumiya E, 7101  
 Matsumoto A, 5829  
 Matsumoto H, 4131, 5043, 6101, 7141  
 Matsumoto M, 2303  
 Matsumoto N, 4445  
 Matsumoto S, 1029, 1035, 1367, 4047, 6429  
 Matsumoto T, 3163, 3983  
 Matsumoto Y, 393, 2065, 3733, 4763, 6171  
 Matsumura K, 2795  
 Matsunaga T, 5593, 6957  
 Matsunaga Y, 1739  
 Matsuno K, 4271  
 Matsuno Y, 645  
 Matsuo M, 1739, 5237, 6443  
 Matsuo T, 5567  
 Matsuo Y, 1107  
 Matsusaka S, 5577  
 Matsushita A, 2787  
 Matsushita D, 75  
 Matsushita M, 4875  
 Matsushita R, 4291  
 Matsushita Y, 1101  
 Matsusita A, 6971  
 Matsuyama R, 6765  
 Matsuyama T, 2073, 2567  
 Matsuzaka K, 5237  
 Matsuzaki G, 6101  
 Mattiucci G, 3417  
 Matuszyk J, 837  
 Mavrogenis AF, 1519  
 Mavropoulou X, 2095  
 Mavroudis D, 901  
 Mayr D, 2117  
 Mazeike A, 3765  
 Mažuran B, 2323  
 Mazzanti M, 6879  
 Mazzarotto R, 465, 5901  
 Mazzeo E, 6499  
 Mazzuca F, 3401  
 McCallum R, 857  
 McTavish H, 3883  
 Meattini I, 6505  
 Mecklin J-P, 3713  
 Medeiros HR, 5151  
 Medeiros LF, 5151  
 Medina P, 6853  
 Medinger M, 5909  
 Međugorac K, 2157  
 Mehra S, 6375  
 Mehta P, 5787  
 Meierovich A, 6417  
 Mekaru K, 3565  
 Meklin J, 575, 3591, 6947  
 Mekuria S, 1513  
 Melichar B, 2209  
 Melo FR, 2525  
 Meng X, 5361  
 Menju T, 3287  
 Merkel S, 2833  
 Messina SG, 3355  
 Messiou C, 7003  
 Meucci R, 281, 1719  
 Meunier J, 3939  
 Meyer H, 2947  
 Meyer H-J, 1015  
 Mezzadri M, 1095  
 Miah AB, 7003  
 Miaihle G, 4115  
 Micci F, 1239, 6115  
 Micera R, 5901  
 Michael M, 6987  
 Michalaki V, 435  
 Michalopoulou F, 6213  
 Michaud A, 1797  
 Michel A, 1161  
 Michel O, 2613  
 Michelakis D, 6769  
 Michell M, 315, 3915  
 Michels J, 4137  
 Michielsen J, 5319  
 Midorikawa R, 4749  
 Migita K, 1367  
 Mihara A, 1637  
 Mihara Y, 4105  
 Mihic-Probst D, 891  
 Mii S, 201  
 Mika A, 4843  
 Mikami M, 6791  
 Miki K, 4183  
 Milano MT, 5801  
 Milella M, 5901  
 Miller E, 6003  
 Miller T, 1963  
 Milošević M, 2323  
 Mimori K, 2941, 3733  
 Mimoun C, 1095  
 Min H-Y, 323  
 Min K, 3247  
 Minagawa Y, 5631  
 Minami H, 5229  
 Minami J, 2239  
 Minami K, 5739  
 Minami Y, 1029, 1035  
 Minamiya Y, 5715  
 Minarik J, 4979  
 Minato K, 1571  
 Minegaki T, 813  
 Mineli V, 6573  
 Mingoli A, 2969, 4223  
 Minni A, 2889  
 Mino-Kenudson M, 3659  
 Miranda-Carbon G, 3669  
 Mirandola A, 1645  
 Mirka H, 6817  
 Misawa T, 293  
 Mistunari K, 5567  
 Misumi Y, 923  
 Miszczyk L, 5861  
 Mitani S, 2247  
 Mitsopoulos V, 5869  
 Mitsudo K, 6845  
 Mitsumori N, 81, 5829  
 Mitsuya K, 6473  
 Mitsuyama S, 4779  
 Mitsuyama T, 3571  
 Mitsuyoshi M, 3371  
 Miura A, 2667  
 Miura I, 2019  
 Miura K, 5277  
 Miura S, 3361  
 Miura Y, 3513  
 Miwa S, 2515, 3551, 6563, 7009  
 Miyachi M, 6159  
 Miyagawa Y, 2871, 4147  
 Miyagi M, 1619  
 Miyagi Y, 2133, 5815, 6407, 6733  
 Miyahara R, 665  
 Miyake H, 1101, 4395, 6337  
 Miyake K, 2475, 2509, 2515, 6765  
 Miyake T, 6437  
 Miyamoto A, 4123  
 Miyamoto H, 1587, 5823, 6465, 7147  
 Miyamoto K, 813  
 Miyamoto S, 2239  
 Miyao S, 1367  
 Miyao T, 5091  
 Miyara K, 4779  
 Miyashita M, 3469, 5481  
 Miyashita T, 5171, 5211  
 Miyata H, 6473  
 Miyata R, 3287  
 Miyata S, 6237  
 Miyata T, 1023, 3361  
 Miyata Y, 5567  
 Miyauchi S, 2667  
 Miyauchi W, 5593  
 Miyawaki M, 3947  
 Miyazaki A, 4319  
 Miyazaki H, 6171  
 Miyazaki K, 413, 421, 923, 957, 5757  
 Miyazaki M, 4095, 6957  
 Miyazaki Y, 5687, 5765  
 Miyazawa D, 5399  
 Miyazawa M, 4033, 4123, 6791, 6791  
 Miyoshi H, 3571  
 Miyoshi N, 5301  
 Miyoshi Y, 2141, 2871, 4147  
 Mizia-Malarz A, 7095  
 Mizobe T, 4695  
 Mizobuchi H, 4457, 4711  
 Mizobuchi H  
 Mizokami A, 1141, 2291, 4087, 4291  
 Mizuguchi H, 161  
 Mizui T, 7101  
 Mizukawa N, 2393  
 Mizumoto S, 3091  
 Mizuochi S, 4105  
 Mizushima T, 5301  
 Mizutani H, 5399  
 Mizutani Y, 5211  
 Młynarski W, 7095  
 Moeng S, 723  
 Moezardalan K, 4029, 4401  
 Mohammed R, 229  
 Mohile NA, 5801  
 Mokbel K, 315, 1809, 3633, 3915, 5351  
 Möller S, 2801



- Mollica V, 597  
Molnar A, 6863  
Momose Y, 2549  
Monaco ML, 3751  
Monecke A, 1015  
Monga D, 5919  
Monga DK, 5933  
Montagnini M, 1691  
Montali F, 4053  
Monteiro KM, 5509  
Montesi G, 3387  
Monzen H, 1981  
Moon D-H, 5883  
Moon SM, 3435  
Moore R, 3669  
Moraes DE, 3055  
Morais S, 1041  
Moran SL, 1463, 2751, 6941  
Morando L, 281  
Morawska M, 6327  
Moreira-Nunes CA, 3055  
Morel A, 2955  
Morganti AG, 465, 3417, 4413, 6499  
Morgen SS, 1475, 5673  
Morgul MH, 1  
Mori M, 2941, 4165, 5659  
Mori S, 3983  
Moriguchi M, 3953  
Morii E, 4875  
Morillon II YM, 5329  
Morimoto J, 2687  
Morimoto K, 2141  
Morimoto M, 5593, 6957  
Morimoto T, 3231  
Morimura R, 3163  
Morinaga S, 1503, 1683, 2275, 3559, 5815, 6563, 7009  
Morine Y, 743  
Morini A, 7127  
Moris D, 2107  
Morisaki T, 2343, 3345, 4047 T, 4663  
Morishima A, 4755  
Morishita A, 121  
Morishita N, 2787, 3931, 6971  
Morita M, 2297, 2303, 4165  
Morita R, 4319  
Moriya T, 2509  
Moriyama M, 4445  
Morizono S, 2911  
Morodomi Y, 5659  
Moroni P, 2079  
Morris DL, 2865  
Mortaki D, 2219  
Mortenson MM, 7053  
Mosca M, 3013  
Mosca PJ, 5245  
Moschetta G, 619  
Moschos MM, 6885  
Motohara T, 5823, 6465, 7147  
Motomura H, 35  
Motomura M, 5271  
Motomura T, 4165  
Motoyama D, 1101  
Motoyama S, 5715  
Motoyama Y, 3231  
Moulisova V, 6817  
Mountzios G, 2095  
Mouret-Reynier M-A, 3905  
Moyama C, 6781  
Mozeika AM, 5291  
Mozolewska P, 4843  
Mroczo B, 1997, 3857  
Msaouel P, 6213  
Msauel P, 709  
Muallem MZ, 5743  
Muders M, 5489  
Mueller CE, 3847, 6195  
Mueller SC, 3119  
Muguruma K, 1147  
Mühlhofer H, 5793  
Mukae Y, 5567  
Mukherjee S, 847  
Muktar S, 3915  
Müller M, 2125  
Mun H, 109  
Munaretto NF, 1463  
Munir M, 5457  
Muraglia A, 5901  
Murakami D, 2073  
Murakami M, 3873, 6545  
Murakami T, 3231  
Murakami Y, 4183  
Murakawa M, 405, 443, 1087, 2359, 2365  
Muraki K, 6443  
Muramatsu H, 1579  
Muramatsu K, 1637  
Muranushi R, 4343  
Murata H, 1619  
Murata T, 2475, 2509  
Murelli F, 3543  
Murgić J, 2323  
Muro K, 2247  
Murofushi KN, 999  
Muro K, 101, 2199, 2373  
Murotani K, 6443  
Murphy ES, 951  
Musa M, 6063  
Muscoli S, 7119  
Musolino C, 1443  
Mustea A, 2591, 3743, 6205  
Muto S, 1345  
Muukkonen O-T, 6923  
Muzzio DO, 841  
Na JM, 3203  
Na K, 5777, 5925  
Naar L, 625  
Nabeshima K, 4373, 4663  
Naccarato AG, 3031  
Nadarajan C, 2975  
Nadisauskiene R, 789  
Nagahara H, 3535, 4157  
Nagai H, 2981, 4173  
Nagai J, 87, 4885  
Nagai K, 5687, 5765  
Nagai Y, 3565  
Nagakawa Y, 2827  
Nagaki Y, 5715  
Nagamatsu H, 4787  
Nagano H, 4763  
Naganuma T, 7141  
Nagaoka T, 4755  
Nagasaka T, 3811  
Nagasawa S, 1503  
Nagashima K, 1071  
Nagashima T, 6407  
Nagata A, 5739  
Nagata H, 7109  
Nagata K, 393  
Nagata M, 6539  
Nagata T, 2911  
Nagata Y, 3559  
Nagata Y, 4183  
Nagayama K, 4047  
Nagayasu T, 2303  
Nagler T, 2117  
Nagy J, 1759  
Naito K, 4763  
Naito R, 1141, 4087  
Naito Y, 4105, 4695, 4749  
Naito Z, 5631  
Naitoh K, 4729, 4741  
Nakabayashi Y, 293, 6517  
Nakade H, 1367  
Nakagawa H, 2981  
Nakagawa I, 3231  
Nakagawa N, 6665  
Nakagawa T, 6699  
Nakahama K, 4229  
Nakajima D, 3287  
Nakajima M, 379  
Nakajima S, 6845  
Nakajo A, 5739  
Nakamatsu K, 1981  
Nakamoto T, 1107, 3565  
Nakamoto Y, 991  
Nakamura H, 957, 5757, 6101  
Nakamura J, 6551  
Nakamura K, 3811, 4023  
Nakamura M, 335, 665, 3231, 4123, 4405  
Nakamura N, 3361  
Nakamura R, 1921, 2053, 5757  
Nakamura S, 2497, 4885, 6159, 6713  
Nakamura T, 2165, 6237, 6539  
Nakamura Y, 923, 2133, 3315, 5481  
Nakane S, 7089  
Nakanishi E, 6957  
Nakanishi H, 6781  
Nakano K, 4875  
Nakano T, 459, 733, 1007, 2291, 2905, 5497  
Nakano Y, 3519  
Nakanoko T, 2297  
Nakao K, 1315  
Nakao M, 1579  
Nakao S, 3535  
Nakao T, 4801  
Nakase H, 3231  
Nakashima K, 4695, 6517  
Nakashima N, 733, 1007  
Nakashima O, 4105, 4695  
Nakashima T, 4183  
Nakashima Y, 6221  
Nakasone T, 3565, 6101  
Nakasu Y, 6473  
Nakata K, 2667  
Nakata S, 5035, 6781  
Nakatani K, 4373  
Nakatsugawa M, 4319  
Nakayama G, 201, 1843, 6665, 6713

- Nakayama H, 2073, 2133, 6407  
 Nakayama S, 4373  
 Nakazawa S, 1307  
 Nakazawa T, 3231  
 Nakazawa Y, 6845  
 Nakazono M, 1503  
 Nakiri M, 1739, 6443  
 Nakura M, 5171  
 Nam RK, 6649  
 Nam SJ, 2481  
 Nam SW, 2033, 4351  
 Namba K, 2667  
 Nambara S, 2941  
 Namgoong J-M, 7057  
 Namima D, 121  
 Nannini M, 1229  
 Naoi Y, 6437  
 Napolitano V, 271  
 Nardi P, 2889  
 Narita R, 5271  
 Narita Y, 2247  
 Narui K, 6733  
 Narui R, 873  
 Narumi K, 1747  
 Naruse I, 1571  
 Nashimoto M, 4719  
 Nasir UM, 5291  
 Nasu K, 4131  
 Nasu S, 2787, 3931, 6971  
 Natsugoe S, 75  
 Natsume A, 3231  
 Naumann DN, 1705  
 Navarini L, 983  
 Navarrete-Navarro J, 6853  
 Navarro L, 6853  
 Naviglio S, 3751  
 Nawa T, 957  
 Nazmy MH, 2739  
 Neborak EV, 1437  
 Neckel N, 6987  
 Nedel CB, 6799  
 Nelson SD, 2515  
 Németh B, 1359  
 Netsu S, 5285  
 Nettersheim D, 3119  
 Neumann K, 6987  
 Ngamkham J, 6285  
 Ngamphaiboon N, 2645  
 Nguyen J, 3991  
 Nguyen QTT, 5969  
 Nguyen T, 1661, 1665, 2257, 2261, 2271, 2841, 2847, 4081  
 Nickkho-Amiry M, 789  
 Nicolaidou E, 2219  
 Nieckula J, 5861  
 Nieder C, 977, 1551  
 Nieto JJ, 2331, 2989  
 Nigri G, 619  
 Nigro E, 3751  
 Nigro MC, 3013  
 Nii K, 733  
 Niibe Y, 393, 2065  
 Niimi A, 4245  
 Nikaido J, 7141  
 Nikaido T, 5025  
 Nikolova B, 5159  
 Nilsson A, 2771  
 Nilsson J, 3897  
 Nimura S, 4663  
 Ninomiya M, 401  
 Nirei K, 4445  
 Nishi K, 4663, 4687  
 Nishi M, 239  
 Nishibuchi I, 4183  
 Nishide T, 4327  
 Nishigori H, 5263  
 Nishiguchi K, 813  
 Nishihara K, 1739, 6101, 6443  
 Nishihira K, 3565  
 Nishikata T, 4707  
 Nishikawa A, 393  
 Nishikawa D, 1127  
 Nishikawa K, 5807, 5829  
 Nishikawa S, 3287, 5577  
 Nishikawa T, 101, 2199, 2373  
 Nishiki H, 3361  
 Nishimura F, 3231  
 Nishimura Y, 1981  
 Nishino H, 2475, 2481, 2509, 4869, 5393, 6083, 6765  
 Nishino K, 4229, 6957  
 Nishio J, 4373  
 Nishio M, 5577  
 Nishizaki K, 2393  
 Nishizaki T, 401  
 Nishizawa Y, 5301  
 Nisman B, 6417  
 Nitsch A, 841, 2591, 6205  
 Nitta H, 1023  
 Niwa Y, 6699  
 Nizri E, 6457  
 Noda D, 3947  
 Noda M, 3733  
 Noda S, 4047  
 Noda S-E, 3513  
 Noda Y, 2787, 3931  
 Nogaki K, 3873, 6545  
 Nogami W, 169  
 Noguchi S, 6437  
 Nogueira Mendes A, 5015  
 Noh WC, 1387  
 Nohara T, 2291  
 Nolte I, 3781  
 Nomi T, 1107  
 Nomoto A, 379  
 Nomoto Y, 5739  
 Nomura A, 957, 5757  
 Nomura H, 5285  
 Nomura S, 5263, 7109  
 Nomura T, 2475, 2509  
 Nomura Y, 4695  
 Nonaka Y, 2911  
 Nonomura N, 1677, 2053, 4875  
 Nonpanya N, 609, 2583, 4989  
 Nori J, 1079  
 Norian LA, 5445  
 Nouriemamzaden F, 3669  
 Nové M, 4921  
 Novelli M, 597  
 Novotny L, 5125  
 Novotny Z, 3527  
 Nozaki Y, 35  
 Nozawa H, 101, 2199, 2373  
 Ntounis T, 6009  
 Ntreta M, 4413  
 Numao N, 1613, 6493  
 Numata M, 405, 443, 1087, 1503, 2337, 2359, 2365, 4067, 5815  
 Numata T, 957  
 Nunes L, 5151  
 Nussbaum DP, 2107  
 Nuzzo M, 6505  
 Nygren P, 2771  
 Nyuya A, 3811  
 Oak ASW, 2467  
 Obara N, 1651, 4365  
 Obara S, 1107  
 Obermayr E, 2487  
 Ochiai S, 7017  
 Oda E, 5823, 6465, 7147  
 Oda M, 1677  
 Oda Y, 759, 5659, 6221  
 Oertel M, 4041  
 Ogane N, 6791  
 Ogasawara N, 1739, 6443  
 Ogasawara S, 4105, 4695  
 Ogata T, 1503, 1683, 2275, 4067, 5815  
 Ogawa K, 379, 1677, 2053, 4095  
 Ogawa M, 1613  
 Ogawa S, 3163, 4299  
 Ogino T, 5301  
 Ogo A, 5043  
 Ogo E, 6443  
 Ogoshi Y, 2667  
 Oguchi M, 999  
 Oguma E, 4729  
 Oguri T, 4245  
 Oh C-H, 5081  
 Oh CH, 5777  
 Oh C-K, 5601  
 Oh D-S, 5097  
 Oh H-K, 4481  
 Oh J-H, 109  
 Oh J-S, 779  
 Oh R-J, 393, 2065  
 Oh S-O, 3839  
 Oh YL, 2933, 3477  
 Ohashi R, 3793, 5631  
 Ohashi T, 3163  
 Ohba K, 5567  
 Ohba S, 1315  
 Ohira C, 35  
 Ohira G, 2637, 2881  
 Ohira H, 6551  
 Ohira K, 6957  
 Ohira M, 1147, 2343, 2637, 2881, 3345, 3535, 4047, 4157  
 Ohira S, 4095, 6957  
 Ohkubo H, 4245  
 Ohkuma M, 3445  
 Ohkura K, 4675  
 Ohlinger R, 2185, 2801  
 Ohno M, 759  
 Ohno S, 915, 3315, 3733  
 Ohno T, 459, 5497  
 Ohsawa M, 1153, 3345, 4387  
 Ohsumi A, 3287  
 Ohta K, 5399  
 Ohta R, 3469

- Ohta T, 5171, 5211  
Ohtsu A, 5091  
Ohtsu H, 3733  
Ohtsuka T, 5739  
Oishi T, 6473  
Oka D, 5091  
Okabe C, 5263  
Okabe H, 1023, 2795  
Okada A, 2981  
Okada C, 5071  
Okada K-I, 4033, 4123  
Okada M, 1153, 3395, 3491, 4387, 4961  
Okada S, 4729, 4741  
Okada T, 5277  
Okamoto A, 6517  
Okamoto H, 923, 2337  
Okamoto I, 5277  
Okamoto K, 1747  
Okamoto K, 3163  
Okamoto M, 459, 3315, 4471  
Okamoto N, 2787, 3931, 6971  
Okamoto S, 5285  
Okamoto T, 293, 373, 4567, 5659  
Okamoto Y, 5807  
Okano N, 459  
Okano S, 5659  
Okasha SM, 3155  
Okauchi S, 413, 421, 957  
Okayama S, 5405  
Okazaki K, 3571, 7141  
Okazaki M, 2667  
Okazaki Y, 4157, 4379  
Okonogi N, 6429  
Okubo H, 5757  
Okubo K, 75  
Okubo-Sato M, 6845  
Okuda K, 4695, 4749, 4773  
Okuda T, 4801, 6159  
Okudaira N, 4885, 7067  
Okumura T, 999  
Okuyama H, 169  
Oláh J, 4237  
Olejar T, 349  
Oliveira FSO, 5151  
Oliveira Kato VDJ, 6355  
Omae K, 6713  
Omari J, 4281  
Omatsu K, 5285  
Omi M, 5285  
Omura G, 5277  
Onaga C, 35  
Ondic O, 3527  
Ono Y, 4567  
Ondrey F, 3071  
Ondrey FG, 5417  
Onishi H, 393  
Ono A, 1571  
Ono R, 161  
Onoda M, 3371  
Onoda N, 4047  
Onoda T, 2393  
Onodera A, 2337  
Onwumere O, 4907  
Ooyama T, 3565  
Oppong MD, 1161  
Orfeuvre H, 3939  
Orish CN, 3669  
Orita Y, 2073  
Orlandella RM, 5445  
Orłowska-Heitzman J, 3505  
Orsaria P, 2231  
Orywal K, 1997, 3857  
Osaka Y, 2827  
Osakabe H, 2275  
Oshi M, 6733  
Oshikiri T, 2165, 6539  
Oshima T, 1087  
Oshima T, 405, 443, 1503, 1683, 2275, 2359, 2365, 4067, 5815, 6407  
Oshino T, 645  
Osnes T, 6979  
Osoegawa A, 3947  
Osowiecki M, 4059  
Ostanin AA, 795  
Ota M, 2297, 4165  
Ota U, 3571  
Ota Y, 2275, 2827  
Otani K, 1677, 2053  
Otoshi T, 7141  
Otsubo A, 5567  
Otsubo R, 2303  
Otsuji E, 3163  
Otsuka A, 1101  
Ottoson N, 1467  
Ou YC, 2995  
Ouaissi M, 3579  
Oualet D, 6063  
Ouchi H, 5211  
Ouchi K, 6159  
Oue N, 5815  
Ou-Yang F, 5529  
Ovčariček S, 2323  
Owada S, 5071  
Owaki T, 5739  
Owczarek D, 6685  
Oya N, 2073, 2567  
Oyama T, 261  
Oyanagi J, 1867  
Ozaki A, 35  
Ozaki M, 393  
Ozasa H, 2981  
Ozawa H, 2871, 4147  
Ozdogan S, 3265  
Ozono S, 6337  
Pace E, 1443  
Paczona V, 4237  
Padula F, 5379  
Paeng JC, 4191  
Paepke S, 2185, 2801  
Paffenholz P, 5539  
Pagkalos A, 6009  
Paik SS, 2961  
Pairojkul C, 6899  
Pakiet A, 4843  
Palek R, 6817  
Palkovics A, 1359  
Palladino G, 4017  
Palli D, 7119  
Palloni A, 597, 3013  
Palmier R, 4011  
Paloheimo L, 6387  
Palombi L, 7119  
Palubinskiene J, 789  
Palumbo B, 3355  
Palumbo I, 3387  
Pan E, 2059, 3453  
Pan M-R, 5529, 6305  
Pan Q-Z, 3819  
Pan Y, 3865, 5221, 6093  
Pan Y-R, 4513, 5059  
Panagopoulos A, 2449  
Panagopoulos I, 97, 1239, 6115  
Pancheva M, 4137  
Panis Y, 3579  
Pantaleo MA, 1229  
Panteris E, 2695  
Paolo O, 7119  
Papadaki C, 901  
Papadimitriou C, 1669  
Papadopoulos C, 3003  
Papadopoulos PP, 625  
Papadopoulou K, 677  
Papakostas P, 305  
Papakotoulas P, 305  
Papalois AE, 5457  
Papandreou C, 305, 435  
Papanikolaou V, 807, 3759  
Papatsimpas G, 305  
Papi S, 7119  
Papp A, 1359  
Pappalardi B, 3417  
Parajuli KR, 2573  
Pareek V, 847  
Parent D, 3905  
Parikh P, 4029  
Park C, 2409  
Park CH, 4929  
Park HJ, 1771, 1855  
Park HY, 2961  
Park I-C, 1387  
Park JH, 1897, 5393, 5883  
Park J-I, 177, 653, 767  
Park JJ, 2627, 5601  
Park JK, 723  
Park JY, 1779  
Park KH, 323, 3983  
Park MH, 1989  
Park NJ, 3477  
Park R, 1495  
Park S, 2933  
Park S-G, 1897  
Park S-H, 451  
Park S-J, 1953, 2601, 3239  
Park SY, 1989, 2961  
Park T-I, 4001  
Park Y, 1771  
Park YH, 2933, 3819  
Park Y-S, 3231  
Parker AS, 1055  
Parrino B, 4913  
Parsai S, 951  
Partynska A, 5981  
Pascarella G, 2231  
Pascher A, 3379  
Pasqua R, 2889  
Passaro A, 427  
Passweg J, 5909  
Paszkievicz-Kozik E, 6685  
Patani F, 6505  
Patnaik MM, 3883  
Patsouras A, 6599  
Pauly L, 1563  
Pautier P, 3939  
Pavarana M, 5901  
Pavlakis K, 1669  
Pawelke J, 6123

- Pawińska-Wąsikowska K, 7095  
 Pawinski A, 977  
 Pech M, 4281  
 Pecoraro C, 4913  
 Pectasides D, 929  
 Pegba-Otemolu I, 2179  
 Pei J-S, 1297, 4465  
 Peisker U, 2185  
 Pejler G, 2525  
 Pellicciaro M, 7119  
 Peltonen J, 6029  
 Peng S-F, 6869  
 Peng T-C, 1175  
 Pennisi MS, 2457  
 Pentheroudakis G, 305, 929  
 Pereira Ferrer V, 2725  
 Pereira MC, 229  
 Pereira S, 1041  
 Peretz L, 5471  
 Peretz T, 6417  
 Perez SV, 3781  
 Pernicone N, 5471  
 Perol D, 3905  
 Perretta T, 939, 1719  
 Perrin C, 3905  
 Perrone AM, 1229  
 Perry N, 315, 3915  
 Persons KS, 565, 719  
 Peschos D, 807, 2219, 3759  
 Pescitelli L, 6485  
 Pesek M, 3459  
 Peteinaris A, 3065  
 Peterfi L, 3485  
 Peters GJ, 4807, 4913  
 Petersen IA, 1463, 6941  
 Peterson CM, 5445  
 Petit T, 3905  
 Petkovic V, 5001  
 Petraki C, 709, 6213  
 Petranović Ovcariček P, 2323  
 Petrea S, 1049  
 Petri GL, 4913  
 Petrovic M, 5001  
 Petrovová E, 3191  
 Petrucciani N, 619  
 Petsri K, 4989  
 Pezzuto A, 983  
 Pfeiffer D, 5793  
 Pfister F, 2591  
 Phelps M, 5707  
 Philipovski A, 857  
 Philippou A, 6213  
 Philipsen PA, 511, 557  
 Philipson L, 5853  
 Phillips A, 3925  
 Phillips OA, 5125  
 Piccolo F, 3417  
 Pichler R, 2861  
 Picklo MJ, 1833, 3697  
 Piechota J, 1997  
 Pieniążek M, 1931  
 Pierscianek D, 1161  
 Pietzner K, 5743  
 Pigneur F, 2079  
 Pikouli A, 5457  
 Pikoulis E, 625, 5457  
 Pilkington GJ, 3081  
 Pilz S, 501  
 Pincus MR, 4857  
 Pinlaor P, 6899  
 Pinlaor S, 6899  
 Piredda M, 5583  
 Piskor BM, 3221  
 Pistolese CA, 281, 939, 1719, 7119  
 Pistolessi S, 3031  
 Piszczek W, 4059  
 Pitman MB, 5679  
 Place V, 1095  
 Plevris N, 5869  
 Ploskonos MV, 1437  
 Pluta A, 4059  
 Pode D, 3967  
 Podhorska-Okolow M, 5981  
 Pohlig F, 1519  
 Poi M, 67, 133  
 Poi MJ, 5707  
 Polanek R, 6123  
 Poleszczuk J, 6685  
 Polioudaki H, 6769  
 Polito R, 3751  
 Pollastro RM, 4017  
 Polyak B, 4857  
 Polyak SW, 4557  
 Pönisch W, 1015  
 Popiela T, 2925  
 Popovic S, 5001  
 Poretta T, 6997  
 Porta J, 5423  
 Portarena I, 281  
 Potter EA, 795  
 Pouckova P, 349  
 Poulas K, 2025  
 Powerski M, 4281  
 Pozet A, 3939  
 Prakhongcheep O, 4989  
 Prasad ML, 6375  
 Pratschke J, 387, 1267  
 Preda L, 1645, 2853  
 Prendes B, 4207  
 Presl J, 3527  
 Pressl G, 2151  
 Preusser M, 965, 6229  
 Privitera V, 3417  
 Procházková K, 7045  
 Prochorec-Sobieszek M, 6685  
 Proietti A, 1691  
 Proskurina AS, 795  
 Provansal M, 3939  
 Przyłipiak A, 3221  
 Przystupski D, 2613  
 Psifis M, 6599  
 Psoma E, 677  
 Psychogiou E, 1697  
 Psyrris A, 929  
 Pucciarelli S, 2079  
 Puchas P, 3109  
 Pula B, 4059  
 Pulkkanen K, 6915  
 Pulvirenti A, 5457  
 Puma A, 2457  
 Puma F, 3355  
 Punt CJA, 4331  
 Puolakkainen P, 1325  
 Purkot J, 5437, 6327  
 Pytlak B, 6685  
 Qi P, 951  
 Qiu X, 1467  
 Raab H-R, 2947  
 Raap U, 2947  
 Rabin KR, 3147  
 Raciborska A, 7095  
 Rad JG, 689  
 Rades D, 287, 367, 1661, 1665, 2257, 2261, 2271, 2841, 2847, 3429, 3499, 3961, 4081, 5787, 6513, 7025, 7077  
 Radice D, 427  
 Ragos V, 807, 3759  
 Ragusa M, 3355  
 Raguse J-D, 6987  
 Rahal MA, 5845  
 Rahkola D, 253  
 Raica M, 5557, 6879  
 Rainer WG, 5735  
 Ramacciato G, 619  
 Ramfidis V, 1697  
 Ramón-Gallegos E, 6273  
 Ramos Gonçalves JC, 5015, 5049  
 Ramos-Esquivel A, 4263  
 Randazzo O, 4913  
 Raselli R, 7119  
 Raskin V, 4253  
 Rathmann B, 1467  
 Rautelin H, 1325  
 Ravichandran S, 5245  
 Razis E, 929  
 Rea T, 5583  
 Rebelo Pontes HA, 6355  
 Rechenberg U, 2185  
 Redenti S, 4907  
 Reece TB, 5361  
 Reeve K, 2125  
 Rehan M, 4547  
 Rehn S, 4041  
 Reich R, 6677  
 Reichrath J, 501, 583  
 Reinehr M, 891  
 Reisz Z, 4237, 6123  
 Reitz D, 2319  
 Ren C-X, 3819  
 Ren Y, 6637  
 Renda I, 1079, 3645  
 Restrepo DJ, 1055, 1059, 1065, 3411  
 Reutzel-Selke A, 1267  
 Rhee E, 2409  
 Ricci A, 983  
 Ricci AD, 597, 1229, 3013  
 Ricci F, 939  
 Ricciardi C, 271  
 Riccioli A, 5379  
 Riccò M, 7127  
 Richardson M, 5801  
 Richert-Przygońska M, 6531  
 Richter K, 5539  
 Ricke J, 4281  
 Ricks-Santi L, 27  
 Riemann B, 3379  
 Riffel P, 4137  
 Riffelmann M, 545  
 Rigopoulos D, 2219  
 Rinker BD, 1059, 1065, 3411  
 Rino Y, 405, 443, 1087, 1503, 1587, 1683, 2133, 2337, 2359, 2365, 4067, 5815, 6407

- Ris F, 2079  
 Rise TV, 1239  
 Ristic-Fira A, 5001  
 Ritter GS, 795  
 Ritter M, 3119  
 Riva G, 2853  
 Rivera-Chávez J, 6637  
 Riziotis C, 3759  
 Rizzo A, 597, 1229, 3013  
 Robain M, 3905  
 Robak T, 4059  
 Robinson AGJ, 6623  
 Roche A, 2179  
 Rodolakis A, 3651  
 Rodrigues-Mascarenhas S, 5049  
 Rodriguez Burbano RM, 6355  
 Rody A, 3973  
 Roengvoraphoj O, 2319  
 Rohregger K, 2151  
 Romano C, 2457  
 Romanowska-Dixon B, 3505  
 Romboli A, 7127  
 Rombouts MD, 1201  
 Romeo V, 271  
 Ronchi A, 4017  
 Ronchi S, 1645, 2853  
 Rontogianni D, 677  
 Rooprai HK, 3081, 5427  
 Rosa C, 6505  
 Rosas R, 3071  
 Rose PS, 1463, 2751, 5735, 6941  
 Rosendorf J, 6817  
 Rossi G, 5901  
 Rossowska J, 2613  
 Rotter N, 825, 3847, 5621, 6195  
 Roukas D, 807, 3759  
 Rouzier R, 1095  
 Rovio P, 3129  
 Rubio CA, 1535, 7031  
 Rudnicki W, 2925  
 Ruemenapf G, 4137  
 Ruetgen B, 3781  
 Rugamba A, 1905, 3209, 5191  
 Ruggieri P, 1519  
 Rui F, 743  
 Ruiz-Garcia H, 1065  
 Ruottinen M, 253, 5701  
 Rusavy Z, 3527  
 Rushing C, 5245  
 Russo A, 7083  
 Russo D, 271  
 Rust BM, 1833, 3697  
 Rutkowski R, 2801  
 Ružić B, 2323  
 Rymkiewicz G, 6685  
 Ryu S, 373, 2627, 6517  
 Ryuno Y, 3513  
 Saavedra Tomasich FD, 6573  
 Saberi F, 1325  
 Sablin M-P, 3905  
 Sabzevari A, 5329  
 Saccia S, 3387  
 Saczko J, 2613  
 Sadashiv S, 5727  
 Sadee W, 5707  
 Saeed A, 1495  
 Saeki H, 2337  
 Sagara Y, 4779  
 Sagawa T, 6957  
 Sahashi H, 7101  
 Saho H, 5739  
 Sai Y, 4291  
 Saikawa Y, 1921  
 Saimanen I, 253, 5701  
 Saito A, 4183  
 Saito E, 7141  
 Saito K, 957, 3873, 5757, 6545  
 Saito M, 1029, 1035, 1247, 4405  
 Saito S, 3513, 5567  
 Saito T, 957, 2073, 2567, 5757  
 Saito Y, 743, 1747  
 Saitoh D, 6171  
 Saitoh W, 2509  
 Sakagami H, 87, 3685, 4885  
 Sakaguchi M, 2667  
 Sakaguchi T, 6319  
 Sakai H, 4695, 4773, 5567  
 Sakai M, 957, 5757  
 Sakai T, 1637, 5237  
 Sakai Y, 1579  
 Sakamori Y, 2981  
 Sakamoto F, 2073  
 Sakamoto H, 2165  
 Sakamoto K, 1117  
 Sakamoto N, 335  
 Sakamoto T, 5593  
 Sakanashi M, 5399  
 Sakata K-I, 1307  
 Sakata N, 4763  
 Sakata T, 4663, 4687  
 Sakimoto T, 4379  
 Sakimura C, 2303  
 Sakuda T, 6319  
 Sakurai A, 7141  
 Sakurai F, 161  
 Sakurai H, 999  
 Sakurai N, 1307  
 Sakuraoka Y, 3983  
 Salakova M, 1597  
 Salama AKS, 5245  
 Salame E, 3579  
 Salehi R, 1325  
 Sallinen H, 6923  
 Sallinen T, 6029  
 Salo T, 6029  
 Salomidou M, 1697  
 Samantas E, 305, 929, 2095  
 Samejima Y, 2787, 3931  
 Samelis G, 305  
 Samhoury L, 3379  
 Sanahuja A, 6853  
 Sanches PRS, 5151  
 Sander C, 6205  
 Sandhu A, 5919, 5933  
 Sandström P, 2757  
 Sanguedolce F, 2439  
 Sanmartín C, 4921  
 Sano K, 1255  
 Sano M, 3685  
 Sano S, 7101  
 Sano T, 7017  
 Sanomachi T, 4961  
 Santoliquido M, 4199  
 Santori F, 7119  
 Sapienza P, 2969, 4223  
 Saponara M, 1229  
 Sarantis P, 5457  
 Sarhadi V, 1325  
 Sarihan M, 3169  
 Sarpong ED, 4907  
 Sartori E, 1543  
 Sasada S, 3395, 3491  
 Sasajima H, 6159  
 Sasaki K, 101, 2199, 2373  
 Sasaki R, 3091, 4445  
 Sasaki Y, 2351  
 Sasaya T, 4319  
 Sasiadek MM, 5667  
 Sata A, 2871, 4147  
 Sato H, 1579, 5277  
 Sato K, 35, 1587, 2777, 2941  
 Sato M, 2911, 4131  
 Sato N, 5823, 6465, 7147  
 Sato R, 3953  
 Sato S, 413, 421, 1587, 2303  
 Sato T, 35, 3287, 4067, 4695, 5263  
 Sato Y, 169, 957, 5211, 5715, 5757, 6221, 6551  
 Satoh H, 413, 421, 957, 5757  
 Satomi-Tsushita N, 1071  
 Sauer IM, 1267  
 Sauer M, 1625  
 Sawabata N, 7089  
 Sawabe M, 1127  
 Sawada K, 5939  
 Sawasaki M, 991  
 Sawatsubashi M, 4687  
 Sawazaki S, 4067  
 Sayan M, 5291  
 Scatozza F, 5379  
 Schacherer D, 143  
 Schallier D, 2265  
 Schanze I, 3423  
 Schell A, 3847, 6195  
 Scherl C, 5621, 6195  
 Schild SE, 287, 367, 1661, 1665, 2257, 2261, 2271, 2841, 2847, 3429, 3499, 3961, 4081, 6513, 7025, 7077  
 Schilling O, 3659  
 Schizas D, 625, 3065, 6009, 6599  
 Schlom J, 5329  
 Schmid SM, 5787  
 Schmidt B, 3459  
 Schmidt CM, 4215  
 Schmidt D, 3119  
 Schmidt PT, 1535  
 Schmidt-Wolf IGH, 5489  
 Schmidt-Wolf R, 3097  
 Schmoeckel E, 2117  
 Schmoor C, 5679  
 Schmuck RB, 1267  
 Schoenrogge M, 153  
 Schöpe J, 583  
 Schoppmann SF, 965  
 Schröder J, 3973  
 Schubert T, 5319  
 Schürer M, 6123  
 Schwenk-Zieger S, 1277  
 Scobioala S, 3379  
 Scott J, 951

- Scott-Barrett S, 2989  
 Scotti GB, 2969  
 Scotti V, 465  
 Sdralis E, 1753  
 Šebek J, 7045  
 Secondino S, 1645  
 Secondulfo C, 4017  
 Sedlmair M, 3459  
 Segarra G, 6853  
 Segura C, 2955  
 Sehouli J, 5743  
 Seidel E, 1267  
 Seidensticker M, 4281  
 Seidesticker R, 4281  
 Seif MW, 789  
 Seino S, 4961  
 Seki M, 4719  
 Seki N, 335  
 Sekiguchi K, 3469  
 Sekine I, 957, 5757  
 Sekine Y, 5091  
 Sekino Y, 1943  
 Seko Y, 3953  
 Sekora A, 3781  
 Selander T, 253, 5701  
 Seleem D, 751  
 Seligson N, 5707  
 Selle F, 3939  
 Selway RP, 5427  
 Semba T, 6699  
 Semkova S, 1963, 5159  
 Sender S, 3781  
 Sentani K, 1943  
 Seo G, 2033  
 Seo HA, 723  
 Seo J-H, 1883  
 Seo JH, 2627  
 Seo Y-S, 779  
 Seong M-K, 1387  
 Sequeda-Juárez A, 6273  
 Serizawa M, 1867  
 Seror J, 1095  
 Serventi JN, 5801  
 Sestini S, 6485  
 Seth A, 6649  
 Seubwai W, 5115  
 Sewell J, 3453  
 Seydafkan S, 4857  
 Sgouros J, 929  
 Shah D, 5919, 5933  
 Shang E, 4907  
 Sharaf K, 2117  
 Sharaf LH, 5125  
 Sharma AK, 6039  
 Shchetynska-Marinova T, 4137  
 Shen L, 4969  
 Shen T-C, 2011, 5503, 5751  
 Sheriff V, 5951  
 Sherman C, 6649  
 Sherman S, 4215  
 Shi H, 87  
 Shi Q, 4401  
 Shiba H, 293  
 Shiba K, 5577  
 Shiba S, 459, 5497  
 Shibata E, 2687  
 Shibata H, 3873, 6545  
 Shibata K, 2497  
 Shibata M-A, 2687  
 Shibata T, 4327, 4445  
 Shibutani M, 2343, 2881, 3535, 4157  
 Shibuya K, 459  
 Shida A, 81  
 Shida Y, 5071  
 Shien K, 2667, 4419  
 Shiga C, 5399  
 Shigehara K, 1141, 2291, 4087  
 Shigematsu K, 5237  
 Shigemura K, 5107  
 Shigeta M, 1943  
 Shih L-C, 1631, 3707, 4465, 5503  
 Shih P-H, 3865, 5221, 6093  
 Shih W-L, 6345  
 Shiina T-A, 35  
 Shima H, 6733  
 Shimada M, 239, 743, 7141  
 Shimada T, 4291  
 Shimamatsu S, 5659  
 Shimatani M, 3571  
 Shimazu K, 6437  
 Shimizu A, 645  
 Shimizu D, 6713, 6733  
 Shimizu H, 3163  
 Shimizu K, 261  
 Shimizu T, 3983, 5481  
 Shimoda M, 6437  
 Shimoda Y, 1503, 1683, 2275  
 Shimohigashi Y, 2567  
 Shimoji Y, 3565  
 Shimokawa T, 923  
 Shimonosono M, 75  
 Shimoya K, 2475  
 Shimoyama Y, 1891  
 Shimura Y, 4291  
 Shin D-Y, 357, 2917  
 Shin E, 4481  
 Shin HJ, 5883  
 Shin J, 7057  
 Shin KM, 1779  
 Shin S-J, 2961  
 Shin YR, 4351  
 Shinden Y, 5739  
 Shinji S, 3469  
 Shinkawa H, 2637, 2881  
 Shinomiya M, 7141  
 Shinomiya N, 6171  
 Shintani A, 4229  
 Shintani T, 393  
 Shioga T, 4105  
 Shiomi A, 1731  
 Shiota M, 335  
 Shioya H, 5237  
 Shiozaki A, 3163  
 Shiozawa M, 1503, 1683, 2275, 2337, 5815  
 Shiozawa S, 5405  
 Shiozawa T, 5757  
 Shiozawa T, 957  
 Shirabe K, 261, 4343  
 Shiraga S, 7053  
 Shirai A, 4701  
 Shiraishi S, 2073, 2567  
 Shirakawa C, 7141  
 Shiraki T, 3983  
 Shirasawa S, 4663, 4687  
 Shirley MB, 2751  
 Shiroyama T, 4229  
 Shirvani A, 535, 551, 565, 719  
 Sho M, 1107, 1367  
 Shoda K, 3163  
 Shoji H, 1071  
 Shouji D, 915  
 Shovman O, 3831  
 Shukuya T, 1867  
 Shumelinsky F, 5319  
 Shuno Y, 101, 2373  
 Shyr C-R, 2715  
 Siddique DA, 5845  
 Sidiropoulou V, 435  
 Sidoni A, 3355  
 Sidorkiewicz I, 3221  
 Sidorov SV, 795  
 Siepe G, 4413, 6499  
 Sieron HL, 1167  
 Sigl M, 4137  
 Signoriello G, 3751  
 Sigstad E, 6979  
 Silkunas M, 3765  
 Silkuniene G, 3765  
 Silver R, 3071  
 Sim J, 2961  
 Simeoni M, 4017  
 Simetić L, 2157  
 Simioni C, 6799  
 Simon F, 1277  
 Simon G, 3905  
 Simonetti E, 2191  
 Simoni N, 465, 5901  
 Simpson RE, 4215  
 Singh P, 3453  
 Singh SR, 2475, 2481, 2509, 2515  
 Sioulas V, 2219  
 Siripoon T, 2645  
 Siritutsoontorn S, 4557  
 Sissala N, 5355  
 Sisti A, 1055, 1059, 1065  
 Sjøgren K, 6399  
 Skála M, 7045  
 Skalli D, 4115  
 Skrickova J, 2209  
 Slagle-Webb B, 6039  
 Sławińska-Brych A, 6151  
 Śledziński T, 4843  
 Slominski AT, 473, 2467  
 Smahelova J, 1597  
 Smalinskiene A, 2003  
 Smesny Trtkova K, 4979  
 Soda M, 7101  
 Söderström D, 6387  
 Soeda S, 5263  
 Soh J, 2667, 4419  
 Šoipi Š, 2323  
 Sokół K, 6685  
 Sokuyev RI, 1437  
 Solovejute R, 2003  
 Soma G-I, 4457, 4711, 4719  
 Somekawa K, 3889  
 Sommer JU, 6195  
 Somville J, 5319  
 Son B-H, 5883  
 Son SW, 723  
 Son YH, 4929  
 Sone K, 4245  
 Song A, 535, 551

- Song C, 2171  
 Song DH, 3203  
 Song S, 2707  
 Sonobe M, 3287  
 Sonoda H, 2199, 2373, 3469  
 Sonoda T, 991, 5577  
 Sonohara F, 1843, 6665  
 Sopo M, 6923  
 Sordillo LA, 1189  
 Sordillo PP, 1189  
 Sorejs O, 1219  
 Sota Y, 6437  
 Soufi M, 4215  
 Sougglari M, 305  
 Souglakos J, 901  
 Sousa Duarte S, 5049  
 Sp N, 1905, 3209, 5191  
 Spaeth D, 3939  
 Spaulding AC, 1055, 1059, 1065, 3411  
 Spengler G, 4921  
 Sperk E, 4137  
 Spiegl-Kreinecker S, 6229  
 Spitaleri G, 427  
 Spyropoulou D, 3003  
 Sriratanasak N, 609, 2583  
 Sritularak B, 4989  
 Srivastava MD, 6997  
 Stagno F, 5313  
 Staibano S, 271  
 Stanzione A, 271  
 Stapenhorst M, 5151  
 Stathopoulos E, 901  
 Stati V, 427  
 Stavrika C, 807, 3759  
 Stavrakakis GS, 5181  
 Steckiewicz P, 4059  
 Steed KL, 9  
 Steele L, 4857  
 Stefanakis S, 709  
 Steffensen KD, 5255  
 Steinkohl F, 2861  
 Stella S, 2457, 5313  
 Stella S  
 Stepulak A, 6151  
 Stergiou H, 305  
 Sterpetti AV, 2969, 4223  
 Stoeckman AK, 6075  
 Stojkovic D, 5001  
 Stokes CS, 527  
 Stomps A, 2185  
 Stope MB, 841, 2591, 3743, 6205  
 Stoyanova E, 5159  
 Stratigos A, 2219  
 Stravodimou A, 4829  
 Strawderman MS, 5801  
 Strohhacker K, 2861  
 Strönisch A, 1267  
 Studeman K, 2225  
 Studer U, 5909  
 Stuschke M, 1161  
 Styczynski J, 1817, 6531, 7095  
 Styler M, 4857  
 Stylianopoulos T, 1375  
 Stylianou A, 1375  
 Su C-H, 6743, 7037  
 Su M, 245  
 Su T-F, 4513, 5059  
 Su Y-C, 6265  
 Su Y-T, 1285  
 Suaris T, 3915  
 Subocz E, 4059  
 Suchy B, 3743  
 Suda T, 5567  
 Sudo M, 2311  
 Suekane S, 1739, 6443  
 Suenaga M, 1843  
 Sueta T, 4687  
 Suga K, 5577  
 Suga Y, 4291  
 Sugano H, 1891, 3445  
 Sugano M, 261  
 Sukanuma N, 2133  
 Sugasawa H, 6171  
 Sugaya K, 1963  
 Sugezawa K, 5593  
 Sugihara T, 7109  
 Sugimachi K, 2297, 4165  
 Sugimoto M, 6551  
 Sugino T, 6473  
 Sugio K, 3947  
 Sugisaki T, 915  
 Sugisawa N, 2475, 2481, 2509, 4869, 5393, 6083, 6765  
 Sugita Y, 87  
 Sugitani M, 4445  
 Sugiura K, 6845  
 Sugiyama H, 5765  
 Sugiyama M, 2297, 4165  
 Sugiyama T, 1101, 6337  
 Suh JK, 7057  
 Suh KJ, 357  
 Suh Y-A, 109  
 Suimon Y, 2019  
 Sukjoi W, 4557  
 Suleymanova I, 6029  
 Sulfaro S, 1135  
 Sulfaro SC, 5877  
 Sumerkent K, 3265  
 Sumi M, 999  
 Sumida I, 1677, 4095  
 Sumitomo M, 4395  
 Sun A, 719  
 Sun H-N, 3819, 4491  
 Sun S, 5025  
 Sun Y, 2475, 2481, 2509, 4869, 4969, 6083  
 Sun Z-Y, 221  
 Sunaga N, 1571  
 Sunagawa Y, 1843, 6665  
 Sundaram S, 3697  
 Sung E-S, 6295  
 Sung S-Y, 5107  
 Sungrapova KY, 1437  
 Suovaniemi O, 6387  
 Supplitt S, 2613  
 Sure U, 1161  
 Surov A, 1015, 4281  
 Sursal TH, 5989  
 Susini T, 1079, 3645  
 Sustr J, 1219  
 Susuki Y, 6221  
 Suwa K, 373  
 Suzaki N, 4123  
 Suzawa K, 2667  
 Suzuki A, 299, 2379, 7067  
 Suzuki C, 6733  
 Suzuki H, 1127, 2787, 3271, 3469, 3931, 4229, 5757, 6971  
 Suzuki K, 915, 3519, 5091  
 Suzuki M, 3277  
 Suzuki N, 4741  
 Suzuki O, 393, 1677, 2053, 4095, 4379  
 Suzuki R, 6551  
 Suzuki S, 2165, 4961, 6539  
 Suzuki Y, 1579  
 Svardal-Stelmer R, 5673  
 Svaton M, 2209  
 Svatoň M, 3459, 7045  
 Swain A, 4663, 4687  
 Swart EL, 1201  
 Syatkin SP, 1437  
 Syllaios A, 1753, 3065, 6009, 6599  
 Syrigos K, 1697  
 Syrjänen K, 575, 1555, 3591, 6387, 6947  
 Szabó ER, 6123  
 Szabó IZ, 6123  
 Szanto A, 6525  
 Szeremet A, 4059  
 Sziójártó AL, 6123  
 Szivos L, 1759  
 Szmitkowski M, 3221  
 Szumera-Ciećkiewicz A, 6685  
 Szutan LA, 6573  
 Szymczyk A, 4059  
 Tabata A, 4675  
 Tabchouri N, 3579  
 Tabrez S, 4547  
 Tabuchi M, 3271  
 Tachezy R, 1597  
 Tachibana S, 2827  
 Tada H, 3559  
 Tada K, 3559, 6563  
 Tada Y, 5277, 5593  
 Tagawa T, 5659  
 Taghizadeh H, 965  
 Tagka A, 2219  
 Tagliaferri L, 3417  
 Tago K, 3983  
 Taguchi J, 5237  
 Taguchi K, 3315  
 Taguchi T, 759  
 Tahata K, 2777  
 Tahira T, 5399  
 Tai C-J, 1631  
 Tai T-S, 6265  
 Tai Y-Y, 6869  
 Tailor K, 2559  
 Taira Y, 3565  
 Tajika M, 2247  
 Tajima H, 5171, 5211  
 Tajima T, 5229  
 Tajiri T, 4245, 6159  
 Tajiri W, 3315  
 Takabe K, 6733  
 Takács I, 1359  
 Takada K, 2239, 2343, 3345  
 Takada N, 1891, 3445  
 Takada S, 5171  
 Takada Y, 393  
 Takaesu G, 6101  
 Takagi K, 4773, 5343  
 Takagi T, 6551  
 Takahara K, 4395

- Takahashi A, 3953  
Takahashi H, 3559, 5277, 5301  
Takahashi K, 2827, 3287, 3571, 4047  
Takahashi M, 201, 1921, 1619, 4047  
Takahashi R, 1147  
Takahashi S, 915, 4327  
Takahashi T, 299, 2379, 5263  
Takahashi Y, 2667, 4419  
Takakuwa O, 4245  
Takami H, 1843, 6665  
Takamura H, 3361, 5171  
Takano Y, 81  
Takao K, 87  
Takaoka M, 3571  
Takaoki F, 1153  
Takasawa R, 35, 3271  
Takashi H, 7009  
Takashima A, 1071  
Takashima T, 2343, 3345, 4047  
Takasu C, 239  
Takasumi M, 6551  
Takata H, 7141  
Takato T, 3793  
Takayama T, 4445  
Takeda S, 1843, 2393, 4741  
Takeda T, 2667, 5301  
Takeda Y, 3445  
Takemoto K, 4787  
Takemura M, 4245  
Takemura T, 7141  
Takeno S, 4183  
Takeshima N, 5285  
Takeshita T, 5631  
Takeshita T, 645  
Takeuchi A, 3551, 4245, 6563, 7009  
Takeuchi H, 1921, 3947  
Takeuchi I, 2701  
Takeuchi M, 3371  
Takeuchi T, 3091  
Takeuchi Y, 4183  
Takezawa Y, 4291  
Takiguchi T, 915  
Takimoto R, 4729, 4741, 4763  
Takizawa K, 4741  
Talaat I, 1555  
Tamagawa A, 443, 1087, 2359, 2365  
Tamagawa H, 405, 443, 1087, 1503, 2337, 2359, 2365, 4067, 5815  
Tamayo P, 6017  
Tambè L, 5313  
Tamiya A, 4229  
Tamiya M, 4229, 6957  
Tamori S, 35  
Tamura H, 6551  
Tamura K, 1101, 4779, 5229  
Tamura M, 1981  
Tamura S, 2351  
Tamura T, 957, 1147, 5757  
Tamura Y, 2787, 6971  
Tan Y, 2515, 2813  
Tan Z-L, 6723  
Tanabe H, 201  
Tanabe M, 6733  
Tanaka A, 2787, 3931, 6971  
Tanaka C, 201, 1843, 6665, 6713  
Tanaka G, 3983  
Tanaka H, 1147, 2637, 2881  
Tanaka K, 2053, 3277, 6665  
Tanaka M, 4779  
Tanaka R, 2637, 2881  
Tanaka S, 261, 2637, 2881, 3287, 3345  
Tanaka T, 101, 2199, 2373, 2787, 4779  
Tanaka Y, 169, 1587, 5829, 7067  
Tanei T, 6437  
Tangboonduangjit P, 2645  
Tanigawa M, 4105, 4695, 4749  
Tanigawa T, 5285  
Taniguchi H, 2247  
Taniguchi M, 1875  
Taniguchi R, 6733  
Taniguchi S, 7089  
Taniguchi Y, 923, 4229, 6563, 7009  
Tanimoto A, 75  
Tanino H, 2475, 2509, 6765  
Tanio A, 5593  
Tanioka K, 4033  
Tanishima Y, 5829  
Taniyama D, 1943  
Tanizawa T, 1029, 1035  
Tanuma S-I, 35  
Taranov OS, 795  
Tarasenko S, 6531  
Tartarisco G, 1443  
Tasaka T, 4701  
Tashiro M, 1843  
Tashiro Y, 2475, 2481, 2509, 3873, 5393, 6545  
Tatemichi M, 5071  
Taube ET, 5743  
Tauchi J, 2637, 2881  
Taugner J, 2319  
Tausch CJ, 2125  
Tavella K, 1079  
Tavolari S, 597, 3013  
Tayeh S, 315, 1809, 3915  
Tazi Y, 3939  
Tazzioli G, 7119  
Teachey DT, 3147  
Tegl V, 6817  
Teishima J, 1943, 4787  
Terada H, 1127, 4719  
Terahara A, 393  
Terakawa T, 3519  
Teramachi H, 1605  
Teranishi S, 3889  
Terao Y, 4741  
Teratani M, 4885  
Terentyev AA, 1437  
Teshima T, 4095, 6957  
Thadi A, 4857  
Thaler CJ, 2117  
Theisen J, 1519  
Theocharis S, 5457  
Theodore C, 4115  
Theodoropoulos G, 5457  
Theodoropoulos P, 6769  
Theofanakis C, 3651  
Thieden E, 557  
Thomakos N, 3065, 3651  
Thomas NWM, 3081  
Thomassin-Naggara I, 4115  
Thongpon P, 6899  
Thonsri U, 5115  
Thuwajit C, 4557, 6285  
Thuwajit P, 6285  
Thway K, 7003  
Tian X, 5545  
Tibbo ME, 6941  
Tierens A, 6115  
Tikkanen M, 1325  
Timme S, 5679  
Timmermann L, 387  
Timotheadou E, 305  
Tirrò E, 2457  
Tiseo M, 4807  
Tober N, 597, 3013  
Toda S, 2133  
Toda Y, 6221  
Todorovic D, 5001  
Todorovic M, 5001  
Togashi K, 4961  
Toh Y, 2297, 4165  
Tohda S, 3155  
Toita T, 3565  
Tőkés T, 6123  
Tokuda Y, 6437  
Tokunaga E, 3315  
Tokunaga KEN, 4701  
Tokunaga T, 239, 2911  
Tokunaga Y, 733  
Tokuyasu N, 5593  
Tolento G, 465  
Tolia M, 3003  
Tolkach Y, 3119  
Tollefsbol TO, 9  
Tomarchio C, 2457  
Tomascova A, 6257  
Tomczak W, 6327  
Tomida S, 2667  
Tomii K, 2981  
Tomimatsu T, 5939  
Tominaga H, 5237  
Tomino T, 401  
Tomiooka K, 3873, 6545  
Tomita K, 7017  
Tomita M, 4023  
Tomita Y, 3361  
Tomiyama E, 4875  
Tomoaki K, 1153  
Tomoda T, 335  
Tomogane M, 5481  
Tomomura A, 87  
Tomomura M, 87  
Tomori K, 1891  
Tomos P, 1697  
Tona Y, 169  
Tonar Z, 6817  
Tone M, 2239  
Tong WL, 2043  
Tong Z, 4969  
Topolcan O, 1219, 3527, 7045  
Toratani M, 6957  
Torigoe T, 4319  
Torres ILS, 5151  
Tortorella S, 2439  
Tosca J, 6853  
Tosti D, 939



- Tóth D, 1759  
 Tóth J, 1759  
 Touboul C, 4115  
 Toumpourleka M, 3003  
 Tower JI, 6375  
 Toya R, 2073, 2567  
 Toyama K, 2373  
 Toyama M, 4471  
 Toyokawa T, 1147  
 Toyooka S, 2667, 4419  
 Trakas N, 6599  
 Traub B, 5545  
 Treska V, 6817, 7045  
 Trevino K, 5845  
 Trifunovic S, 5001  
 Trignani M, 6505  
 Tripodaki S, 305  
 Troeltzsch D, 6987  
 Troja A, 2947  
 Trovarelli G, 1519  
 Trumbull D, 6381  
 Trypaki M, 901  
 Tsai C-B, 703, 4523  
 Tsai C-J, 6723, 6743, 7037  
 Tsai C-W, 695, 703, 1297, 2011, 3707, 4465, 4523, 5503, 5751, 6743, 7037  
 Tsai E-T, 2675  
 Tsai F-J, 5751  
 Tsai I-J, 2995  
 Tsai K-W, 6247  
 Tsai M-H, 1631, 2387  
 Tsai Y-H, 5141  
 Tsakiris DA, 5909  
 Tsangaridou E, 6769  
 Tsaniras SC, 2449  
 Tsao T-Y, 2995  
 Tsatsaris G, 6009  
 Tseng B-J, 5141  
 Tseng J-J, 5517  
 Tseng S-H, 5141  
 Tsiambas E, 807, 2219, 3759  
 Tsilikis I, 3065  
 Tsitsopoulos E, 2219  
 Tsoneva I, 5159  
 Tsoukalas N, 305, 3003  
 Tsubamoto H, 991  
 Tsubouchi K, 4299  
 Tsuchida A, 2275, 2827  
 Tsuchihashi K, 4319  
 Tsuchiya H, 2515, 3559, 6563, 7009  
 Tsuchiya K, 6159  
 Tsuchiya S, 3953, 7109  
 Tsuda N, 2073  
 Tsuda Y, 1029  
 Tsuji H, 379  
 Tsujimoto H, 6171, 7109  
 Tsujimoto M, 813  
 Tsujimura T, 3231  
 Tsukagoshi M, 4343  
 Tsukahara K, 5277  
 Tsukahara T, 4319  
 Tsumura S, 1117  
 Tsunoda T, 4663, 4687  
 Tsutsui K, 121  
 Tsutsui S, 4681  
 Tu C-Y, 5895  
 Tu H-F, 1427, 6723  
 Tu YN, 2043  
 Tu Y-T, 6247  
 Tuckey RC, 2467  
 Tufman A, 1451  
 Tumor Z, 751  
 Tung K-L, 3255  
 Tung M-C, 2995  
 Tungsukruthai S, 4989  
 Tunoglu S, 5641  
 Tuomainen K, 6029  
 Turbitt WJ, 5445  
 Turchetti D, 597  
 Ture U, 3265  
 Turnbull HL, 2331  
 Turnovcova K, 5989  
 Tvilsted S, 3429, 3499, 3961, 6513  
 Tzardi M, 901  
 Tzeng H-E, 5751  
 Überall I, 4979  
 Ubiali P, 1135, 5877  
 Uchida D, 1247  
 Uchida H, 1677, 3733  
 Uchida K, 3571  
 Uchida Y, 4687  
 Uchiyama T, 4567  
 Ueda K, 1739, 2911, 6443  
 Ueda M, 2941, 5263  
 Ueda N, 3361  
 Ueda T, 4183  
 Ueda Y, 4095, 5939  
 Uehara H, 2297  
 Uejima C, 5593  
 Uemura K, 1739  
 Uemura M, 1677, 2053, 4875  
 Uemura T, 4245  
 Uenishi J, 5035  
 Ueno H, 6171, 7109  
 Ueno M, 4033, 4123  
 Ueno T, 5043, 5807  
 Uenosono Y, 75  
 Ueo H, 3315  
 Uesawa Y, 87, 4885  
 Uezato J, 3277  
 Uga T, 4779  
 Ugga L, 271  
 Ujike T, 4875  
 Ukai S, 3271  
 Ukimura O, 5481  
 Uloza V, 2003  
 Um S-W, 3435  
 Umabayashi M, 4663  
 Umehara T, 2911  
 Umekita Y, 5593  
 Umemura A, 3953  
 Umemura S-I, 2549  
 Umikawa M, 6101  
 Unger J, 2801  
 Unger K, 1277  
 Unno M, 4869, 5393  
 Unuma H, 4701  
 Ura T, 2247  
 Urakami S, 5295  
 Uramoto H, 1875  
 Urasinska E, 1973  
 Uribe Cruz C, 5151  
 Ursini LA, 6505  
 Ursu RG, 53  
 Usami E, 1605, 1605, 7135  
 Ushigome T, 373  
 Usuba T, 293  
 Utispan K, 2657  
 Uto Y, 4675, 4701  
 Utpatel K, 2185  
 Utriainen T, 6915  
 Utsumi M, 6539  
 Uwer L, 3905  
 Vaeteewoottacharn K, 6899  
 Vagios S, 1669  
 Vai A, 2853  
 Valabrega S, 619  
 Valachis A, 5853  
 Valentini V, 3417, 4413, 6499  
 Valerio MR, 1711  
 Vallario A, 1079  
 Valle M, 4263  
 Valsami S, 6599  
 Valvo F, 1645, 2853  
 Vamvakaris I, 1697  
 Van AJM, 1201  
 Van Beeck A, 5319  
 Van De Sande M, 5319  
 Van Loon K, 865  
 Van Oijen MGH, 4331  
 Van Otterlo WAL, 229  
 Van Praag V, 5319  
 Vangundy Z, 67, 133, 5707  
 Vaňková B, 7045  
 Vanni G, 281, 939, 1719, 7119  
 Vanzi E, 1079  
 Varga B, 4921  
 Varga Z, 2125, 4237  
 Varinská L, 3191  
 Varthalitis I, 305  
 Vassi E, 2025  
 Vassiliu P, 625  
 Veena V, 1915  
 Végváry Z, 4237  
 Verburg FA, 2323  
 Verde F, 271  
 Vereczkei A, 1359  
 Vergadis C, 625  
 Vermeulin T, 3905  
 Veronikis AJ, 719  
 Vesely S, 847  
 Veskokoukis AS, 2025  
 Vestergaard Madsen C, 5255  
 Vetvicka D, 349  
 Vetvicka V, 3139  
 Vetvickova J, 3139  
 Vidal AC, 1459  
 Vieira Sobral M, 5015, 5049  
 Vieni S, 1711, 7083  
 Viggiano D, 4017  
 Vilcu M, 1049  
 Villani S, 1691  
 Villanucci A, 1079  
 Villman K, 5853  
 Vincent J, 4011  
 Vinodnadat A, 1555  
 Virga J, 1759  
 Virgilio E, 1691, 4053, 7127  
 Vischioni B, 1645, 2853  
 Vistejnova L, 6817  
 Visvikis A, 677  
 Vitale SR, 2457  
 Vitali GC, 2079  
 Vitolo V, 1645, 2853  
 Vlasak P, 3527  
 Vodička J, 7045

- Vogt T, 583  
 Vollkommer T, 3333  
 Vollmar B, 153  
 Volterrani D, 2191  
 Von Brandenstein M, 5539  
 Von Eisenhart-Rothe R, 1519, 5793  
 Von Kroge S, 3333  
 Voth LC, 6075  
 Voutouri C, 1375  
 Voutsadakis IA, 4829  
 Voutyritsa E, 6599  
 Wada H, 873  
 Wada K, 4095, 6957  
 Wada N, 1921, 7141  
 Wada R, 5631  
 Wada Y, 3873, 6545  
 Waer CN, 751  
 Wagenpfeil S, 583  
 Wagner R, 5727  
 Waiwitikhit S, 4557  
 Wakabayashi H, 4885  
 Wakabayashi K, 161  
 Wakabayashi T, 3231  
 Wakatsuki K, 1367  
 Wakatsuki M, 5497  
 Wakita A, 5715  
 Walewski J, 6685  
 Walker EJ, 865  
 Wallerich S, 3883  
 Walter KA, 5801  
 Walter L, 4937  
 Wang C, 4875  
 Wang D, 5707  
 Wang E, 4157  
 Wang H, 245  
 Wang H-C, 6743, 7037  
 Wang J, 5457  
 Wang L, 1651, 4365  
 Wang R, 245  
 Wang S, 2559  
 Wang T-F, 1175  
 Wang Y, 1619  
 Wang Y-C, 695, 703, 1297, 2011, 2387, 3707, 4523, 5503, 5751, 6743, 7037  
 Wang Z-H, 703, 2011, 4523, 5503  
 Wanner M, 891  
 Waraasawapati S, 5115  
 Ward KA, 4857  
 Warnnissorn M, 4557  
 Warren KT, 5801  
 Warshaw AL, 3659  
 Wasa J, 1619  
 Waszczuk-Gajda A, 4059  
 Watakabe T, 2073, 2567  
 Watanabe A, 4343  
 Watanabe D, 299, 2379  
 Watanabe H, 413, 421, 915, 1101, 1683, 2275  
 Watanabe I, 4471  
 Watanabe K, 1101, 3889, 6473  
 Watanabe M, 1867, 4567  
 Watanabe S, 6551  
 Watanabe T, 2141, 2827, 2871, 5263, 7089  
 Watrowski R, 2487  
 Wattanathana W, 2583  
 Wazir U, 5351  
 Weber GF, 2833  
 Wegner R, 6003  
 Weichert W, 3109  
 Weidler J, 6229  
 Weiher H, 5489  
 Weinberger V, 3527  
 Weiss M, 3743  
 Weiss TS, 143  
 Wellner UF, 3659  
 Wen Y-C, 3865, 5221, 6093  
 Wen YL, 3605  
 Wendt EHU, 153  
 Weng W-C, 2995  
 Weyant MJ, 5361  
 Whang-Peng J, 3865, 5221, 6093  
 Wi YC, 2961  
 Wichary R, 4059  
 Wickström M, 53  
 Wiczew D, 2613  
 Wiegand S, 1167  
 Wieland I, 3423  
 Wiewrod R, 3379  
 Wiggins E, 1459  
 Wijnhoven BPL, 5343  
 Wilson B, 27  
 Witteler J, 3429, 3499, 3961, 6513, 7025, 7077  
 Woisetschläger M, 2757  
 Wojciechowska M, 4059  
 Wolf I, 6457  
 Won KY, 191  
 Won SJ, 2627  
 Wongkham C, 5115  
 Wongkham S, 5115  
 Wongtrakoongate P, 2645  
 Woo SU, 3801  
 Woo T, 6407  
 Word B, 3669  
 Wörtler K, 5793  
 Wu C-C, 6247  
 Wu C-H, 3255  
 Wu C-Y, 221  
 Wu D, 6051  
 Wu H-C, 2011  
 Wu HH, 5845  
 Wu J-Y, 2675  
 Wu Q, 635  
 Wu S-Y, 3255  
 Wu T-K, 5059  
 Wu Y-T, 3255  
 Wuertz B, 3071  
 Wulf HC, 511, 557  
 Wundsam H, 2151  
 Wüster J, 6987  
 Wysocki M, 1817, 7095  
 Xie D-P, 3819  
 Xie H, 5411  
 Xie X, 5545  
 Xing M, 5371  
 Xoxakos I, 709  
 Yabumoto A, 2343, 3345  
 Yaegashi H, 1141, 2291, 4087, 4291  
 Yaegashi N, 1255  
 Yagi M, 4095  
 Yahara K, 393  
 Yaltirik CK, 3265  
 Yamada A, 6733  
 Yamada H, 413, 421, 957, 4701, 5757  
 Yamada K, 393, 3873  
 Yamada S, 201, 743, 1843, 1875, 3231, 6429, 6665, 6713  
 Yamada T, 405, 1503, 1683, 2275, 2351, 3469, 4067, 4271, 4655, 4763, 5815  
 Yamada Y, 299, 957, 2379, 3287, 5405, 5757, 6221  
 Yamaguchi K, 3953, 6473  
 Yamaguchi S, 1651, 4365  
 Yamamoto A, 2637  
 Yamamoto H, 2667, 4419, 5301, 6221  
 Yamamoto J, 2475, 2481, 2509, 4869, 5393, 6083, 6765  
 Yamamoto K, 393, 665, 4457, 4711  
 Yamamoto M, 2165, 3889, 4961, 5593, 6539  
 Yamamoto N, 379, 1683, 1867, 2515, 3551, 5815, 6563, 7009  
 Yamamoto S, 1613, 5295, 6493, 6733, 7067  
 Yamamoto T, 393, 2065, 4373, 4567  
 Yamamoto Y, 101, 3163, 5171, 5757  
 Yamamoto-Shimajima K, 4567  
 Yamamura K, 1023, 2795, 5823, 6465, 7147  
 Yamana H, 121  
 Yamanaka T, 923, 1587, 2133  
 Yamane M, 2667, 4419  
 Yamano T, 4687  
 Yamanouchi K, 2303  
 Yamao T, 1023  
 Yamaoka Y, 1731  
 Yamashiro K, 1315  
 Yamashita H, 393, 645, 2065, 4961  
 Yamashita K, 2165, 4763, 6539  
 Yamashita M, 4457, 4711  
 Yamashita T, 957, 2133, 5277, 5757  
 Yamashita Y, 3277  
 Yamashita Y-I, 1023, 2795  
 Yamatsuji T, 5807  
 Yamauchi A, 5043  
 Yamaue H, 4033, 4123  
 Yamazaki T, 3873, 6545  
 Yamazoe S, 2637, 2881  
 Yamori T, 6171  
 Yan L, 1833, 3697  
 Yanaga K, 81, 293, 373, 1891, 3445, 5829  
 Yanagihara K, 1307, 5687  
 Yanagita S, 75  
 Yanagitani N, 5577  
 Yanai H, 4419  
 Yang C-C, 6305  
 Yang F-Y, 2675  
 Yang H, 4969  
 Yang H-R, 1297  
 Yang J-S, 4523, 5503


- Yang JW, 3203  
 Yang M-D, 695, 1297, 6869  
 Yang T-M, 1297  
 Yang YM, 1905, 3209, 5191  
 Yang Z, 635  
 Yano H, 2303, 4105, 4695, 4749  
 Yano M, 4131, 6791  
 Yashiro M, 1147, 2637, 2881  
 Yashod P, 5427  
 Yasuda M, 6791  
 Yasui T, 4395  
 Yasui W, 1943, 5815  
 Yasumoto K, 4729, 4741, 4763  
 Yasuoka S, 6493  
 Yatabe S, 3445  
 Yaylim İ, 5641  
 Yeh C-C, 1285  
 Yeh T-M, 6345  
 Yen C-C, 4947  
 Yen C-M, 6743, 7037  
 Yen C-Y, 221  
 Yenilmez EN, 5641  
 Yildirim E, 5649  
 Yildiz M, 5649  
 Yilmaz SG, 3265  
 Yim K, 4537  
 Yin F, 1625, 3991, 5411  
 Yin M-C, 703, 4523  
 Yip-Schneider M, 4215  
 Yi-Te C, 5107  
 Ylä-Herttua S, 6923  
 Yokokawa T, 915  
 Yokomakura N, 2911  
 Yokomichi N, 4741  
 Yokomise H, 733, 1007, 4327  
 Yokomizo A, 335  
 Yokomizo H, 5405  
 Yokose T, 6407  
 Yokota R, 4471  
 Yonai S, 6429  
 Yoneda A, 5271  
 Yonekura S, 1739  
 Yonemitsu Y, 5687  
 Yonese J, 1613, 6493  
 Yonezawa H, 3559, 6563, 7009  
 Yoo HJ, 341  
 Yoo J-S, 3209  
 Yoo SH, 4351  
 Yoon JH, 213  
 Yoon J-H, 4529, 6835  
 Yoon SK, 2033  
 Yoon S-S, 357, 1395, 2917  
 Yoon SZ, 5601  
 Yoon YE, 2961  
 Yoon YJ, 191  
 Yoon YM, 5611  
 Yoshida D, 2905  
 Yoshida H, 169, 2787, 2981, 3469, 4271, 6971  
 Yoshida K, 299, 2379, 3371, 5071, 7067  
 Yoshida R, 2073  
 Yoshida T, 2133, 6159  
 Yoshida Y, 4655, 4663, 4763  
 Yoshii D, 2795, 7147  
 Yoshii M, 1147  
 Yoshikawa D, 7089  
 Yoshikawa K, 239  
 Yoshikawa T, 405, 1107, 1153, 1683, 2275, 4067, 4387  
 Yoshikawa Y, 2941  
 Yoshimatsu G, 4655, 4763  
 Yoshimatsu K, 5405  
 Yoshimitsu M, 4471  
 Yoshimura F, 4655, 4763  
 Yoshimura H, 2239  
 Yoshimura K, 2981, 5211  
 Yoshimura M, 6781  
 Yoshimura T, 1605, 7135  
 Yoshino A, 5939  
 Yoshinori O, 6551  
 Yoshioka H, 2981, 4801  
 Yoshioka Y, 999, 1677, 2053  
 Yoshiyama H, 1307  
 Yoshizawa K, 3271  
 Yoshizawa T, 5577  
 Yoshizumi T, 4165  
 You J-S, 779  
 Youssef O, 1325  
 Yu C, 703  
 Yu C-C, 695, 1297  
 Yu J, 1345  
 Yu L-Y, 3819, 4491  
 Yu S-K, 779  
 Yuasa T, 1613, 6493  
 Yubakami M, 3163  
 Yuda M, 5829  
 Yue C-H, 4513  
 Yukawa N, 405, 443, 1087, 1503, 1587, 1683, 2337, 2359, 2365, 4067  
 Yuki H, 5823, 6465, 7147  
 Yumita N, 2549  
 Yun C-S, 4929  
 Yun CW, 5611  
 Yun S-H, 177, 653, 767  
 Yuno T, 5567  
 Yunokawa M, 5285  
 Yunoki T, 335  
 Yusenko MV, 3485, 6863  
 Yutaka Y, 3287  
 Zabrodsky M, 349  
 Zaffaroni N, 4913  
 Zagouri F, 929  
 Zaha A, 5509  
 Zaidi S, 7003  
 Zajac M, 6327  
 Zajkowska A, 4425  
 Zajkowska M, 3221  
 Zang W, 245  
 Zannoni GF, 2429  
 Zaravinos A, 1375  
 Zarling L, 1527  
 Zaucha JM, 4059  
 Zawirska D, 4059  
 Zblewski DL, 3883  
 Zechner D, 153  
 Zeillinger R, 2487  
 Zeina N, 857  
 Zeller A, 1095  
 Zeller B, 6115  
 Zemanova M, 2209  
 Zemanova P, 2209  
 Zenker M, 3423  
 Zeppa P, 4017  
 Zeybek U, 5641  
 Zhang B, 2419  
 Zhang J, 635  
 Zhang R, 4755  
 Zhang X, 733, 5411, 5707  
 Zhang Y-Q, 4491  
 Zhao C, 3119  
 Zhao M, 2515  
 Zhao Q-L, 5025  
 Zhao R, 6051  
 Zhao S, 1875  
 Zharhary D, 1255  
 Zhelev Z, 1963, 5159  
 Zhou S, 5545  
 Zhu D, 3819  
 Zhu G, 6083  
 Ziemlewicz T, 1527  
 Zikan M, 3527  
 Zinn W, 1481  
 Ziparo E, 5379  
 Ziras N, 305  
 Zissel G, 3097  
 Zizioli V, 1543  
 Zografos GC, 5457  
 Zoppi S, 4913  
 Zoppoli G, 3543  
 Zoras O, 6769  
 Zotos P-A, 3065  
 Zucchetti C, 3387  
 Zuccon U, 5877  
 Zygmunt M, 841, 2185, 2801

**Errata**


Volume 24, No. 2C, page 1319: The name of the 4th Author should read: LUZ-MA-ADRIANA BALDERAS-PEÑA

ENRIQUE ACEVEDO-NUÑO<sup>1</sup>, ALEJANDRO GONZÁLEZ-OJEDA<sup>1</sup>,  
GONZALO VÁZQUEZ-CAMACHO<sup>2</sup>, LUZ-MA-ADRIANA BALDERAS-PEÑA<sup>1</sup>,  
HÉCTOR MORENO-VILLA<sup>3</sup> AND HÉCTOR MONTOYA-FUENTES<sup>4</sup>


Volume 28, No. 1, page 330: Figure 1C should be replaced by:



Volume 28, No. 1, page 331: Figure 3B should be replaced by:



Volume 37, No. 7, page 3620: Figure 3 should be replaced by:



Volume 38, page 1849: The legend of Figure 1 should read:

Figure 1. A: Green fluorescent protein-red fluorescent protein (GFP-RFP)-expressing dual-color XPA-I human pancreatic cancer cells *in vitro*. Cancer cells were initially transduced with RFP and the neomycin-resistance gene. The cells were subsequently transduced with histone H2B-GFP and the hygromycin-resistance gene. Double transformants were selected with G418 and hygromycin, and stable clones were established. Images were captured under FV1000 confocal microscopy (28). B: High-magnification imaging of XPA-I pancreatic cancer cells and stellate cells in the liver of cyan fluorescent protein (CFP)-expressing nude mice.  $B_i$ ,  $B_{ii}$ : XPA-I-GFP-RFP pancreatic cancer cells in the host liver 3 hours after splenic injection. White arrows indicate XPA-I pancreatic cancer cells.  $B_{iii}$ ,  $B_{iv}$ : Twenty-eight days after co-injection of XPA-I-GFP-RFP pancreatic cancer cells and RFP stellate cells, liver metastases were observed in the host CFP nude mice. White arrows indicate XPA-I-GFP-RFP pancreatic cancer cells. Yellow arrows indicate RFP stellate cells. White arrow in  $B_{iv}$  shows dividing cancer cells.

Volume 38, No. 7, page 3919: The 6th line of Materials and Methods should read:

TCR (wt%) were H: 1.0%, C: 6.5%, O: 0.5% and W: 90.0%.

Volume 39, No. 1, page 119: The No. 6 affiliation should read:

<sup>6</sup>IEO European Institute of Oncology, IRCCS, Milan, Italy

Volume 39, No. 2, page 909: The No. 3 affiliation should read:

<sup>3</sup>IEO European Institute of Oncology, IRCCS, Milan, Italy

Volume 39, No. 6, page 2800: The 4th line of Materials and Methods should read:

composition of TCR (wt%) is H: 1.0%, C: 6.5%, O: 0.5%, W:

Volume 39, No. 8, page 4265: Affiliation No 20 should read:

<sup>20</sup>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Volume 39, No. 11, page 5911: The affiliation of the first Author should read:

<sup>1</sup>Department of General Surgery, Anhui Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, P.R. China;

Volume 39, No. 11, page 5920: Right column, lines 1-3 should read:

The G2 group was treated with implantation of <sup>125</sup>I seeds in the tumor. The G3 group was treated with <sup>125</sup>I seeds in the tumor and injection of Robo1-specific BiCAR-NK cells provided by ATCG Corp. Ltd., Suzhou, P.R. China. <sup>125</sup>I seeds (diameter,

Volume 39, No. 11, page 5924: The following sentence should be added at the end of Acknowledgements:

Assistance from Baolei Wang, Kunkun Han and Huashun Li (ATCG Corp. Ltd.) for Robo1 Car-NIK cell culture is gratefully acknowledged.

Volume 40, page 677: In the Abstract, Patients and Methods, the words FAS -671 should be replaced by FAS -670.

Volume 40, page 709: The name of the 3rd Author should read: Pavlos Msaouel

Volume 40, No. 2, page 795: The name of the 12th Author should read:

ELENA R. CHERNYKH<sup>6</sup>

Vol. 40, No. 6, page 3091: Hirokazu Tanino should be added as 9th Author. The Authors' list should read:

SACHIKO INUBUSHI<sup>1,2,3</sup>, HIROKI KAWAGUCHI<sup>1</sup>, SACHIKO MIZUMOTO<sup>4</sup>,  
TOMONARI KUNIHISA<sup>4</sup>, MOTOI BABA<sup>4</sup>, YUKIYA KITAYAMA<sup>5</sup>, TOSHIFUMI TAKEUCHI<sup>5</sup>,  
ROBERT M. HOFFMAN<sup>2,3</sup>, HIROKAZU TANINO<sup>4</sup> and RYOHEI SASAKI<sup>1</sup>

Volume 40, No. 7, page 3902: After the Authors' Contributions section, the following Acknowledgements section should be added:

#### **Acknowledgements**

We thank Malin Holmgren, Department of Oncology, Gävle Hospital, Sweden for her valuable contribution to the paper.

Volume 40, No. 10, page 5351: The Authors' list and affiliation numbers should read:

UMAR WAZIR<sup>1,2</sup> and KEFAH MOKBEL<sup>1</sup>

Volume 40, No. 11, page 6417: The name of the 7th Author should read: Amichay Meirovitz.

BENJAMIN NISMAN<sup>1#</sup>, TANIR M. ALLWEIS<sup>2,3#</sup>, EINAT CARMON<sup>4</sup>, LUNA KADOURI<sup>1</sup>,  
BELLA MALY<sup>5</sup>, OFRA MAIMON<sup>1</sup>, AMICHAY MEIROVITZ and TAMAR PERETZ<sup>1</sup>

## Instructions for Authors 2020

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. Each article should include a concrete conclusion constituting of a “new piece of knowledge” backed up by scientific evidence. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal’s secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts exceeding 4 printed pages will be subject to excess page charges. The 4 printed pages correspond approximately to twelve (12) document pages (~250 words per double-spaced typed page in Arial 12), including abstract, text, tables, figures, and references. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors’ contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dalglish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O’ Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 *Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region*.

2000-2015. Geneva, World Health Organisation, 2016. Available at [http://www.who.int/healthinfo/global\\_burden\\_disease/estimates/en/index2.html](http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html). Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).

**Nomenclature and Abbreviations.** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

**Clinical Trials.** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

**Ethical Policies and Standards.** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

**Submission of Manuscripts.** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)

**Galley Proofs.** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email ([iiar@iiar-anticancer.org](mailto:iiar@iiar-anticancer.org)) within two days.

### **Specific information and additional instructions for Authors**

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for peer-review in confidence to two-three suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.



5. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
  6. Authors should pay attention to the following points when writing an article for AR:
    - The Instructions to Authors must be followed in every detail.
    - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
    - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
    - Results given in figures should not be repeated in tables.
    - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
    - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
    - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
    - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
    - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
    - References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
    - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
  7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
  8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
  9. Articles submitted to AR may be rejected without review if:
    - they do not fall within the journal's policy.
    - they do not follow the instructions for authors.
    - language is unclear.
    - results are not sufficient to support a final conclusion.
    - results are not objectively based on valid experiments.
    - they repeat results already published by the same or other authors before the submission to AR.
    - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
  10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
  11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to [journals@iiar-anticancer.org](mailto:journals@iiar-anticancer.org)
  12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
  13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
- (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2020** - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

## Editorial Staff

Managing Editor and Executive Publisher: GEORGE J. DELINASIOS, Athens, Greece  
Production Editor: E. ILIADIS, Athens, Greece

## Editorial Office

International Institute of Anticancer Research,  
1st km Kapandritiou-Kalamou Rd.,  
Kapandriti, P.O.Box 22, Attiki 19014, Greece  
Tel and Fax: +30-22950-53389

## U.S. Branch

Anticancer Research USA, Inc.,  
111 Bay Avenue, Highlands, NJ, USA

*E-mails:* Editor: editor@iiar-anticancer.org; Journals: journals@iiar-anticancer.org; IIAR: iiar@iiar-anticancer.org

*IIAR websites:* [www.iiar-anticancer.org](http://www.iiar-anticancer.org); [www.iiarjournals.org](http://www.iiarjournals.org)

**Publication Data:** ANTICANCER RESEARCH (AR) is published monthly. Each annual volume contains twelve issues and index.

**Copyright:** Once a manuscript has been published in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

**ANTICANCER RESEARCH is available in print (ISSN: 0250-7005) and online (ISSN: 1791-7530) through Stanford University HighWire Press with access to full text/PDF articles from all previous volumes since January 1st, 2004. For online/print subscription rates, please visit the IIAR websites: [www.iiar-anticancer.org](http://www.iiar-anticancer.org); [www.ar.iiarjournals.org](http://www.ar.iiarjournals.org)**

**Annual Subscription Rates 2021:** Institutional subscription online: US\$ 1,898.00. Institutional subscription print & online: US\$ 2,277.00. Personal subscription online: US\$ 897.00. Personal subscription print & online: US\$ 1,277.00. Prices include rapid delivery and insurance. Previous volumes of Anticancer Research (Vol. 1-40, 1981-2020) are available at 50% discount on the above rates.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the publisher (e-mail: [subscriptions@iiar-anticancer.org](mailto:subscriptions@iiar-anticancer.org)).

**Correspondence:** (subscription orders, reprint orders, change of address, disposition of submitted manuscripts, advertising rates requests, and general editorial matters) should be directed to Dr. G.J. Delinasios, Executive Publisher and Managing Editor, Editorial Office.

**Advertising:** Correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including *Current Contents Life Sciences and Medical Sciences*, *Science Citation Index Expanded*, *Index Medicus*, *Biological Abstracts*, *PubMed*, *PubMed Central*, *Chemical Abstracts*, *BIOSIS Previews*, *Essential Science Indicators*, *Excerpta Medica*, *University of Sheffield Biomedical Information Service*, *Current Clinical Cancer*, *AIDS Abstracts*, *Elsevier Bibliographic Database*, *EMBASE*, *Compendex*, *GEOBASE*, *EMBiology*, *Elsevier BIOBASE*, *FLUIDEX*, *World Textiles*, *Scopus*, *Progress in Palliative Care*, *Cambridge Scientific Abstracts*, *Cancergram (International Cancer Research Data Bank)*, *MEDLINE*, *Reference Update - RIS Inc.*, *PASCAL-CNRS*, *Inpharma-Reactions (Datastar, BRS)*, *CABS*, *Immunology Abstracts*, *Telegen Abstracts*, *Genetics Abstracts*, *Nutrition Research Newsletter*, *Dairy Science Abstracts*, *Current Titles in Dentistry*, *Inpharma Weekly*, *BioBase*, *MedBase*, *CAB Abstracts/Global Health Databases*, *Investigational Drugs Database*, *VINITI Abstracts Journal*, *Leeds Medical Information*, *PubsHub*, *Sociedad Iberoamericana de Información Científica (SIIC) Databases*.

Obtaining permission to reuse or reproduce our content: AR has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit [www.copyright.com](http://www.copyright.com) and enter the title that you are requesting permission for in the 'Get Permission' search box. For assistance in placing a permission request, Copyright Clearance Center can be contacted directly at: Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. Phone: +1-978-750-8400. Fax: +1-978-646-8600. E-mail: [info@copyright.com](mailto:info@copyright.com).

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

PHOTOCOMPOSITION BY IIAR  
PRINTED BY ENTYPPO, GREECE  
PRINTED ON ACID-FREE PAPER